

GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE

BACKGROUND OF THE INVENTION

5 Coronary artery disease and myocardial infarction

The major complications of Coronary Artery Disease, i.e. Myocardial Infarction (MI) and Acute Coronary Syndrome (ACS), are the leading causes of hospital admissions in industrialized countries. Cardiovascular disease continues to be the principle cause of death in the United States, Europe and Japan. The costs of the disease are high both in terms of morbidity and mortality, as well as in terms of the financial burden on health care systems.

Myocardial Infarction generally occurs when there is an abrupt decrease in coronary blood flow following a thrombotic occlusion of a coronary artery previously damaged by atherosclerosis (i.e. in subjects with coronary artery disease). In most cases, infarction occurs when an atherosclerotic plaque fissures, ruptures or ulcerates and when conditions favor thrombogenesis. In rare cases, infarction may be due to coronary artery occlusion caused by coronary emboli, congenital abnormalities, coronary spasm, and a wide variety of systemic, particularly inflammatory diseases. Medical risk factors for MI include cigarette smoking, diabetes, hypertension and serum total cholesterol levels > 200 mg/dL, elevated serum LDL cholesterol, and low serum HDL cholesterol. Event rates in individuals without a prior history of cardiovascular disease are about 1%. In individuals who have had a first MI or ACS, the risk of a repeat MI within the next year is 10-14%, despite maximal medical management including angioplasty and stent placement.

Atherosclerosis can affect vascular beds in many large and medium arteries. Myocardial infarction and unstable angina (acute coronary syndrome (ACS)) stem from coronary artery atherosclerosis (Coronary Artery Disease), while ischemic stroke most frequently is a consequence of carotid or cerebral artery atherosclerosis. Limb ischemia caused by peripheral arterial occlusive disease (PAOD) may occur as a consequence of iliac, femoral and popliteal artery atherosclerosis. The atherosclerotic diseases remain common despite the wide-spread use of medications that inhibit thrombosis (aspirin) or treat medical risk factors such as elevated cholesterol levels in blood (statins), diabetes, or hypertension (diuretics and anti-hypertensives).

Atherosclerotic disease is initiated by the accumulation of lipids within the artery wall, and in particular, the accumulation of low-density lipoprotein (LDL) cholesterol. The trapped LDL becomes oxidized and internalized by macrophages. This causes the formation of atherosclerotic lesions containing accumulations of cholesterol-engorged macrophages, referred to as "foam

cells". As disease progresses, smooth muscle cells proliferate and grow into the artery wall forming a "fibrous cap" of extracellular matrix enclosing a lipid-rich, necrotic core. Present in the arterial walls of most people throughout their lifetimes, fibrous atherosclerotic plaques are relatively stable. Such fibrous lesions cause extensive remodeling of the arterial wall, outwardly displacing the external, elastic membrane, without reduction in luminal diameter or serious impact on delivery of oxygen to the heart. Accordingly, patients can develop large, fibrous atherosclerotic lesions without luminal narrowing until late in the disease process. However, the coronary arterial lumen can become gradually narrowed over time and in some cases compromise blood flow to the heart, especially under high demand states such as exercise. This can result in reversible ischemia causing chest pain relieved by rest called stable angina.

In contrast to the relative stability of fibrous atherosclerotic lesions, the culprit lesions associated with myocardial infarction and unstable angina (each of which are part of the acute coronary syndrome) are characterized by a thin fibrous cap, a large lipid core, and infiltration of inflammatory cells such as T-lymphocytes and monocyte/macrophages. Non-invasive imaging techniques have shown that most MI's occur at sites with low- or intermediate- grade stenoses, indicating that coronary artery occlusion is due most frequently to rupture of culprit lesions with consequent formation of a thrombus or blood clot and not solely due to luminal narrowing by stenosis. Plaque rupture may be due to erosion or uneven thinning of the fibrous cap, usually at the margins of the lesion where macrophages enter, accumulate, and become activated by a local inflammatory process. Thinning of the fibrous cap may result from degradation of the extracellular matrix by proteases released from activated macrophages. These changes producing plaque instability and risk of MI may be augmented by production of tissue-factor procoagulant and other factors increasing the likelihood of thrombosis.

In acute coronary syndrome, the culprit lesion showing rupture or erosion with local thrombosis typically is treated by angioplasty or by balloon dilation and placement of a stent to maintain luminal patency. Patients experiencing ACS are at high risk for a second coronary event due to the multi-vessel nature of coronary artery disease with event rates approaching 10-14% within 12 months after the first incident.

The emerging view of MI is as an inflammatory disease of the arterial vessel wall on preexisting chronic atherosclerotic lesions, sometimes triggering rupture of culprit lesions and leading to local thrombosis and subsequent myocardial infarction. The process that triggers and sustains arterial wall inflammation leading to plaque instability is unknown, however, it results in the release into the circulation of tumor necrosis factor alpha and interleukin-6. These and other cytokines or biological mediators released from the damaged vessel wall stimulate an inflammatory response in the liver causing elevation in several non-specific general inflammatory markers including C-reactive protein. Although not specific to atherosclerosis, elevated C-reactive protein (CRP) and serum amyloid A appear to predict risk for MI, perhaps as surrogates for vessel wall inflammation. Many general inflammatory markers predict risk of coronary heart disease, although these markers are not specific to atherosclerosis. For example, Stein (Stein,

S., *Am J Cardiol*, 87 (suppl):21A-26A (2001)) discusses the use of any one of the following serum inflammatory markers as surrogates for predicting risk of coronary heart disease including C-reactive protein (CRP), serum amyloid A, fibrinogen, interleukin-6, tissue necrosis factor-alpha, soluble vascular cell adhesion molecules (sVCAM), soluble intervascular adhesion molecules (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, and matrix metalloprotease type-9. Elevation in one more of these serum inflammatory markers is not specific to coronary heart disease but also occurs with age or in association with cerebrovascular disease, peripheral vascular disease, non-insulin dependent diabetes, osteoarthritis, bacterial infection, and sepsis.

Elevated CRP or other serum inflammatory markers is also prognostic for increased risk of a second myocardial infarct in patients with a previous myocardial infarct (Retterstol, L. et al., *Atheroscler.*, 160: 433-440 (2002)).

Although classical risk factors such as smoking, hyperlipidemia, hypertension, and diabetes are associated with many cases of coronary heart disease (CHD) and MI, many patients do not have involvement of these risk factors. In fact, many patients who exhibit one or more of these risk factors do not develop MI. Family history has long been recognized as one of the major risk factors. Although some of the familial clustering of MI reflects the genetic contribution to the other conventional risk factors, a large number of studies have suggested that there are significant genetic susceptibility factors, beyond those of the known risk factors (Friedlander Y, et al., *Br. Heart J.* 1985; 53:382-7, Shea S. et al., *J. Am. Coll. Cardiol.* 1984; 4:793-801, and Hopkins P.N., et al., *Am. J. Cardiol.* 1988; 62:703-7). Major genetic susceptibility factors have only been identified for the rare Mendelian forms of hyperlipidemia such as a familial hypercholesterolemia.

Genetic risk is conferred by subtle differences in genes among individuals in a population. Genes differ between individuals most frequently due to single nucleotide polymorphisms (SNP), although other variations are also important. SNP are located on average every 1000 base pairs in the human genome. Accordingly, a typical human gene containing 250,000 base pairs may contain 250 different SNP. Only a minor number of SNPs are located in exons and alter the amino acid sequence of the protein encoded by the gene. Most SNPs may have little or no effect on gene function, while others may alter transcription, splicing, translation, or stability of the mRNA encoded by the gene. Additional genetic polymorphism in the human genome is caused by insertion, deletion, translocation, or inversion of either short or long stretches of DNA. Genetic polymorphisms conferring disease risk may therefore directly alter the amino acid sequence of proteins, may increase the amount of protein produced from the gene, or may decrease the amount of protein produced by the gene.

As genetic polymorphisms conferring risk of disease are uncovered, genetic testing for such risk factors is becoming important for clinical medicine. Examples are apolipoprotein E testing to identify genetic carriers of the apoE4 polymorphism in dementia patients for the

differential diagnosis of Alzheimer's disease, and of Factor V Leiden testing for predisposition to deep venous thrombosis. More importantly, in the treatment of cancer, diagnosis of genetic variants in tumor cells is used for the selection of the most appropriate treatment regime for the individual patient. In breast cancer, genetic variation in estrogen receptor expression or heregulin type 2 (Her2) receptor tyrosine kinase expression determine if anti-estrogenic drugs (tamoxifen) or anti-Her2 antibody (Herceptin) will be incorporated into the treatment plan. In chronic myeloid leukemia (CML) diagnosis of the Philadelphia chromosome genetic translocation fusing the genes encoding the Bcr and Abl receptor tyrosine kinases indicates that Gleevec (STI571), a specific inhibitor of the Bcr-Abl kinase should be used for treatment of the cancer. For CML patients with such a genetic alteration, inhibition of the Bcr-Abl kinase leads to rapid elimination of the tumor cells and remission from leukemia.

Restenosis

Coronary balloon angioplasty was introduced in the late 1970s as a less invasive method for revascularization of coronary artery disease patients than the coronary artery bypass graft (CABG) surgeries. Since then there has been a quick progress in the development of new percutaneous devices to revascularize areas with limited blood flow. However, the expanded use of angioplasty has shown that the arteries react to angioplasty by a proliferative process that limits the success of this treatment. This process is known as restenosis.

Restenosis is defined as a re-narrowing of the treated segment, which equals or exceeds 50% of the lumen in the adjacent normal segment of the artery. Depending on the patient population studied, the restenosis rates range from 30% to 44% of lesions treated by balloon dilation. This problem prompted a search for interventional techniques that minimizes the risk of restenosis. Several clinical trials have shown a significant reduction in the restenosis rates with endovascular stenting. The purpose of stenting is to maintain the arterial lumen by a scaffolding process that provides radial support. Stents, usually made of stainless steel, are placed in the artery either by a self-expanding mechanism or, using balloon expansion. However, in-stent restenosis still remains a major problem in the field of percutaneous, transluminal coronary angioplasty (PTCA), requiring patients to undergo repeated procedures and surgery. Restenosis is the result of the formation of neointima, a composition of smooth muscle-like cells in a collagen matrix. The current treatment modalities for in-stent restenosis include repeat balloon angioplasty, repeat stenting, cutting balloon angioplasty, directional coronary atherectomy, rotational coronary atherectomy, brachytherapy, and drug-eluting stents (DES). The restenosis problem can be minimised by local intravascular irradiation (intracoronary brachytherapy) and by the introduction of DES and these treatments have been shown to successfully preventing cell proliferation after stent implantation or angioplasty.

Intracoronary brachytherapy is a treatment in which sealed sources of radioactive material are used to deliver radiation at a very short distance by placing them in the artery lumen at the site of the atherosclerotic lesion. The physical benefit of brachytherapy is that

doses of radiation can be delivered almost directly to the target with a very rapid falloff of dose to the surrounding normal tissue. The rationale underlining this modality is based on the ability of ionizing radiation to inhibit cell proliferation, in this case, the proliferation of smooth muscle cells that tend to form a neointima. In the near future, it would be important to be able to classify patients with respect to the risk of having in-stent restenosis. This classification can potentially be made on the basis of genetic risk factors. The outcome of the classification may determine which therapy is most appropriate and also where coronary bypass surgery has to be considered.

Aneurysms

Degenerative changes of the arterial wall may cause localized dilatation, or aneurysm, of the artery, including abdominal aorta aneurysm (AAA) and intracranial aneurysm (IA). Atherosclerotic changes of the vessel wall are found in the majority of AAA that are characterized histopathologically by chronic inflammation, destructive remodelling of elastic media and depletion of medial smooth muscle cells resulting in marked weakening of the aortic wall. In contrast, berry aneurysms of intracranial arteries are not associated with atherosclerosis. Furthermore, the histopathological features of IA are different. The typical berry aneurysms of intracranial arteries, located at arterial bifurcations, have a thin, or no, media and the internal elastic lamina is either absent or severely fragmented.

Both AAA and IA represent a degenerative process of the arteries leading to their enlargement that is usually asymptomatic with natural history culminating in either a therapeutic intervention or rupture. Rupture of IA leads to subarachnoid haemorrhage, and rupture of both IA and AAA have high morbidity and mortality. In the case of AAA the rupture risk increases with the growth rate as well as the size of the aneurysm.

Intracranial aneurysm (IA), also called cerebral aneurysm or brain aneurysm is a cerebrovascular disorder in which weakness in the wall of a cerebral artery or vein causes a localized dilation or ballooning of the blood vessel.

A common location of cerebral aneurysms is on the arteries at the base of the brain, known as the Circle of Willis. Approximately 85% of cerebral aneurysms develop in the anterior part of the Circle of Willis, and involve the internal carotid arteries and their major branches that supply the anterior and middle sections of the brain. It is believed that aneurysms may result from congenital defects, preexisting conditions such as high blood pressure and atherosclerosis, or head trauma. Cerebral aneurysms occur more commonly in adults than in children but they may occur at any age.

Cerebral aneurysms are classified both by size and shape. Small aneurysms have a diameter of less than 15mm. Larger aneurysms include those classified as large (15 to 25mm),

giant (25 to 50mm), and super giant (over 50mm). Saccular aneurysms are those with a saccular outpouching and are the most common form of cerebral aneurysm. Berry aneurysms are saccular aneurysms with necks or stems resembling a berry. Fusiform aneurysms are aneurysms without stems.

- 5 A small, unchanging aneurysm will produce no symptoms. Before a larger aneurysm ruptures, the individual may experience such symptoms as a sudden and unusually severe headache, nausea, vision impairment, vomiting, and loss of consciousness, or the individual may be asymptomatic, experiencing no symptoms at all. Onset is usually sudden and without warning. Rupture of a cerebral aneurysm is dangerous and usually results in bleeding into the
- 10 meninges or the brain itself, leading to a subarachnoid hemorrhage (SAH) or intracranial hematoma (ICH), either of which constitutes a stroke. Rebleeding, hydrocephalus (the excessive accumulation of cerebrospinal fluid), vasospasm (spasm, or narrowing, of the blood vessels), or multiple aneurysms may also occur. The risk of rupture from an unruptured cerebral aneurysm varies according to the size of an aneurysm, with the risk rising as the aneurysm size increases.
- 15 The overall rate of aneurysm rupture is estimated at 1.3% per year. The risk of short term re-rupture increases dramatically after an aneurysm has bled, though after approximately 6 weeks the risk returns to baseline.

- Emergency treatment for individuals with a ruptured cerebral aneurysm generally includes restoring deteriorating respiration and reducing intracranial pressure. Currently there
- 20 are two treatment options for brain aneurysms: surgical clipping or endovascular coiling. Either surgical clipping or endovascular coiling is usually performed within the first three days to occlude the ruptured aneurysm and reduce the risk of rebleeding.

- The prognosis for a patient with a ruptured cerebral aneurysm depends on the extent and location of the aneurysm, the person's age, general health, and neurological condition. Some
- 25 individuals with a ruptured cerebral aneurysm die from the initial bleeding. Other individuals with cerebral aneurysm recover with little or no neurological deficit. The most significant factors in determining outcome are severity of the aneurysm and age.

- Abdominal aortic aneurysm (AAA)* is a localized dilatation of the abdominal aorta, that exceeds the normal diameter by more than 50%. The normal diameter of the infrarenal aorta is
- 30 2 cm. It is caused by a degenerative process of the aortic wall. The aneurysm is most commonly located infrarenally (90%), other possible locations are suprarenal and pararenal. The aneurysm can extend to include one or both of the iliac arteries. An aortic aneurysm may also occur in the thorax.

- AAA is uncommon in individuals of African, African American, Asian, and Hispanic
- 35 heritage. The frequency varies strongly between males and females. The peak incidence is among males around 70 years of age, the prevalence among males over 60 years totals 2-6%. The frequency is much higher in smokers than in non-smokers (8:1). Other risk factors include

hypertension and male sex. In the US, the incidence of AAA is 2-4% in the adult population. Rupture of the AAA occurs in 1-3% of men aged 65 or more, the mortality being 70-95%.

The exact causes of the degenerative process remain unclear. Known risk factors include genetic factors, hemodynamic influences, atherosclerosis, and various other factors such as infection, trauma, connective tissue disorders, arterities, etc. AAAs are commonly divided according to their size and symptomatology. An aneurysm is usually considered to be present if the measured outer aortic diameter is over 3 cm (normal diameter of aorta is around 2 cm). The natural history is of increasing diameter over time, followed eventually by the development of symptoms (usually rupture). If the outer diameter exceeds 5 cm, the aneurysm is considered to be large. For aneurysms under 5 cm, the risk of rupture is low, so that the risks of surgery usually outweigh the risk of rupture. Aneurysms less than 5cm are therefore usually kept under surveillance until such time as they become large enough to warrant repair, or develop symptoms. The vast majority of aneurysms are asymptomatic. The risk of rupture is high in a symptomatic aneurysm, which is therefore considered an indication for surgery. Possible symptoms include low back pain, flank pain, abdominal pain, groin pain or pulsating abdominal mass. The complications include rupture, peripheral embolisation, acute aortic occlusion, aortocaval or aortoduodenal fistulae. On physical examination, a palpable abdominal mass can be noted. Bruits can be present in case of renal or visceral arterial stenosis.

The main treatment options for asymptomatic AAA are immediate repair and surveillance with a view to eventual repair. Surveillance is indicated in small aneurysms, where the risk of repair exceeds the risk of rupture. As an AAA grows in diameter the risk of rupture increases. Although some controversy exists around the world, most vascular surgeons would not consider repair until the aneurysm reached a diameter of 5cm. The threshold for repair varies slightly from individual to individual, depending on the balance of risks and benefits when considering repair versus ongoing surveillance. The size of an individual's native aorta may influence this, along with the presence of comorbidities that increase operative risk or decrease life expectancy. Currently, the main modes of repair available for an AAA are open aneurysm repair (OR), and endovascular aneurysm repair (EVAR). Open repair is indicated in young patients as an elective procedure, or in growing or large, symptomatic or ruptured aneurysms. Open repair has been the mainstay of intervention from the 1950's until recently. Endovascular repair first became practical in the 1990's and although it is now an established alternative to open repair, its role is yet to be clearly defined. It is generally indicated in older, high-risk patients or patients unfit for open repair. However, endovascular repair is feasible for only a proportion of AAA's, depending on the morphology of the aneurysm. The main advantage over open repair is that the peri-operative period has less impact on the patient.

Stroke

Stroke is a group of diverse disorders encompassing several pathophysiological mechanisms. The clinical phenotype of stroke is complex but is broadly divided into: Ischemic

and hemorrhagic stroke. The majority of stroke events, appr 80%, is due to ischemia (cerebral infarction), that occurs when a cerebral artery becomes completely occluded and the blood supply to a part of the brain is totally or partially blocked (due to thrombosis or an embolism). Ischemic stroke is further subdivided into large artery disease (LAD) (also called large vessel disease, LVD), cardioembolic stroke and small vessel disease. Approximately 25% of ischemic stroke events are due to large-artery disease of the carotid and vertebral arteries, the two pairs of large arteries that supply the brain with blood. The most common cause of large-artery disease is atherosclerosis. Cardioembolic strokes are caused by an embolism that originates inside the heart. Embolism of cardiac origin accounts for about 1/4 of ischemic strokes. Strokes due to cardioembolism are in general severe and prone to early and long-term recurrence. Ischemic heart disease, rheumatic mitral stenosis, and prosthetic cardiac valves are major sources of cardioembolic stroke but atrial fibrillation remains the commonest cause.

There is a continued and great need to understand the genetic variants conferring risk (increased and decreased) of the cardiovascular diseases. The present invention provides genetic variants that have been shown to be associated with susceptibility to cardiovascular disease, including MI, Coronary Artery Disease (CAD), Intracranial aneurysm (IA), Abdominal Aorta Aneurysm (AAA), Peripheral Arterial Disease (PAD) and Restenosis. These variants are useful in risk management and methods for therapeutic intervention of cardiovascular diseases.

SUMMARY OF THE INVENTION

The present invention relates to methods of determining a susceptibility to cardiovascular diseases, including Coronary Artery Disease, Myocardial Infarction, Peripheral Artery Disease, Stroke, Restenosis, Intracranial Aneurysm and Abdominal Aorta Aneurysm. The invention also relates to various uses, kits, procedures and apparatus useful in the determination of a susceptibility to cardiovascular disease based on evaluation of certain polymorphic markers and/or haplotypes that have been found to be associated with susceptibility to cardiovascular disease.

In one aspect, the invention relates to a method for determining a susceptibility to cardiovascular disease in a human individual, comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual or in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the polymorphic markers set forth in Table 10, and markers in linkage disequilibrium therewith, and wherein the presence of the at least one allele is indicative of a susceptibility to cardiovascular disease. The method may in one embodiment relate to determination of the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual. In another embodiment, the method relates to determination of the presence or absence of at least one

allele of at least one polymorphic marker in a genotype dataset derived from the individual. The genotype dataset is derived from the individual in the sense that the information that is relates to a particular nucleic acid sample as a template relates to a single individual, for whom genetic information is derived.

5 In another aspect, the present invention relates to a method of determining a susceptibility to cardiovascular disease in a human individual, comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, wherein the at least one polymorphic marker is selected from markers associated with LD Block C09 (SEQ ID NO:94), wherein determination of the
10 presence or absence of the at least one allele is indicative of a susceptibility to cardiovascular disease. In one embodiment, the at least one polymorphic marker is selected from the markers set forth in Table 3, and markers in linkage disequilibrium therewith.

In an alternative aspect, the invention relates to a method of diagnosing a susceptibility to Cardiovascular Disease in a human individual, the method comprising determining the
15 presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, or in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the group of markers associated with LD block C09, wherein the presence of the at least one allele is indicative of a susceptibility to Cardiovascular Disease. In one embodiment, linkage disequilibrium is used as a quantitative
20 measure of the degree to which specific markers are associated with LD Block C09.

In another aspect, the invention relates to a method of determining a susceptibility to cardiovascular disease in a human individual, comprising determining whether at least one at-risk allele in at least one polymorphic marker is present in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the markers within the
25 LD Block C09 (SEQ ID NO:94), and markers in linkage disequilibrium therewith, and wherein determination of the presence of the at least one at-risk allele is indicative of increased susceptibility to cardiovascular disease in the individual.

The genotype dataset comprises in one embodiment information about marker identity, and the allelic status of the individual, i.e. information about the identity of the two alleles
30 carried by the individual for the marker. The genotype dataset may comprise allelic information about one or more marker, including two or more markers, three or more markers, five or more markers, one hundred or more markers, etc. In some embodiments, the genotype dataset comprises genotype information from a whole-genome assessment of the individual including hundreds of thousands of markers, or even one million or more markers.

35 In one embodiment, the at least one polymorphic marker is present within the genomic segment LD Block C09, with the nucleotide sequence as set forth in SEQ ID NO:94. In another embodiment, the at least one polymorphic marker comprises at least one marker selected from rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970,

rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, rs10757278, rs10757274, rs1333049, D9S1870, and markers in linkage disequilibrium therewith. In another embodiment, the at least one polymorphic marker is selected from rs10757278, rs10757274, and rs10333049, and markers in linkage disequilibrium therewith. In another embodiment, the at least one
 5 polymorphic marker comprises at least one marker in strong linkage disequilibrium, as defined by numeric values for $|D' |$ of greater than 0.8 and/or r^2 of greater than 0.2, with one or more markers selected from the group consisting of the markers set forth in Table 3.

In one embodiment, the method of determining a susceptibility, or diagnosing a susceptibility of, cardiovascular disease, further comprises assessing the frequency of at least
 10 one haplotype in the individual. In one such embodiment, the at least one haplotype is selected from the haplotypes that comprise at least one polymorphic marker within the genomic segment LD Block C09 (SEQ ID NO:94). In another embodiment, the at least one haplotype is selected from haplotypes that are in linkage disequilibrium with at least one marker as set forth in Table 3. In another embodiment, the at least one haplotype is selected from the haplotypes that
 15 comprise at least one polymorphic marker selected from at least one marker selected from rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970, rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, rs10757278, rs10757274, rs1333049, D9S1870, and markers in linkage disequilibrium therewith.

In another aspect, the invention relates to a method of determining a susceptibility to
 20 Cardiovascular disease in a human individual, comprising determining whether at least one at-risk allele in at least one polymorphic marker is present in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the markers set forth in Table 3, and markers in linkage disequilibrium therewith, and wherein determination of the presence of the at least one at-risk allele is indicative of increased susceptibility to
 25 Cardiovascular disease in the individual. The genotype dataset comprises in one embodiment information about marker identity, and the allelic status of the individual, i.e. information about the identity of the two alleles carried by the individual for the marker. The genotype dataset may comprise allelic information about one or more marker, including two or more markers, three or more markers, five or more markers, one hundred or more markers, etc. In some
 30 embodiments, the genotype dataset comprises genotype information from a whole-genome assessment of the individual including hundreds of thousands of markers, or even one million or more markers.

In one embodiment, the at least one polymorphic marker is present within SEQ ID NO:94, as set forth herein. In another embodiment, the at least one polymorphic marker
 35 comprises at least one marker selected from rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970, rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, rs10757278, rs10757274, rs1333049, D9S1870, and markers in linkage disequilibrium therewith. In another embodiment, the at least one polymorphic marker comprises at least one marker in strong linkage disequilibrium, as defined by numeric values for $|D' |$ of greater than 0.8

and/or r^2 of greater than 0.2, with one or more markers selected from the group consisting of the markers set forth in Table 3. In one preferred embodiment, the at least one polymorphic marker is selected from markers rs10757278, rs10757274, and rs1333049, and markers in linkage disequilibrium therewith. In another preferred embodiment, the at least one polymorphic marker is selected from markers rs10757278, rs10757274, and rs1333049. In yet another embodiment, the at least one polymorphic marker is selected from markers associated with LD Block C09 (SEQ ID NO:94). In one such embodiment, the at least one polymorphic marker is in linkage disequilibrium with at least one polymorphic marker within LD Block C09 (SEQ ID NO:94).

In one embodiment, the method of determining a susceptibility, or diagnosing a susceptibility of, Cardiovascular disease, further comprises assessing the frequency of at least one haplotype in the individual. In one such embodiment, the at least one haplotype is selected from the haplotypes that comprise at least one polymorphic marker as set forth in Table 10, and polymorphic markers in linkage disequilibrium therewith. In another embodiment, the at least one haplotype is selected from the haplotypes that comprise at least one polymorphic marker as set forth in Table 3, and polymorphic markers in linkage disequilibrium therewith. In another embodiment, the at least one haplotype is selected from the haplotypes that comprise at least one polymorphic marker selected from rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970, rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, rs10757278, rs10757274, rs10333049, D9S1870, and markers in linkage disequilibrium therewith.

In certain embodiments of the invention, determination of the presence of at least one at-risk allele of at least one polymorphic marker in a nucleic acid sample from the individual is indicative of an increased susceptibility to the Cardiovascular disease. In one embodiment, the increased susceptibility is characterized by a relative risk (RR) or odds ratio (OR) of at least 1.15. In another embodiment, the increased susceptibility is characterized by a relative risk (RR) or odds ratio (OR) of at least 1.20. In another embodiment, the increased susceptibility is characterized by a relative risk (RR) or odds ratio (OR) of at least 1.30.

In some embodiments, the presence of rs7041637 allele A, rs2811712 allele A, rs3218018 allele A, rs3217992 allele A, rs2069426 allele C, rs2069422 allele A, rs1333034 allele A, rs1011970 allele G, rs10116277 allele T, rs1333040 allele T, rs2383207 allele G, rs1333050 allele T, D9S1814 allele O, rs10757278 allele G, rs1333049 allele C, rs10757274 allele G, and/or D9S1870 allele X (composite allele of all alleles smaller than 2) is indicative of increased susceptibility of the Cardiovascular disease.

In particular embodiments, the presence of at least one protective allele in a nucleic acid sample from the individual is indicative of a decreased susceptibility of Cardiovascular disease. In another embodiment, the absence of at least one at-risk allele in a nucleic acid sample from the individual is indicative of a decreased susceptibility of Cardiovascular disease.

Another aspect of the invention relates to a method of assessing a susceptibility to Cardiovascular disease in a human individual, comprising screening a nucleic acid from the individual for at least one polymorphic marker or haplotype in the genomic segment with the sequence as set forth in SEQ ID NO:94, that correlates with increased occurrence of

Cardiovascular disease in a human population, wherein the presence of an at-risk marker allele in the at least one polymorphism or an at-risk haplotype in the nucleic acid identifies the individual as having elevated susceptibility to the Cardiovascular disease, and wherein the absence of the at least one at-risk marker allele or at-risk haplotype in the nucleic acid identifies the individual as not having the elevated susceptibility.

In one such embodiment, the at least one polymorphic marker or haplotype comprises at least one polymorphic marker selected from the markers set forth in Table 10, and polymorphic markers in linkage disequilibrium therewith. In another embodiment, the at least one marker or haplotype comprises at least one polymorphic marker selected from the markers set forth in Table 3, and polymorphic markers in linkage disequilibrium therewith. In another embodiment, the at least one polymorphic marker or haplotype comprises at least one polymorphic marker selected from the markers rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970, rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, rs10757278, rs10757274, rs10333049, D9S1870, and markers in linkage disequilibrium therewith. In certain embodiments, linkage disequilibrium is characterized by numeric values for $|D'|$ of greater than 0.8 and/or r^2 of greater than 0.2.

Certain embodiments of the invention further comprise a step of screening the nucleic acid for the presence of at least one at-risk genetic variant for a Cardiovascular disease not associated with LD Block C09 (SEQ ID NO:94). Such additional genetic variants can in specific embodiments include any variant that has been identified as a susceptibility or risk variant for Cardiovascular disease.

In another aspect of the present invention, the presence of the marker or haplotype found to be associated with Cardiovascular disease, and as such useful for determining a susceptibility to Cardiovascular disease, is indicative of a different response rate of the subject to a particular treatment modality for Cardiovascular disease.

In another aspect, the invention relates to a method of identification of a marker for use in assessing susceptibility to a Cardiovascular disease in human individuals, the method comprising:

identifying at least one polymorphic marker in linkage disequilibrium with at least one of the markers within LD Block C09 (SEQ ID NO:94);

determining the genotype status of a sample of individuals diagnosed with, or having a susceptibility to, Cardiovascular disease; and

determining the genotype status of a sample of control individuals;

wherein a significant difference in frequency of at least one allele in at least one polymorphism in individuals diagnosed with, or having a susceptibility to, the Cardiovascular disease, as compared with the frequency of the at least one allele in the control sample is indicative of the at least one polymorphism being useful for assessing susceptibility to the Cardiovascular disease.

In one embodiment, "significant" is determined by statistical means, e.g. the difference is statistically significant. In one such embodiment, statistical significance is characterized by a P-value of less than 0.05. In other embodiments, the statistical significance is characterized a P-value of less than 0.01, less than 0.001, less than 0.0001, less than 0.00001, less than 0.000001, less than 0.0000001, less than 0.000000001, or less than 0.000000001.

In one embodiment, the at least one polymorphic marker is in linkage disequilibrium, as characterized by numerical values of r^2 of greater than 0.2 and/or $|D'|$ of greater than 0.8 with at least one marker selected from markers set forth in Table 21. In another embodiment, the at least one polymorphic marker is in linkage disequilibrium, as characterized by numerical values of r^2 of greater than 0.2 and/or $|D'|$ of greater than 0.8 with at least one marker selected from markers rs10757276, rs10757274, and rs1333049.

In one embodiment, an increase in frequency of the at least one allele in the at least one polymorphism in individuals diagnosed with, or having a susceptibility to, a Cardiovascular disease, as compared with the frequency of the at least one allele in the control sample, is indicative of the at least one polymorphism being useful for assessing increased susceptibility to the Cardiovascular disease. In another embodiment, a decrease in frequency of the at least one allele in the at least one polymorphism in individuals diagnosed with, or having a susceptibility to, a Cardiovascular disease, as compared with the frequency of the at least one allele in the control sample is indicative of the at least one polymorphism being useful for assessing decreased susceptibility to, or protection against, the Cardiovascular disease.

Another aspect of the invention relates to a method of genotyping a nucleic acid sample obtained from a human individual, comprising determining the presence or absence of at least one allele of at least one polymorphic marker in the sample, wherein the at least one marker is selected from the markers set forth in Table 3 and Table 21, and markers in linkage disequilibrium therewith, and wherein determination of the presence or absence of the at least one allele of the at least one polymorphic marker is predictive of a susceptibility of a Cardiovascular disease.

In one embodiment, genotyping comprises amplifying a segment of a nucleic acid that comprises the at least one polymorphic marker by Polymerase Chain Reaction (PCR), using a nucleotide primer pair flanking the at least one polymorphic marker. In another embodiment, genotyping is performed using a process selected from allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, nucleic acid sequencing, 5'-exonuclease

digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation analysis. In one particular embodiment, the process comprises allele-specific probe hybridization. In another embodiment, the process comprises DNA sequencing. In a preferred embodiment, the method comprises:

- 1) contacting copies of the nucleic acid with a detection oligonucleotide probe and an enhancer oligonucleotide probe under conditions for specific hybridization of the oligonucleotide probe with the nucleic acid;

wherein

 - a) the detection oligonucleotide probe is from 5-100 nucleotides in length and specifically hybridizes to a first segment of the nucleic acid whose nucleotide sequence is given by SEQ ID NO:94 that comprises at least one polymorphic site;
 - b) the detection oligonucleotide probe comprises a detectable label at its 3' terminus and a quenching moiety at its 5' terminus;
 - c) the enhancer oligonucleotide is from 5-100 nucleotides in length and is complementary to a second segment of the nucleotide sequence that is 5' relative to the oligonucleotide probe, such that the enhancer oligonucleotide is located 3' relative to the detection oligonucleotide probe when both oligonucleotides are hybridized to the nucleic acid; and
 - d) a single base gap exists between the first segment and the second segment, such that when the oligonucleotide probe and the enhancer oligonucleotide probe are both hybridized to the nucleic acid, a single base gap exists between the oligonucleotides;
- 2) treating the nucleic acid with an endonuclease that will cleave the detectable label from the 3' terminus of the detection probe to release free detectable label when the detection probe is hybridized to the nucleic acid; and
- 3) measuring free detectable label, wherein the presence of the free detectable label indicates that the detection probe specifically hybridizes to the first segment of the nucleic acid, and indicates the sequence of the polymorphic site as the complement of the detection probe.

In a particular embodiment, the copies of the nucleic acid are provided by amplification by Polymerase Chain Reaction (PCR). In another embodiment, the susceptibility determined is increased susceptibility. In another embodiment, the susceptibility determined is decreased susceptibility.

Another aspect of the invention relates to a method of assessing an individual for probability of response to a therapeutic agent for preventing and/or ameliorating symptoms associated with a Cardiovascular disease, comprising: determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, wherein the at least one polymorphic marker is selected from the markers set forth in Table 21, and markers in linkage disequilibrium therewith, wherein determination of the presence of the at least one allele of the at least one marker is indicative of a probability of a positive response to the Cardiovascular disease therapeutic agent. In one embodiment, the at least one polymorphic marker is selected from marker rs1333040, rs10116277, rs2383207 and rs10757278, and markers in linkage disequilibrium therewith. In one embodiment, the therapeutic agent is selected from beta blockers, anticoagulation agents, including heparin and/or low molecular weight heparin, antiplatelet agents, such as clopidogrel, aspirin, beta blockers, including metoprolol and carvedilol, ACE inhibitors, Statins, Aldosterone antagonists, including eplerenone, leukotriene synthesis inhibitors, the agents set forth in Agent Table I, Agent Table II, (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, atreleuton, and 4-((S)-2-[4-(4-Chloro-phenoxy)-phenoxyethyl]-pyrrolidin-1-yl)-butyramide, also known as DG-051. Other embodiments may include any one or a combination of the therapeutic agents described herein to be useful for therapeutic intervention of Cardiovascular disease.

Yet another aspect of the invention relates to a method of predicting prognosis of an individual diagnosed with, a Cardiovascular disease, the method comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, wherein the at least one polymorphic marker is selected from the group consisting of rs1333040, rs10116277, rs2383207 and rs10757278, and markers in linkage disequilibrium therewith, wherein determination of the presence of the at least one allele is indicative of a worse prognosis of the Cardiovascular disease in the individual. The prognosis may in certain embodiment relate to susceptibility of recurrent MI events, recurrent stroke events, or susceptibility to other complications relating to a Cardiovascular disease.

A further aspect of the invention relates to a method of monitoring progress of a treatment of an individual undergoing treatment for a Cardiovascular disease, the method comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, wherein the at least one polymorphic marker is selected from the group consisting of rs1333040, rs10116277, rs2383207 and rs10757278, and markers in linkage disequilibrium therewith, wherein determination of the presence of the at least one allele is indicative of the treatment outcome of the individual. The treatment may in certain embodiments be surgical treatment. In other embodiments, the treatment is by administration of a therapeutic agent, optionally including lifestyle changes or alterations in environmental exposure to risk factors for cardiovascular disease, as described further herein.

In one embodiment, the method further comprises assessing at least one biomarker in a sample from the individual. The biomarker is in certain embodiments a cardiac marker or an inflammatory marker. In one embodiment, the at least one biomarker is selected from creatin kinase, troponin, glycogen phosphorylase, C-reactive protein (CRP), serum amyloid A, fibrinogen, interleukin-6, tissue necrosis factor-alpha, soluble vascular cell adhesion molecules (sVCAM), soluble intervascular adhesion molecules (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, matrix metalloprotease type-9, serum sCD40L, leukotrienes, leukotriene metabolites, interleukin-6, tissue necrosis factor-alpha, myeloperoxidase (MPO), and N-tyrosine. In one embodiment, the leukotriene is selected from LTB₄, LTC₄, LTD₄ and LTE₄. In another embodiment, the method further comprises analyzing non-genetic information to make risk assessment, diagnosis, or prognosis of the individual. The non-genetic information is in one embodiment selected from age, gender, ethnicity, socioeconomic status, previous disease diagnosis, medical history of subject, family history of Cardiovascular disease, biochemical measurements, and clinical measurements. In a particular preferred embodiment, a further step comprising calculating overall risk is employed.

Another aspect of the invention relates to analyzing a sample comprising genomic DNA from a human individual or a genotype dataset derived from a human individual for the presence or absence of at least one at-risk allele of at least one at-risk variant for cardiovascular disease not in linkage disequilibrium with any one of the markers set forth in Table 10. Thus, the variants described herein to be associated with Cardiovascular disease may be combined with other genetic variants for Cardiovascular disease, that are not genetically related (i.e., not in linkage disequilibrium with) the markers described herein. Such analysis may be undertaken in combination with any of the methods described herein. Furthermore any two markers herein, or any other combination of markers and/or haplotypes described herein to be associated with cardiovascular disease may be combined to assess an increased susceptibility to cardiovascular disease.

In some embodiments of the methods of the invention, non-genetic information is analyzed, to make risk assessment, diagnosis, or prognosis of the individual. The non-genetic information is in certain embodiments selected from age, gender, ethnicity, socioeconomic status, previous disease diagnosis, medical history of subject, family history of cardiovascular disease, biochemical measurements, and clinical measurements. Combined genetic factors and/or combinations of genetic and non-genetic factors may be analyzed by known methods, to generate a combined risk.

The invention also relates to a kit for assessing susceptibility to a Cardiovascular disease in a human individual, the kit comprising reagents for selectively detecting the presence or absence of at least one allele of at least one polymorphic marker in the genome of the individual, wherein the polymorphic marker is selected from the markers set forth in Tables 10,, and markers in linkage disequilibrium therewith, and wherein the presence of the at least one allele is indicative of a susceptibility to a Cardiovascular diseases.

In one embodiment, the at least one polymorphic marker is present within the genomic segment with the sequence as set forth in SEQ ID NO:94. In another embodiment, the at least one polymorphic marker is selected from the group of markers set forth in Table 21, and markers in linkage disequilibrium therewith. In another embodiment, the at least one
5 polymorphic markers is selected from rs1333040, rs10116277, rs2383207 and rs10757278, and markers in linkage disequilibrium therewith.

In one embodiment, the reagents comprise at least one contiguous oligonucleotide that hybridizes to a fragment of the genome of the individual comprising the at least one polymorphic marker, a buffer and a detectable label. In one embodiment, the reagents comprise at least one
10 pair of oligonucleotides that hybridize to opposite strands of a genomic nucleic acid segment obtained from the subject, wherein each oligonucleotide primer pair is designed to selectively amplify a fragment of the genome of the individual that includes one polymorphic marker, and wherein the fragment is at least 30 base pairs in size. In a particular embodiment the at least one oligonucleotide is completely complementary to the genome of the individual. In another
15 embodiment, the at least one oligonucleotide can comprise at least one mismatch to the genome of the individual. In one embodiment, the oligonucleotide is about 18 to about 50 nucleotides in length. In another embodiment, the oligonucleotide is 20-30 nucleotides in length.

In one preferred embodiment, the kit comprises:

a detection oligonucleotide probe that is from 5-100 nucleotides in length; an enhancer
20 oligonucleotide probe that is from 5-100 nucleotides in length; and an endonuclease enzyme;

wherein the detection oligonucleotide probe specifically hybridizes to a first segment of the nucleic acid whose nucleotide sequence is given by SEQ ID NO:94 that comprises at least one polymorphic site; and wherein the detection oligonucleotide probe comprises a detectable label at its 3' terminus and a quenching moiety at its 5' terminus; wherein the enhancer
25 oligonucleotide is from 5-100 nucleotides in length and is complementary to a second segment of the nucleotide sequence that is 5' relative to the oligonucleotide probe, such that the enhancer oligonucleotide is located 3' relative to the detection oligonucleotide probe when both oligonucleotides are hybridized to the nucleic acid; wherein a single base gap exists between the first segment and the second segment, such that when the oligonucleotide probe and the
30 enhancer oligonucleotide probe are both hybridized to the nucleic acid, a single base gap exists between the oligonucleotides; and wherein treating the nucleic acid with the endonuclease will cleave the detectable label from the 3' terminus of the detection probe to release free detectable label when the detection probe is hybridized to the nucleic acid.

A further aspect of the invention relates to the use of an oligonucleotide probe in the
35 manufacture of a diagnostic reagent for diagnosing and/or assessing susceptibility to Cardiovascular disease in a human individual, wherein the probe hybridizes to a segment of a nucleic acid whose nucleotide sequence is given by SEQ ID NO: 94 that comprises at least one polymorphic site, wherein the fragment is 15-500 nucleotides in length. In one embodiment, the

polymorphic site is selected from the polymorphic markers rs1333040, rs10116277, rs2383207 and rs10757278, and markers in linkage disequilibrium therewith

Yet another aspect of the invention relates to a computer-readable medium on which is stored: an identifier for at least one polymorphic marker; an indicator of the frequency of at least one allele of said at least one polymorphic marker in a plurality of individuals diagnosed with a Cardiovascular disease; and an indicator of the frequency of the least one allele of said at least one polymorphic markers in a plurality of reference individuals; wherein the at least one polymorphic marker is selected from the polymorphic markers set forth in Table 10, and markers in linkage disequilibrium therewith. In one embodiment, the at least one polymorphic marker is selected from rs1333040, rs10116277, rs2383207 and rs10757278, and markers in linkage disequilibrium therewith.

Another aspect relates to an apparatus for determining a genetic indicator for Type 2 diabetes in a human individual, comprising: a computer readable memory; and a routine stored on the computer readable memory; wherein the routine is adapted to be executed on a processor to analyze marker and/or haplotype information for at least one human individual with respect to at least one polymorphic marker selected from the markers set forth in Table 10, and markers in linkage disequilibrium therewith, and generate an output based on the marker or haplotype information, wherein the output comprises a risk measure of the at least one marker or haplotype as a genetic indicator of a Cardiovascular disease for the human individual.

In one embodiment, the routine further comprises an indicator of the frequency of at least one allele of at least one polymorphic marker or at least one haplotype in a plurality of individuals diagnosed with a Cardiovascular disease, and an indicator of the frequency of at the least one allele of at least one polymorphic marker or at least one haplotype in a plurality of reference individuals, and wherein a risk measure is based on a comparison of the at least one marker and/or haplotype status for the human individual to the indicator of the frequency of the at least one marker and/or haplotype information for the plurality of individuals diagnosed with the Cardiovascular disease.

The present invention, as described herein, may be reduced to practice using any one, or a combination of, the polymorphic markers described herein as being useful for the determination of a susceptibility to cardiovascular disease. This includes markers that are shown herein to be associated with cardiovascular disease, but also includes markers that are in linkage disequilibrium with such variants. In one embodiment, the at least one marker is selected from the markers set forth in any of the Tables 3, 10, 21 and 26. In another embodiment, the at least one marker is selected from the markers set forth in Table 10. In another embodiment, the at least one marker is selected from the markers set forth in Table 3 and Table 21. In another embodiment, the at least one marker is selected from the markers set forth in Table 3. In another embodiment, the at least one marker is selected from the markers set forth in Table 21. In another embodiment, the at least one marker is selected from markers in linkage

disequilibrium with the CDKN2A and/or CDKN2B genes. In another embodiment, the at least one marker is selected from the markers rs10811650, rs10116277, rs1333040, rs10738607, rs4977574, rs6475608, D9S1870, rs2383207, rs1333045, rs1333046, rs10757278 and rs1333048. In another embodiment, the at least one marker is selected from the markers
 5 rs1333040, rs10116277, rs2383207 and rs10757278. In another embodiment the at least one marker is rs1333040 (SEQ ID NO:59). In another embodiment, the at least one marker is rs10116277 (SEQ ID NO:56). In another embodiment, the at least one marker is rs2383207 (SEQ ID NO:82). In another embodiment, the at least one marker is rs10757278 (SEQ ID NO:88). In some embodiments, the at least one marker is further optionally selected from
 10 markers in linkage disequilibrium with any one or a combination of more than one of the above mentioned markers.

The Cardiovascular disease in the various aspects of the invention relating to methods, uses, apparatus or kits is in some embodiments an arterial disease. In one such embodiment, the arterial disease phenotype is selected from Myocardial Infarction, Acute Coronary Syndrome
 15 (ACS), Coronary Artery Disease, Stroke, Peripheral Artery Disease, Restenosis, Intracranial Aneurysm and Aorta Abdominal Aneurysm, transluminal coronary angioplasty (PTCA), and coronary artery bypass surgery (CABG). In one embodiment, the Cardiovascular disease is Myocardial Infarction. In another embodiment, the Cardiovascular disease is Myocardial Infarction or Coronary Artery Disease. In yet another embodiment, the Cardiovascular disease is
 20 Myocardial Infarction, Coronary Artery Disease, Aorta Abdominal Aneurysm or Intracranial Aneurysm. In another embodiment, the Cardiovascular Disease is Myocardial Infarction, Coronary Artery Disease, Restenosis, Aorta Abdominal Aneurysm or Intracranial Aneurysm. In one embodiment, the Stroke phenotype is Large Artery Atherosclerotic Stroke and/or Cardiogenic Stroke. The Restenosis phenotype is in one embodiment Coronary In-stent
 25 Restenosis. In certain embodiments, the In-stent Restenosis is either Restenosis following Bare Metal Stent (BMS) placement, or it is Restenosis following placement of a Drug Eluting Stent (DES).

Variants (markers and/or haplotypes comprising polymorphic markers) in linkage disequilibrium with the markers and haplotypes of the present invention are also useful for the
 30 methods and kits of the invention. The invention therefore also pertains to markers in linkage disequilibrium with the markers and haplotypes of the invention. In certain embodiments of the methods, uses, apparatus or kits of the invention, linkage disequilibrium is characterized by specific cutoff values for a quantitative measure of linkage disequilibrium. In one such embodiment, linkage disequilibrium is characterized by specific cutoff values for r^2 . In another
 35 such embodiment, linkage disequilibrium is characterized by specific cutoff values for $|D'|$. In yet another embodiment, linkage disequilibrium is characterized by specific cutoff values for r^2 and $|D'|$. In one preferred embodiment, linkage disequilibrium is characterized by values for r^2 of greater than 0.1. In another preferred embodiment, linkage disequilibrium is characterized by values for r^2 of greater than 0.2. Other cutoff values for r^2 are also possible, including, but not
 40 limited to, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 0.95, 0.96, 0.97, 0.98, 0.99. In another preferred

embodiment, linkage disequilibrium is characterized by values for $|D'|$ of greater than 0.5. In another preferred embodiment, linkage disequilibrium is characterized by values for $|D'|$ of greater than 0.8. Other cutoff values for $|D'|$ are also possible, including, but not limited to, 0.2, 0.3, 0.4, 0.6, 0.7, 0.8, 0.9, 0.95, 0.96, 0.97, 0.98 and 0.99. In certain embodiments, linkage disequilibrium is characterized by numeric cutoff values for either $|D'|$ and r^2 . In one such embodiment linkage disequilibrium is characterized by numeric cutoff values for either $|D'|$ of greater than 0.8 and r^2 of greater than 0.2, or both.

In certain other embodiments of the methods, uses, apparatus or kits of the invention, the individual is of a specific human ancestry. In one embodiment, the ancestry is selected from black African ancestry, Caucasian ancestry and Chinese ancestry. In another embodiment, the ancestry is black African ancestry. In another embodiment, the ancestry is African American ancestry. In another embodiment, the ancestry is European ancestry. In another embodiment, the ancestry is Caucasian ancestry. The ancestry is in certain embodiment self-reported by the individual who undergoes genetic analysis or genotyping. In other embodiments, the ancestry is determined by genetic determination comprising detecting at least one allele of at least one polymorphic marker in a nucleic acid sample from the individual, wherein the presence or absence of the allele is indicative of the ancestry of the individual.

In other particular other embodiments of the methods, uses, apparatus or kits of the invention, the presence of at least one at-risk variant, i.e. an at-risk allele in at least one polymorphic marker or an at-risk haplotype, is indicative of an early onset of the Cardiovascular disease. Early onset is in some embodiments categorized as onset before age 75. In other embodiments, early onset is categorized as onset before age 70, before age 65, before age 60, before age 55, before age 50, before age 45, or before age 40. Other values for categorization of age at onset are also contemplated, including, but not limited to, all integer values of age, and such age categories are also within scope of the invention. In certain embodiments, the Cardiovascular disease is Myocardial Infarction, and the age at onset is below 50 for males and/or below 60 for females.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention.

FIG. 1 shows a) Association results for 127 SNPs located in a 1 Mb interval (21.6 – 22.6 Mb, Build 34) on chromosome 9. Plotted is $-\log P$, where P is the P -value adjusted for relatedness of the individual against the chromosomal location of the SNPs. b) The corresponding pair-wise correlation r^2 between 1004 common SNPs in the same region from the HapMap release 19 for

the CEU population. c) Location of two recombination hot-spots based on the HapMap dataset (*Nature* 437, 1299-1320 (27 October 2005)) that define the LD-block (position 21,920,147 to 21,149,982 in NCBI Build 36; SEQ ID NO:94 that includes the strongest association results. d) The pair-wise correlation structure in the region measured by D' for the same set of SNPs as used in panel b. All four panel use the same horizontal Mb scale indicated in panel a.

DETAILED DESCRIPTION OF THE INVENTION

A description of preferred embodiments of the invention follows.

10 Definitions

Unless otherwise indicated, nucleic acid sequences are written left to right in a 5' to 3' orientation. Numeric ranges recited within the specification are inclusive of the numbers defining the range and include each integer or any non-integer fraction within the defined range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by the ordinary person skilled in the art to which the invention pertains.

The following terms shall, in the present context, have the meaning as indicated:

A "polymorphic marker", sometime referred to as a "marker", as described herein, refers to a genomic polymorphic site. Each polymorphic marker has at least two sequence variations characteristic of particular alleles at the polymorphic site. Thus, genetic association to a polymorphic marker implies that there is association to at least one specific allele of that particular polymorphic marker. The marker can comprise any allele of any variant type found in the genome, including SNPs, microsatellites, insertions, deletions, duplications and translocations.

An "allele" refers to the nucleotide sequence of a given locus (position) on a chromosome. A polymorphic marker allele thus refers to the composition (i.e., sequence) of the marker on a chromosome. Genomic DNA from an individual contains two alleles (e.g., allele-specific sequences) for any given polymorphic marker, representative of each copy of the marker on each chromosome. Sequence codes for nucleotides used herein are: A = 1, C = 2, G = 3, T = 4. For microsatellite alleles, the CEPH sample (Centre d'Etudes du Polymorphisme Humain, genomics repository, CEPH sample 1347-02) is used as a reference, the shorter allele of each microsatellite in this sample is set as 0 and all other alleles in other samples are numbered in relation to this reference. Thus, e.g., allele 1 is 1 bp longer than the shorter allele in the CEPH sample, allele 2 is 2 bp longer than the shorter allele in the CEPH sample, allele 3 is 3 bp longer than the lower allele in the CEPH sample, etc., and allele -1 is 1 bp shorter than the shorter

allele in the CEPH sample, allele -2 is 2 bp shorter than the shorter allele in the CEPH sample, etc.

Sequence conucleotide ambiguity as described herein is as proposed by IUPAC-IUB. These codes are compatible with the codes used by the EMBL, GenBank, and PIR databases.

IUB code	Meaning
A	Adenosine
C	Cytidine
G	Guanine
T	Thymidine
R	G or A
Y	T or C
K	G or T
M	A or C
S	G or C
W	A or T
B	C G or T
D	A G or T
H	A C or T
V	A C or G
N	A C G or T (Any base)

5

A nucleotide position at which more than one sequence is possible in a population (either a natural population or a synthetic population, e.g., a library of synthetic molecules) is referred to herein as a "polymorphic site".

10 A "Single Nucleotide Polymorphism" or "SNP" is a DNA sequence variation occurring when a single nucleotide at a specific location in the genome differs between members of a species or between paired chromosomes in an individual. Most SNP polymorphisms have two alleles. Each individual is in this instance either homozygous for one allele of the polymorphism (i.e. both chromosomal copies of the individual have the same nucleotide at the SNP location), or the individual is heterozygous (i.e. the two sister chromosomes of the individual contain different
15 nucleotides). The SNP nomenclature as reported herein refers to the official Reference SNP (rs) ID Identification tag as assigned to each unique SNP by the National Center for Biotechnological Information (NCBI).

20 A "variant", as described herein, refers to a segment of DNA that differs from the reference DNA. A "marker" or a "polymorphic marker", as defined herein, is a variant. Alleles that differ from the reference are referred to as "variant" alleles.

A "microsatellite" is a polymorphic marker that has multiple small repeats of bases that are 2-8 nucleotides in length (such as CA repeats) at a particular site, in which the number of repeat lengths varies in the general population. An "indel" is a common form of polymorphism comprising a small insertion or deletion that is typically only a few nucleotides long.

A "haplotype," as described herein, refers to a segment of genomic DNA that is characterized by a specific combination of alleles arranged along the segment. For diploid organisms such as humans, a haplotype comprises one member of the pair of alleles for each polymorphic marker or locus. In a certain embodiment, the haplotype can comprise two or more alleles, three or more alleles, four or more alleles, or five or more alleles. Haplotypes are described herein in the context of the marker name and the allele of the marker in that haplotype, e.g., "G rs10757278" refers to the 3 allele of marker rs7758851 being in the haplotype, and is equivalent to "rs10757278 allele G". Furthermore, allelic codes in haplotypes are as for individual markers, i.e. 1 = A, 2 = C, 3 = G and 4 = T.

The term "susceptibility", as described herein, refers to an individual (or group of individuals) being prone to developing a certain state (e.g., a certain trait, phenotype or disease), or being less able to resist a particular state than the average individual. The term encompasses both increased susceptibility and decreased susceptibility. Thus, particular alleles at polymorphic markers and/or haplotypes of the invention as described herein may be characteristic of increased susceptibility (i.e., increased risk) of cardiovascular disease, as characterized by a relative risk (RR) or odds ratio (OR) of greater than one for the particular allele or haplotype. Alternatively, the markers and/or haplotypes of the invention are characteristic of decreased susceptibility (i.e., decreased risk) of cardiovascular disease, as characterized by a relative risk of less than one.

The term "and/or" shall in the present context be understood to indicate that either or both of the items connected by it are involved. In other words, the term herein shall be taken to mean "one or the other or both".

The term "look-up table", as described herein, is a table that correlates one form of data to another form, or one or more forms of data to a predicted outcome to which the data is relevant, such as phenotype or trait. For example, a look-up table can comprise a correlation between allelic data for at least one polymorphic marker and a particular trait or phenotype, such as a particular disease diagnosis, that an individual who comprises the particular allelic data is likely to display, or is more likely to display than individuals who do not comprise the particular allelic data. Look-up tables can be multidimensional, i.e. they can contain information about multiple alleles for single markers simultaneously, or they can contain information about multiple markers, and they may also comprise other factors, such as particulars about diseases diagnoses, racial information, biomarkers, biochemical measurements, therapeutic methods or drugs, etc.

A "computer-readable medium", is an information storage medium that can be accessed by a computer using a commercially available or custom-made interface. Exemplary computer-readable media include memory (e.g., RAM, ROM, flash memory, etc.), optical storage media (e.g., CD-ROM), magnetic storage media (e.g., computer hard drives, floppy disks, etc.), punch cards, or other commercially available media. Information may be transferred between a system

of interest and a medium, between computers, or between computers and the computer-readable medium for storage or access of stored information. Such transmission can be electrical, or by other available methods, such as IR links, wireless connections, etc.

A "nucleic acid sample" is a sample obtained from an individual that contains nucleic acid. In certain embodiments, i.e. the detection of specific polymorphic markers and/or haplotypes, the nucleic acid sample comprises genomic DNA. Such a nucleic acid sample can be obtained from any source that contains genomic DNA, including as a blood sample, sample of amniotic fluid, sample of cerebrospinal fluid, or tissue sample from skin, muscle, buccal or conjunctival mucosa, placenta, gastrointestinal tract or other organs.

The term "cardiovascular disease therapeutic agent", as described herein, refers to an agent that can be used to ameliorate or prevent symptoms associated with a cardiovascular disease.

The term "coronary artery disease therapeutic agent", as described herein, refers to an agent that can be used to ameliorate or prevent symptoms associated with coronary artery disease. Such agents can for example be statins, beta blockers, calcium channel blockers, cardiac glycosides, antihypertensive agents, diuretics, agents acting on the renin-angiotensin system, and aspirin.

The term "coronary stenosis" or "coronary stenosis therapeutic method", as described herein, refers to methods that can be used to ameliorate or prevent symptoms associated with coronary artery disease. Such methods can be balloon angioplasty, stenting, cutting balloon angioplasty, percutaneous transluminal coronary angioplasty (PTCA), directional coronary atherectomy, rotational coronary atherectomy, brachytherapy, drug-eluting stent (DES) insertion, metal stent insertion, or coronary artery surgeries, such as Coronary Artery Bypass Surgery (CABG).

The term "cardiovascular disease-associated nucleic acid", as described herein, refers to a nucleic acid that has been found to be associated to cardiovascular disease. This includes, but is not limited to, the markers and haplotypes described herein and markers and haplotypes in strong linkage disequilibrium (LD) therewith.

The term "LD Block C09", as described herein, refers to the Linkage Disequilibrium (LD) block on Chromosome 9 between positions 21,920,147 and 22,149,982 base pairs on Chromosome 9 of NCBI (National Center for Biotechnology Information) Build 34, Build 35 and Build 36. The nucleotide sequence of the LD Block region from these Builds is set forth in SEQ ID NO:94.

The term "cardiovascular disease", as described herein, refers to the class of diseases that involve the heart or blood vessels (arteries and veins). In one embodiment, the invention pertains to arterial disease, which relate to atherosclerotic events, which are believed to have

similar causes and mechanisms. Cardiovascular diseases have certain common risk factors (age, smoking, Diabetes mellitus, hypercholesterolemia, obesity, high blood pressure, stress, depression, elevated heart rate, sleep deprivation, environmental exposure).

The abbreviations "PCTA", "CABG", "MI", "PAD", "CAD", "LAA", "IA", and "AAA", as described herein, refer to the following: "PCTA" refers to Transluminal Coronary Angiopathy, "CABG" refers to Coronary Artery Bypass Surgery, "MI" refers to Myocardial Infarction, "PAD" refers to Peripheral Artery Disease, "CAD" refers to Coronary Artery Disease, "LAA Stroke" refers to Large Artery Atherosclerotic Stroke, "IA" refers to Intracranial Aneurysm and "AAA" refers to Abdominal Aortic Aneurysm.

The term "early onset", as described herein, refers to onset of a disease that is lower than is typically observed. In the present exemplary context, the term, as applied to the MI phenotype, is defined as a MI event before the age of 50 for males and before the age of 60 for females. The term can, in alternative embodiments of the invention, be defined in alternative manner as known to the skilled person and described in further detail herein.

Association of genetic variants to Coronary Artery Disease

Through an association study between SNP markers on a chip containing approximately 317,000 such SNPs, the present invention has identified association of certain markers on chromosome 9 with cardiovascular diseases. The original discovery was made when an analysis of SNP data from patients diagnosed with Myocardial Infarction was made, as illustrated in Table 1 and Table 12. Several markers in a region described herein as LD block C09 were found to be strongly associated with MI, with RR values as high as 1.2. Two microsatellites within the region, D9S1814 and D9S1870, were found also to be correlated with the MI phenotype. The composite allele X of D9S1870 (a composite of all alleles shorter than 2 (alleles, -6, -4, -2 and 0, respectively), was found to associate strongly with MI (Table 1). Further investigations identified close to 90 additional markers that are strongly correlated with the five markers giving strongest association to MI (rs10116277, rs1333040, rs2383207, D9S1814 and D9S1870; see Table 3). These markers could thus serve as surrogate markers for any of these five markers and therefore be used in the methods of the present invention.

The D9S1870 marker was subsequently genotyped in a very large sample of individuals (over 70,000), including additional MI cases as well as other cardiovascular diseases, plus tens of thousands of additional population controls. A replication study in three cohorts from the US was also performed, all containing individuals of Caucasian origin. Results of these studies for the phenotype MI revealed replication of the original finding (Table 4 and 12-14), with a combined p-value of approximately 10^{-12} . The corresponding population attributable risk is about 17% for this variant.

Further studies of this variant revealed a significant correlation to age at onset of MI. Arbitrarily defining early-onset MI as MI before age 50 for males and below age 60 for females revealed an increase in this early-onset group of 1.33, compared to 1.21 for all MI cases. Multiple regression of the number of copies of the composite X allele of D9S1870 and the age of onset of MI revealed a very significant decrease in age at onset for each copy of X carried by the MI individuals (Table 8). This shows that other definitions of age at onset of MI than the cutoff of 50 for males and 60 for females could also be used for detecting this trend in age at onset with carrier status for the X allele.

The present invention has also identified association between other cardiovascular diseases and variants within the LD block C09, using the X allele of D9S1870 as surrogate marker. Thus significant association was found to Peripheral Artery Disease (PAD), even after removing individuals diagnosed with MI from the PAD cohort. We also observed increased risk of Stroke as broad phenotype, as well as the Stroke subphenotype Large Vessel disease (LVD) (Table 5 and Table 29). We have also investigated association of the at-risk variants to the related disorders peripheral artery disease (PAD) and abdominal aorta aneurysm (AAA) As can be seen in Table 29, these markers are associated with these related disorders. The association is particularly compelling for AAA, wherein significant association is observed for a large number of markers in addition to these three, as shown in Table 30. These results illustrate that the markers and haplotypes of the invention are indeed reflective of disorders related to coronary artery disease, MI and in-stent restenosis, such as abdominal aorta aneurysm.

A further analysis of individuals with diagnosis of in-stent restenosis was performed (Table 9). Significant association was detected for both mild restenosis (<50%) and severe restenosis (>50%). This indicates that the present invention can be used to indicate which individuals are at increased risk of in-stent restenosis after undergoing transluminal coronary angioplasty (PTCA).

The known genes located within the LD block C09, are called CDKN2A and CDKN2B. These genes encode three proteins that are known as ARF (also known as p19^{ARF} and p14^{ARF}), p15^{INK4a} and p16^{INK4a}, all of which encode tumor suppressor proteins. p15^{INK4a} has its own open reading frame, but p16^{INK4a} and ARF have different first exons that are spliced to a common second and third exons. Despite the sharing of exons between p16^{INK4a} and ARF the proteins are encoded in different reading frames. Therefore, p16^{INK4a} and ARF are proteins that do not share homology. The products of these genes have been extensively studied and are known to play a widespread role in tumor suppression. Recent data has suggested that the ARF, p15^{INK4a} and p16^{INK4a} locus also has a role in aging of cells, i.e. the decline of replicative potential of self-renewing cells. Several groups have shown that the expression of p16^{INK4a} increases with aging in many tissues of rodents and humans. It has even been proposed that the expression of p16^{INK4a} could be used as a biomarker of physiologic, as opposed to chronologic age.

Human cancers frequently have homozygous deletions of the ARF, p15^{INK4b} and p16^{INK4a} locus with reduced expression of all three proteins, and decreased tumor suppressor activity. Knock-out studies of mice deficient for ARF, p15^{INK4b} or p16^{INK4a} have revealed that these strains are more prone to cancers than wild-type mice. Furthermore, mice with overexpression of the ARF, p15^{INK4b} or p16^{INK4a} locus show reduction in incidence of spontaneous cancers. Since cancer is the principal cause of death in mice on this background one may argue that the tumor resistance of the mice overexpressing the ARF, p15^{INK4b} or p16^{INK4a} locus would also lead to longer lifespan of these mice. However, this is not the case since these mice demonstrate a normal lifespan. This may suggest that the increased ARF, p15^{INK4b} or p16^{INK4a} locus function and diminished tumor incidence may come at the expense of excess mortality from non-malignant causes related to aging (Cell, 127, Oct. 20, 2006), such as atherosclerotic disease.

Sequencing of the exons of CDKN2A and CDKN2B regions, including exons, exon-intron junctions and potential regulatory regions was performed using the primers as indicated in Table 12, resulting in the identification of a number of SNPs, as shown in Table 13. Three of those SNPs were not found in public databases, and the flanking sequences of those SNPs are indicated in Table 14. As it is possible that SNP markers or other polymorphisms in LD with the markers found to be associating to MI in this region of chromosome 9 show association with a higher risk, we genotyped these additional markers by sequencing, as indicated in Table 13. Several of the markers show association to MI with RR values as high as 1.7-1.8, in particular markers SG09S291 and rs2069416. These markers, and/or other markers within the CDKN2A and CDKN2B genes that are in LD with the markers of the present invention as described herein, are thus also within the scope of the invention, as those markers may represent either true disease-causing variants, or variants in strong LD with an underlying causative variant(s).

Investigation of association of the rs10757278 variant to Intracranial Aneurysm shows significant association to this phenotype in the original Icelandic cohort, as well as replication in independent cohorts from the Netherlands and Finland (e.g., Table 32). Furthermore, the original finding of association to AAA was replicated in several cohorts from Belgium, Canada, USA, Netherlands, UK and New Zealand (Table 32). These results show that the rs10757278 marker, and markers in LD therewith, are indeed significantly associated with cardiovascular disorders, including the arterial diseases than myocardial infarction, peripheral artery disease, stroke, intracranial aneurysm and abdominal aortic aneurysm.

The original discovery of the association between variants on chromosome 9p21 and cardiovascular diseases described herein (see also Helgadóttir, A., et. al., *Science* 316:1491-3 2007) has been replicated in several independent studies, including studies of subjects with CAD and controls. The association with CAD/MI in Caucasians has been replicated in 4,251 cases and 4,443 controls of the PROCARDIS Consortium (*Hum Mol Genet.* Epub 2007 Nov 29.), in an Italian population including 416 MI cases and 308 controls (*J Hum Genet.* 2008;53(2):144-50. Epub 2007 Dec 8.), in participants of the Framingham Heart Study (*BMC Med Genet.* 2007 Sep 19;8 Suppl 1:S5.), and in the Northwick Park Heart Study II (*Clin Chem.* Epub 2008 Feb 4).

The association of rs10757278, as well as other correlated SNPs, with CAD has also been confirmed in Asian populations from Japan and Korea with comparable odds ratios as published for Caucasians (see *Arterioscler Thromb Vasc Biol.* 2008 Feb;28(2):360-5. Epub 2007 Nov 29, and *J Hum Genet.* Epub 2008 Feb 9). These studies, together with the data shown herein, clearly indicate that variants within the LD Block C09 region on Chromosome 9p21 are associated with cardiovascular disease in all populations.

Assessment for markers and haplotypes

The genomic sequence within populations is not identical when individuals are compared. Rather, the genome exhibits sequence variability between individuals at many locations in the genome. Such variations in sequence are commonly referred to as polymorphisms, and there are many such sites within each genome. For example, the human genome exhibits sequence variations which occur on average every 500 base pairs. The most common sequence variant consists of base variations at a single base position in the genome, and such sequence variants, or polymorphisms, are commonly called Single Nucleotide Polymorphisms ("SNPs"). These SNPs are believed to have occurred in a single mutational event, and therefore there are usually two possible alleles possible at each SNPsite; the original allele and the mutated allele. Due to natural genetic drift and possibly also selective pressure, the original mutation has resulted in a polymorphism characterized by a particular frequency of its alleles in any given population. Many other types of sequence variants are found in the human genome, including microsatellites, insertions, deletions, inversions and copy number variations. A polymorphic microsatellite has multiple small repeats of bases (such as CA repeats, TG on the complementary strand) at a particular site in which the number of repeat lengths varies in the general population. In general terms, each version of the sequence with respect to the polymorphic site represents a specific allele of the polymorphic site. These sequence variants can all be referred to as polymorphisms, occurring at specific polymorphic sites characteristic of the sequence variant in question. In general terms, polymorphisms can comprise any number of specific alleles. Thus in one embodiment of the invention, the polymorphism is characterized by the presence of two or more alleles in any given population. In another embodiment, the polymorphism is characterized by the presence of three or more alleles. In other embodiments, the polymorphism is characterized by four or more alleles, five or more alleles, six or more alleles, seven or more alleles, nine or more alleles, or ten or more alleles. All such polymorphisms can be utilized in the methods and kits of the present invention, and are thus within the scope of the invention.

In some instances, reference is made to different alleles at a polymorphic site without choosing a reference allele. Alternatively, a reference sequence can be referred to for a particular polymorphic site. The reference allele is sometimes referred to as the "wild-type"

allele and it usually is chosen as either the first sequenced allele or as the allele from a "non-affected" individual (e.g., an individual that does not display a trait or disease phenotype).

Alleles for SNP markers as referred to herein refer to the bases A, C, G or T as they occur at the polymorphic site in the SNP assay employed. The allele codes for SNPs used herein are as follows: 1=A, 2=C, 3=G, 4=T. The person skilled in the art will however realise that by assaying or reading the opposite DNA strand, the complementary allele can in each case be measured. Thus, for a polymorphic site (polymorphic marker) containing an A/G polymorphism, the assay employed may either measure the percentage or ratio of the two bases possible, i.e. A and G. Alternatively, by designing an assay that determines the opposite strand on the DNA template, the percentage or ratio of the complementary bases T/C can be measured. Quantitatively (for example, in terms of relative risk), identical results would be obtained from measurement of either DNA strand (+ strand or - strand). Polymorphic sites (polymorphic markers) can allow for differences in sequences based on substitutions, insertions or deletions. For example, a polymorphic microsatellite has multiple small repeats of bases (such as CA repeats) at a particular site in which the number of repeat lengths varies in the general population. Each version of the sequence with respect to the polymorphic site represents a specific allele of the polymorphic site.

Typically, a reference sequence is referred to for a particular sequence. Alleles that differ from the reference are referred to as "variant" alleles. For example, the genomic DNA sequence from position 21,920,147 to position 22,149,982 base pairs on Chromosome 9 of NCBI Build 34 ("LD block C09"; SEQ ID NO:94) represents a reference sequence. A variant sequence, as used herein, refers to a sequence that differs from the reference sequence but is otherwise substantially similar. Alleles at the polymorphic genetic markers that make up the haplotypes described herein are variants. Additional variants can include changes that affect a polypeptide. Sequence differences, when compared to a reference nucleotide sequence, can include the insertion or deletion of a single nucleotide, or of more than one nucleotide, resulting in a frame shift; the change of at least one nucleotide, resulting in a change in the encoded amino acid; the change of at least one nucleotide, resulting in the generation of a premature stop codon; the deletion of several nucleotides, resulting in a deletion of one or more amino acids encoded by the nucleotides; the insertion of one or several nucleotides, such as by unequal recombination or gene conversion, resulting in an interruption of the coding sequence of a reading frame; duplication of all or a part of a sequence; transposition; or a rearrangement of a nucleotide sequence, as described in detail herein. Such sequence changes alter the polypeptide encoded by the nucleic acid. For example, if the change in the nucleic acid sequence causes a frame shift, the frame shift can result in a change in the encoded amino acids, and/or can result in the generation of a premature stop codon, causing generation of a truncated polypeptide. Alternatively, a polymorphism associated with coronary artery disease and in-stent restenosis or a susceptibility to coronary artery disease and in-stent restenosis can be a synonymous change in one or more nucleotides (i.e., a change that does not result in a change in the amino acid sequence). Such a polymorphism can, for example, alter splice sites, affect the stability or

transport of mRNA, or otherwise affect the transcription or translation of an encoded polypeptide. It can also alter DNA to increase the possibility that structural changes, such as amplifications or deletions, occur at the somatic level. The polypeptide encoded by the reference nucleotide sequence is the "reference" polypeptide with a particular reference amino acid sequence, and polypeptides encoded by variant alleles are referred to as "variant" polypeptides with variant amino acid sequences.

A haplotype refers to a segment of DNA that is characterized by a specific combination of alleles arranged along the segment. For diploid organisms such as humans, a haplotype comprises one member of the pair of alleles for each polymorphic marker or locus. In a certain embodiment, the haplotype can comprise two or more alleles, three or more alleles, four or more alleles, or five or more alleles, each allele corresponding to a specific polymorphic marker along the segment. Haplotypes can comprise a combination of various polymorphic markers, e.g., SNPs and microsatellites, having particular alleles at the polymorphic sites. The haplotypes thus comprise a combination of alleles at various genetic markers.

Detecting specific polymorphic markers and/or haplotypes can be accomplished by methods known in the art for detecting sequences at polymorphic sites. For example, standard techniques for genotyping for the presence of SNPs and/or microsatellite markers can be used, such as fluorescence-based techniques (e.g., Chen, X. et al., *Genome Res.* 9(5): 492-98 (1999); Kuttyavin et al., *Nucleic Acid Res.* 34:e128 (2006)), utilizing PCR, LCR, Nested PCR and other techniques for nucleic acid amplification. Specific methodologies available for SNP genotyping include, but are not limited to, TaqMan genotyping assays and SNPiex platforms (Applied Biosystems), mass spectrometry (e.g., MassARRAY system from Sequenom), minisequencing methods, real-time PCR, Bio-Plex system (BioRad), CEQ and SNPstream systems (Beckman), Molecular Inversion Probe array technology (e.g., Affymetrix GeneChip), and BeadArray Technologies (e.g., Illumina GoldenGate and Infinium assays). By these or other methods available to the person skilled in the art, one or more alleles at polymorphic markers, including microsatellites, SNPs or other types of polymorphic markers, can be identified.

In certain methods described herein, an individual who is at an increased susceptibility (i.e., at risk) for cardiovascular disease is an individual in whom at least one specific allele at one or more polymorphic marker or haplotype conferring increased susceptibility for cardiovascular disease is identified (i.e., at-risk marker alleles or haplotypes). In one aspect, the at-risk marker or haplotype is one that confers a significant increased risk (or susceptibility) of cardiovascular disease. In one embodiment, significance associated with a marker or haplotype is measured by a relative risk. In one embodiment, significance associated with a marker or haplotype is measured by a relative risk (RR). In another embodiment, significance associated with a marker or haplotype is measured by an odds ratio (OR). In a further embodiment, the significance is measured by a percentage. In one embodiment, a significant increased risk is measured as a risk (relative risk and/or odds ratio) of at least 1.2, including but not limited to: at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, 1.8, at least 1.9, at least 2.0, at

least 2.5, at least 3.0, at least 4.0, and at least 5.0. In a particular embodiment, a risk (relative risk and/or odds ratio) of at least 1.2 is significant. In another particular embodiment, a risk of at least 1.3 is significant. In yet another embodiment, a risk of at least 1.4 is significant. In a further embodiment, a relative risk of at least 1.5 is significant. In another further embodiment, a significant increase in risk is at least 1.7 is significant. However, other cutoffs are also contemplated, e.g., at least 1.15, 1.25, 1.35, and so on, and such cutoffs are also within scope of the present invention. In other embodiments, a significant increase in risk is at least about 20%, including but not limited to about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, 300%, and 500%. In one particular embodiment, a significant increase in risk is at least 20%. In other embodiments, a significant increase in risk is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% and at least 100%. Other cutoffs or ranges as deemed suitable by the person skilled in the art to characterize the invention are however also contemplated, and those are also within scope of the present invention. In certain embodiments, a significant increase in risk is characterized by a p-value, such as a p-value of less than 0.05, less than 0.01, less than 0.001, less than 0.0001, less than 0.00001, less than 0.000001, less than 0.0000001, less than 0.00000001, or less than 0.000000001.

An at-risk polymorphic marker or haplotype of the present invention is one where at least one allele of at least one marker or haplotype is more frequently present in an individual at risk for cardiovascular disease (affected), compared to the frequency of its presence in a healthy individual (control), and wherein the presence of the marker or haplotype is indicative of susceptibility to cardiovascular disease. The control group may in one embodiment be a population sample, i.e. a random sample from the general population. In another embodiment, the control group is represented by a group of individuals who are disease-free. Such disease-free control may in one embodiment be characterized by the absence of one or more specific disease-associated symptoms. In another embodiment, the disease-free control group is characterized by the absence of one or more disease-specific risk factors. Such risk factors are in one embodiment at least one environmental risk factor. Representative environmental factors are natural products, minerals or other chemicals which are known to affect, or contemplated to affect, the risk of developing the specific disease or trait. Other environmental risk factors are risk factors related to lifestyle, including but not limited to food and drink habits, geographical location of main habitat, and occupational risk factors. In another embodiment, the risk factors comprise at least one additional genetic risk factor.

As an example of a simple test for correlation would be a Fisher-exact test on a two by two table. Given a cohort of chromosomes, the two by two table is constructed out of the number of chromosomes that include both of the markers or haplotypes, one of the markers or haplotypes but not the other and neither of the markers or haplotypes. Other statistical tests of association known to the skilled person are also contemplated and are also within scope of the invention.

In other embodiments of the invention, an individual who is at a decreased susceptibility (i.e., at a decreased risk) for a disease or trait is an individual in whom at least one specific allele at one or more polymorphic marker or haplotype conferring decreased susceptibility for the disease or trait is identified. The marker alleles and/or haplotypes conferring decreased risk are also said to be protective. In one aspect, the protective marker or haplotype is one that confers a significant decreased risk (or susceptibility) of the disease or trait. In one embodiment, significant decreased risk is measured as a relative risk (or odds ratio) of less than 0.9, including but not limited to less than 0.9, less than 0.8, less than 0.7, less than 0.6, less than 0.5, less than 0.4, less than 0.3, less than 0.2 and less than 0.1. In one particular embodiment, significant decreased risk is less than 0.7. In another embodiment, significant decreased risk is less than 0.5. In yet another embodiment, significant decreased risk is less than 0.3. In another embodiment, the decrease in risk (or susceptibility) is at least 20%, including but not limited to at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% and at least 98%. In one particular embodiment, a significant decrease in risk is at least about 30%. In another embodiment, a significant decrease in risk is at least about 50%. In another embodiment, the decrease in risk is at least about 70%. Other cutoffs or ranges as deemed suitable by the person skilled in the art to characterize the invention are however also contemplated, and those are also within scope of the present invention.

The person skilled in the art will appreciate that for markers with two alleles present in the population being studied (such as SNPs), and wherein one allele is found in increased frequency in a group of individuals with a trait or disease in the population, compared with controls, the other allele of the marker will be found in decreased frequency in the group of individuals with the trait or disease, compared with controls. In such a case, one allele of the marker (the one found in increased frequency in individuals with the trait or disease) will be the at-risk allele, while the other allele will be a protective allele.

A genetic variant associated with a disease or a trait (e.g. cardiovascular disease) can be used alone to predict the risk of the disease for a given genotype. For a biallelic marker, such as a SNP, there are 3 possible genotypes: homozygote for the at risk variant, heterozygote, and non carrier of the at risk variant. Risk associated with variants at multiple loci can be used to estimate overall risk. For multiple SNP variants, there are k possible genotypes $k = 3^n \times 2^p$; where n is the number autosomal loci and p the number of gonosomal (sex chromosomal) loci. Overall risk assessment calculations usually assume that the relative risks of different genetic variants multiply, i.e. the overall risk (e.g., RR or OR) associated with a particular genotype combination is the product of the risk values for the genotype at each locus. If the risk presented is the relative risk for a person, or a specific genotype for a person, compared to a reference population with matched gender and ethnicity, then the combined risk – is the product of the locus specific risk values – and which also corresponds to an overall risk estimate compared with the population. If the risk for a person is based on a comparison to non-carriers of the at risk allele, then the combined risk corresponds to an estimate that compares the person

with a given combination of genotypes at all loci to a group of individuals who do not carry risk variants at any of those loci. The group of non-carriers of any at risk variant has the lowest estimated risk and has a combined risk, compared with itself (*i.e.*, non-carriers) of 1.0, but has an overall risk, compare with the population, of less than 1.0. It should be noted that the group of non-carriers can potentially be very small, especially for large number of loci, and in that case, its relevance is correspondingly small.

The multiplicative model is a parsimonious model that usually fits the data of complex traits reasonably well. Deviations from multiplicity have been rarely described in the context of common variants for common diseases, and if reported are usually only suggestive since very large sample sizes are usually required to be able to demonstrate statistical interactions between loci.

By way of an example, let us consider a total of eight variants that have been described to associate with prostate cancer (Gudmundsson, J., *et al.*, *Nat Genet* 39:631-7 (2007), Gudmundsson, J., *et al.*, *Nat Genet* 39:977-83 (2007); Yeager, M., *et al.*, *Nat Genet* 39:645-49 (2007), Amundadottir, L., *et al.*, *Nat Genet* 38:652-8 (2006); Haiman, C.A., *et al.*, *Nat Genet* 39:638-44 (2007)). Seven of these loci are on autosomes, and the remaining locus is on chromosome X. The total number of theoretical genotypic combinations is then $3^7 \times 2^1 = 4374$. Some of those genotypic classes are very rare, but are still possible, and should be considered for overall risk assessment. It is likely that the multiplicative model applied in the case of multiple genetic variant will also be valid in conjunction with non-genetic risk variants assuming that the genetic variant does not clearly correlate with the "environmental" factor. In other words, genetic and non-genetic at-risk variants can be assessed under the multiplicative model to estimate combined risk, assuming that the non-genetic and genetic risk factors do not interact.

Using the same quantitative approach, the combined or overall risk associated with a plurality of variants associated with any cardiovascular disease, as described herein, may be assessed.

Linkage Disequilibrium

The natural phenomenon of recombination, which occurs on average once for each chromosomal pair during each meiotic event, represents one way in which nature provides variations in sequence (and biological function by consequence). It has been discovered that recombination does not occur randomly in the genome; rather, there are large variations in the frequency of recombination rates, resulting in small regions of high recombination frequency (also called recombination hotspots) and larger regions of low recombination frequency, which are commonly referred to as Linkage Disequilibrium (LD) blocks (Myers, S. *et al.*, *Biochem Soc*

Trans 34:526-530 (2006); Jeffreys, A.J., et al., *Nature Genet* 29:217-222 (2001); May, C.A., et al., *Nature Genet* 31:272-275(2002)).

Linkage Disequilibrium (LD) refers to a non-random assortment of two genetic elements. For example, if a particular genetic element (e.g., "alleles" of a polymorphic marker) occurs in a population at a frequency of 0.50 (50%) and another occurs at a frequency of 0.50 (50%), then the predicted occurrence of a person's having both elements is 0.25 (25%), assuming a random distribution of the elements. However, if it is discovered that the two elements occur together at a frequency higher than 0.25, then the elements are said to be in linkage disequilibrium, since they tend to be inherited together at a higher rate than what their independent allele frequencies would predict. Roughly speaking, LD is generally correlated with the frequency of recombination events between the two elements. Allele or haplotype frequencies can be determined in a population by genotyping individuals in a population and determining the frequency of the occurrence of each allele or haplotype in the population. For populations of diploids, e.g., human populations, individuals will typically have two alleles or allelic combinations for each genetic element (e.g., a marker, haplotype or gene).

Many different measures have been proposed for assessing the strength of linkage disequilibrium (LD). Most capture the strength of association between pairs of biallelic sites. Two important pairwise measures of LD are r^2 (sometimes denoted Δ^2) and $|D'|$. Both measures range from 0 (no disequilibrium) to 1 ('complete' disequilibrium), but their interpretation is slightly different. $|D'|$ is defined in such a way that it is equal to 1 if just two or three of the possible haplotypes are present, and it is <1 if all four possible haplotypes are present. Therefore, a value of $|D'|$ that is <1 indicates that historical recombination may have occurred between two sites (recurrent mutation can also cause $|D'|$ to be <1 , but for single nucleotide polymorphisms (SNPs) this is usually regarded as being less likely than recombination). The measure r^2 represents the statistical correlation between two sites, and takes the value of 1 if only two haplotypes are present.

The r^2 measure is arguably the most relevant measure for association mapping, because there is a simple inverse relationship between r^2 and the sample size required to detect association between susceptibility loci and SNPs. These measures are defined for pairs of sites, but for some applications a determination of how strong LD is across an entire region that contains many polymorphic sites might be desirable (e.g., testing whether the strength of LD differs significantly among loci or across populations, or whether there is more or less LD in a region than predicted under a particular model). Measuring LD across a region is not straightforward, but one approach is to use the measure r , which was developed in population genetics. Roughly speaking, r measures how much recombination would be required under a particular population model to generate the LD that is seen in the data. This type of method can potentially also provide a statistically rigorous approach to the problem of determining whether LD data provide evidence for the presence of recombination hotspots. For the methods described herein, a significant r^2 value can be at least 0.1 such as at least 0.1, 0.15, 0.2, 0.25,

0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, or at least 0.99. In one preferred embodiment, the significant r^2 value can be at least 0.2. Alternatively, linkage disequilibrium as described herein, refers to linkage disequilibrium characterized by values of $|D'|$ of at least 0.2, such as 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.85, 0.9, 0.95, 0.96, 0.97, 0.98, or at least 0.99. Thus, linkage disequilibrium represents a correlation between alleles of distinct markers. It is measured by correlation coefficient or $|D'|$ (r^2 up to 1.0 and $|D'|$ up to 1.0). In certain embodiments, linkage disequilibrium is defined in terms of values for both the r^2 and $|D'|$ measures. In one such embodiment, a significant linkage disequilibrium is defined as $r^2 > 0.1$ and $|D'| > 0.8$. In another embodiment, a significant linkage disequilibrium is defined as $r^2 > 0.2$ and $|D'| > 0.9$. Other combinations and permutations of values of r^2 and $|D'|$ for determining linkage disequilibrium are also contemplated, and are also within the scope of the invention. Linkage disequilibrium can be determined in a single human population, as defined herein, or it can be determined in a collection of samples comprising individuals from more than one human population. In one embodiment of the invention, LD is determined in a sample from one or more of the HapMap populations (caucasian, african, japanese, chinese), as defined (<http://www.hapmap.org>). In one such embodiment, LD is determined in the CEU population of the HapMap samples. In another embodiment, LD is determined in the YRI population. In yet another embodiment, LD is determined in samples from the Icelandic population.

If all polymorphisms in the genome were independent at the population level (i.e., no LD), then every single one of them would need to be investigated in association studies, to assess all the different polymorphic states. However, due to linkage disequilibrium between polymorphisms, tightly linked polymorphisms are strongly correlated, which reduces the number of polymorphisms that need to be investigated in an association study to observe a significant association. Another consequence of LD is that many polymorphisms may give an association signal due to the fact that these polymorphisms are strongly correlated.

Genomic LD maps have been generated across the genome, and such LD maps have been proposed to serve as framework for mapping disease-genes (Risch, N. & Merikangas, K, *Science* 273:1516-1517 (1996); Maniatis, N., et al., *Proc Natl Acad Sci USA* 99:2228-2233 (2002); Reich, DE et al, *Nature* 411:199-204 (2001)). It is also now established that many portions of the human genome can be broken into series of discrete haplotype blocks containing a few common haplotypes; for these blocks, linkage disequilibrium data provides little evidence indicating recombination (see, e.g., Wall, J.D. and Pritchard, J.K., *Nature Reviews Genetics* 4:587-597 (2003); Daly, M. et al., *Nature Genet.* 29:229-232 (2001); Gabriel, S.B. et al., *Science* 296:2225-2229 (2002); Patil, N. et al., *Science* 294:1719-1723 (2001); Dawson, E. et al., *Nature* 418:544-548 (2002); Phillips, M.S. et al., *Nature Genet.* 33:382-387 (2003)). There are two main methods for defining these haplotype blocks: blocks can be defined as regions of DNA that have limited haplotype diversity (see, e.g., Daly, M. et al., *Nature Genet.* 29:229-232 (2001); Patil, N. et al., *Science* 294:1719-1723 (2001); Dawson, E. et al., *Nature* 418:544-548 (2002); Zhang, K. et al., *Proc. Natl. Acad. Sci. USA* 99:7335-7339 (2002)), or as regions

between transition zones having extensive historical recombination, identified using linkage disequilibrium (see, e.g., Gabriel, S.B. et al., *Science* 296:2225-2229 (2002); Phillips, M.S. et al., *Nature Genet.* 33:382-387 (2003); Wang, N. et al., *Am. J. Hum. Genet.* 71:1227-1234 (2002); Stumpf, M.P., and Goldstein, D.B., *Curr. Biol.* 13:1-8 (2003)). More recently, a fine-scale map of recombination rates and corresponding hotspots across the human genome has been generated (Myers, S., et al., *Science* 310:321-32324 (2005); Myers, S. et al., *Biochem Soc Trans* 34:526530 (2006)). The map reveals the enormous variation in recombination across the genome, with recombination rates as high as 10-60 cM/Mb in hotspots, while closer to 0 in intervening regions, which thus represent regions of limited haplotype diversity and high LD. The map can therefore be used to define haplotype blocks/LD blocks as regions flanked by recombination hotspots. As used herein, the terms "haplotype block" or "LD block" includes blocks defined by any of the above described characteristics, or other alternative methods used by the person skilled in the art to define such regions. Haplotype blocks (LD blocks) can be used to map associations between phenotype and haplotype status, using single markers or haplotypes comprising a plurality of markers. The main haplotypes can be identified in each haplotype block, and then a set of "tagging" SNPs or markers (the smallest set of SNPs or markers needed to distinguish among the haplotypes) can then be identified. These tagging SNPs or markers can then be used in assessment of samples from groups of individuals, in order to identify association between phenotype and haplotype. If desired, neighboring haplotype blocks can be assessed concurrently, as there may also exist linkage disequilibrium among the haplotype blocks.

It has thus become apparent that for any given observed association to a polymorphic marker in the genome, it is likely that additional markers in the genome also show association. This is a natural consequence of the uneven distribution of LD across the genome, as observed by the large variation in recombination rates. The markers used to detect association thus in a sense represent "tags" for a genomic region (i.e., a haplotype block or LD block; e.g., the C09 LD block) that is associating with a given disease or trait, and as such are useful for use in the methods and kits of the present invention. One or more causative (functional) variants or mutations may reside within the region found to be associating to the disease or trait. Such variants may confer a higher relative risk (RR) or odds ratio (OR) than observed for the tagging markers used to detect the association. The present invention thus refers to the markers used for detecting association to the disease, as described herein, as well as markers in linkage disequilibrium with the markers. Thus, in certain embodiments of the invention, markers that are in LD with the markers and/or haplotypes of the invention, as described herein, may be used as surrogate markers. The surrogate markers have in one embodiment relative risk (RR) and/or odds ratio (OR) values smaller than for the markers or haplotypes initially found to be associating with the disease, as described herein. In other embodiments, the surrogate markers have RR or OR values greater than those initially determined for the markers initially found to be associating with the disease, as described herein. An example of such an embodiment would be a rare, or relatively rare (such as < 10% allelic population frequency) variant in LD with a more

common variant (> 10% population frequency) initially found to be associating with the disease, such as the variants described herein. Identifying and using such markers for detecting the association discovered by the inventors as described herein can be performed by routine methods well known to the person skilled in the art, and are therefore within the scope of the present invention.

Determination of haplotype frequency

The frequencies of haplotypes in patient and control groups can be estimated using an expectation-maximization algorithm (Dempster A. *et al.*, *J. R. Stat. Soc. B*, 39:1-38 (1977)). An implementation of this algorithm that can handle missing genotypes and uncertainty with the phase can be used. Under the null hypothesis, the patients and the controls are assumed to have identical frequencies. Using a likelihood approach, an alternative hypothesis is tested, where a candidate at-risk-haplotype, which can include the markers described herein, is allowed to have a higher frequency in patients than controls, while the ratios of the frequencies of other haplotypes are assumed to be the same in both groups. Likelihoods are maximized separately under both hypotheses and a corresponding 1-df likelihood ratio statistic is used to evaluate the statistical significance.

To look for at-risk and protective markers and haplotypes within a linkage region, for example, association of all possible combinations of genotyped markers is studied, provided those markers span a practical region. The combined patient and control groups can be randomly divided into two sets, equal in size to the original group of patients and controls. The marker and haplotype analysis is then repeated and the most significant p-value registered is determined. This randomization scheme can be repeated, for example, over 100 times to construct an empirical distribution of p-values. In a preferred embodiment, a p-value of <0.05 is indicative of an significant marker and/or haplotype association.

Haplotype Analysis

One general approach to haplotype analysis involves using likelihood-based inference applied to NEsted MOdels (Gretarsdottir S., *et al.*, *Nat. Genet.* 35:131-38 (2003)). The method is implemented in the program NEMO, which allows for many polymorphic markers, SNPs and microsatellites. The method and software are specifically designed for case-control studies where the purpose is to identify haplotype groups that confer different risks. It is also a tool for studying LD structures. In NEMO, maximum likelihood estimates, likelihood ratios and p-values are calculated directly, with the aid of the EM algorithm, for the observed data treating it as a missing-data problem.

Even though likelihood ratio tests based on likelihoods computed directly for the observed data, which have captured the information loss due to uncertainty in phase and missing genotypes, can be relied on to give valid p-values, it would still be of interest to know how much information had been lost due to the information being incomplete. The information measure for haplotype analysis is described in Nicolae and Kong (Technical Report 537, Department of Statistics, University of Statistics, University of Chicago; *Biometrics*, 60(2):368-75 (2004)) as a natural extension of information measures defined for linkage analysis, and is implemented in NEMO.

For single marker association to a disease, the Fisher exact test can be used to calculate two-sided p-values for each individual allele. Usually, all p-values are presented unadjusted for multiple comparisons unless specifically indicated. The presented frequencies (for microsatellites, SNPs and haplotypes) are allelic frequencies as opposed to carrier frequencies. To minimize any bias due the relatedness of the patients who were recruited as families for the linkage analysis, first and second-degree relatives can be eliminated from the patient list. Furthermore, the test can be repeated for association correcting for any remaining relatedness among the patients, by extending a variance adjustment procedure described in Risch, N. & Teng, J. (*Genome Res.*, 8:1273-1288 (1998)), DNA pooling (*ibid*) for sibships so that it can be applied to general familial relationships, and present both adjusted and unadjusted p-values for comparison. The differences are in general very small as expected. To assess the significance of single-marker association corrected for multiple testing we can carry out a randomization test using the same genotype data. Cohorts of patients and controls can be randomized and the association analysis redone multiple times (e.g., up to 500,000 times) and the p-value is the fraction of replications that produced a p-value for some marker allele that is lower than or equal to the p-value we observed using the original patient and control cohorts.

For both single-marker and haplotype analyses, relative risk (RR) and the population attributable risk (PAR) can be calculated assuming a multiplicative model (haplotype relative risk model) (Terwilliger, J.D. & Ott, J., *Hum. Hered.* 42:337-46 (1992) and Falk, C.T. & Rubinstein, P., *Ann. Hum. Genet.* 51 (Pt 3):227-33 (1987)), i.e., that the risks of the two alleles/haplotypes a person carries multiply. For example, if RR is the risk of A relative to a, then the risk of a person homozygote AA will be RR times that of a heterozygote Aa and RR^2 times that of a homozygote aa. The multiplicative model has a nice property that simplifies analysis and computations — haplotypes are independent, i.e., in Hardy-Weinberg equilibrium, within the affected population as well as within the control population. As a consequence, haplotype counts of the affecteds and controls each have multinomial distributions, but with different haplotype frequencies under the alternative hypothesis. Specifically, for two haplotypes, h_i and h_j , $\text{risk}(h_i)/\text{risk}(h_j) = (f_i/p_i)/(f_j/p_j)$, where f and p denote, respectively, frequencies in the affected population and in the control population. While there is some power loss if the true model is not multiplicative, the loss tends to be mild except for extreme cases. Most importantly, p-values are always valid since they are computed with respect to null hypothesis.

Linkage Disequilibrium Using NEMO

LD between pairs of markers can be calculated using the standard definition of D' and r^2 (Lewontin, R., *Genetics* 49:49-67 (1964); Hill, W.G. & Robertson, A. *Theor. Appl. Genet.* 22:226-231 (1968)). Using NEMO, frequencies of the two marker allele combinations are estimated by maximum likelihood and deviation from linkage equilibrium is evaluated by a likelihood ratio test. The definitions of D' and r^2 are extended to include microsatellites by averaging over the values for all possible allele combination of the two markers weighted by the marginal allele probabilities.

Risk assessment and Diagnostics

Within any given population, there is an absolute risk of developing a disease or trait, defined as the chance of a person developing the specific disease or trait over a specified time-period. For example, a woman's lifetime absolute risk of breast cancer is one in nine. That is to say, one woman in every nine will develop breast cancer at some point in their lives. Risk is typically measured by looking at very large numbers of people, rather than at a particular individual. Risk is often presented in terms of Absolute Risk (AR) and Relative Risk (RR). Relative Risk is used to compare risks associating with two variants or the risks of two different groups of people. For example, it can be used to compare a group of people with a certain genotype with another group having a different genotype. For a disease, a relative risk of 2 means that one group has twice the chance of developing a disease as the other group. The Risk presented is usually the relative risk for a person, or a specific genotype of a person, compared to the population with matched gender and ethnicity. Risks of two individuals of the same gender and ethnicity could be compared in a simple manner. For example, if, compared to the population, the first individual has relative risk 1.5 and the second has relative risk 0.5, then the risk of the first individual compared to the second individual is $1.5/0.5 = 3$.

As described herein, certain polymorphic markers and haplotypes comprising such markers are found to be useful for risk assessment of cardiovascular disease, e.g., arterial diseases, e.g. myocardial infarction, coronary artery disease, restenosis, peripheral artery disease, stroke, intracranial aneurysm and abdominal aortic aneurysm. Risk assessment can involve the use of the markers for diagnosing a susceptibility to the cardiovascular disease. Particular alleles of polymorphic markers are found more frequently in individuals with cardiovascular disease, than in individuals without diagnosis of cardiovascular disease. Therefore, these marker alleles have predictive value for detecting cardiovascular disease, or a susceptibility to cardiovascular disease, in an individual. Tagging markers within haplotype blocks or LD blocks comprising at-risk markers, such as the markers of the present invention, can be used as surrogates for other markers and/or haplotypes within the haplotype block or LD

block. Markers with values of r^2 equal to 1 are perfect surrogates for the at-risk variants, i.e. genotypes for one marker perfectly predicts genotypes for the other. Markers with smaller values of r^2 than 1 can also be surrogates for the at-risk variant, or alternatively represent variants with relative risk values as high as or possibly even higher than the at-risk variant. The at-risk variant identified may not be the functional variant itself, but is in this instance in linkage disequilibrium with the true functional variant. The present invention encompasses the assessment of such surrogate markers for the markers as disclosed herein. Such markers are annotated, mapped and listed in public databases, as well known to the skilled person, or can alternatively be readily identified by sequencing the region or a part of the region identified by the markers of the present invention in a group of individuals, and identify polymorphisms in the resulting group of sequences. As a consequence, the person skilled in the art can readily and without undue experimentation genotype surrogate markers in linkage disequilibrium with the markers and/or haplotypes as described herein. The tagging or surrogate markers in LD with the at-risk variants detected, also have predictive value for detecting association to the cardiovascular disease, or a susceptibility to the cardiovascular disease, in an individual. These tagging or surrogate markers that are in LD with the markers of the present invention can also include other markers that distinguish among haplotypes, as these similarly have predictive value for detecting susceptibility to cardiovascular disease.

The present invention can in certain embodiments be practiced by assessing a sample comprising genomic DNA from an individual for the presence of variants described herein to be associated with cardiovascular disease. Such assessment includes steps of detecting the presence or absence of at least one allele of at least one polymorphic marker, using methods well known to the skilled person and further described herein, and based on the outcome of such assessment, determine whether the individual from whom the sample is derived is at increased or decreased risk (increased or decreased susceptibility) of cardiovascular disease. Alternatively, the invention can be practiced utilizing a dataset comprising information about the genotype status of at least one polymorphic marker described herein to be associated with cardiovascular disease (or markers in linkage disequilibrium with at least one marker shown herein to be associated with cardiovascular disease). In other words, a dataset containing information about such genetic status, for example in the form of genotype counts at a certain polymorphic marker, or a plurality of markers (e.g., an indication of the presence or absence of certain at-risk alleles), or actual genotypes for one or more markers, can be queried for the presence or absence of certain at-risk alleles at certain polymorphic markers shown by the present inventors to be associated with cardiovascular disease. A positive result for a variant (e.g., marker allele) associated with cardiovascular disease, as shown herein, is indicative of the individual from which the dataset is derived is at increased susceptibility (increased risk) of at least one cardiovascular disease (e.g., arterial diseases, e.g. myocardial infarction, coronary artery disease, restenosis, peripheral artery disease, stroke, intracranial aneurysm and abdominal aortic aneurysm).

In certain embodiments of the invention, a polymorphic marker is correlated to a cardiovascular disease by referencing genotype data for the polymorphic marker to a look-up table that comprises correlations between at least one allele of the polymorphism and the disease. In some embodiments, the table comprises a correlation for one polymorphism. In other embodiments, the table comprises a correlation for a plurality of polymorphisms. In both scenarios, by referencing to a look-up table that gives an indication of a correlation between a marker and cardiovascular disease, a risk for cardiovascular disease, or a susceptibility to cardiovascular disease, can be identified in the individual from whom the sample is derived. In some embodiments, the correlation is reported as a statistical measure. The statistical measure may be reported as a risk measure, such as a relative risk (RR), an absolute risk (AR) or an odds ratio (OR).

The markers and haplotypes of the invention, e.g., the markers presented in Tables 1-36 herein, e.g. the markers in Table 3, 10 and 21, may be useful for risk assessment and diagnostic purposes for cardiovascular disease (e.g., arterial diseases, e.g. myocardial infarction, coronary artery disease, restenosis, peripheral artery disease, stroke, intracranial aneurysm and abdominal aortic aneurysm), either alone or in combination. Thus, even in the cases where the increase in risk by individual markers is relatively modest, i.e. on the order of 10-30%, the association may have significant implications. Thus, relatively common variants may have significant contribution to the overall risk (Population Attributable Risk is high), or combination of markers can be used to define groups of individual who, based on the combined risk of the markers, is at significant combined risk of developing a cardiovascular disease.

Biomarkers

The cardiovascular diseases are known to have several common biomarkers, which are believed to relate to increased risk of developing cardiovascular disease. These include elevated fibrinogen, PAI-1, homocysteine, asymmetric dimethylarginine, C-reactive protein and B-type natriuretic peptide (BNP). These common biomarkers underscore the common etiology for the cardiovascular diseases. Recently, urinary peptides have been shown to be promising biomarkers for cardiovascular disease, in particular Coronary Artery Disease (CAD) (Zimmerli, L.U., et al., *Mol Cell Proteomics* 7:290-8 (2008)). These have the advantage of being non-invasive, only requiring a urine sample from the individual to be assessed. In one application, a pattern of polypeptides in the urine sample is characteristic of increased risk of CAD.

Many general inflammatory markers are predictive of risk of coronary heart disease, including CAD and MI, although these markers are not specific to atherosclerosis. For example, Stein (Stein, S., *Am J Cardiol*, 87 (suppl):21A-26A (2001)) discusses the use of any one of the following serum inflammatory markers as surrogates for predicting risk of coronary heart disease including C-reactive protein (CRP), serum amyloid A, fibrinogen, interleukin-6, tissue necrosis factor-alpha, soluble vascular cell adhesion molecules (sVCAM), soluble intervascular adhesion

molecules (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, and matrix metalloprotease type-9.

A significant association between CRP levels in serum and increased risk for coronary heart disease was found in the Women's Health Study, with the highest relative risk of 4.5 seen for those women in the highest quintile of serum CRP (Ridker, P.M. *et al.*, *New England. J. Med.*, 347: 1557-1565 (2001)). A similar correlation between increased serum CRP and increased risk for coronary heart disease in women has been reported (Ridker, P.M. *et al.*, *New Engl. J. Med.*, 342:836-843 (2000); Bermudez, E.A. *et al.*, *Arterioscler. Thromb. Vasc. Biol.*, 22: 1668-1673 (2002)). A similar correlation between increased serum inflammatory markers such as CRP and increased risk for coronary heart disease has been reported for men (Doggen, C.J.M. *et al.*, *J. Internal Med.*, 248:406-414 (2000) and Ridker, P.M. *et al.*, *New England. J. Med.*, 336: 973-979 (1997)). Elevated CRP or other serum inflammatory markers is also prognostic for increased risk of a second myocardial infarct in patients with a previous myocardial infarct (Retterstol, L. *et al.*, *Atheroscler.*, 160: 433-440 (2002)). Emerging evidence also suggests that elevated CRP is an independent risk factor for adverse clinical outcomes. See, *e.g.*, Ridker *et al.*, *N. Engl. J. Med.* 352: 1 (January 6, 2005).

The end products of the leukotriene pathway are potent inflammatory lipid mediators derived from arachidonic acid. They can potentially contribute to development of atherosclerosis and destabilization of atherosclerotic plaques through lipid oxidation and/or proinflammatory effects, and LTC₄, LTD₄, and LTE₄, are known to induce vasoconstriction. On the other hand, LTB₄ is a strong proinflammatory agent. Increased production of these end products of the leukotriene pathway, could therefore serve as a risk factor for MI and atherosclerosis, whereas both inflammation and vasoconstriction/vasospasm have a well established role in the pathogenesis of MI and atherosclerosis.

In certain embodiments of the invention, the genetic risk variants for cardiovascular disease, such as MI, CAD, AAA, IA, stroke and/or PAD are assessed in combination with at least one biomarker. For example, levels of an inflammatory marker in an appropriate test sample (*e.g.*, serum, plasma or urine) can be measured and the determination of the biomarker level in the sample, relative to a control (either a normal, disease-free control, or a random sample from the population) is made. The result of the analysis can be analyzed in combination with genetic risk conferred by the variants described herein, to determine overall risk. Representative inflammatory markers include: C-reactive protein (CRP), serum amyloid A, fibrinogen, serum sCD40L, a leukotriene (*e.g.*, LTB₄, LTC₄, LTD₄, LTE₄), a leukotriene metabolite, interleukin-6, tissue necrosis factor-alpha, soluble vascular cell adhesion molecules (sVCAM), soluble intervascular adhesion molecules (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, matrix metalloprotease type-9, myeloperoxidase (MPO), and N-tyrosine. In a preferred embodiment, the marker is CRP, sCD40L or MPO. The determination of biomarkers can be made by standard methods known to the skilled person. For example, in one embodiment, production of a leukotriene metabolite is

stimulated in a first test sample from the individual, using a calcium ionophore. The level of production is compared with a control level. The control level is a level that is typically found in control individual(s), such as individual who are not at risk for MI, CAD, AAA, IA, stroke or PAD; alternatively, a control level is the level that is found by comparison of disease risk in a population associated with the lowest band of measurement (e.g., below the mean or median, the lowest quartile or the lowest quintile) compared to higher bands of measurement (e.g., above the mean or median, the second, third or fourth quartile; the second, third, fourth or fifth quintile).

As described in the above, the haplotype block structure of the human genome has the effect that a large number of variants (markers and/or haplotypes) in linkage disequilibrium with the variant originally associated with a disease or trait may be used as surrogate markers for assessing association to the disease or trait. The number of such surrogate markers will depend on factors such as the historical recombination rate in the region, the mutational frequency in the region (i.e., the number of polymorphic sites or markers in the region), and the extent of LD (size of the LD block) in the region. These markers are usually located within the physical boundaries of the LD block or haplotype block in question as defined using the methods described herein, or by other methods known to the person skilled in the art. However, sometimes marker and haplotype association is found to extend beyond the physical boundaries of the haplotype block as defined. Such markers and/or haplotypes may in those cases be also used as surrogate markers and/or haplotypes for the markers and/or haplotypes physically residing within the haplotype block as defined. As a consequence, markers and haplotypes in LD (typically characterized by r^2 greater than 0.1, such as r^2 greater than 0.2, including r^2 greater than 0.3, also including r^2 greater than 0.4) with the markers and haplotypes of the present invention are also within the scope of the invention, even if they are physically located beyond the boundaries of the haplotype block as defined. This includes markers that are described herein (e.g., Tables 1-36; e.g., Tables 3, 10, and 21), but may also include other markers that are in strong LD (e.g., characterized by r^2 greater than 0.1 or 0.2 and/or $|D'| > 0.8$) with one or more of the markers listed in Tables 1-35, including the markers set forth in Tables 3, 10 and 21.

For the SNP markers described herein, the opposite allele to the allele found to be in excess in patients (at-risk allele) is found in decreased frequency in cardiovascular disease. These markers and haplotypes are thus protective for cardiovascular disease, i.e. they confer a decreased risk or susceptibility of individuals carrying these markers and/or haplotypes developing cardiovascular disease.

Certain variants of the present invention, including certain haplotypes comprise, in some cases, a combination of various genetic markers, e.g., SNPs and microsatellites. Detecting haplotypes can be accomplished by methods known in the art and/or described herein for

detecting sequences at polymorphic sites. Furthermore, correlation between certain haplotypes or sets of markers and disease phenotype can be verified using standard techniques. A representative example of a simple test for correlation would be a Fisher-exact test on a two by two table.

5 In specific embodiments, a marker allele or haplotype associated with cardiovascular disease (e.g., marker alleles as listed in Tables 3, 10 and 21) is one in which the marker allele or haplotype is more frequently present in an individual at risk for cardiovascular disease, (affected), compared to the frequency of its presence in a healthy individual (control), wherein the presence of the marker allele or haplotype is indicative of cardiovascular disease or
10 a susceptibility to cardiovascular disease. In other embodiments, at-risk markers in linkage disequilibrium with one or more markers found to be associated with cardiovascular disease, including coronary artery disease and in-stent restenosis (e.g., markers as listed in Tables 3, 10 and 21) are tagging markers that are more frequently present in an individual at risk for cardiovascular disease (affected), compared to the frequency of their presence in a healthy
15 individual (control), wherein the presence of the tagging markers is indicative of increased susceptibility to cardiovascular disease. In a further embodiment, at-risk markers alleles (i.e. conferring increased susceptibility) in linkage disequilibrium with one or more markers found to be associated with cardiovascular disease (e.g., marker alleles as listed in Tables 3, 10 and 21, and markers in linkage disequilibrium therewith), are markers comprising one or more allele that
20 is more frequently present in an individual at risk for cardiovascular disease, compared to the frequency of their presence in a healthy individual (control), wherein the presence of the markers is indicative of increased susceptibility to the cardiovascular disease.

Study population

25 In a general sense, the methods and kits of the invention can be utilized from samples containing nucleic acid material (DNA or RNA) from any source and from any individual. In preferred embodiments, the individual is a human individual. The individual can be an adult, child, or fetus. The nucleic acid source may be any sample comprising nucleic acid material, including biological samples, or a sample comprising nucleic acid material derived therefrom.
30 The present invention also provides for assessing markers and/or haplotypes in individuals who are members of a target population. Such a target population is in one embodiment a population or group of individuals at risk of developing the disease, based on other genetic factors, biomarkers, biophysical parameters (e.g., weight, BMD, blood pressure), or general health and/or lifestyle parameters (e.g., history of disease or related diseases, previous
35 diagnosis of disease, family history of disease).

The invention provides for embodiments that include individuals from specific age subgroups, such as those over the age of 40, over age of 45, or over age of 50, 55, 60, 65, 70, 75, 80, or 85. Other embodiments of the invention pertain to other age groups, such as

individuals aged less than 85, such as less than age 80, less than age 75, or less than age 70, 65, 60, 55, 50, 45, 40, 35, or age 30. Other embodiments relate to individuals with age at onset of the disease in any of the age ranges described in the above. It is also contemplated that a range of ages may be relevant in certain embodiments, such as age at onset at more than age 45 but less than age 60. Other age ranges are however also contemplated, including all age ranges bracketed by the age values listed in the above. The invention furthermore relates to individuals of either gender, males or females.

The Icelandic population is a Caucasian population of Northern European ancestry. A large number of studies reporting results of genetic linkage and association in the Icelandic population have been published in the last few years. Many of those studies show replication of variants, originally identified in the Icelandic population as being associating with a particular disease, in other populations (Stacey, S.N., *et al.*, *Nat Genet.* May 27 2007 (Epub ahead of print; Helgadóttir, A., *et al.*, *Science* 316:1491-93 (2007); Steinthorsdóttir, V., *et al.*, *Nat Genet.* 39:770-75 (2007); Gudmundsson, J., *et al.*, *Nat Genet.* 39:631-37 (2007); Amundadóttir, L.T., *et al.*, *Nat Genet.* 38:652-58 (2006); Grant, S.F., *et al.*, *Nat Genet.* 38:320-23 (2006)). Thus, genetic findings in the Icelandic population have in general been replicated in other populations, including populations from Africa and Asia.

The markers of the present invention found to be associated with cardiovascular disease are believed to show similar association in other human populations. Particular embodiments comprising individual human populations are thus also contemplated and within the scope of the invention. Such embodiments relate to human subjects that are from one or more human population including, but not limited to, Caucasian populations, European populations, American populations, Eurasian populations, Asian populations, Central/South Asian populations, East Asian populations, Middle Eastern populations, African populations, Hispanic populations, and Oceanian populations. European populations include, but are not limited to, Swedish, Norwegian, Finnish, Russian, Danish, Icelandic, Irish, Kelt, English, Scottish, Dutch, Belgian, French, German, Spanish, Portuguese, Italian, Polish, Bulgarian, Slavic, Serbian, Bosnian, Czech, Greek and Turkish populations. The invention furthermore in other embodiments can be practiced in specific human populations that include Bantu, Mandenk, Yoruba, San, Mbuti Pygmy, Orcadian, Adygel, Russian, Sardinian, Tuscan, Mozabite, Bedouin, Druze, Palestinian, Balochi, Brahui, Makrani, Sindhi, Pathan, Burusho, Hazara, Uygur, Kalash, Han, Dai, Daur, Hezhen, Lahu, Miao, Oroqen, She, Tujia, Tu, Xibo, Yi, Mongolian, Naxi, Cambodian, Japanese, Yakut, Melanesian, Papuan, Karitinan, Surui, Colombian, Maya and Pima.

In one preferred embodiment, the invention relates to populations that include black African ancestry such as populations comprising persons of African descent or lineage. Black African ancestry may be determined by self reporting as African-Americans, Afro-Americans, Black Americans, being a member of the black race or being a member of the negro race. For example, African Americans or Black Americans are those persons living in North America and having origins in any of the black racial groups of Africa. In another example, self-reported

persons of black African ancestry may have at least one parent of black African ancestry or at least one grandparent of black African ancestry. In another embodiment, the invention relates to individuals of Caucasian origin.

The racial contribution in individual subjects may also be determined by genetic analysis.

- 5 Genetic analysis of ancestry may be carried out using unlinked microsatellite markers such as those set out in Smith *et al.* (*Am J Hum Genet* **74**, 1001-13 (2004)).

- In certain embodiments, the invention relates to markers and/or haplotypes identified in specific populations, as described in the above. The person skilled in the art will appreciate that measures of linkage disequilibrium (LD) may give different results when applied to different
10 populations. This is due to different population history of different human populations as well as differential selective pressures that may have led to differences in LD in specific genomic regions. It is also well known to the person skilled in the art that certain markers, e.g. SNP markers, have different population frequency in different populations, or are polymorphic in one population but not in another. The person skilled in the art will however apply the methods available and as
15 thought herein to practice the present invention in any given human population. This may include assessment of polymorphic markers in the LD region of the present invention, so as to identify those markers that give strongest association within the specific population. Thus, the at-risk variants of the present invention may reside on different haplotype background and in different frequencies in various human populations. However, utilizing methods known in the art
20 and the markers of the present invention, the invention can be practiced in any given human population.

Utility of Genetic Testing

- The person skilled in the art will appreciate and understand that the variants described
25 herein in general do not, by themselves, provide an absolute identification of individuals who will develop a particular cardiovascular disease. The variants described herein do however indicate increased and/or decreased likelihood that individuals carrying the at-risk or protective variants of the invention will develop symptoms associated with at least one cardiovascular disease (e.g., MI, CAD, IA, AAA, restenosis, stroke PAD). This information is however extremely valuable in
30 itself, as outlined in more detail in the below, as it can be used to, for example, initiate preventive measures at an early stage, perform regular physical and/or mental exams to monitor the progress and/or appearance of symptoms, or to schedule exams at a regular interval to identify early symptoms, so as to be able to apply treatment at an early stage.

- The knowledge about a genetic variant that confers a risk of developing cardiovascular
35 disease offers the opportunity to apply a genetic test to distinguish between individuals with increased risk of developing the disease (i.e. carriers of the at-risk variant) and those with decreased risk of developing the disease (i.e. carriers of the protective variant). The core values

of genetic testing, for individuals belonging to both of the above mentioned groups, are the possibilities of being able to diagnose disease, or a predisposition to disease, at an early stage and provide information to the clinician about prognosis/aggressiveness of disease in order to be able to apply the most appropriate treatment.

5 Individuals with a family history of cardiovascular diseases and carriers of at-risk variants may benefit from genetic testing since the knowledge of the presence of a genetic risk factor, or evidence for increased risk of being a carrier of one or more risk factors, may provide increased incentive for implementing a healthier lifestyle (e.g., lose weight, increase exercise, give up smoking, reduce stress, etc.), by avoiding or minimizing known environmental risk factors for
10 cardiovascular diseases. Genetic testing of patients may furthermore give valuable information about the primary cause of the cardiovascular disease and can aid the clinician in selecting the best treatment options and medication for each individual.

 The present invention can be thus be used for risk assessment for cardiovascular disease, including diagnosing whether an individual is at risk for developing a cardiovascular disease,
15 such as Myocardial Infarction, Coronary Artery Disease, PAD, AAA, IA, stroke or restenosis. The polymorphic markers of the present invention can be used alone or in combination, as well as in combination with other factors, including known biomarkers, for risk assessment of an individual for cardiovascular disease. Many factors known to affect the predisposition of individual towards developing risk of developing Cardiovascular disease are known to the person skilled in the art
20 and can be utilized in such assessment. These include, but are not limited to, age, gender, smoking status, physical activity, waist-to-hip circumference ratio, family history of Cardiovascular Disease, previously diagnosed cardiovascular disease, obesity, diagnosis of Diabetes mellitus, stress, depression, elevated heart rate, hypertriglyceridemia, low HDL cholesterol, hypertension, elevated blood pressure, cholesterol levels, HDL cholesterol, LDL
25 cholesterol, triglycerides, apolipoprotein AI and B levels, fibrinogen, ferritin, C-reactive protein and leukotriene levels. Methods known in the art can be used for such assessment, including multivariate analyses or logistic regression, as described further herein.

METHODS

30 Methods for risk assessment cardiovascular disease are described herein and are encompassed by the invention. The invention also encompasses methods of assessing an individual for probability of response to a therapeutic agent for a cardiovascular disease, methods for predicting the effectiveness of a therapeutic agent for cardiovascular disease, nucleic acids, polypeptides and antibodies and computer-implemented functions. Kits for
35 assaying a sample from a subject to detect susceptibility to cardiovascular disease are also encompassed by the invention.

Diagnostic methods

In certain embodiments, the present invention pertains to methods of diagnosing, or aiding in the diagnosis of, cardiovascular disease (e.g., MI, CAD, IA, AAA, stroke, PAD, restenosis) or a susceptibility to cardiovascular disease, by detecting particular alleles at genetic markers that appear more frequently in subjects with at least one cardiovascular disease or subjects who are susceptible to cardiovascular disease. In a particular embodiment, the invention is a method of diagnosing a susceptibility to cardiovascular disease by detecting at least one allele of at least one polymorphic marker (e.g., the markers described herein). The present invention describes methods whereby detection of particular alleles of particular markers or haplotypes is indicative of a susceptibility to cardiovascular disease. Such prognostic or predictive assays can also be used to determine prophylactic treatment of a subject prior to the onset of symptoms of the cardiovascular disease. The present invention pertains in some embodiments to methods of clinical applications of diagnosis, e.g., diagnosis performed by a medical professional. In other embodiments, the invention pertains to methods of diagnosis or determination of a susceptibility performed by a layman. Recent technological advances in genotyping technologies, including high-throughput genotyping of SNP markers, such as Molecular Inversion Probe array technology (e.g., Affymetrix GeneChip), and BeadArray Technologies (e.g., Illumina GoldenGate and Infinium assays) have made it possible for individuals to have their own genome assessed for up to one million SNPs simultaneously, at relatively little cost. The resulting genotype information, made available to the individual can be compared to information from the public literature about disease or trait risk associated with various SNPs. The diagnostic application of disease-associated alleles as described herein, can thus be performed either by the individual, through analysis of his/her genotype data, or by a health professional based on results of a clinical test. In other words, the diagnosis or assessment of a susceptibility based on genetic risk can be made by health professionals, genetic counselors or by the layman, based on information about his/her genotype and publications on various risk factors. In the present context, the term "diagnosing", "diagnose a susceptibility" and "determine a susceptibility" is meant to refer to any available diagnostic method, including those mentioned above.

In addition, in certain other embodiments, the present invention pertains to methods of diagnosing, or aiding in the diagnosis of, a decreased susceptibility to cardiovascular disease, by detecting particular genetic marker alleles or haplotypes that appear less frequently in patients diagnosed with cardiovascular disease than in individual not diagnosed with cardiovascular disease or in the general population.

As described and exemplified herein, particular marker alleles or haplotypes (e.g. the markers and haplotypes as listed in Tables 3, 10 and 21, and markers in linkage disequilibrium therewith) are associated with cardiovascular disease. In one embodiment, the marker allele or haplotype is one that confers a significant risk or susceptibility to cardiovascular disease. In another embodiment, the invention relates to a method of diagnosing a susceptibility to

cardiovascular disease in a human individual, the method comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, or in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the group consisting of the polymorphic markers listed in Table 3, 10 or 21, and markers in linkage disequilibrium therewith. In another embodiment, the invention pertains to methods of diagnosing a susceptibility to cardiovascular disease in a human individual, by screening for at least one marker allele or haplotype as listed in Table 21 or markers in linkage disequilibrium therewith. In another embodiment, the marker allele or haplotype is more frequently present in a subject having, or who is susceptible to, cardiovascular disease (affected), as compared to the frequency of its presence in a healthy subject (control, such as population controls). In certain embodiments, the significance of association of the at least one marker allele or haplotype is characterized by a p value < 0.05. In other embodiments, the significance of association is characterized by smaller p-values, such as < 0.01, <0.001, <0.0001, <0.00001, <0.000001, <0.0000001, <0.00000001 or <0.000000001.

In these embodiments, the presence of the at least one marker allele or haplotype is indicative of a susceptibility to cardiovascular disease (e.g., MI, CAD, IA, Stroke, AAA, restenosis, PAD). These diagnostic methods involve detecting the presence or absence of at least one marker allele or haplotype that is associated with cardiovascular disease. The haplotypes described herein include combinations of alleles at various genetic markers (e.g., SNPs, microsatellites). The detection of the particular genetic marker alleles that make up the particular haplotypes can be performed by a variety of methods described herein and/or known in the art. For example, genetic markers can be detected at the nucleic acid level (e.g., by direct nucleotide sequencing or by other means known to the skilled in the art) or at the amino acid level if the genetic marker affects the coding sequence of a protein encoded by a cardiovascular disease, including coronary artery disease and in-stent restenosis -associated nucleic acid (e.g., by protein sequencing or by immunoassays using antibodies that recognize such a protein). The marker alleles or haplotypes of the present invention correspond to fragments of a genomic DNA sequence associated with cardiovascular disease. Such fragments encompass the DNA sequence of the polymorphic marker or haplotype in question, but may also include DNA segments in strong LD (linkage disequilibrium) with the marker or haplotype (e.g., as determined by particular values of r^2 and/or $|D'|$).

In one embodiment, diagnosis of a susceptibility to cardiovascular disease can be accomplished using hybridization methods, including, but not limited to, Southern analysis; Northern analysis, and/or *in situ* hybridizations (see Current Protocols In Molecular Biology, Ausubel, F. et al., eds., John Wiley & Sons, including all supplements). The presence of a specific marker allele can be indicated by sequence-specific hybridization of a nucleic acid probe specific for the particular allele. The presence of more than one specific marker allele or a specific haplotype can be indicated by using several sequence-specific nucleic acid probes, each being specific for a particular allele. In one embodiment, a haplotype can be indicated by a

single nucleic acid probe that is specific for the specific haplotype (i.e., hybridizes specifically to a DNA strand comprising the specific marker alleles characteristic of the haplotype). A sequence-specific probe can be directed to hybridize to genomic DNA, RNA, or cDNA. A "nucleic acid probe", as used herein, can be a DNA probe or an RNA probe that hybridizes to a complementary sequence. One of skill in the art would know how to design such a probe so that sequence specific hybridization will occur only if a particular allele is present in a genomic sequence from a test sample.

To determine or diagnose a susceptibility to cardiovascular disease, a hybridization sample is formed by contacting the test sample containing an cardiovascular disease -associated nucleic acid, such as a genomic DNA sample, with at least one nucleic acid probe. A non-limiting example of a probe for detecting mRNA or genomic DNA is a labeled nucleic acid probe that is capable of hybridizing to mRNA or genomic DNA sequences described herein. The nucleic acid probe can be, for example, a full-length nucleic acid molecule, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length that is sufficient to specifically hybridize under stringent conditions to appropriate mRNA or genomic DNA. For example, the nucleic acid probe can comprise all or a portion of the nucleotide sequence of LD Block C09 (SEQ ID NO:94), as described herein, optionally comprising at least one allele of a marker described herein, or at least one haplotype described herein, or the probe can be the complementary sequence of such a sequence. In a particular embodiment, the nucleic acid probe is a portion of the nucleotide sequence of LD Block C09 (SEQ ID NO:94), as described herein, optionally comprising at least one allele of a marker described herein, or at least one allele of one polymorphic marker or haplotype comprising at least one polymorphic marker described herein, or the probe can be the complementary sequence of such a sequence. Other suitable probes for use in the diagnostic assays of the invention are described herein.

Hybridization can be performed by methods well known to the person skilled in the art (see, e.g., Current Protocols in Molecular Biology, Ausubel, F. et al., eds., John Wiley & Sons, including all supplements). In one embodiment, hybridization refers to specific hybridization, i.e., hybridization with no mismatches (exact hybridization). In one embodiment, the hybridization conditions for specific hybridization are high stringency.

Specific hybridization, if present, is then detected using standard methods. If specific hybridization occurs between the nucleic acid probe and the coronary artery disease and in-stent restenosis -associated nucleic acid in the test sample, then the sample contains the allele that is complementary to the nucleotide that is present in the nucleic acid probe. The process can be repeated for other markers of the present invention, or markers that make up a haplotype of the present invention, or multiple probes can be used concurrently to detect more than one marker alleles at a time. It is also possible to design a single probe containing more than one marker alleles of a particular haplotype (e.g., a probe containing alleles complementary to 2, 3, 4, 5 or all of the markers that make up a particular haplotype). Detection of the particular markers of the haplotype in the sample is indicative that the source of the sample has the particular

haplotype (e.g., a haplotype) and therefore is susceptible to cardiovascular disease (e.g., MI, CAD, IA, Stroke, AAA, restenosis, PAD).

In one preferred embodiment, a method utilizing a detection oligonucleotide probe comprising a fluorescent moiety or group at its 3' terminus and a quencher at its 5' terminus, and an enhancer oligonucleotide, is employed, as described by Kutayavin *et al.* (*Nucleic Acid Res.* 34:e128 (2006)). The fluorescent moiety can be GIG Harbor Green or Yakima Yellow, or other suitable fluorescent moieties. The detection probe is designed to hybridize to a short nucleotide sequence that includes the SNP polymorphism to be detected. Preferably, the SNP is anywhere from the terminal residue to -6 residues from the 3' end of the detection probe. The enhancer is a short oligonucleotide probe which hybridizes to the DNA template 3' relative to the detection probe. The probes are designed such that a single nucleotide gap exists between the detection probe and the enhancer nucleotide probe when both are bound to the template. The gap creates a synthetic abasic site that is recognized by an endonuclease, such as Endonuclease IV. The enzyme cleaves the dye off the fully complementary detection probe, but cannot cleave a detection probe containing a mismatch. Thus, by measuring the fluorescence of the released fluorescent moiety, assessment of the presence of a particular allele defined by nucleotide sequence of the detection probe can be performed.

The detection probe can be of any suitable size, although preferably the probe is relatively short. In one embodiment, the probe is from 5-100 nucleotides in length. In another embodiment, the probe is from 10-50 nucleotides in length, and in another embodiment, the probe is from 12-30 nucleotides in length. Other lengths of the probe are possible and within scope of the skill of the average person skilled in the art.

In a preferred embodiment, the DNA template containing the SNP polymorphism is amplified by Polymerase Chain Reaction (PCR) prior to detection. In such an embodiment, the amplified DNA serves as the template for the detection probe and the enhancer probe.

Certain embodiments of the detection probe, the enhancer probe, and/or the primers used for amplification of the template by PCR include the use of modified bases, including modified A and modified G. The use of modified bases can be useful for adjusting the melting temperature of the nucleotide molecule (probe and/or primer) to the template DNA, for example for increasing the melting temperature in regions containing a low percentage of G or C bases, in which modified A with the capability of forming three hydrogen bonds to its complementary T can be used, or for decreasing the melting temperature in regions containing a high percentage of G or C bases, for example by using modified G bases that form only two hydrogen bonds to their complementary C base in a double stranded DNA molecule. In a preferred embodiment, modified bases are used in the design of the detection nucleotide probe. Any modified base known to the skilled person can be selected in these methods, and the selection of suitable bases is well within the scope of the skilled person based on the teachings herein and known bases available from commercial sources as known to the skilled person.

In another hybridization method, Northern analysis (see Current Protocols in Molecular Biology, Ausubel, F. et al., eds., John Wiley & Sons, *supra*) is used to identify the presence of a polymorphism associated with cardiovascular disease. For Northern analysis, a test sample of RNA is obtained from the subject by appropriate means. As described herein, specific hybridization of a nucleic acid probe to RNA from the subject is indicative of a particular allele complementary to the probe. For representative examples of use of nucleic acid probes, see, for example, U.S. Patent Nos. 5,288,611 and 4,851,330.

Additionally, or alternatively, a peptide nucleic acid (PNA) probe can be used in addition to, or instead of, a nucleic acid probe in the hybridization methods described herein. A PNA is a DNA mimic having a peptide-like, inorganic backbone, such as N-(2-aminoethyl)glycine units, with an organic base (A, G, C, T or U) attached to the glycine nitrogen via a methylene carbonyl linker (see, for example, Nielsen, P., et al., *Bioconjug. Chem.* 5:3-7 (1994)). The PNA probe can be designed to specifically hybridize to a molecule in a sample suspected of containing one or more of the marker alleles or haplotypes that are associated with cardiovascular disease. Hybridization of the PNA probe is thus diagnostic for cardiovascular disease.

In one embodiment of the invention, a test sample containing genomic DNA obtained from the subject is collected and the polymerase chain reaction (PCR) is used to amplify a fragment comprising one or more markers or haplotypes of the present invention. As described herein, identification of a particular marker allele or haplotype associated with cardiovascular disease, can be accomplished using a variety of methods (e.g., sequence analysis, analysis by restriction digestion, specific hybridization, single stranded conformation polymorphism assays (SSCP), electrophoretic analysis, etc.). In another embodiment, diagnosis is accomplished by expression analysis using quantitative PCR (kinetic thermal cycling). This technique can, for example, utilize commercially available technologies, such as TaqMan® (Applied Biosystems, Foster City, CA). The technique can assess the presence of an alteration in the expression or composition of a polypeptide or splicing variant(s) that is encoded by a nucleic acid associated with a cardiovascular disease. Further, the expression of the variant(s) can be quantified as physically or functionally different.

In another embodiment of the methods of the invention, analysis by restriction digestion can be used to detect a particular allele if the allele results in the creation or elimination of a restriction site relative to a reference sequence. A test sample containing genomic DNA is obtained from the subject. PCR can be used to amplify particular regions that are associated with cardiovascular disease (e.g. the polymorphic markers and haplotypes of Table 3, 10 or 21, and markers in linkage disequilibrium therewith) nucleic acid in the test sample from the test subject. Restriction fragment length polymorphism (RFLP) analysis can be conducted, e.g., as described in Current Protocols in Molecular Biology, *supra*. The digestion pattern of the relevant DNA fragment indicates the presence or absence of the particular allele in the sample.

Sequence analysis can also be used to detect specific alleles at polymorphic sites associated with cardiovascular disease, including coronary artery disease and in-stent restenosis (e.g. the polymorphic markers and haplotypes of Table 3, 10 or 21, and markers in linkage disequilibrium therewith). Therefore, in one embodiment, determination of the presence or absence of a particular marker alleles or haplotypes comprises sequence analysis. For example, a test sample of DNA or RNA can be obtained from the test subject. PCR or other appropriate methods can be used to amplify a portion of a nucleic acid associated with cardiovascular disease, and the presence of a specific allele can then be detected directly by sequencing the polymorphic site (or multiple polymorphic sites) of the genomic DNA in the sample.

In another embodiment, arrays of oligonucleotide probes that are complementary to target nucleic acid sequence segments from a subject, can be used to identify polymorphisms in a nucleic acid associated with cardiovascular disease (e.g. the polymorphic markers of Table 3, 10, and 21, and markers in linkage disequilibrium therewith). For example, an oligonucleotide array can be used. Oligonucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. These arrays can generally be produced using mechanical synthesis methods or light directed synthesis methods that incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis methods, or by other methods known to the person skilled in the art (see, e.g., Fodor, S. et al., *Science*, 251:767-773 (1991); Pirrung et al., U.S. Patent No. 5,143,854 (see also published PCT Application No. WO 90/15070); and Fodor, S. et al., published PCT Application No. WO 92/10092 and U.S. Patent No. 5,424,186, the entire teachings of each of which are incorporated by reference herein). Techniques for the synthesis of these arrays using mechanical synthesis methods are described in, e.g., U.S. Patent No. 5,384,261; the entire teachings of which are incorporated by reference herein. In another example, linear arrays can be utilized. Additional descriptions of use of oligonucleotide arrays for detection of polymorphisms can be found, for example, in U.S. Patent Nos. 5,858,659 and 5,837,832, the entire teachings of both of which are incorporated by reference herein.

Other methods of nucleic acid analysis that are available to those skilled in the art can be used to detect a particular allele at a polymorphic site associated with cardiovascular disease. Representative methods include, for example, direct manual sequencing (Church and Gilbert, *Proc. Natl. Acad. Sci. USA*, 81: 1991-1995 (1988); Sanger, F., et al., *Proc. Natl. Acad. Sci. USA*, 74:5463-5467 (1977); Beavis, et al., U.S. Patent No. 5,288,644); automated fluorescent sequencing; single-stranded conformation polymorphism assays (SSCP); clamped denaturing gel electrophoresis (CDGE); denaturing gradient gel electrophoresis (DGGE) (Sheffield, V., et al., *Proc. Natl. Acad. Sci. USA*, 86:232-236 (1989)), mobility shift analysis (Orita, M., et al., *Proc. Natl. Acad. Sci. USA*, 86:2766-2770 (1989)), restriction enzyme analysis (Fiavell, R., et al., *Cell*, 15:25-41 (1978); Geever, R., et al., *Proc. Natl. Acad. Sci. USA*, 78:5081-5085 (1981)); heteroduplex analysis; chemical mismatch cleavage (CMC) (Cotton, R., et al., *Proc. Natl. Acad. Sci. USA*, 85:4397-4401 (1985)); RNase protection assays (Myers, R., et al., *Science*, 230:1242-

1246 (1985); use of polypeptides that recognize nucleotide mismatches, such as *E. coli* mutS protein; and allele-specific PCR.

In another embodiment of the invention, diagnosis of cardiovascular disease or a susceptibility to cardiovascular disease can be made by examining expression and/or composition of a polypeptide encoded by a nucleic acid associated with cardiovascular disease in those instances where the genetic marker(s) or haplotype(s) of the present invention result in a change in the composition or expression of the polypeptide. Thus, diagnosis of a susceptibility to cardiovascular disease can be made by examining expression and/or composition of one of these polypeptides, or another polypeptide encoded by a nucleic acid associated with cardiovascular disease, in those instances where the genetic marker or haplotype of the present invention results in a change in the composition or expression of the polypeptide. The haplotypes and markers of the present invention that show association to cardiovascular disease may play a role through their effect on one or more of these nearby genes (e.g., the CDKN2A and CDKN2B genes). Possible mechanisms affecting these genes include, e.g., effects on transcription, effects on RNA splicing, alterations in relative amounts of alternative splice forms of mRNA, effects on RNA stability, effects on transport from the nucleus to cytoplasm, and effects on the efficiency and accuracy of translation.

Thus, in another embodiment, the variants (markers or haplotypes) of the invention showing association to cardiovascular disease affect the expression of a nearby gene (e.g., CDKN2A and/or CDKN2B). It is well known that regulatory element affecting gene expression may be located far away, even as far as tenths or hundreds of kilobases away, from the promoter region of a gene. By assaying for the presence or absence of at least one allele of at least one polymorphic marker of the present invention, it is thus possible to assess the expression level of such nearby genes. It is thus contemplated that the detection of the markers or haplotypes of the present invention can be used for assessing expression for one or more of the CDKN2A and/or CDKN2B genes.

A variety of methods can be used for detecting protein expression levels, including enzyme linked immunosorbent assays (ELISA), Western blots, immunoprecipitations and immunofluorescence. A test sample from a subject is assessed for the presence of an alteration in the expression and/or an alteration in composition of the polypeptide encoded by a nucleic acid associated with cardiovascular disease. An alteration in expression of a polypeptide encoded by a nucleic acid associated with cardiovascular disease can be, for example, an alteration in the quantitative polypeptide expression (i.e., the amount of polypeptide produced). An alteration in the composition of a polypeptide encoded by a nucleic acid associated with a cardiovascular disease is an alteration in the qualitative polypeptide expression (e.g., expression of a mutant polypeptide or of a different splicing variant). In one embodiment, diagnosis of a susceptibility to cardiovascular disease is made by detecting a particular splicing variant encoded by a nucleic acid associated with cardiovascular disease, or a particular pattern of splicing variants.

Both such alterations (quantitative and qualitative) can also be present. An "alteration" in the polypeptide expression or composition (e.g., the CDKN2A and/or CDKN2B polypeptides), as used herein, refers to an alteration in expression or composition in a test sample, as compared to the expression or composition of the polypeptide in a control sample. A control sample is a sample that corresponds to the test sample (e.g., is from the same type of cells), and is from a subject who is not affected by, and/or who does not have a susceptibility to, cardiovascular disease. In one embodiment, the control sample is from a subject that does not possess a marker allele or haplotype associated with cardiovascular disease, as described herein. Similarly, the presence of one or more different splicing variants in the test sample, or the presence of significantly different amounts of different splicing variants in the test sample, as compared with the control sample, can be indicative of a susceptibility to cardiovascular disease. An alteration in the expression or composition of the polypeptide in the test sample, as compared with the control sample, can be indicative of a specific allele in the instance where the allele alters a splice site relative to the reference in the control sample. Various means of examining expression or composition of a polypeptide encoded by a nucleic acid are known to the person skilled in the art and can be used, including spectroscopy, colorimetry, electrophoresis, isoelectric focusing, and immunoassays (e.g., David et al., U.S. Pat. No. 4,376,110) such as Immunoblotting (see, e.g., Current Protocols In Molecular Biology, particularly chapter 10, *supra*).

For example, in one embodiment, an antibody (e.g., an antibody with a detectable label) that is capable of binding to a polypeptide encoded by a nucleic acid associated with cardiovascular disease (e.g., CDKN2A and/or CDKN2B polypeptides) can be used. Antibodies can be polyclonal or monoclonal. An intact antibody, or a fragment thereof (e.g., Fv, Fab, Fab', F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a labeled secondary antibody (e.g., a fluorescently-labeled secondary antibody) and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin.

In one embodiment of this method, the level or amount of polypeptide encoded by a nucleic acid associated with cardiovascular disease in a test sample is compared with the level or amount of the polypeptide in a control sample. A level or amount of the polypeptide in the test sample that is higher or lower than the level or amount of the polypeptide in the control sample, such that the difference is statistically significant, is indicative of an alteration in the expression of the polypeptide encoded by the nucleic acid, and is diagnostic for a particular allele or haplotype responsible for causing the difference in expression. Alternatively, the composition of the polypeptide in a test sample is compared with the composition of the polypeptide in a control sample. In another embodiment, both the level or amount and the composition of the polypeptide can be assessed in the test sample and in the control sample.

In another embodiment, the diagnosis of a susceptibility to cardiovascular disease is made by detecting at least one marker or haplotypes of the present invention (e.g., associated alleles of the markers listed in Table 3, 10 and/or 21, and markers in linkage disequilibrium therewith), in combination with an additional protein-based, RNA-based or DNA-based assay.

5

Kits

Kits useful in the methods of the invention comprise components useful in any of the methods described herein, including for example, primers for nucleic acid amplification, hybridization probes, restriction enzymes (e.g., for RFLP analysis), allele-specific
 10 oligonucleotides, antibodies that bind to an altered polypeptide encoded by a nucleic acid associated with cardiovascular disease (e.g., MI, CAD, IA, Stroke, AAA, restenosis, PAD) (e.g., antibodies that bind to a polypeptide encoded by LD Block C09 (SEQ ID NO:94), or the CDKN2A and/or CDKN2B genes or fragments thereof, e.g., a genomic segment comprising at least one polymorphic marker and/or haplotype of the present invention) or to a non-altered (native)
 15 polypeptide encoded by a nucleic acid associated with a cardiovascular disease, means for amplification of a nucleic acid associated with a cardiovascular disease, means for analyzing the nucleic acid sequence of a nucleic acid associated with a cardiovascular disease, means for analyzing the amino acid sequence of a polypeptide encoded by a nucleic acid associated with a cardiovascular disease, etc. The kits can for example include necessary buffers, nucleic acid
 20 primers for amplifying nucleic acids of the invention (e.g., a nucleic acid segment comprising one or more of the polymorphic markers as described herein), and reagents for allele-specific detection of the fragments amplified using such primers and necessary enzymes (e.g., DNA polymerase). Additionally, kits can provide reagents for assays to be used in combination with the methods of the present invention, e.g., reagents for use with other diagnostic assays as
 25 described herein.

In one embodiment, the invention pertains to a kit for assaying a sample from a subject to detect cardiovascular disease or a susceptibility to cardiovascular disease, wherein the kit comprises reagents necessary for selectively detecting at least one allele of at least one polymorphism of the present invention in the genome of the individual. In a particular
 30 embodiment, the reagents comprise at least one contiguous oligonucleotide that hybridizes to a fragment of the genome of the individual comprising at least one polymorphism of the present invention. In another embodiment, the reagents comprise at least one pair of oligonucleotides that hybridize to opposite strands of a genomic segment obtained from a subject, wherein each oligonucleotide primer pair is designed to selectively amplify a fragment of the genome of the
 35 individual that includes one polymorphism, wherein the polymorphism is selected from the group consisting of the polymorphisms as listed in any of the Tables 3, 10 and 21, and polymorphic markers in linkage disequilibrium therewith. In yet another embodiment the fragment is at least 20 base pairs in size. Such oligonucleotides or nucleic acids (e.g., oligonucleotide primers) can

be designed using portions of the nucleic acids flanking polymorphisms (e.g., SNPs or microsatellites) that are indicative of a cardiovascular disease. In another embodiment, the kit comprises one or more labeled nucleic acids capable of detecting one or more specific polymorphic markers or haplotypes associated with cardiovascular disease, and reagents for detection of the label. Suitable labels include, e.g., a radiolabel, a fluorescent label, an enzyme label, an enzyme co-factor label, a magnetic label, a spin label, an epitope label.

In particular embodiments, the polymorphic marker or haplotype to be detected by the reagents of the kit comprises one or more markers, two or more markers, three or more markers, four or more markers or five or more markers selected from the group consisting of the markers in Table 3, 10 and 21, and markers in linkage disequilibrium therewith. In another embodiment, the marker or haplotype to be detected comprises the markers listed in Table 3, 10 or 21. In another embodiment, the marker or haplotype to be detected comprises at least one marker from the group of markers in strong linkage disequilibrium, as defined by values of r^2 greater than 0.2, to at least one of the group of markers consisting of rs10757278, rs10116277, rs1333040, D9S1814, D9S1870 and rs2383207. In yet another embodiment, the marker or haplotype to be detected comprises at least one marker selected from the group of markers consisting of rs10757278, rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970, rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, and D9S1870.

In one preferred embodiment, the kit for detecting the markers of the invention comprises a detection oligonucleotide probe, that hybridizes to a segment of template DNA containing a SNP polymorphisms to be detected, an enhancer oligonucleotide probe and an endonuclease. As explained in the above, the detection oligonucleotide probe comprises a fluorescent moiety or group at its 3' terminus and a quencher at its 5' terminus, and an enhancer oligonucleotide, is employed, as described by Kutayavin et al. (*Nucleic Acid Res.* 34:e128 (2006)). The fluorescent moiety can be Gg Harbor Green or Yakima Yellow, or other suitable fluorescent moieties. The detection probe is designed to hybridize to a short nucleotide sequence that includes the SNP polymorphism to be detected. Preferably, the SNP is anywhere from the terminal residue to -6 residues from the 3' end of the detection probe. The enhancer is a short oligonucleotide probe which hybridizes to the DNA template 3' relative to the detection probe. The probes are designed such that a single nucleotide gap exists between the detection probe and the enhancer nucleotide probe when both are bound to the template. The gap creates a synthetic abasic site that is recognized by an endonuclease, such as Endonuclease IV. The enzyme cleaves the dye off the fully complementary detection probe, but cannot cleave a detection probe containing a mismatch. Thus, by measuring the fluorescence of the released fluorescent moiety, assessment of the presence of a particular allele defined by nucleotide sequence of the detection probe can be performed.

The detection probe can be of any suitable size, although preferably the probe is relatively short. In one embodiment, the probe is from 5-100 nucleotides in length. In another

embodiment, the probe is from 10-50 nucleotides in length, and in another embodiment, the probe is from 12-30 nucleotides in length. Other lengths of the probe are possible and within scope of the skill of the average person skilled in the art.

In a preferred embodiment, the DNA template containing the SNP polymorphism is amplified by Polymerase Chain Reaction (PCR) prior to detection, and primers for such amplification are included in the reagent kit. In such an embodiment, the amplified DNA serves as the template for the detection probe and the enhancer probe.

Certain embodiments of the detection probe, the enhancer probe, and/or the primers used for amplification of the template by PCR include the use of modified bases, including modified A and modified G. The use of modified bases can be useful for adjusting the melting temperature of the nucleotide molecule (probe and/or primer) to the template DNA, for example for increasing the melting temperature in regions containing a low percentage of G or C bases, in which modified A with the capability of forming three hydrogen bonds to its complementary T can be used, or for decreasing the melting temperature in regions containing a high percentage of G or C bases, for example by using modified G bases that form only two hydrogen bonds to their complementary C base in a double stranded DNA molecule. In a preferred embodiment, modified bases are used in the design of the detection nucleotide probe. Any modified base known to the skilled person can be selected in these methods, and the selection of suitable bases is well within the scope of the skilled person based on the teachings herein and known bases available from commercial sources as known to the skilled person.

In one such embodiment, the presence of the marker or haplotype is indicative of a susceptibility (increased susceptibility or decreased susceptibility) to Cardiovascular disease. In another embodiment, the presence of the marker or haplotype is indicative of response to a therapeutic agent for a Cardiovascular disease. In another embodiment, the presence of the marker or haplotype is indicative of prognosis of a Cardiovascular disease. In yet another embodiment, the presence of the marker or haplotype is indicative of progress of treatment of a cardiovascular disease. Such treatment may include intervention by surgery, medication or by other means (e.g., lifestyle changes).

In a further aspect of the present invention, a pharmaceutical pack (kit) is provided, the pack comprising a therapeutic agent and a set of instructions for administration of the therapeutic agent to humans diagnostically tested for one or more variants of the present invention, as disclosed herein. The therapeutic agent can be a small molecule drug, an antibody, a peptide, an antisense or RNAi molecule, or other therapeutic molecules. In one embodiment, an individual identified as a carrier of at least one variant of the present invention is instructed to take a prescribed dose of the therapeutic agent. In one such embodiment, an individual identified as a homozygous carrier of at least one variant of the present invention is instructed to take a prescribed dose of the therapeutic agent. In another embodiment, an individual identified

as a non-carrier of at least one variant of the present invention is instructed to take a prescribed dose of the therapeutic agent.

In certain embodiments, the kit further comprises a set of instructions for using the reagents comprising the kit.

Therapeutic agents

Variants of the present invention (e.g., the markers and/or haplotypes of the invention as described herein, e.g., the markers listed in Table 3, 10 and 21) can be used to identify novel therapeutic targets for cardiovascular disease. For example, genes containing, or in linkage disequilibrium with, variants (markers and/or haplotypes) associated with cardiovascular disease, or their products (e.g., the CDKN2A and CDKN2B genes and their gene products), as well as genes or their products that are directly or indirectly regulated by or interact with these genes or their products, can be targeted for the development of therapeutic agents to treat cardiovascular disease, or prevent or delay onset of symptoms associated with cardiovascular disease. Therapeutic agents may comprise one or more of, for example, small non-protein and non-nucleic acid molecules, proteins, peptides, protein fragments, nucleic acids (DNA, RNA), PNA (peptide nucleic acids), or their derivatives or mimetics which can modulate the function and/or levels of the target genes or their gene products.

The nucleic acids and/or variants of the invention, or nucleic acids comprising their complementary sequence, may be used as antisense constructs to control gene expression in cells, tissues or organs. The methodology associated with antisense techniques is well known to the skilled artisan, and is described and reviewed in *Antisense Drug Technology: Principles, Strategies, and Applications*, Crooke, ed., Marcel Dekker Inc., New York (2001). In general, antisense nucleic acid molecules are designed to be complementary to a region of mRNA expressed by a gene, so that the antisense molecule hybridizes to the mRNA, thus blocking translation of the mRNA into protein. Several classes of antisense oligonucleotide are known to those skilled in the art, including cleavers and blockers. The former bind to target RNA sites, activate intracellular nucleases (e.g., RNaseH or RNase L), that cleave the target RNA. Blockers bind to target RNA, inhibit protein translation by steric hindrance of the ribosomes. Examples of blockers include nucleic acids, morpholino compounds, locked nucleic acids and methylphosphonates (Thompson, *Drug Discovery Today*, 7:912-917 (2002)). Antisense oligonucleotides are useful directly as therapeutic agents, and are also useful for determining and validating gene function, for example by gene knock-out or gene knock-down experiments. Antisense technology is further described in Lavery et al., *Curr. Opin. Drug Discov. Devel.* 6:561-569 (2003), Stephens et al., *Curr. Opin. Mol. Ther.* 5:118-122 (2003), Kurreck, *Eur. J. Biochem.* 270:1628-44 (2003), Dias et al., *Mol. Cancer Ther.* 1:347-55 (2002), Chen, *Methods Mol. Med.* 75:621-636 (2003), Wang et al., *Curr. Cancer Drug Targets* 1:177-96 (2001), and Bennett, *Antisense Nucleic Acid Drug Dev.* 12:215-24 (2002).

The variants described herein can be used for the selection and design of antisense reagents that are specific for particular variants. Using information about the variants described herein, antisense oligonucleotides or other antisense molecules that specifically target mRNA molecules that contain one or more variants of the invention can be designed. In this manner, expression of mRNA molecules that contain one or more variant of the present invention (markers and/or haplotypes) can be inhibited or blocked. In one embodiment, the antisense molecules are designed to specifically bind a particular allelic form (i.e., one or several variants (alleles and/or haplotypes)) of the target nucleic acid, thereby inhibiting translation of a product originating from this specific allele or haplotype, but which do not bind other or alternate variants at the specific polymorphic sites of the target nucleic acid molecule.

As antisense molecules can be used to inactivate mRNA so as to inhibit gene expression, and thus protein expression, the molecules can be used to treat a disease or disorder, such as a cardiovascular disease. The methodology can involve cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Such mRNA regions include, for example, protein-coding regions, in particular protein-coding regions corresponding to catalytic activity, substrate and/or ligand binding sites, or other functional domains of a protein.

The phenomenon of RNA interference (RNAi) has been actively studied for the last decade, since its original discovery in *C. elegans* (Fire *et al.*, *Nature* 391:806-11 (1998)), and in recent years its potential use in treatment of human disease has been actively pursued (reviewed in Kim & Rossi, *Nature Rev. Genet.* 8:173-204 (2007)). RNA interference (RNAi), also called gene silencing, is based on using double-stranded RNA molecules (dsRNA) to turn off specific genes. In the cell, cytoplasmic double-stranded RNA molecules (dsRNA) are processed by cellular complexes into small interfering RNA (siRNA). The siRNA guide the targeting of a protein-RNA complex to specific sites on a target mRNA, leading to cleavage of the mRNA (Thompson, *Drug Discovery Today*, 7:912-917 (2002)). The siRNA molecules are typically about 20, 21, 22 or 23 nucleotides in length. Thus, one aspect of the invention relates to isolated nucleic acid molecules, and the use of those molecules for RNA interference, i.e. as small interfering RNA molecules (siRNA). In one embodiment, the isolated nucleic acid molecules are 18-26 nucleotides in length, preferably 19-25 nucleotides in length, more preferably 20-24 nucleotides in length, and more preferably 21, 22 or 23 nucleotides in length.

Another pathway for RNAi-mediated gene silencing originates in endogenously encoded primary microRNA (pri-miRNA) transcripts, which are processed in the cell to generate precursor miRNA (pre-miRNA). These miRNA molecules are exported from the nucleus to the cytoplasm, where they undergo processing to generate mature miRNA molecules (miRNA), which direct translational inhibition by recognizing target sites in the 3' untranslated regions of mRNAs, and subsequent mRNA degradation by processing P-bodies (reviewed in Kim & Rossi, *Nature Rev. Genet.* 8:173-204 (2007)).

Clinical applications of RNAi include the incorporation of synthetic siRNA duplexes, which preferably are approximately 20-23 nucleotides in size, and preferably have 3' overlaps of 2 nucleotides. Knockdown of gene expression is established by sequence-specific design for the target mRNA. Several commercial sites for optimal design and synthesis of such molecules are known to those skilled in the art.

Other applications provide longer siRNA molecules (typically 25-30 nucleotides in length, preferably about 27 nucleotides), as well as small hairpin RNAs (shRNAs; typically about 29 nucleotides in length). The latter are naturally expressed, as described in Amarzguoui *et al.* (*FEBS Lett.* 579:5974-81 (2005)). Chemically synthetic siRNAs and shRNAs are substrates for *in vivo* processing, and in some cases provide more potent gene-silencing than shorter designs (Kim *et al.*, *Nature Biotechnol.* 23:222-226 (2005); Siolas *et al.*, *Nature Biotechnol.* 23:227-231 (2005)). In general siRNAs provide for transient silencing of gene expression, because their intracellular concentration is diluted by subsequent cell divisions. By contrast, expressed shRNAs mediate long-term, stable knockdown of target transcripts, for as long as transcription of the shRNA takes place (Marques *et al.*, *Nature Biotechnol.* 23:559-565 (2006); Brummelkamp *et al.*, *Science* 296: 550-553 (2002)).

Since RNAi molecules, including siRNA, miRNA and shRNA, act in a sequence-dependent manner, the variants of the present invention (*e.g.*, the markers and haplotypes set forth in Tables 3, 10 and 21) can be used to design RNAi reagents that recognize specific nucleic acid molecules comprising specific alleles and/or haplotypes (*e.g.*, the alleles and/or haplotypes of the present invention), while not recognizing nucleic acid molecules comprising other alleles or haplotypes. These RNAi reagents can thus recognize and destroy the target nucleic acid molecules. As with antisense reagents, RNAi reagents can be useful as therapeutic agents (*i.e.*, for turning off disease-associated genes or disease-associated gene variants), but may also be useful for characterizing and validating gene function (*e.g.*, by gene knock-out or gene knock-down experiments).

Delivery of RNAi may be performed by a range of methodologies known to those skilled in the art. Methods utilizing non-viral delivery include cholesterol, stable nucleic acid-lipid particle (SNALP), heavy-chain antibody fragment (Fab), aptamers and nanoparticles. Viral delivery methods include use of lentivirus, adenovirus and adeno-associated virus. The siRNA molecules are in some embodiments chemically modified to increase their stability. This can include modifications at the 2' position of the ribose, including 2'-O-methylpurines and 2'-fluoropyrimidines, which provide resistance to RNase activity. Other chemical modifications are possible and known to those skilled in the art.

The following references provide a further summary of RNAi, and possibilities for targeting specific genes using RNAi: Kim & Rossi, *Nat. Rev. Genet.* 8:173-184 (2007), Chen & Rajewsky, *Nat. Rev. Genet.* 8: 93-103 (2007), Reynolds, *et al.*, *Nat. Biotechnol.* 22:326-330 (2004), Chi *et al.*, *Proc. Natl. Acad. Sci. USA* 100:6343-6346 (2003), Vickers *et al.*, *J. Biol.*

Chem. 278:7108-7118 (2003), Agami, *Curr. Opin. Chem. Biol.* 6:829-834 (2002), Lavery, *et al.*, *Curr. Opin. Drug Discov. Devel.* 6:561-569 (2003), Shi, *Trends Genet.* 19:9-12 (2003), Shuey *et al.*, *Drug Discov. Today* 7:1040-46 (2002), McManus *et al.*, *Nat. Rev. Genet.* 3:737-747 (2002), Xia *et al.*, *Nat. Biotechnol.* 20:1006-10 (2002), Plasterk *et al.*, *curr. Opin. Genet. Dev.* 10:562-7
 5 (2000), Boshier *et al.*, *Nat. Cell Biol.* 2:E31-6 (2000), and Hunter, *Curr. Biol.* 9:R440-442 (1999).

A genetic defect leading to increased predisposition or risk for development of a cardiovascular disease, or a defect causing the disease, may be corrected permanently by administering to a subject carrying the defect a nucleic acid fragment that incorporates a repair sequence that supplies the normal/wild-type nucleotide(s) at the site of the genetic defect. Such
 10 site-specific repair sequence may encompass an RNA/DNA oligonucleotide that operates to promote endogenous repair of a subject's genomic DNA. The administration of the repair sequence may be performed by an appropriate vehicle, such as a complex with polyethelenimine, encapsulated in anionic liposomes, a viral vector such as an adenovirus vector, or other pharmaceutical compositions suitable for promoting intracellular uptake of the
 15 administered nucleic acid. The genetic defect may then be overcome, since the chimeric oligonucleotides induce the incorporation of the normal sequence into the genome of the subject, leading to expression of the normal/wild-type gene product. The replacement is propagated, thus rendering a permanent repair and alleviation of the symptoms associated with the disease or condition.

The present invention provides methods for identifying compounds or agents that can be used to treat cardiovascular disease. Thus, the variants of the invention are useful as targets for the identification and/or development of therapeutic agents. In certain embodiments, such methods include assaying the ability of an agent or compound to modulate the activity and/or
 25 expression of a nucleic acid that includes at least one of the variants (markers and/or haplotypes) of the present invention, or the encoded product of the nucleic acid (e.g., one or both of the CDKN2A and CDKN2B genes). This in turn can be used to identify agents or compounds that inhibit or alter the undesired activity or expression of the encoded nucleic acid product. Assays for performing such experiments can be performed in cell-based systems or in cell-free systems, as known to the skilled person. Cell-based systems include cells naturally expressing
 30 the nucleic acid molecules of interest, or recombinant cells that have been genetically modified so as to express a certain desired nucleic acid molecule.

Variant gene expression in a patient can be assessed by expression of a variant-containing nucleic acid sequence (for example, a gene containing at least one variant of the present invention, which can be transcribed into RNA containing the at least one variant, and in
 35 turn translated into protein), or by altered expression of a normal/wild-type nucleic acid sequence due to variants affecting the level or pattern of expression of the normal transcripts, for example variants in the regulatory or control region of the gene. Assays for gene expression include direct nucleic acid assays (mRNA), assays for expressed protein levels, or assays of collateral compounds involved in a pathway, for example a signal pathway. Furthermore, the

expression of genes that are up- or down-regulated in response to the signal pathway can also be assayed. One embodiment includes operably linking a reporter gene, such as luciferase, to the regulatory region of the gene(s) of interest.

5 Modulators of gene expression can in one embodiment be identified when a cell is contacted with a candidate compound or agent, and the expression of mRNA is determined. The expression level of mRNA in the presence of the candidate compound or agent is compared to the expression level in the absence of the compound or agent. Based on this comparison, candidate compounds or agents for treating cardiovascular disease can be identified as those modulating the gene expression of the variant gene. When expression of mRNA or the encoded
10 protein is statistically significantly greater in the presence of the candidate compound or agent than in its absence, then the candidate compound or agent is identified as a stimulator or up-regulator of expression of the nucleic acid. When nucleic acid expression or protein level is statistically significantly less in the presence of the candidate compound or agent than in its absence, then the candidate compound is identified as an inhibitor or down-regulator of the
15 nucleic acid expression.

The invention further provides methods of treatment using a compound identified through drug (compound and/or agent) screening as a gene modulator (i.e. stimulator and/or inhibitor of gene expression).

20 *Methods of assessing probability of response to therapeutic agents and methods, methods of monitoring treatment progress and methods for treating cardiovascular disease*

As is known in the art, individuals can have differential responses to a particular therapy (e.g., a therapeutic agent or therapeutic method). Pharmacogenomics addresses the issue of how genetic variations (e.g., the variants (markers and/or haplotypes) of the present invention)
25 affect drug response, due to altered drug disposition and/or abnormal or altered action of the drug. Thus, the basis of the differential response may be genetically determined in part. Clinical outcomes due to genetic variations affecting drug response may result in toxicity of the drug in certain individuals (e.g., carriers or non-carriers of the genetic variants of the present invention), or therapeutic failure of the drug. Therefore, the variants of the present invention may
30 determine the manner in which a therapeutic agent and/or method acts on the body, or the way in which the body metabolizes the therapeutic agent.

Accordingly, in one embodiment, the presence of a particular allele of a polymorphic marker, or the presence of a haplotype as described herein is indicative of a different response rate to a particular treatment modality for a cardiovascular disease. This means that a patient
35 diagnosed with cardiovascular disease, or at risk for a cardiovascular disease, and carrying a certain allele at a polymorphic or haplotype of the present invention (e.g., the at-risk alleles and/or haplotypes of the invention) would respond better to, or worse to, a specific therapeutic,

drug and/or other therapy used to treat the cardiovascular disease. Therefore, the presence or absence of the marker allele or haplotype could aid in deciding what treatment should be used for a the patient. For example, for a newly diagnosed patient, the presence of a marker or haplotype of the present invention may be assessed (e.g., through testing DNA derived from a blood sample or other sample containing genomic DNA, as described herein). If the patient is positive for a marker allele or haplotype at (that is, at least one specific allele of the marker, or haplotype, is present), then the physician recommends one particular therapy (e.g., one particular therapeutic agent or a combination of therapeutic agents), while if the patient is negative for the at least one allele of a marker, or a haplotype, then a different course of therapy may be recommended (which may include recommending that no immediate therapy, other than serial monitoring for progression of the disease, be performed). Thus, the patient's carrier status could be used to help determine whether a particular treatment modality should be administered. The value lies within the possibilities of being able to diagnose the disease at an early stage and provide information to the clinician about prognosis/aggressiveness of the disease in order to be able to apply the most appropriate treatment.

As one example, the application of a genetic test for restenosis can identify subjects who are at high risk of developing restenosis after coronary stent procedure. While it is know that some treatment methods for coronary artery disease, such as introducing drug-eluting stents and brachytherapy, are associated with decreased risk of in-stent restenosis, the use of these methods are restricted because of number of reasons, including economical reasons. Identification of individuals within the group of those undergoing coronary stent procedure who are carriers of genetic risk variants for in-stent restenosis will allow targeting of those individuals that would benefit most from therapy associated with decreased risk of in-stent restenosis.

The present invention also relates to methods of monitoring effectiveness of a treatment for a cardiovascular disease, including coronary artery disease, MI, stroke, PAD, IA, AAA and restenosis. This can be done based on the genotype and/or haplotype status of the markers and haplotypes of the present invention, or by monitoring expression of genes that are associated with the variants (markers and haplotypes) of the present invention (e.g., CDKN2A and CDKN2B). The risk gene mRNA or the encoded polypeptide can be measured in a tissue sample (e.g., a peripheral blood sample, or a biopsy sample). Expression levels and/or mRNA levels can thus be determined before and during treatment to monitor its effectiveness. Alternatively, or concomitantly, the genotype and/or haplotype status of at least one risk variant for cardiovascular disease as presented herein is determined before and during treatment to monitor its effectiveness.

The treatment modules of a cardiovascular disease to which the invention pertains includes, but is not limited to, methods of treatment for myocardial infarction or susceptibility to myocardial infarction; methods of prophylaxis therapy for myocardial infarction; methods of treatment for transient ischemic attack or stroke, or susceptibility to stroke; methods of treatment for claudication, PAD or susceptibility to PAD; methods of treatment for acute

(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy)methyl)-1-methyl-2(1H)-quinolinone otherwise known as ZD-2138, 1-((4-chlorophenyl)methyl)-3-((1,1dimethylethyl)thio)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-Indole-2-propanoic acid otherwise known as MK-886, 4-(3-(4-(2-Methylimidazol-1-yl)-phenylsulfanyl)-phenyl)-tetrahydro-pyran-4-carboxylic acid
 5 amide otherwise known as CJ-13610. Additional agents include those described in Penning *et al.*, *Med Chem.* 2002 45(16):3482-90, Penning, *Curr Pharm Des.* 2001, 7(3):163-79 and Penning *et al.*, *J Med Chem.* 2000 43(4):721-35. In another embodiment, the agent alters metabolism or activity of a leukotriene (*e.g.*, LTA₄, LTB₄, LTC₄, LTD₄, LTE₄, Cys LT₁, Cys LT₂),
 10 activity of a leukotriene receptor (*e.g.*, BLT₁, BLT₂, CysLTR₁, and CysLTR₂).

In other preferred embodiments, the agent alters activity and/or nucleic acid expression of LTA₄H. Preferred agents include those set forth in the Agent Table II; but also include the following agents: 1-[2-[4-(phenylmethyl)phenoxy]ethyl]-2-methyl-4-tetrazolylpiperidine; 1-[2-[4-(4-oxazolyl)phenoxy]phenoxy]ethylpyrrolidine; 3-[methyl{3-[4-(2-
 15 thienylmethyl)phenoxy]propyl}amino]propionic acid; methyl 3-[methyl{3-[4-(2-thienylmethyl)phenoxy]propyl}amino]propionate; 3-[methyl{3-[4-(3-thienylmethyl)phenoxy]propyl}amino]propionic acid; methyl-3-[methyl{3-[4-(3-thienylmethyl)phenoxy]propyl}amino]propionate; 3-[methyl{3-[4-(4-
 20 fluorophenoxy)phenoxy]propyl}amino]propionic acid; 3-[methyl{3-[4-(4-biphenyloxy)phenoxy]propyl}amino]propionic acid; N-{3-[[3-[4-(phenylmethyl)phenoxy]propyl]methylamino]propionyl}benzenesulfonamide; 1-[2-[4-(phenylmethyl)phenoxy]ethyl]-2-methyl-4-(1H-tetrazol-5-yl)piperidine; 1-[2-[4-(phenylmethyl)phenoxy]ethyl]-4-(1H-tetrazol-5-yl)piperidine. In another embodiment, preferred agents can be: ethyl-1-[2-[4-(
 25 (phenylmethyl)phenoxy]ethyl]-4-piperidine-carboxylate, otherwise known as SC-56938; [4-[5-(3-Phenyl-propyl)thiophen-2-yl]butoxy]acetic acid, otherwise known as RP64966; (R)-S-[[4-(dimethylamino)phenyl]methyl]-N-(3-mercapto-2methyl-1-oxopropyl)-L-cysteine, otherwise known as SA6541. In one preferred embodiment, the therapeutic agent is 4-[(5)-2-[4-(4-Chloro-phenoxy)-phenoxy-methyl]-pyrrolidin-1-yl]-butyramide, also known as DG-051.

The agents for treating or preventing a cardiovascular disease can be administered alone,
 30 or in combination with a statin. Statins include, but are not limited to, the agents roxuvastatin, fluvastatin, atorvastatin, lovastatin (also known as mevinlin), simvastatin, pravastatin, pitavastatin, mevastatin, crevastatin, ML-236A, ML-236B, MBV-530A and MB-530B.





All agents listed in the above and in Agent Table I and Agent Table II also include their optically pure enantiomers, salts, chemical derivatives, and analogues.

coronary syndrome (e.g., unstable angina, non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI)); methods for reducing risk of MI, stroke or PAD; methods for decreasing risk of a second myocardial infarction or stroke; methods of treatment for atherosclerosis, such as for patients requiring treatment (e.g., angioplasty, stents, revascularization procedure) to restore blood flow in arteries (e.g., coronary, carotid, and/or femoral arteries); methods of treatment for asymptomatic ankle/brachial index of less than 0.9; and/or methods for decreasing leukotriene synthesis (e.g., for treatment of myocardial infarction, stroke or PAD), methods for treatment of abdominal aorta aneurysm, methods for treatment of intracranial aneurysm.





Treatment of coronary artery disease and MI may be categorized as (i) preventive treatment and (ii) disease management. The main goal of the latter is to minimize damage to the heart and prevent further complications. The first line of disease management typically includes one or more of administration of oxygen, aspirin, glyceryl nitrate (nitroglycerin) and analgesia, such as morphine or related drugs. Once diagnosis of MI is made, additional therapy may include beta blockers, anticoagulation agents, including heparin and/or low molecular weight heparin, and possibly also antiplatelet agents, such as clopidogrel. Secondary prevention, i.e. the management of risk of a recurrent MI, typically includes one or more of the following: Antiplatelet drug therapy, including aspirin and/or clopidogrel, beta blocker therapy, including metoprolol and carvedilol, ACE inhibitor therapy, Statin therapy, Aldosterone antagonist therapy, including eplerenone. Further, non-therapeutic administration of food supplements such as omega-3 fatty acids may be beneficial.

New preventive therapy for cardiovascular disease, including CAD, MI and stroke, includes agents that act on the formation and/or rupture of plaques, and also includes phosphodiesterase inhibitors. Such therapeutic agents are useful in the methods of the invention, as described herein. This includes, but is not limited to, agents that target the leukotriene synthesis pathway. The leukotriene synthesis inhibitor can be any agent that inhibits or antagonizes a member of the leukotriene synthesis pathway (e.g., FLAP, 5-LO, LTC4S, LTA4H, and LTB4DH). For example, the leukotriene synthesis inhibitor can be an agent that inhibits or antagonizes FLAP polypeptide activity (e.g., a FLAP inhibitor) and/or FLAP nucleic acid expression (e.g., a FLAP nucleic acid antagonist). In another embodiment, the leukotriene synthesis inhibitor is an agent that inhibits or antagonizes polypeptide activity and/or nucleic acid expression of another member of the leukotriene biosynthetic pathway (e.g., LTC4S, LTA4H) or that increases breakdown of leukotrienes (e.g., LTB4DH). In preferred embodiments, the agent alters activity and/or nucleic acid expression of FLAP, LTA4H or of 5-LO. Preferred agents include those set forth in the Agent Table I herein. In another embodiment, preferred agents can be: 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethylthio)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-Indole-2-propanol acid otherwise known as MK-0591, (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, otherwise known as BAY-x-1005, 3-(3-(1,1-dimethylethylthio-5-(quinoline-2-ylmethoxy)-1-(4-chloromethylphenyl)Indole-2-yl)-2,2-dimethylpropionaldehyde oxime-0-2-acetic acid otherwise known as A-81834; or can be zileuton, atreleuton, 6-((3-fluoro-5-

Agent Table I

Product Name (Code)	Structure	Chemical Name	Patent Ref	Date Patent Issued/Applica- tion Published	MOA
Abbott		(R)-4-(4-(4-(2-chlorophenyl)-2-methyl-1-methyl-2-propoxy)-N-hydroxyurea	US 5288751, US 5288743, US 5516558	2/22/94 04/01/97	S-LPO inhibitor
Abbott		3-(3-(1,1-dimethylethylthio-5-(quinoline-2-ylmethoxy)-4-(chloromethyl)phenyl)indole-2-yl)-2,2-dimethylpropanaldehyde oxime-O-2-acetic acid	WO9203132, US 5459150	3/5/1992, 10/17/95	FLAP inhibitor
Abbott		3-(3-(1,1-dimethylethylthio-5-(pyridin-2-ylmethoxy)-4-(chloromethyl)indole-2-yl)-2,2-dimethylpropanaldehyde oxime-O-2-acetic acid	WO9203132, US 5459150	3/5/1992, 10/17/95	S-LPO inhibitor
Abbott					FLAP inhibitor
AstraZeneca			EP 623614	09/11/94	S-LPO inhibitor

Agent Table 1

AstraZeneca	ZD-2138		5-((3-fluoro-5-((tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy)methyl)-2-methyl-2(1H)-quinolinone) (alternatively NH can be N-methyl)	EP 466452		5-LPO inhibitor
Bayer	BAY-X-1005		(R)-(+)-alpha-cyclopentyl 4-(2-quinolinylmethoxy)-benzoic acid	US 4970215 EP 344519, DE 19880531		FLAP inhibitor
Merck	MK-0591		1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha, alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-indole-2-propanoic acid	EP 419049, US 19890822		FLAP inhibitor
Merck	MK-866		(3-[3-(4-chlorobenzyl)-3-(4-butythio-5-isopropylindol-2-yl)]-2,2-dimethyl-propanoic acid			5-LPO inhibitor
Merck	MK-866		1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha, alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-indole-2-propanoic acid	EP 419049, US 19890822		5-LPO inhibitor
Pfizer	CJ-13510		4-(3-(4-(2-methyl-imidazol-1-yl)-phenylsulfanyl)-phenyl)-tetrahydro-pyran-4-carboxylic acid amide			5-LPO inhibitor

Agent Table II

Target	Compound ID	Chemical Name	Patent / Reference
LTA4H Inhibitor	SC-57461A	3-[methyl[3-[4-(phenylmethyl)phenoxy]-propyl]amino]propionic acid	Penning, T.D. et.al. Bioorg Med. Chem. Letters (2003), 13, 1137-1139. Ibid, (2002), 12, 3383-3386
LTA4H Inhibitor	SC-56938	Ethyl-1-[2-[4-(phenylmethyl)phenoxy]ethyl]-4-piperidine-carboxylate	Penning, T.D. et.al. Bioorg Med. Chem. Letters (2003), 13, 1137-1139. Ibid, (2002), 12, 3383-3386. US 6,506,87 6A1
LTA4H Inhibitor	RP 64966	[4-[5-(3-Phenyl-propyl)thiophen-2-yl]butoxy]acetic acid	WO9627585
LTA4H Inhibitor	SA 6541	(R)-S-[[4-(dimethylamino)phenyl]methyl]-N-(3-mercapto-2methyl-1-oxopropyl-L-cysteine	WO9809943
LTA4H Inhibitor	SA-9499/ SA-6541	(R)-3-(4-Dimethylamino-benzylsulfanyl)-2-((R)-3-mercapto-2-methyl-propionylamino)-propionic acid	
LTB4 Receptor Antagonist	Amelubant/ BIL-284	Carbamic acid,(((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)phenyl)methoxy)phenyl)iminomethyl)-ethyl ester	US 6,576,669
LTB4 Receptor Antagonist	BIRZ-227	5-Chloro-2-[3-(4-methoxy-phenyl)-2-pyridin-2-yl-pyrrolidin-1-yl]-benzoxazole	Journal of Organic Chemistry 1998,63:2(326-330).
LTB4 Receptor Antagonist	CP 195543	2-[[[(3S,4R)-3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)benzoic acid	Process: WO 98/11085 1998, priority US 60/26372 1996; J. Pharmacology and Exper. Therapy, 1998, 285: 946-54
LTB4 Receptor Antagonist	Ebselen	2-Phenylbenzo[d]iselenazol-3-one	Journal of Cerebral Blood Flow and Metabolism 1995, July 2-6 (S162); Drugs of the Future 1995, 20:10 (1057)
LTB4 Receptor Antagonist	LTB 019; CGS-25019C	4-[5-(4-Carbamimidoyl-phenoxy)-pentyloxy]-N,N-diisopropyl-3-methoxy-benzamide maleate	ACS Meeting 1994, 207th:San Diego (MED1 003); International Congress of the Inflammation Research Association 1994, 7th:White Haven (Abs W23)
LTB4 Receptor Antagonist	LY 210073	5-(2-Carboxy-ethyl)-6-[6-(4-methoxy-phenyl)-hex-5-enyloxy]-9-oxo-9H-xanthene-2-carboxylic acid	J Med Chem 1993 36 (12) 1726-1734
LTB4 Receptor Antagonist	LY 213024	5-(3-carboxybenzoyl)-2-(decyloxy)benzenepropanoic acid	J Med Chem 1993 36 (12) 1726-1734

Target	Compound ID	Chemical Name	Patent / Reference
LTB4 Receptor Antagonist	LY 255283	1-[5-ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyloxy]phenyl]ethanone	EP 276064 B 1990, priority US 2479 1987
LTB4 Receptor Antagonist	LY 264086	7-carboxy-3-(decyloxy)-9-oxo-9H-xanthene-4-propanoic acid	US 4996230 1991, priority US 481413 1990
LTB4 Receptor Antagonist	LY 292728	7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo-9H-xanthene-4-propanoic acid disodium salt	EP 743064 A 1996, priority US 443179 1995
LTB4 Receptor Antagonist	LY-293111 (VML-295)	Benzoic acid, 2-(3-(3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy)-2-propylphenoxy)-	Proceedings of the American Society for Clinical Oncology 2002, 21:1 (Abs 343) [LY-293111 for Cancer] SCRIP World Pharmaceutical News 1997, 2272 (13) [for VML-295]
LTB4 Receptor Antagonist	ONO 4057; LB 457	(E)-2-(4-carboxybutoxy)-6-[[6-(4-methoxyphenyl)-5-hexenyl]oxy]benzenepropanoic acid	EP 405116 A 1991
LTB4 Receptor Antagonist	PF 10042	1-[5-hydroxy-5-[8-(1-hydroxy-2-phenylethyl)-2-dibenzofuranyl]-1-oxopentyl]pyrrolidine	EP 422329 B 1995, priority US 409630 1989
LTB4 Receptor Antagonist	RG-14893	8-Benzoyloxy-4-[(methylphenethyl-carbamoyl)-methyl]-naphthalene-2-carboxylic acid	SCRIP World Pharmaceutical News 1996, 2168 (20)
LTB4 Receptor Antagonist	SB-201993	3-{6-(2-Carboxy-vinyl)-5-[6-(4-methoxy-phenyl)-octyloxy]-pyridin-2-ylmethylsulfanylmethyl}-benzoic acid	WO-09500487
LTB4 Receptor Antagonist	SC-52798	7-[3-(2-Cyclopropylmethyl-3-methoxy-4-thiazol-4-ylphenoxy)-propoxy]-8-propyl-chroman-2-carboxylic acid	Bioorganic and Medicinal Chemistry Letters 1994, 4:6 (811-816); Journal of Medicinal Chemistry 1995, 38:6 (858-868)
LTB4 Receptor Antagonist	SC-53228	3-{7-[3-(2-Cyclopropylmethyl-3-methoxy-4-methylcarbamoylphenoxy)-propoxy]-8-propyl-chroman-2-yl}-propionic acid	International Congress of the Inflammation Research Association 1994, 7th:White Haven (Abs W5)
LTB4 Receptor Antagonist	WAY 121006	3-fluoro-4'-(2-quinolinylmethoxy)-[1,1'-biphenyl]-4-acetic acid	Drugs under Experimental and Clinical research 1991, 17:8 (381-387)
LTB4 Receptor Antagonist	ZD-2138	3-Amino-3-(4-methoxy-tetrahydro-pyran-4-yl)-acrylic acid 1-methyl-2-oxo-1,2-dihydro-quinolin-6-ylmethyl ester	International Symposium on Medicinal Chemistry 1994, 13th:Paris (P 197)

Alternatively, biological networks or metabolic pathways related to the markers and haplotypes of the present invention can be monitored by determining mRNA and/or polypeptide levels. This can be done for example, by monitoring expression levels or polypeptides for several genes belonging to the network and/or pathway, in samples taken before and during treatment. Alternatively, metabolites belonging to the biological network or metabolic pathway can be determined before and during treatment. Effectiveness of the treatment is determined by comparing observed changes in expression levels/metabolite levels during treatment to corresponding data from healthy subjects.

In a further aspect, the markers of the present invention can be used to increase power and effectiveness of clinical trials. Thus, individuals who are carriers of the at-risk variants of the present invention may be more likely to respond to a particular treatment modality. In one embodiment, individuals who carry at-risk variants for gene(s) in a pathway and/or metabolic network for which a particular treatment (e.g., small molecule drug, e.g. the small molecule drugs as listed in the above, e.g., the drugs listed in Agent Table I and Agent Table II) is targeting, are more likely to be responders to the treatment. In another embodiment, individuals who carry at-risk variants for a gene, which expression and/or function is altered by the at-risk variant, are more likely to be responders to a treatment modality targeting that gene, its expression or its gene product.

In a further aspect, the markers and haplotypes of the present invention can be used for targeting the selection of pharmaceutical agents for specific individuals. Personalized selection of treatment modalities, lifestyle changes (e.g., change in diet, exercise, weight loss program, smoking abstinence, less stressful lifestyle, etc.) or combination of the two, can be realized by the utilization of the at-risk variants of the present invention. Thus, the knowledge of an individual's status for particular markers of the present invention, can be useful for selection of treatment options that target genes or gene products affected by the at-risk variants of the invention. Certain combinations of variants may be suitable for one selection of treatment options, while other gene variant combinations may target other treatment options. Such combination of variant may include one variant, two variants, three variants, or four or more variants, as needed to determine with clinically reliable accuracy the selection of treatment module.

In addition to the diagnostic and therapeutic uses of the variants of the present invention, the variants (markers and haplotypes) can also be useful markers for human identification, and as such be useful in forensics, paternity testing and in biometrics. The specific use of SNPs for forensic purposes is reviewed by Gill (*Int. J. Legal Med.* 114:204-10 (2001)). Genetic variations in genomic DNA between individuals can be used as genetic markers to identify individuals and to associate a biological sample with an individual. Genetic markers, including SNPs and microsatellites, can be useful to distinguish individuals. The more markers

that are analyzed, the lower the probability that the allelic combination of the markers in any given individual is the same as in an unrelated individual (assuming that the markers are unrelated, i.e. that the markers are in perfect linkage equilibrium). Thus, the variants used for these purposes are preferably unrelated, i.e. they are inherited independently. Thus, preferred markers can be selected from available markers, such as the markers of the present invention, and the selected markers may comprise markers from different regions in the human genome, including markers on different chromosomes.

In certain applications, the SNPs useful for forensic testing are from degenerate codon positions (i.e., the third position in certain codons such that the variation of the SNP does not affect the amino acid encoded by the codon). In other applications, such for applications for predicting phenotypic characteristics including race, ancestry or physical characteristics, it may be more useful and desirable to utilize SNPs that affect the amino acid sequence of the encoded protein. In other such embodiments, the variant (SNP or other polymorphic marker) affects the expression level of a nearby gene, thus leading to altered protein expression.

Computer-Implemented aspects

The present invention also relates to computer-implemented applications of the polymorphic markers and haplotypes described herein to be associated with cardiovascular disease. Such applications can be useful for storing, manipulating or otherwise analyzing genotype data that is useful in the methods of the invention. One example pertains to storing genotype information derived from an individual on readable media, so as to be able to provide the genotype information to a third party (e.g., the individual), or for deriving information from the genotype data, e.g., by comparing the genotype data to information about genetic risk factors contributing to increased susceptibility to cardiovascular disease, and reporting results based on such comparison.

One such aspect relates to computer-readable media. In general terms, such medium has capabilities of storing (i) identifier information for at least one polymorphic marker or a haplotype; (ii) an indicator of the frequency of at least one allele of said at least one marker, or the frequency of a haplotype, in individuals with cardiovascular disease (e.g., MI; CAD, IA, AAA, stroke, restenosis, PAD); and an indicator of the frequency of at least one allele of said at least one marker, or the frequency of a haplotype, in a reference population. The reference population can be a disease-free population of individuals. Alternatively, the reference population is a random sample from the general population, and is thus representative of the population at large. The frequency indicator may be a calculated frequency, a count of alleles and/or haplotype copies, or normalized or otherwise manipulated values of the actual frequencies that are suitable for the particular medium.

Additional information about the individual can be stored on the medium, such as ancestry information, information about sex, physical attributes or characteristics (including height and weight), biochemical measurements (such as blood pressure, blood lipid levels, lipid levels, such as cholesterol levels), biomarkers relevant for cardiovascular disease, as described further herein, or other useful information that is desirable to store or manipulate in the context of the genotype status of a particular individual.

The invention furthermore relates to an apparatus that is suitable for determination or manipulation of genetic data useful for determining a susceptibility to cardiovascular disease in a human individual. Such an apparatus can include a computer-readable memory, a routine for manipulating data stored on the computer-readable memory, and a routine for generating an output that includes a measure of the genetic data. Such measure can include values such as allelic or haplotype frequencies, genotype counts, sex, age, phenotype information, values for odds ratio (OR) or relative risk (RR), population attributable risk (PAR), or other useful information that is either a direct statistic of the original genotype data or based on calculations based on the genetic data.

The markers and haplotypes shown herein to be associated with increased susceptibility (e.g., increased risk) of cardiovascular disease, are in certain embodiments useful for interpretation and/or analysis of genotype data. Thus in certain embodiments, an identification of an at-risk allele for a cardiovascular disease, as shown herein, or an allele at a polymorphic marker in LD with any one of the markers shown herein to be associated with cardiovascular disease, is indicative of the individual from whom the genotype data originates is at increased risk of cardiovascular disease. In one such embodiment, genotype data is generated for at least one polymorphic marker shown herein to be associated with cardiovascular disease, or a marker in linkage disequilibrium therewith. The genotype data is subsequently made available to the individual from whom the data originates, for example via a user interface accessible over the internet, together with an interpretation of the genotype data, e.g., in the form of a risk measure (such as an absolute risk (AR), risk ratio (RR) or odds ratio (OR)) for the cardiovascular disease. In another embodiment, at-risk markers identified in a genotype dataset derived from an individual are assessed and results from the assessment of the risk conferred by the presence of such at-risk variants in the dataset are made available to the individual, for example via a secure web interface, or by other communication means. The results of such risk assessment can be reported in numeric form (e.g., by risk values, such as absolute risk, relative risk, and/or an odds ratio, or by a percentage increase in risk compared with a reference), by graphical means, or by other means suitable to illustrate the risk to the individual from whom the genotype data is derived. In particular embodiments, the results of risk assessment is made available to a third party, e.g., a physician, other healthcare worker or genetic counselor.

Markers useful in various aspects of the invention

The above-described applications can all be practiced with the markers and haplotypes of the invention that have in more detail been described with respect to methods of assessing susceptibility to cardiovascular disease and described in detail herein. Thus, these applications can in general be reduced to practice using any of the markers listed in Tables 1-35, and markers in linkage disequilibrium therewith. In some embodiments, the marker is selected from the markers set forth in Tables 3, 10 or 21, and markers in linkage disequilibrium therewith. In one embodiment, the markers or haplotypes are present within the genomic segment whose sequence is set forth in SEQ ID NO:94. In another embodiment, the markers and haplotypes comprise at least one marker selected from rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970, rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, rs10757278, rs10757274, rs10333049, D9S1870, optionally including markers in linkage disequilibrium therewith. In one specific embodiment, linkage disequilibrium is defined by numerical values for r^2 of greater than 0.2. In another embodiment, the marker or haplotype comprises at least one marker selected from rs7041637 allele A, rs2811712 allele A, rs3218018 allele A, rs3217992 allele A, rs2069426 allele C, rs2069422 allele A, rs1333034 allele A, rs1011970 allele G, rs10116277 allele T, rs1333040 allele T, rs2383207 allele G, rs1333050 allele T, D9S1814 allele O, rs10757278 allele G, rs10333049 allele C, rs10757274 allele G, and/or D9S1870 allele X (composite allele of all alleles smaller than 2), wherein the indicated allele is indicative of increased susceptibility of the Cardiovascular disease.

Nucleic acids and polypeptides

The nucleic acids and polypeptides described herein can be used in methods and kits of the present invention. An "isolated" nucleic acid molecule, as used herein, is one that is separated from nucleic acids that normally flank the gene or nucleotide sequence (as in genomic sequences) and/or has been completely or partially purified from other transcribed sequences (e.g., as in an RNA library). For example, an isolated nucleic acid of the invention can be substantially isolated with respect to the complex cellular milieu in which it naturally occurs, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. In some instances, the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix. In other circumstances, the material can be purified to essential homogeneity, for example as determined by polyacrylamide gel electrophoresis (PAGE) or column chromatography (e.g., HPLC). An isolated nucleic acid molecule of the invention can comprise at least about 50%, at least about 80% or at least about 90% (on a molar basis) of all macromolecular species present. With regard to genomic DNA, the term "isolated" also can refer to nucleic acid molecules that are separated from the chromosome with which the genomic DNA is naturally associated. For example, the isolated nucleic acid molecule can contain less than about 250 kb,

200 kb, 150 kb, 100 kb, 75 kb, 50 kb, 25 kb, 10 kb, 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of the nucleotides that flank the nucleic acid molecule in the genomic DNA of the cell from which the nucleic acid molecule is derived.

The nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated. Thus, recombinant DNA contained in a vector is included in the definition of "isolated" as used herein. Also, isolated nucleic acid molecules include recombinant DNA molecules in heterologous host cells or heterologous organisms, as well as partially or substantially purified DNA molecules in solution. "Isolated" nucleic acid molecules also encompass *in vivo* and *in vitro* RNA transcripts of the DNA molecules of the present invention. An isolated nucleic acid molecule or nucleotide sequence can include a nucleic acid molecule or nucleotide sequence that is synthesized chemically or by recombinant means. Such isolated nucleotide sequences are useful, for example, in the manufacture of the encoded polypeptide, as probes for isolating homologous sequences (e.g., from other mammalian species), for gene mapping (e.g., by *in situ* hybridization with chromosomes), or for detecting expression of the gene in tissue (e.g., human tissue), such as by Northern blot analysis or other hybridization techniques.

The invention also pertains to nucleic acid molecules that hybridize under high stringency hybridization conditions, such as for selective hybridization, to a nucleotide sequence described herein (e.g., nucleic acid molecules that specifically hybridize to a nucleotide sequence containing a polymorphic site associated with a haplotype described herein). In one embodiment, the invention includes variants that hybridize under high stringency hybridization and wash conditions (e.g., for selective hybridization) to a nucleotide sequence that comprises the nucleotide sequence of LD Block C09 (SEQ ID NO:94) or a fragment thereof (or a nucleotide sequence comprising the complement of the nucleotide sequence of LD Block C09 as set forth in SEQ ID NO:94), wherein the nucleotide sequence comprises at least one at-risk allele of at least one polymorphic marker, or at least one haplotype, as described herein.

The percent identity of two nucleotide or amino acid sequences can be determined by aligning the sequences for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first sequence). The nucleotides or amino acids at corresponding positions are then compared, and the percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = # of identical positions/total # of positions x 100). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, of the length of the reference sequence. The actual comparison of the two sequences can be accomplished by well-known methods, for example, using a mathematical algorithm. A non-limiting example of such a mathematical algorithm is described in Karlin, S. and Altschul, S., *Proc. Natl. Acad. Sci. USA*, 90:5873-5877 (1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0), as described in Altschul, S. et al., *Nucleic Acids Res.*, 25:3389-3402 (1997). When utilizing BLAST and Gapped

BLAST programs, the default parameters of the respective programs (e.g., NBLAST) can be used. See the website on the world wide web at ncbi.nlm.nih.gov. In one embodiment, parameters for sequence comparison can be set at score=100, wordlength=12, or can be varied (e.g., W=5 or W=20). Other examples include the algorithm of Myers and Miller, CABIOS (1989), ADVANCE and ADAM as described in Torellis, A. and Robotti, C., *Comput. Appl. Biosci.* 10:3-5 (1994); and FASTA described in Pearson, W. and Lipman, D., *Proc. Natl. Acad. Sci. USA*, 85:2444-48 (1988). In another embodiment, the percent identity between two amino acid sequences can be accomplished using the GAP program in the GCG software package (Accelrys, Cambridge, UK).

The present invention also provides isolated nucleic acid molecules that contain a fragment or portion that hybridizes under highly stringent conditions to a nucleic acid that comprises, or consists of, the nucleotide sequence of LD Block C09 (SEQ ID NO:94), or a nucleotide sequence comprising, or consisting of, the complement of the nucleotide sequence of LD Block C09 (SEQ ID NO:94), wherein the nucleotide sequence comprises at least one polymorphic allele contained in the markers and haplotypes described herein. The nucleic acid fragments of the invention are at least about 15, at least about 18, 20, 23 or 25 nucleotides, and can be 30, 40, 50, 100, 200, 500, 1000, 10,000 or more nucleotides in length.

The nucleic acid fragments of the invention are used as probes or primers in assays such as those described herein. "Probes" or "primers" are oligonucleotides that hybridize in a base-specific manner to a complementary strand of a nucleic acid molecule. In addition to DNA and RNA, such probes and primers include polypeptide nucleic acids (PNA), as described in Nielsen, P. *et al.*, *Science* 254:1497-1500 (1991). A probe or primer comprises a region of nucleotide sequence that hybridizes to at least about 15, typically about 20-25, and in certain embodiments about 40, 50 or 75, consecutive nucleotides of a nucleic acid molecule comprising a contiguous nucleotide sequence from LD Block C09 and comprising at least one allele of at least one polymorphic marker or at least one haplotype described herein, or the complement thereof. In particular embodiments, a probe or primer can comprise 100 or fewer nucleotides; for example, in certain embodiments from 6 to 50 nucleotides, or, for example, from 12 to 30 nucleotides. In other embodiments, the probe or primer is at least 70% identical, at least 80% identical, at least 85% identical, at least 90% identical, or at least 95% identical, to the contiguous nucleotide sequence or to the complement of the contiguous nucleotide sequence. In another embodiment, the probe or primer is capable of selectively hybridizing to the contiguous nucleotide sequence or to the complement of the contiguous nucleotide sequence. Often, the probe or primer further comprises a label, e.g., a radiolotope, a fluorescent label, an enzyme label, an enzyme co-factor label, a magnetic label, a spin label, an epitope label.

The nucleic acid molecules of the invention, such as those described above, can be identified and isolated using standard molecular biology techniques and the sequence information provided by the nucleotide sequence of LD Block C09 (SEQ ID NO:94). See generally *PCR Technology: Principles and Applications for DNA Amplification* (ed. H.A. Erlich,

Freeman Press, NY, NY, 1992); *PCR Protocols: A Guide to Methods and Applications* (Eds. Innis, et al., Academic Press, San Diego, CA, 1990); Mattila, P. et al., *Nucleic Acids Res.*, 19:4967-4973 (1991); Eckert, K. and Kunkel, T., *PCR Methods and Applications*, 1:17-24 (1991); PCR (eds. McPherson et al., IRL Press, Oxford); and U.S. Patent 4,683,202, the entire teachings of each of which are incorporated herein by reference.

In general, the isolated nucleic acid sequences of the invention can be used as molecular weight markers on Southern gels, and as chromosome markers that are labeled to map related gene positions. The nucleic acid sequences can also be used to compare with endogenous DNA sequences in patients to identify a susceptibility to a cardiovascular disease, and as probes, such as to hybridize and discover related DNA sequences or to subtract out known sequences from a sample (e.g., subtractive hybridization). The nucleic acid sequences can further be used to derive primers for genetic fingerprinting, to raise anti-polypeptide antibodies using immunization techniques, and/or as an antigen to raise anti-DNA antibodies or elicit immune responses.

Two polypeptides, as described herein (or a region of the polypeptides) are substantially homologous or identical when the amino acid sequences are at least about 45-55%. In other embodiments, two polypeptides (or a region of the polypeptides) are substantially homologous or identical when they are at least about 70-75%, at least about 80-85%, at least about 90%, at least about 95% homologous or identical, or are identical. A substantially homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid molecule comprising the nucleotide sequence of LD Block C09 (SEQ ID NO:94) or a portion thereof, and further comprising at least one polymorphism as shown in Table 3, 10 or 21, wherein the encoding nucleic acid will hybridize to the nucleotide sequence of LD Block C09 (SEQ ID NO:94), under stringent conditions as more particularly described herein. In one embodiment, the polypeptide comprises all or a portion of the amino acid sequence of CDKN2A and/or CDKN2B.

Antibodies

Polyclonal antibodies and/or monoclonal antibodies that specifically bind one form of the gene product but not to the other form of the gene product are also provided. Antibodies are also provided which bind a portion of either the variant or the reference gene product that contains the polymorphic site or sites. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain antigen-binding sites that specifically bind an antigen. A molecule that specifically binds to a polypeptide of the invention is a molecule that binds to that polypeptide or a fragment thereof, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains the polypeptide. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind to a polypeptide of the invention. The term

"monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of a polypeptide of the invention. A monoclonal antibody composition thus typically displays a single binding affinity for a particular polypeptide of the invention with which it immunoreacts.

Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a desired immunogen, e.g., polypeptide of the invention or a fragment thereof. The antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide. If desired, the antibody molecules directed against the polypeptide can be isolated from the mammal (e.g., from the blood) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein, *Nature* 256:495-497 (1975), the human B cell hybridoma technique (Kozbor et al., *Immunol. Today* 4: 72 (1983)), the EBV-hybridoma technique (Cole et al., *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, 1985, Inc., pp. 77-96) or trioma techniques. The technology for producing hybridomas is well known (see generally *Current Protocols in Immunology* (1994) Coligan et al., (eds.) John Wiley & Sons, Inc., New York, NY). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with an immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds a polypeptide of the invention.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating a monoclonal antibody to a polypeptide of the invention (see, e.g., *Current Protocols in Immunology*, supra; Galfre et al., *Nature* 266:550-52 (1977); R.H. Kennel, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); and Lerner, *Yale J. Biol. Med.* 54:387-402 (1981)). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods that also would be useful.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody to a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with the polypeptide to thereby isolate immunoglobulin library members that bind the polypeptide. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™* Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT

Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09590; PCT Publication No. WO 90/02809; Fuchs *et al.*, *Bio/Technology* 9: 1370-1372 (1991); Hay *et al.*, *Hum. Antibod. Hybridomas* 3:81-85 (1992); Huse *et al.*, *Science* 246: 1275-1281 (1989); and Griffiths *et al.*, *EMBO J.* 12:725-734 (1993).

Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art.

In general, antibodies of the invention (e.g., a monoclonal antibody) can be used to isolate a polypeptide of the invention by standard techniques, such as affinity chromatography or immunoprecipitation. A polypeptide-specific antibody can facilitate the purification of natural polypeptide from cells and of recombinantly produced polypeptide expressed in host cells. Moreover, an antibody specific for a polypeptide of the invention can be used to detect the polypeptide (e.g., in a cellular lysate, cell supernatant, or tissue sample) in order to evaluate the abundance and pattern of expression of the polypeptide. Antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. The antibody can be coupled to a detectable substance to facilitate its detection. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Antibodies may also be useful in pharmacogenomic analysis. In such embodiments, antibodies against variant proteins encoded by nucleic acids according to the invention, such as variant proteins that are encoded by nucleic acids that contain at least one polymorphic marker of the invention, can be used to identify individuals that require modified treatment modalities.

Antibodies can furthermore be useful for assessing expression of variant proteins in disease states, such as in active stages of a cardiovascular disease, or in an individual with a predisposition to a disease related to the function of the protein, in particular a cardiovascular disease. Examples are provided by biomarker (e.g., cardiac markers), as described further herein. Antibodies specific for a variant protein of the present invention that is encoded by a

nucleic acid that comprises at least one polymorphic marker or haplotype as described herein (e.g., CDKN2A and/or CDKN2B) can be used to screen for the presence of the variant protein, for example to screen for a predisposition to cardiovascular disease as indicated by the presence of the variant protein.

5 Antibodies can be used in other methods. Thus, antibodies are useful as diagnostic tools for evaluating proteins, such as variant proteins of the invention, in conjunction with analysis by electrophoretic mobility, isoelectric point, tryptic or other protease digest, or for use in other physical assays known to those skilled in the art. Antibodies may also be used in tissue typing. In one such embodiment, a specific variant protein has been correlated with expression in a
10 specific tissue type, and antibodies specific for the variant protein can then be used to identify the specific tissue type.

 Subcellular localization of proteins, including variant proteins, can also be determined using antibodies, and can be applied to assess aberrant subcellular localization of the protein in cells in various tissues. Such use can be applied in genetic testing, but also in monitoring a
15 particular treatment modality. In the case where treatment is aimed at correcting the expression level or presence of the variant protein or aberrant tissue distribution or developmental expression of the variant protein, antibodies specific for the variant protein or fragments thereof can be used to monitor therapeutic efficacy.

 Antibodies are further useful for inhibiting variant protein function (e.g., CDKN2A and/or
20 CDKN2B), for example by blocking the binding of a variant protein to a binding molecule or partner. Such uses can also be applied in a therapeutic context in which treatment involves inhibiting a variant protein's function. An antibody can be for example be used to block or competitively inhibit binding, thereby modulating (i.e., agonizing or antagonizing) the activity of the protein. Antibodies can be prepared against specific protein fragments containing sites
25 required for specific function or against an intact protein that is associated with a cell or cell membrane. For administration *in vivo*, an antibody may be linked with an additional therapeutic payload, such as radionuclide, an enzyme, an immunogenic epitope, or a cytotoxic agent, including bacterial toxins (diphtheria or plant toxins, such as ricin). The *in vivo* half-life of an antibody or a fragment thereof may be increased by pegylation through conjugation to
30 polyethylene glycol.

 The present invention further relates to kits for using antibodies in the methods described herein. This includes, but is not limited to, kits for detecting the presence of a variant protein in a test sample. One preferred embodiment comprises antibodies such as a labelled or labelable antibody and a compound or agent for detecting variant proteins in a biological sample, means
35 for determining the amount or the presence and/or absence of variant protein in the sample, and means for comparing the amount of variant protein in the sample with a standard, as well as instructions for use of the kit.

 The present invention will now be exemplified by the following non-limiting examples.

EXEMPLIFICATION

The following contains description of the identification of susceptibility factors found to be associated with coronary artery disease and in-stent restenosis through single-point analysis of SNP markers and microsatellite markers.

METHODS

The study was approved by the Data Protection Commission of Iceland and the National Bioethics Committee.

Icelandic coronary artery disease and in-stent restenosis cohort

The association between markers in LD block C09 to coronary artery disease was originally discovered as an association between the markers and myocardial infarction, which is the most feared complication of coronary artery disease (subphenotype of coronary artery disease).

Over the last eight years individuals who have suffered an MI we have been recruited through cardiovascular disease (CVD) genetic programs at deCODE. Currently blood samples have been collected from 2525 MI patients. The individuals who had suffered an MI were identified from a registry of over 10,000 individuals who: a) had an MI before the age of 75 in Iceland in the years 1981 to 2002 and satisfy the MONICA criteria (*J Clin Epidemiol* 41, 105-14 (1988)); b) participated in a large prospective epidemiology study (1) done by the Icelandic Heart Association (IHA) over the past 30 years and had MI prior to 1981; c) had MI discharge diagnosis from the major hospitals in Reykjavik in the years 2003 and 2004. MI diagnoses of all individuals in the registry follow strict diagnostic rules based on signs, symptoms, electrocardiograms, cardiac enzymes and necropsy findings (2). The patients were contacted through collaborating physicians in the CVD genetic programs at deCODE. Most of the participants in the study visited the IHA and had their blood drawn, although participants who lived outside the Reykjavik area visited their local health care center.

Additional subjects with coronary artery disease, but are without known history of myocardial infarction, are identified from a list of those who have undergone coronary stent procedure in the major hospitals in Reykjavik in the years 1993 and 2003.

For over 700 subjects on this list, information on in-stent restenosis is available, including subjects with variable degree of restenosis (0-100% in-stent restenosis). A confirmed proband

with restenosis is a subject who has 50% in-stent stenosis or more as determined by coronary angiography read by an intervention cardio/radiologist.

The controls used for the study were recruited as a part of various genetic programs at deCODE. The medical history for the controls were unknown unless if the control subjects also had participated in any of the CVD genetic programs (i.e. MI, stroke, peripheral vascular disease, type II diabetes, obesity, familial combined hyperlipidemia, coronary restenosis, and hypertension genetic programs). Individuals with known MI, stroke, peripheral vascular or coronary artery disease were excluded as controls.

Subjects from the United States

Cohort from Philadelphia

The study participants from Philadelphia were enrolled at the University of Pennsylvania Medical Center through the PENN CATH study program which studies the association of biochemical and genetic factors to coronary artery disease (CAD) in subjects undergoing cardiac catheterization. A total of 3850 subjects have participated. For the purpose of the current study we selected from the PENN CATH study individuals diagnosed with one of the following coronary artery disease: MI based on criteria for acute MI in terms of elevations of cardiac enzymes and electrocardiographic changes, or a self-reported history of MI, history of coronary artery bypass surgery (CABG) or percutaneous, transluminal coronary angioplasty (PTCA). To use as controls we selected individuals who were without significant luminal stenosis on coronary angiography (luminal stenosis less than 50%). Ethnicity information was self-reported.

The University of Pennsylvania Institutional Review Board approved the study and all subjects provided written informed consent.

Cohort from Cleveland

The study participants were enrolled at the Cleveland Clinic Heart Center through the Genebank program, which is a registry of data in conjunction with biological samples for individuals undergoing coronary catheterization. The diagnostic criteria for MI were based on at least two of the following: prolonged chest pain, ECG patterns consistent with acute MI or significant elevation of cardiac enzymes. Subjects from the Genebank registry who were without significant luminal stenosis (<50% stenosis), as assessed with coronary angiography, and were without previous history of CAD, were selected as controls for the current study.

This study was approved by the Cleveland Clinic Foundation Institutional Review Board on Human Subjects and all subjects gave written informed consent.

Cohort from Atlanta

5 The study participants were enrolled at the Emory University Hospital, the Emory Clinic and Grady Memorial Hospitals through its Emory Genebank study and Clinical Registry in Neurology (CRIN). The Emory Genebank studies the association of biochemical and genetic factors with CAD in subjects undergoing cardiac catheterization. For the purpose of the current study those subjects who had a self-reported history of MI, CABG, or PTCA, were selected and
10 used as a patient group. Control subjects were selected from a group of individuals with non-vascular neurological diseases (mainly Parkinson's and Alzheimer's diseases) recruited from CRIN, their spouses, unrelated friends and community volunteers. These subjects were matched for age, and ethnicity to the patient population. Controls were excluded if they had a known history of MI or coronary artery disease. All subjects provided written informed consent.
15 Information on ethnicity was self-reported.

Genotyping

A genome-wide scan of 1570 Icelandic individuals diagnosed with myocardial infarction (MI) and 7088 population controls was performed using Infinium HumanHap300 SNP chips from
20 Illumina for assaying approximately 317,000 single nucleotide polymorphisms (SNPs) on a single chip (Illumina, San Diego, CA, USA). SNP genotyping for replication in other case-control cohorts was carried using the Centaurus platform (Nanogen).

Statistical Methods for Association Analysis

25 To test individual markers for association to disease phenotypes such as coronary artery disease or myocardial infarction, we use a likelihood ratio test to calculate a two-sided P-value for each allele of the marker. We calculate relative risk (RR) and population attributable risk (PAR) assuming a multiplicative model (C. T. Falk, P. Rubinstein, *Ann Hum Genet* 51 (Pt 3), 227 (1987); J. D. Terwilliger, J. Ott, *Hum Hered* 42, 337 (1992)). To elucidate the linkage
30 disequilibrium between markers in the region we used the CEPH Caucasian HapMap data. We calculated LD between pairs of SNPs using the standard definition of D' (R. C. Lewontin, *Genetics* 50, 757 (1964)) and for the correlation coefficient r^2 (W. G. Hill, A. Robertson, *Genetics* 60, 615 (Nov, 1968)). For the Icelandic cohort, to take into account that some of the individuals are related to each other, we obtained the null statistic of the test statistic either by simulating
35 genotypes through the Icelandic genealogy or from the test statistic for all the 300,000 tested

for association in the initial genome-wide association scan (citation). Model-free estimates of the genotype relative risk are generated as follows: RR of genotype G_1 compared to genotype G_0 was estimated by $[n(G_1)/n(G_0)]/[m(G_1)/m(G_0)]$ where n and m denote genotype counts in patients and controls respectively. Results from different cohorts were combined using a Mantel-Haenszel
 5 model (citation) where cohorts are allowed to have different population frequencies for the alleles/genotypes but assume to have common relative risks.

We use multiple regression to test for association between markers and quantitative traits, such as age of onset of MI in the cases, where the number of copies of the at-risk variant carried by an individual is taken as explanatory variable and the quantitative trait as the
 10 response variable. The association is adjusted for age and gender, where appropriate, by including corresponding terms in the regression analysis as explanatory variables.

Correction for relatedness of the subjects and Genomic Control

Some of the individuals in both the Icelandic patient and control groups are related to
 15 each other, causing the chi-square test statistic to have a mean >1 and median >0.675 (Devlin, B & Roeder, K., *Biometrics* 55, 997 (1999)). We estimated the inflation factor for the genome-wide association by calculating the average of the 305,953 chi-square statistics, which was a method of genomic control (Devlin, B & Roeder, K., *Biometrics* 55, 997 (1999)) to adjust for both relatedness and potential population stratification. The inflation factor was estimated as
 20 1.129 and the results presented from the genome-wide association are based on adjusting the chi-square statistics by dividing each of them by 1.129. For the Icelandic replication cohort and the combined Icelandic replication and discovery cohort, we used a previously described procedure where we simulated genotypes through the genealogy of 708,683 Icelanders to estimate the adjustment factor (S9). The corresponding adjustment factors were 1.092 and
 25 1.029, respectively.

PCR screening of cDNA libraries

cDNA libraries were constructed from whole blood (pool of 90 individuals), EBV-transformed human lymphoblastoid cells (pool of 90 individuals), human cardiac myocyte cells
 30 (Sciencell, Cat.no. 6200), human aortic smooth muscle cells (Sciencell, Cat.no. 6110), human cardiac fibroblast ventricular cells (Sciencell Cat.no. 6310) and human primary umbilical vein endothelial cells (HUVEC) (pool of 4 individuals). Total RNA was isolated using the RNeasy RNA Isolation kit (Qiagen, Cat.no. 75144), the RNeasy RNA Isolation from whole blood kit (Qiagen, Cat.no. 52304) or the miRvana RNA Isolation kit, using the total RNA isolation procedure (Ambion
 35 Inc. Cat.no. 1560) according to manufacturer's recommendations. cDNA libraries were prepared at deCODE using the High Capacity cDNA Archive Kit with random primers (Applied Biosystems PN 4322171). In addition to the libraries above, two commercial cDNA libraries from whole heart (Clontech-639304) and aorta (Clontech-639325) were screened.

PCR screening was carried out using the Advantage2® Polymerase mix (Clontech cat.no. 639202) according to manufacturer's instructions with primers from Operon Biotechnologies. The PCR reactions were carried out in 10 µl volume at a final concentration of 3.5 µM of forward and reverse primers, 2 mM dNTP, 1x Advantage 2 PCR buffer, 0.2 µl of Advantage enzyme and 0.5 µl of cDNA library. (See Table 23). Expression was detected for all of the ESTs in several of the libraries tested (Table 24). None of the ESTs have an open reading frame larger than 77 bp. Many of them overlap with a recently reported antisense non-coding RNA whose expression has been shown to cocluster with p14/ARF (Pasmant, E., et al., *Cancer Res* 67, 3963 (2007)).

Sequencing of CDKN2A and CDKN2B

PCR amplifications and sequencing reactions were set up on Zymark SciClone ALH300 robotic workstations and amplified on MJR Tetrads. PCR products were verified for correct length by agarose gel electrophoresis and purified using AMPure (Agencourt Bioscience). Purified products were sequenced using an ABI PRISM Fluorescent Dye Terminator system, repurified using CleanSEQ (Agencourt), and resolved on Applied Biosystems 3730 capillary sequencers. SNP calling from primary sequence data was carried out using deCODE Genetics Sequence Miner software. All CDKN2A and CDKN2B variants identified by the automated systems were confirmed by manual inspection of primary signal traces. Samples from 96 early onset MI patients were sequenced using primers indicated in Table 25 and a list of the SNPs identified is provided in Table 26.

Surveying for candidate regulatory variants in the candidate region

The University of California Santa Cruz genome browser (genome.ucsc.edu) was used to extract positions of SNPs and conserved TF binding sites for a 600 kb surrounding the MI region (hg release 17, chromosome 9, bases 21800000 to 22400000). The two tables were cross referenced with Python scripts and SNPs that resided in binding sites were interrogated for LD with rs1333040 in the CEU sample of Hapmap (release 22). The analyses were implemented for release 18 of the human genome, and the results converted to hg 17 coordinates.

This bioinformatic analysis of 600 kb surrounding the MI region yielded 16 SNPs which coincide with conserved binding sites for transcription factors (Table 27). Lack of LD to SNPs tagging the MI haplotype enabled exclusion of a half of the 16 SNPs from this candidate list. The remaining polymorphisms could impact gene function by altering conserved TF binding sites. In parallel we looked for correlation between SNPs located in conserved blocks (based on Multiz alignments available through the UCSC genome browser, release hg 18) and the MI haplotype tagging SNPs. While about half of the 74 SNPs are represented in HapMap, we found none that were highly correlated with the MI haplotype (data not shown). In sum, these analyses do not identify particular SNPs as putative regulatory variants on the MI haplotypes. Note of caution, the analysis will only detect a proportion of the functional candidates in the region because; i) the MI haplotypes have not been sequenced fully, ii) several candidate SNPs are not typed in

Hapmap, hence it is unknown whether they sit on the risk conferring haplotypes. In addition, it is a realistic possibility that polymorphisms in less conserved regions are the functional MI variants.

Example 1.

5 *Genome-wide association study*

We successfully genotyped 1570 Icelandic myocardial infarction patients and 7088 population control individuals without known history of coronary artery disease (Cohort A) using the Illumina 330K chip. We performed a genome-wide scan for association to MI, testing individually each of the 309,091 SNPs that was successfully genotyped. Three markers
 10 (rs10116277, rs1333040, rs2383207), all located in a single LD block (denoted herein as LD block C09) on chromosome 9p show strong association to MI (see Figure 1 and Table 1a). All three markers are strongly correlated (Table 2) and the population frequency of the at-risk variants range from 42% to 49%, and the corresponding relative risk is approximately 1.2. The risk alleles of the same three markers also showed a significant correlation to lower age at onset
 15 within the MI patient – individuals carrying the at-risk variant are at significant risk of developing MI at a younger age than individuals who are non-carriers of the at-risk allele (Table 8a).

The LD-block LD block C09 containing the three associated marker is flanked and defined by two recombination hot-spots – one at approximately 21,920,000bp in Build 34, the other approximately 22,150,000bp on chromosome 9 (*Nature* 437, 1299-1320 (27 October 2005))).
 20 Investigating other genetic markers in LD block C09, we identified two micro-satellite markers, D9S1870 and D9S1814, that are strongly correlated with the at-risk alleles of the markers rs10116277, rs1333040, and rs2383207. Table 1b shows the association of each of the alleles of the microsatellite markers to MI in the same cohort of MI patients and controls that was used in the genome-wide association scan. For marker D9S1814 the associated allele was allele 0,
 25 however for D9S1870 multiple alleles (alleles -4, -2 and 0) showed increased risk of MI. By investigating the correlation between the different alleles of D9S1870 to the at-risk alleles of the markers rs10116277, rs1333040 and rs2383207, observed that by pooling together all alleles of D9S1870 shorter than 2 (alleles -6, -4, -2 and 0 respectively), the composite allele, denoted X, was strongly correlated to the original at-risk alleles of the SNP (Table 2). Composite allele X of
 30 D9S1870 and allele 0 of D9S1814 show similar association to MI as the at-risk alleles of rs10116277, rs1333040 and rs2383207 (Table 1c) and all five at-risk alleles are highly correlated (Table 2).

Further investigation of all SNPs in the HapMap v9 CEU dataset that are located in the chromosomal region defined by LD block C09 identified further 88 markers that are strongly
 35 correlated with the at-risk allele of at least one of the five markers rs10116277, rs1333040, rs2383207, D9S1814 and D9S1870 (Table 3) and hence those markers could also be used as surrogate markers to tag the observed association to MI in LD block C09.

We genotyped the micro-satellite marker D9S1870 in a large cohort of over 70,000 Icelanders that included, among others, 668 additional MI cases and 58,643 additional controls without known history of coronary artery disease (Cohort B). In addition we typed the microsatellite D9S1870 in three replication cohorts from US including; 549 MI patients and 606 controls from Cleveland; 580 MI cases and 404 controls from UPenn; and 400 MI cases and 477 controls from Emory. All individuals in the US cohorts are of Caucasian origin. We tested the composite allele X for association to MI in all four cohorts (Table 4a and b), and all but one (Cleveland) showed significant association. Combining the results from the four replication cohorts (Table 4c) yielded a combined P-value = 2.65×10^{-8} . Combined with the original Icelandic cohort used in the genome-wide association (Cohort A) the P-value is 1.44×10^{-12} and, assuming a multiplicative model, each allele X confers an estimated relative risk (RR) of 1.214 [95%CI:1.151-1.281] per copy carried, compare with the risk for non-carriers. The corresponding combined population attributable risk (PAR) is 17.1%.

If we investigate separately the risk conferred for individuals heterozygous for the risk allele X and individuals homozygous for X, relative to individuals that do not carry X (Table 7a), the estimated genotype relative risk (GRR) for heterozygous individuals is 1.204 [CI:1.094-1.324] and for homozygous individuals GRR is 1.507 [CI:1.360-1.670]. This is consistent with the multiplicative model, i.e an additive contribution of the allele X to the risk of MI.

We further investigated the correlation of the risk allele X to age of onset of MI in all four cohorts. Restricting the analysis to early-onset MI cases, defined as a MI event before the age of 50 for males and before the age of 60 for females, the relative risk for the cohorts combined increases to 1.331 [CI:1.223-1.449; $P = 3.96 \times 10^{-11}$; PAR = 24.7%] compared to 1.214 for all MI cases (Table 6c). Correspondingly the genotype relative risk increases to 1.314 [CI:1.105-1.562] and 1.790 [CI:1.517-2.113] for heterozygous and homozygous carriers of allele X respectively (Table 7b). Alternatively, we tested using multiple regression the correlation between the number of copies of X carried by individuals in the MI case group and the age of onset of MI (Table 8b). Combining results from all four cohorts, we observed that the mean age of onset decreased by 0.95 year [SE=0.25] for each copy of X carried by the MI individuals ($P = 0.000099$).

Among individuals typed for the marker D9S1870 in the Icelandic and the Emory cohort are individuals that have undergone percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft surgery (CABG), both indicative of severe coronary artery disease (CAD). We tested if those individuals also had an increased frequency of the risk allele X compared to controls, speculating that the variant might predispose individuals to a more general coronary artery disease than just MI (Table 5a and c). In both cohorts we observed similarly increased risk for PTCA and CABG as for MI, if not stronger, that was very significant in the Icelandic cohort, although for the Emory cohort only the association to PTCA was significant. It should be noted, however, that the number of individuals with PTCA and CABG in the Emory

cohort is small. This association remained in the Icelandic cohort even after removing known MI cases from the PTCA and CABG groups (Table 5b).

In addition, in the Icelandic cohort we investigated the association to other diseases related to coronary artery disease, such as peripheral artery disease (PAD) and stroke phenotypes such as infarct or transient ischemic attack (TIA). For 1661 PAD cases we observed a very significant association, $P = 5.36 \times 10^{-5}$ and $RR = 1.154$ [CI:1.074-1.239] (Table 5a) - this association remained significant after removing MI cases from the PAD cohort in the analysis although the effect was somewhat weaker (Table 5b). For 1678 individuals with infarct or TIA we did not observe significant association to X, however, for individuals diagnosed with large vessel diseases (LVD) - the stroke sub-phenotype that is most closely related to coronary artery disease - we observed an increased risk, $RR = 1.120$ or 1.172 if we include or exclude MI cases respectively (Table 5a and b). There are however only 197 individuals in the Icelandic cohort diagnosed with LVD and this association is not statistically significant.

We investigated the frequency of the risk variant X of marker D9S1870 in a group of 454 Icelandic individuals for which we had information on in-stent restenosis and that are genotyped for the variant. The cohort was divided into individuals with severe in-stent restenosis (50% or greater) and individuals with mild in-stent restenosis (less than 50%). As all those individuals have undergone PTCA, and hence have coronary artery disease, both groups have significantly higher frequency of the variant X than is observed in controls (Table 9a). However, the frequency in the group of individuals with severe restenosis is higher than in the group with mild restenosis, $RR = 1.067$ [CI:0.827-1.376], and although this difference is not significant (Table 9b), this suggests that the variant could be indicative of the severity of in-stent restenosis in coronary artery disease patients that have undergone PT

Example 2.

A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction

Coronary artery disease (CAD), including acute myocardial infarction (MI), is the leading cause of death worldwide (Thom, T., et al., *Circulation* 113:e85 (2006)). Identification of the underlying genetic architecture of heart disease may provide improved risk assessment and better measures for prevention and treatment.

To this end we conducted a genome-wide association study on Icelandic patients with MI, using the Illumina Hap300 chip. After quality filtering, 305,953 SNPs were tested for association to MI in a sample of 1607 cases, with age at onset before 70 in males and 75 in females, and 6728 controls without a history of CAD (Helgadóttir, A., et al., *Science* 316:1491 (2007)). The results were adjusted for relatedness between individuals and potential population stratification using a method of genomic control (3). Although none of the SNPs were significant after adjusting for the number of tests performed more signals bordering on significance were

observed than expected by chance. Hence, we further explored the SNPs that were closest to genome wide significance.

The strongest association to MI was observed with three correlated SNPs, rs1333040, rs2383207 and rs10116277, each with odds ratio (OR) around 1.22 for the risk allele and P of approximately 1×10^{-6} (Table 15). All three SNPs are located within the linkage disequilibrium (LD) block on chromosome 9p21 denoted herein as LD block C09 (Fig. 1). Apart from these three SNPs, eleven other SNPs in the same LD block showed nominally significant association to MI. The associations to these SNPs tended to become weaker after accounting for the association to the three SNPs mentioned above (Table 15). After adjustment, a few remained nominally significant ($P < 0.05$), but none had a $P < 0.01$.

To replicate the observed associations we genotyped the three SNPs, rs1333040, rs2383207 and rs10116277, in an additional 665 Icelandic MI cases and 3533 controls and in three case-control sample sets of European descent from three cities from the United States: Philadelphia, Atlanta, and Durham (2). For consistency we used the same age at onset criteria in the association analysis as for the discovery group. The association to MI was replicated with significance in all four groups (Table 16). When the replication sets were combined using a Mantel-Haenszel model (Mantel, N. & Haenszel, *J. Natl. Cancer Inst.* 22:719 (1959)), all three SNPs showed highly significant association to MI ($P < 1 \times 10^{-8}$), with ORs comparable to those observed in the Icelandic discovery samples. When all groups were combined, rs2383207 showed the most significant association ($P = 2.0 \times 10^{-16}$), with an OR of 1.25 (95% CI 1.18-1.31) for the risk allele G. It is noted that rs2383207 and rs10116277 are highly correlated ($r^2 = 0.90$) and their effects could not be reliably distinguished from each other in these data. The SNP rs1333040 is also substantially correlated with rs2383207 and rs10116277 ($r^2 = 0.57$ and 0.67 respectively). In an attempt to refine this association signal, we identified the SNPs that are substantially correlated with rs2383207 ($r^2 > 0.5$) based on the Hapmap CEU data and are not part of the Illumina Hap300 chip. Among the 36 such SNPs, we selected eight to be genotyped. Each of the 36 SNPs was either one of the eight or it had a very good surrogate among them ($r^2 > 0.90$) (Table 21). With data from all case-control groups combined, allele G of the refinement SNP rs10757278 showed the strongest association to the disease (OR = 1.28, $P = 1.2 \times 10^{-20}$; Tables 12 and 16). Furthermore, while rs2383207 was no longer significant after adjusting for rs10757278 ($P = 0.25$), rs10757278 remained significant with adjustment for rs2383207 ($P = 2.0 \times 10^{-5}$). Among the SNPs in this region that showed very significant association to the disease when tested individually, none was significant after adjustment for rs10757278 with the exception of the refinement SNP rs13330406, which was marginally significant ($P = 0.044$) with adjustment (Table 22). Henceforth, for simplicity of presentation, we focus on the most significant SNP rs10757278 in the main text but additional results for other SNPs in the region are provided Tables 16 to 20.

To investigate the mode of inheritance in more detail, we computed genotype specific ORs for rs10757278. With results from all groups combined, relative to non-carriers, the ORs for

heterozygous and homozygous carriers of the risk allele G were 1.26 and 1.64, respectively (Table 13). Assuming a frequency of 45.3% for the allele, the average of the frequencies in Iceland and the US, the corresponding PAR is 21%.

Because the impact of genetic factors on CAD has been shown to be greater at early ages (5) we investigated the correlation of allele G of rs10757278 to age at onset of MI. Note that in this analysis we used all cases with a known age at onset including those who had onset after the age of 70 or 75 for males and females, respectively. This added a total of 973 cases to the study groups compared to what was used in the case-control analyses. Regressing the age at onset on the number of risk alleles showed that, for each copy of the risk allele, the age at onset of MI was on average reduced by approximately one year ($P = 2.9 \times 10^{-7}$) (Table 18). Alternatively, restricting the case-control analysis to early onset MI, defined as an MI before the age of 50 for males and before the age of 60 for females, the allelic OR for rs10757278 G in all groups combined increased to 1.42 (95% CI 1.31 - 1.53) (Table 19). Relative to non-carriers, genotype specific OR for early onset MI is 1.49 and 2.02 for heterozygous and homozygous carriers of the risk allele, respectively (Table 13).

Having established that allele G of rs10757278 is associated to MI, we explored its impact on the broader phenotype of CAD (Table 14). To eliminate bias that could have arisen from the selection of the most significant variants in the initial genome-wide study, the cases and controls from the Icelandic discovery group (Iceland A) were not included here. We do note that if the latter were included, there would be little change to the estimated effects, but the results would become more significant due to the larger sample sizes. Also, the group from Durham did not have CAD cases without MI. As expected, rs10757278 was associated with high significance to CAD (OR = 1.29, $P = 3.6 \times 10^{-14}$ for the groups combined). After removal of MI cases from the analyses, the associations remained significant for the groups from Iceland and Atlanta, but not in the Philadelphia group. Combining results from the three groups gave an OR of 1.24 ($P = 0.000011$).

The variants on chromosome 9q21 associated to MI are located in an LD block that contains the *CDKN2A* and *CDKN2B* genes. The proteins encoded by these genes, called p16^{INK4a}, ARF and p15^{INK4b} have a critical role in regulating cell proliferation, cell aging/senescence, and apoptosis in many cell types (Kim, W.Y. & Sharpless, N.E. *Cell* 127:265 (2006)). These are all important features of atherogenesis, the underlying cause of MI and CAD (Lusis, A.). *Nature* 407:233 (2000); Minamino, T. & Komuro, I. *Circ Res* 100:15 (2007)). Sequencing of 93 early onset MI patients across exons, exon-intron junctions, and regulatory regions of *CDKN2A* and *CDKN2B* did not reveal obvious candidates for functional variants or other variants that could account for the observed association to rs10757278 (Tables 25 and 26). In addition to *CDKN2A* and *CDKN2B* genes, the LD block contains two exons of the mRNA transcript AF109294, a hypothetical methylthioadenosine phosphorylase fusion protein mRNA and several ESTs that are expressed in various tissues (Helgadottir, A., et al., *Science* 316:1491 (2007)). The functional relevance of the variants of this genomic region to MI/CAD remains to be elucidated.

In summary, we have shown that a common genetic variant located in the vicinity of the tumor suppressor genes *CDKN2A* and *CDKN2B* on chromosome 9p21 associate to MI. This is the first common variant discovered to consistently confer substantial risk (OR > 1.20) of MI in multiple case-control groups of European descent. Due to its high frequency, the population attributable risk of the variant is approximately 21% for MI in general and approximately 31% for early onset cases, which is substantial from a public health point of view. However, as the relative risks are not extremely high, it explains only a small fraction of the familial clustering of the disease and would not generate large linkage scores. Hence, others susceptibility variants remain to be identified and some could be located in candidate regions identified by genome-wide linkage scans (Zintzaras, E. & Kitzlos, G., *J Hum Genet* 51:1015 (2006); Wang Q., et al., *Am J Hum Genet* 74:262 (2004); Samani, N.J., et al., *Am J Hum Genet* 77:1011 (2005)). There is evidence supporting that the variant identified here could increase the risk of CAD in general in addition to their impact on MI, an observation that warrants further investigation. The mechanism whereby the genetic variants exert their effects in the pathogenesis of MI remains to be elucidated.

Example 3.

Genotyping of polymorphic markers identified through sequencing

Sequencing of the exons of *CDKN2A* and *CDKN2B* genes, the exon-intron junctions and potential regulatory regions using the primers as indicated in Table 25 resulted in the identification of a number of SNPs, as shown in Table 26. Flanking sequences for three of those SNPs that were not found in public databases are indicated in Table 31. As it is possible that SNP markers or other polymorphisms in LD with the markers found to be associating to MI in this region of chromosome 9 show association with a higher risk, we genotyped these additional markers by sequencing, as indicated in Table 28. Several of the markers show association to MI with RR values as high as 1.7-1.8, in particular markers SG09S291 and rs2069416.

Example 4

Association to related cardiovascular disorders

We have investigated association of the at-risk variants of the invention to the related disorders peripheral artery disease (PAD), abdominal aorta aneurysm (AAA) and large vessel disease stroke (LVD) for three of the markers giving signal on Chromosome 9 as presented herein. As can be seen in Table 29, these markers are associated with these related disorders. The association is particularly compelling for AAA, wherein significant association is observed for a large number of markers in addition to these three, as shown in Table 30. These results

illustrate that the markers and haplotypes of the invention are indeed reflective of disorders related to coronary artery disease, MI and in-stent restenosis, such as abdominal aorta aneurysm.

5 Example 5

Further refinement of association to the arterial phenotypes AAA, IA and Stroke.

To investigate the effect of rs10757278 on other cardiovascular diseases in more detail, we further explored the association to abdominal aortic aneurysm (AAA) and Stroke, and also investigated the arterial disorder intracranial aneurysm (IA).

Methods

Study Populations

Coronary artery disease groups

The coronary artery disease groups from Iceland and the United States were as described above (see also Helgadottir, A., *et.al.*, *Science* 316:1491-3 (2007))

Icelandic controls

The 14278 Icelandic controls used in the association study were selected among individuals who have participated in various GWA studies and were recruited as part of genetic programs at deCODE. The medical histories of the controls were unknown unless they had also participated in one or more of the CVD genetic programs (i.e. MI, stroke, PAD, T2D, obesity, familial combined hyperlipidemia, coronary restenosis, and hypertension). Individuals with known MI, stroke, PAD or CAD, or with T2D were excluded as controls. Of the 14259 controls 9202 overlap with those used in our previous GWA study in MI (Helgadottir, A., *et.al.*, *Science* 316:1491-3 (2007)). The controls included 5615 males and 8644 females and their mean age was 55.2 (SD 21.7). The breakdown of the control group into the various genetic programs was approximately (with the frequency of the two variants, rs10757278 allele G and rs10811661 allele T in parenthesis): Schizophrenia 500 (0.428/0.825), Prostate cancer 900 (0.447/0.815), Breast Cancer 1300 (0.433/0.817), Colon Cancer 700 (0.413/0.817), Addiction 2600 (0.444/0.814), Anxiety 900 (0.442/0.824), Infectious diseases 1200 (0.434/0.821), Population Controls 700 (0.427/0.830), Microarray expression studies 400 (0.445/0.817), Longevity 1100 (0.450/0.819), Migraine 1100 (0.446/0.818), Restless Leg Syndrome 400 (0.439/0.812), Alzheimer disease 350 (0.457/0.822), Asthma 1300 (0.419/0.819), Dyslexia 600 (0.438/0.830). No significant differences in frequencies were observed between the disease groups for either of the two variants ($P = 0.52$ and $P = 0.99$ for rs10757278 and rs10811661, respectively).

Stroke groups

Icelandic stroke patients were recruited from a registry of over 4000 individuals which includes individuals diagnosed with ischemic stroke or TIA at the major hospital in Reykjavik, the Landspítali University Hospital, during the years 1993 to 2002. Stroke patients have been enrolled over the past nine years through the cardiovascular disease (CVD) genetics program at deCODE. Swedish patients with ischemic stroke or TIA attending the stroke unit or the stroke outpatient clinic at Karolinska University Hospital, Huddinge unit in Stockholm, Sweden were recruited from 1996 to 2002 as part of an ongoing genetic epidemiology study, the South Stockholm Ischemic Stroke Study (SSISS). All patients from Iceland and Sweden had clinically relevant investigations performed, including brain imaging with computed tomography (CT) or/and magnetic resonance imaging (MRI) as well as ancillary diagnostic investigations including duplex ultrasonography of the carotid and vertebral arteries, echocardiography, Holter monitoring, MR-angiography, CT-angiography and standardized blood tests. Patients were classified into ischemic subtypes according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification by a physician reviewing original imaging and data (Adams, H.P. Jr., et al., *Stroke* 24:35-41 (1993)). Patients classified with cardioembolic stroke and documented atrial fibrillation were excluded from the analysis. The Swedish controls used in this study are population-based controls recruited from the same region in central Sweden as the patients, representing the general population in this area. The individuals were either blood donors (recruited in 2001) or healthy volunteers (collected in 1990-1994) recruited by the Clinical Chemistry Department at the Karolinska University Hospital to represent a normal reference population. These stroke studies from Iceland and Sweden were approved by relevant Institutional Review Boards or ethics committees and all participants provided written informed consent.

Intracranial aneurysm groups

Icelandic IA patients were identified through an inpatient database from 1994-2006 at the Landspítali University Hospital, which is the only hospital with a neurosurgical service in the country. All patients in the years 1996-2006 with the ICD10 diagnosis I60.0-7 (aneurysmal subarachnoid hemorrhage), I67.1 (ruptured cerebral aneurysm) and I69.0 (sequelae of subarachnoid haemorrhage) were enrolled, as well as patients with the ICD9 diagnosis 430 (subarachnoid hemorrhage from ruptured cerebral aneurysm) in the years 1994-1996. This totalled 367 IA patients. All patients had clinically relevant investigations performed, including CT scan of the head and/or conventional cerebral angiogram, CT-angiogram or MRI angiogram. DNA samples were available for 170 of the 367 patients.

Dutch patients with ruptured (91.5%) or unruptured (8.5%) IA admitted to the University Medical Center Utrecht were used for the study. Ruptured intracranial aneurysms were defined by symptoms suggestive of subarachnoid hemorrhage (SAH) combined with subarachnoid blood on CT and a proven aneurysm at angiography (conventional angiogram, CT- or MR-angiogram) and unruptured intracranial aneurysms were identified by CT or MR angiography or conventional angiography. Multiple intracranial aneurysms were found in 20.5%

of cases. Mean age at time of SAH was 49.5 years (range 10-84) and 66.1% of the patients were females. The controls were healthy Dutch blood bank donors of European origin.

Finnish IA patients admitted for treatment of intracranial aneurysm at either the University Hospital of Kuopio, or University Hospital of Helsinki, in Finland, were used for the study. This study group and the Finnish controls used have been described previously (Weinsheimer, S. *et al.*, *Stroke* 38:2670-6 (2007)).

The Icelandic, Dutch and Finnish IA studies were approved by relevant Institutional Review Boards or ethics committees and all participants provided written informed consent.

Peripheral arterial disease groups

Icelandic patients with PAD were recruited from a registry of individuals diagnosed with PAD at the major hospital in Reykjavik, the Landspítali University Hospital, during the years 1983 to 2006. The PAD diagnosis was confirmed by vascular imaging or segmental pressure measurements. PAD patients have been enrolled over the past nine years as part of the CVD genetics program at deCODE.

Italian patients and controls were recruited among subjects consecutively admitted to the Department of Internal Medicine and Angiology of the A. Gemelli University Hospital of Rome, from 2000 to 2001. Inclusion criteria for the PAD group were European descent and presence of PAD. Diagnosis of PAD was performed in accordance with established criteria (*J Vasc Surg* 4:80-94 (1986)). All patients had an ankle/arm pressure index lower than 0.8 and were at Fontaine's stage II, with intermittent claudication and no rest pain or trophic lesions. Inclusion criteria for the control group were European descent, absence of PAD and CAD and no relationship with cases. Additional, exclusion criteria from the study were tumours, chronic inflammatory diseases, and autoimmune diseases (Flex, A., *et al.*, *Eur J Vasc Endovasc Surg* 24: 264-8 (2002)).

Swedish PAD patients and controls were recruited at the Department of Vascular Diseases at Malmö University Hospital, a single referral centre for all patients with critical limb ischemia in the three southernmost health-care districts in Sweden (723,750 inhabitants in 2001). The diagnosis of critical limb ischemia was made in accordance with TransAtlantic Inter-Society Consensus scientific criteria of ulceration, gangrene, or rest pain caused by PAD proven by ankle pressure (<50 to 70 mm Hg), reduced toe pressure (<30 to 50 mm Hg), or reduced transcutaneous oxygen tension (Dormandy, J.A. & Rutherford, R.B., *J Vasc Surg* 31:S1-S296 (2000)). Diagnosis was confirmed by an experienced vascular surgery consultant and toe pressure measurements in patients with arteries in the affected leg that were noncompressible and the ankle pressure was >50 to 70 mm Hg. The control group consisted of healthy individuals included in a health screening programme for a preventive medicine project. None of those had symptomatic PAD (Barani, J., *et al.*, *J Vasc Surg* 42:75-80 (2005)).

New Zealand PAD patients were recruited from the Otago-Southland region of the country, the vast majority (>97%) being of Anglo-European ancestry as reported previously (Jones G.T., *et al.*, *Clin Chem* 53:679-85 (2007)). PAD was confirmed by an ankle brachial index<0.7, pulse volume recordings and angiography/ultrasound imaging. The control group consisted of elderly individuals with no previous history of vascular disease from the same

geographical region. Controls were asymptomatic for PAD and had ankle brachial indexes >1 . An abdominal ultrasound scan excluded concurrent AAA from both the PAD and control groups.

The Icelandic, Italian, Swedish, and New Zealand PAD studies were approved by relevant Institutional Review Boards or ethics committees and all participants provided written informed consent.

Abdominal aortic aneurysm groups

Icelandic patients with AAA were recruited from a registry of individuals who were admitted either for emergency repair of symptomatic or ruptured AAA or for an elective surgery to the Landspítali, University Hospital, in Reykjavík, Iceland in the years 1980-2005. Subjects with AAA were enrolled over the last nine years as part of the CVD genetics program at deCODE. In some of the analyses AAA cases that overlapped with a comprehensive list of CAD patients (Helgadóttir, A., *et al.*, *Science* 316:1491-3 (2007)) diagnosed in Iceland in the years 1981-2006 were excluded. Of the 397 (288 males and 109 females, mean age 75.3 (SD 8.7)) AAA cases, 208 overlapped with the CAD patients. Of the 189 (131 males and 58 females, mean age 75.5 (SD 9.3)) remaining CAD, information was not available for 138 cases and 51 individuals reported in a questionnaire as not having been diagnosed with CAD.

UK patients with AAA referred to vascular surgeons at 93 UK hospitals were entered into UK Small Aneurysm Trial. For the purpose of the current study those randomised to surveillance in the UK Small Aneurysm Trial with AAA diameter 4.0-5.5 cm were selected as a patient group, although some patients had been monitored before their aneurysm reached the 4.0cm threshold for the trial. Mean AAA diameter at baseline was 4.5 cm (3.2-5.5 cm) (Eriksson, P., *et al.*, *Br J Surg* 92:1372-6 (2005)). Information on the occurrence of CAD was available for 97% (466 out of 479) of AAA cases. History of CAD was regarded as positive if the subject was under treatment for angina, had a previous MI, coronary artery bypass graft surgery or angioplasty or if ECG coding had any indications of ischaemia, as judged by two independent expert observers. Among those with this information, the frequency of CAD amongst the AAA subjects was 52%. Controls were of European descent, recruited from England.

Belgian and Canadian patients with AAA who were admitted either for emergency repair of ruptured AAA or for an elective surgery to the University Hospital of Liège in Belgium and to Dalhousie University Hospital in Halifax Canada, respectively, were used for this study. Details of these case-control sets have been previously reported (Ogata, T., *et al.*, *J Vasc Surg* 41:1036-42 (2005)). All patients were of European descent and had a diameter of infrarenal aorta ≥ 3 cm. Thirty-five patients were diagnosed with AAA using ultrasonography and did not undergo surgery because of old age or because the aneurysm was relatively small. Approximately 40% of AAA patients had a family history of AAA. For Belgian AAA patients, information on CAD history was ascertained for those who underwent surgery through interviews as well as from medical files. In addition, all patients underwent cardiologic explorations such as transthoracic echography, stress tests and coronary angiography if CAD was suspected. CAD information for this study was available for 45% (79 out of 176) of AAA cases from Belgium. Among those with this information, the frequency of CAD amongst the AAA subjects was 29%. Control samples (51%

males) of European descent were obtained from spouses of AAA patients or from individuals admitted to the same hospitals for reasons other than AAA.

Patients admitted to the University Hospital of Pittsburgh for either elective or emergency surgery for AAA were selected for the study (St Jean, P.L., *et al.*, *Ann Hum Genet* 59:17-24 (1995)). History of CAD was self-reported and was available for 86% (87 out of 101). Among those with this information, the frequency of CAD amongst the AAA subjects was 48%. Controls were selected from participants of the PENN CATH study program at the University of Pennsylvania Medical Center Philadelphia. The control group represents individuals who were without significant luminal stenosis on coronary angiography (luminal stenosis less than 50%) and did not have a history of MI. These are the same controls as were used in the association analysis for the CAD samples from Pennsylvania (Helgadóttir, A., *et al.*, *Science* 316:1491-3 (2007)).

New Zealand patients with AAA were recruited from the Otago-Southland region of the country, the vast majority (>97%) being of Anglo-European ancestry as reported previously (Jones, G.T., *et al.*, *Clin Chem* 53:679-85 (2007)). Approximately 80% of patients had undergone surgical AAA repair (typically AAA's >50mm in diameter). Controls were the same vascular disease free individuals as described for comparison with the New Zealand PAD group. CAD information was available for 98% (575 out of 588) of the AAA patients. Of those with information the frequency of CAD was 40%.

AAA sample set from the Netherlands was recruited from 8 centres in the country, mostly when patients visited their vascular surgeon or in rare cases during hospital admission. The controls were healthy Dutch blood donors of European origin. Information on other CVD was self-reported and available for 69% (330 out of 480). Treatment for angina pectoris, previous MI, coronary bypass surgery or stent insert was considered as CAD. Of the 330 with information, 96 had CAD (29%).

These AAA studies from Iceland, UK, Belgium, Canada, Pennsylvania, The Netherlands and New Zealand were approved by relevant Institutional Review Boards or ethics committees and all participants provided written informed consent.

SNP Genotyping.

SNP genotyping for all samples was carried out at deCODE genetics in Reykjavik, Iceland. Individual SNP genotyping was carried out with the Centaurus (Nanogen) platform (Kutyavin, I.V., *et al.*, *Nucleic Acids Res* 34:e128 (2006)). The quality of each Centaurus SNP assay was evaluated by genotyping each assay in the CEU and/or YRI HapMap samples and comparing the results to the HapMap data. The key markers rs10757278 and rs10811661 were re-genotyped on more than 10% of samples and a mismatch was observed in less than 0.5% of samples. For some of the samples we had previously genotyped the SNPs rs1333040, rs2383207, and rs10116277 either with the Illumina 317K Bead chip or with the Centaurus method. These SNPs are highly correlated with rs10757278 ($r^2 = 0.57, 0.87, \text{ and } 0.90$, respectively, in the HapMap CEU dataset) and were used to impute the genotypes for rs10757278 where they were missing. In addition, for a large number of the Icelandic samples the SNP rs2383208, which is present on

the Illumina 317K Bead chip, was previously genotyped. This SNP is a perfect surrogate for the SNP rs10811661 ($r^2 = 1$ in the HapMap CEU dataset) and was used to impute genotypes for rs10811661.

The SNPs did not deviate from Hardy Weinberg Equilibrium in any of study cohorts used for the analyses.

Association Analysis

We used a standard likelihood ratio statistics, implemented in the NEMO software (to calculate two-sided P values and odds ratio (OR) for each individual allele, assuming a multiplicative model for risk, i.e., that the risk of the two alleles a person carries multiply. Allelic frequencies, rather than carrier frequencies are presented for the markers, and, for the Icelandic study groups, P values are given after adjustment for the relatedness of the subjects by simulating genotypes through the genealogy of 708,683 Icelanders as previously described (Stefansson, H., *et al.*, *Nat Genet* **37**:129-37 (2005)). When estimating genotype specific OR (Table 34) genotype frequencies in the population were estimated assuming HWE. Heterogeneity tests were performed assuming that the estimates of OR for various groups have log-normal distributions. A likelihood ratio chi-square test was used with associated degrees of freedom equal to the number of groups compared minus one.

In general, allele/haplotype frequencies are estimated by maximum likelihood and tests of differences between cases and controls are performed using a generalized likelihood ratio test. This method is particularly useful in situations where there are some missing genotypes for the marker of interest and genotypes of another marker, which is in strong LD with the marker of interest, are used to provide some partial information. To handle uncertainties with phase and missing genotypes, maximum likelihood estimates, likelihood ratios and P values are computed directly for the observed data, and hence the loss of information due to uncertainty in phase and missing genotypes is automatically captured by the likelihood ratios.

The correlation of rs10757278 allele G and rs10811661 allele TT to both age and sex was tested in the Icelandic control population. Neither of the alleles demonstrated significant association to these covariates. In addition, no significant difference was detected in the frequency of the variants between males and females within the AAA cases (data not shown). Furthermore, including age and sex as covariates in the association analysis of rs10757278 allele G to AAA in the Icelandic samples had negligible impact on the results. Thus, for simplicity, the association analysis is presented without adjustment for age and sex.

The possibility that the association results observed for rs10757278 allele G to AAA was influenced by population stratification was addressed for the UK AAA cases and controls by typing 13 SNPs identified by the WTCCC as showing strong evidence for geographic differentiation in the WTCCC samples (*Nature* **447**:661-78 (2007)). Only one of those SNPs showed nominally significant difference between the UK AAA cases and controls ($P = 0.017$), which is not significant if we adjust for having tested 13 SNPs. If we adjust for this SNP in the case-control analysis, the association of rs10757278 allele G to AAA in the UK case-control group

is not affected ($P = 0.0052$ and $OR = 1.36$ instead of $P = 0.0063$ and $OR = 1.35$). In the Icelandic case-control analysis we have adjusted for the relatedness of the study individuals. This adjustment has been shown to agree very well with the adjustment based on genomic control, which would include adjustment for any population stratification, in recent publications of genome-wide association studies in the Icelandic population (Steinthorsdottir, V., *et al.*, *Nat Genet* **39**:770-5 (2007); Gudmundsson, J. *et al.*, *Nat Genet* **39**:631-7 (2007)). Most importantly, the very similar allelic odds ratios obtained from the five AAA data sets makes it highly unlikely that population stratification has any substantial impact on the estimates of the effect.

Results from multiple case-control groups were combined using a Mantel-Haenszel model in which the groups were allowed to have different population frequencies for alleles, haplotypes and genotypes but were assumed to have common relative risks (Mantel, N. & Haenszel, W. *J Natl Cancer Inst* **22**: 719-48 (1959)).

Results

The results shown in Table 32 shows results from the Icelandic IA cohort, replication cohorts, and a combined analysis for the cohorts. When data from the multiple case-control groups studied were combined separately for IA, AAA, PAD and LAA/cardiogenic stroke, rs10757278 allele G showed significant association to all of the four phenotypes. However, the estimated effect size differed substantially and was strongest for AAA (combined analysis, $OR = 1.31$, $P = 1.2 \times 10^{-12}$) and IA (combined analysis, $OR = 1.29$, $P = 2.5 \times 10^{-6}$). In addition to the high overall statistical significance, it is also important to note that the estimated risk conferred by rs10757278 allele G to IA and AAA was very similar across the three IA sample sets from Iceland ($OR = 1.36$), Finland ($OR = 1.33$), and the Netherlands ($OR = 1.24$) (P_{het} , the P -value for the test of heterogeneity = 0.75), and the seven AAA sample sets from Iceland ($OR = 1.37$), Belgium ($OR = 1.21$), Canada ($OR = 1.29$), Pennsylvania US ($OR = 1.39$), United Kingdom (UK) ($OR = 1.35$), Netherlands ($OR = 1.31$), and New Zealand ($OR = 1.25$), ($P_{het} = 0.98$). The effect of rs10757278 allele G on IA and AAA is comparable to that previously reported for CAD (Helgadottir, A., *et al.* *Science* **316**:1491-3 (2007)) (Table 32).

Because of high co-morbidity between AAA and CAD, we explored the nature of the effect of the variant on the two conditions, by repeating the association analysis for AAA after removing cases with evidence of CAD. As shown in Table 33, the effect of rs10757278 allele G on AAA without evidence of CAD was only slightly smaller than that for the whole sample sets, or $OR = 1.3$ for the Icelandic, 1.31 for UK, 1.19 for Pennsylvania, 1.20 for Belgian, 1.25 for The Netherlands, and 1.18 for the New Zealand sample sets. For the six different groups with available CAD information, after removing known CAD cases the combined OR was 1.25 and $P = 3.0 \times 10^{-6}$, indicating that the association to AAA is not simply a consequence of the association between rs10757278 allele G and CAD. To our knowledge there is no evidence in the literature suggesting co-segregation of IA and CAD. Furthermore, the gender ratio in IA is also different

from that for the atherosclerotic diseases such as CAD; IA is more frequent in females than in males, and the peak incidence is also at a younger age than for CAD (Schievink, W.I., *N Engl J Med* 336:28-40 (1997)). The effect of rs10757278 allele G on IA is thus not mediated through CAD.

When genotype-specific effects were studied based on data from all seven AAA and the three IA sample sets the ORs for heterozygous and homozygous carriers of the risk allele G were estimated to be 1.36 and 1.74, respectively for AAA and 1.38 and 1.72, respectively, for IA (Table 34). Assuming a population frequency of 47.5% for the G allele, the corresponding population attributable risk is about 26% for both AAA and IA. It is noted that rs10757278 allele G is the first common sequence variant described that affects the risk of IA or AAA.

The prevalence of AAA (defined as > 3 cm aortic diameter) has been reported to be 4.3% and 1.0% in men and women over 50 years of age, respectively (Lederle, F.A., et al., *J Vasc Surg* 34:122-6 (2001); Lederle, F.A., et al. *Arch Intern Med* 160:1425-30 (2000)), and 2-5% of the general population have IA (Brisman, J.L., et al., *N Engl J Med* 355:928-39 (2006)). Both AAA and IA represent a degenerative process of the arteries leading to their enlargement that is usually asymptomatic with natural history culminating in either a therapeutic intervention or rupture. Rupture of IA leads to subarachnoid haemorrhage, and rupture of both IA and AAA have high morbidity and mortality (Brisman, J.L., et al., *N Engl J Med* 355:928-39 (2006); Thompson, R.W. *Cardiovasc Surg* 10: 389-94 (2002)). In the case of AAA the rupture risk increases with the growth rate as well as the size of the aneurysm. While patients from the UK study group included only those with small asymptomatic aneurysms (aortas <5.5cm diameter), the other study groups included mainly patients undergoing aneurysm repair and are therefore likely to be biased towards larger and symptomatic aneurysms (aortas >5.5 cm diameter). Despite recruitment differences the ORs were similar, suggesting that the variant does not confer direct risk of the growth of aortic aneurysms. This concept was further investigated in the sample set from UK, where the subjects with small asymptomatic AAA had been followed with sequential aortic aneurysm size measurements (Eriksson, P. et al., *Br J Surg* 92:1372-6 (2005)). As shown in Table 35, there is no evidence of an association between rs10757278 allele G and either aneurysm growth or rupture. Rather there is some indication that allele G is correlated with slow growth. The difference in average growth rates between the homozygous GG group and the heterozygous AG group is -0.46 mm/year and is nominally significant ($P = 0.05$), an observation that warrants further investigation. If confirmed, this inverse association would echo previous findings where slower aneurysm growth rates were observed in patients with low ankle/brachial pressure index, a marker of generalised atherosclerosis (Brady A.R., et al., *Circulation* 110:16-21 (2004)). These data suggest that the sequence variant leads to increased susceptibility of developing aneurysm rather than increasing the risk of rapid aneurysm progression.

The effect of rs10757278 allele G on the risk of PAD and LAA/cardiogenic stroke appeared to be weaker than that for AAA, IA and CAD (Table 32). In the Icelandic samples there was no

difference in the frequency of rs10757278 allele G between the AAA and IA cases, however the frequency was lower in both the PAD and LAA/cardiogenic stroke cases than in the combined group of AAA and IA cases ($P=0.012$ and $P=0.052$, respectively). Furthermore, after excluding PAD and LAA/cardiogenic stroke subjects with known CAD from the analysis the effect was reduced even further, particularly for PAD (Table 33).

We tested the association of several variants in the LD block C09 region with MI in African American samples. As shown by the results presented in Table 36, the effect in African Americans is comparable in magnitude, as measured by Relative Risk, to the effect in Caucasian samples. The lack of nominal statistical significance of the association (p-value less than 0.05) in the African American samples for many of the markers is due to the relatively small samples size. Most importantly, the association observed in African Americans, together with reported association in Asian samples originating from Japan and Korea with comparable risk to that determined for Caucasians (see *Arterioscler Thromb Vasc Biol.* 2008 Feb;28(2):360-5. Epub 2007 Nov 29, and *J Hum Genet.* Epub 2008 Feb 9) shows that the genetic effects originally discovered in Caucasian samples from Iceland manifests itself in other human populations. The effect therefore has implications for cardiovascular disease in all major human populations..

These data demonstrate that rs10757278 allele G has less effect on the atherosclerotic diseases, PAD and LAA/cardiogenic stroke, than on CAD. In contrast, the effect on the two aneurysmal diseases, AAA with weaker association to atherosclerosis and IA with no such relationship, was comparable to that on CAD, suggesting that the variant plays a role in a pathophysiological component common to these arterial phenotypes. This may involve abnormal vascular remodelling and/or repair which has been identified as a key in the pathogenesis CAD, AAA and IA (Chatzidislis, Y.S. et al., *J Am Coll Cardiol* 49:2379-93 (2007); Hashimoto, T. et al., *Neurol Res* 8:372-80 (2006); Moore, J.E., Jr., et al, *Atherosclerosis* 110:225-40 (2006)). The sequence variant rs10757278 allele G on chromosome 9p21, and/or variants in linkage disequilibrium with rs10757278, may thus function as a genetic determinant of the tissue response to unfavourable conditions that prevail in the lower abdominal aorta, in the circle of Willis where IAs occur, and in those regions of the coronary tree that are prone to develop unstable, rupture prone atherosclerotic plaques.

TABLES

Table 1: a) Results for the 12 SNPs in LD block C09 that showed nominally significant association to myocardial infarction in the Icelandic discovery cohort (Cohort A) of 1570 MI cases and 7088 controls. Shown is the frequency of the risk allele in cases and controls, the corresponding relative risk (RR), the unadjusted *P*-value and the *P*-value after adjusting for the relatedness of cases and controls. Also included are results for a test of association to MI for the same SNPs conditioned on the association of the SNP rs1333040. b) Association to MI for the different alleles of the micro-satellites D9S1814 and D9S1870 in Cohort A. c) Association to MI of the at-risk allele 0 for D9S1814 and of the composite at-risk allele X of D9S1870 in Cohort A. The composite allele X includes alleles -6, -4, -2 and 0 of D9S1870.

SNP	Allele	Position	Frequency		RR	<i>P</i>	<i>P</i> *	Conditioned on rs1333040		
			Cases	Controls				RR**	<i>P</i> **	<i>r</i> ² ***
a) rs7041637	A	21951866	0.251	0.232	1.104	0.031	0.044	1.003	0.96	0.12
rs2811712	A	21988035	0.890	0.874	1.171	0.010	0.016	1.146	0.040	0.05
rs3218018	A	21988139	0.894	0.878	1.174	0.010	0.016	1.149	0.038	0.03
rs3217992	A	21993223	0.376	0.344	1.149	0.00071	0.0015	1.015	0.80	0.28
rs2069426	C	21996273	0.895	0.880	1.159	0.019	0.028	1.134	0.063	0.02
rs2069422	A	21998026	0.891	0.874	1.174	0.0092	0.015	1.149	0.037	0.05
rs1333034	A	22034122	0.890	0.874	1.168	0.012	0.018	1.143	0.043	0.05
rs1011970	G	22052134	0.801	0.772	1.189	0.00034	0.00081	1.114	0.050	0.13
rs10116277	T	22071397	0.463	0.419	1.195	7.05×10^{-6}	2.63×10^{-5}	1.054	0.52	0.67
rs1333040	T	22073404	0.538	0.491	1.209	1.56×10^{-6}	6.98×10^{-6}	NA	NA	NA
rs2383207	G	22105959	0.502	0.456	1.204	2.64×10^{-6}	1.11×10^{-5}	1.102	0.15	0.57
rs1333050	T	22115913	0.694	0.672	1.107	0.017	0.025	1.005	0.92	0.27
b) D9S1814	-2	22078225	0.019	0.019	1.049	0.79	0.81	-	-	-
D9S1814	0	22078225	0.500	0.451	1.217	1.35×10^{-6}	6.17×10^{-6}	-	-	-
D9S1814	2	22078225	0.359	0.385	0.896	0.016	0.023	-	-	-
D9S1814	4	22078225	0.112	0.149	0.720	4.00×10^{-6}	1.60×10^{-5}	-	-	-
D9S1870	-6	22093010	0.019	0.020	0.961	0.79	0.81	-	-	-
D9S1870	-4	22093010	0.039	0.029	1.352	0.0090	0.015	-	-	-
D9S1870	-2	22093010	0.376	0.339	1.177	0.00011	0.00031	-	-	-
D9S1870	0	22093010	0.044	0.043	1.038	0.72	0.74	-	-	-
D9S1870	2	22093010	0.072	0.074	0.974	0.74	0.76	-	-	-
D9S1870	4	22093010	0.166	0.200	0.797	2.96×10^{-5}	9.31×10^{-5}	-	-	-
D9S1870	6	22093010	0.104	0.114	0.905	0.14	0.17	-	-	-
D9S1870	8	22093010	0.079	0.080	0.989	0.88	0.89	-	-	-
D9S1870	10	22093010	0.072	0.077	0.931	0.37	0.40	-	-	-
D9S1870	12	22093010	0.021	0.018	1.152	0.34	0.37	-	-	-
c) D9S1814	0	22078225	0.500	0.451	1.217	1.35×10^{-6}	6.17×10^{-6}	1.118	0.099	0.53
D9S1870	X	22093010	0.486	0.438	1.211	2.52×10^{-6}	1.07×10^{-5}	1.113	0.081	0.55

* *P*-value adjusted for relatedness of cases and controls.

** *P*-value adjusted for relatedness and conditioned on the association to rs1333040, and the corresponding relative risk.

*** Pair-wise correlation *r*² between the SNP and the at-risk variant rs1333040

Table 2: Pair-wise correlation among the 5 markers, 3 SNPs and 2 micro-satellites, that show strongest association to myocardial infarction in LD block C09, based on the HapMap v19 CEU dataset. In the upper right corner are shown values for the correlation coefficient r^2 , while in the lower left corner are values for D' .

	Marker	r^2				
		rs10116277	rs1333040	D9S1814	D9S1870	rs2383207
D'	rs10116277	-	0.667	0.806	0.839	0.905
	rs1333040	1.000	-	0.528	0.550	0.569
	D9S1814	0.964	0.829	-	0.651	0.743
	D9S1870	1.000	1.000	0.954	-	0.779
	rs2383207	1.000	0.879	0.893	1.000	-

Table 3: List of all SNPs (from HapMap v19 CEU dataset) in LD block C09 that are correlated, with correlation coefficient $r^2 \geq 0.2$, with at least one of the five markers (rs10116277, rs1333040, D9S1814, D9S1870 or rs2383207). For each SNP shown the table includes the position (in Build 34 and in SEQ ID NO:94) and the correlation coefficient r^2 to each of the five at-risk markers.

SNP	Position ^a	Position ^b	D9S1814	D9S1870	rs1333040	rs2383207	rs10116277
rs7041637	21951868	31720	0.18	0.12	0.20	0.21	0.15
rs3218020	21987872	67726	0.46	0.33	0.37	0.55	0.41
rs3217992	21993223	73077	0.43	0.28	0.34	0.53	0.38
rs1063192	21993367	73221	0.22	0.09	0.27	0.28	0.16
rs2069418	21999698	79552	0.19	0.06	0.25	0.25	0.14
rs2069416	22000004	79658	0.41	0.24	0.32	0.50	0.36
rs573687	22001642	81496	0.23	0.07	0.28	0.20	0.17
rs545226	22002422	82276	0.31	0.18	0.24	0.40	0.27
rs10811640	22003411	83265	0.21	0.09	0.29	0.29	0.19
rs10811641	22004137	83991	0.41	0.27	0.33	0.50	0.36
rs2106120	22007101	86955	0.23	0.10	0.31	0.32	0.21
rs2106119	22007550	87404	0.23	0.10	0.31	0.32	0.21
rs643319	22007836	87690	0.22	0.09	0.29	0.32	0.20
rs7044859	22008781	88635	0.23	0.10	0.31	0.32	0.21
rs523096	22009129	88983	0.17	0.05	0.22	0.23	0.12
rs10757264	22009732	89586	0.21	0.09	0.29	0.30	0.19
rs10965212	22013795	93648	0.29	0.14	0.38	0.40	0.27
rs1292137	22014023	93877	0.24	0.09	0.31	0.34	0.21
rs1292136	22014351	94205	0.30	0.16	0.37	0.41	0.28
rs10811644	22015087	94921	0.25	0.11	0.33	0.34	0.22
rs7035484	22015240	95094	0.24	0.10	0.32	0.33	0.22
rs10738604	22015493	95347	0.49	0.35	0.41	0.60	0.44
rs615552	22016077	95931	0.17	0.06	0.21	0.20	0.10
rs543830	22016639	96493	0.23	0.08	0.28	0.31	0.17
rs1591136	22016834	96688	0.29	0.14	0.38	0.40	0.27

SNP	Position ^a	Position ^b	D9S1814	D9S1870	rs1333040	rs2383207	rs10116277
rs7049105	22018801	98655	0.29	0.14	0.38	0.40	0.27
rs679038	22019080	98934	0.23	0.08	0.28	0.31	0.17
rs10965215	22019445	99299	0.27	0.13	0.35	0.38	0.25
rs564398	22019547	99401	0.21	0.07	0.26	0.29	0.15
rs7865618	22021005	100859	0.24	0.10	0.29	0.31	0.18
rs10115049	22022119	101973	0.29	0.14	0.36	0.40	0.27
rs634537	22022152	102006	0.24	0.08	0.29	0.33	0.20
rs2157719	22023366	103220	0.26	0.11	0.32	0.33	0.19
rs2151280	22024719	104573	0.27	0.15	0.36	0.38	0.25
rs1008878	22026112	105966	0.24	0.12	0.30	0.32	0.18
rs1556515	22026367	106221	0.26	0.13	0.32	0.35	0.20
rs1333037	22030765	110619	0.28	0.12	0.34	0.36	0.21
rs1360590	22031443	111297	0.31	0.15	0.40	0.43	0.29
rs1412828	22033926	113780	0.23	0.08	0.28	0.31	0.17
rs1360589	22035317	115171	0.30	0.12	0.36	0.40	0.23
rs7028570	22038683	118537	0.31	0.14	0.40	0.43	0.29
rs944801	22041670	121524	0.30	0.12	0.36	0.40	0.23
rs10965219	22043687	123541	0.30	0.13	0.40	0.48	0.27
rs7030641	22044040	123894	0.30	0.12	0.36	0.40	0.23
rs10120688	22046499	126353	0.38	0.18	0.47	0.51	0.35
rs2184061	22051562	131416	0.50	0.24	0.59	0.44	0.40
rs1537378	22051614	131468	0.50	0.24	0.59	0.44	0.40
rs8181050	22054391	134245	0.47	0.22	0.55	0.40	0.38
rs8181047	22054465	134319	0.33	0.49	0.38	0.28	0.21
rs10811647	22055002	134856	0.70	0.49	0.59	0.83	0.62
rs1333039	22055657	135511	0.47	0.22	0.55	0.40	0.38
rs10965224	22057276	137130	0.45	0.21	0.53	0.40	0.35
rs10811650	22057693	137447	0.70	0.49	0.59	0.83	0.63
rs10811651	22057830	137684	0.48	0.23	0.58	0.41	0.39
rs4977756	22058652	138506	0.47	0.22	0.55	0.40	0.38
rs10757269	22062264	142118	0.84	0.66	0.80	0.78	0.84
rs9632884	22062301	142155	0.93	0.65	0.80	0.78	0.84
rs1412832	22067543	147397	0.32	0.48	0.37	0.28	0.22
rs10116277	22071397	151251	-	0.67	0.81	0.84	0.90
rs10965227	22071796	151650	0.28	0.02	0.13	0.18	0.31
rs6475606	22071850	151704	1.00	0.67	0.81	0.84	0.90
rs1333040	22073404	153258	0.67	-	0.53	0.55	0.57
rs1537370	22074310	154164	1.00	0.67	0.81	0.84	0.90
rs7857345	22077473	157327	0.36	0.55	0.43	0.32	0.26
rs10738607	22078094	157948	1.00	0.89	0.81	0.84	0.90
rs10757272	22078260	158114	1.00	0.67	0.81	0.84	0.90
rs4977574	22088574	168428	1.00	0.67	0.81	0.84	0.90
rs2891168	22088619	168473	1.00	0.67	0.81	0.84	0.90
rs1537371	22089568	169422	1.00	0.67	0.81	0.84	0.90
rs1556516	22090176	170030	1.00	0.87	0.81	0.84	0.90
rs6475608	22091702	171556	0.36	0.54	0.42	0.31	0.25
rs7859727	22092165	172019	1.00	0.66	0.80	0.84	0.90
rs1537373	22093341	173195	1.00	0.67	0.81	0.84	0.90
rs1333042	22093813	173667	0.97	0.63	0.81	0.81	0.94
rs7859362	22095927	175781	0.90	0.57	0.74	0.78	1.00
rs1333043	22096731	176585	0.94	0.60	0.74	0.81	0.97
rs1412834	22100131	179985	0.90	0.57	0.74	0.78	1.00
rs7341786	22102241	182095	0.88	0.54	0.71	0.75	0.97
rs10511701	22102599	182453	0.88	0.54	0.71	0.75	0.97

SNP	Position ^a	Position ^b	D9S1814	D9S1870	rs1333040	rs2383207	rs10116277
rs10733376	22104469	184323	0.90	0.57	0.74	0.78	1.00
rs10738609	22104495	184349	0.90	0.57	0.74	0.78	1.00
rs2383206	22105026	184880	0.90	0.57	0.74	0.78	1.00
rs944797	22105286	185140	0.90	0.57	0.74	0.78	1.00
rs1004638	22105589	185443	0.90	0.57	0.74	0.78	1.00
rs2383207	22105959	185813	0.90	0.57	0.74	0.78	-
rs1537374	22106046	185900	0.90	0.57	0.74	0.78	1.00
rs1537375	22106071	185925	0.90	0.57	0.74	0.78	1.00
rs1333045	22108195	189049	0.69	0.37	0.52	0.60	0.65
rs10738610	22113766	193620	0.94	0.60	0.77	0.78	0.97
rs1333046	22114123	193977	0.94	0.60	0.77	0.78	0.97
rs10757278	22114477	194331	0.90	0.57	0.74	0.75	0.87
rs1333047	22114504	194358	0.90	0.59	0.72	0.74	0.88
rs4977575	22114744	194598	0.90	0.59	0.72	0.74	0.88
rs1333048	22115347	195201	0.97	0.63	0.77	0.81	0.94
rs1333049	22115503	195357	0.90	0.59	0.72	0.74	0.88
rs1333050	22115913	195767	0.17	0.27	0.06	0.15	0.20

^aPosition with respect to NCBI Build 34, Build 35 or Build 36

^bPosition with respect to SEQ ID NO:94 (LD Block C09)

Table 4: a) Association of the composite at-risk allele X of the micro-satellite D9S1870 to myocardial infarction (MI) in a replication cohort (Cohort B) of 668 Icelandic MI cases and 58,543 controls and in the combined Icelandic cohort (Cohort A+B). Included in the table is the number of cases n and controls m , the allele frequency in cases and controls, the corresponding P value adjusted for relatedness of the study individuals, the relative risk (RR) with 95% confidence interval (CI), and the population attributed risk (PAR). Known CAD or CVD cases have been excluded from the control cohort. b) Association of allele X to MI in three distinct US replication cohorts. All cases and controls in those three cohorts are of Caucasian origin. c) Combined association results, using a Mantel-Haenzel model, for the composite at-risk allele X in all replication cohorts combined, and in all cohorts combined, respectively.

Cohort (n/m)	Frequency		P*	RR	CI	PAR
	Cases	Controls				
a) Iceland						
Cohort B (668/58643)	0.501	0.441	1.39×10 ⁻⁵	1.274	[1.142,1.420]	0.203
Cohort A+B (2238/65731)	0.491	0.441	8.91×10 ⁻¹⁰	1.221	[1.145,1.301]	0.169
b) US replication cohorts						
Cleveland (549/606)	0.501	0.478	0.27	1.097	[0.932,1.292]	0.087
UPenn (580/404)	0.539	0.483	0.014	1.252	[1.048,1.499]	0.205
Emory (400/477)	0.548	0.482	0.0064	1.299	[1.076,1.569]	0.236
c) Combined**						
Replication cohorts (2197/60130)			2.65×10 ⁻⁸	1.231	[1.144,1.324]	0.183
All cohorts (3767/67218)			1.44×10 ⁻¹²	1.214	[1.161,1.281]	0.171

* P-values for the Icelandic cohorts are adjusted for relatedness using simulations (see methods)

** Mantel-Haenzel model was used to combine the results from the different cohorts.

Table 5: a) Association of the composite at-risk allele X of D9S1870 in Icelandic cases with various cardiovascular disease phenotypes. Included in the table are association results for individuals who have undergone PTCA or CABG, for the combined MI and CAD (PTCA and CABG) cohort, individuals with PAD or that have had infarct or TIA, and stroke patients diagnosed with LVD. In all tests the same set of 65,731 Icelandic controls without known CAD complications is used. b) Association of allele X in Iceland to the same coronary artery disease phenotypes as in a) after excluding all known cases of MI from the list of cases. c) Association of allele X to PTCA, CABG and a combined phenotype MI and other CAD, in the Emory cohort.

Phenotype (n)	Frequency		RR	CI	P	P*	PAR
	Cases	Controls					
a) Iceland							
PTCA (1791)	0.489	0.441	1.211	[1.129,1.298]	2.69E-08	8.60E-08	0.163
CABG (642)	0.514	0.441	1.338	[1.189,1.506]	3.38E-07	1.31E-06	0.243
MI + other CAD (3513)	0.488	0.441	1.209	[1.148,1.273]	2.57E-14	6.24E-13	0.162
PAD(1661)	0.477	0.441	1.154	[1.074,1.239]	5.36E-05	8.58E-05	0.123
Stroke, infarct + TIA (1878)	0.448	0.441	1.027	[0.958,1.102]	0.45	0.45	0.023
Stroke, LVD (197)	0.469	0.441	1.120	[0.915,1.370]	0.27	0.27	0.098
b) Iceland, excl. MI cases							
PTCA (941)	0.483	0.441	1.183	[1.077,1.300]	0.00033	0.00045	0.144
CABG (221)	0.501	0.441	1.270	[1.044,1.545]	0.013	0.017	0.202
PAD(1322)	0.464	0.441	1.096	[1.012,1.186]	0.021	0.025	0.079
Stroke, Infarct + TIA (1390)	0.450	0.441	1.037	[0.960,1.119]	0.35	0.38	0.032
Stroke, LVD (153)	0.480	0.441	1.172	[0.934,1.470]	0.17	0.17	0.138
c) Emory							
PTCA (141)	0.567	0.482	1.408	[1.079,1.839]	0.012	NA	0.302
CABG (112)	0.549	0.482	1.308	[0.977,1.751]	0.071	NA	0.242
MI + other CAD (476)	0.551	0.482	1.320	[1.103,1.581]	0.0025	NA	0.250

* P-value adjusted for relatedness using simulations.

Table 6: Association of the composite at-risk allele X of D9S1870 to early-onset MI or CAD a) in Iceland, b) in the three US replication cohorts, c) in all early-onset MI cohorts combined. Early-onset MI is defined as a MI event before the age 50 for males and before the age of 60 for females.

5

Phenotype (n)	Frequency		RR	CI	P	P*	PAR
	Cases	Controls					
a) Iceland							
Early onset MI (646/65731)	0.514	0.441	1.339	[1.193,1.503]	3.63E-07	7.51E-07	0.243
Early onset CAD (320/65731)	0.532	0.441	1.439	[1.227,1.687]	6.12E-06	7.40E-06	0.298
Early onset MI+CAD (877/65731)	0.511	0.441	1.325	[1.200,1.464]	9.87E-09	2.70E-08	0.235
b) US cohorts							
Emory EO MI (222/477)	0.559	0.482	1.359	[1.084,1.703]	0.0078	NA	0.273
Cleveland EO MI (183/606)	0.514	0.478	1.155	[0.914,1.459]	0.2281	NA	0.133
Upenn EO MI (275/490)	0.569	0.473	1.469	[1.191,1.811]	0.00033	NA	0.330
c) All cohorts combined							
Early onset MI (1326/67304)	-	-	1.331	[1.223,1.449]	3.96E-11	NA	0.247

* P-value adjusted for relatedness using simulations.

Table 7: Model-free estimates of the genotype relative risks (GRR) of the composite allele X of D9S1870. Included is the risk for heterozygous carriers (OX) and homozygous carriers (XX) compared with risk for non-carriers (OO) and the corresponding 95% confidence intervals (CI). Results are shown for a) all MI cases versus controls and b) for early-onset MI cases versus controls for the whole Icelandic cohort, the three US replication cohorts and for all the cohorts combined using a Mantel-Haenzel model.

Phenotype (n/m)	Genotype relative risk (GRR)			
	OX	CI	XX	CI
a) All MI cases				
Iceland (2238/65731)	1.173	[1.060,1.298]	1.507	[1.338,1.697]
Cleveland(549/606)	1.077	[0.804,1.443]	1.204	[0.860,1.686]
UPenn (679/490)	1.443	[1.074,1.938]	1.728	[1.228,2.431]
Emory (400/477)	1.213	[0.836,1.760]	1.669	[1.144,2.435]
Combined (3866/67304)	1.204	[1.094,1.324]	1.507	[1.360,1.670]
b) Early onset MI cases				
Iceland (641/65731)	1.191	[0.982,1.444]	1.803	[1.453,2.237]
Cleveland (183/606)	1.432	[0.932,2.201]	1.867	[1.176,2.964]
UPenn (275/490)	1.692	[1.134,2.524]	2.237	[1.440,3.476]
Emory (222/477)	1.089	[0.567,2.017]	1.328	[0.827,2.133]
Combined (1321/67304)	1.314	[1.105,1.562]	1.790	[1.517,2.113]

Table 8: a) Association of the risk alleles of the markers rs10116277, rs1333040 and rs2383207 to age of onset of MI in the Icelandic Cohort A. The analysis is done using multiple regression where age of onset of MI is taken as the response variable and the number of copies of X is used as explanatory variable. The analysis is adjusted for gender by include sex of the individuals as an explanatory variable. Included in the table is the effect size, the standard error of the mean (SE) and the corresponding P-value. b) Association of the composite at-risk allele X of D9S1870 to age-of-onset of MI in the combined Icelandic MI patient cohort, and for the three US replication cohorts. Results for the four cohorts are combined weighting the contribution from each cohort proportional to the inverse of the standard error. In all tests only cases with known age-of-onset are included.

Cohort/Marker (n)	Effect	SE	P
a) SNPs in Iceland A			
rs10116277 (1293)	-0.94	0.32	0.0039
rs1333040 (1293)	-1.01	0.32	0.0018
rs2383207 (1293)	-0.79	0.32	0.015
b) D9S1870 allele X			
Iceland (2127)	-0.93	0.29	0.0016
Cleveland (424)	-0.47	0.79	0.55
UPenn (646)	-1.19	0.69	0.083
Emory (403)	-1.38	0.67	0.11
Combined (3600)	-0.95	0.25	0.000099

Table 9: a) Association of the composite risk allele X of D9S1870 to either mild (<50%) or severe (≥50%) in-stent restenosis in coronary artery disease patients that have undergone PTCA compared to controls without known history of CAD. b) Comparison of the frequency of the risk variant X in patients with severe in-stent restenosis to patients with mild in-stent restenosis.

Phenotype (n,m)	Frequency		RR	CI	P
	Cases	Controls			
a) Restenosis patients vs controls					
Mild restenosis, < 50% (323/65731)	0.492	0.441	1.228	[1.050,1.436]	0.010
Severe restenosis (≥50% (193/65731)	0.509	0.441	1.313	[1.071,1.608]	0.0086
b) Severe vs mild restenosis (193/323)					
	0.509	0.492	1.067	[0.827,1.376]	0.62

Table 10.

A. SNP markers within LD Block C09 (Between 21,920,147 and 22,149,982 on C09; NCBI Build 34, Build 35 and Build 36 (SEQ ID NO:94)).

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs7864029	C/G	21920147	+	1
rs2518714	A/C	21920303	+	157
rs10965187	A/G	21920505	+	359
rs2811715	G/T	21920571	+	425
rs2518715	C/T	21920700	+	554
rs12002708	A/C	21920762	+	616
rs10811639	A/G	21920803	+	657
rs11998828	C/T	21920812	+	666
rs7866374	A/G	21921609	+	1453
rs4977570	G/T	21921642	+	1496
rs7390564	G/T	21921642	+	1496
rs7869004	G/T	21921896	+	1750
rs974679	A/G	21922245	+	2099
rs2891010	A/G	21922261	+	2115
rs12003714	A/G	21922386	+	2220
rs28756321	C/G	21923029	+	2883
rs12000395	A/G	21923096	+	2950
rs2188126	C/G	21923125	+	2979
rs12003027	C/T	21924442	+	4296
rs7023582	A/C	21924684	+	4538
rs28613732	A/G	21925807	+	5661
rs10965188	C/G	21925874	+	5728
rs12552975	C/T	21926059	+	5913
rs7875199	C/T	21926381	+	6235
rs12238992	A/C	21927299	+	7153
rs7021848	C/T	21927351	+	7205
rs7036999	A/G	21927875	+	7729
rs12345808	A/G	21928367	+	8221
rs35148759	C/T	21929306	+	9160
rs7872310	A/G	21929387	+	9241
rs2811716	C/T	21930017	+	9871
rs10965189	A/C	21930588	+	10442
rs4308829	C/T	21931196	+	11050
rs10965180	A/G	21931385	+	11239
rs10965191	A/G	21932535	+	12389
rs12345373	A/G	21933189	+	13053
rs4877750	A/C	21934317	+	14171
rs10965193	A/G	21934544	+	14398
rs4246843	C/T	21934627	+	14481
rs4382559	A/G	21934818	+	14672
rs4360371	A/C	21935562	+	15416
rs16938595	A/T	21935605	+	15459
rs10965194	A/G	21936214	+	16068
rs2811717	C/T	21936322	+	16176
rs6475598	C/T	21936322	+	16176
rs2811718	A/T	21936891	+	16745
rs10965196	C/G	21937472	+	17328
rs2811719	C/G	21937472	+	17326
rs2811720	C/G	21937957	+	17811
rs6475599	C/G	21937957	+	17811
rs11521166	C/T	21938376	+	18230
rs2518718	A/T	21938489	+	18343
rs10965197	C/T	21938666	+	18520
rs2108117	G/T	21939527	+	19361
rs2108118	A/T	21939528	+	19382
rs2427852	A/T	21940432	+	20286
rs2157718	C/T	21940446	+	20300

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs2263145	C/T	21940452	+	20306
rs2427853	C/T	21940472	+	20326
rs2362894	C/G	21940523	+	20377
rs2427854	A/T	21940721	+	20575
rs7047211	A/T	21940722	+	20576
rs11532909	A/T	21940723	+	20577
rs13297154	A/T	21940725	+	20579
rs13298455	A/T	21940741	+	20595
rs2891092	A/G	21940782	+	20636
rs6415737	A/G	21940782	+	20636
rs4503179	A/G	21940879	+	20733
rs12349081	A/C	21941902	+	21756
rs2518722	C/T	21942826	+	22780
rs10757260	A/G	21943137	+	22991
rs28369665	C/T	21944487	+	24341
rs10965199	C/T	21944653	+	24507
rs10757261	A/G	21944953	+	24607
rs12335859	A/G	21945460	+	25314
rs12335941	A/G	21945669	+	25523
rs2027938	A/G	21946078	+	25832
rs9667608	C/T	21946230	+	26084
rs2518716	A/G	21946470	+	26324
rs2027939	A/G	21946492	+	26346
rs7869996	C/T	21946914	+	26768
rs10965200	C/G	21948142	+	27096
rs717326	A/G	21948524	-	28376
rs35116241	A/C	21949093	+	28947
rs2518717	C/T	21949751	+	29605
rs3948753	A/G	21949860	+	29714
rs2106115	C/T	21949900	+	29754
rs10965201	C/G	21949950	+	29804
rs2106116	C/T	21949966	+	29820
rs10965202	A/G	21951180	+	31034
rs1985742	A/T	21951227	+	31081
rs7041637	A/C	21951868	+	31720
rs2263146	C/T	21953048	+	32902
rs35732310	A/C	21953841	+	33695
rs4518744	A/C	21954015	+	33869
rs2188127	C/G	21955232	+	35086
rs3731257	C/T	21956221	-	36075
rs3731256	C/T	21956617	-	36471
rs11793581	G/T	21957446	+	37300
rs28695347	A/C	21957706	+	37560
rs3731255	C/G	21957855	-	37709
rs3731253	C/G	21957952	-	37808
rs3088440	A/G	21958159	+	38013
rs11515	C/G	21958189	-	38053
rs34011899	A/C	21958712	+	38586
rs2255962	A/G	21959827	+	39681
rs2518719	A/G	21960427	+	40281
rs3731249	A/G	21960916	-	40770
rs6413464	G/T	21960979	-	40833
rs34170727	C/T	21960988	-	40842
rs6413463	A/T	21960989	-	40843
rs35741010	A/G	21961054	-	40908
rs34886500	C/T	21961063	-	40917
rs4987127	A/G	21961085	-	40939
rs11552822	G/T	21961108	-	40962
rs34968276	A/C	21961109	-	40963
rs11552823	C/T	21961116	-	40970
rs3731247	C/T	21961352	-	41206

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs12377672	C/T	21961416	+	41272
rs3731246	C/G	21961969	-	41843
rs3731245	A/G	21962445	-	42289
rs3731244	A/G	21962613	-	42667
rs3731243	A/G	21963050	-	42904
rs2811708	G/T	21963422	+	43276
rs3731241	A/G	21963767	-	43621
rs13289666	C/T	21963857	+	43711
rs3731240	A/G	21964131	-	43985
rs3731239	C/T	21964218	-	44072
rs3814960	A/C/G/T	21965017	+	44871
rs3731238	A/G	21965561	-	45415
rs3731237	A/G	21965728	-	45582
rs3731236	C/T	21966978	-	46830
rs3731235	G/T	21967450	-	47304
rs12350633	C/G	21967553	+	47407
rs3731234	A/C	21967579	-	47433
rs3731233	A/T	21968358	-	48212
rs3731232	C/G	21968443	-	48297
rs2518720	C/T	21968979	+	48633
rs3731230	C/T	21969163	-	48017
rs2518721	A/G	21969204	+	49058
rs3731229	A/C	21969497	-	49351
rs3731228	A/G	21969602	-	49456
rs2811709	A/G	21970151	+	50005
rs3731227	C/T	21970744	-	50598
rs3731226	C/T	21970792	-	50646
rs13297747	C/G	21970941	+	50795
rs36170221	C/G	21970941	+	50795
rs36153543	C/T	21970944	+	50798
rs7674405	C/T	21970944	+	50798
rs13302595	C/T	21971034	+	50888
rs13301751	A/G	21971039	+	50893
rs13302611	C/T	21971068	+	50922
rs13302761	C/T	21971100	+	50954
rs13302792	C/T	21971168	+	51022
rs3731225	A/G	21971351	-	51205
rs3731224	C/T	21971411	-	51265
rs4074785	A/G	21971583	+	51437
rs3731223	A/G	21973834	-	53688
rs3731222	A/G	21973914	-	53768
rs3731221	A/G	21974010	-	53864
rs3731220	A/G	21974019	-	53873
rs3731219	A/G	21974086	-	53940
rs3731218	C/T	21974331	-	54185
rs3731217	G/T	21974661	-	54515
rs3731216	G/T	21975576	-	55430
rs3731215	C/T	21975771	-	55625
rs3731214	A/G	21975968	-	55822
rs3731213	A/G	21976218	-	56072
rs3731212	C/T	21976271	-	56125
rs3731211	A/T	21976847	-	56701
rs3731210	A/G	21976859	-	56713
rs3731208	C/T	21977155	-	57009
rs3731207	C/T	21977353	-	57207
rs12376353	C/G	21977433	+	57267
rs3731206	A/G	21977472	-	57326
rs3731205	A/G	21977522	-	57376
rs3731204	A/G	21977584	-	57438
rs10757262	A/T	21977874	+	57728
rs3731202	A/G	21978800	-	58654

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs3731201	A/G	21978896	-	58750
rs3731199	A/G	21979330	-	59184
rs3731198	A/G	21979477	-	59331
rs7036656	C/T	21980457	+	60311
rs7867492	C/T	21981016	+	60870
rs3731197	A/G	21981371	-	61225
rs3731196	A/G	21981652	-	61506
rs3731195	C/T	21981695	-	61549
rs3731194	C/G	21981752	-	61606
rs2811710	C/T	21981823	+	61777
rs3731192	G/T	21982274	-	62128
rs3731191	C/T	21983048	-	62802
rs2811711	C/T	21983964	+	63818
rs3731190	C/T	21984282	-	64136
rs2518723	A/G	21985882	-	65736
rs7860185	C/T	21986986	+	66840
rs3218024	A/G	21987437	-	67281
rs3218023	C/T	21987597	-	67451
rs3218022	A/G	21987723	-	67577
rs3218021	G/T	21987752	-	67608
rs3218020	C/T	21987872	-	67726
rs3218019	A/G	21987904	-	67758
rs2811712	A/G	21988035	+	67889
rs3218018	A/C	21988139	-	67993
rs3218016	A/G	21988273	-	68127
rs3218015	C/G	21988392	-	68246
rs3218013	C/T	21988556	-	68410
rs3218012	C/T	21988680	-	68514
rs3218011	A/G	21988676	-	68530
rs3218010	A/G	21988733	-	68587
rs3218009	C/G	21988757	-	68611
rs10965208	A/G	21988965	+	68819
rs2811713	A/G	21989328	+	69182
rs2811714	C/T	21989334	+	69188
rs3218007	A/G	21989800	-	69654
rs3218006	G/T	21989980	-	69834
rs3218005	A/G	21990247	-	70101
rs3218004	C/G	21990687	-	70541
rs3218003	C/G	21990770	-	70624
rs3218002	C/T	21990841	-	70695
rs3218001	C/G	21990959	-	70813
rs3218000	C/T	21991078	-	70932
rs3217999	C/T	21991572	-	71426
rs3217998	A/C	21991667	-	71521
rs3217997	A/G	21992316	-	72170
rs3217996	C/T	21992322	-	72176
rs3217994	A/G	21992864	-	72718
rs3217993	C/T	21993169	-	73023
rs3217992	A/G	21993223	-	73077
rs1063192	C/T	21993367	-	73221
rs3217990	A/C	21993521	-	73375
rs3217989	A/G	21993790	-	73644
rs3217988	A/G	21994082	-	73936
rs2285329	C/T	21994153	-	74007
rs10965209	A/G	21994669	+	74523
rs3217987	C/T	21995081	-	74815
rs11792943	A/G	21995123	+	74977
rs11792944	G/T	21995127	+	74981
rs3217986	A/C	21995330	-	75184
rs3217985	C/T	21995453	-	75307
rs3217984	C/G	21995493	-	75347

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs3217983	C/T	21995623	-	75477
rs3217982	C/T	21995647	-	75501
rs3217981	A/G	21996269	-	76123
rs2069426	A/C	21996273	-	76127
rs974336	A/G	21996348	-	76202
rs3217980	C/T	21996607	-	76461
rs2069425	C/T	21996793	-	76847
rs2285328	C/T	21996966	-	78820
rs2285327	A/G	21997048	-	76902
rs3217979	A/G	21997187	-	77041
rs3217978	G/T	21997330	-	77184
rs2069423	C/T	21997771	-	77625
rs2069422	A/C	21998028	-	77880
rs2069421	A/G	21998313	-	78167
rs3217976	A/C	21998439	-	78293
rs2069420	A/T	21998504	-	78358
rs2069419	A/C/T	21999337	-	79191
rs2069418	C/G	21999698	-	79552
rs3217974	A/C	21999908	-	79762
rs3217973	C/T	21999980	-	79814
rs2069416	A/C/T	22000004	-	79858
rs495490	C/T	22000412	-	80266
rs3808845	A/G	22000575	+	80429
rs3808846	A/G	22000846	+	80800
rs575427	C/T	22001477	-	81331
rs573687	C/T	22001642	-	81496
rs13298881	C/T	22002051	+	81905
rs16935753	A/G	22002229	+	82083
rs16935754	C/T	22002236	+	82090
rs545226	C/T	22002422	-	82276
rs7032979	C/T	22002457	+	82311
rs10811640	G/T	22003411	+	83265
rs10757263	C/T	22003805	+	83659
rs10811641	C/G	22004137	+	83991
rs7042051	C/T	22004758	+	84612
rs7027610	C/T	22004872	+	84726
rs7045307	C/T	22005057	+	84811
rs1101330	G/T	22005465	-	85319
rs13295358	A/C	22005465	+	85319
rs1101329	A/G	22005897	-	85851
rs1633381	A/G	22005997	-	85851
rs10217269	C/T	22006173	+	86027
rs10217281	A/G	22006617	+	86471
rs10965211	C/T	22006891	+	86745
rs28451206	C/G	22006921	+	86775
rs2157718	G/T	22007025	-	86879
rs2106120	A/C	22007101	-	86955
rs16905582	A/T	22007425	+	87279
rs2106119	C/T	22007550	+	87404
rs643319	G/T	22007836	-	87690
rs575237	C/T	22008108	-	87862
rs642323	C/T	22008121	-	87875
rs7044859	A/T	22008781	+	88635
rs523096	C/T	22009129	-	88983
rs518394	C/G	22009673	-	89527
rs10757264	A/G	22009732	+	89586
rs490005	C/T	22010493	-	90347
rs7856281	C/T	22010757	+	90611
rs34623146	A/G	22010822	+	90676
rs597816	A/G	22011172	-	91026
rs7048912	A/G	22011425	+	91279

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs668447	C/T	22011615	-	91469
rs567453	C/G	22011737	-	91591
rs7018665	A/G	22011819	+	91673
rs11515247	C/T	22012269	+	92123
rs581876	A/G	22012376	-	92230
rs7039304	A/T	22012786	+	92640
rs11789770	C/G	22012982	+	92836
rs10985212	A/T	22013795	+	93649
rs1292137	A/T	22014023	-	93877
rs504318	A/T	22014023	-	93877
rs1282136	A/G	22014351	-	94205
rs496892	A/G	22014351	-	94205
rs647186	A/C	22014965	-	94819
rs10811643	A/G	22014966	+	94820
rs10811644	A/T	22015087	+	94921
rs7035484	C/G	22015240	+	95094
rs10738604	A/G	22015493	+	95347
rs11791383	C/G	22015814	+	95688
rs815552	A/G	22016077	-	95931
rs1591137	C/T	22016483	-	96337
rs813312	C/T	22016594	-	96448
rs543830	A/T	22016639	-	96483
rs1591136	C/G	22016834	-	96688
rs10985214	A/T	22017274	+	97128
rs599452	C/T	22017402	-	97256
rs598664	A/G	22017551	-	97406
rs7049105	A/G	22018801	+	98655
rs678038	C/T	22019080	-	98934
rs10985215	A/G	22019445	+	99299
rs564398	A/G	22019547	-	99401
rs4977753	C/T	22020027	+	99881
rs862463	C/T	22020438	-	100292
rs7865818	A/G	22021005	+	100859
rs649436	C/T	22021085	-	100939
rs10115049	A/G	22022119	+	101973
rs634537	A/C	22022152	-	102006
rs2157719	A/G	22023366	-	103220
rs1759417	A/G	22023389	-	103243
rs1633383	A/G	22023532	-	103386
rs2151280	C/T	22024719	-	104573
rs1008878	G/T	22026112	+	105966
rs7029531	C/G	22026170	+	106024
rs1556515	A/G	22026367	-	106221
rs35975148	A/T	22027071	+	106925
rs17694478	C/G	22027171	+	107025
rs12376000	C/T	22029426	+	109280
rs1333037	A/G	22030765	-	110619
rs7028469	G/T	22031342	+	111198
rs1360590	A/G	22031443	-	111297
rs17684493	C/G	22031898	+	111852
rs12352425	A/G	22032086	+	111940
rs12888542	A/C	22032227	+	112081
rs10965216	C/T	22032879	+	112733
rs1412830	A/G	22033612	-	113466
rs1333036	A/G	22033619	-	113673
rs1412829	C/T	22033926	-	113780
rs1333035	C/T	22034059	-	113913
rs1333034	A/G	22034122	-	113976
rs10985217	A/T	22034317	+	114171
rs13290048	C/T	22034804	+	114658
rs28419335	A/G	22035035	+	114889

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs28621545	G/T	22035037	+	114891
rs1360589	A/G	22035317	-	115171
rs12338105	C/G	22035344	+	115198
rs1333033	A/G	22035653	-	115507
rs17834131	A/G	22036168	+	116022
rs12340618	A/G	22037050	+	116904
rs7851706	C/T	22037437	+	117291
rs12683931	A/G	22037916	+	117770
rs10120806	C/T	22037945	+	117799
rs7027950	C/T	22038391	+	118245
rs7028268	A/G	22038414	+	118268
rs7028570	A/G	22038683	+	118537
rs10757285	C/T	22038859	+	118713
rs10738605	C/G	22039130	+	118984
rs10757266	C/T	22039555	+	119409
rs10811645	A/G	22039656	+	119510
rs2151279	C/T	22039845	-	119699
rs6475603	A/G	22040612	+	120480
rs944799	A/G	22040613	+	120467
rs944800	A/G	22040898	+	120752
rs17694555	A/G	22041295	+	121149
rs944801	C/G	22041670	+	121524
rs6475804	C/T	22042734	+	122588
rs10757287	C/G	22042810	+	122664
rs4433231	G/T	22043244	+	123098
rs11780231	A/G	22043591	+	123445
rs7854869	A/C	22043651	+	123505
rs10965219	A/G	22043687	+	123541
rs7027048	A/G	22043709	+	123563
rs17756311	A/G	22043895	+	123749
rs7030841	C/T	22044040	+	123894
rs17694572	A/G	22044356	+	124210
rs7874804	C/T	22044680	+	124544
rs2383204	A/G	22045048	+	124902
rs7036489	A/G	22045892	+	125846
rs7039467	A/G	22046213	+	126067
rs7866660	A/T	22046233	+	126087
rs10965220	A/G	22046270	+	126133
rs7853090	C/T	22046295	+	126149
rs7866783	A/G	22046359	+	126213
rs10120688	A/G	22046499	+	126353
rs13292618	A/G	22047339	+	127193
rs10121501	C/G	22047390	+	127244
rs13299593	C/T	22048018	+	128772
rs7021816	A/C	22049277	+	129131
rs10757268	C/T	22049905	+	129759
rs2095144	C/T	22050136	-	129990
rs2383205	A/G	22050935	+	130769
rs2184061	G/T	22051562	-	131416
rs1537378	C/T	22051614	-	131468
rs4977754	A/C	22052012	+	131866
rs1011970	G/T	22052134	+	131988
rs10965221	G/T	22052989	+	132853
rs8181050	A/G	22054391	+	134245
rs8181047	A/G	22054465	+	134319
rs10811647	C/G	22055002	+	134856
rs1333038	A/G	22055572	+	135426
rs4144864	C/T	22055856	+	135510
rs1333039	C/G	22055857	+	135511
rs4977755	A/T	22056363	+	136217
rs28557075	A/G	22056572	+	136426

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs10965223	A/G	22057004	+	136858
rs10965224	A/T	22057276	+	137130
rs10811648	C/T	22057542	+	137396
rs10811649	C/T	22057554	+	137408
rs10811850	A/G	22057593	+	137447
rs10811651	A/G	22057830	+	137684
rs16905597	A/G	22058074	+	137928
rs1412831	A/G	22058646	+	138500
rs4977756	A/G	22058652	+	138506
rs16905599	A/G	22059144	+	138898
rs34871414	A/C	22059537	+	139391
rs7042970	A/G	22059580	+	139434
rs4451405	C/T	22061750	+	141604
rs4645630	A/G	22061751	+	141605
rs12555547	C/G	22062040	+	141894
rs10757269	A/G	22062264	+	142118
rs9632884	C/G	22062301	+	142165
rs9632885	A/G	22062638	+	142492
rs10757270	A/G	22062719	+	142573
rs17781197	C/T	22062730	+	142584
rs10965226	G/T	22063170	+	143024
rs16923583	A/T	22063334	+	143188
rs1855185	G/T	22063996	+	143850
rs7855162	C/T	22064793	+	144647
rs1831733	C/T	22066071	+	145925
rs1831734	C/T	22066208	+	148082
rs10757271	A/G	22066795	+	146649
rs10811652	A/C	22067085	+	146939
rs1412832	C/T	22067543	+	147397
rs7855680	C/T	22068306	+	148159
rs6475606	C/G	22069020	+	148874
rs16905613	A/G	22070363	+	150217
rs7858034	A/T	22070791	+	150845
rs12347950	A/G	22071128	+	150982
rs1412833	A/G	22071346	+	151200
rs10116277	G/T	22071397	+	151251
rs10965227	A/G	22071786	+	151650
rs6475608	C/T	22071850	+	151704
rs1547704	A/G	22072340	+	152194
rs1547705	A/C	22072375	+	152229
rs10965228	A/G	22072380	+	152234
rs7853953	A/C	22073017	+	152671
rs1333040	C/T	22073404	+	153258
rs1537370	C/T	22074310	+	154164
rs10122102	G/T	22074633	+	154487
rs1970112	C/T	22075598	+	155452
rs10120722	A/C	22076840	+	156694
rs16905635	C/T	22076883	+	156737
rs7857345	C/T	22077473	+	157327
rs10738606	A/T	22078090	+	157944
rs10738607	A/G	22078094	+	157948
rs10757272	C/T	22078260	+	158114
rs16905640	A/G	22078558	+	158410
rs13300638	G/T	22078937	+	158791
rs13284693	A/T	22079014	+	158868
rs12235973	A/T	22079193	+	159047
rs10757273	A/C	22080301	+	160155
rs10965230	C/T	22080418	+	160270
rs9644859	A/G	22080521	+	160375
rs7018916	C/T	22080683	+	160537
rs7020031	C/T	22080753	+	160807

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs7034707	C/T	22080811	+	160665
rs34587771	C/T	22081731	+	161585
rs34555767	G/T	22081924	+	161778
rs7866503	G/T	22081924	+	161778
rs7869527	A/G	22082097	+	161951
rs2210538	A/G	22082257	+	162111
rs7870178	A/G	22082551	+	162405
rs34184423	A/G	22082924	+	162778
rs34168773	A/T	22083299	+	163153
rs9722878	G/T	22083462	+	163316
rs7848875	A/G	22084281	+	164135
rs35537809	A/G	22084330	+	164184
rs4977757	A/G	22084330	+	164184
rs7388840	A/G	22084330	+	164184
rs10738608	A/C	22084796	+	164650
rs35869261	A/T	22085567	+	165421
rs35062160	G/T	22085730	+	165584
rs2891167	C/T	22085851	+	165705
rs10757274	A/G	22086055	+	165909
rs16905644	C/T	22087022	+	166876
rs8475807	A/G	22087693	+	167547
rs7037832	A/G	22088038	+	167892
rs1333041	C/G	22088374	+	168228
rs4977574	A/G	22088574	+	168428
rs2881168	A/G	22088819	+	168473
rs10965231	A/G	22088874	+	168528
rs11787814	A/G	22088683	+	168537
rs1537371	A/C	22089588	+	169422
rs7858476	A/T	22089940	+	169794
rs1558516	C/G	22090176	+	170030
rs12238050	A/C	22090726	+	170580
rs10965232	C/T	22091120	+	170974
rs13292938	G/T	22091258	+	171113
rs7028026	A/G	22091435	+	171289
rs6475608	C/T	22091702	+	171556
rs10125231	A/G	22092126	+	171982
rs7859727	C/T	22092165	+	172019
rs1537372	G/T	22093183	+	173037
rs10965233	A/G	22093314	+	173168
rs1537373	G/T	22093341	+	173195
rs7022719	C/T	22093748	+	173602
rs1333042	A/G	22093813	+	173667
rs4336695	C/G	22094450	+	174304
rs7872591	A/C	22095595	+	175449
rs7859362	C/T	22095927	+	175781
rs10757275	A/G	22096225	+	176079
rs6475609	A/G	22096271	+	176125
rs1333043	A/T	22096731	+	176585
rs7855190	C/T	22098069	+	177923
rs10217720	A/G	22098942	+	178796
rs10217426	C/G	22099387	+	179241
rs1412834	C/T	22100131	+	179985
rs17761319	G/T	22100478	+	180332
rs16905648	A/G	22101973	+	181827
rs7341786	A/C	22102241	+	182095
rs7341791	A/G	22102427	+	182281
rs10511701	C/T	22102599	+	182453
rs17834367	C/T	22102606	+	182460
rs7032115	A/G	22102943	+	182797
rs13301984	C/G	22103324	+	183178
rs16905652	A/T	22103924	+	183778

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs10733376	C/G	22104469	+	184323
rs10738609	A/G	22104495	+	184349
rs2383206	A/G	22105026	+	184880
rs10965234	G/T	22105078	+	184932
rs10965235	A/C	22105105	+	184959
rs4990722	G/T	22105217	+	185071
rs944796	C/G	22105285	+	185139
rs944797	C/T	22105286	+	185140
rs1004638	A/T	22105589	-	185443
rs10965236	C/G	22105633	+	185487
rs2383207	A/G	22105959	+	185813
rs1537374	A/G	22106046	+	185900
rs1537375	C/T	22106071	+	185925
rs1537376	C/T	22106220	+	186074
rs7851006	A/G	22107669	+	187523
rs17834457	C/T	22108026	+	187880
rs17761448	G/T	22108102	+	187956
rs7854631	A/C	22108378	+	188232
rs4977758	A/T	22108481	+	188335
rs4977759	C/T	22108885	+	188739
rs1333044	A/G	22109128	+	188982
rs1333045	C/T	22109195	+	189049
rs12885422	A/C	22111167	+	191021
rs10217586	A/T	22111349	+	191203
rs7860589	C/T	22111353	+	191207
rs7020671	A/T	22112193	+	192047
rs10965237	A/C	22112530	+	192384
rs13285121	A/T	22112912	+	192766
rs7869069	G/T	22113590	+	193444
rs10738610	A/C	22113786	+	193620
rs7864016	A/C	22113967	+	193821
rs1333046	A/T	22114123	+	193977
rs7857118	A/T	22114140	+	193994
rs17761458	A/G	22114368	+	194222
rs10757277	A/G	22114450	+	194304
rs10811656	C/T	22114472	+	194326
rs10757278	A/G	22114477	+	194331
rs1333047	A/T	22114504	+	194358
rs10757279	A/G	22114630	+	194484
rs4977575	C/G	22114744	+	194598
rs1333048	A/C	22115347	+	195201
rs1333049	C/G	22115503	+	195357
rs1333050	C/T	22115913	+	195767
rs12345189	A/G	22116454	+	196306
rs12336106	A/G	22116885	+	196739
rs10757281	C/T	22117613	+	197467
rs10811657	A/G	22117641	+	197495
rs17834529	C/G	22117777	+	197631
rs1889086	C/T	22117879	-	197733
rs10965238	A/G	22117883	+	197737
rs10965239	A/G	22117965	+	197819
rs12379111	C/G	22118180	+	198034
rs10811658	A/G	22118800	+	198454
rs12347779	C/G	22118709	+	198563
rs10965240	C/T	22119164	+	199018
rs7020996	C/T	22119579	+	199433
rs10965241	C/G	22119594	+	199448
rs10965243	A/G	22120065	+	199919
rs10965244	A/T	22120389	+	200243
rs10965245	A/G	22120515	+	200369
rs2891169	A/G	22121825	+	201679

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs4977576	A/C	22121861	+	201715
rs2383208	A/G	22122076	+	201930
rs10965246	C/T	22122698	+	202552
rs10965247	A/G	22122729	+	202583
rs10965248	C/T	22122878	+	202732
rs10965249	C/T	22123131	+	202985
rs7045889	A/G	22123251	+	203105
rs10965250	A/G	22123284	+	203138
rs10217782	C/T	22123845	+	203499
rs10811659	C/T	22123716	+	203570
rs12686509	A/T	22123767	+	203621
rs10757282	C/T	22123984	+	203838
rs10965251	A/G	22124029	+	203883
rs10811660	A/G	22124008	+	203922
rs10811661	C/T	22124094	+	203948
rs10757283	C/T	22124172	+	204026
rs10811662	A/G	22124253	+	204107
rs7019437	C/G	22124302	+	204156
rs7019472	C/T	22124395	+	204249
rs7019778	A/C	22124651	+	204505
rs13287212	G/T	22125071	+	204925
rs10965252	A/G	22125819	+	205773
rs12555274	C/G	22126440	+	206294
rs1333051	A/T	22126489	+	206343
rs10965253	G/T	22126687	+	206541
rs7018475	G/T	22127685	+	207539
rs9969854	G/T	22127710	+	207584
rs11791416	A/G	22128105	+	207959
rs10757284	C/G	22128458	+	208312
rs4977761	C/T	22128762	+	208616
rs35660019	A/G	22128865	+	208719
rs10811663	A/G	22129220	+	209074
rs10965254	A/G	22129485	+	209339
rs10965255	C/T	22130019	+	209873
rs2065501	A/C	22130224	+	210078
rs2085503	A/T	22130338	+	210190
rs7866021	C/T	22130339	+	210193
rs7866410	G/T	22130627	+	210481
rs12340450	A/T	22130678	+	210532
rs7854629	A/G	22131034	+	210888
rs7026735	C/T	22131269	+	211123
rs2065504	G/T	22131552	+	211406
rs2065505	A/G	22131780	+	211644
rs4977577	C/T	22131875	+	211729
rs6475810	C/T	22131894	+	211748
rs12376511	C/T	22132756	+	212610
rs10811664	A/G	22132907	+	212761
rs7859532	A/C	22132958	+	212810
rs7862836	A/G	22133133	+	212987
rs7849199	A/T	22133293	+	213147
rs7849302	C/T	22133377	+	213231
rs10757287	A/T	22133570	+	213424
rs2151285	A/T	22134255	-	214109
rs2151284	C/G	22134276	-	214130
rs2151283	G/T	22134305	-	214159
rs2151282	A/G	22134316	-	214170
rs7867100	A/G	22134460	+	214314
rs7853656	G/T	22134530	+	214364
rs2065500	A/G	22135694	+	215548
rs7030345	A/T	22135739	+	215593
rs13298423	A/C	22136196	+	216050

Marker	Type of polymorphism	Location (NCBI Build 34/35/38)	Orientation	Location (SEQ ID NO:1)
rs13298664	C/T	22136202	+	216056
rs10811665	C/T	22136604	+	216458
rs7022662	C/G	22137715	+	217569
rs13286296	A/T	22137761	+	217615
rs13285137	A/C	22137863	+	217717
rs28752115	A/G	22137944	+	217798
rs12341394	C/T	22138055	+	217909
rs28539212	A/G	22138269	+	218123
rs4614078	C/G	22140034	+	219888
rs7856219	C/T	22140261	+	220115
rs7043398	A/C	22140707	+	220561
rs12337417	C/T	22140792	+	220646
rs12115577	A/T	22140863	+	220717
rs10811666	A/T	22140867	+	220721
rs13293520	C/T	22140897	+	220751
rs7873930	C/T	22141050	+	220904
rs6475611	A/G	22141139	+	220993
rs7047414	A/C	22141412	+	221266
rs10865256	A/G	22141465	+	221319
rs10865257	C/T	22141528	+	221382
rs7849231	C/T	22142401	+	222255
rs4097833	C/G	22142520	-	222374
rs6475612	A/G	22142580	+	222434
rs6475613	G/T	22142643	+	222497
rs7021554	C/T	22142884	+	222738
rs6475614	C/T	22143265	+	223119
rs7853123	A/G	22143360	+	223214
rs10965258	A/G	22143663	+	223517
rs7853621	A/T	22143714	+	223568
rs7045424	C/T	22144009	+	223863
rs6475615	A/G	22144408	+	224262
rs12001831	G/T	22144411	+	224265
rs13295528	A/T	22144432	+	224286
rs7046009	C/T	22144458	+	224312
rs10965259	C/T	22144489	+	224343
rs10965260	A/T	22144539	+	224393
rs10965261	C/T	22144585	+	224439
rs10965262	C/T	22144592	+	224440
rs7030057	C/T	22144626	+	224482
rs10965263	C/G	22144648	+	224502
rs10965264	C/G	22144655	+	224509
rs7046289	C/T	22144664	+	224518
rs7029976	A/T	22144682	+	224536
rs10965265	G/T	22144683	+	224537
rs7046298	C/T	22144684	+	224538
rs7030278	C/G	22144691	+	224545
rs12343752	A/G	22145075	+	224929
rs7033903	A/G	22145090	+	224944
rs944802	A/G	22145709	-	225563
rs1930590	C/T	22146785	-	226639
rs7028213	G/T	22147360	+	227214
rs7856172	C/T	22147489	+	227343
rs7042842	A/G	22147512	+	227366
rs7856274	G/T	22147532	+	227386
rs7869966	C/G	22147546	+	227400
rs7869852	A/T	22147555	+	227409
rs7870203	C/G	22147567	+	227421
rs7870099	C/T	22147624	+	227478
rs7856433	C/T	22147671	+	227525
rs7856740	G/T	22147902	+	227756
rs1333052	A/C	22147908	+	227762

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs12238587	A/T	22148168	+	228022
rs10738611	A/G	22148598	+	228452
rs10122243	C/T	22148924	+	228778
rs10757288	C/T	22149416	+	229270
rs10811667	A/C	22149982	+	229836

B. Microsatellite markers within LD Block on C09 (between 21,920,147 and 22,149,982; NCBI Build 34/35/36).

S

Marker	Start position	End position	strand	Forward primer	Reverse Primer
DG9S762	21977346	21977478	+	TTATTACGAGCCTGGTCTGGA	CTGTTCCGTGCAGGATGAATG
DG9S761	21980412	21980677	+	CCCATCTAAGGGTAGAGAAGC	AAGCAAGATTCCAAACAGTAAACA
DG9S760	21994905	21995264	+	AGCAATCTAGGCGTTTGCAC	TGCTGGCCTTTGCTCTTACT
DG9S746	22034929	22035109	+	TGCTAAATGATCTATTTCCACCAT	CCYTTGCATAGGGAGACCAC
D9S1814	22078225	22078501	+	CTTCGATTGCTGGGATTATG	GGGCCTGTGAACCTACTGAC
D9S1870	22093010	22093220	-	TGGGTATGGTTTCTGG	TTGAGGCAGGTCAAATAA

Table 11. Amplimers for surrogate SNPs for rs10116277, rs1333040, and/or rs2383207 in the CEU population, as listed in Table 3.

5	rs7041637	TTTCGCAATGCTTATTTTCAATTTCTTCAGAAATGCCTTAAAGATATTAATGGAGGTAACAACTTAA TCTCAAATAGTAATCCATAGACAGAATATGTAA[A/C]AGCAATGTTCTCTGATCTGTTCTTTGGCTTCTATT CCCTAGAGAAATAGTTCTCTAAGACCAAACAGTCTATAGATAGAATTGTAGCAACAGTCAATTAT
10	rs3218020	GTGGAGAGAAAATGATTATACTTTGAGCTATATGGCTCCAATAAACAAAGATAGATCCCTCAATTT AAATTTGATCCTCAGAAAACCTGAGGGTCAGAGAA[C/T]CCCTCAGGCATGACGGGATAATGTGACAGTTA ATTTGGTATGTCAACTTGGCTAGGCTGTGGTACCCAGTGTGTGAGTCAAACACCAGTCTAAATATTGC
15	rs3217992	AGTACTATATTACACTGTTTTTTTTGTTTGTGTTTGTAGTTTTTTTTATTAAAGCAAACCTCAAACA TTATTGGGTATCAATTACCACCTGGTTGTATT[A/G]AAATAGTAACCTATCAATGCCATGTAAAAATTAATTC CATTTTCGAAGCCACCTGGCAGACAGGTTTAGCTGTTTCATCAGCAGCCTAATATATACTGTT
20	rs1063192	CATTATACTGGGTCATGAAAAATTATCCCTTGAAATAGATATGAAACATGTTACTTCATTTCTGGTT TAAATAACTTGTGGAATCTTTCCTAATGACAAC[C/T]TGATATTAAGGGAAACTAAAGAAAATGTTATTGTG GATCCACAGTACTATATTACACTGTTTTTTTGTGTTTGTGTTTAGTTTTTTTTATTAAAGCA
25	rs2069418	TGATACAAGTTATGAAACTTGTGAAGCCCAAGTACTGCCTGGGGATGAATTTAAGTTTGTATGACA GGTGCAGAGCTGTGCTTTCAGACATCTTAAGAAA[C/G]ACGGAGTTATTTTGAATGACTTCTCTCGGTC ACAAGGGAGCCACCAACGTCTCCACAGTGAACCAACTGGCTGGCTGAAGGAACAGAAATCCTCTGCT
30	rs2069416	AAATAAAAAAAGATACCTGACAAAGTGGGTTTAAATAGGTAAGAGTGCAAACAAAGATTTACTGT ACAAATATGATGAAACTGGGATCTCAGATTCTTA[A/C/T]AGTATAATTTTTTTTTGTCTTATGTGTGCCAGG TTGCCACTCTCAATCTCGAACTAGTTTTTTTCTCTTTAAGGGTTGTATCCATAATGCAAAAATGGA
35	rs573687	GTCCAAGACAAATGTGCTATTGTATTACATGTGAAATGTCATCTTTGAAGTCTGGTAAGGGTGTGC TGTGAGGTGAGCCATCTGGAACACAGTGTAGA[C/T]TGAAAAATAATTATAAGCCAGTTTATTACTTTTT TCCAGTTAAGCCTACCATGACAGCTGCTAAAAAAAACACTATGTAGTATAAAGGGTAAAAAGACTC
40	rs545226	GGGGTGCAGGTTGTGGTGTGGCCACACTTCTTCTTGGCGCAATTGACAGCATAGGGGTGCAGG AGAGCATAGCGCTTATGGCAGATCATCTTGTTTCAG[C/T]TGATTTCTAGGTGAGCTGGAAGAGTGAAGG CTCAATAATGCCACCTCGCAGGTGCAGCACCAGGTGCGGGGTGGGCCTGTTCTGGACGTTGTAGTCTGA
45	rs10811640	TCTTAATTTTTACACATTTTACTTTTCATTTCTTTTAAACTGTTATTAATAATTTATTCATTTGAATA AGGATTAAAATAAGGCTAGGATATTGAAATT[G/T]GTTGAAATTGCTACAGTCTCTGTATCTCTCTCTC TCTTTTTTTCTTATAAGGGACAGGTTTCATTACCTTGTGACCAGGCTGGAGTGCAATACT
50	rs10811641	TGTGATTCTAGCAGCCATGGATAATTATTTATAGATTATTATTTTCTTGGGGATGGCAAAATGGT GATATTCTAATTTTACTATTCTTCATTTACTAG[C/G]TGGAATGTCTTTTAAATTATTTATTTATTTA TTATTTGAGACAGAGTCTTGCACTGTCAACCAGGCTGGAGTGAGTGGTGTGATCATAGCTCAC
55	rs2106120	TGCGCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACTGCGCCTCGCCAACTTC CTTATTTTAAATGCCATTTCCCACTAAAAATAAAAC[A/C]AGTAATCTTTGAAAAAAGTTAATATTATGTA TAGGACTGGAAGTATATAAGATAAACTGGAATATATTGTCATACCAGAAATCAAAGATTTTGTCAA

rs2106119

ATTACTGATGTGACAAGGTACACAAGCCAATGTTGACATAATGTTTTCAAAATGGGGTGTCTGCTG
TAACTGAACATAAATAATAACTTTATTCAAGAA[C/T]GAGTTTCAATGATAGGACAAAACCTTGATAAAATG
AATAAATAAATAATTATATGCCAGAGTTCAGTAAACCCTGTGTGTACACCTGAAAAAGCTCAAACCT

rs643319

GAACAGAGCAGAAGAGAGTCTGGATACACAAATTTACAATTATTGGCTCCCATCAACATATCTAA
CTCAAGCATAAAGTTGTTTCAGCAGTAGTTTAAG[G/T]TTGGTTACTAATGCAACACCTCTTGCATGCAAT
GGCCCATTAATTATCTTCAACTTTAAAAGGTTCTTTGTTTTTAAATGCTTATAATGAACAAATA

rs7044859

TATGTGATGTAAAGAGCGCCAACATGTTTATATCCTCCTATTTCAATCTACTTTTACTTCATCTACA
TTTTTAGCAATAATGTGAACATGAAATCTTGAA[A/T]AATTAGCTATCTGTAATATATTTACTCATCCACTCA
AAATATTGAGCCCCCCCCAATAAATATCATACACTATATTCTAGGTACAGGTGATAAACAATTCA

rs10757264

CCAGTGAAAGTTAGAGAGAGGGGTCTAGAGCTCAGGGAGGAGTGTGTATCCCTAATTTAGACTA
ATTTGCATTAAACAGCTGTAGTAATGCAATTTTCTCT[A/G]TACTGAAATGCAGACATTTGAGTATAGAAAAT
TAGCAGACATTTGAATATAGAAGAAAGATTTACTTTCTTCAGAAAAAGAATAGTAGAGTATAAAGAA

rs10965212

TCTGTGCCACTGCACTCCAGCCTGGGTGAGTTGAGAGTCCGTATCAAAGCAAACCTACACATTTT
TGTGGCCTGTTTTTAGCTCTATCAAGTCAGTTACA[A/T]TCTTCTGTATTCTAGCTTTTTTATCTGTAAGCTC
CTGCAATGCTTTATTAGAATTTTAGTTCTTTGCATTTGTTACAACATACTCCTATAACTCTGC

rs1292137

TAAAAGAAAAAATAATCCAAATGTCAGCAACCTCAAAGATTGAAGGTAGATGAGCCCACAAAGAT
AAGAAATAATCAGCACAGAACAAGTCAAACTCAA[A/T]AATCAAGAGTACCTTCTTTCTCCAAAGGACC
ACATCACCTCTCTGGCAAGCGTTTCAAGTACCAGGCTGAGGCTGAGATGGCTGAAATGATAGAAGCAGAA

rs10811644

CAAGACCACTCTGCAGATATCAAGTCTGAAAATTCCCTAGGGCCAAAGTCTATTATGGGAGCAA
GTTGAGCCTAGAGGGATCGCCATCCCTGTCCATGC[A/T]CTGCTGTAGACACTCCTGCACTAAACCCTCTG
GGCTCCACATCAGCTGGCTTGCTGCTCTACCACTTGCTTGCTCTTGGGGGCTCCACCCAGAGAGA

rs7035484

GTCTCTTGGGGGCTCCACCCAGAGAGATGTGGGTGAGCAATCATTGAGTTCAATCAGCCCAGGA
TGGAGAGTCTGTGCTATGGGCCCAAGCCAGGGGCT[C/G]TCTGTCTGGTGACGAGCAGCTGGGGGGTGG
GGTGGGACCTGTGGGAGATGGACTGGCCTCCTCTCCTTGAGTCAACTGCTGCTTATTGGAGGTGTGGATG

rs10738604

CCATTGCAGAGGTAGTGGCAGAGAGGCTTTGAGTTGTCCGTGGCGGCTCTGTCCAGGGAGTTGC
TGAGTTGCTATTGGCTTGATATCTCTGGTGGGGTGT[A/G]GCTAGAGGTCCAGGCCTGGAGGACCTGCTC
GTTGAAGAGATGTGGGAATGGGCACCCACATAACAGTCTGTTCACTTTCCATAGGGCTGCTGTAGTATG

rs615552

GGGGAGCTTAAGCAGGGGTGGAAGGGGAACCCAGCACAGAACAGCTGCCCGACAAAAATGTG
GCCACACTGCTTTTTTTTTTTTTTAGCAGGTCCCCA[A/G]TCCCGTTCTCATCACTGGGTAGAGTCTCCC
ATCTGGGGTCCCCGGCTACCCCAACTGGTGTCTCTGACTGAGAGAGGTTTCAGACTTCCATGGGACCT

rs543830

TGGGCAAAAGTAGCTGCGACTTTGGCAAAGCTGGAGGTTAGACCCCCAAACATACCCAGGAGG
TTAGACTCCCATACATACCCAGAAAAGAGGCTGAA[A/T]CCAGCGAGATCAGCAGAGAAGGTCTACAGG
CCCCACTTCCACAGCGCCTCACAGGATAAGACCCACTGGCTTGGAAATCCAGCTAGCCACCAGTAGCAAC

rs1591136

AAGTGGTAAGTGAATGCGCAACTCTGGGAATCCACACTGCTCTCACAGATCTTTGCAAACCTCAG
ATCAGGAGATCCCCCTTGTAAGTCACTCCATTAGG[C/G]CCTTCACACACAGCCACGTGGAGTCTCAGCA
GAGCAGCCACTCAGGCATGCATGGAGACCCAAGAGCTTTAGCTACTCCAGCTTTCTGGGTGTCTGGGCA

rs7049105

CTTAACAGCAAAGTATCAGATTCAATTTATAAAACAATGTGACTGATCTTTATGTATGGTTTGTGAAA
CATTTATGCAGTGTCACTTCAGAAAACCTCTGCC[A/G]TTATAGATTTGAATTGATTAAGGATATCCACTCCT
TTCCTTGGCATGATACAAATAAATTACTAAAGTATAATTGTAACAATGATAAATAAGTGACAA

rs679038

CACCCCTTTGGGAAGGGGATCAAAATATAGTGATTTTCTAATTCTAAGATTCGTTCTGTGTATATT
AGCTGCTATTCTTCTAGAAAGAAGACTTTCACCA[C/T]CGTCCCTTGGATTTTCTTTTAATTTTGTATGG
TTTAAATTGCATCATCATTTCTTTTGTATGTCCAAATTGTCCCAATTAAGCCAGTTAGAGAAACA

rs10965215

TAATGGGATTCTGATGGAATGTTTAGTCTGAATCTAATCACATAGAGACTTGTCTGACAAATCCA
GATTTTTTGGATGTTTTGCAGGACTATTTGCCAC[A/G]ACATTTCAAAGGATTTCCAAGAGAGAATATTGGT
GTCCATGCTGTGATGATTCTCAGCTCCTCTCATCTGATCTCCGTCCTGGCCCCCATGACTTTCTTT

rs564398

CTCTTCTTTTATCACACAGACCTGAAAGATGATGGTTTCCCAAACAGCACTTACAGCAATAGGTGT
GGGCCTCAGTGGCACATACCACACCTTAACCTACC[A/G]CAAAGAAAGTCATGGGGGCCAGGACGGAGAT
CAGATGAGAGGAGCTGAGGAATCATCACAGCATGGACACCAATATTCTCTCTTGGGAATCCTTTGAAATG

rs10115049

CAAAATCTTTCCCTAAGGGAGATTTTCAAGATGAGGCCCCAGCCTTGGTAGACACCTTGATTGCAGT
CTTGTGAGAGATTGTGAAGCAGAGCTATTCTCAGA[A/G]TTCATGGGTGTTTTAAGCTATGAGGTTTTTTTT
GGGGGGAGAATGGTCATTTGTGATTCACTATACATAAGTCTACAAAAGTCATTCCAGAAGTGATTCT

rs634537

TGGGGCTCACAAACCACATGATTCTACCTCCACTGAATCACTTCTGGAATGACTTTTGTAGACTTAT
GTATAGCTGAATCACAAATGACCATTCTCCCCC[A/C]AAAAAAACCTCATAGCTTAAACACCCCATGAATT
CTGAGAATAGCTCTGCTTCACAATCTCTCAAGACTGCAATCAAGGTGTCTACCAAGGCTGGGGG

rs2157719

TTTTTATAGTGTGACTCATTTACATATGCATGTGTATGTTTAGGTGCTATTATTAAATTTTGTCTGGC
ATATAGTGAGGAAATTGTGATTCAAATTCGTCC[A/G]TATGTACTCTCCCCCACCATCTGCTCTGCCCTC
CATTTACCAGAAGGCTAGCTTTAGCTACTTGTGCATGTAAACAGAAGCAAGCAACACTGTGAAA

rs2151280

GAACATAGATACTCCTTCATTCATGTATTGTCTATGGGTGAGTCTTTATTACAACAGCAGAGATGA
GTAGTTGTGACAGAACTCGATGGCCCTCAAAG[C/T]GAAACAAGCTACTATCAGGACCTCTATAGAAAA
AGTTTGCCAACCTCTACACTGTAGTATGCCTTAAGGATTTTAGAAGATTGAGTATGATAAACACTT

rs1008878

GAAGGGATGATCAGTCCTTCCCTCCTCTATTTTCTTGAGCCCCGTTTTTACCTTTCTTTTCTCTC
TCCTTTCTTATCATGAAGAATAAAGACAAATGA[G/T]AACAGATCTACCTTAGGCTGATACAGGGCAGGGA
ATCCATTTAATAATAAAACGTGGGTCAAATTCACTTTTCTCCTTTTGAATTGAAATTATATTGTG

rs1556515

ATTTGATGCAACTTACACACTGTTGTTATACCTCTAGAATTTAAATGACAATTTTTTAAATAATTTTG
GGGGGCCTAGATTTGCTATTTAACCTATCAAA[A/G]AATTGTGTCTTACAGTATTATTCAAATGTAGTGTGT
AAAGACTTATACTATTGGTCTTAAGCACTACTGGTTGTTTAGGCTTTTCTCTTTCTCTGTAG

rs1333037

ACATTTATATAATTAAGATGCTAACACTGACTGACAGAAATGTCAGTAAGATGAAATCAGACTGCA
TGGGAGTTTTATGTTACATTAATTTGTAAATTGT[A/G]TATCTCTGTATTTCATGTGAGTGTGGCTATCATGA
TGTTAGACATCCAGCTACAAAGGAGGCATTCTGTGCACACACACAGTCTCCAATCTTCTGTTTACCT

rs1360590

TAGACAAAGTTTAATGTTCCCTTTTATATGTTTTCTTGGTAAACAAAAATTGTCTCAGGGTTATFAT
GCATATATGATATTGTCAAGAACTTTCTGGGT[A/G]CTGTGGGGCAAAGTCTTCTCCATAAATAAGCTAG
GGTTGATTGGAGTTTTCACTTTGAAAAATATCGCACAGGAGGATCTCAACAGCTAGACAATTTCCA

rs1412829

AAATTAAATGACATACGTAAAGTCCTCAATAAATAATAGCTCTTATTACCATTGCTATGGTTACTAT
CACTATTCTGTATTTCTTTTGCCATTCTCA[C/T]GCTTGAATATGAATCTCATGGGTAGAGTTTCCCAA
GCATGATATGTGTAGTACTACTAAAGGCAAGATTTTGGGTGCATACAGACAAAAAATAATTTA

5

rs1360589

AAACCAGAGGAGTAAAATTTCTACTTTACCAGTAATTAGCAGTGTGGAGTTGAGTAAATAAACCTC
TCTAAGTCTCAGTTTCTACATCTACTAAATCTAA[A/G]CAAATTCAAAACAGTGATTATTTTCATTAGATTAGA
TATTTTGATTAGTCTTAAATGTCTAATATATAATAAACACTCAACAGGTAGTAGCTATTCTATGT

10

rs7028570

TCATTTCTTCTTTTAAGGTCTTAATTTCTTGTTTTTCGAGTTTCATGGGAGATATCCAGTCACCAAT
CCAATCCATATCGGGGAAAAGTACAACAAATGA[A/G]TGAAATTTGTAACCAACCTTGGATGATGGAATAA
GACATTTGGGAGAACACAGGAGAAGTGGGGAGGTTAAGGAGGGATAGCTCTGTGAAAATTTTGCAT

15

rs944801

AACTAATTCTCCAAATTTGCAATTTGGCAGCATCCTACTGGGACTCTAGAAGGCTGATAAATCATG
GAGAGTAGGTATTCATATAGGAACCTATGAAAGCT[C/G]TATGTAGTAAACACTACTTAAGAAGGCCTTACA
TTTCATAAAAAGTTGGAGATTTTGTGGAGACTCATAAATGCATCCTTTATATCAGTGAAGTTTTT

20

rs10965219

ACTCGTAGCCAGAGCTACCTTCCAGATGACTTCTTTCTACCACTTTCTTTCTTCCCAGTGTAAGAG
AATGCAAGTATATGCTGATGTTTGGAGCAAGAAC[A/G]TTCAAAAATTTCTTATTAACATAACTTCTAATG
GAAATACAGTATACTACTATGGTGCATACAAAGAAGAAATAGCAACATATATTTGTTTTAGACCTG

25

rs7030641

ATAAGCAGCCTTAAATTAAAAAAGTTAACTCATACTAACTGYGTGACCTGGGATAAGTT
ACTGACCCTCTTTAGGGCTTAGGGTCCTAATCTG[C/T]AAAACGGAAATTATAATAAACCTTAGCTAGCA
TTTCTTGTGCACATACTATAAGCTGGTGATAAACAATTTATACACACTATCTCATTTAATCCTCAC

30

rs10120688

TCCAATGCAAAAGAATAATAGGAGCAAAAGCACAGTGGTGAGAAATTGGAGGGGAACTGTGAAA
ATTGCCACATAGATTAGAGGCAGGAAAATAAAGGAC[A/G]GCTAAGTTTATATAGTGAACAGTGAGCCGC
ATGGACACAGGTGACTGTTTTCTCCTTTTGAACCCCTGCTTACTCCAGAGTCACCACCTCTCCTGGCTT

35

rs2184061

TATTTCTGAGTATTAATTCCTGTTTCCAATAGATTACTCTTTTAAACATAGCACTACTACTTACCTAA
TGAAATTTAGTTGCTATTAATGGATGAATTTT[G/T]TATCTAACAGGCTTGATTTTGATTATGCATTTTAAAT
GTCAGTCAGACACATATTAATAATGATCCATGTTTGTAGCTAATAGGCCCAATATATACTTTT

40

rs1537378

GTAAGGGCTGGGACAAATAAACACAAGTAATTTCAAATATATTAATAATAATATTCTGAGTATTAA
TTCCTGTTTCCAATAGATTACTCTTTTAAACA[C/T]AGCACTACTACTTACCTAATGAAATTTAGTTGCTAT
TAATGGATGAATTTTGTATCTAACAGGCTTGATTTTGATTATGCATTTTAAATGTCAGTCAGAC

45

rs8181050

TGGTGGTCCTAAAGTGGCATTAAAGGAGCCAATAAATTGTCAATTCCTACCTTAGCTCTGTGTCAGAT
GAAATACACAGCATAGTGTGGGGAGAAAATGTTG[A/G]GCTTATTGGGGATGGGGTCTTTCACATAAAGG
AAGAAGGTTTCAGAAAGGCATAGTGGTATGAAAAGAGGAGAAACCAAAGGGAGGAAGGTCAATAAAGGG

50

rs8181047

CAGCATAGTGTGGGGAGAAAATGTTGGGCTTATTGGGGATGGGGTCTTTCACATAAAGGAAGAA
GGTTTCAGAAGGCATAGTGGTATGAAAAGAGGAGAA[A/G]CCAAAGGGAGGAAGGTCAATAAAGGGTTA
AGAACGAGGGGAGGCAAATTGACTTTCTTTCAGCATATGAGGATTATAGGAATGGAAACCTTAATTGGAAT

55

rs10811647

GAGGATTTAATGCAATTGTTTGTGGGAAAGCACTTTAAACAACCTCTAAATTACGATATATATGCTAG
GTTTTATTGTTACCCACACCTTTGATGTATTTCT[C/G]TTGTACTCTTCACTGTATCTGTAACACATTCCTT
AGGATAATTAGGGCTACCTTTTAACAAAGCCAAGATTCATTTATAGTGGAAGCTGGCACCTGG

60

rs1333039

CTTCTGCTATTGAACGAACTTTTGTAAAGGTAGCTCCCAAGCAGGTTTCAGTAGCTTTGTTCTATTA
TCACCTTTTCTACTGACAGTGATTTTTTTCCTTT[C/G]AAGGCCTGGGACATGGAGACTGCTTTTCTGCAGAA
ACCACATCCCTGGAGTAATGAGCTACACCTACCTCAATTATTTCAGTGCAGTACAACACTCCAGG

5

rs10965224

ACATTGTGCACATGTACCCTAGAACTTAAAGTATAATAATAAACAAAAAAACCCTGCACAATCT
CTAGTATTCAGATGGAGACTAAGCATGATTTTTC[A/T]TATAAAGAGCAGATCAGAATGTTGTATCTTTTA
TTCAGAAGACTGGAGTTAATCACTGTTATCTTTAGTACTTAGTGCTGCCAAGGCTGTGTGTTTACA

10

rs10811650

ACAGAGTGCTTATTTAAAGAAAAATAAAAAAGAACACACACACACACGCACGCACACACACACGCA
CGCACACACACACACATGTAGCTACATGTCTAGGA[A/G]GGATGTGGAGAGCTGAAATATGAAGGCAAAA
TAAAAATCTTTTCAAAGTATACAGCCTACAGTGGTTAGCACAGAGCTGGCCACATAGCAGGGGTTTC

15

rs10811651

CAATAATGTAGAAGCAAAGAGCCTAAAGTGTTTTCATAAATCTTAAGTGGTAGCTTTATGTTCCAG
TTCAGCAAAACACAAATTTGAAGGCAATCTGTAC[A/G]TAGGGTTTCAGGTGAAGAAGGCAAAGGAATCA
ATGAAATTGTAAAAGCTTTCCAAATTTGCCTTTTCTCTTAAGATTGTCTTTCTCTCATTCTCTTCTCC

20

rs4977756

TTTCTGTAGCAGAAGTGTAAGGGTGTTACTCGTAGGAGGCCTCTATTGAACTCTTTTCCAGTGAC
GTAGTGTGTGGTCTTTAAGTGGCTTTGCAATGATA[A/G]TAAGATCAGCATTGCATTAATGAATGAGCTCC
TTTAGTAAACGTGGATATGTGCTTTCTGAATCTATTGTTTGTTTTCCCAAGTCATAAACAGTGAAT

25

rs10757269

CCATTTAGAGTACTTGCCTCTGAGGGAAATAAAAAATTTGCTAGCAATTTTCTCTAAATGACATTATC
ATAGGCACCTTAATTCCTTGATAGGTTCTTTAG[A/G]TAATTTTTTATAATGAAGCAATTAATTTGATTCAC
GAAAGTAAGTTCTAGTTTATATAAAGACCAGATCTGGCCTATTTCTTAGCTTGTCTACATTTG

30

rs9632884

TGCTAGCAATTTTCTCTAAATGACATTATCATAGGCACTTAATTCCTTGATAGGTTCTTTAGATAA
TTTTTTTATAATGAAGCAATTAATTTGATTCAC[C/G]AAAGTAAGTTCTAGTTTATATAAAGACCAGATCTG
GCCTATTTCTTAGCTTGTCTACATTTGAGTAGTCCATTGCTGGAAAATGACCTGGAGCTTTT

35

rs1412832

AAGTTGCTCTCAACATACTTAAAGTTTTCCAATAACTGAATTAATATCAGTTTATCAGTTTAATATA
AACAAATTAGGGTAAATGAAAAATAAAATTTTTCAG[C/T]TCTTTGGTTCCATTAGCCATGGTTTCAGGAGCAGAAT
AGTCACCTGAGGCTAGTGACAACGCTTTTGGATCACAGGAAAGAAGAAAAAAATCAAAATAAT

40

rs10116277

TTATAACTAATGAGGCAATGTGTCTTGAGTATTTGAATTAAGTCTCTAGAAATCGATTCTTGGGGA
GGTTATTTACTTTGAAGTGATGGACAGAGTGATG[G/T]AGATTTATGAGTGAAGTCTTGTCTGATTTGGAA
ATATAGAGTTGTTTAGGCTAGGTATTACCAACCCAAAGTTGACACTTGAGTCACCTAAGTTCTTCTC

45

rs10965227

TATTAGTTGTGTAATCTTGAAAAATCTCTGACACTTTTCCCTCTGACTCAGTTTCCCCATCTGGCA
CCCAATCTTTTACAGTGTTATGAAAAATAGGGA[A/G]AATGTAGAAAGGAAGAACATGGCACCCAATCCTT
AATGGACACTCAGTGAAAGCTGGCTATCATCATCATTTTGGGGTTGTTGTGTTCTACAAATGTAT

50

rs6475606

TCCCCATCTGGCACCCAATCTTTTACAGTGTTATGAAAAATAGGGAAATGTAGAAAGGAAGAAC
ATGGCACCCAATCCTTAATGGACACTCAGTGAAAG[C/T]TGGCTATCATCATCATTTTGGGGTTGTTGTG
TTCTACAAATGTATTTTCCAGGAGTTTTTTTACTCTGTCTCTCTTTCCCTTCATATACCCCCAGCC

55

rs1333040

TGGGAAGGATGAATTAATGGGATGGAGTGCAGGGGATGCAGAGTGCCCACTTATGGAATGATTT
CATTCAAGAGAGACAGGAGGGTCAGAGGTAAGAATG[C/T]TACCGCTGGGACAGAGAGGAAGGTACAGA
TATGAGATATGGTAAGAAGGTATACTACAACAGTGGCTCCCAATCTCAATGAGTAGCCAGTTCTCATGGA

60

5

10

15

20

25

30

35

40

45

50

55

60

AATTTATTGAGTAGACAGCCAACCCCTGTATTGTA CTCTTTAAAAAATATTTAGGCTTTTTAA
 ATGCTGAGGCAAGGGGACATACCAAACCTAAC[A/G]GGCACATTGGGGTTTCTGGCTATTGAAATAAA
 AATGTCCTTACATAACACTGATGTACTGGAATAGCACTGCGTTCCAGTGACGGTTATTGCAACTCAG

rs7859362

GGAGCATGATGTGCTTTGATTCAACTATGGGCTTTATTACTTAAGTGGGTTACTTTGGTTAA
 GTTGTGTTGACTCTTGTGTTTTGAGATGGAGTCAG[C/T]CTGGGAGACTCCAGCTCTGTCGCCCAGGCCGGA
 GTGCAATGGCAGCATCTTGGCTCACTGCAACCTCTGCCTCCCGGATACAAGCGATTCTCATGCCTTA

rs1333043

CTGGCACAAAGTAGGCACTTCATATATAAAAGCTGTGATTATTGATGAACCAGTAGTGAGGTACAT
 AACTGGGGAAGGAGAAGGGGCCAGTTTGTGGGAA[A/T]GCITTTTTAGTTATTAATAGTAAGGTGGTAAA
 ATAATAATAGTAATAATAACCAAAGTTACTGAAAACAAATACAGTGCTAAACTCTTTAAAGGAGT

rs1412834

CYTCTTTAGCTGTAAATAAGTAATTGTATGAGGTGATGGTTAAGGTGATTTACTAATTTTACAATTC
 TATTATTTTATGAATAGACCTAGTTAGGATAG[C/T]TTGAAATAGATACTTAATCCACTATTATTCTCTCT
 CTAAGATATAGTTACTAGTTGATCATACTTTTCTTAAAGGCTGAACTGAATTCTCTGATATCA

rs7341786

GAAACATACTGGTTAATGGAATTCCAGAAAGGACTGAACAATCAAACCATTTTGAAGGACAGCAT
 AGAGCTGGACTCTAGAACAGCCAAAACAAGGGGTT[A/C]AACCCTGCGAGGGATCTCTCTCCAACCTCT
 GCTCAGGCTTTTCTCCCTGGCTTGACTTTCTCTCTTTCACTGTAGATTGGCTTCTCTCACATGGCAAG

rs10511701

TATTATGTGTGGCTGACTATATAAAACATGGATATTTTCTTGAATCACTTGGTTTGAAGTGGGAG
 AAGACCATTTCTCAAACAAGGAAGTGCAATTTA[C/T]AGAAGGTAGTAGAATAGGCAGATAAAACAATA
 TTCTTCACTATATTGCTCAAATAATCCCATGACATTTTATGATATTTATAAAGAGAGTTCTAAAGT

rs10733376

GAGAAAGATGTTAAGATGAAATTAGATGTGCAAGAGATTGCGCGAGGTAACCTTGTGGGAGAAA
 ATGGAGAGGTACATAGAGGAGCCTGGGCAGACTGT[C/G]TGGCTACTATGTAAGACTCATCCCCATGAAG
 GAGAAAGGAGAGGAAGGCAAGAAGAAAAACCTTAAGATTTCAATTCTAAGAACGTTTGACAAAGCTG

rs10738609

TGTGCAAGAGATTGCGCGAGGTAACCTTGTGGGAGAAAATGGAGAGGTACATAGAGGAGCCTG
 GGCAGACTGTGTGGCTACTATGTAAGACTCATCCCC[A/G]TGAAGGAGAAAGGAGAGGAAGGCAAGAA
 GAAAAACCTTAAGATTTCAATTCTAAGAACGTTTTGACAAAGCTGATTAGGAGTATTTAAGGCAAGCTGC

rs2383206

AAATACTTTAACTCATGGCCCGATGATTTTCAGTTAACCAAATTTCTCCCTTACTATCCYGGTTGCC
 CTTCTGTCTTTTCTTAGAAATGTTATGTAGT[A/G]TTTGCAAGATGGCCTGAATCCTGAACCCCCATCT
 TCAATGAGCACCAATGGAATTATAGATTCCCAGCTGTAGAGCTATGTCAGACAAAGGAAACTT

rs944797

CTCTTCTTGGTGGCTTAAAGTTAGGCTGAAGAAGATTTACATFATGTTGTGCATGACCTCTTTAG
 TTTGGTCTACTTATACTTTCAAGGAGGGAAGAC[C/T]GGGGAAGGTGTCCCTTAGTGAGCATATTTTGTA
 CAAATGAAAACAGGGTACTAACCTTATGCCAGGACGCATGCATAAACTAGGATGTTCTGAGAAAA

rs1004638

AGAACCTTAATGGGAGCACAGGTCCCACCCACCCCTTGCTACCCCATGTACTTGTTCCTCATCTTCA
 CCCAAGAGAGGAAACACTCTGGAAGTAGGGCAGC[A/T]TAAGTGAAGCAGAGTGAAAAGGAATGTGAAG
 TTTTGAGAAGAAAGAAAAGGCTAAAGTGTCTATCTTCCACATTGCTTTTTTCAGGTTTCTCTTCGGAA

rs2383207

GATGAAAAATTCATATTCATCTGAATTTTATAAGTGAATCATGAGAACTCAAAGATACTTAGCCCTT
 GGGACCATTTTTTACTCCTGTTCCGATCCCTTC[A/G]GCTAAGCATGATTATTTACTATTTTCACTATTAG
 TTATGTCTTGTGAAAAAGTATGAAAAGAGCTGCCCAATAAATTAGAGTGTATGCTCAACATTCT

rs1537374

TTCCGATCCCTTCAGCTAAGCATGATTATTTACTATTTTCACTATTAGTTATGTCTTGTGAAAAA
 GTATGAAAAGAGCTGCCCAATAAATTAGAGTGT[A/G]TGCTCAACATTCTCTTAGCTTCTTTATCTCTTTCC
 AAAATTGGATCAAATGACATTGGACATGATCAACTTCTTACTGTTTGACAAACATCTGAGGATA

rs1537375

TTATTTACTATTTTCAGCTATTAGTTATGTCTTGTGAAAAAGTATGAAAAGAGCTGCCCAATAAAT
TAGAGTGTATGCTCAACATTCTCTTAGCTTCTT[C/T]ATCTCTTCCAAAATTGGATCAAATGACATTGGAC
ATGATCAACTTCTTACTGTTTTGACAAACATCTGAGGATACCTTTATAATTGATAATTTGGACTA

5

rs1333045

TTTTGTGCCTCAGTTTCCTCATTCAATATGGGTGTAATAACTGTGCCTGTCTTGTAGGATTATTGTG
AGGCCCAAGTGCAATAATATATAGTACACTGTG[C/T]CTGGCATCTAGTAAGCATTCAATAAGATGACATG
AAGATAACACAGATATATCTTAACATGTAATTATGATTTTGCTTATTCAAGGCCAAGCATTCCAAT

10

rs10738610

GAAGAAGAAGACAGTCAGAGAGAAGTGAGGGCTTACTTTTCATGTTTAAAGTCTGTTATGTGGTA
AAGGGATTAGATTTATCTGTGTTGTTCCAGGGGAC[A/C]GAAATAGGACAAATGGATGCAAAATAGAGTGA
GGAAGATTTAAACAAATGGAGAAGACATTCTAAAATCAACTACAATGAGCGTAAACAAATGACAACGGA

15

rs1333046

TCATATGCATAGACAAATACACCAAACCTGATGAATATTTGCCTTGTATAATCTTTTGTAGTTTTTTT
ATGAACATATATTACTCAAACAATTTAGAACA[A/T]TTGGCAATATATATATATTTTCAATTTATAAAAGGTTAG
GAAGATTAATTACACTTTCTGAGGTCGCAACTAAAAGCCAAGATTTTAATCCATTTCTATTG

20

rs10757278

AGTGTCACTGGAAAGTGACAAAGAGGACAGTTAAGTTAGTTGGAAGTGAAGTGAAGGCCAGACAG
GGCTGTGGGACAAGTCAGGGTGTGGTCAATCCGGTA[A/G]GCAGCGATGCAGAATCAAGACAGAGTAGT
TTCTCCTTCTCTCTCTCTTTAATTGTAACGCCTTTTATAACAAACAAATATTATGCTTATTTCTGTCTT

25

rs1333047

CAGTTAAGTTAGTTGGAAGTGAAGTGAAGGCCAGACAGGGCTGTGGGACAAGTCAGGGTGTGGTC
ATTCCGGTAAGCAGCGATGCAGAATCAAGACAGAGT[A/T]GTTTCTCCTTCTCTCTCTCTTTAATTGTAA
CGCCTTTTATAACAAACAAATATTATGCTTATTTCTGTCTTTAAATTTTTGTAGTAATTTCTCATCA

30

rs4977575

TTTTCTAGTTGAGCTATCATTATATTTATTATGTGGAAGTGAAGGTAGTCTGGCTACTTGGGAA
CAGCGTGGAGTCTAGCCATGTCAAGGCCAGAAGT[C/G]GTCTCAGCTAAGTTAGAATGTGATACCATTGT
TTACACAAGTGTGGCCTGCCTCAAGATAGGGTGAGGTGTTTTATGACCACAGGCTTTATGAGTTATA

35

rs1333048

TGACTCTGAAGATCATACCCGAAGTAGAGCTGCAAAGATATTTGGAATATTGGTAATATCCAATAA
AGAATGACCTTCATGCTATTTTGAGGAGATGTTT[A/C]AATGTGCAATTATTGAAATATTATAAAATACAA
ATAAACTAACTCTGCTTCATATTTCCAACCTGTGTATGACACTTCTTAGGCTATCATTTTATTCCAA

40

rs1333049

TTCCAACCTGTGTATGACACTTCTTAGGCTATCATTTTATTCCAAATTTATGGTCACTACCTACTG
TCATTCCTCATACTAACCATATGATCAACAGTT[C/G]AAAAGCAGCCACTCGCAGAGGTAAAGCAAGATATA
TGGTAATAACTGTGTTGACAAAAGTATGCAGAAGCAGTCACATTTATACAGTAGTGAAGGAAATGT

45

rs1333050

AATTACAGTATATCTAAAAAAGAATAATATATAACAACTGAAAAAATAAAATAGTTGATATAAGCA
GATATTTCAAAGATCTGCCAGACATATTGTTAAA[C/T]GAAAAATCTAGATACAAAATTGTTTATAGTTCTCTT
TCATACTATAGCCAAAGAAAATTCAGAAAAAACTACTTACAGTTGATCCTTGAATAATGCAGCA

50

Table 1.2: Association results for the MI phenotype for rs2383207 (G) and rs10757278 (G), in 9p21 in Iceland and the US. Results are shown for the Initial Icelandic discovery MI case-control group (Iceland A), an independent Icelandic replication group (Iceland B) and for the three US replication groups of Caucasian origin. Also included are the results for the MI case-control groups combined.

Study population (n/m) ^a	Frequency		OR (95% CI)	P
Variant (allele)	Controls	Cases		
Iceland A (1607/6728)				
rs2383207 (G)	0.455	0.506	1.22 (1.13-1.33)	1.4×10 ⁻⁶
rs10757278 (G)	0.434	0.489	1.25 (1.15-1.36)	1.5×10 ⁻⁷
Iceland B (665/3533)				
rs2383207 (G)	0.462	0.525	1.29 (1.15-1.45)	0.000028
rs10757278 (G)	0.436	0.503	1.31 (1.16-1.47)	0.000014
Atlanta (586/1284)				
rs2383207 (G)	0.541	0.593	1.23 (1.07-1.42)	0.0030
rs10757278 (G)	0.484	0.551	1.31 (1.14-1.50)	0.00015
Philadelphia (582/504)				
rs2383207 (G)	0.524	0.602	1.37 (1.16-1.63)	0.00026
rs10757278 (G)	0.470	0.550	1.38 (1.17-1.64)	0.00019
Durham (1137/718)				
rs2383207 (G)	0.513	0.559	1.20 (1.05-1.37)	0.0060
rs10757278 (G)	0.460	0.521	1.28 (1.12-1.46)	0.00027
Combined Iceland^b (2274/10260)				
rs2383207 (G)	0.458	0.511	1.24 (1.16-1.33)	3.3×10 ⁻¹⁰
rs10757278 (G)	0.435	0.493	1.26 (1.18-1.35)	5.3×10 ⁻¹²
US groups^c (2315/2508)				
rs2383207 (G)	0.526	0.585	1.25 (1.15-1.36)	1.1×10 ⁻⁷
rs10757278 (G)	0.471	0.541	1.31 (1.21-1.43)	1.5×10 ⁻¹⁰
Replication groups^d (2980/6041)				
rs2383207 (G)	0.494	0.555	1.27 (1.18-1.36)	1.4×10 ⁻¹¹
rs10757278 (G)	0.454	0.522	1.31 (1.22-1.40)	1.0×10 ⁻¹⁴
All groups^{b,d} (4589/12768)				
rs2383207 (G)	0.492	0.548	1.25 (1.18-1.31)	2.0×10 ⁻¹⁶
rs10757278 (G)	0.453	0.517	1.28 (1.22-1.35)	1.2×10 ⁻²⁰

^a Number of MI cases (n) and controls (m). ^b When combining the Icelandic cohorts they are analysed together and the results adjusted for relatedness in the combined group. ^c For the combined groups OR and P value are calculated using a Mantel-Haenszel model and the frequency in cases and controls is a simple average over the frequency in the individual groups. ^d When combining Icelandic and US groups, the frequency in cases and controls is the average over the two populations.

Table 13: Genotype specific odds ratio for the risk allele of rs10757278. Shown is the risk for heterozygous carriers (OX) and homozygous carriers (XX) compared to the risk for non-carriers (OO), together with 95% confidence intervals (CI), and the population attributable risk (PAR). The lower part of the table includes the corresponding values when the analysis is restricted to early-onset MI cases.

Study population (n/m) ^a	Genotype specific Odds Ratio ^b			
Variant (allele)	00	0X (95% CI)	XX (95% CI)	PAR ^b
Iceland^c (2272/10261)				
rs10757278 (G)	1	1.25 (1.12-1.39)	1.58 (1.38-1.81)	0.19
US groups (2315/2508)				
rs10757278 (G)	1	1.28 (1.14-1.45)	1.72 (1.45-2.03)	0.23
All groups (4587/12769)				
rs10757278 (G)	1	1.26 (1.16-1.36)	1.64 (1.47-1.82)	0.21
Early onset MI (< 50 for males; < 60 for females)				
Iceland^c (621/10261)				
rs10757278 (G)	1	1.38 (1.13-1.69)	1.94 (1.53-2.46)	0.27
US groups (1080/2508)				
rs10757278 (G)	1	1.56 (1.32-1.85)	2.08 (1.69-2.58)	0.34
All groups (1701/12769)				
rs10757278 (G)	1	1.49 (1.31-1.69)	2.02 (1.72-2.36)	0.31

^aNumber of MI cases (n) and control (m). ^bGenotype specific odds ratio for heterozygous (OX) and homozygous carrier (XX) compared to non-carriers (OO).

^cPopulation attributable risk (PAR). ^dFor the Icelandic groups, *P* values and OR were adjusted for relatedness using simulations.

Table 14: Association of the G allele of rs10757278 to coronary artery disease (CAD). The association results are shown for CAD, both including and excluding known MI cases. Results are shown for the Icelandic case-control group (excluding the discovery group), for two of the US groups, and for the groups combined.

Study population (n1/n2/m) ^a	All CAD cases				Excluding MI cases		
	Cont.frq	Case.frq	OR (95% CI)	P	Case.frq	OR (95% CI)	P
Iceland ^b (1563/773/3533)							
rs10757278 (G)	0.439	0.496	1.26 (1.15-1.37)	1.9×10 ⁻³	0.490	1.22 (1.09-1.37)	0.00050
Atlanta (724/128/1284)							
rs10757278 (G)	0.484	0.552	1.31 (1.15-1.50)	0.000036	0.557	1.34 (1.04-1.73)	0.028
Philadelphia (709/126/504)							
rs10757278 (G)	0.470	0.547	1.36 (1.16-1.60)	0.00019	0.528	1.26 (0.96-1.66)	0.10
Combined							
US groups ^c (1433/254/1788)							
rs10757278 (G)	0.477	0.550	1.33 (1.20-1.47)	2.7×10 ⁻³	0.542	1.30 (1.08-1.57)	0.0059
All groups ^c (2995/1027/5321)							
rs10757278 (G)	0.458	0.523	1.29 (1.21-1.38)	3.6×10 ⁻¹⁴	0.525	1.24 (1.13-1.37)	0.000011

^a Number of all cases (n₁), cases excluding MI patients (n₂), and controls (m). ^b Individuals used in the initial discovery group have been excluded both from cases and controls. ^c For the combined groups, the allelic frequency in cases and controls is a simple average over the individual groups or, when combining Icelandic and US groups, the average over the two populations.

Table 15: Association to MI on 9p21

Shown are all SNPs in the region 21.92 to 22.12 (NCBI build 34) on 9p21 that show nominally significant association to MI in the genome-wide association study. Results are shown for 1607 MI cases and 6728 controls from the Icelandic discovery cohort. Also included are the corresponding results if the association test is done adjusting for the observed association to the three SNPs, rs1333040, rs10116277 and rs2383207 (indicated in bold).

SNP	Allele	Position	Frequency		OR	P^a	OR ^b	P^b
			Controls	MI cases				
rs10757260	A	21943137	0.606	0.627	1.09	0.041	1.10	0.037
rs7041637	A	21951866	0.233	0.253	1.12	0.021	0.99	0.91
rs2811712	A	21988035	0.875	0.893	1.10	0.0076	1.16	0.022
rs3218018	A	21988139	0.879	0.896	1.20	0.0074	1.17	0.021
rs3217992	A	21993223	0.344	0.378	1.16	0.00055	0.98	0.75
rs2069426	C	21996273	0.881	0.897	1.18	0.0146	1.15	0.038
rs2069422	A	21998026	0.875	0.894	1.20	0.0059	1.17	0.018
rs2151280	T	22024719	0.464	0.486	1.09	0.038	0.96	0.43
rs1333034	A	22034122	0.875	0.893	1.19	0.0073	1.17	0.021
rs1011970	G	22052134	0.772	0.806	1.22	9.2×10^{-5}	1.14	0.020
rs10116277	T	22071397	0.418	0.468	1.22	1.9×10^{-6}	na	na
rs1333040	T	22073404	0.490	0.542	1.23	6.1×10^{-7}	na	na
rs2383207	G	22105959	0.455	0.506	1.22	1.4×10^{-6}	na	na
rs1333050	T	22115913	0.671	0.693	1.11	0.020	0.97	0.61

^a P value adjusted using genomic controls. ^b P value and OR adjusted for the observed association to rs1333040, rs2383207 and rs10116277.

Table 16: Association to MI. Shown is the association for the risk alleles of the three SNPs from the genome-wide study, rs1333040, rs2383207 and rs10116277, and the most significant refinement SNP, rs10757278, to MI in the combined Icelandic case-control group and in the three US case-controls groups.

Study population (n/m) ^a	Controls		Cases		OR (95% CI)	P
	AA/Aa/aa	Freq.	AA/Aa/aa	Freq.		
Iceland A (1607/6728)						
rs1333040 (T)	1770/3315/1636	0.490	342/783/478	0.542	1.23 (1.14-1.34)	6.1×10 ⁻⁷
rs2383207 (G)	2022/3280/1418	0.455	389/811/408	0.506	1.22 (1.13-1.33)	1.4×10 ⁻⁶
rs10116277 (T)	2305/3212/1208	0.418	454/805/350	0.468	1.22 (1.13-1.33)	1.9×10 ⁻⁶
rs10757278 (G)	592/869/318	0.434	413/770/376	0.489	1.25 (1.15-1.36)	1.5×10 ⁻⁷
Iceland B (665/3533)						
rs1333040 (T)	893/1750/889	0.499	135/312/188	0.541	1.18 (1.05-1.33)	0.0065
rs2383207 (G)	1016/1770/746	0.462	146/319/171	0.525	1.29 (1.15-1.45)	0.000026
rs10116277 (T)	1150/1770/602	0.421	178/317/148	0.480	1.27 (1.12-1.43)	0.00010
rs10757278 (G)	224/366/128	0.436	160/328/161	0.503	1.31 (1.16-1.47)	0.000014
Atlanta (596/1284)						
rs1333040 (T)	190/588/369	0.573	63/253/230	0.648	1.37 (1.19-1.58)	0.000016
rs2383207 (G)	273/603/381	0.541	100/270/206	0.593	1.23 (1.07-1.42)	0.0030
rs10116277 (T)	266/571/310	0.503	114/273/190	0.555	1.28 (1.12-1.47)	0.00041
rs10757278 (G)	341/618/287	0.484	119/291/175	0.551	1.31 (1.14-1.50)	0.00015
Philadelphia (582/504)						
rs1333040 (T)	80/225/172	0.585	55/263/232	0.661	1.38 (1.16-1.65)	0.00031
rs2383207 (G)	105/250/127	0.524	86/274/197	0.602	1.37 (1.16-1.63)	0.00026
rs10116277 (T)	120/222/125	0.505	86/262/178	0.587	1.39 (1.18-1.65)	0.00013
rs10757278 (G)	137/254/103	0.470	118/281/169	0.550	1.38 (1.17-1.64)	0.00019
Durham (1137/718)						
rs1333040 (T)	101/364/230	0.588	159/520/427	0.618	1.14 (0.99-1.30)	0.067
rs2383207 (G)	158/377/176	0.513	230/535/353	0.559	1.20 (1.05-1.37)	0.0060
rs10116277 (T)	168/368/174	0.504	256/526/334	0.534	1.13 (0.99-1.29)	0.076
rs10757278 (G)	189/370/134	0.460	261/545/304	0.521	1.28 (1.12-1.46)	0.00027
Combined						
Iceland^b (2274/10260)						
rs1333040 (T)	2663/5065/2525	0.493	477/1095/666	0.542	1.21 (1.14-1.30)	1.6×10 ⁻⁴
rs2383207 (G)	3036/5050/2164	0.458	535/1130/579	0.511	1.24 (1.16-1.33)	3.3×10 ⁻¹⁰
rs10116277 (T)	3405/4982/1810	0.419	632/1122/498	0.471	1.23 (1.15-1.32)	1.1×10 ⁻⁶
rs10757278 (G)	816/1235/446	0.435	573/1099/537	0.493	1.26 (1.18-1.35)	5.3×10 ⁻¹²
US groups^c (2315/2508)						
rs1333040 (T)		0.582		0.642	1.27 (1.17-1.39)	3.6×10 ⁻⁶
rs2383207 (G)		0.526		0.585	1.25 (1.15-1.36)	1.1×10 ⁻⁷
rs10116277 (T)		0.504		0.562	1.24 (1.14-1.35)	3.1×10 ⁻⁷
rs10757278 (G)		0.471		0.541	1.31 (1.21-1.43)	1.5×10 ⁻¹⁰
Replication groups^d (2980/8041)						
rs1333040 (T)		0.541		0.592	1.24 (1.16-1.33)	1.3×10 ⁻⁹
rs2383207 (G)		0.494		0.555	1.27 (1.18-1.38)	1.4×10 ⁻¹¹
rs10116277 (T)		0.463		0.521	1.25 (1.17-1.34)	1.3×10 ⁻¹⁰
rs10757278 (G)		0.454		0.522	1.31 (1.22-1.40)	1.0×10 ⁻¹⁴
All groups^{b,d} (4589/12768)						
rs1333040 (T)		0.538		0.592	1.24 (1.17-1.30)	4.1×10 ⁻¹⁵
rs2383207 (G)		0.492		0.548	1.25 (1.18-1.31)	2.0×10 ⁻¹⁶
rs10116277 (T)		0.492		0.548	1.24 (1.17-1.30)	1.8×10 ⁻¹⁵
rs10757278 (G)		0.453		0.517	1.28 (1.22-1.35)	1.2×10 ⁻²⁰

^a Number of MI cases (n) and controls (m). ^b When combining the Icelandic cohorts they are analysed together and the results adjusted for relatedness in the combined group. ^c For the combined groups OR and P value are calculated using a Mantel-Haenszel model and the frequency in cases and controls is a simple average over the frequency in the individual groups. ^d When combining Icelandic and US groups, the frequency in cases and controls is the average over the two populations.

Table 17: Genotype specific odds ratio.

The upper part shows the genotype specific odds ratios for the risk alleles of the three SNPs from the genome-wide study, rs1333040, rs2383207 and rs10116277, and the most significant refinement SNP, rs10757278, for all MI cases. Shown is the risk for heterozygous carriers (OX) and homozygous carriers (XX) compared to the risk for non-carriers (OO), together with 95% confidence intervals (CI). Also included is the population attributed risk (PAR). The lower part of the table includes the corresponding values when the analysis is restricted to early-onset MI cases.

Study population (n/m) ^a		Genotype specific Odds Ratio ^b			PAR ^c
Variant (allele)	OO	OX (95% CI)	XX (95% CI)		
Iceland^d (2272/10261)					
rs1333040 (T)	1	1.18 (1.05-1.32)	1.46 (1.28-1.68)	0.17	
rs2383207 (G)	1	1.26 (1.13-1.40)	1.53 (1.34-1.76)	0.19	
rs10116277 (T)	1	1.23 (1.11-1.37)	1.52 (1.32-1.74)	0.17	
rs10757278 (G)	1	1.25 (1.12-1.39)	1.58 (1.38-1.81)	0.19	
US groups (2315/2508)					
rs1333040 (T)	1	1.34 (1.18-1.55)	1.65 (1.38-1.97)	0.28	
rs2383207 (G)	1	1.18 (1.04-1.34)	1.54 (1.30-1.82)	0.19	
rs10116277 (T)	1	1.16 (1.03-1.31)	1.52 (1.29-1.79)	0.17	
rs10757278 (G)	1	1.28 (1.14-1.45)	1.72 (1.45-2.03)	0.23	
All groups (4587/12768)					
rs1333040 (T)	1	1.24 (1.14-1.35)	1.52 (1.37-1.69)	0.22	
rs2383207 (G)	1	1.22 (1.13-1.32)	1.54 (1.39-1.71)	0.20	
rs10116277 (T)	1	1.20 (1.11-1.30)	1.53 (1.38-1.69)	0.18	
rs10757278 (G)	1	1.26 (1.16-1.36)	1.64 (1.47-1.82)	0.21	
Early onset MI (< 50 for males; < 60 for females)					
Iceland^d (621/10261)					
rs1333040 (T)	1	1.28 (1.01-1.63)	1.94 (1.50-2.50)	0.27	
rs2383207 (G)	1	1.30 (1.04-1.62)	1.80 (1.40-2.32)	0.24	
rs10116277 (T)	1	1.32 (1.06-1.63)	1.86 (1.44-2.40)	0.24	
rs10757278 (G)	1	1.38 (1.13-1.69)	1.94 (1.53-2.46)	0.27	
US groups (1080/2508)					
rs1333040 (T)	1	1.58 (1.29-1.94)	2.00 (1.58-2.53)	0.38	
rs2383207 (G)	1	1.40 (1.16-1.67)	1.88 (1.52-2.33)	0.31	
rs10116277 (T)	1	1.50 (1.26-1.79)	1.90 (1.53-2.35)	0.32	
rs10757278 (G)	1	1.56 (1.32-1.85)	2.08 (1.69-2.58)	0.34	
All groups (1701/12769)					
rs1333040 (T)	1	1.46 (1.25-1.70)	1.95 (1.65-2.32)	0.34	
rs2383207 (G)	1	1.36 (1.18-1.56)	1.84 (1.56-2.17)	0.28	
rs10116277 (T)	1	1.43 (1.25-1.64)	1.87 (1.58-2.20)	0.29	
rs10757278 (G)	1	1.49 (1.31-1.69)	2.02 (1.72-2.36)	0.31	

^aNumber of MI cases (n) and control (m). ^bGenotype specific odds ratio for heterozygous (OX) and homozygous carriers (XX) compared to non-carriers (OO).

^cPopulation attributed risk (PAR). ^dFor the Icelandic groups, P values and OR were adjusted for relatedness using simulations.

Table 18: Association to age at onset of MI.

Shown is the association of the risk alleles of the three SNPs from the genome-wide study, rs1333040, rs2383207 and rs10116277, and the most significant refinement SNP, rs10757278, to age at onset of MI. The results are based on regressing the sex adjusted age at onset on the number of risk alleles an individual carries. The combined analysis is done by including a cohort indicator as a explanatory variable in the regression. All MI cases with known age at onset, including late-onset MI, from the four study groups are included in the analysis; this adds 973 MI cases to the study groups compared to the case-controls analysis.

Study population (n/m) ^a	Effect (s.e.m.)	P
Iceland (2896/750)		
rs1333040 (T)	-1.20 (0.31)	0.00012
rs2383207 (G)	-1.04 (0.31)	0.00080
rs10116277 (T)	-1.05 (0.31)	0.00069
rs10757278 (G)	-1.08 (0.31)	0.00042
Atlanta (611/40)		
rs1333040 (T)	-1.36 (0.69)	0.050
rs2383207 (G)	-1.16 (0.65)	0.075
rs10116277 (T)	-1.47 (0.64)	0.023
rs10757278 (G)	-1.35 (0.65)	0.038
Philadelphia (555/82)		
rs1333040 (T)	-0.85 (0.78)	0.28
rs2383207 (G)	-1.01 (0.76)	0.19
rs10116277 (T)	-1.01 (0.76)	0.18
rs10757278 (G)	-1.25 (0.74)	0.092
Durham (1213/101)		
rs1333040 (T)	-0.89 (0.46)	0.19
rs2383207 (G)	-1.11 (0.46)	0.017
rs10116277 (T)	-1.14 (0.46)	0.013
rs10757278 (G)	-1.19 (0.46)	0.0098
Combined		
US groups (2379/223)		
rs1333040 (T)	-0.97 (0.36)	0.0014
rs2383207 (G)	-1.09 (0.34)	0.0014
rs10116277 (T)	-1.19 (0.34)	0.00039
rs10757278 (G)	-1.26 (0.34)	0.00019
All groups (5275/793)		
rs1333040 (T)	-1.10 (0.23)	2.7×10^{-6}
rs2383207 (G)	-1.06 (0.23)	3.5×10^{-6}
rs10116277 (T)	-1.12 (0.23)	9.2×10^{-7}
rs10757278 (G)	-1.16 (0.23)	2.9×10^{-7}

^a n is the number of MI cases used in the regression and m is the number of MI cases used that were not included in the case-control analysis.

Table 19: Association to early-onset MI.

Shown is the association of the risk alleles of the three SNPs from the genome-wide study, rs1333040, rs2383207 and rs10116277, and the most significant refinement SNP, rs10757278, to early-onset MI in the combined Icelandic case-control group and in the three US case-controls groups. Early-onset MI is defined as a MI event before the age of 50 for males and before the age of 60 for females.

Study population (n/m) ^a	Controls		Cases		OR (95% CI)	P
Variant (allele)	AA/Aa/aa	Frq.	AA/Aa/aa	Frq		
Iceland^b (621/10281)						
rs1333040 (T)	2663/5065/2525	0.493	114/293/210	0.576	1.40 (1.24-1.57)	1.9×10 ⁻⁶
rs2383207 (G)	3038/5050/2184	0.458	133/310/176	0.533	1.35 (1.20-1.52)	3.4×10 ⁻⁷
rs10116277 (T)	3465/4982/1810	0.419	156/308/153	0.496	1.36 (1.21-1.53)	1.9×10 ⁻⁷
rs10757278 (G)	816/1235/446	0.435	142/299/166	0.518	1.40 (1.24-1.57)	3.5×10 ⁻⁶
Atlanta (305/1284)						
rs1333040 (T)	190/588/369	0.573	27/131/121	0.659	1.44 (1.20-1.74)	0.00011
rs2383207 (G)	273/603/381	0.541	45/145/105	0.600	1.27 (1.06-1.52)	0.0082
rs10116277 (T)	296/571/310	0.504	47/150/97	0.584	1.38 (1.16-1.65)	0.00035
rs10757278 (G)	341/618/287	0.484	53/161/86	0.558	1.35 (1.13-1.61)	0.00099
Philadelphia (211/504)						
rs1333040 (T)	80/225/172	0.585	17/102/83	0.661	1.38 (1.09-1.75)	0.0075
rs2383207 (G)	105/250/127	0.524	30/95/75	0.618	1.47 (1.17-1.85)	0.0011
rs10116277 (T)	120/222/125	0.505	27/97/66	0.593	1.42 (1.13-1.79)	0.0026
rs10757278 (G)	137/254/103	0.470	39/103/63	0.561	1.44 (1.15-1.81)	0.0017
Durham (564/720)						
rs1333040 (T)	101/384/230	0.588	64/249/234	0.651	1.31 (1.11-1.54)	0.0012
rs2383207 (G)	156/377/176	0.513	91/271/192	0.596	1.40 (1.20-1.64)	0.000026
rs10116277 (T)	166/366/174	0.504	97/278/178	0.572	1.31 (1.12-1.53)	0.00070
rs10757278 (G)	189/370/134	0.459	105/278/168	0.559	1.49 (1.28-1.75)	5.0×10 ⁻⁷
Combined						
US groups^c (1080/2508)						
rs1333040 (T)		0.582		0.657	1.37 (1.23-1.52)	1.6×10 ⁻⁶
rs2383207 (G)		0.526		0.605	1.37 (1.23-1.52)	4.8×10 ⁻⁶
rs10116277 (T)		0.504		0.583	1.36 (1.22-1.51)	9.5×10 ⁻⁶
rs10757278 (G)		0.471		0.559	1.43 (1.29-1.59)	1.7×10 ⁻¹¹
All groups^c (1701/12769)						
rs1333040 (T)		0.538		0.617	1.38 (1.28-1.50)	1.6×10 ⁻¹⁶
rs2383207 (G)		0.492		0.569	1.38 (1.26-1.47)	8.2×10 ⁻¹⁵
rs10116277 (T)		0.462		0.540	1.36 (1.26-1.47)	9.2×10 ⁻¹⁵
rs10757278 (G)		0.453		0.539	1.42 (1.31-1.53)	3.3×10 ⁻¹⁶

^a Number of MI cases (n) and controls (m). ^b For the Icelandic group the P value and CI are adjusted for relatedness using simulations. ^c For the combined groups, the frequency in cases and controls is a simple average over the frequency in the individual group or, when combining Icelandic and US groups, the average over the two populations.

Table 20: Association to coronary artery disease.

Association of the risk alleles of the three SNPs from the genome-wide study, rs1333040, rs2383207 and rs10116277, and the most significant refinement SNP, rs10757278, to coronary artery disease (CAD) in an Icelandic group of CAD patients and in groups of CAD patients from two of the US study groups. The study group from Durham does not include any CAD patients in addition to the MI patients and was excluded from this part of the analysis. Also included are the corresponding results if all known MI cases are excluded from the CAD patient group.

Study population (n ₁ /n ₂ /n) ^a	Controls		All CAD cases				Excluding MI cases			
Variant (allele)	AA/Aa/aa	Frq.	AA/Aa/aa	Frq.	OR (95% CI)	P	AA/Aa/aa	Frq.	OR (95% CI)	P
Iceland^b (1563/773/3533)										
rs1333040 (T)	893/1750/889	0.499	308/697/413	0.533	1.15 (1.05-1.25)	0.0020	152/328/192	0.527	1.12 (1.00-1.25)	0.057
rs2383207 (G)	1016/1770/746	0.462	353/732/387	0.513	1.23 (1.13-1.34)	2.2×10 ⁻⁶	186/353/185	0.500	1.17 (1.04-1.31)	0.0067
rs10116277 (T)	1160/1770/802	0.421	409/707/333	0.474	1.24 (1.14-1.35)	9.5×10 ⁻⁷	204/333/158	0.468	1.21 (1.08-1.35)	0.0010
rs10757278 (G)	224/368/128	0.439	393/745/376	0.496	1.26 (1.15-1.37)	1.9×10 ⁻⁷	203/365/188	0.490	1.22 (1.09-1.37)	0.00050
Atlanta (724/128/1284)										
rs1333040 (T)	190/588/369	0.572	75/310/281	0.649	1.38 (1.21-1.58)	2.4×10 ⁻⁶	12/57/51	0.655	1.42 (1.09-1.86)	0.010
rs2383207 (G)	273/603/381	0.541	117/335/249	0.595	1.25 (1.09-1.42)	0.00093	17/65/43	0.606	1.30 (1.00-1.69)	0.046
rs10116277 (T)	296/571/310	0.503	130/341/228	0.571	1.31 (1.15-1.50)	0.000038	16/68/38	0.598	1.47 (1.13-1.90)	0.0039
rs10757278 (G)	341/618/287	0.484	139/362/207	0.552	1.31 (1.15-1.50)	0.000036	20/71/32	0.557	1.34 (1.04-1.73)	0.026
Philadelphia (709/126/504)										
rs1333040 (T)	80/225/172	0.585	59/273/235	0.648	1.31 (1.11-1.55)	0.00170	24/49/47	0.588	1.02 (0.76-1.35)	0.92
rs2383207 (G)	105/250/127	0.524	89/285/200	0.600	1.36 (1.15-1.60)	0.00023	25/52/46	0.587	1.29 (0.98-1.71)	0.072
rs10116277 (T)	120/222/125	0.504	90/274/180	0.582	1.37 (1.16-1.61)	0.00017	26/52/43	0.566	1.23 (0.93-1.62)	0.14
rs10757278 (G)	137/254/103	0.470	146/339/208	0.547	1.36 (1.16-1.60)	0.00019	30/57/38	0.528	1.26 (0.96-1.66)	0.10
Combined										
US groups^c (1433/254/1788)										
rs1333040 (T)		0.579		0.649	1.35 (1.22-1.50)	1.9×10 ⁻⁶		0.621	1.23 (1.01-1.51)	0.044
rs2383207 (G)		0.533		0.598	1.29 (1.17-1.43)	9.8×10 ⁻⁷		0.597	1.30 (1.08-1.57)	0.0068
rs10116277 (T)		0.504		0.577	1.34 (1.21-1.48)	2.1×10 ⁻⁶		0.577	1.35 (1.12-1.63)	0.0018
rs10757278 (G)		0.477		0.550	1.33 (1.20-1.47)	2.7×10 ⁻⁶		0.542	1.30 (1.08-1.57)	0.0059
All groups^c (2996/1027/5321)										
rs1333040 (T)		0.539		0.591	1.22 (1.14-1.31)	3.2×10 ⁻⁹		0.590	1.14 (1.04-1.26)	0.0082
rs2383207 (G)		0.497		0.555	1.25 (1.17-1.34)	1.3×10 ⁻¹¹		0.565	1.20 (1.09-1.32)	0.00019
rs10116277 (T)		0.462		0.525	1.28 (1.20-1.37)	1.7×10 ⁻¹³		0.541	1.25 (1.13-1.37)	7.8×10 ⁻⁶
rs10757278 (G)		0.458		0.523	1.29 (1.21-1.38)	3.6×10 ⁻¹⁴		0.525	1.24 (1.13-1.37)	0.000011

^a Number of all cases (n₁), cases excluding MI patients (n₂), and controls (n). ^b Individuals used in the initial discovery group have been excluded both from cases and controls. ^c For the combined groups, the allelic frequency in cases and controls is a simple average over the individual groups or, when combining Icelandic and US groups, the average over the two populations.

Table 21: Markers correlated with the at-risk signal.

All SNPs in the LD-block (based on the HapMap v19 CEU dataset) that are correlated, with $r^2 \geq 0.5$, to at least one of the three SNPs, rs1333040, rs10116277 and rs2383207, together with the correlation coefficients D' and r^2 . Additional markers selected for typing on both the Icelandic and all the US case/control groups are indicated in bold italic.

SNP	Position ^a	Position ^b	Freq	rs1333040		rs10116277		rs2383207	
				D'	r^2	D'	r^2	D'	r^2
rs10811647	22055002	134856	0.449	0.95	0.49	0.92	0.70	0.92	0.62
rs10811650	22057593	137447	0.450	0.95	0.49	0.93	0.70	0.92	0.63
rs9632884	22062301	142155	0.521	0.96	0.65	1	0.93	0.93	0.84
rs10116277	22071397	151251	0.500	1	0.67	1	1	1	0.90
rs6475606	22071850	151704	0.500	1	0.67	1	1	1	0.90
rs1333040	22073404	153258	0.600	1	1	1	0.67	0.88	0.57
rs1537370	22074310	154164	0.500	1	0.67	1	1	1	0.90
rs7857345	22077473	157327	0.733	1	0.55	1	0.36	0.61	0.26
rs10738607	22078094	157948	0.504	1	0.69	1	1	1	0.90
rs10757272	22078260	158114	0.500	1	0.67	1	1	1	0.90
rs4977574	22088574	168428	0.500	1	0.67	1	1	1	0.90
rs2891168	22088619	168473	0.500	1	0.67	1	1	1	0.90
rs1537371	22089568	169422	0.500	1	0.67	1	1	1	0.90
rs1556516	22090176	170030	0.500	1	0.67	1	1	1	0.90
rs6475608	22091702	171556	0.737	1	0.54	1	0.36	0.8	0.25
rs7859727	22092165	172019	0.496	1	0.66	1	1	1	0.90
rs1537373	22093341	173195	0.500	1	0.67	1	1	1	0.90
rs1333042	22093813	173667	0.508	0.96	0.63	1	0.97	1	0.94
rs7859362	22095927	175781	0.525	0.88	0.57	1	0.90	1	1
rs1333043	22096731	176585	0.517	0.92	0.60	1	0.94	1	0.97
rs1412834	22100131	179985	0.525	0.88	0.57	1	0.90	1	1
rs7341780	22102241	182095	0.533	0.84	0.54	1	0.88	1	0.87
rs10511701	22102599	182453	0.533	0.84	0.54	1	0.88	1	0.97
rs10733376	22104469	184323	0.525	0.88	0.57	1	0.90	1	1
rs10738609	22104495	184349	0.525	0.88	0.57	1	0.90	1	1
rs2383206	22105026	184880	0.525	0.88	0.57	1	0.90	1	1
rs944797	22105286	185140	0.525	0.88	0.57	1	0.90	1	1
rs1004638	22105589	185443	0.525	0.88	0.57	1	0.90	1	1
rs2383207	22105959	185813	0.525	0.88	0.57	1	0.90	1	1
rs1537374	22106046	185900	0.525	0.88	0.57	1	0.90	1	1
rs1537375	22106071	185925	0.525	0.88	0.57	1	0.90	1	1
rs1333045	22109195	189049	0.548	0.68	0.37	0.92	0.69	0.85	0.65
rs10738610	22113766	193620	0.517	0.92	0.60	1	0.94	1	0.97
rs1333046	22114123	193977	0.517	0.92	0.60	1	0.94	1	0.97
rs10757278	22114477	194331	0.491	0.95	0.57	0.96	0.90	1	0.87
rs1333047	22114504	194358	0.492	0.96	0.58	0.97	0.90	1	0.88
rs4977575	22114744	194598	0.492	0.96	0.58	0.97	0.90	1	0.88
rs1333048	22115347	195201	0.508	0.96	0.63	1	0.97	1	0.94
rs1333049	22115503	195357	0.492	0.96	0.59	0.97	0.90	1	0.88

^a Base-pair location in NCBI Build 34, Build 35 and Build 36.

^b Position in SEQ ID NO:94 (LD block C09)

Table 22a: Association to MI for additional markers typed in the LD block C09.

Association to MI of the three SNPs from the genome-wide association study and of the 10 highly correlated refinement markers. The association is calculated for the combined Icelandic and US case-control groups with OR and P-values combined using a Mantel-Haenszel model. Also included are the corresponding adjusted P values for each marker when the association is tested conditional on the observed association of each of the other markers.

SNP	Allele	Position ^a	Frequency ^b		Unadjusted		Adjusted P values										
			Controls	Cases	OR	P	rs10811660	rs10116277	rs1333040	rs10738607	rs4977574	rs6475608	rs2383207	rs1333045	rs1333046	rs10757276	rs1333048
rs10811660	G	22057503	0.398	0.449	1.21	3.0×10^{-12}	na	0.79	0.10	0.43	0.47	1.6×10^{-6}	0.47	0.063	1.00	0.51	0.86
rs10116277	T	22071397	0.461	0.516	1.24	1.8×10^{-10}	1.2×10^{-4}	na	0.011	0.47	0.63	3.0×10^{-9}	0.20	0.0046	0.38	0.67	0.65
rs1333040	T	22073404	0.537	0.592	1.24	4.1×10^{-13}	6.6×10^{-6}	na	0.18	0.11	1.6 $\times 10^{-4}$	0.011	2.3×10^{-4}	0.027	0.15	0.050	
rs10738607	G	22078094	0.463	0.525	1.27	2.1×10^{-19}	6.2×10^{-5}	2.5×10^{-6}	4.2×10^{-8}	na	0.056	7.1×10^{-13}	2.8×10^{-4}	8.0×10^{-6}	0.0015	0.61	0.0079
rs4977574	G	22088574	0.465	0.525	1.27	1.1×10^{-13}	1.8×10^{-6}	1.8×10^{-4}	1.7×10^{-5}	0.43	na	2.7×10^{-12}	0.0021	7.3×10^{-6}	0.033	0.61	0.076
rs6475608	C	22091702	0.700	0.737	1.18	6.3×10^{-8}	0.058	0.52	0.84	0.71	0.72	na	0.70	0.83	0.93	0.73	0.93
rs2383207	G	22105959	0.492	0.549	1.25	2.0×10^{-16}	9.2×10^{-5}	0.017	3.8×10^{-4}	0.42	0.73	3.2×10^{-19}	na	0.0020	0.56	0.25	0.78
rs1333045	C	22109195	0.508	0.563	1.24	6.3×10^{-15}	3.4×10^{-5}	0.024	4.1×10^{-4}	0.92	0.85	1.2×10^{-6}	0.15	na	0.50	0.17	0.62
rs1333046	A	22114123	0.468	0.526	1.25	2.5×10^{-17}	6.2×10^{-7}	0.0036	1.5×10^{-4}	0.20	0.68	5.0×10^{-11}	0.038	5.0×10^{-4}	na	0.044	0.74
rs10757276	G	22114477	0.453	0.517	1.28	1.2×10^{-20}	4.8×10^{-10}	2.7×10^{-6}	4.8×10^{-7}	0.039	0.0041	5.0×10^{-14}	2.0×10^{-5}	2.6×10^{-7}	2.4×10^{-5}	na	1.1×10^{-4}
rs1333048	C	22115347	0.472	0.532	1.26	6.0×10^{-18}	1.6×10^{-7}	9.5×10^{-4}	4.6×10^{-4}	0.39	0.94	1.2×10^{-11}	0.017	2.4×10^{-6}	0.24	0.10	na

^a Base-pair location in NCBI Build 34. ^b The frequency in cases and controls is a simple average over the frequency in Iceland and in US.

Table 22b: Genotype count for additional markers typed in the LD block C09.

Genotype counts in cases and controls for the eight additional refinement SNPs typed in the LD block C09 and for the three SNPs from the genome-wide study, rs1333040, rs2383207 and rs10116277. Genotype counts are shown for the combined Icelandic case-control group (Iceland A+B) and for the three US replication cohorts. For each SNP counts are shown for the risk allele a and the wild type allele A.

SNP	Risk Allele	Position ^a	Iceland A+B		Philadelphia		Atlanta		Durham	
			Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases
			AA/aA/aa	AA/aA/aa	AA/aA/aa	AA/aA/aa	AA/aA/aa	AA/aA/aa	AA/aA/aa	AA/aA/aa
rs10811850	G	22057593	819/1015/279	652/878/336	143/193/74	107/239/119	293/394/147	165/271/133	202/380/112	344/527/222
rs10116277	T	22071397	3465/4982/1810	632/1122/498	120/222/125	86/262/178	296/571/310	114/273/190	166/366/174	256/526/334
rs1333040	T	22073404	2663/5065/2525	477/1095/865	80/225/172	55/263/232	190/588/369	83/253/230	101/364/230	159/520/427
rs10738607	G	22078094	1502/2326/933	558/1099/547	131/244/116	105/278/173	332/603/312	114/283/186	187/373/137	261/552/312
rs4977574	G	22088574	1507/2335/964	554/1105/566	130/246/119	103/286/180	332/597/325	115/274/188	187/383/144	267/549/316
rs6475608	C	22091702	235/980/1135	170/870/1069	36/200/250	26/199/342	101/476/616	24/210/330	58/276/353	67/415/588
rs2383207	G	22105959	3038/5050/2184	535/1130/579	105/250/127	85/274/197	273/603/381	100/270/206	156/377/176	230/535/353
rs1333045	C	22109195	610/1264/638	433/1102/855	115/262/114	95/289/180	286/605/347	93/290/200	159/378/169	218/548/345
rs1333046	A	22114123	1519/2266/959	583/1078/564	123/244/120	102/274/181	315/586/330	114/273/191	182/378/154	251/539/323
rs10757278	G	22114477	816/1235/446	573/1099/537	137/254/103	116/281/169	341/618/287	119/291/175	189/370/134	261/545/304
rs1333048	C	22115347	1372/2202/926	473/947/478	119/247/120	99/274/184	210/418/231	108/286/188	175/379/154	247/532/325

^a Base-pair location in NCBI Build 34.

Table 23: Primers in the AF109294 gene and ESTs used for PCR screening of cDNA libraries.

ESTs*	Forward primer	Reverse primer
AF109294	TTGGTGTCCATGCTGTGATGATT	GGTTGGGGACCCCTGGTGTA
CN277071	GGTCAAGCATCACTGTTAGGTGT	GAGGCGGGCGAATCACGA
AW169296	GCTCAGAGCAATTCCAGTGCAAG	GGTCCAGTCCTGGTTCTGC
BX100299	TCTCATTGGGGATACGAAGCTCT	TCTGGCCCTAGCCTCCATGT
ESTs*	Nested forward primer	Nested reverse primer
AF109294	AACTCCAAAGAAACCATCAGAGG	TGGGGACCCCTGGTGTAAGTG
CN277071	CTTTCCCGAGTCAGTACTGCTTTCT	CGGGCGAATCACGAGGTC
AW169296	TTCCAGTGCAAGTATGGTCTGTGA	CCAGTCCTGGTTCTGCCACA
BX100299	TCATTGGGGATACGAAGCTCTACA	CAGAAAGCTGCAAAGGCCTCA

ESTs* names are from NCBI Build 36.

Table 24. Expression analysis of ESTs and AF109294 in various cDNA libraries by PCR screening

ESTs	cDNA libraries						
	Whole blood	EBV transf. lymphoblasts	Whole heart	Aorta	Cardiac fibro-myocytes	Ventricular fibroblasts	Endothelial cells (HUVEC)
AF109294	positive	nd	nd	positive	positive	nd	nd
CN277071	positive	positive	nd	positive	positive	positive	positive
AW169296	positive	positive	positive	positive	positive	positive	positive
BX100299	positive	positive	nd	positive	positive	positive	positive

nd: not detected. positive: generated PCR products that were confirmed by sequencing

Table 25: Primers used for sequencing of *CDKN2A* and *CDKN2B*.

Primer alias	Forward primer	Primer alias	Reverse primer
CDKA.1e-f.F	AAAGAAGCCAGACACGGAAG	CDKA.1e-f.R	GTAAGTGAATCCAGCCAACC
CDKA.1f.F	GGATGAGGCAGCGTGGAC	CDKA.1f.R	AAGCCGTGTCTCAAGATCG
CDKA.1g.F	TCCGGTTTGGCAGCAGTC	CDKA.1g.R	CTAGCAAATGGCAGAACCA
CDKA.1h.F	CAACAGTGTGAGAAACGATGC	CDKA.1h.R	ATCAGTCACCGAAGGTCTTA
CDKA.3b.F	CTTGATCTCCCAAAGTGAAGG	CDKA.3b.R	CGACTCTGGAGGACGAAGTT
CDKA.4d.F	AGATCTCGGAACGGCTCT	CDKA.4d.R	GAGGCGTGCAGCGGTTTA
CDKA.4e.F	GGAAGAAAGGAAAGCGAGGT	CDKA.4e.R	CGGGATCAAGGGGAGTCG
CDKA.4f.F	TCTTCGCGTAGAATGGTTGT	CDKA.4f.R	AGCCCGCGAGGTTTAGGAC
CDKA.4g.F	CCTGAGCGCGGTCTAAGC	CDKA.4g.R	CGTTTTGTCTTGGGTTTGTACC
CKDN2A.1.F	CCCCCTTCAGATCTTCTCAGC	CKDN2A.1.R	AGCACCGGAGGAAGAAAGAG
CKDN2A.2.F	CCCGCACCTCCTCTACCC	CKDN2A.2.R	AGTGAACGCCTCAAACACG
CKDN2A.3.F	TTGGCAAGGAAGGAGGACTG	CKDN2A.3.R	TACCAGGCAATGTACACGTG
CKDN2A.4.F	GGTTCCTAAGTCAGAAACCCCTAGT	CKDN2A.4.R	AGCTTAGGATGTGTGGCACT
CKDN2A.5.F	AGTCTTCATTGCTCCGCAGT	CKDN2A.5.R	GACACGCTGGTGGTGCTG
CKDN2A.6.F	ATCTATGCGGGCATGGTTAC	CKDN2A.6.R	ACAGTGCTCTCTGCCTGTGAC
CKDN2A.7.F	CAAAATGCTTGTCTATGAAGTCG	CKDN2A.7.R	GTGAAGCCATTGCGAGAA
CKDN2A.8.F	TTTCAATCGGGGATGTCTGC	CKDN2A.8.R	CCAAGTGAAGTCAATTATATAACTCGTT
p14.1.F	ATTCACCCAGGATATTCG	p14.1.R	GGTCCAGTCTGCAGTTAAG
p14.2.F	CTGCGCACCATGTTCTCG	p14.2.R	CGAGCAGCACCAGAATCC
CDKB.06.F	CCCTACTGACTATTACATATCAATGC	CDKB.06.R	CAGAAAATTAATATAOCTGTAAAGTTCC
CDKB.07.F	TTTTAACCATTTAAGGCATAGGA	CDKB.07.R	GCAAAOCTCAAACATTATTGG
CDKB.08.F	CTGCTGATGAAACAGCTAAACC	CDKB.08.R	GCACTCAATCATTAGAGGCTACA
CDKB.09.F	TCTTGGAATTTAAGATATAGAGGTCAA	CDKB.09.R	TGCACAAAGAAATGCATCTAGT
CDKB.10.F	GTTAGAGAAAGAAAGCCACCTTAG	CDKB.10.R	ACAAGTCATTTGAGAGTGGAGAC
CDKB.11.F	AACATATGCTCTGATTCTCAACTAAC	CDKB.11.R	GGGATTTAATTTCCAGGGTTG
CDKB.12.F	CAAACATTGAGAGAAGGGAACC	CDKB.12.R	GGAAGAACTACAGCTCTTAAATGTAGC
CDKB.13.F	TCTGCACCCTGAGACACTCTA	CDKB.13.R	GGAGACCCTCGCCCAACT
CDKB.14.F	TAAGAGCAAAGGCCAGCATCC	CDKB.14.R	CACTCACCATGAAGCGAAAC
CDKB.15.F	TAATCACTGCCTTCTCCCACTC	CDKB.15.R	GGAGGGCTTCCTGGACAC
CDKB.16.F	GGGTGGGAAATTGGGTAA	CDKB.16.R	GGAAAGTGGATTGCATCAGC
CDKB.17.F	GGCAGGTATGGGAGATGC	CDKB.17.R	TCTCCCTAAACCATTACTCC
CDKB.23.F	ACAATACACAGATTTCAATATAGTAGCTTAG	CDKB.23.R	TAGTGGAGAAGGTGCCACAG
CDKB.24.F	TAGGTTCCAGCCCGATCC	CDKB.24.R	GGCTGGCTCCCACTCTG
CDKB.25.F	TTCTGGCGCTCAAGAACC	CDKB.25.R	CAGAAGGGAGCCACCAAC
CDKB.26.F	CACTGCCCTCAGCTCCTA	CDKB.26.R	CCTGACAAAGTGGGTTTAAATAGGT
CDKB.27.F	TGCATTATGGATACAACCCCTTA	CDKB.27.R	TCTTCTCAGCACTCCGAAC
CDKB.28.F	CGGATGCTACATTGGATAGG	CDKB.28.R	GGCTCAAGAATTGGGTCA
CDKB.29.F	GAAGGGAAACCGGTAGCA	CDKB.29.R	CCATAATGTCTTTCTATTTGACG

Table 26: Sequencing variants in *CDKN2A* and *CDKN2B*.

Shown are all SNPs identified through sequencing of *CDKN2A* and *CDKN2B* for 93 early onset MI cases using primers in Table 25. Many of the SNPs identified in the sequencing effort are rare, and have low correlation with rs10757278. These SNPs cannot account for the correlation of rs10757278 to the disease. Two common SNPs, rs3217992 and rs2069416 have modest correlation with rs10757278 ($r^2 = 0.36$ and 0.37 respectively). rs3217992 is a part of the Illumina Hap300 chip. For Iceland A, rs10757278 gave a P value of 1.5×10^{-7} , while rs3217992 gave a P value of 5.4×10^{-4} . Hence rs3217992 cannot account for the association of rs10757278. Neither can rs2069416 since it is highly correlated with rs3217992 ($r^2 > 0.8$ both in HapMap CEU and Iceland). SNP rs1063192, which has r^2 of 0.23 with rs10757278 in these sequenced individuals, is also an Illumina SNP and did not even show nominal significance in Iceland A ($P > 0.05$). Rs2069418 is highly correlated with rs1063192.

MAF ^a	A	B	Position ^b	Position ^a	rs names	D ^c	r ² ^c	Location
CDKN2A								
0.069	A	G	21058159	38013	rs3088440	0.5	0.02	Exon3
0.176	C	G	21058199	38053	rs11515	0.44	0.03	Exon3
0.005	C	T	21900074	40528		1	0	Intron2
0.042	T	C	21900916	40770	rs3731249	1	0.04	Exon2
0.005	A	G	21961188	41042		1	0	Exon2
0.01	G	C	21964859	44713	rs1800586	1	0.01	Exon1
0.356	C	T	21965017	44871	rs3814960	0.18	0.02	5'UTR
0.042	A	T	21965319	45173	SG09S293*	1	0.04	5'UTR
0.036	T	C	21965561	45415	rs3731238	1	0.03	5'UTR
0.057	A	C	21965807	45651	SG09S291*	0.49	0.01	5'UTR
0.094	C	T	21983964	63818	rs2811711	0.42	0.02	5'UTR
CDKN2B								
0.005	A	G	21957014	36888		1	0.01	3'UTR
0.01	A	G	21957207	37061		1	0.01	3'UTR
0.01	G	T	21957291	37145		1	0.01	3'UTR
0.005	C	A	21957479	37333		1	0.01	3'UTR
0.005	G	C	21957838	37692		1	0.01	3'UTR
0.071	A	G	21958159	38013		0.33	0.01	3'UTR
0.38	G	A	21984218	44072	rs3731239	0.41	0.13	3'UTR
0.005	G	C	21964355	44209		1	0.01	3'UTR
0.01	G	T	21985044	64899		1	0.01	3'UTR
0.005	T	C	21985467	65321		1	0.01	3'UTR
0.323	T	C	21985882	65738	rs2518723	0.29	0.07	3'UTR
0.422	T	C	21993223	73077	rs3217992	0.78	0.36	Exon2
0.388	G	A	21993387	73221	rs1063192	0.53	0.23	Exon2
0.005	C	A	21993417	73271		1	0	Exon2
0.005	C	T	21993591	73445		1	0.01	Exon2
0.078	G	T	21995330	75184	rs3217986	0.58	0.03	Exon2
0.005	C	G	21995493	75347	rs3217984	1	0.01	Exon2
0.104	T	G	21996273	76127	rs2080426	0.08	0	Intron1
0.005	A	G	21996303	76157		1	0.01	Intron1
0.104	T	C	21996348	76202	rs974336	0.08	0	Intron1
0.005	G	A	21996538	76390		1	0.01	Intron1
0.382	G	C	21999898	79552	rs2069418	0.55	0.23	5'UTR
0.011	G	A	21999916	79709		1	0.01	5'UTR
0.005	T	C	21999953	79807		1	0.01	5'UTR
0.1	del	A	21999996	79850	rs2069417	0	0	5'UTR
0.395	A	T	22000004	79858	rs2069416	0.8	0.37	5'UTR
0.089	G	A	22000412	80266	rs495490	0.03	0	5'UTR
0.021	A	G	22000681	80535	SG09S492*	1	0.02	5'UTR
0.005	C	G	22001083	80937		1	0.01	5'UTR

MAF ^a	A	a	Position ^b	Position ^c	rs names	D' ^c	r ² ^c	Location ^d
0.005	C	G	22001158	81012		1	0.01	5'UTR

^a MAF ; minor allele frequency.

^b Base-pair location in NCBI Build 34.

^c Correlation to the refinement SNP rs10757278 based on the 93 sequenced MI cases.

^d Position in SEQ ID NO:94 (LD Block C09).

*Alternate names used herein for non-public SNPs

Table 27: SNPs in conserved TF bindings sites within the MI region.

SNP		TF binding site			LD to rs1333040		
Name	Location	TF Name	Start	End	D'	r ²	P
rs16935754	22002235	PAX2	22002234	22002253	nd	nd	nd
rs36113513	22023540	FOXO4	22023540	22023551	nd	nd	nd
rs35834365	22023550	FOXO4	22023540	22023551	nd	nd	nd
rs17694493	22031997	STAT	22031995	22032004	0.41	0.05	0.03
rs1412830	22033611	FOXO4*	22033601	22033615	nd	nd	nd
rs1412830	22033611	FOXO3*	22033601	22033615	nd	nd	nd
rs4977758	22108480	EV11	22108480	22108496	nd	nd	nd
rs34974971	22126835	EV11	22126830	22126839	nd	nd	nd
rs6475610	22131893	AREB6	22131892	22131905	0.11	0.01	0.36
rs10757289#	22150453	MRF2	22150444	22150458	0.14	0.02	0.22
rs10757289#	22150453	SEF1	22150452	22150471	0.14	0.02	0.22
rs1679013	22196986	BACH1	22196977	22196992	0.01	0	0.86
rs1679014	22197036	PAX6	22197025	22197046	0.21	0	0.57
rs10965286	22205659	GATA6	22205657	22205667	1	0.01	0.31
rs7043065	22323165	OCT1	22323163	22323176	nd	nd	nd
rs1969926	22347344	SOX9	22347334	22347348	nd	nd	nd
rs10113901	22364031	HNF1	22364024	22364039	0.06	0	0.64
rs7046709	22366969	MEF2	22366953	22366975	0.13	0.01	0.34

All coordinates are for human genome release 17 (build 35).

*Two related TFs recognize the same motif.

A SNP lands in two partially overlapping TF binding sites.

LD between SNPs and the rs1333040 is summarized by D', r² and a P value determined by Chi-square tests the CEU hapmap sample. nd: Measures of LD could not be ascertained for SNPs not represented in the CEU hapmap.

Table 28

Shown are all SNP association results from sequencing of CDKN2A and CDKN2B using primers in Table 25 and association results for early onset MI cases and controls.

location ^a	rs names	Allele	RR	#aff	aff.freq	#con	con.freq	p-value	Variation
21958158	rs3088440	A	0.7284	118	0.080508	674	0.107567	0.194719	G/a
21958199	rs11515	C	1.0349	118	0.161017	668	0.158437	0.858926	G/c
21960916	rs3731249	T	1.4053	119	0.037815	680	0.027206	0.384391	C/t
21964218	rs3731239	A	1.0712	96	0.518782	87	0.603448	0.748682	A/g
21965017	rs3814960	C	0.8697	118	0.347458	686	0.379738	0.34197	T/c
21965319	SG09S293	A	1.4498	119	0.037815	682	0.026393	0.344886	T/a
21965561	rs3731238	T	1.2498	120	0.033333	689	0.026851	0.582384	C/t
21965807	SG09S291	A	1.7884	120	0.058333	687	0.033479	0.077647	C/a
21983984	rs2811711	C	0.8304	119	0.088235	675	0.103704	0.458559	T/c
21985802	rs2518723	T	1.0818	65	0.323077	49	0.306122	0.784909	C/t
21993223	rs3217982	T	1.3279	96	0.421875	88	0.354651	0.188816	C/t
21993367	rs1063192	A	1.27	93	0.602151	80	0.54375	0.273278	A/g
21995330	rs3217985	T	1.1274	96	0.821875	88	0.912791	0.753194	T/g
21998273	rs2069426	T	1.0602	96	0.104187	86	0.098837	0.666531	G/t
21998348	rs974336	T	1.0078	96	0.104187	87	0.103448	0.982048	G/t
21999098	rs2089418	C	1.4107	93	0.61828	87	0.534483	0.107509	G/g
22000004	rs2069416	A	1.6529	93	0.387097	85	0.276471	0.026841	T/a/g
22000004	rs2069418	T	0.6509	93	0.509892	85	0.670568	0.050387	T/a/g
22000004	rs2069416	G	0.804	93	0.043011	85	0.052941	0.880944	T/a/g
22000412	rs495490	A	1.2051	95	0.910526	85	0.894118	0.600156	A/g
22000681	SG09S492	A	3.587	94	0.021277	83	0.006024	0.208723	G/a

^alocation applies to NCBI build 34. Allele: the allele shown is the one tested for association to myocardial infarction. RR is the relative risk. #aff: number of affected individuals. Aff.freq: frequency of allele in affected individuals. #con: number of controls. Con.freq.: frequency of allele in controls. Variation*: Shown are the alleles of the SNPs with major allele shown with capital letters.

Table 29: Association to atherosclerosis in other vascular beds.

Shown is the association of the SNPs, rs1333040, rs2383207 and rs10116277 to peripheral artery disease (PAD), abdominal aorta aneurysm (AAA), and to large vessel disease stroke (LVD).

Study population (n/m) ^a Variant (allele)	Frequency		RR (95% CI)	P
	Controls	Cases		
Iceland PAD (1504/3533)				
rs1333040 (T)	0.499	0.503	1.01 (0.93-1.11)	0.75
rs2383207 (G)	0.462	0.461	1.08 (0.99-1.18)	0.082
rs10116277 (T)	0.421	0.438	1.07 (0.98-1.17)	0.12
Emory PAD (34/1284)				
rs1333040 (T)	0.573	0.721	1.92 (1.12-3.30)	0.017
rs2383207 (G)	0.541	0.692	1.91 (1.15-3.17)	0.012
rs10116277 (T)	0.504	0.676	2.08 (1.25-3.39)	0.0044
Iceland LVD (154/3533)				
rs1333040 (T)	0.499	0.527	1.12 (0.87-1.44)	0.39
rs2383207 (G)	0.462	0.488	1.11 (0.88-1.41)	0.38
rs10116277 (T)	0.421	0.457	1.16 (0.91-1.48)	0.24
Iceland AAA (287/3533)				
rs1333040 (T)	0.499	0.572	1.34 (1.12-1.60)	0.0012
rs2383207 (G)	0.462	0.536	1.35 (1.13-1.61)	0.00073
rs10116277 (T)	0.421	0.485	1.30 (1.08-1.54)	0.0035

^a Number of cases (n) and controls (m). ^b Individuals used in the initial discovery group have been excluded both from cases and controls. ^c For the combined groups, the allelic frequency in cases and controls is the weighted average over the individual groups.

Table 30: Association of refinement markers to MI, early-onset MI and AAA in Iceland.

Shown is the association to MI, early-onset MI and AAA case-control groups for 10 of the markers included in Table 23b. All tests use the same set of 10260 controls.

5

SNP	Allele	Position	MI (2270/10260)				Early-onset MI (621/10260)				AAA (323/10260)				CAD* (508/10260)			
			Con.frq	Case.frq	OR	P	Con.frq	Case.frq	RR	P	Con.frq	Case.frq	RR	P	Con.frq	Case.frq	RR	P
rs10116277	T	22071397	0.419	0.471	1.23	3.2E-10	0.419	0.496	1.36	1.3E-07	0.419	0.488	1.32	6.0E-04	0.419	0.456	1.16	0.024
rs1333040	T	22073404	0.493	0.541	1.21	6.7E-09	0.493	0.576	1.40	1.3E-08	0.493	0.579	1.41	2.7E-05	0.493	0.519	1.11	0.130
rs10738807	G	22078084	0.441	0.497	1.25	8.4E-12	0.441	0.521	1.38	4.0E-08	0.441	0.522	1.38	5.8E-05	0.441	0.474	1.14	0.043
rs4977574	G	22088574	0.444	0.499	1.25	2.0E-11	0.443	0.522	1.37	8.3E-08	0.444	0.527	1.39	3.8E-05	0.443	0.474	1.13	0.056
rs6475608	C	22091702	0.683	0.709	1.13	1.7E-03	0.689	0.737	1.26	6.3E-04	0.693	0.752	1.35	1.8E-03	0.696	0.722	1.14	0.110
D9S1870	X	22093010	0.440	0.490	1.22	2.5E-09	0.441	0.513	1.34	1.2E-06	0.441	0.507	1.31	1.2E-03	0.441	0.471	1.13	0.073
rs2383207	G	22106959	0.458	0.511	1.24	6.5E-11	0.458	0.535	1.36	1.4E-07	0.458	0.537	1.38	7.4E-05	0.458	0.487	1.13	0.066
rs1333045	C	22109195	0.503	0.551	1.21	2.9E-08	0.506	0.575	1.32	3.5E-06	0.508	0.580	1.34	4.2E-04	0.508	0.554	1.20	0.007
rs1333046	A	22114123	0.439	0.494	1.24	4.8E-11	0.440	0.518	1.37	8.3E-08	0.442	0.528	1.42	1.7E-05	0.440	0.472	1.14	0.053
rs10757278	G	22114477	0.435	0.492	1.26	2.8E-12	0.434	0.518	1.40	1.2E-08	0.436	0.522	1.41	1.8E-06	0.435	0.474	1.17	0.016

* Known cases of MI are excluded from the CAD cases. * For the microsatellite D9S1870, all alleles smaller than 2 have been combined in to a composite risk allele X.

Table 31. Amplimers for non-public SNPs identified in table 26.**SG09S293**

5 GGAAGCAGCCCTCGCCAGAGCCAGCGTTGGCAAGGAAGGAGGACTGGGCTCCTCCCCACCTGCC
 CCCCACACCGCCCTCCGGCCTCCCTGCTCCAGCCGCGCTCCCCCGCCTGCCAGCAAAGGCGTG
 TTTGAGTGCCTTCACTCTGTTAAAAAGAAATCCGCCCGCCCGCTTTCCTTCCTCCGCGATACAA
 CCTTC[C/T/a]AACTGCCAAATTGAATCGGGGTGTTTGGTGTATAGGGAAAGTATGGCTTCTTCT
 TTTAATCATAAGAAAAAGCAAACCTATTCTTCTAGTTGTGAGAGCCCCACCGAGAATCGAAATC
 10 ACCTGTACGACTAGAAAGTGTCCCCCTACCCCTCAACCCTTGATTTTCAGGAGCGCGGGGTTCA
 CTAAGTCAGAAACCCTAGTTCAAAGGA

SG09S291

ATTGGAAGGACGGACTCCATTCTCAAAGTCATAATTCCTAGACCAGAAAAAGTGCTCAGTGTTCTA
 15 GAAGCAGAGTTG[C/a]ACAGTGATCCAAAGACCAGCTTCAAATACTGTCTCTCTTACACT
 TCTCACATTTCTCTTCTACTGAAAAATACCTTGCATTTTCGTAATTATAAAGGGGAAGGGAATA
 TGAGTGCCCCCTGCTTTATAGGGGTGTTGTGAGTTTAAATGATGTATTAATACATATAAGCCTTAA
 GAACAGTGCCACACATCCTAAGCTAATACCTGTTAGCTCTTGAATTATCCGCTTTGAGGACTGGCT
 20 TGCAATCTGTTTTGAGGCATAGAAAGAAAATGCTTTGGAGCAGGACGCGGTGGCTCACACCTGT
 AATCCAGCACTTTGGGAAGCCGAGGCGGGCA

SG09S492

TGAATCAACATTTATTACTTAAAAATATTTAAAAACATTTACGCGGATGCTACATTGGATAGGAAGAGA
 ACCGCAAGTTATGGATTTGTTGCCTAAAAACTTTGGTGAGGAACTGCATAAGTGGACCTCTCCTAA
 25 AAGTGAACAaTTTTTGTTFACAGAAATCATTTTGGTTCGGAGTGCTGAGGAAGACAAAGTCTTAACA
 GGAGGGCAATTGCTTGTGTATTGCAAAATGAGAGTCTTACATGTTTTTTTAGGATACCTTAGCT
 CTGACTCCTCATCCCCCAAATCCCTGTAGAATTAAAAAAAgCTTTTCTTTTAAAGGCAGTGGAAGT
 GCCACCACCATGGAAGTGCTGGTTAGGGCTGAAAATCTACTGACAGAGCCTCAACAGAGCTGAAA
 TCCACCTGGACAGG[G/a]AAGGGAACCGGGTAGCATTATAACAATTTCTTTTCTTTCCCATCC
 30 AACCCCCATTTCTAGTCTTCAGTTTCTTAATTTCTCTACCTTTTACTCTTATGCTCTTGTTTGACC
 TTTGAGTTTCTCTGAACTTATCAGAAAAGTTAGGACAAGATAGTCTGACCCAATTCTTGAGCCATT
 TTCTTAGGTAGTAAATATGTCAGAAAAATGAAAGCTGTTTGGAGTTGATAAGGAAATGGAAGATAA
 TGTTTTTCTTTGAGGGgGACATAAAGAATGGTGATAGGGAAAGAACCAATGACTAAGTAAATGAC
 TGAGAATCTTGACGAGGCAGATGTGTGAGCTTCGCGAAGCAAGTTGACTGAATGAAAAACAAT
 35 TTGGGTAGGGAAAACGTTGCCGGGGGCATTCGC

Table 32: Association between rs10757278 allele G and arterial diseases

Phenotype	Frequency		OR (95% CI)	P
	Study population (n/m)	Controls		
Abdominal Aortic Aneurysm (AAA)				
Iceland (14259/398)	0.437	0.515	1.37 (1.18-1.58)	2.6 × 10 ⁻⁶
Belgium (267/176)	0.527	0.574	1.21 (0.92-1.58)	0.18
Canada (150/206)	0.470	0.533	1.29 (0.96-1.74)	0.097
Pennsylvania, US (447/101)	0.468	0.549	1.39 (1.02-1.89)	0.037
The Netherlands (915/476)	0.461	0.529	1.31 (1.12-1.53)	0.00078
UK (252/478)	0.470	0.545	1.35 (1.09-1.68)	0.0064
New Zealand (442/588)	0.474	0.530	1.25 (1.05-1.50)	0.012
All groups (16732/2836)			1.31 (1.22-1.42)	1.2 × 10 ⁻¹²
Intracranial Aneurysm (IA)				
Iceland (14259/170)	0.437	0.514	1.36 (1.10-1.69)	0.0048
The Netherlands (915/844)	0.461	0.516	1.24 (1.08-1.43)	0.0029
Finland (307/320)	0.400	0.469	1.33 (1.06-1.66)	0.015
All groups (15481/1134)			1.29 (1.16-1.43)	2.5 × 10 ⁻⁶
Peripheral Artery Disease (PAD)				
Iceland (14259/1764)	0.437	0.473	1.16 (1.07-1.25)	0.00014
Italy (181/179)	0.510	0.499	0.96 (0.71-1.29)	0.78
Sweden (143/206)	0.427	0.507	1.38 (1.02-1.87)	0.036
New Zealand (463/450)	0.474	0.491	1.07 (0.89-1.29)	0.47
All groups (15025/2599)			1.14 (1.07-1.22)	6.1 × 10 ⁻⁵
LAA /Cardiogenic Stroke				
Iceland (14259/415)	0.437	0.473	1.16 (1.00-1.34)	0.046
Sweden (734/290)	0.433	0.488	1.15 (0.95-1.39)	0.16
All groups (15012/705)			1.15 (1.03-1.28)	0.015
Coronary Artery Disease (CAD)^a				
Iceland (14259/3051)	0.437	0.492	1.25 (1.17-1.32)	1.9 × 10 ⁻¹²
Atlanta (1246/840)	0.478	0.544	1.30 (1.15-1.48)	0.000033
Philadelphia (447/724)	0.467	0.547	1.38 (1.17-1.63)	0.00017
Durham (614/1201)	0.455	0.521	1.30 (1.13-1.50)	0.00018
All groups (16566/5539)			1.28 (1.22-1.34)	1.2 × 10 ⁻²³

Association results for rs10757278 allele G for the arterial diseases: AAA, IA, PAD, combined LAA (Large Artery Atherosclerotic)/cardiogenic stroke, and CAD, and for T2D, in several study populations. Also included are the results for each phenotype after combining the study populations using a Mantel-Haenszel model. Number of controls (n) and cases (m) is shown. The results for the Icelandic population are adjusted for relatedness of the individuals.

^aThe results presented for CAD have been published previously¹ (apart from the Icelandic control group that has been increased) and are presented here for comparison of the results with the other arterial phenotypes.

Table 33. Association between rs10757278 allele G and arterial diseases after excluding known CAD cases from the sample sets

Phenotype	Frequency		OR (95% CI)	P
	Study population (n/m)	Controls Cases		
Abdominal Aortic Aneurysm (AAA)				
Iceland (14259/190)	0.437	0.503	1.30 (1.06-1.60)	0.013
Belgium (267/156)	0.527	0.573	1.20 (0.91-1.60)	0.200
Pennsylvania, US (447/62)	0.469	0.513	1.19 (0.82-1.74)	0.36
The Netherlands (915/380)	0.461	0.517	1.25 (1.06-1.48)	0.0087
UK (252/220)	0.470	0.536	1.31 (1.02-1.70)	0.038
New Zealand (442/360)	0.474	0.516	1.18 (0.97-1.44)	0.097
All groups (16639/2017)			1.25 (1.14-1.37)	3.0 × 10 ⁻⁶
Peripheral Artery Disease (PAD)				
Iceland (14259/732)	0.437	0.463	1.12 (1.00-1.25)	0.055
Italy (181/113)	0.509	0.488	0.92 (0.66-1.28)	0.62
New Zealand (463/326)	0.474	0.491	1.07 (0.87-1.31)	0.51
All groups (14882/1171)			1.09 (0.99-1.20)	0.075
LAA/Cardiogenic Stroke				
Iceland (14259/278)	0.437	0.458	1.09 (0.92-1.30)	0.32
Sweden (734/213)	0.433	0.467	1.15 (0.92-1.42)	0.22
All groups (14993/491)			1.11 (0.97-1.27)	0.12

Association results are shown for rs10757278-G for the arterial diseases: AAA, IA, PAD, combined LAA (Large Artery Atherosclerotic)/cardiogenic stroke, after excluding cases with known CAD. Number of controls (n) and cases (m) is shown. The results for the Icelandic population are adjusted for relatedness. No information on CAD was available for the AAA group from Canada and the PAD group from Sweden. Those study groups were excluded from this analysis. Information on the occurrence of CAD among the AAA cases was available for 97% (466 out of 479) of AAA cases from UK, 86% (87 out of 101) of cases from Pennsylvania, 45% (79 out of 176) of cases from Belgium, 69% (330 out of 476) of cases from The Netherlands, and 98% (575 out of 588) of cases from New Zealand. Among those with this information, the frequency of CAD amongst the AAA subjects was 52% in the UK group, 48% in the Pennsylvania group, 29% in the Belgium group, 29% in the Dutch group and 40% in the group from New Zealand.

Table 34: Genotype specific odds ratio for rs10757278 for abdominal aortic aneurysm and intracranial aneurysm

Study population (n/m)	Genotype Specific Odds Ratio		
	AA	AG (95% CI)	GG (95% CI)
Abdominal Aortic Aneurysm (AAA)			
Iceland (14259/398)	1	1.22 (0.95-1.56)	1.85 (1.39-2.45)
Belgium (287/176)	1	1.42 (0.91-2.20)	1.52 (0.87-2.66)
Canada (150/206)	1	1.04 (0.69-1.57)	1.62 (0.90-2.91)
Pennsylvania, US (447/101)	1	2.00 (1.17-3.44)	2.06 (1.06-4.03)
The Netherlands (915/476)	1	1.43 (1.12-1.84)	1.76 (1.28-2.43)
UK (252/478)	1	1.60 (1.19-2.15)	1.95 (1.26-3.03)
New Zealand (442/588)	1	1.22 (0.94-1.58)	1.50 (1.04-2.17)
Combined (16732/2836)	1	1.36 (1.21-1.52)	1.74 (1.49-2.02)
Intracranial Aneurysm (IA)			
Iceland (14259/170)	1	1.39 (0.96-2.02)	1.80 (1.24-2.93)
The Netherlands (915/644)	1	1.34 (1.08-1.66)	1.61 (1.20-2.16)
Finland (307/320)	1	1.45 (1.08-1.98)	1.79 (1.12-2.86)
Combined (15481/1134)	1	1.38 (1.18-1.63)	1.72 (1.39-2.13)

Genotype specific odds ratios for rs10757278 for AAA and IA cases versus controls. Shown is the risk for heterozygous carriers (AG) and homozygous carriers (GG) compared to the risk for non-carriers (AA), together with 95% confidence intervals (CI). Results are shown for the AAA case-control groups from Iceland, Belgium, Canada, Pennsylvania, US, UK, The Netherlands and New Zealand and for all the groups combined and for the IA case-control groups from Iceland, The Netherlands and Finland. Number of controls (n) and cases (m) is shown. Tests of heterogeneity showed no significant difference in the genotype specific odds ratio between the different study groups. For AAA, $P_{het} = 0.38$ and $P_{het} = 0.95$ for the AG and the GG genotype, and for IA, $P_{het} = 0.91$ and $P_{het} = 0.81$.

Table 35: Correlation between growth rate of AAA and genotypes for rs10757278 from the UK Small Aneurysm Trial

Genotype of rs10757278	n	Mean baseline diameter (mm)	Linear growth rate (mm/year)	Mean difference (95%CI)
AA	79	45.3	3.20	0.03 (-0.38-0.41)
AG	214	44.8	3.15	reference
GG	107	44.7	2.53	-0.46 (-0.93-0.00)

Linear growth rates were determined as previously described¹⁸. At least three AAA diameter measurements and growth rate were available for 400 patients who had been genotyped for rs10757278 and n is the number of individuals with the different genotypes. The largest group (AG) was set as the reference group and then the growth rates in the other genotype groups were compared with the mean of the reference group. This leads to estimation of the mean difference [95%CI] of the growth rates in the homozygous groups. The analysis of the average difference was adjusted for age, sex, smoking status, baseline diameter and curvature in growth pattern. In this cohort there were 24 ruptured AAA; 6 with the AA genotype, 14 with AG, and 4 with GG.

Table 36: Association of SNPs in chromosome 9p21 region to MI in African-Americans. We tested 9 SNPs for association with MI in African Americans. These SNPs included 2 SNPs from the genome-wide scan on MI in Icelanders (rs10116277 and rs2383207) and rs10757278, which showed strongest association with MI in Caucasians, as well as six other SNPs that were correlated with rs10757278 in Caucasians. As shown in the Table all, SNPs have greater frequency in cases compared to the control groups and the odds ratios are comparable to that for Caucasians.

SNP	Allele	Position	Combined ^a		Philadelphia (93/139)				Durham (252/243)				Cleveland (46/81)				Atlanta (81/357)			
			RR (95CI)	Pa	Con.frq	Case.frq	OR	P	Con.frq	Case.frq	RR	P	Con.frq	Case.frq	RR	P	Con.frq	Case.frq	RR	P
rs8181050	A	22054391	1.30 (0.91-1.86)	0.14	0.921	0.920	0.99	0.98	0.912	0.926	1.20	0.43	0.897	0.913	1.34	0.51	0.934	0.957	2.08	0.075
rs10116277	T	22071397	1.37 (1.05-1.80)	0.022	0.888	0.893	1.05	0.89	0.870	0.901	1.35	0.13	0.896	0.891	1.39	0.41	0.866	0.934	1.82	0.049
rs10738607	G	22078094	1.12 (0.92-1.35)	0.27	0.238	0.290	1.31	0.22	0.233	0.254	1.12	0.43	0.228	0.244	1.09	0.77	0.226	0.220	0.97	0.87
rs4977574	G	22088574	1.20 (0.97-1.48)	0.096	0.175	0.250	1.57	0.051	0.184	0.204	1.13	0.430	0.160	0.163	1.02	0.95	0.173	0.187	1.10	0.68
rs2383207	G	22105959	1.34 (1.03-1.74)	0.027	0.881	0.877	0.96	0.88	0.872	0.906	1.43	0.078	0.877	0.880	1.04	0.83	0.888	0.945	2.18	0.015
rs1333045	C	22109195	1.22 (1.04-1.43)	0.014	0.455	0.497	1.18	0.38	0.472	0.525	1.24	0.093	0.416	0.435	1.08	0.78	0.472	0.544	1.33	0.094
rs1333046	A	22114123	1.19 (0.99-1.44)	0.068	0.227	0.294	1.42	0.11	0.257	0.291	1.18	0.24	0.204	0.213	1.06	0.88	0.240	0.258	1.10	0.61
rs10757278	G	22114477	1.19 (0.98-1.45)	0.08	0.183	0.257	1.54	0.059	0.194	0.223	1.20	0.250	0.160	0.152	0.94	0.88	0.187	0.198	1.07	0.74
rs1333048	C	22115347	1.16 (0.96-1.40)	0.12	0.277	0.301	1.13	0.57	0.288	0.321	1.17	0.25	0.251	0.304	1.30	0.37	0.283	0.303	1.10	0.61

^a Results for the four African-American cohorts are combined using a Mantel-Haenszel model. Shown is the association to MI in four African-American MI case-control groups for 9 markers in the chromosome 9p21LD-block (LD Block C09). These SNPs are correlated in Caucasians. The markers include 2 SNPs from the genome-wide scan (rs10116277 and rs2383207) and rs10757278 that showed strongest association with MI in Caucasians, and six other correlated SNPs.

Table 37. Key to sequence listing.

Sequence	SEQ ID NO:
rs7041637	1
rs3218020	2
rs3217992	3
rs1063192	4
rs2069418	5
rs2069418	6
rs573687	7
rs545226	8
rs10811640	9
rs10811641	10
rs2106120	11
rs2106119	12
rs643319	13
rs7044859	14
rs10757264	15
rs10965212	16
rs1292137	17
rs10811644	18
rs7035484	19
rs10738604	20
rs615552	21
rs543830	22
rs1691136	23
rs7049105	24
rs679038	25
rs10965215	26
rs564398	27
rs10115049	28
rs634537	29
rs2157719	30
rs2151280	31
rs1006878	32
rs1555515	33
rs1333037	34
rs1360590	35
rs1412829	36
rs1360589	37
rs7028570	38
rs944801	39
rs10965219	40
rs7030641	41
rs10120688	42
rs2184061	43
rs1537378	44
rs8181050	45
rs8181047	46
rs10811647	47
rs1333039	48
rs10965224	49
rs10811650	50
rs10811851	51
rs4977756	52
rs10757289	53
rs9632884	54
rs1412832	55
rs10116277	56
rs10965227	57
rs6475006	58
rs1333040	59
rs1537370	60

rs7857345	61
rs10738607	62
rs10757272	63
rs4977574	64
rs2891168	65
rs1537371	66
rs1556516	67
rs6475608	68
rs7859727	69
rs1537373	70
rs1333042	71
rs7859362	72
rs1333043	73
rs1412834	74
rs7341786	75
rs10511701	76
rs10733376	77
rs10738609	78
rs2383206	79
rs944797	80
rs1004638	81
rs2383207	82
rs1537374	83
rs1537375	84
rs1333045	85
rs10738610	86
rs1333046	87
rs10757278	88
rs1333047	89
rs4977575	90
rs1333048	91
rs1333049	92
rs1333050	93
LD Block C09	94

SEQUENCE LISTING

<110> daCODE Genetics

<120> GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE

<130> 2507-PC00

<160> 94

<170> PatentIn version 3.4

<210> 1

<211> 201

<212> DNA

<213> Homo sapiens

<400> 1

tttcgcaatg	cttatttttca	atctcttcag	aaatgcctta	aagatattaa	tgagagtaac	60
aacttaaatct	caaatagtaa	tccatagaca	gaatatgtaa	magcaatgtt	ctctgatctg	120
ttctttggct	tctattccct	agagaaatag	ttctctaaga	ccaaacagtc	tatagataga	180
attgtagcaa	cagtcaatta	t				201

<210> 2

<211> 201

<212> DNA

<213> Homo sapiens

<400> 2

gtggagagaa	aatgattata	ctttgagcta	tatggctcca	ataaacaag	atagatccct	60
caatttaaat	ttgatcctca	gaaaactgag	ggtcagagaa	yccctcaggc	atgacgggat	120
aatgtgacag	ttaatttggg	atgtcaactt	ggctaggctg	tggtaccag	tgtttgagtc	180
aaacaccagt	ctaatatttg	c				201

<210> 3

<211> 201

<212> DNA

<213> Homo sapiens

<400> 3

agtactatat	tacactgttt	tttttggttg	ttttgttagt	tttttttatt	taaagcaaac	60
ctcaaacatt	attgggtatc	aattaccacc	tggttgtatt	raaatagtaa	cttatcaatg	120
ccatgtaaaa	attaattoca	ttttcgaagc	cacctggcag	acagggttag	ctgtttcatc	180
agcagcctaa	tatatactgt	t				201

<210> 4

<211> 201

<212> DNA

<213> Homo sapiens

<400> 4

cattatactg	ggtcattgaa	aattatccct	tgaatagat	atgaacatg	ttacttcatt	60
tctgggttaa	alaacttggt	gaatctttcc	taatgacaac	ytgatattaa	gggaaactaa	120
agaaaatggt	attgtggatc	ccacagtact	atattacact	gttttttttg	tttgttttgt	180
tagttttttt	tatttaaagc	a				201

<210> 5

<211> 201

<212> DNA

<213> Homo sapiens

<400> 5

tgatacaagt	tatgaasactt	gtgaagccca	agtaactgct	ggggatgaat	ttaacttgta	60
tgacaggtgc	agagctgtcg	ctttcagaca	tcttaagaaa	sacggagtta	ttttgaatga	120
ctttctctcg	gtcacaaagg	agccaccaac	gtctccacag	tgaaaccaac	tggttggtgt	180
aaggaacaga	aatcctctgc	t				201

<210> 6
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 6
 aaatcaaaaat aagatccctg acaaaagtggg tttaaatagg taagagtgca aacaaagatt 60
 tactgtacaa atatgatga actgggatct cagattctta hagtataatt tttttttgtc 120
 ttatgtgtgc cagggtgcca ctctcaatct cgaactagtt tttttctctt ttaaggggtg 180
 tatccataat gcaaaaatgg a 201

<210> 7
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 7
 gtccaagaca aatgtgctat tgtattacat gtgaaatgtc atctttgaag tctggtaagg 60
 gtgtgctgtg aggtgagcca tctggaaac acagtgtaga ytgaanaata attataagcc 120
 agttttattac ttttttccag ttaagcctac catgacagct gclaaaaaaa acactatgta 180
 gtataaaggg taaaaagac c 201

<210> 8
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 8
 ggggtgcagg ttgttgggtt gccacactt cttcttgcgg caattgacag cataggggtg 60
 caggagagca tagcgttat gccagatcat cttgtttcag ytgatttct aggtgagctg 120
 gaagagtga ggctcaataa tgccaacctg cagggtgcagc accaggtgcg ggggtgggctg 180
 tttctggacg ttgtagtctg a 201

<210> 9
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 9
 tcttaatttt tacacatttt acttttcatt tctttttaa ctgttattaa taattttatc 60
 atttgaataa ggattaaaat aaggetagga tattgaaatt ygttgaaatt gctacagtct 120
 cttgtatctc tctctctctc tttttttct tataagggac aggtttcatt caccttgtcg 180
 accaggtcgg agtgcaatac t 201

<210> 10
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 10
 tgtgattcta gcagccatgg ataattttt catagattat tttttcttg gggatggcaa 60
 aatggtgata ttctaatttt actattcctt catttactag stggaatgtc tttttaaatt 120
 atttatttat ttatttatta ttgagacag agtcttgac tgtcaccacg gctggagtgc 180
 agtgggtgtga tcatagctca c 201

<210> 11
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 11
 tgcgcgcctc ggcctcccaa agtgctggga ttacaggcgt gagcoactgc gcctcgccaa 60
 ctcccttatt ttaaagtcca tttccocta aaaataaaac magtaattct ttgaanaaa 120
 gttaatatta tglataggac tggagata taagataaaa otggaatata ttgtcatacc 180
 agaaatcaaa gattttgtca a 201

<210> 12
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 12
 attactgatg tgacaaggta cacaaagccaa tgttgacata atgttttcaa aatgggggtgt 60
 ctgctgtaac tgaactaaat ataataactt tattcaagaa ygagtttcaa tgataggaca 120
 aaacttgata aaatgaataa ataataatt atatgccaga gttcagtaaa ccctgtgtgt 180
 acacctgaaa aagctcaaac t 201

<210> 13
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 13
 gaacagagca gaagagagtc tggatacaca aatttcacaa ttattggctc ccatcaacat 60
 atctaactca agcataaagt tgtttcagca gtagttaaag yttggttact aatgcaacac 120
 ctctttgcat gcaatggccc attaaattat ctccaacttt aaaagggtcc tttgttttta 180
 aatgcttata atgaacaaat a 201

<210> 14
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 14
 tatgtgatgt aaagagcgcc aacatgttta tatcctccta ttccaatcta cttttacttc 60
 atctacattt ttagcaataa tgtgaacatg aatctctgaa waattagcta tetgtaatat 120
 atttactcat ccaactcaaaa tattgagccc cccaataaa tatcatacac tatattctag 180
 gtacagggtga taacaattc a 201

<210> 15
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 15
 ccagtgaag tttagagagag gggctctagag ctccagggagg agtgtgtatc cctaatttag 60
 actaatttgc attaacagct gtagttaatgc aattttctct xtactgaaat gcagacattt 120
 gagtatagaa aattagcaga catttgaata tagaagaaag atttacttte cttcagaaaa 180
 agaatagtag agtataaaga a 201

<210> 16
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 16
 tcgtgccact gcactccagc ctgggtgagt tgagagtcgg tatcaaaagc aaacctacac 60
 atttttgttg cctgttttta gctctatcaa gtcagttaca wtcttctgta ttctagcttt 120
 tttatctgta agtcctgca atgctttatt agaattttta gttcctttgc attttgttac 180
 aacatactcc tataactctg c 201

<210> 17
 <211> 169
 <212> DNA
 <213> Homo sapiens
 <400> 17
 taaaagaaaa aataatccaa atgtcagaaa cctcaaaagt tgaaggtaga tgagcccaca 60
 aggataagaa ataactcagca caagaacact gaaaactcaa wacatcacct ctctggcaag 120
 cgttcagtac caggctgagg ctgagatggc tgaaatgata gaagcagaa 169

<210> 18
 <211> 201

```

<212> DNA
<213> Homo sapiens
<400> 18
caagaccact ctgcagatat caagtctgaa aattccccta gggccaaagt ctattatggg    60
agcaagttga gcctagaggg atcgccatcc ctgtccatgc wctgtctgtag acactcctgc    120
actaaacctt ctgggctcca catcagctgg ctgtctgtct taccactttg cttgtctctt    180
gggggctcca cccagagag a                                     201

<210> 19
<211> 201
<212> DNA
<213> Homo sapiens
<400> 19
gtctcttggg ggctccaccc cagagagatg tgggtcagca atcattcagt tcaatcagcc    60
caggatggag agtctgtgct atgggcccac gccaggggct stctgtcttg tgacgagcag    120
ctgggggggtg ggttgggacc tgtgggagat ggactggcct cctctccttg agtcaactgc    180
tgcttatttg aggtgtggat g                                     201

<210> 20
<211> 201
<212> DNA
<213> Homo sapiens
<400> 20
ccattgcaga ggtagtggca gagaggcttt cagttgtccg tggcggctct gtccagggag    60
ttgctgagtt gctattggct tgatatctct ggtgggggtg rgctagaggt ccaggcctgg    120
aggacctgct cgttgaagag atgtgggaat gggcaccac ataacagtc gttcactttt    180
ccatagggct gctgtagtat g                                     201

<210> 21
<211> 201
<212> DNA
<213> Homo sapiens
<400> 21
ggggagctta agcaggggtg gaaggggaac cccagcacag aacagctgcc cgacaaaaat    60
gtggccacac tgcttttttt ttttttttag caggtcccca xtcccgttcc tcatcaactg    120
gtagagtctc ccactctggg tccccggcta cccaactgg tgttctctga ctgagagagg    180
tttcagactt ccattgggacc t                                     201

<210> 22
<211> 201
<212> DNA
<213> Homo sapiens
<400> 22
tgggcaaaag tagctgcgac tttggcaaag ctggaggtta gacccccaaa cataccccag    60
gaggttagac tccatacat accccagaaa agaggetgaa wccagcgaga tcagcagaga    120
aggtctacag gccccacttc cacagcgctt cacaggataa gacccactgg cttggaattc    180
cagctagcca ccagtagcaa c                                     201

<210> 23
<211> 201
<212> DNA
<213> Homo sapiens
<400> 23
aagtggtaag tgaatgcgca actctgggaa tccacactgc tctcacagat ctttgcaaac    60
ctcagatcag gagatccctt tgtgaactca ctccattagg sccttcacac acagccactg    120
ggagtctcag cagagcagcc actcaggcat gcatggagac ccaagagctt tagctactcc    180
agctttcttg gtgtctgggc a                                     201

<210> 24
<211> 201
<212> DNA

```

<213> Homo sapiens
 <400> 24
 cttaacagca aagtatcaga ttcatTTata aaacaatgtg actgatcttt atgtatgggt 60
 tgtgaacat ttatgcagtg tcaattcaga aaactctgcc rttatagatt tgaattgatt 120
 aaggatatcc actcctttcc ttggcatgat acaaatAaat tactaaagta taattgtaac 180
 aatgataaat ataagtgaca a 201

<210> 25
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 25
 caccctttgg ggaaggggat caaaatctag tgattttcta attctaagat tegtctctgtg 60
 tatattagct gctattcttc tagaaagaag actttcacca ycgTcccttg gatttttttt 120
 tttattttt gtatggttta aattgcatca tcattctttt tgatgtccaa attgtcccaa 180
 attaagccag ttagagaanc a 201

<210> 26
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 26
 taatgggatt cctgatggaa tgtttagtct gaatctaact acatagagac ttgtctgaca 60
 aatccagatt ttttggatgt ttTgcaggac tatttgcac racatttcaa aggattccaa 120
 gagagaatat tggTgtccat gctgtgatga ttcctcagct cctctcatct gatctccgtc 180
 ctggcccccA tgactttctt t 201

<210> 27
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 27
 ctcttctttt atcacacaga cctgaaagat gatggtttcc oaaacagcac ttacagcaat 60
 aggtgtgggc ctCagtggca cataccacac cctaactacc rcaagaaag tcatgggggc 120
 caggacggag atcagatgag aggagctgag gaatcatcac agcatggaca ccaatattct 180
 ctcttggAat cctttgaaat g 201

<210> 28
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 28
 caaatctttc cctaagggag atttcagatg aggccccag ccttggtaga caccttgatt 60
 gcagtcttgt gagagattgt gaagcagagc tattctcaga rttcatgggt gttttaagct 120
 atgaggtttt ttttgggggg agaattgtca tttgtgattc agctctacat aagtctacaa 180
 aagtcattcc agaagtgatt c 201

<210> 29
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 29
 tggggctcac aaccacatga ttctacctc actgaatcac ttctggaatg acttttgtag 60
 acttatgtat agctgaatca caaatgacca ttctccccc maaaaaacc tcatagctta 120
 aaacaccat gaattctgag aatagctctg cttcacaatc tctcacaaga ctgcaatcaa 180
 ggtgtctacc aaggctgggg g 201

<210> 30
 <211> 201
 <212> DNA
 <213> Homo sapiens

<400> 30
 tttttatagt gtgactcatt tacatatgca tgtgtatgtt taggtgctat tattaaattt 60
 tgctggcata tagtgaggaa attgtgatlc aaattcgtcc xtatgtactc ctccccacc 120
 atctgtctctg cccctccatt taccagaagg ctagectttag ctacttgtgc atgtaaaaca 180
 gaagcaagca acactgtgaa a 201

<210> 31
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 31
 gaacatagat actccttcat tcctgtattg tctatgggtg agtcctttatt acaacagcag 60
 agatgagtag ttgtgacaga aactcgatgg cctcgaagag ygaaacaagc tactatcagg 120
 acctctatag aaaaagtttg ccaacctcta cactgtagta tgcottaagg atttttagaa 180
 gattgagtat gataaacact t 201

<210> 32
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 32
 gaagggatga tcagtccttc cctcctctat tttcttgagc cccgtttllo acottttcttt 60
 ttctctctcc tttcttatca tgaagaataa agacaaatga kaacagatct accttaggct 120
 gatacagggc aggggaatcca ttttaatasta aaacgtgggt caaaattcac tttctctctt 180
 ttgaattgaa atttatattg g 201

<210> 33
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 33
 atttgatgca acctacacac tgttggtata cctctagaat taaaatgaca attttttaaa 60
 taattttggg gggcctagat ttgctattta acctatcaaa raattgtgtc ttacaglatt 120
 attaaaatgt agtgtgtataa gacttatact attgggtcota agcactactg gttgttttag 180
 gctttttctc tttctctgta g 201

<210> 34
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 34
 acatttatat aattaagatg ctaacactga ctgacagaaa tgtcagtaag atgaaatcag 60
 actgcatggg agttttatgt tacattaatt tgtaaattgt xtatctctgt attcatgtga 120
 gtgtggctat catgatgta gacatccagc tacaaggag gcattcgtgc acacacacag 180
 tctccaatct tctgtttacc t 201

<210> 35
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 35
 tagacaaagt ttaatgttcc cttttatatg ttttcctggg aaacaaaaat tgtctcaggg 60
 ttattatgca tatatgatat tgtcaagaaa ctttctgggt xctgtggggc aaagtcttct 120
 ccataaataa gctagggttg attggagttt toactttgaa aaatatcgca caggaggatc 180
 lcaacagcta gacaatttcc a 201

<210> 36
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 36

```

aaattaaatg acatacgtta agtccctcaat aaataatagc tcttattacc attgctatgg      60
ttactatcac tatttctgtta ttttcttttg ccattccctca ygcttgaata tgaatctcat      120
gggtagagtt tcccaaagca tgatatgtgt agtactacta aaggcaagat tttgggtgca      180
tacagacaaa aaaataattt a                                     201

```

```

<210> 37
<211> 201
<212> DNA
<213> Homo sapiens
<400> 37

```

```

aaaccagagg agtaaaattc tactttcacc agtaattagc agtgtggagt tgagttaata      60
aacctctcta agtctcagtt tctacatcta cttaaactta rcaaattcaa aacagtgatt      120
atttcattag attagatatt ttgattagtc ttaaattgct aatatataat aaacactcaa      180
caggtagtag ctattctatg t                                     201

```

```

<210> 38
<211> 201
<212> DNA
<213> Homo sapiens
<400> 38

```

```

tcattttcttc ttttaaggtc ttaatttctt gtttttcgag tttcatggga gatatccagt      60
caccaatcca atccatatcg gggaaaagta caacaaatga rtgaaatttg taaccaacct      120
tggatgatgg aataagacat ttgggagaac acaggagaag tggggagggt aaggagggat      180
agctctgtga aaattttgca t                                     201

```

```

<210> 39
<211> 201
<212> DNA
<213> Homo sapiens
<400> 39

```

```

aactaattct ccaaatttgc aatttggcag cactctactg ggactctaga aggctgataa      60
atcatggaga gtaggtattc atataggaac tatgaaagct statgtagta aacactactt      120
aagaaggcct tacatttcac aaaaagttag agatttttgt ggagactcat aaaatgcacg      180
ctttatatca gtgaagtttt t                                     201

```

```

<210> 40
<211> 201
<212> DNA
<213> Homo sapiens
<400> 40

```

```

actcgtagcc agagctacct tccagatgac ttctttctac cactttcttt ctccccagtg      60
taagagaatg caagtatatg ctgatgtttg gagcaagaac xttcaaaaat tttcttatta      120
acataacttc taatggaaat acagtatact actatggtgc atacaanga gaaatagcaa      180
catatatattg ttttagacct g                                     201

```

```

<210> 41
<211> 201
<212> DNA
<213> Homo sapiens
<400> 41

```

```

ataagcagcc ttaaattaaa aaaaaaaaaa ttaactcata actaactgtg tgacctggga      60
taagttactg accctcttta gggcttaggg tctaactctg yaaaacggaa attataataa      120
taaccttagc tagcatttct tgtgcacata ctataagctg gtgataaaca atttatacac      180
actatctcat ttaactctca c                                     201

```

```

<210> 42
<211> 201
<212> DNA
<213> Homo sapiens
<400> 42

```

```

tccaatgcas aagaataata ggagcaaaag cacagtgggt agaaattgga ggggaactgt      60

```


gaaaattgcc	acatagatta	gagggcaggaa	aataaaggac	rgctaagttt	atatagtgaa	120
cagtgaagc	catggacaca	ggtagactgtt	ttctcctttt	tgaacccctg	cttaactcag	180
agtcaccacc	tctcttggt	t				201

<210> 43

<211> 201

<212> DNA

<213> Homo sapiens

<400> 43

tattctgagt	attaattcct	gtttccaaat	agattactct	tttaaacata	gcactactac	60
ttacctaatg	aaatttagtt	gctattaatg	gatgaatttt	ktatctaaca	ggcttgattt	120
tgattatgca	ttttaaatgt	cagtcagaca	catattaata	atgatccatg	tttgtagcta	180
ataggcccaa	tatatacttt	t				201

<210> 44

<211> 201

<212> DNA

<213> Homo sapiens

<400> 44

gtaagggtcg	ggacaaataa	acacaagtaa	ttttcaaata	tattaataat	aatattctga	60
gtattaatcg	ctgtttccaa	atagattact	cttttaaaaca	yagcactact	acttacctaa	120
tgaattttag	ttgctattaa	tggatgaatt	ttgtatctaa	caggcttgat	tttgattatg	180
catttttaaat	gtcagtcaga	c				201

<210> 45

<211> 201

<212> DNA

<213> Homo sapiens

<400> 45

tggtaggtcct	aaagtggcat	taaggagcca	ataaattgtc	attectacct	tagctctgtg	60
tcagatgaaa	tacacagcat	agtgtgggga	gaaaatgttg	rgcttatttg	ggatggggtc	120
tttcacataa	aggaagaagg	tttcagaagg	catagtggta	tgaasagagg	agaaaccaa	180
gggaggaagg	tcaataaagg	g				201

<210> 46

<211> 201

<212> DNA

<213> Homo sapiens

<400> 46

cagcatagtg	tggggagaaa	atgttgggct	tattggggat	ggggtctttc	acataaagga	60
agaaggtttc	agaaggcata	gtggtatgaa	aagaggagaa	rccaaagggg	ggaaggtcaa	120
taaagggtta	agaacgagg	gaggcaaatt	gactttcttt	cagcatatga	ggattatagg	180
aatgggaacc	ttaattggaa	t				201

<210> 47

<211> 201

<212> DNA

<213> Homo sapiens

<400> 47

gaggatttaa	tgcaattggt	tgtgggaaag	cactttaaca	actctaaatt	acgatataata	60
tgctagggtt	tattgttacc	cacaccttg	atgtatttct	stttgtactc	ttcactgtat	120
ctgtaacaca	ttccctagga	taattagggc	taccttttaa	caaagccaag	attctattta	180
tagtggttaag	ctggcacctg	g				201

<210> 48

<211> 201

<212> DNA

<213> Homo sapiens

<400> 48

cttctgctat	tgaacgaact	ttttgttaag	gtagctccca	agcaggttca	gtagctttgt	60
tctattatca	cttttctact	gacagtgatt	tttttctctt	saaggcctgg	gacatggaga	120

ctgctttttct gcagaascca cctcccttgg agtaalgagc tacacctacc tcaattattc 180
 agtgcagtag aacactccag g 201

<210> 49
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 49

acattgtgca catgtacct agaacttaaa gtataataat aaacaaasaa aaccactgca 60
 caactcttag tattcagatg gagactaagc atgatttttc wtataaaaga gcagatcaga 120
 atgttgtatc ttttattcag aagactggag ttaatcactg ttatcttttag tacttagtgc 180
 tgccaaggct gtgtgttcac a 201

<210> 50
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 50

acagagtgtc tatttaaaaga aaaaataaaaa gaacacacac acacacgcac gcacacacac 60
 acgcacgcac acacacacac atgtagctac atgtctagga rggatgtgga gagctgaaat 120
 atgaaggcaa antaaacac ctttttcaaa gtatacagcc tacagtgggt agcacagagc 180
 tggccacata gcagggggtt c 201

<210> 51
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 51

caataatgta gaagcaaaaga gcctaaagtg ttttcataaa tcttaagtgg tagctttatg 60
 ttccagttca gcaaaacaca aattttgaagg caatctgtac rttagggttc aggtgaagaa 120
 ggcaaaaggaa tcaatgaaat tgtaaaagct ttccaaattt gcctttttct ttaagattgt 180
 ctttctctca ttctcttctc c 201

<210> 52
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 52

tttctgtagc agaagtgtaa ggggtgttact cgtaggaggc ctotattgaa ctcttttcca 60
 gtgacgtagt gtgtggtctt taagtggctt tgcaatgata rtaagatcag cattgcatta 120
 ctgaatgagc tcttttagta aacgtggata tgtgctttct gaatctattt gtttgttttt 180
 cccaagtcat aaacagtga t 201

<210> 53
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 53

ccatttagag tacttgcttc tgagggaaat aaaaatttgc tagcaatttt ctctaaatga 60
 cattatcata ggcacttaat tcttgatag gttcttttag rtaatttttt tataatgaag 120
 caattaattt gattcacgaa agtaagtttc tagtttatat aaagaccaga tctggcctat 180
 ttcttagctt gtctacattt g 201

<210> 54
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 54

tgctagcaat tttctctaaa tgacattatc ataggcactt aattccttga taggttcttt 60
 tagataattt ttttataatg aagcaattaa ttgattcac saaagtaagt ttctagttta 120

tataaagacc agatctggcc tatttcttag ctgtctaca tttagagtag tccattgctg 180
gaaaatgacc ctggagcttt t 201

<210> 55

<211> 201

<212> DNA

<213> Homo sapiens

<400> 55

aagttgctct caacatactt aaggttttcc aataactgaa ttaaatatca gtttatcagt 60
ttaatatata caattagggg aatgaaaaat aaattttcag ycttttggtt ccattagcca 120
tggttcaggga gcagaatagc cacctgaggg tagtgacaac gcttttggtt cacaggaaag 180
aagaaaaaaa atcaaaataa t 201

<210> 56

<211> 201

<212> DNA

<213> Homo sapiens

<400> 56

ttataactaa tgaggcaatg tgtottgagt attttgaatt aactctctag aatcgattct 60
tgaggaggtt atttactttg aagtgatgga cagagtgtag kagatttatg agtgaactct 120
tgtctgattt ggaaatatag agttgttttag gctagggtatt accaaccctt agttgacact 180
tgagtcacct aagttcttct c 201

<210> 57

<211> 201

<212> DNA

<213> Homo sapiens

<400> 57

tattagttgt gtaactctga aaaaatctct gacacttttc cctctgactc agtttcccca 60
tctggcacc c aatcttttcc agtggttatga aaataggga raatgtagaa aggaagaaca 120
tggaacccaa tcttaaatgg acactcagtg aaagctggct atcatcatca tttttggggt 180
tgttgtgttc tacaatgtat t 201

<210> 58

<211> 201

<212> DNA

<213> Homo sapiens

<400> 58

tccccatctg gcaccacaac ttttacagtg ttatgaaaaa tagggaaaat gtagaaagga 60
agaacatggc acccaatcct taatggacac tcagtgaag ytggtatca tcatcatttt 120
tggtgtgtgt gtgttctaca aatgtatttt ccaggaggt ttttttactc tgtctcctct 180
ttccttcata taccctcagc c 201

<210> 59

<211> 201

<212> DNA

<213> Homo sapiens

<400> 59

tgggaaggat gaattaatgg gatggagtg aggggatgca gagtgcacc tttatggaatg 60
atttcattca agagagacag gagggtcaga ggtaagaatg ytaccgctgg gacagagagg 120
aaggtacaga tatgagatat ggtaagaagg tatactacaa cagtggctcc caaatctcaa 180
tgagtagcca gttctcatgg a 201

<210> 60

<211> 201

<212> DNA

<213> Homo sapiens

<400> 60

tttgagccca agtctctttc tgactctagg cttagagctt tagggctatt tcacaaaagg 60
gctgttctta ggtcaggcat gacaacttct atattacctt ygtaaaagaa gcaatataat 120
ctaccactat taaattttgc aggttaattt tataattatgt ttaaatacag aaactttat 180

ttaaaaactca gttgaatttc t 201
 <210> 61
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 61
 gaaactggat cccatgatgac attgaaccat tgactgaatc taccctggaa ccacagaggaa 60
 ataactccta gttttttaaa gatgctttta gttgtgtttt ytattacaag tacctgagag 120
 catcctaact aatcaatgct aaatgcatct ctcaagagtt atgcttattt ttcagaaatg 180
 cctagtggaa atttctattg c 201
 <210> 62
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 62
 tccttcacat gactgagact atttccttgc cacaatcaga agaactaaaa gaaaggaggaa 60
 tatctgttaa tatatgaatt tatctaaatg tcatgcagtg rcttctaaaa tcatctggtg 120
 tgctctgttt ccccttggag gtgacttagg cctggcatcc caaacaatac atactggagt 180
 gaagctccag gaaaccctga g 201
 <210> 63
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 63
 atacatactg gagtgaagct ccaggaaacc ctgaggagaa gagaagggtt taaagagcaa 60
 tcagccttcg attgctggga ttatgaaagg tcgtaagaag ygaatgttgc aatgttttat 120
 tatacttgat attgaagcaa ggacaagtaa taatttatta ttctctccat gtcagtggta 180
 tttacclttt tggaatcatg t 201
 <210> 64
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 64
 ataaaaataa aataaaataa aaaatgaaaa acaaagtcga ctgttaacca catgtcagta 60
 gcatgtttgc tttcagggtg catcaaatgc attctatagc rcaggatgtt ccagtcactc 120
 taacaaaaga tgtctgtttt ggaacaccaa ctctgtatca gttacttcag acactttctc 180
 tcattgagtc cttcagcaa g 201
 <210> 65
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 65
 aaccacatgt cagtgcgatg tttgctttca gggatcatca aatgcattct atagcacagg 60
 atgttcagat cactctaaca aaagatgtcc tgtttgggac rccaactctg tatcagttac 120
 ttcagacact ttctctcatt gagtcccttc agcaagccct tttagggtta tgttcttaga 180
 tgaggaaacc aagtcttaga a 201
 <210> 66
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 66
 atattttctt gtttttagat gcacatatat gtactttttt agctggtcac ttctttctga 60
 aattggaatg aatcttacaa tcaatggcat gttataattt mattggcagc attatttgtc 120
 tcttaagggc ccccaataa tagtgtgtca cataactgat agcatctcaa attagatgaa 180
 atacagtagt ccaggcaaga a 201

```

<210> 67
<211> 201
<212> DNA
<213> Homo sapiens
<400> 67
gttatgggat aaagggcgata gtatttltatt gactatattt tattctttta attattcttc 60
taatttctta aaacaacttt attgagggtat aacttccacg stataatttc acccaatttca 120
agtgcattgaa ttcaagtgatt tttagtagag tcattgagta gtgtaacctt tcttacaatg 180
gttatagcac attttttatca t 201

<210> 68
<211> 201
<212> DNA
<213> Homo sapiens
<400> 68
tgttttcttt tatttttctt tctaaaaata tcaacggtt cattgcaacc ctaacctctt 60
tcaacacaca cacacacaca cacacacaca cacacacaca yggcttctag attctacatg 120
tacaagagtg caaatcaaac taccatagaa aaactaagaa gagaggcta gaagcaagag 180
gctgatacac tatctcaggc t 201

<210> 69
<211> 201
<212> DNA
<213> Homo sapiens
<400> 69
aaccaacact taaatgcag ggaatttaag ataaaaattt gataaaaatg ggaagatttg 60
gccgtattgg gctcatggta actgagatgc atctgaatga yaggcattcc tttgaattgc 120

acatttgctc ttgtttttac tataggccac tctcactttc tgttttttcc cccggctttg 180
aaacgatcag ttttagtact g 201

<210> 70
<211> 201
<212> DNA
<213> Homo sapiens
<400> 70
atgactgggc aattatgtca ttatcaccac tgatatatag ctggaagagt ttagtgttgc 60
cctgctaaga tctggatttt cttttctgga gcttggctat kggggcattg agaagtcacg 120
ccaggagggtt ggtcagaggc taacccaaaa agctttgctt aactctgggc tacagctggg 180
ggttgccaga gagaagtgc t 201

<210> 71
<211> 201
<212> DNA
<213> Homo sapiens
<400> 71
aattttatttg agtagacagc caacccccctg tattgtactc ctttaaaaaa tatttttaggc 60
tttttaaatg ctgaggcaag gggacatacc aaacactaac rggcacattg gggttttctg 120
gctattgaaa taaaaatgtc cttacataac actgatgtac tggaaatagca ctgcgttcca 180
gtgacggtta ttgcaactca g 201

<210> 72
<211> 201
<212> DNA
<213> Homo sapiens
<400> 72
ggagcatgat gtgctttgat ttcaactatg ggctttatta cttactaact gggttacttt 60
ggttaagtgg ttgactctt gttttttgag atggagtcag yctgggagac tccagctctg 120
tcgcccaggc cggagtgcac tggcacgatc ttggctcact gcaacctctg cctccccgat 180
acaagcgaat ctcatgcctt a 201

```

<210> 73
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 73
 ctggcacaaa gtaggcactt catatatana agctglgatt attgatgaac cagtagtgag 60
 gtacataact ggggaaggag aagggggccag ttglggggaa wgctttttta gttatttaata 120
 gtaagggtgtt aaaataataa tagtaastaat aacccaaaagt tactgaaaac taaatacagt 180
 gctaaactct ttaaaaggag t 201

<210> 74
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 74
 cttcttttagc tglaaataag taattgtatg aggtgatggt taagggtgatt tactaatttt 60
 acaattctat tatttttatga atagaccota gttaggatag yttgaaatag atacttaatc 120
 cactattatt ctctcttcta agatatagtt aclaagttgat catacttttc cttaaaggct 180
 gaactgaatt ctctgatatc a 201

<210> 75
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 75
 gaaacatact gggttaatgga attccagaaa ggactgaaca ataaaaccat tttgaaggac 60
 agcatagagc tggactctag aacagccaaa acaagggggtt maaccactgc gagggatctc 120
 tctccaactc ttgctcaggc tttctctccct ggcttgactt tcttctcttt cactgtatag 180
 tggcttctct cacttggaag g 201

<210> 76
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 76
 tatttatgtgt ggctgactat ataaaaacat ggatattttc ttggaalcac ttggtttgac 60
 tgggagaaga coattctcaa aacaaaggaa gtgcaattta yagaaggtag tagaataggc 120
 agataaaaca ataattcttc actatattgc tcaaataatc ccatgacat ttttagtata 180
 ttataaagag agttctaaag t 201

<210> 77
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 77
 gagaaagatg ttaagatgaa attagatgtg caagagattc gccgaggtaa accttgtggg 60
 agaaaatgga gaggtacata gaggagcctg ggccagactgt stggctacta tgtaagactc 120
 atccccatga aggagaaagg agaggaaggc aaagaagaaa aaccttaaga ttccaattct 180
 aagaacgttt tgacaaagct g 201

<210> 78
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 78
 tgtgcaagag attcgccgag gtaaaccttg tgggagaaaa tggagaggta catagaggag 60
 cctgggcaga ctgtgtggct actatgtaag actcatcccc rtgaaggaga aaggagagga 120
 aggcacagaa gaaaaacctt aagatttcaa ttctaagsac gttttgacaa agctgattag 180
 gagtatttaa ggcacagctg c 201

<210> 79
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 79
 aaataacttta actcatggcc cgatgatttt cagttaacca aattctccct tactatcctg 60
 gttgcccttt ctgtcttttt cttagaatg ttattgtagt rtttgcaaga tggcctgaat 120
 cctgaacccc ccactctcaa tgagcaccac atggtaatta tagattccca gctgtagagc 180
 tatgtcagac aaaggaaact t 201

<210> 80
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 80
 ctcttccttg gtggcttaaa gttaggctga agaagattta cattatgttg tgcatgaact 60
 ctctagtttg gttctactta tactttcaag gaggggaagac yggggaagggt gtcccttagt 120
 gagcatattt tgtacaaatg aaaacagggt actaacactt atgccaggac gcatgcataa 180
 actaggatgg ttctgagaaa a 201

<210> 81
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 81
 agaaccttaa tgggagcaca ggtcccaccc accccttgct accccatgta ctgtttccca 60
 tcttcaccca agagaggaaa cactctggaa ctagggcagc wtaagtgaag cagagtgaaa 120
 aggaatgtga agttttgaga agaaagaaaa ggctaaaagt tctatctttc cacattgctt 180
 ttttcaggtt tctcttcgga a 201

<210> 82
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 82
 gatgaaaaat tcatattcat ctgaatttta taagtgaatc atgagaactc aaagataactt 60
 agcccttggtg accatttttt actcctgttc ggatcccttc rgctaagcat gattatttac 120
 tattttcagc tattagttat gtcttgttga aaaagtatga aaagagctgc ccaataaatt 180
 agagtgtatg ctcaacattc t 201

<210> 83
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 83
 ttcggaatccc ttcaagctaag catgattatt tactatcttc agctattagt tatgtcttgt 60
 tgaaaaagta tgaaaagagc tgcccaataa attagagtggt rtgctcaaca ttctcttagc 120
 ttctttatct ctttccaaaa ttggatcaaa tgacattgga catgatcaac ttcttactgt 180
 ttgacaaac atctgaggat a 201

<210> 84
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 84
 ttatttacka ttttcagcta ttagttatgt cttgttgaas aagtatgaaa agagctgccc 60
 aataaattag agtgtatgct caacattctc ttagcttctt yatctctttc caaaattgga 120
 tcaaatgaca ttggacatga tcaacttctt actgttttga caaacatctg aggatacttt 180
 tataattgat aatttggaat a 201

<210> 85

<211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 85
 ttttgtgcct cagtttcctc attcaatatg ggtgtaataa ctgtgcctgt ctctgtaggat 60
 tattgtgagg cccaagtgcg ataatatata gtacactgtg yctggcatct agtaagcatt 120
 cattaagatg acatgaagat aacacagata tatcttaaca tgtsattatg attttgccta 180
 ttcaaggcca agcattccaa t 201

<210> 86
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 86
 gaagaagaag acagtcagag agaagtgagg gcttactttt catgttttaa gtctgttatg 60
 tggtaaaagg attagattta tctgtgttgt tccaggggac mgaaatagga caaatggatg 120
 caaatagagt gaggaagatt taaaacaaat ggagaagaca ttctaaaatc aactacaatg 180
 agcgtaaaca atgacaacgg a 201

<210> 87
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 87
 tcatatgcat agacaaatac accaaactga tgaatatitg ccttgtataa tctttttgta 60
 gtttttttat gaacatatat tactcaaaca atttagaaca wtggcaata tatatatatt 120
 tcaattataa aaggttagga agatkaatta cactttctga ggtcgcaact aaagccaag 180
 attttaatcc atttctattt g 201

<210> 88
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 88
 agtgtcactg gaaagtgcga aagaggacag ttaagttagt tggaaactga ctgaggccag 60
 acagggctgt gggacaagtc aggggtgtgt cattccgta rgcagcgatg cagaatcaag 120
 acagagtagt ttctccttct ctctctctct ttaattgtaa cgccttttat aacaaacaaa 180
 tattatgctt atttctgtct t 201

<210> 89
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 89
 cagttaagtt agttggaact gaactgaggc cagacagggc tgtgggacaa gtcagggtgt 60
 ggtcattccg gtaagcagcg atgcagaalc aagacagagt wgtttctcct tctctctctc 120
 tctttaattg taacgccttt tataacaaac aaatattatg cttatttctg tctttaaatt 180
 tttttagta atttctcalt a 201

<210> 90
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 90
 ttttctagtt gagctatcat tcatatttat tatgtggaac tagaggtagt cctggctact 60
 tgggaacagc gtggagtcta gccatgtcag gccacagaagt sgtctcagct aagttagaat 120
 gtgataccat tgtttacaca agtgtggcct gccttcaaga taggggtgagg tgttttatga 180
 ccacaggctt tatgaattat a 201

<210> 91

<211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 91
 tgactctgaa gatcataccc gaagtagagc tgcaaagata ttltggaatat tggtaatatc 60
 caataaagaa lgaccttcat gctattttga ggagatgttt maatgtcgaa ttattgaaat 120
 atttataaaa tacaaataaa ctaactctgc ttcaatttcc aacttgtgta tgacacttct 180
 taggctatca tttcattcca a 201

<210> 92
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 92
 ttccaaacttg tgtatgacac ttcttaggct atcattttcat tccaaattta tggtcactac 60
 cctactgtca ttccctcatc taaccataty atcaacagtt saaaagcagc cactcgaga 120
 ggtaagcaag atatattggt aatactgtgt tgacaaaagt atgcagaagc agtcacattt 180
 atacagtagt gaaggaaatg t 201

<210> 93
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 93
 aattacagta tatctaaaaa aagaataata tataacaact gaaaaataaa aatagttgat 60
 ataagcagat attccaagat ctgccagaca tattgttaa ygaanaatct agatacaaaa 120
 ttgtttatag ttctctttca tactatagcc aaagaaaatt cagaaaaaac tacttacagt 180
 tgatccttga ataattgcagc a 201

<210> 94
 <211> 229836
 <212> DNA
 <213> Homo sapiens
 <400> 94
 gtaaaactcaa aattctcttt ttttgggaaa atgaaaccaa gggagctaatt cagagccaaa 60
 ccccatgtac ccaagtgtta gcaggcatga atgtagctac cagctacctg ggtgtgttgt 120
 catccttggg atttttgggg gctgtcctca tctcttcttt tgttttgaca tctctacttg 180
 tcttaaaacc caaggagcct tctgtgtttg tggccaatca gtttaccat gctctctcat 240
 taaatggact ggaacttgta ccatagatta tgtacctctg gacatcttta tactcctctg 300
 caatctctct ctccagcac caatccatgg gaattctatc ttgccagggt tgaaggaggc 360
 tatccaatta attcccttc ttatgggct cagcattata gctgggtatg gaacctaaac 420
 tgccggaatc tcaaaagcct ccttgaccta tagccaactc tgaaggaaa tagccagcaa 480
 gtttaatatc atggctaaaa cctcaacct ggccagagca aattaacact tttagcagttg 540
 tagtctctca aaactgtcaa ggactagata tgttaattgc agcacaggga ggaatttgtt 600
 tagctttaga tgaanaatgt tgcctttggg taaatcaatc agtaaaagta caaaacaaca 660
 tcagacaact cctaaatcga gccctcagct tacaagaaca agcctctctg ggttagttag 720
 atttgtaagg aacctggaaa tgggatcttc cctgggttct tcccttttta ggccacatg 780
 tttagcctcta ctttgcctcc tttagctca tgtcttcaaa aatctaataa cccaatttgt 840
 ctcccttctc tcacctttag atgatcaagt tccagatgat cctcagttag ggataccatc 900
 ctttcaatat tcaagagtca ccttctaca gaggactcct agacttccca tcagtgggac 960
 atggcagagg tgaatcctg cccctgtctc ccttagacct ggctggatcc tgcttccaac 1020
 aacccatgca gccacctgc cctgacagct agcaagaggc caagacccac agaacaatca 1080
 ccatacacc tctgtcagca ggaagcagtt acagaagact gaccttcac cagtttccca 1140
 aagaattggg tcatggattt ttgcggggga aaatgttaga gtaggttaatt aggcagacat 1200
 gagtaaggga ggagagacc cctccaacta ggaatgtcag gtgagcatca gatcatcatc 1260
 aggtgttgtt taaaactctc ctctaaaata ataattaggt gcaactggca gcagggaag 1320
 acaatctccc aatagataga aaagtctga agctgggtat cagcagottc ctagttagat 1380
 ctcaggattt gggcaagcag gctcaaacat gggcactaag aggcanaatc gtggagtta 1440
 actggtatcc agacttctc taaaaacaca tgactcatgc acatgtggac agcctgcccc 1500
 aagggaanaa caaaagagga gagatgcaa accccagaag catgccaata tataaaaccc 1560
 caagtctaag gtcaaacagg gcacttggat ttctcaagtt gccacttgg cctcttctca 1620

agtgtacttt	atttcctttc	attcctgtct	taaaaacttt	tacatttcac	tcctgtctca	1680
aaacttgctt	cagtctttca	ctctgcctta	tgcoccttgg	aagaattatl	tccttcaaga	1740
tggcaaaaag	caagctgtct	cagacccata	cagatttgcct	gctgtcaaca	ggaggataac	1800
ttgagcccag	aagggttaagg	ctgcggtgag	ccttgattat	gccactgtct	tcagccctgg	1860
caacagaatg	agactctatt	tttttttctt	ttaaaaagac	tttttacaaa	aggcaaaatg	1920
ataatgganc	taaaaatgta	cgttgactga	cttaactcca	actgcttctt	ccctcaattg	1980
aaaccacctt	tgcaaaaatt	ataacagtga	gaaaattatg	gcagttaggg	tgatctgate	2040
aagccaaaac	ccatcttgcg	tttagccttc	aagctgccca	taattattcc	tgggcttagg	2100
ccaagctaac	tttgggagac	acttgggtcta	tagtttaaat	gataatagtc	cttccctaaa	2160
altcaaccac	ctcagcaaa	ctgatgagag	gccaccaggc	aaggaggata	gaggagtcta	2220
aattctgcta	aggtgtagat	ataaacagtt	tcacagccatt	altctggagg	tcacaaaatg	2280
tgcaacttct	tcaattactc	ctgcagataa	catcaglatl	ttagaacctc	agaltggcct	2340
tttgagatgt	cttttcagggt	tttttttgtgt	gtctgactac	cgatggctcc	acctggaccc	2400
accaaccact	cctgtggccc	catccagaag	caactcagca	tgcataagga	ctatttccca	2460
cacccctatg	attgcacccc	caaccaatta	gcagcaagga	cttattggct	aaaacagccc	2520
cattcatccc	ccaaaccctc	catgaaaaac	cctagctttc	aaatttccgg	ggaagctgat	2580
ttgagcaata	ataaaatacg	tctcccattt	agccaactct	acatgtataa	aactctttct	2640
ctattgcaat	tcccctgcct	tgataaatga	taaatcagct	ctatctgggc	agcaggcaag	2700
aagaaccctgt	tgagtcctta	caatatcctt	ctttctaccc	tcctctgcct	aattactctg	2760
aatctactaa	ctttttcact	cagttatttt	tccactttga	agacaaaaag	ttagaaaaaa	2820
aaatgcctta	tgaanttagt	ccctcagaat	aaaccagctg	ggcttttctt	agccacctgt	2880
atgctttagt	caaaatctaa	gctcagaggc	aatagtgaat	ggcttttctt	tcccaaagga	2940
aaactctcag	aaatlctgct	aagctatcca	cactgagtg	aggtatagaa	catgctttgc	3000
cctatttatt	catgggcacc	alcctgaact	cagtaactta	gctttttctt	tttgaagctg	3060
gatggggaag	acacagatct	agctgaatta	gttgcbaaaa	tatgctatct	ggcataaaga	3120
ttattttgag	agagttattt	tgagactcct	tgtaaagagaa	atttatatct	acaaaggaag	3180
tctccattta	taagcttgct	tctctgcato	aggaagaaaa	gaaggactaa	atcaccagac	3240
actcttaacc	aatggagaag	gagtttaagt	aacaaaacct	aoctttgttt	aagggtgctt	3300
ttctggctct	ctgccattaa	gatctacatt	ttccacctcg	tctcctctag	gacctgaggg	3360
ttatctcttt	gatattgcaa	tgccaggag	attactcaoc	agaagaagaa	gaagaaatag	3420
agctaattgg	aaatltagca	aataaaaaaa	tcttgttttt	tctcccagaa	acagtgaaaa	3480
gcttttagcca	tcccttagat	aatcttaact	tgttccatct	gccagaaaca	caatttggat	3540
tcagaaattc	tttatgaact	gtttttgtat	tattgtacct	ggcacatggc	tacagttttc	3600
aaatgaaaac	tgtgaaatct	gcttctgtct	gtattttatg	tatgtctgtg	tatgcatgta	3660
tgtgtaatat	ttttctacct	ctagagacta	tcctaaaaat	aactttatata	gagctgtatt	3720
taattgcctt	aaagaaaaag	cacttataca	aattaaagtat	tttttaaact	ttcagaaaaa	3780
taagacctag	cgcaaatglt	cttcaagttg	atattgttaa	aagaagaaac	ttcagccaaa	3840
ttaaacttaa	agaagttaa	ltgagcaatg	aatgattcac	aaatcaggca	gcctocagag	3900
ttacagctga	ttcatggaga	ctccagggat	gcctcatggt	cagaacaaat	ttatagacaa	3960
aaaaagggga	gtgacataca	gaatttagaa	gtgaagtaca	gaaagagctg	gactggttac	4020
aggttgggtg	ttgccttatt	tgaacacagt	ttgaacactc	agcagtgtct	agctggttga	4080
agtatggcta	ctagaattgg	ccaagactcg	gctattgtta	caggaacgta	ctcctaaatt	4140
aggttttcaa	tcttgtctac	ctgttaagtt	aggttacagt	tcattccaaa	ggactcaaat	4200
atagaagtac	ggagtcttcc	tcaggctatc	ttcagttctc	tttaacagta	tgatacggga	4260
taatcttcag	taaataaaaa	tttctttaag	tttgttggat	taactaaagc	aggcattgtct	4320
tcagagttgt	caacattaaa	tataatacat	acatacagtt	tttttctacc	aggggttacl	4380
aggcaaataa	gtttgttatt	gtaactagat	gtttaagatt	ataaaactgt	cagtttaatc	4440
taagugcaaa	agtgaaaatg	tggtagctat	tttattaagt	acagcggtaa	agcaagrata	4500
tattaagtat	agcagtaaag	caaaaaaaca	aaaaaaaaca	agtaattaac	tttttttgg	4560
tttttttttt	tgagacggag	tctctctctg	ttgcccaggc	tggaatgcag	tggcacaatc	4620
tcagctcact	gcaacctcca	cctcccggtg	tcaaggcatt	ctcctacctc	agcctcctga	4680
gtagctggga	ttacaggcgt	gcaccaccat	gcccggctaa	tttttgtatt	tttagtagag	4740
atggtgtttc	acctgtttgg	tcaggctggt	ctcagactcc	tgacctcatg	atctgtctgc	4800
ctcggcctcc	caaagtgtct	ggattacagg	catgagccac	caagcccggc	cttaactttt	4860
ttttagggtc	ttgcttttgt	gatatttggc	taacatacat	atgctgtaaa	aattgttaant	4920
aggaanaatat	taataatgag	atgttgacta	gctttgtctg	tctaataaaa	tttcataagt	4980
caattaaaaat	taagaacaa	tgaattatag	aatagaattc	aattgaattc	tattgaatac	5040
acttgctgaa	tacaacaatt	gaattgtaaa	tagaatagaa	attataaatg	aacttttcaa	5100
tagtaattat	tttttaatac	gggtacttaa	aattgtgtca	acttcttaac	aaaagaaatg	5160
gaggcaaat	tagtataaac	agtttatttg	ggccaaattt	gagaactgca	atgtgggaga	5220
cacgtcttca	agttgclatg	aataaaaact	ccaattagca	gcagttacaa	gcggrrtttt	5280

tttttttaag	aagggggcagt	tottttagttg	catataaact	attgattggc	tatacatttt	5340
tttttaacca	taaattccag	gagcatgaac	ataatgggtg	aggggtcacat	cccttgggca	5400
tggattttgg	gcaggatgtg	acaaaaatct	catactccatg	tctctctggg	cctgalaaat	5460
tttgcatact	ttatatagtt	cagactcttc	cgagctacgt	ttctttctct	tccttttggg	5520
tgagtttttt	tttcttctga	aagttttgat	gatcaacatt	ttagatgtaa	gtttgtccca	5580
tgtcactgga	agacttagtt	ttagtttagtc	tcatcccaca	ttggagggaag	agaggagaga	5640
taaaatggct	taagaaatgca	gtgaagtctc	aaggccaagt	tgattggcaa	cacaaaggga	5700
cagggcaatg	gtatttcagg	tcatctgctt	acaaaggagc	tatggcatgt	tggatcattt	5760
ctaagcatct	agctatcatt	atttttagtgt	ttttgttgat	tttggacatc	tagaagtgca	5820
aagtataatc	aatttgagaa	taaaagacat	gatgcaaata	aagacaatta	ctaacaaaag	5880
ccagatctga	aaaatgtttt	tatttccgaa	ggcgaccaaa	taaaatagtt	tctacttctt	5940
tgtgctgalc	taaagatcaa	tgtataggag	atctccagt	atgagtttgt	ccactcaggc	6000
agagctgcct	ttttaaaata	aaaattatga	atgcataagt	caatgtattt	gaatttaact	6060
ccacaagtat	tgggttaacaa	tacagatatg	gtcgcttcca	aggtgttttg	agggagtttt	6120
gtattttagt	gcattccaca	ttggaggcca	tgtcttttga	tgtcttcac	tcctggaacc	6180
acactgtatt	gtttggacat	atctatccag	acagatgatg	ataaattttg	catatctcac	6240
atagttcaga	ctgctctggg	ctacttttct	ttctcaatag	cttctcatig	ttaaacttatg	6300
cctgtagagt	tttgctaaac	taaattagat	aattggacatt	tattaaatat	ttagatcatt	6360
tccaaataac	ataaaatgct	gaaacattaa	ttgcttaaca	taagttaatc	tacttttggg	6420
ttltattaca	aagggaactaa	atatattttac	atctgttaaa	aaacacttta	aactgtacta	6480
tgagaangaa	tctacttcta	tagaaattat	aaaalgggtat	atttatagat	ttaccatttt	6540
atggaatacc	ccataaccgt	tcacaatttc	ttatttcccta	gttttcacta	gaaattgaag	6600
ttactaagag	ttlaacaattt	taactaatat	agagttagtta	aaaagactaa	aaataataag	6660
ggagataaact	atatgcaaaag	aaagtaagac	atgttttttg	taaggaaagc	cataagggtat	6720
aaggatgtgc	tttttttttaa	ggaaaaggaa	gaataatttg	gtctagtgtg	gagggttatit	6780
aaaggtttgt	tcagaatgaa	tgaagataa	aatctaattg	gatacaaaaa	ggaagagaga	6840
tgacacacac	acaaaatgaa	tgaactctgt	atggacaagt	tggctagaac	tgaatgtatt	6900
ataaggtttt	aaaaatgagt	cttgaccaag	cactgtggct	cacgcctgta	atcccagcac	6960
tttggggaggc	caaggcgggc	agatcatgag	gtcaagagat	caagaccatg	gtgaaactcc	7020
atctctacta	aaaatacaaa	aattagctgg	gcgtgggtgg	gcgcacctgt	agtcaccagct	7080
actaggggagg	ctgaggcagg	agaatcgcat	gaacccagga	ggcagagggt	gcagtgaact	7140
gagatcacac	cactgcactc	cagcctggcg	acacagtga	actccatctc	aaaaaaaata	7200
agagtcttaa	tatcaaaagt	aaactgatgc	aaaactagaa	tttgggtctt	tctgtgaaaa	7260
tgacagtttt	cttttttaag	agtattgtct	cagtttttaa	aagtatttgt	gaaaaatttt	7320
cctttccctt	gtaactaatc	ggcctacaaa	atgaagattt	tgtgttttct	caaaaataat	7380
ctttgtgctt	cgtgttgoot	ttttttggtc	tttaatttact	taagaaaatt	gaatcttccc	7440
aacaaaagag	ctagttttgt	ttgttttgtt	tttacagtta	ttasactttc	tctatttgcc	7500
tttgaaacct	cttagtttgt	actttttgtg	tcttcacagt	gacttttgat	atatttaaat	7560
aagtgtttaa	aacatttgat	atttttgcca	gacttccata	aaccaaatte	taaactaaat	7620
ctttttttta	acctcaagct	aagtaggatt	ttccagatgg	atttccctgg	tctctcaaaa	7680
gaactttgtt	tctttcccta	tagaaagaga	ggtoaggcac	agtggctcag	gcctgttaatt	7740
ctagcacttt	gggaggccaa	ggtaggcaga	tcacttgagc	ctgggagttt	gagaccagcg	7800
tgagtaacct	agggagaccc	ttctctacaa	aaatttagcct	ggcagcccag	cgtgtgtggc	7860
catgcctgta	atcctagcac	tttgaggagg	taagggtggc	tgattgcctg	agctcaggag	7920
tttgagccca	gtctggggcag	caagggtgaa	ccccatctct	actaaaaata	caaaaaatta	7980
tctgggcatg	gcggcggtgt	cctgtagttc	cagttacttg	ggaggctgag	gcaggaggat	8040
tgtttgaatc	cgggaggcag	aggttgagct	gagccaagat	cacaccactg	cactccagcc	8100
tcggcaacag	agcgagagtc	cttctcaaaa	aaaaaataaa	aaatttagcct	aacatgggtgt	8160
catgcctgta	gtcccagcta	cttggggagg	tgaggtggga	ggatcacctg	aacctaaagg	8220
ggttcaggct	gcagtgagcc	atgattatgc	tactgtattc	cagcctgggc	aagaaagtga	8280
gaccttggaa	aaaaaaagaa	agaaagaaag	ggaaaaagaa	agaaagaaag	aaaaaaagag	8340
aattgcatag	gaagllguca	aalaagggtg	atgttttaacc	ttcttatgtt	ataatattat	8400
tcatgttaag	tttccagatg	ttctgtgaac	ttctacaact	ccgatatgtc	ctgatattgt	8460
atcagtcata	atttttagtta	ccttaaaatg	ttgtgtttct	cagaaataac	aaattacatt	8520
gtcaattgca	ttataatgaa	ctttcatcag	atcttttaacc	atggccattt	ttaggtctgt	8580
tgtcatccac	aaacagtagt	tttactctga	tactttcctg	aaagtatttc	caaatgcttt	8640
gtttgcagga	agatttatgg	aaaaatattga	aattgtgtgg	tttctggtaa	cttttaagatc	8700
ataacattgg	actgcataag	aatttccagg	actctatttg	aaaaactaaa	tttataaaat	8760
tgtanccca	agatcaagta	gaagaaat	taattacatg	gtgatatgg	ttggctgtgt	8820
ccctactgaa	atctcaactt	gaattgtatc	tccagaat	cccacatgtt	gtgggagggg	8880
ccaggggaga	ggttattgaa	tcatggagtc	tggctcttcc	catgctattc	tcgtgatagt	8940

gaataggtct	catgagatct	gatgggttaa	tcagggggtt	ctgcttttgc	ttcttctcca	9000
tttccaccatc	aggtaagaag	tgccttttcag	ctcccgccat	aattctgagg	cctcccccagc	9060
cacgtggaac	tgtaagtcca	attaaacctc	tttttctctc	cagtctctgg	tatgtcttta	9120
tcagcagtg	gaaaacggac	taatgcacat	gggataaaat	glattgataa	taatgataat	9180
tttatgactt	ttcgttttgaa	acattgctgt	ttcttttaatg	tctaattttt	cagatttaac	9240
gtaacttttt	ctttctttcc	ttaagctatc	tatagcttac	agaaattttag	cagattatac	9300
ctttatcaac	agaaaagaag	catatacttt	ctctcttacc	tgatccctcc	agaattcaga	9360
aactattagc	aagtattatt	atttcccagg	caatatagtt	atatgcataa	ctgcaataag	9420
aatatgttct	tctgggctgg	gcgcagtatc	tcatgctgt	aatcccgaca	ctttgggagg	9480
ccaaggagg	ctgatcactt	gaggccaaaga	gtttgagacc	agcatggcca	acatggtgaa	9540
acccagctc	tatgaaaaaa	taataataat	aatastaata	caaaaattaa	ctagggtatgg	9600
tgggtcacgc	ttgtaatccc	agctactcag	gtggctgagg	cacaagaatt	gcttgaacct	9660
gggaggtgga	ggctgaagrg	atctgagatt	gtgccactgc	actctagcct	gggtgacaga	9720
gtgagactct	gtctcaaaaa	aaaaagaata	tattcttctc	ataacaggac	acaattagaa	9780
acactggtta	tattaccaag	gttttaataa	gaatatcata	cttaaaaaata	tgtgtaaaaat	9840
tttatatgac	cagccgggtg	tgggtggtcca	cgccgttaat	cccagcactt	tgggaggccg	9900
aggcaggtgg	atcacctgag	gtcgggagtt	tgaaccgaag	cctggccaac	aggaccctta	9960
aggaccctta	aggagatttt	aagaacctaa	tgaagaagag	aattcaccca	aaattatagg	10020
tattgcagat	gaagtctgat	gacaagtcct	tggcttgcct	tcctagcttg	gaagactttt	10080
ttaaattcta	atttgagact	ccttattaaa	agtcocagca	aagtatactt	tgaaaaagct	10140
tatgtaatga	atcactatct	ttactatact	tatgtaagta	atcaggccaa	gtglaacggg	10200
actaggccta	ttttgcaaac	aaatcagttt	tactgtgatt	atttttggaa	tgggcattgac	10260
tataaagaga	aaaactatat	attagtagaa	aactatagca	cacccattgt	tagattctag	10320
cctagttcac	tgtctttgag	gttttgttat	ctacttgtaa	actgaactgg	atcctgaatt	10380
ctaatttctc	ccagtatctg	gctatgactt	ctaccgagct	gactacaaat	ttgagggttc	10440
ccttgacctc	ttcctcatgt	tcaataattt	actaggacaa	tlaacgggaa	ctcaggaaaa	10500
cacatatgat	tgccagttta	taatgaaaaa	tacaatttag	gaatagccaa	gtggaagaga	10560
ttcatggggc	anggtatggg	ggctctttct	tccatgcctt	ctccaggtgc	accatcatcc	10620
tagcancctca	ttgtgttcac	caaccagaaa	gctctctgaa	ccccaaagtt	tagaggttag	10680
tatggaggtt	ttattacata	ggatatgatta	gttaaatgac	caaccattgg	tgcttgaaca	10740
ttatctttac	tgcctttctt	cccccaacct	ccagaagtgg	aaaggggtgc	taaaagttac	10800
aaacctctta	tatttgcttt	cagggtgacaa	ctttcaaagt	gagttggagc	aaagaccaaa	10860
catatatattg	catgaaatca	tgacatctta	tagtaatat	tgattttcaa	actctgcattg	10920
tataatagtt	acttaaaatt	taaattaaat	tttaaaatgt	accagttatg	cagctgaatt	10980
ttgggtacttt	ttcccttggc	ttttgctggg	atctgaaatcc	accatcattt	ccctgtacaa	11040
tatctgccat	tggagatcca	attgggaaaa	tacattttaa	gaaaaaatct	aagaagcatc	11100
tcataggttg	tggttccctt	gcattccacac	tcattatcat	ggtatttatct	tccccaaggt	11160
gggtaaatgt	atatccctgg	ctaatatcaa	gattagcact	agctgtctgt	agataccatt	11220
tagaaaagtt	ttctctacat	gtcctctctc	accactccta	ttcaacatag	tattgggaagt	11280
taaaaaaaa	gttttctcta	cttgaaacta	aaatttatgg	cagactatat	gcttccgaat	11340
gttctaasaac	cttactagaa	gacaaaacatt	gtcaaaggta	ggaatgtggc	caacatgtca	11400
ggtaacgcct	ataacaaatt	aaaatctggc	gattgctgcc	aagataccca	caaaactatc	11460
ggaggcaact	gctgtcaaaa	gaccataaag	atgattctgg	agacaaaggc	ctgtgggaagt	11520
caataaaata	atggtcaaaag	tggacaagat	ttaaaaaat	taggattcag	aaagaagcca	11580
attgtcattt	aggaaacaat	tatctgataa	caaagctcag	tgcctcttta	gggctgacat	11640
tcatgluacat	attaaatatt	gtagaactga	taaggcttgg	tggatttatat	ttgacaaagg	11700
ttatttgtat	ttcaaaaagg	aatcaacttt	tgagacaaag	gaatgcttta	attcattcaa	11760
caaatatttg	ccaagtaacct	acttttaggg	tatgatgggt	tgtaaaaaaa	tttttgcctgc	11820
latcatggag	tttagaatat	agaggtaagg	ccaatattaa	tctagcaaca	ttaaactcttg	11880
tgtaatgtga	aactgaggta	gataagtgct	caagaaaaaa	agggttctgta	aaagtttata	11940
tcaaaagatc	ctgatcaaaag	aagtattcta	ggggaaktaa	tcattaaact	gagagctgaa	12000
ggaagagttg	ggttgaatgg	cataaatctt	aaaatgagac	agggtttata	cctgagggtt	12060
ggkatattag	tttactaggg	gtgtataaca	aagtatcaca	aactgggttag	tttaataaac	12120
agaaatgtat	tgcctctaag	ctctggaggc	taaatatctg	agatcaagggt	gctggtaagg	12180
ctgtttcctt	ctgggttgat	gaggagatt	ctttttcatg	actctctcct	agattctagt	12240
gatttgcctgg	aatctggtg	tttcttgact	tgtacacctt	tgcctttgtt	atagactgat	12300
gttgtctccc	cctaaaaactt	atgtgtttaa	atcctaacc	ccagtgtgat	gggattagga	12360
ggtggctctt	ctttggggaa	ataattaggt	aatgagtggt	caaccctcat	caatggaatt	12420
agtaccctta	gaaaaatgac	tccagaaagc	tctctcatcc	cttctgctat	gtggggacac	12480
agtgaacaagg	gggccatctg	taaagcagaa	agcaggccct	caccagacac	taattctgcc	12540
agtgccctga	tctgggactt	cccagccctc	agaaccatga	taataaatt	tctgttgttt	12600

aagccactag	cttatgggtat	ttttgttgtt	agtcacaaca	gactgagata	gccttcatct	12660
ccacatggca	ttttttttct	tgtgtctttg	tgaatnaatt	tcttcttttt	ataaggacac	12720
cactcatatt	tgattaggag	tctacctaa	tccagtataa	gcttatctta	atgaattatg	12780
cctgcaatga	ctctatttcc	aaactaagtc	acatttttag	gtattgcagt	taggacctca	12840
acatatgtat	ttttggggga	gacacaatac	aactcttacc	agttgagaaa	gagacaatgg	12900
gagcanagaa	gatttgaaat	ttacctgctg	acttagctag	gttaatcatg	agagaacaaa	12960
aagctttcat	ttgaaaaagc	ttcaggaaat	tcagtgttct	caaaggagag	ttggatttgt	13020
tttatacca	gaagggggct	gsaactatct	gaggaggagg	ttcaggctat	aaagattata	13080
cagattgatt	attgagaaaa	gtacaaaagg	gcacagtgca	aagtttggga	ggtggagaag	13140
tttgagtcaa	aaataaggaa	gtatagagag	cattatttggg	atgatgggaa	ggtaaaaata	13200
actggccagg	attaattgct	tctattcata	tctctgcctg	atgaaaatgg	gagtggagaag	13260
tgtgatggct	ttagtctcaa	atgccttctt	gagaaaggcc	saagaattta	gactgcccag	13320
tccagaacaa	tgtcagtcoc	aatagggtata	gtctctgttc	tcttggccag	aactagaatc	13380
aattactggc	tccalcattc	actagatgtg	tgcgtttggg	ccagttacag	tacctctcta	13440
agaccgagct	ttctcattct	taaaatgagt	ataataataa	caottagtgt	aggaagcttg	13500
tgtagtacgt	ctcagtatca	ctattgaagg	gctggaggat	tctcatgccc	tcgataaact	13560
gtgtgatctc	tccagtcctc	tattttctga	ttttaaaact	gtcatagtaa	tgcttttagag	13620
tactglaata	acaacttatg	gagatcttat	ttataaaaag	taatttgaga	aatagaaaag	13680
taacacctag	ttactttttt	cctagttatt	ttggggccagg	attgtgttct	gtgactgtgt	13740
ctaaatgcac	catgagagga	cgcccaggga	aggcacctcc	actccattct	atctcattcc	13800
tctttcttag	tgtgagttca	tctgtgtgtc	tgattttatt	tctttaatcc	acctggctcc	13860
atcaaaaggg	catttcagtt	agttgctcca	cttcagttta	tgggagataa	gtcttctcca	13920
gattttctcta	atggccaata	aagtcaaatc	cttatcctct	ttgggcttta	ctcaaaaatg	13980
cttgtttcagt	tagggctcta	gttttattcc	ccagagattc	tgcattgttt	atactgatct	14040
tgccagggcc	ttcatctttt	gggctagtct	ctggaaaatc	tacctctggt	cctgtgcact	14100
tttccccctc	tagattctag	aaggaaaagc	aatgaatagc	gtctcccaca	aagatatttc	14160
caagacctaa	cccccagtac	ctgtgaatag	tgagagtaaa	atgatttagtg	gctgccagag	14220
gttcaagaga	aggagagaaa	tattgaatag	gtgaaggaca	ggggattttt	tagagcagtg	14280
aagttattct	gtatactgta	attgtgtatg	catgacatgt	ttttcataa	cccatggac	14340
tttacaatac	aaagaatgaa	cttaaggat	gcaaaattta	aaaatcactt	aggagggggc	14400
agggccaagg	tggtagatta	gaagcagctc	atgtgtgtctg	ctctcataga	gaggaaacaa	14460
aagggttagt	gaacattgac	cctccagggtc	gatcatctga	aaaaccatgc	tgggatccat	14520
caaggcagtg	ggtgaacaca	gaglacagag	atgacaaaag	ttgggcacca	gcctttcagg	14580
actcagatg	aagccaagag	aacctctcca	acatgggaaa	gggttagtga	gtgagagccc	14640
ccagagggaat	tcacactctg	cacagggacc	cacacaagac	ttgggaatggg	agaatcccc	14700
tggacccct	ggacacctgc	caccacccatg	ctcctagact	gaggcagaga	gccaactaga	14760
tgttttgcag	gggcaactct	tgagtccaag	gggacctcta	caagccttgg	ccoctttagt	14820
agaccagcac	tgtttccaca	gccccaaaag	agggccacagt	tgcagtgcct	gggagaagta	14880
agattgcccc	gccccctctt	gctggacagg	gcttgatggc	agcttctggc	ccagcagtc	14940
cacttcagcc	tgaacttgtc	tggccactcc	aatcaccctt	caccacttgg	atcttggcgg	15000
gcaaccctcg	atagagcttc	cagcccagta	gtcccacttc	tgtgtcaact	tagccatgg	15060
acacagcctc	ctgttgtccc	aggaaagcact	cagacattag	ggcaggagaa	tgtaccatc	15120
ctcaccactg	atagccaggt	ggcccagtg	tctacttca	atggggactc	agctggaggg	15180
ctcagcctcc	catgtctcca	agaaatgcat	agacagcagg	gtgtgtagcc	ccaaccatcc	15240
ctgccactgg	tagagggcg	ggcaatgctt	cctagaacct	ctggcccaga	ggtcctatat	15300
ctgtgggaac	tcagccagtg	cgcacagcct	cctgtctgtc	caggaaglat	ctggatggta	15360
gggtgggtgt	ccccaaacac	ccctgtctgt	ggaaagccagg	tgagccatgc	ctgttagaac	15420
ttctggctca	gtgtgtctac	ttctgccaga	atttgcctgag	ggtcacaacc	tctgtctgcc	15480
ctggaaacac	ccagagagca	gggtgagcaa	ctccactcac	acotgcctcc	catagccaga	15540
caggggccac	ccaatagagc	ttccaaoccca	gcagttctgt	tctacctgca	ctctgtgaaa	15600
aggcacaagc	ccgtgtttct	ccaagaagca	catggatagt	atatttagtgc	tgacttggca	15660
aggatacagc	ttgtctgcca	acagcagctc	ctgcctgagg	gaacacccatg	gaccggaaaa	15720
cccaacaaaa	aacataggca	cagagacagt	aattggaggg	ggctcctcca	agaocaggga	15780
gtggactaga	attgaaacca	gtcaaccgaa	gccactttat	acaataatga	aacccccaa	15840
ggcatcaag	aaagaaaaag	caaaaaaaa	aaaaaaaat	ccactcaaat	tacagcaatg	15900
ttaaagactg	aaagaaacac	agcccataca	aatgagaag	atccagcaca	agaactctgg	15960
caactcaaaa	aaccagagtg	ccttctttac	tccaagcaac	tgcactagtt	tcccagcaag	16020
ggtccttaac	taggctgaaa	tggctaaaat	gatggaaata	aaactcagaa	tacagataag	16080
aatgaagatc	attgagattc	agacaatgtt	gaaacccaat	ccaagtaagc	taagaatcac	16140
aataaantga	tacggaaatt	gatcgatgaa	atagccatca	taaaaaagaa	cccaatgat	16200
ctgatatagc	ttaaaaaacac	actaacggaa	ttgcacaatg	taattacaaa	tattaacagc	16260

agaacagacc	aagclgagga	aagaacctca	gagctcaag	actggctctc	tgaataaact	16320
cattcagata	aaadattaaa	aaagaataaa	caaaacctac	aagaaataga	agattatgta	16380
aagagaccaa	ttataggact	cactggcatc	tatgaaagag	atggggagaa	agcaagaaac	16440
ttggaaaaca	tattttagga	tgtcatacat	aaaacttcc	caacctcatg	agacaggcta	16500
acattcaagt	ccaggaatg	cagagaaccc	ctgctgacat	tacacaaaaa	gacctatccc	16560
aagacccata	attatcagat	actccaaggt	tgaattttaa	aaaaaaaaaa	aaaaagacaa	16620
aggcagctag	agaaaaacggg	caagtccgtt	gcaaagggaa	tcccatcagg	cttacaggag	16680
acctttcagc	agaaactcta	caagccagaa	gagggttggg	gocctatattc	agcatttcttt	16740
ttttatgaga	cagagtctcg	ctgtttccac	caggctggag	tgcagtgggtg	cgatctcggc	16800
tcactgcaag	ctccgcctcc	tgggttcaca	ccattctcct	gocctcagcct	cccgagtgc	16860
tgggactaca	ggtgcccacc	accatgcggg	gctaattttt	tttttttttt	tttttgtatt	16920
tttagtagag	acgggggtttc	accatgltag	ccaggatggg	cttgatctnc	tgaacctegt	16980
aggaggtcct	cctgacccgc	ctcggcctcc	ccatatattc	agcattctta	aagaaaaaat	17040
ttacaatcaa	gaattttaca	tctggccaaa	ctaaacttca	caagtaaaaa	gaataagat	17100
cattttctta	caagcaaatg	cttaggggat	tcattaccac	cacacctgcc	ttataaaaa	17160
tcctgagagg	agcactaaat	atggaaagac	cattacaagc	cactacagga	acacatttaa	17220
gtacacagac	cgatgacact	gaaaaagcac	cacagaaaaa	aaagtctgca	taataatcag	17280
ctaaaagcat	gattacaaaa	tcaaatccac	acatattagt	actaagctaa	tgggctaaat	17340
gatccaatta	aaagggcgag	agtggcaagc	tgaataaaga	agcaaggccc	aatgggtatc	17400
tgtcttcaag	agaacctct	ccatgacagt	gacactata	ggctcaaaa	gaagggcg	17460
agaaaagtct	atgaaacaga	agaaatcaga	ggttacaatc	ttaatttcag	acaagatgga	17520
ctttaaacaa	acaaacatca	aaaaatata	agaagggtat	tataataac	cottcaattc	17580
aatgggtcaa	ttcaacaaga	aggtataact	ctcctaata	tgcagacat	ctaaccaca	17640
agcaccaga	ttcacaaaac	aagttcttag	agacctaaca	agggacttag	aacccccaca	17700
caataatatt	gggagccttc	aacatcccac	tgcagaat	agacagatca	tcaaggcaga	17760
aaattacaa	acataattaa	gacctgaatg	caatacttga	ccaaaggagc	ggaatagata	17820
cctatagAAC	ttgccatcca	aaaacaacaa	aaatccatt	cttctcattg	ccacatggca	17880
catactccaa	aatcaaacac	aaaattggac	ataaacaa	actcagcaaa	tlaaaaaaaa	17940
aaacagaaat	ataccaacca	caatcttaga	ccacagcaca	acaaaaatag	aaataagttc	18000
taagaacata	actcagaacc	ataaaattac	ataggaatta	acaaatctgc	ctctggaata	18060
cccttgggta	aacaacaaaa	ttaaggcaga	ataaaagaaa	ttctttgaaa	ttaattgagaa	18120
aaagatntaa	catatccaaa	tctctgggaa	acagctaagg	ccatgttaag	agagggaagt	18180
ttatagcact	aaatacccac	atcaaaaatt	tagaaagatc	tcaaatatac	gacctaacat	18240
cacaaccagg	agaactagag	aagcaagagc	aaagtaagac	cccaaagcca	ccugaagaca	18300
agaaataacc	aaaatccag	ctgaactgaa	gaaaactgag	acactgaaaa	ccatacaaaa	18360
gatcaacaaa	tccaggagtt	ggttattaga	aaatattgat	aagataagata	gactactggc	18420
tagactgata	aagaaaaaaa	gacagaagtt	ccaaataaac	acaattagaa	atgacaaagg	18480
agacgttacc	actgaaccca	cagatataaa	aaaaaacatt	gaagactact	ataaacactt	18540
ttaagcacac	aaactagaaa	atttagaagg	ctgggtgtgg	tcgatcacgc	ctataatccc	18600
agcacttttg	gaggccaagg	agggctggatc	acaaggtcag	tagatcatga	tcactctggc	18660
caacatgggt	aaaccccac	tctactaaaa	tataaaaaaa	aaaaaaaaaa	ttagctgggc	18720
ccagtggcat	gtccagttag	tccagctac	ttgggaggtc	tgaggcagag	gaatcacttg	18780
aacctgggag	gcggagggtt	ctgtgagctg	aggttgagcc	actgcactcc	agcctgggtg	18840
cacagtgaga	ctccatctca	aaaaaaaaaa	aaaagaagaa	aaaaagaana	gaaaatttag	18900
agaaatgga	taaaatccaa	gacacataaa	ccagggaagaa	actgaatccc	taaacaaaa	18960
aacaatgagt	tccaaagtta	aatcagtagt	aaaaagccaa	ctgtattaat	gcattcttat	19020
gttgctataa	agaaatacct	gagattgggt	aactataaag	aaaagagggt	taattgggtta	19080
acagttctgc	aagctgtaca	ggaagcatga	cagcttcttg	gaaggcctca	gggaactttt	19140
aatcattgca	gaaggcaaa	ggaagcatg	tatgtcttac	atggccagag	cagggggaag	19200
agagagagag	gggaggtgct	acatactttt	aaacaaccag	atttgtgaga	attctatcac	19260
gagaacagca	gtagtgggat	ggtgctaacc	cattagaaac	cacccccatg	atctaatac	19320
ctcccacaag	tcccacctc	caacactggg	gattaaaaat	gaacatgaga	tttgggttgg	19380
ttcacaggta	taaacatat	catctactaa	acataaaaa	cccaggacta	cacagattca	19440
cagccaaatt	ctaccagatg	tagacagaat	agctgggtgc	attoataatg	aagctattcc	19500
aaaaaaktga	gggaaggagg	ctccctccca	actccttctg	tgaaggccagc	atcatcctga	19560
taacgaacc	tggcagagac	aaaacaaaaa	aagaaaactt	caggccatta	tccttgatgc	19620
acatagatgc	aaaactcctc	aacaaaatac	tagcaactga	atccagcagc	acagtgtaaa	19680
gctaattccac	cactatcaag	caggctttat	ccctgggatg	caagattggg	ttaacataga	19740
caaaacatat	gtttgtgtga	ttcattacac	aaacagaact	aaaaatgaaa	accacatgat	19800
aattccaata	catgcagaaa	aggcttttga	taaaattoag	catcccttca	tgttaaaaac	19860
tctcgataaa	ctatgcattg	aagaaacata	cctgaaataa	attagagcca	tgtatgacaa	19920

atccacagac	aacatcctac	tgaatgggca	aaagtltggaa	gcattttccct	tgaasactag	19980
aacagccaga	cacgatggct	catgacctga	atctcagcac	tttgggaagc	aaaggcaggg	20040
agaccacttg	agcccaggag	tttgagacca	gcctgggtcaa	catagggaaa	ccctgtcttt	20100
acaaaaaaat	aagaaaaatt	agccaggcgt	gatggcacac	acctgtgggtc	ccagctactc	20160
gggaggctga	aatgggagga	tcacctgagc	ctgggagctc	aaggctgcag	tgagctatga	20220
tcacactact	gcactcaagc	ctgggtaaga	gtgaaacccct	gaccaaaaaa	aaaaaaaaga	20280
aaagataaaa	gaaagaggcc	aggcgtgggtg	gctcaggccct	gtaattctag	cactttggga	20340
ggccgaggca	ggcggatcac	ctgagattgg	gagctcgaga	ccagcctgac	caacatggag	20400
aaacccctgtc	tctactaaaa	atacaaaatt	agcggggcgtg	atggltgcaltg	cctgtaatcc	20460
cagctgctcg	ggaggctgag	gcaggagaat	cgtttgaatc	caggaggcag	aggttgcagt	20520
gcgtgagat	tgtgucaltg	cactacagcc	tgggcaacaa	gagcaaaaaa	aaaataaaaa	20580
tgaaaaataa	aaaataaaaa	aaaaataaag	aagaaagaaa	agaaaactgg	cacaaacaag	20640
aalgcctctct	ctcaccactc	ctatttgaca	tagtatttgg	agtcttgggt	gcagcaatta	20700
ggcaagagaa	agaaataaaa	ggcatccaaa	taggaagaga	gggagtcaaa	ctatccctgt	20760
ttcaaatgac	atgaltctat	acctagaaaa	ccccatagtc	tctgcccaca	agcacattaa	20820
tctgattcac	atcttcagca	aagtttcagc	atacaaatgc	aacatacaaa	agtcagtttc	20880
attcctatac	cccgatagct	ttcaagctga	tagcaaaatc	aggaacacta	tcaccaccaca	20940
attgtttataa	aaagaacaaa	atacctagaa	atacagctag	ccagggatgt	ggaagatctc	21000
tacaacagga	attatataac	actgctcaaa	gaaatatggg	atgatgcaaa	caaatggaaa	21060
aacattttat	tctcatggat	aagaaaaatc	aatatcatta	atatggccat	agcgcccaaa	21120
gcaattttaca	gatgcattgt	tattcctaac	aaactaccaa	tggcattagt	cacaaaacct	21180
aaaaaantaa	aaaaaactgtt	ttaaaatcca	tatgaaacca	aaaaagacct	ttatagccaa	21240
ggcaattctta	agcaaaaaga	acaaagctgg	aggcatcacg	ttacccaact	tcacactatg	21300
ctacggggct	acagtaacca	aaacagcatg	gtactggcac	aaaaacaggg	acatggacca	21360
atggaacaga	atagagagcc	cagaataaag	gccacaacca	ctggatattt	gacaaagctg	21420
acatcattct	accatnaaga	tacatgcaca	caaatgttca	ttgcagcact	attcacagta	21480
gcaagatgg	gaatcaacct	aaatgcccat	caaaggtaga	ttagataaag	gaaatgtgat	21540
acatatcac	cacataatac	tatgcagaca	taaaaaggaa	tgagatcatg	tcccttacag	21600
caacataaat	ggagctggag	gtcattatgc	taagcaaaact	aacacaggaa	cagaaaacca	21660
aaataccaca	tgttcttact	tataattggg	agctaaagga	tgagaacaca	tggaactag	21720
gaggggtaca	acagccactg	gtgctacttt	gagggcggag	ggtgggagga	gggagaggat	21780
cagaaaaaat	acctgtttgg	tattatgctt	attgcccagt	gatgaaattt	cctgtacacc	21840
aaacccctct	acacacagct	tcactctat	aaacagctctg	cacatgtacc	cttgaaacct	21900
aaataactat	tacaataagt	aaatacatat	ttttaaaant	catttagaat	gtcagaaaaat	21960
tccaggattg	tattagtctg	ttcttgcact	gtlatgaata	aacacctgtg	actgggtaaa	22020
tttataaaga	aaagagggtt	aattggctca	cagttccact	ggcagtacag	aaagcatgac	22080
agcttctggg	gaggcctcag	gaaactttca	atcatgggtg	aaggcaaaaga	gcaagcaggg	22140
atgtcttaca	tggccagagc	aggaggaaga	gagaaggtag	acgggctaca	cacctacaca	22200
accagatctc	gtgtgaactc	tatcacaaaga	atagcactag	gaggatgggtg	ctaaaccatt	22260
agaaaccacc	cccatgatcc	aatcaccaga	cccacaagga	cgcacctcca	acattggggga	22320
ttatgattga	acatgagatt	tgttttagga	ccagatccca	aactatatca	aggatagagt	22380
glagaatatg	acaaaataat	ctaaactgtat	tacaatgtg	tgaacacaac	tcactgcagg	22440
tgttggttaa	agaagltgcag	acctaaagtaa	cttttggaaa	ttagltggagt	ctgtaatact	22500
aaatgaaaaa	ctgtttlataa	acgccacact	cttgtttttc	acagggatat	gggttaacaa	22560
ttctataact	tctatacgtg	tgtattggaa	ttgagcaglt	aagtaaatga	tggtaaatgt	22620
tgggtagtga	ggctgggttt	tctctgctgg	agtggaggtt	tatgctaata	caaagggagg	22680
gagctaaaaat	aatctctgtg	gtaatggatt	acagttggat	atattaatat	taaaatcatat	22740
ttggcttaaat	gtagatacac	atggctacat	acacgtacac	atggctacat	atagacacat	22800
atagatatgt	gtacatacat	gattagtata	cacaaacgtt	cccttccatt	gacaaatgag	22860
aaggccctaga	agcaacagta	ccccagtagt	aacaagcaca	totggcatcc	agttcatggt	22920
ttgfaatagc	actctgcaat	aaagggaaac	agggtctctt	agaaaaattg	gtgtttctag	22980
gactagggca	ggaaatatat	atgatgagcc	tgtaacattt	tgtagtgcga	gaaaggaaag	23040
aagtgtcaac	aacaaaaaca	agcccacaaa	gatggggctg	tgtcaaatag	atgtactgaa	23100
agagccaata	ccaagaactc	ctgacgccaa	atctggaaaca	ctttggggaa	acaaataaag	23160
cagtatggaa	ttglaacaca	aagtataaaa	taaatagcca	tgaagctaca	ctaataaag	23220
taaaataagt	aataaataaa	taaatggggg	caaagaaaca	atcttccatg	cagaaaaact	23280
ccaaatgatt	tatgtagata	tggcaacctt	aaggagataa	agcataactc	ctcactgttt	23340
cagttcaggg	cacacatagt	gactttcttc	caaagagtat	agtatgaaaa	agggaaataa	23400
aagagttaact	tgtgatggaa	aagcctgaca	agcacaataat	acctcagcag	agtgatcagg	23460
gtcaacataa	acagtaataa	atcatatcaa	cagtatgttc	tcttgakaty	atacagtgaa	23520
aatcatctag	tcatctcttt	ttttttttta	gatggagttc	tgtctctgtc	accagggctg	23580

gagtgcattg	gagtgcattt	ggctcactgc	aacatccacc	tcctgggttc	aagcgattcc	23640
cctgcctcag	cctcccgaqt	agctgggatt	acaggcgccc	gccaccatgc	ccagctaalt	23700
tttgtatttt	tcgtagagac	agggtttcac	cactttgacc	aggctgggtg	cgaactcctg	23760
accttgggtg	gtccactctc	ctcatccccc	caaagtgtcg	ggattacagg	cgttaagccac	23820
cgcgcttggc	tgaanaatgc	ccttaacctc	tgtagtcttc	ttccccaaaa	aaacattatc	23880
cctgtctaat	aatgacaaag	acatctaaca	aatccccaaa	gatagatatt	taaaaaatac	23940
ctgacccatt	cttctcaaac	tgltcaagatg	accaaaagca	ggaacaaactg	aaaagctgtc	24000
ataaccaaga	ggggcctlgag	aagacatgat	gatgaatgtg	tatatgatat	tctggatggg	24060
ttcttgggtt	gcaaaaggga	atttatgcac	aaactaaagg	aatttgatta	aaacatggac	24120
tttcagttat	ggtaattgct	tgatatttgt	tcatttaattg	caataaatat	accttgctaa	24180
tgtaatatat	tcataaagg	gaaactgggt	acagagttaa	tgagaactcg	ctagactata	24240
ttctaatagt	tctgtaaatc	taaaactatt	gtaaaaatca	agtttaottt	aaaaatatta	24300
ctgactgtct	tggttctgtt	ttactacctt	ttttttttct	tttttttgag	tcagggtctc	24360
cctctgtcac	ccaggctgga	gtgcagtggt	gtgatcttg	ctcactgcaa	cctctgcctc	24420
ccgggttcaa	gcaattctcc	cacctcagcc	tcagagggtt	gaataatact	tctttgtttt	24480
aatcattcag	ctcagattaa	aaacacggcc	taatttctta	atgtcaacta	ttgccttgcc	24540
ctctgttata	tcctaccttc	tcccattcgt	tatagtcact	ctctagtatg	gtattgagtt	24600
gggatgtgtc	atctgcccac	caaatlttta	tatttttgtg	agagatgggg	tttttgtcatg	24660
ttcccagggc	tagtctcaaa	ctcctgagct	caaggcagtc	gcccaccttg	gcccacccaa	24720
gcgctgagat	tacaggctatg	agccacattg	tcagccattt	tcattttact	tttctttccc	24780
attgagccca	attcttaaaa	acatccagtg	gcagcttagc	ttgggtgtct	tggtcagctt	24840
ctggagggtt	gaatgatact	tctttgcttt	tctttgcttt	aatcattcag	ctcagattta	24900
aaaatttctt	aatgtcaact	attggttgc	ccctgttat	attctacctt	cttccattcg	24960
ctatcctaac	tctctagtat	ggltattgag	tggggatgtg	cacacacagg	caaacacaca	25020
cacatcacaca	tcccacatac	tatacagtg	tgtgtgaaa	ctgtgtcaga	ccagctagag	25080
agacccaatt	gtlaaatatt	caagaatgag	gcaaggcagt	tattaagcac	atccattatt	25140
aaaaattaaa	ggataaagtt	acaalttaagt	aatcatattt	aaaaagaaa	gttataaata	25200
atatcattac	ttctattttat	tttactatta	tctatacttt	ttgaggttaa	gtctactgta	25260
tttctataat	ggaattctca	ctactgtgtg	tgtactctct	tgaltccgta	tttgggtgatg	25320
tcacccctgat	atgacatcat	atcattgata	tgtatgaaa	tagaccatgg	gtggagtatt	25380
tgtaccatgg	atattgaaaa	aacttaaatc	agagcttgag	ttattgtttt	gttgattttc	25440
tactttaaaa	agatggatgt	gcttaataac	cggccttaaa	aagatggggg	aaaatgttat	25500
cacgggtta	actgtagggt	aagctctaaa	atgtttgtag	ctgttacatt	tgaatagcac	25560
aaaatattga	ggaatattct	ttaagtgttt	gaaaacagtt	ttaaactcag	caaagaggtt	25620
aactgatatt	gttaacaaga	ttcaacttca	ttcaattcta	ttgttatact	ctcatcttac	25680
tgttcaatat	aatgaaat	gtcaattgat	attcatttga	gagttactct	catltgttaa	25740
ttgcaaccat	aggttaacta	aagatacaag	agtttggota	aatcagtgag	aacattgtat	25800
gagataagtt	tcattatata	gaatagagaa	tattatatat	tttattatta	tttgtaagtt	25860
ttgtattaca	tatccattat	gtcagtaaaa	tttataataa	acatgtacat	atttattttt	25920
tgtggttgtt	tattaaacag	ttactagcaa	attgtctagt	acacacattc	cttatcaaaa	25980
atgtgggaat	tatttgcaac	ataaatgaga	acatatgagg	ttatacgtag	taggtacaat	26040
cttaagaga	caaacacaaa	gtatgattga	tacttccact	agacatottg	tcaagagaa	26100
tataattccca	aataggtatc	acaaaaaalt	ttgttgaac	tagacctttc	cacaagctat	26160
gggtcctctat	aatacatat	ttttaccaga	gtttcttcat	ctaattaggt	ttttaaattg	26220
tggtaagaa	aagatacaga	taaatgaatt	agatgcagcc	tggccaatat	gggtgaaacc	26280
catctctact	aaaaatacaa	aaattagctg	ggtgtggtgg	cagacgcctg	taatcccagc	26340
tactcgggag	gctgaggcag	aagaattgct	gggagccggg	aggcagaggt	tgcagtgagc	26400
tgagattgcy	ccactgcact	ccagcctggg	cgacagagcg	agactccaac	tcttaaaaaa	26460
aaaaaaaac	aatcaatta	gatgtattaa	ttagggaatcl	gctatgaact	gaattgtgtt	26520
cccccaagat	ttacatgttg	aagcgtaac	ctccaatgtg	gcaatattta	cagatcgggc	26580
ctttaaagag	glaattgagg	ctacaagagg	ttgttaagggt	ggagccctaa	tccagttagaa	26640
ctggagctct	tacaagagga	agacacacca	aagggtgcag	ggcacagaga	aaaggccatg	26700
laaggacaca	gtgggaagg	gccatctaca	agccaatgag	agaggcctca	ggagaaacca	26760
aatctgtcaa	catcaacatc	ttgatcttgt	acttcagcc	tccagactat	gaaaaaaaca	26820
ctattgtttg	agccgcctctg	tctgtggtat	acctgttacc	atggtgtttg	taggggaagcc	26880
ctagtaaaact	aaaacaaaat	cttagattgt	aagtaataga	aatcaactgt	aggtagatta	26940
tagcagaag	aggacagaaa	tgcaggtaaa	agttacaact	ggaaactgca	gtgctatagg	27000
aagcccaaga	tgttctcttt	ttctgtatct	cctctctgct	atagcctatc	tatttttatc	27060
tgaacatctt	tattccacac	atctttatct	cacagctata	ctgtccata	tgatagtcac	27120
aaggacatg	cggcttttta	aatttaataa	aattcagttc	ttcagtcaca	ttaagatat	27180
tgcaaatatt	aaatagctac	atatggctac	tgtgttggac	actgtagata	tagcacacct	27240

ccatcattgt	agatagtctt	tttggacagc	actggattat	aggattacca	gagatcaagg	27300
taaacctccc	ttgaagttga	aggtaaacct	ccattttaacc	attaggacac	ctcagctgta	27360
tcactccctt	ttaaggccct	tatttagatt	lgsatttata	attttttatc	atttttctta	27420
gggactgata	tcaccagtga	cccttaggga	aaggattagt	agtgaggaga	aucattatnt	27480
tgtattgttt	gaatgtaaat	acatccatgt	acaaactgca	taatatTTTT	taaggatttg	27540
gagttttgta	ttgctcatca	ttgtatccaa	acacccagta	tagtacctta	acaggtaatg	27600
ttaggaagtc	gaagagatgg	acatacgggt	aatgctaaat	cctgtgatgg	tgagaagatg	27660
ctctggttat	gcctaattct	ttctgcttca	agcccaagcta	ggtctgggaa	ttgcttgggg	27720
aaactggaag	cctgaaccag	aggactgtgt	gcattgtgtc	atgctgtcgt	gcgtgtgtgt	27780
gtactggtag	gtaataaata	actactgtgt	atctgacact	atggtagttt	atacttttta	27840
tgtctactct	aaacaaccaac	actacaaagt	agtcaacctt	gtacccattt	tataaatgag	27900
gaaactaaga	ctaactcatt	tatcctgggt	tgttcttttt	tcttttcttg	ttagtgcatt	27960
ttgacagita	cacaattggt	actaaataga	atgtagccag	ttctagagaa	acttcattct	28020
accagtgttt	attttattat	tttatttttt	attagataat	tcatactctt	ggatcaaaaa	28080
ctggtagcaa	attgtattta	gcacgaagta	aatcttccct	cacacactac	cctcaggcaa	28140
ccgtcaacaa	cctcttgtgt	gtctttacag	aaatatTTTT	tgtgtataca	acacatatac	28200
gaaktatttct	aaaattttaat	ttggagtatt	ttacalactc	caaactcttt	ttttcacttg	28260
acaatatatc	ttgaaaatca	ttatatatta	ctagatctgc	tgaatttott	ttaatagcta	28320
tatgttattt	gttgtaggaa	agcctcaaaa	tttattcaaa	tcctactca	tttatgattg	28380
ttgtttcata	tcttttggtt	ttacaaagct	tcagtgacca	ttcctataaa	taggccaatt	28440
tgcacatgtg	gaaatatatc	tgagaataaa	attctlagag	gtagagtgtc	tgagtcacaa	28500
ttaaaggcaa	agagtcttta	aaclcttcat	agataattgt	aatTTTTatc	catagatgtt	28560
atacaaatat	acttcccttc	agcaatgttt	atccataccc	tttccaatac	taagggaacc	28620
ctttcttgta	caagagaaaa	agaaagaaag	aaaaatcaat	ctaatttgct	taraggcacc	28680
taaagatttl	tttttttttg	gccttgccca	gaagttaatg	atttcagtga	acctaccctt	28740
caccatcccc	atttcttgga	ataatattaa	tactactttc	caactgaaac	tctgagatca	28800
cattctttct	tttctatttt	atataatact	ggcctacttt	atatatgact	gggatggagg	28860
ttgtlcatct	tgctcatctg	tgtattatgc	aaatttgctt	ccaagcagat	tggcctcttg	28920
caaccctggt	gagaggtgac	agcatgtctg	cagtcctcag	agccctcgct	tgcaacctcc	28980
ctgcctygge	tcccactttg	gcggcatttg	aggagccctt	cagcccccac	ctgcactgtg	29040
ggagcccttt	tctgggctgg	ccaaggctgg	agcccactcc	ctcagcttgc	aggaggtgtt	29100
tgagggagag	gcgcgagcgg	gaaccggggc	tgcctgcggc	gcttgccggc	cagctggagt	29160
tccgggtggg	cggtggcttg	gcggcccgcc	actcagagca	gncagccagc	cccgtggccc	29220
ccgaggaatg	agggacttag	caccggggcc	agtggctgcg	gagagtgtac	tggatcccc	29280
agcagtgcct	gcccaccggc	gctgtgctcg	atttctcgcc	gggccttagc	tgccttcccc	29340
cggggcaggg	cttgggacct	gcagcccgcc	atgcctgagc	ctcccaacca	ctccatgggc	29400
tctgtgctg	cccgagcctc	cccgaagagc	accacccctt	gctccaaggc	gcccagtcct	29460
aacgaccacc	caagggtgta	cgaatgcgag	cgcaaggcgc	aggactygca	ggcagctcca	29520
cctgcagccc	tgggtgcagga	tccactaggt	gaagccagct	gggctcctga	gtctgggtgg	29580
gacgtggaga	acctttgtat	ctagttcagg	gattgtaaac	gcaccaatca	gcgcctgac	29640
aaaacaggcc	actgggctct	accantcagc	aggatgtggg	tggggccaga	taagagaata	29700
aaagcaggct	gcgggaggca	gcattggcaa	cccactcggg	tccccttctg	caccgtggaa	29760
gttttgttct	ttcactcttt	gcaataaatc	ttgctactgc	tcactctttg	ggtccacgcc	29820
gtttttatga	ctgttaacac	tcagtgcgaa	gatctgcagc	ttcactcctg	agcccagcga	29880
gaccacgagc	ccatygagag	gaacaaacaa	ctccagccgc	gctgcgttaa	gagctgtaac	29940
attcacccgc	aaggctctga	gcttcaactc	tgagccagcg	agaccaggaa	cccaccgaa	30000
agaagaagct	ccgaacacat	ctgaacatca	gaagggagag	actccagacg	cgtcatctta	30060
agagctgtaa	cactcacggc	gaaggctctg	agcttcaactc	ctgagcccaac	gagaccacga	30120
accaccagag	aggaagaaac	tccgaacaca	tctgaacatc	agaagggaca	gactccagac	30180
gcaocacctt	aagagctgta	acactcaccc	cgagggtccg	cggtctcatt	cttgaagtca	30240
gtgagaccaa	gaacccacca	attccggaca	cactgggtca	ctttctgact	gcactttctt	30300
gaagtattcg	tctttggctc	tgtggtagta	ccagtgggac	aacctcactt	gcctgtaaac	30360
tacttctctg	aggtattttc	cctaacaacg	tgaatatcat	tccattttct	tgcttgctct	30420
ttctcatgact	ctcalttcaa	tggctccttag	aaaaacactt	ttttgattat	tattcagctt	30480
tgtaataact	atttcttcag	ttcccatcc	ataaagtctt	tgatttagag	gtcaaatctg	30540
ttttgcttta	ctatttccat	ctaaagcttg	aaagtatggg	aattaataaa	aacattccac	30600
atgttaaat	agotttaaat	ttagcttttaa	aagaagatag	cagttaatca	gtcttgatga	30660
cgtagagggt	gacaggtaga	aggatcctaa	aatttaattc	ctgggctgct	aacttcaaat	30720
ctcatctgta	tcaacagttt	tctcaottaa	gtcatttaaca	tcgaaaattt	ttttattaaa	30780
tgattttata	ttgggagagt	actattttct	tttctcccca	cctccagtta	tgagaagata	30840
ctkattccca	gctttttctg	ggtagagcta	ttcaattttt	tttttttttt	tttttttttt	30900

tttttttttt	tttttgagat	ggagtttcaac	tcttgttacc	taggttggag	tgcattgctg	30960
caaatcttgc	tcactgcaac	ctccacctcc	caggttcaag	cgagtctect	gcctcagctt	31020
ctggggtagc	tgagattaca	ggtaaglgcc	cccacgccc	gctaattttt	gtatttttag	31080
aagagatggg	gtttcaccat	attagtcagg	ctgatctcga	actcctgacc	tcattgtgac	31140
caccgccttc	tgccttccaa	agtgcctggg	ttgcaggcgt	gaaccacogc	atccagccca	31200
atttgttttt	tcaatctttt	tggcactcta	ccaaatcagc	aaggctcttc	ttagttaggg	31260
gaacagaagg	gatttagtct	taataaattt	ttctccatgc	catggggaag	actctctcag	31320
aaggtagcat	ctagaacaga	acattgaaaa	gtttataaac	aacaccagta	cttcataott	31380
ttgtttttatc	ttccctttga	gatagacgtt	tagtccctta	ctgttattac	ctagcacaat	31440
atctggcaca	cagtaggtgg	ccactgatta	tttcttgaat	gaagtaagga	atgagaatat	31500
tacctacaga	gttagagctc	tggcatttac	ttccttccag	atttcataca	tcttttttta	31560
gtaatgaatg	caaacaggct	ctggggcagc	tacattatcc	ttctgaatca	agacagggat	31620
ttcgcaatgc	ttattttcaa	tttcttcaga	aatgccttaa	agataattaat	ggaggttaaca	31680
acttaatctc	aaatagtaat	ccatagacag	aatatgtaac	agcaatgttc	tctgatctgt	31740
tctttggcct	ctattcccta	gagaaatagt	tctctaagac	caaacagctc	atagatagaa	31800
ttgtagcaac	agtcaattat	gatgttagct	atttgagaga	cggttgagaa	ttcagaaaaa	31860
actactgaaa	tgttgtaaga	caactcactc	aaagaacagt	tcaaalagtg	gaaaggggaa	31920
atgatgatgt	atccatttat	tttgttctat	tttttccaa	ttcataggat	agcaaatgct	31980
gccattttat	ttattttttt	atttttcata	agttattggg	gtacagggtg	tgtttggtta	32040
catgagtaag	ttcttttagtg	gtgacttgtg	agatatgggt	tcacccttca	cctgagttag	32100
atacactgaa	ccatatttgt	sgtcttttat	ccctcgcccc	ctccatctct	tccccgttag	32160
tctccaaagt	ccattgtatc	attcttatgc	ctttgcattc	tcatagctta	gctccacat	32220
atcagtgaga	acatacaatg	cttgggtttt	cattcctgag	gtagttcact	tagaatagta	32280
gtctccallc	tcattccaggc	cactgcaaat	gctgttaatt	cattcctttt	catggctgtg	32340
tagtattcca	ttatatatat	atataatata	cacagtttct	ttatacactc	attgattgat	32400
gggcttttgg	gttagtttga	cgatttttgc	atttgtaatt	gtgctgctat	aaacatgctt	32460
atgcaagtat	cttttccaaa	taatgatccc	tttctctttg	ggtagaaacc	cagtagtggg	32520
attgctggat	caaatggtag	ttctactttt	agttctttaa	ggaatctcca	cactgttttc	32580
catagttagct	gtacttggtt	acattcccaa	cagtgttgta	aagggtgttc	ctgtccacca	32640
caccatgccc	aacatctact	gttttttgat	tttttgatta	tggccattct	tgcaggagta	32700
tagcattgtg	gttttgattt	gcatttctct	gatcattagt	gatgttgagc	attttttcat	32760
grrtgttgg	cagttgtata	tcttcttttg	agaattgtct	tttcatgtcc	ttagccact	32820
ttttgatgaa	attgttttgt	ttttttctct	acagatttgt	ttgagttcat	tgtagattct	32880
ggatatcagt	cctttgtcag	acgcatagat	tgtgaagggt	ttctcccact	ctgugggttg	32940
tctatttact	ctgctgactg	ttccttttgc	tgtgaaaaaa	ctcttttagtt	taactgggtc	33000
ccagctacgt	accttttgatt	ttattgcatt	tgcatttttg	ttcttgggtc	tgaatccctt	33060
gcctagltcaa	tgtctagaag	ggtttttcca	atgttatcgt	ctagaatttt	tatagtttca	33120
ggctctagg	tttagtctct	aatccatctt	gagttgattt	ttgtataagg	tggagattga	33180
ggatccagtt	tcatttctct	attatgtggc	tagccaatta	tcccagcaac	atttgtttaa	33240
aagggtgtcc	tttcccogtt	ttatatattt	gttctgctgt	tcaaagatca	gttggctgta	33300
agtatttggg	tttatttctg	agttctctgt	tctgttccat	cagtctatgt	gcctattttt	33360
atactagtac	atgctgtttt	ggtagctgtg	cctttatagt	atagtttgaa	agcaggtagc	33420
atgatgcctc	cacatttgtt	ctttttgctt	agtcttactt	tggctgtgca	ggctcttttt	33480
tggtttccata	tgaatttttag	aattgttttt	tctaattctg	tgaagaatga	tggtaggtatt	33540
ttgatgggga	ttgcattgaa	ttttagagatt	tttttggcgg	tatgggtcatt	ttcacaatat	33600
tgattctgct	catccatgag	catgggatat	gtttccattt	gtatgttgtc	tattalttgt	33660
ttcagcagtg	ttttgtagtt	tttctttag	aggtcttttg	actccctggg	aaggcatatt	33720
cctaagtatt	tgatttgatt	tgaatttttt	tttttttttt	ttgcccgtac	tgtaaaaggg	33780
gttaagttct	tgaatttgatt	ttctgcttgg	tgcgtgtttg	tgtatagaag	agotactgat	33840
ttgtatatac	tcaatttcta	tccagaaact	ttgctgaatt	cttttatcaa	ttctagttag	33900
tttctggagg	agtccttagg	gttttcaagg	tcaacgatca	tatcatcagc	aaacagtga	33960
agtttgactt	cctttttact	gatttggata	ccctttttat	ttttctctct	catctgattg	34020
ctctggctag	aacttccagt	actatgttga	agaggagtgg	tgagagtggg	catccttgtt	34080
ccagttttca	gaggaaatgc	tttcaacttt	tccattccag	tattatgttg	gctgtgggtt	34140
ttcatagatg	gcttttatta	catttaaggta	tgtcccttgt	atgccaatat	tgtctgagag	34200
tttaatcata	acaggatgct	gaattttgtc	aatgtctttt	tctgcatcta	ttgagatgat	34260
catgtgatgt	tttgttttta	attctgtttt	cgtggtgtat	cacatatgtt	aatcatccc	34320
tacattcctg	gtatgaaacc	cacttgatca	tgtcatgggt	gattattttt	tgatattgtt	34380
ttggattctg	ttagctagta	ttttgttaag	gatttttagca	tcaatgcccc	acaaggatat	34440
caactctgtag	tttttaaatg	tgcctttctg	gacgggcaag	gtggctaagg	ctgttaatcc	34500
caacactttg	ggaggtccag	gagggcggac	cacttgaggt	caggagttcg	agatcagcct	34560

ggcnaaatg	gtgaaaatcc	gtctctacta	aaaaggtgtt	gtggcgggog	ectgtaatct	34620
cagctactga	ggaggctgag	gcaggagaat	cgcttgcacc	cgggaggcgg	aggttgaggt	34680
gagccgagat	cgccaccactg	cactccagcc	tgggcgacag	agaaagactc	cgctcnaaaa	34740
aaaaaaaaa	aaaaaaaaaaa	gttgttttct	gclatttctt	gaactttatt	acgtaaaatga	34800
gacacgtgag	atctggaagg	aggtggaggt	gaagaccctc	ccacctggcc	tgcattccaga	34860
gtacttgagg	tgtggcactg	gcgtgggccc	caggaaggat	cccagccagt	tttgggtgctg	34920
gaggccccgg	caaaggaagg	gctgctctcc	cgteccoggg	gctccgaggt	cgccgcaccc	34980
gggcgcgccl	gggcctcgtc	acccgcgctc	gtgacgcgtg	cttccaaagg	aaacttttac	35040
aggtttcggg	gggcagggcc	ttttattgoc	cttctgctcc	acagcccccg	tgtttaatcg	35100
gttgggtggg	aggtttcctt	cgtecgltgg	tttgaaagt	ccccgcctcc	aaaccgcagt	35160
cccgagtcga	gttctgcagc	ctcagggcct	cgaaacagcca	tgtttagaat	ccgtecttct	35220
ttcctgctcc	atctaccctt	ccccctctgg	ttcttttttt	tcactggaga	aagcccaccc	35280
gagtctctca	gcctgcttcg	gaggttactg	cgccctcctc	cacgggtagt	tctgggaccc	35340
gggtctagt	cgcggtlccg	gagcaggctc	ctccctggag	tcgtcaggcc	cagtatgcgt	35400
gtgctcagtg	tgctcgggaa	acacgcgtgg	gctttaacag	cagatctcca	taaaagggtc	35460
ccggagatag	cctctgcctg	gcccgaaggcc	cagtgcctca	aagcggacgc	ctttgcgctc	35520
ccggagggtgc	tcacaccaca	gcggagcctg	ctggcgagtg	gagcgttagga	ctgcgaacca	35580
gcaatctccc	gagaagcggc	gagggggagg	ggaatgtctg	tgaatcggtt	atccctccca	35640
ccccagcag	aagtcgggga	aatgggggtg	gaagggggaa	aaagggagag	aacagggagt	35700
gggttgagga	agggtaagga	ggaaggtgag	cttctctacag	ctgcggggga	aggtggagaa	35760
aattttcagg	gggacagctg	agtggtagag	ctagcgagct	tcagagaaat	gltgacagac	35820
agatgccuag	aaagtgagga	tgccgggcat	gggcactgcg	taccaggcac	aggagatata	35880
tgagggoagg	aaattggcac	atcataagca	tttgaccatc	ctgccttaaa	acaaaaaaaa	35940
ttgaacaaca	acaacaacaa	aagataatag	caaaagtggc	acagttagtga	gctcgcaggg	36000
cccatctcta	tatagaacaa	cagaaaaata	agcaaaagct	gccagaattg	acttcgtggg	36060
oactctggga	aacagtaang	aagttttaca	gcaaccaagt	gagtgcgtga	ccaaggcaaa	36120
ggtaactgaa	acgcaatgat	agagaagagg	ggcagggaag	tgttgggtag	acaaaggcgg	36180
gtccctggta	agggccctcc	cctgggcctg	tgcccactgg	acctagggtga	ggacaggcac	36240
tccttccctc	acgcccnaat	gttgcatatc	ccaagaccac	cctgtcccg	cacgccccca	36300
tcctttgctt	atgaaaaacc	tgagacccta	gcaggcgagc	acacaagcgg	ctctatgtcc	36360
agaggaactc	atcgggagga	ctggacgtgg	agcgggggac	cccagcggaa	gggagcacgc	36420
cagtgggaaga	gcacactgac	agaccatagg	agtcagctcg	ttatattatc	atagtataat	36480
attalaaaaat	tattataata	caatnaaat	atnaaatat	aaataatgtg	ataaatatgg	36540
ataaaaaata	taattacata	ttkataat	tatgagaaca	ctatgaataa	ttttaagcca	36600
aaaaacaact	cgatgttcat	cactggatga	gtagacgagc	aatttccagt	atattcatac	36660
aatgggaatat	gattcagcca	taaaatgaaa	tgagggtactg	atacatgctg	cagcaggaat	36720
gaacccccaa	aacactacac	ttgggtgaag	aagccagaca	cggaagggtca	catattgtat	36780
gatcccat	ataagaaata	ttcagaatag	gtaaatccat	agagacaaaa	ggagttttgt	36840
agttgccagg	agttggaggc	aagaagagtt	taacaggltat	gcttaatggg	gctccttatg	36900
cagttgaoga	aaatgttttg	ggctagatag	gagtgatggg	tgcataacat	tgtactaaat	36960
gccactgaat	ctactacttt	aaaaattttt	gttttatgtt	atgtggcggtg	tacctaaaaa	37020
aaaaaaatag	aggtgcagtg	ctccagcacg	ggatgaggca	gcgtggacag	gagcatctcc	37080
caacctcagt	gaagtctgag	ccgcgtgctt	gcaacaatcc	oactgtggca	gagaaccgca	37140
gagttccttc	cggtttggca	gcagtcatte	gcaacctcac	agccctctgg	aaccccagcc	37200
tggggggtctc	agaacgcccga	ggcggggact	gggagccgag	tcggattccg	agaotatggg	37260
ccagggttgg	ctggattcag	ttacctggct	gaggcctggt	gagcaaaaata	tcccaaacct	37320
cgcgatgat	ggaaggggaa	gcccgatata	tacggatctc	cagatgtgoc	agtcctcaggt	37380
ctatcgatat	gaggtccccc	tagagtttct	attcatcatl	ttaacccgat	ttcctcgatc	37440
ttgagacacg	gcttttgata	ttttatcacc	tcaagataaa	tagtggttaga	tgtclaatag	37500
cagcgttttt	ctaagagata	catgaacaa	cagtgtcaga	aacgatgctg	tcttccatgc	37560
gatgaaattg	ttgttaatag	tgctcaataa	atgttgacaa	tcaatgagtg	aatgaatgaa	37620
aattlatttta	ctcttttggt	agcttttggt	ctgccatttg	ctagcagtggt	gactcaagag	37680
aagccagtaa	ccccctggag	cttccctagt	tcacanaaatg	cttgtcatga	agtcgacagc	37740
ttccggaggcc	tgcgaggctc	gcaagaaatg	cccacatgaa	tgtgcgctta	gggcgtgagt	37800
gctcactcca	gaaaactcca	acacagtgaa	aaggcagaag	cggtgttttt	ctttttttaca	37860
tttttataag	aatakatata	aaatgatata	aatggacatt	tacggtagtg	gggggaaggca	37920
tatatctaog	ttanaaggca	ggacattttt	aaaagctcta	ttttctaaat	gaaaactacg	37980
aaagcggggg	gggttgtggc	gggggaggtt	gtggccctgt	aggaccttcg	gtgactgatg	38040
atctaagttt	cccgagggtt	ctcagagcct	ctctggttct	ttcaatcggg	gatgcttgca	38100
gagggcagaa	agaaancagg	cgttagaana	ctgagggtcaa	agatgtgtgg	cacatcccg	38160
cctcctctct	tgccgtccct	accggcattg	aaatacttat	ggataaagtt	ctcgcaatgg	38220

etlcaegtgc	atgtaecgcg	cgccaccgcl	ctccccaccc	tceetgggtcc	agcagctagt	38280
ccactgccc	cctggctgct	ccaggcgccg	cgaccgctca	agcgcctccag	gtccaccgcg	38340
cggaggccag	agaaagcgcg	accgcgcggc	ccgcagggtt	gcaagaagaa	aacgagtggt	38400
atataatgag	tctcagtggt	tgctcacaat	gccaggcgcg	aaggcgtaga	gatgtggcct	38460
ttcccttccc	gcacccccag	gcactctttg	cacctgggtc	ggagtgaagc	agccagcttg	38520
cgataaccaa	aggcgccctc	aggctctggc	gctectcggc	ggantccgt	agcttcccta	38580
cgcattgctg	cttctacaaa	cccacaaatg	gtttccgac	atttctgaan	caaaatggat	38640
gctcatttat	tcattgtgct	tggtctctgc	cttctctctc	aatctcggtg	cgtatgggct	38700
ccagctcgcc	gttcgggtct	cccgaggcag	catttacact	tgagagcttc	aagattatct	38760
tattcctgag	ggagcatttg	cacttgaaag	tctcttttta	cgtttattcc	tgaggcagca	38820
tttgcaactg	agtttctttc	tcccgtagct	tgcattagat	tctccgacca	ctcttttagct	38880
tctctctcta	ttcacacttc	atatttacc	attgcattgg	ttttataaac	tcgctctctg	38940
aaaatagatt	gttatcttcc	ttaacgltcg	tttcccaggt	cgggcaagat	agcttgggac	39000
tgtaatccca	gtacttttag	aggaggagg	gggatgctcg	cttgagccca	gataacatgg	39060
tgagaccttc	glctctattt	aacaaacaaa	caaaccaggg	cgtcgtggcg	tgcaacctgt	39120
gtcccagcta	gtcgggaggg	tcagggtggg	gaaccccttg	agccaggggg	tttgaggctg	39180
cagtgaagct	tgatcgogcc	actgcaactc	aggttgggca	acagatcgac	tctgtctcca	39240
aatgtaaaac	ccatgagggc	aagactcttg	tttgggtcca	ttcaccttgg	cgtgcccacc	39300
acctagaaca	gggctgatca	cgcagtagaa	tctaaccata	taattaattg	tgcttgaaga	39360
gggggtgttg	ggagtaaga	gaaggaaagg	aggagggaag	aaatgaaaga	cttgtgtgtt	39420
tggaattaaat	ataattaggt	tggttaagag	tcgttcaggt	tattcatttg	cttgtggccc	39480
aatlcagtag	ttttactccc	tctcccactt	ggctctcag	gctttttgct	cagccctgga	39540
accgcgctgt	aattggcagc	tccttctaaa	tcgggaccgg	gatgctagct	gtaactggag	39600
ccgaagtctc	cttcttcacc	tcccgggacc	tggtgtctag	ctgtaactgg	aggggaattg	39660
cggggggggg	gggaggaggg	gccaggtaaa	gaagaacttc	gcgtctttaa	cttcgaagg	39720
gattttgcgt	tctgtattta	cagcatctcc	aagcagaggg	cttagagcta	actcttcacc	39780
ctgtectccc	cagctcccct	atggcccaag	gagcccaatg	cccccggtct	gggccaanaa	39840
aagatggatt	tcataatctt	caaggctcat	ttttacctta	aatattcggt	tttaattccc	39900
tgtaactggt	catatatcta	ttttgtttca	aaaaaaatg	ttcctccccc	cagaacaact	39960
tgagtaattg	tygcagtttc	agcagacagc	tgtaggagta	gggaactggg	ggcaatggaat	40020
gggggcggag	ggaggtagct	ttgagatcac	aaaaaggaag	ggcaaggcca	aggaggacca	40080
taattctacc	ttcatcgctc	agcgatctct	tgcaaaagtt	taagagggaa	aggagccaac	40140
tcgggtgcac	agactgccag	ggtcagcgaa	gtcttggtcc	tgatgtcccc	agaacccctt	40200
ggggcagctc	tggaanaact	taccgcataa	agcggagggt	cagattagct	gaggagggtc	40260
agattagttg	agttgtgcag	aagagccgag	atcgagagat	ctccagatga	tgccacgcac	40320
aattgggttt	ggaaatectg	aggttgggtc	agccagcttg	gtatgcaaat	gaggaaacag	40380
acctggtaag	tggtatgcac	tgcccttagt	ttggagggaag	agggggcact	agacctctag	40440
cctcttgagt	cttcattgct	ccgcagctca	ggccttgaa	tagcagaggg	taggtgtttg	40500
ggtgggtgga	tgctttggga	agtataatgt	acaaaatggg	ctttcacgtg	cgcaagttca	40560
tttcgggatt	atttccattt	tgccgcctgt	gcggggcagg	gcgataggga	gactcaggcc	40620
gtccccccga	ttgtcccggt	agctgagcca	agaccggaga	ctgggtctcc	gggtcgaact	40680
ttctgtgctg	gaaatgaat	gctctgagct	ttggaagctc	tcagggtaca	aattctcaga	40740
tcactcagtc	tcacctgagg	gaccttccgc	ggcatctatg	cgggcattgt	tactgcctct	40800
ggtgcccccc	gcagcccgcc	gcaggtaacc	tgcgacatcg	cgatggccca	gctcctcagc	40860
caggtccacg	ggcagacggc	cccaggcatc	gcgcacgtcc	agccgcgccc	cggcccgggt	40920
cagcaccacc	agcgtgtcca	ggaagccctc	ccgggcagcg	tcgtgcacgg	gtcgggttag	40980
agtggcgggg	tcggcgagct	tggtctccgc	gcegtggagc	agcagcagct	ccgccactcg	41040
ggcgctgccc	atcatcatga	cctgccagag	agaacagaat	ggtcagagcc	agggtggggg	41100
ccggcatgac	ggaaagggaag	cttgtgtaga	gccccctcac	cgccaaagcag	acccccacac	41160
aagccccagg	tgtctaatga	cccctacatt	tgcttccagt	ttccaatttc	ctctcttgagt	41220
tctctatcca	ttcttcagta	cacaaatgaat	tccattatat	cctccgaact	tctgcgggag	41280
tgctcgtcaca	ggcagagagc	actgtgaggg	acgggcacaaa	tagcaaaagg	gcagggacag	41340
actgactttt	actccagggt	aacttccgtt	atttcccctg	agatacaact	actgaatttt	41400
cttcttgaaa	ttatgttagg	cctggagatt	tttttttttt	tttttgttca	ctgctgtata	41460
tccaagcgca	gaatglggta	attgttaaaa	agagaaaact	tgtttgtttg	ttaaaacaaa	41520
ttctcacaaa	acttttaagt	tacacttagc	ttctgggaat	gttgaaacttc	aattttotttt	41580
tcatttatatt	agttttaaaa	ttatatattg	ggatagtaca	gttgtatata	tttatgtggg	41640
acaatatgaa	gttatgatct	ttgaacacaa	tggggaatta	ttaagtcaag	ctaagtaaac	41700
tatccatcat	ctcaaatatt	tgacattttt	gtcaaatgag	agcatttggt	atttactatt	41760
tagctatatt	catcatgcta	tgaacacat	ctcaaaaaaa	acaatcaaac	ttattcctcc	41820
catcttaact	gaggctttat	atcttgatta	ccatctcccc	attcctccca	ccccccagct	41880

ctagtaacca	ccattctact	ctttactgct	aagaalgtaa	ttgttttata	tttcacagat	41940
aagtgagaac	atgtgatatt	tgtctttctg	tggttggtct	atttcattta	gcataatgct	42000
ctccaattcc	aaaacttcaa	tttcttcaag	tataasataa	gaaggclagt	ttaatttacc	42060
ctaaaatlcc	ttctgtggt	aggctgata	atgcccccc	acccccaatg	tctatgtcct	42120
aatcctcaaa	aactttlaat	acattaaact	atgtggcaaa	agaggctttg	cagatgtgat	42180
tttaattaalg	gtcttgagg	agattatcca	gaattttcag	ggtgggcca	acataacccc	42240
aagtgttttt	attagaggg	cacagtcaga	gagaagatac	aagaatggaa	gcacaggcca	42300
cagagaaaa	acagagacca	tgagocagg	aatttgatgg	tcactagaag	ctggaaaaa	42360
caaggaaaac	gattgcccc	tagagtttcc	aaaaggaatg	aaaccttgtg	gaccttttt	42420
tgaacttctga	tctctagaac	tgtaaaaaa	taattttgtg	ttgtttttag	ctaaccacatt	42480
tgtgataaalt	tgtaacagca	gcagttagga	actaaaaaac	ttcccagggt	tatgatttga	42540
gagttcatta	aacaagagat	ggtcacctct	ttggttccct	aatcatcttg	gaancacagc	42600
catttccaga	gaggaaat	aaaatactgt	ctgcagtcct	agcaacotta	aaatttgagt	42660
gctgcaggt	ggagtagac	aatttatttt	aggataactg	ttatttgtta	tatttagttg	42720
aggatggtgg	tgttaaagag	gagttactta	tttttaggta	catttcatac	taaacacaaa	42780
ttgcataatt	tgcctaaatc	aaggaaattat	actaaattat	atlatgggta	ttaaatccctg	42840
tcctgagaaa	gtgaaactga	ctcagttttc	aaagagacaa	agagaaagta	taagcaaac	42900
aaattgcagc	tacaaaaaga	aagacaaaat	gttgacgtat	atttattgtt	tttgttattc	42960
aatgaagtcc	ttcgtcttgg	tcataaaaact	agccttaaag	gtttttctta	tatttcatag	43020
tatgaaaaat	ctaaaaagta	acccatatgt	aaatatttaa	atcatgatag	aaatccaaag	43080
caaaaagaaa	atgaatcaat	tgaattlaaa	tgtgtaggat	gcttaaacc	atttgataat	43140
atatccattt	gataatatac	taatatgaat	ttagtaactt	aaaatgttat	ataaataaat	43200
gttcttatat	taaacaccaa	tgtagttagg	attctaagcc	aacatcattt	ccctttttct	43260
acatgttctt	ctcccgctct	cattaasaat	tgtcaaaact	atccactttt	ctttttcctt	43320
tttgttttta	aacaaataag	gtctcttcta	agatattgta	ggactacaaa	gccaaaactcc	43380
cgggttcaag	ctggtggcaa	aatttttagag	atgctaagtt	acccatgtat	taattacttt	43440
taaatcctcc	cctaactccc	tcacaaaaca	ggagttagga	gaggagaaac	acctctgttc	43500
aaaaatgagg	aattgaaaac	tcttatcaca	ataaaactat	atcaagtaag	ctaaagatag	43560
taaaagagca	aaaatgttag	oagatattcc	caaaatggta	actacalatt	acctctggaa	43620
tgatcacatg	aatgtggotc	attatttcc	aagttccctac	agcaaacata	tatttatttg	43680
ccctactcag	ttaaaataaa	acacaatatg	tagttgcttc	tgaataattt	ttctctctct	43740
cttctctct	ttctttcttt	cgacaaaagtc	toactctgtc	acccaggctg	gagtgaagtg	43800
gctccatctc	gctgttcaact	acaacotcag	cctcccggt	tcaagcgatt	ctcctgcctc	43860
aacctccga	gtagctggga	ttacaggcgc	ctgccaccac	ccccggctac	tttttgtatl	43920
tttagtagag	gcgaggtttc	acctgttggc	caggctggtc	togaaotccc	gacctcaggt	43980
gattcccccc	gccttgatct	cccaaagtga	agggattaca	aggcgtgagg	caccgcgcgc	44040
ggcgccttct	gaataaattt	gatcaaaatt	tatatccgat	atttattcca	acatacacca	44100
cagatttcca	ctgataatcc	ctcctagtta	gaaagataag	ctccatccag	glatctgtga	44160
attggagget	aagtaglccc	agcacctctt	acatttcttt	aagactccct	ttttatccca	44220
aacgttcgta	aattttgtat	ctgataaaga	gcatacttcc	atclaataca	aatatgtttc	44280
cccttcaga	tcttctcagc	attcgagaga	ctgttacgcg	cgtggctcct	cattctctct	44340
ccttggttc	ccaagccccc	agggcgctgc	caggagagg	tctgtgatta	caaaccctt	44400
ctgaaaactc	ccaggaagc	ctcccttttt	tcgggaat	cgaagcgcta	cctgattcca	44460
attccccgc	aaacttcgtc	ctccagagtc	gcccgccalc	ccctgctccc	gctgcagacc	44520
ctctacccac	ctggatcggc	ctccgacctt	aactattcgg	tgcgttgggc	agcgccccc	44580
cctccagcag	cgcccgccc	tctctaccc	gaccccggtc	cgcgccctg	gccagccagc	44640
cagccgaagg	ctccatgctg	ctcccgccg	cgggtccat	gctgctccc	gccgcccgt	44700
gcctgctctc	ccctctcccg	cagccgcgga	gcgcacgcg	tcggccccc	cctctggtga	44760
ccagccagcc	cctcctcttt	cttctccgg	tgtggcgga	agagccccc	ccgaacclgt	44820
ccctcaaate	ctctggagg	accgcgglat	ctttccagge	aaagggacgc	cgtgagcgag	44880
tgtcggagg	aggtgctatt	aactccgagc	acttagcgaa	tgtggcaccc	clgaagtcgc	44940
ccaggttgg	gtctccccg	ggggcaccag	cgggaagcag	ccctcgccag	agcagcggt	45000
ggcaaggag	gggactggg	ctcctccccc	cctgcccccc	acacccgccc	ccggcctccc	45060
tgtcccagc	cgcctcccc	cgcctgccag	caaaggcgtg	tttgagtgcg	ttcactctgt	45120
taaaaagaaa	tcggccccc	ccccgtttcc	ttcctccggc	atacaacctt	cctaactgcc	45180
aaattgaatc	ggggtgtttg	gtgtcatagg	gaaagtatgg	cttcttcttt	taatcataag	45240
aaaaagcaaa	actattcttt	cctagtgtgtg	agagccccc	cgagaatcga	aatcacctgt	45300
acgactagaa	agtgtccccc	tacccctcca	accttgatt	ttcaggagcg	cggggttcac	45360
taagtacagaa	accctagttc	aaaggattcc	ttttggagag	tcggactgct	ctctccttcc	45420
cctcccttcc	ccctcctgcg	tgtaaaacgg	ctgltcgggg	caaggttttc	tcagacgtgt	45480
acattgcctg	gtataagagc	agactcggaa	aagatgaggt	ttatttaata	cggagggggg	45540

agaattctgc	ctgtaggcag	ataggaaaaat	ggggaggagg	tcattggaag	gacggactcc	45600
atlcctcaag	tcataattcc	tagaccagaa	aaagtgtcca	gtgttctaga	agcagagttg	45660
cacagtgaic	caaagaccag	cttcaaatac	tgtcctgtct	ccttcacact	tcctcacattt	45720
ctctttccta	ctgaaaatac	cttgcatitt	tcgttaattat	aaagggggaa	gggaatatga	45780
gtgccccctg	ctttataggg	gttgtttgtga	gttttaaatga	tgtatttaata	catataagcc	45840
ttaagaacag	tgccacacat	cctaagctaa	tacctgttag	ctcttgaatt	atccgctttg	45900
aggactggct	tgcnatcttg	ttttgaggyca	tagaaagaaa	atgcttttga	gcaggacgcg	45960
gtggctcaca	cctgtaatcc	cagcactttg	ggaagccgag	gcgggcagat	cacctgaggt	46020
caggagttcg	aggccagctt	ggccaaaatg	gtgacacccc	gtctctacta	aaaaaocaaa	46080
aattagctgg	ccatggtggc	gcacgtgltg	aattccagct	actcaggagg	ctgaggcagg	46140
agaatcgcct	gaacccggga	ggcagaggtt	gcagtaagcc	gagatcgcgc	caccacccctc	46200
cagcctgggt	gacagaatga	gaactccgact	caaaaaaaatg	aaaaaaatg	ctttggatag	46260
aattatcact	attacatcaa	aggaaagtcc	ggatgcgggtg	gctcagctct	ataatcccag	46320
cattctggga	ggccgagaca	ggcggatcac	ctgaggccag	gagttcgaga	caagcctgac	46380
caacatggcg	aaacctgtgc	tctactaaaa	aatacaaaat	tagcggggct	tgggtggcgca	46440
tgcctgtaat	cccagctact	cggaggctga	tgtaggagaa	tcgcttgaac	ccaggagaaag	46500
gcgagaggtg	cagtgaagccg	agatcgcgcc	attgcactcc	agcctgggag	acaagagcga	46560
aacttggctc	caagaaaaa	agaaagaaag	aaagaaagaa	agaccaagaa	gaacttactc	46620
cctgaaaaga	ttatgggcac	cctccaccac	cctcacttac	aaagaaaagt	taaacagcac	46680
taaaagagtat	aacaagcgca	aggaggtaaa	agttctaatt	tttccctgtga	ctactacttt	46740
ttaagcttat	caaaaacatg	tactacgttt	taaaaaatgg	attgctcaga	ctttgctgat	46800
gccttaagca	catgcttaat	ctgectactg	gataatccag	ctctgtttaa	aagttatat	46860
lcaatccctg	gttgacttaa	accttgtaga	cccagtatat	cttgtacttt	tagtgtctgc	46920
ttgattttaa	aacatgtagt	ttttaaaaatg	aagccaatga	aaacaatttg	ggatgtcaag	46980
tatgttatta	aaatctacaa	tgcattactg	taccatttat	attttccctcg	gggtacctct	47040
caattagctg	tgtagcaatg	atagggaaaa	ttcaaactat	cgataaataa	aattatttta	47100
gtttagttta	agatatttta	tgatggagga	ggaagaaagt	ggttgccagg	atgggagggg	47160
gggaacacag	ttccatcact	aatacaatgg	ttctttcttt	ttgtttgttt	gtttttgtgtg	47220
tttttttag	atggagtttc	gctctgttgc	ccaggcttga	gtgaaatggc	acccgacgat	47280
ctctctcggt	tcactgcaac	ctccgcctcc	cgggttcgag	caattctcct	gcctcagccl	47340
cccagatagc	tgggattaca	ggcacatgct	gccatacca	gctaattttt	gtattattag	47400
tagagacggg	gtttcactat	gtlggctagg	cttgtctcga	actcctgacc	tcaggtgalc	47460
caccacactt	agcctcccaa	agtgtctggg	ttacaggcat	gagccatcgt	gcccggccct	47520
cagtggttct	taattggggg	gggagagtg	gaagagtagg	ctccttcaag	agtctgttga	47580
aataaatacc	ttcttctcaa	aaaagaaagt	aggtaatgat	tttttttaaa	aaagatgtgt	47640
tcacttgca	atgtattttc	agataaaact	ttcagtgaat	tcagggaatt	ctctgaaact	47700
ctuccatgga	ttcctacatc	aagaactctt	tcagctcttg	tgaaaaatat	atatagctat	47760
tgggtgaagaa	gatgggagat	gcaaccatat	aaaaacaaca	tttggatgca	ttataaacag	47820
gtgtaaaagt	tgactgcttt	ggaaatacca	agaacaagtt	ttagatatgt	tatatccta	47880
ctcttgagta	gagctctgga	aggattatgg	catcoltggg	tggggccatt	ttgtcttaga	47940
aattgaagtc	cttatccat	tataaactct	atgtaggggg	gaggggggag	ggatagcatt	48000
aggagatata	cctaaltgcta	aatgatgagt	tgatgggtgc	agcacacca	catggcacat	48060
gtatcacat	gtaacaaaac	tgcacattgt	gcacatgtac	tctaaaactt	aaagtataaa	48120
taataataaa	attaaaaaaa	tattatgtaa	ataakttaata	atagtgggaa	aactttccta	48180
gtttttctgt	taaaagagccc	attatactcc	cagtttactc	atacatatcg	acctgaggtg	48240
caaaatcccta	gaagaatgaa	aatataaagt	octggatctc	tgtgctcctt	atgocagctc	48300
cagatttcc	atgtgcaaaa	tgggattata	atatattttca	tgtggccata	aaatatgata	48360
atgtalgtcc	aaaagctttt	aatgtaaaaa	tttactacat	ttactaaatt	tactaaagtt	48420
tgttggttat	tgttattatt	attctcacac	ttacttttcc	tctttcctga	gaatgccatt	48480
cttttttttag	atttgcactg	ccttlgcagt	tttgaanaatt	ctacacgtga	aatttaaac	48540
tgtcttaatt	ctgatcagtc	ttataacaaa	aaaagactac	cacctgttca	ttcattcaac	48600
aagctcagaa	actaagggca	gacatgggg	gggggcagag	gggagtaggt	caaacatagt	48660
atctctacag	tcagactgcc	agggttcaaa	cctcaactgt	tccacttatt	ggttcttttaa	48720
cttttatcaa	agttactcaa	catgtctggg	cctctgtttt	ctcatttgca	tgattaggat	48780
aataactgta	cttgcctcaa	acagttgttt	agggattaaa	tgaagcatgt	aacgctctta	48840
gaagagcaaa	ataaagcaca	gaatgatata	agaaaatgaa	aagggtgacca	aactcattct	48900
cattttgtctc	tagtaggcaa	aggcttccgg	atgctgagag	ctgatcccag	tcttgaagaa	48960
tgatgtgaga	gtttaaagat	ggaaaagaag	gagaaagata	ttctaggcag	aggtaaagag	49020
atgtgcaag	gcatagaagt	ttaggaaaaac	tgaagtgtat	tcatttagac	ttattcctga	49080
aaaccagcct	gtgaaggact	cctcagagag	ccaaaagaaa	aactaggata	atgggatggc	49140
aaggaaagtgg	ggacactgcg	ttgactactc	tttcatagct	tggttgtgat	agttcaaggc	49200

cctatgccat	gaagtgaagg	agatggagg	tggaggagac	ctgagcacac	atatacctgg	49260
aaggggcaagt	gccaaagtga	gagaaggga	agtlagaaaa	gaataaaaga	aaagttaaagt	49320
acacaggcaa	gataggatat	ttttgaggac	ttgaggtooc	tcaaaaataa	tgaagaaata	49380
gaactcaaaag	tacagcgggtg	gttatagatt	ttgtcacaag	agatacatag	atlttgggagg	49440
gagaaaagggt	cagaacgggg	aggaagltga	ggcacttcc	tctatgaatg	aggaggttag	49500
cittgtttgca	gagtgaana	aagatgggtcg	gttaggaagt	ttgagaatcg	taagggtttg	49560
gaatacctct	tatgagtaga	gaggatgggt	tgagtaagac	tcagacagag	aagccttttg	49620
ttttgtttctt	taaaaccaga	ctggagaacc	cagctgaggg	tggagatcat	gacacagtag	49680
ggacacctga	ttacttttctt	laaactaaag	aaagccctgc	agtgggtgcta	ctacttcagc	49740
aaccctacaa	atcaaagact	agtcataata	gatgtgaata	ttaatccaac	atattaccat	49800
aaagagacag	aaagatactt	gagaaggtag	tggtccagag	ttgggttctg	gttctgatgc	49860
ggcattgtag	gattggcaat	atgcacgtat	ttcatgggat	aagcaagatg	atlttgttag	49920
gaaaataaag	ggagttagag	caatagctct	acactgagac	caagtgaacg	ttctcatgta	49980
tcraatgaac	taktttttga	ctgcaaaatc	ttttgagalt	atlttctagat	tcattgtcca	50040
taattttcaa	aatgggctct	ctctgttct	attgtttacg	cttgagggtga	gataatacac	50100
acatattttct	ttaccagttt	caatattaac	attattatta	aagataaattg	ttttaaatat	50160
agcttgggtgt	taaaaacaaa	atatacatag	aatatctctg	gggagataca	ggaaaagctg	50220
ttacctgtga	ggtaaggaaa	tgaagaactg	ggalgggcat	gtgacttact	tttcacattc	50280
catgatttat	attgtttgaa	ttltgtacta	tgltccatggc	ctttctaatg	aattaaabaa	50340
acataataaaa	actagtagac	aaataagtta	cttttatlag	aatcatcatt	cataacttta	50400
gttgaaaaag	agtaactgag	tacctaabat	atgtcaggca	ctcggottaa	agttgtcaat	50460
attaatttaag	aaagaaggltt	tcttaagtcaa	gagcatgtat	tggtaaacaac	catcaatata	50520
tttgctttctc	tgccaggcgc	ggtggctcac	gcoctgtaate	ccagcacttt	gggaggccga	50580
ggcggggcga	tcacgagggtc	aggagatcta	gaccatccta	ggtaacacgg	tgaaccccca	50640
tctctactaa	agatacaaaa	aattagccag	gcgagggtggc	gggcacctgt	agtcacagct	50700
actccggagg	ctgaggaagg	agaatggcgt	gaacccgggg	ggcggagctt	gcagtgaacc	50760
gagatcgccg	cactgcaactc	cagcctgggc	aacagagcga	gaactccgtct	caaaaaaaaa	50820
aaatgtatat	atataatatac	acgtatatat	atatacgtgt	atataatata	atacgtgtat	50880
atataatatac	gtgtatatat	atataacgtt	gtatatatat	atacgtgtat	atataatata	50940
acgtgtatat	atatacgtgt	atataatata	atacgtgtat	atataatata	acgtgtatat	51000
atataatatac	gtgtatatat	atataatata	gtatatatat	atatacgtgt	atataatata	51060
ttgtcttctc	ggaggaggaa	ggtgggtcttg	aactgggatg	agctcttgag	tggagcctac	51120
agtaatcatt	tgaggaggga	agactggggt	gatgcattct	gataaatgac	acctcacact	51180
tggtttaacca	ggaaaanaag	atlttcagagt	ctggaaaagc	tcccaataat	aaagagaatt	51240
cottaggaag	tagcttatga	gagcgagata	tatgccctgt	aatggagctc	ccagggtacag	51300
ctgtgttaag	ccttcataga	tgagttctag	aataggatgt	tgggtgcaat	agataattat	51360
ttgaaggcaa	aggcaatggg	ggaataattc	catgcacccc	tttaatttag	aaaagcaata	51420
atgtaaggaa	attagagtcc	ctgtcctagt	tctaccacct	actttgttac	cctgaaaaaa	51480
tgactttttt	ttttttttac	tagcttcaat	gltctgtatct	acaaaacggg	tataatcaca	51540
aacatgtaaa	aacagattgt	ggttllagccc	cgaagtgcc	aagtgtcctc	gaagctgccc	51600
cgataaaaaa	ttctgataat	cgagtccaat	gtgggtggta	agagcatttt	aaacgggaaa	51660
gaaacacttt	cttaggtana	taattgcaa	gtatttaatt	acttatgttc	cacaaggaaa	51720
aaagatacgt	tcagcatgaa	aggagacctt	ctgagaaagt	agagcagacc	tccaaacaga	51780
tttgctaaga	aaaaacaatg	tgtccctggg	agtagatctc	tgaagtttc	aaaacatttg	51840
atgtttcttt	ctccctttta	ctattctcta	tttaattaaa	ttcaatatag	cacaattatt	51900
tagtatttgc	tataaggaag	gtactctttt	agaaactctg	tgccaacttc	cctcattcag	51960
aattactgta	aaatttatct	tcctactcaa	actggatcct	agtaaggagt	acaaaatgca	52020
aaattotttg	atgtgtttga	gatttaattgc	ataattatag	ttaagtcaca	atlttcaacc	52080
ttagtttcca	aatgtttaac	tgggtataga	attagcagta	cctatttatca	tcttcccaag	52140
aatattttga	aggaaactta	aaagtatat	acttattata	tagcagggtat	cttttctaaa	52200
ttatgtgcaa	aacaaatgtg	atrttaaatc	tatgtgagaa	atttactatt	aaaatatctc	52260
taggggtgtac	tcttgtgaaa	tgagggatct	ttgcagctca	tggagacaat	tattocttaa	52320
ctttttttga	atgttttttt	atgttgataa	attactttgtg	gcgaattact	tatatctatt	52380
tgtagctatt	tgtcagctg	agaacactaa	aagattagca	cagtatgtat	gtatgtacat	52440
actatatgca	catatttgggt	atataatgtat	attatgtaca	gcacagatat	tgagaattga	52500
cctcaactctg	aggaaacaaa	laagtaataa	acataattag	aggagatagg	cagaaagaaa	52560
tagagataat	aaaaaattca	ttaaaagtgg	ccaagaaaat	aatggctatc	atlttttcaa	52620
ccccagcta	tgtgacaagc	atcaagcagt	tttatatgtg	taatttataa	ttccacagct	52680
gtcccagggg	atagagagta	ttattctttc	ttcataaatgc	agacaaaaaa	aaaagctcag	52740
agtgtcttaag	taataaggaa	aagaaaaglt	caaacttaag	gttctcaglt	ctgttttgaga	52800
ggtcctcact	ctccctacta	caataatgtt	tcctaattgat	aatttatcca	gtacattgtg	52860

gacaaactcat	caatgcttcc	ttttctttga	ggactctgct	ttagagcaag	ttgcaaaaacc	52920
tgggccaaga	ttactgactc	tccattttca	gaaactactg	tgcttctatg	attattcttc	52980
agtagtaata	catagtata	gaaatttggg	actcaaagac	acgcaaagtc	cctgaaagt	53040
cacttaattc	agtcctctca	tttttgaatg	atttgcttcc	ctgattaaag	ctcacatatt	53100
taaaaataat	taagggaatta	gctgcacata	gaaaatgaaa	aactacccca	cacaaagcaa	53160
taattatkaa	cattttgaaa	tacttcttcc	tttttctttg	cttaattctt	acattgtgaa	53220
tattatgcaa	ttttgaatg	agctttttct	aacttattac	agcattttcc	aaacttctcc	53280
aaaaacactt	cataaatgct	acttttaaca	gctgtaacac	atcccactgg	aaaaagttat	53340
aatttactta	atgatgtccc	tgttgtcaga	tatttaagggt	gtttctaatt	gctactaaaa	53400
atagtattgc	agtttttcaa	agggtagaag	gctcttgaa	atattgtaaa	actgcttttt	53460
aaaaagccac	cattttgatc	tatagataac	naaatggagg	agtggtagac	attgaggaac	53520
tatgtagcta	tggttactca	gctaalaat	gtttgctgta	gctgttgaa	tcagttcttc	53580
tctccattct	ccatttcttc	tatggccaca	gctacttaat	tggactaat	gtgggtggcg	53640
ggaaatgcca	accatatact	taatcataat	tttggasatg	acacatatgc	aagtgggaca	53700
agcctagtct	ttaaactcag	atagaactga	cctctcattt	accagctctg	tgggcttgaa	53760
taagttatgt	aaactttctg	agcctttatt	tcttcacctc	acaaagtggg	gaaaaataaaa	53820
tttaccocat	aggttactg	tgaggaaata	agaatgtcag	atatataaaa	atccgggtgc	53880
acggtaggct	ctcaataaat	gggtgctttt	aattttttga	gaattatata	gacatttact	53940
atgaagttaa	tcattttaggt	catcaaaaata	aatgtccttt	tgagtaattt	ttcattaatt	54000
cctgtacatt	ctagcaggta	tctgtgggtt	caacaagcaa	attctcttct	aaaaggtagt	54060
atgctacctc	tgaattctaa	ccctctgaaa	aaacagcttc	tttgtaacaa	agtttcccat	54120
gttatgacag	aagaatttcc	aaaaaaaacc	cctcattaaa	tcatgagaag	tgacactgga	54180
gagtgtcact	gtgttcagtg	tttctctctg	attcattgct	acccacctcc	actgcttgga	54240
gtgcattttc	agtggaaagt	acaatggaga	aactacagtt	aaaactgagg	aattgcaaaa	54300
tttactttct	ctaaaactact	tttccaaacc	tccctctttt	tcattcttga	taggacagat	54360
tttccctctc	caaataatgct	gtccttttta	attgctaaca	caagcatata	taatatctca	54420
tttctgctta	tgctgtgat	gtacgcaggt	gctgttagag	ttctgagata	atgttgaaag	54480
tcacagataa	ataataatgt	attcggtttt	cactactggg	agtggaggtt	taatatctact	54540
gtttcactga	taggttttaac	actgggttag	gataacttaa	tttcaggggc	accattctac	54600
tggaaagctt	tctcatcaaaa	tggagaatgg	ttgtccccc	tttgccctc	taaaaaacta	54660
tcccttaaaa	gtagcttgct	ttcttgggac	tctatagtct	tactgttatg	ttcaattttc	54720
tgtgtccttt	cctgaactta	ggagagttct	gaagccaatc	tccctcttga	tattattaaa	54780
gattgcaaga	aaattttctt	gtgttagacc	attcttcccc	aaatcacatt	cttcacctga	54840
tatgtgatcc	aactccactc	aagggaatca	acttcttgat	gaatatataat	caactttgat	54900
taaaataagta	actgcttcc	attcatgttt	tagcactttt	cacatacaga	tttaacattt	54960
ccactcatgt	tttcccttga	gtctctgggt	tgagggtaga	gttttatctt	ttgtgttgtt	55020
acggttaaga	tgataacttc	cataattaat	ttttcaaaa	ggcaatgata	acagaatata	55080
ctgtatgttt	actctgtact	gatttataaac	ccccagtc	atttagcctt	aagaagcat	55140
actatttagt	gtattttgtg	ttactctttg	atgctactat	tctaaataac	ttcttcacat	55200
ttgcataaaa	ataactgaag	gtcaccctcc	aaggtaggca	ttttgaatgt	cgtlaaggatg	55260
acagtaatgt	ttctgcctat	cattcctttc	atcacacaga	cacacacaca	cataattttt	55320
tatactaaag	aattttttaga	aaattgtttt	ggccaanaat	gttgattcag	atattcagac	55380
tgtgacaacc	attctgaagg	aattaaaaat	ccagttatct	tcagtgatcc	ctttggaaat	55440
tattattctg	ggttattaga	tagatagact	ataaactttt	tttccagttt	tctaaagcta	55500
ccttgatttc	ctgtcttaga	aaacaggggt	tcacaaacac	tgetttaat	ctctttaatg	55560
atratgaata	ctagaatagc	ttagagggtat	acccataaag	ccaccatata	gatcttctgt	55620
acagatgtga	atttaaaaagt	atgcaaat	acactgattt	tacctaacac	cttggaaacat	55680
accaggagtc	tgaatacata	aatatatatt	tattatgala	tgtatatttt	taaagtggag	55740
tttagaaatt	tctagctaca	ctgaaaaatt	ataatgaagt	aggtattttac	tgtaaaaaac	55800
taatgtgctt	tcttaagggtc	atagtttaai	taggcactat	aataactgac	aaacgtacac	55860
tgtglaaaa	tttacagtga	ctcttcacac	atactatttt	atctacctct	tattacggga	55920
ctaccatagg	gtctcaggtt	tacagatgag	aacatgaaag	cactgagagt	ttctcactct	55980
tcattctggg	accatgacag	ctaataagca	aaagaaatag	aatctgctca	caggctcatgt	56040
gaatgctaaa	gaaagtaatc	ttlcaactgc	acgcttcaag	tggttcctgt	gctgggtgaat	56100
aggtatccca	cttattgctt	ttaaattaa	gtaggaataa	gtastttata	tgtacagtca	56160
tatgagaatt	ttlcaactgg	tttatttttg	tcaaaaaata	aatttttgaa	agatgttaac	56220
ctcctttcaa	ccaataaata	tttactgtga	cttatacggc	tgatgcttga	gtatagtaga	56280
ggcccaaaag	ggtkaagcga	ctttcaaaat	aatagtttaac	taaaagagat	ggaactgaaa	56340
ccatatacat	attttatagca	ctccatgggc	aaccaagttc	aactatata	gaattactag	56400
tcaatgactt	ttggtagggc	atgcaaacct	tctgagcctc	agtcctccaga	tctacaaaat	56460
gaaaaaatga	aacattgaaa	acataaggat	attgtgataa	ttaaattaga	taatggaaagt	56520

tgaagtgtcc	tattattgtt	aagctccctcc	taattgtttt	tgaagaaaaac	aataacttta	56580
ccatgtgatt	taggaagaaa	gttccaataa	gcttttaaaa	attaaatgtt	aaataataa	56640
tattcaactt	caactattca	gcatgtaaat	tgcattgagt	aaaattcaaa	gtglccgatg	56700
ttggacattt	aacaattaga	tgttcaactg	ggggagtcat	tgttctctag	acagctgctg	56760
tttctttaaa	ttgggtgaga	gagttatata	attgctgagt	cagatgatct	ggcagcctga	56820
aagagaatga	gagcaagaaa	atggtggcac	tcgagaaaaa	aaagcaaaac	aagctttttc	56880
ctaatacatc	agcaaagtcg	ctggtgtaat	attagacaaa	ttttagctta	aaagcagaaa	56940
aatgatcatt	tgaagggcat	gatattttag	ttttctttat	aattgttact	ttttagctta	57000
catttttcat	ctatatttcc	cccccatca	ctgtgctttt	acagagacat	aaagacccat	57060
catttttgtc	ataaatgctt	tattctgtta	tggtacattt	ttcctgcaat	cttgccctga	57120
tcttagataa	gcataagtta	aacctgtgaa	acacttgtgc	tttgattttt	cttttttaca	57180
taatttttag	ttgtcatggt	tattacgaga	ctggctctgga	tcataaaatg	aaagaaaacc	57240
cttattacaa	cacacacaca	cacacacaca	cacacacaca	cacacagaga	gagagagaga	57300
gagagagaga	tccattcatc	ctgcacgaac	agaaaagaag	gtatatagtg	ttttaaaaag	57360
acaaacgtatc	ttatatagct	tatgtggaaa	ttttctgtct	gggtctgtaa	gctttaaaac	57420
acaaatatac	cttgttatat	ttttttctct	caaactatgt	tctgactgta	aaaaatgtgt	57480
atctacaaga	cattcttttc	caattcatatc	aaagggctac	ataataataa	agggctctct	57540
tcaatttggtg	aaataactcc	bcactgattt	actcagactc	tcctccctgg	gatccagtaa	57600
actgactcta	aacttaaaat	cttacctaaa	atcctggacc	tcaattcaaa	gataaagaag	57660
cagaaataag	gtttaaaag	taaaatttgt	catatttgtc	aaatttgtgc	ccaattggcc	57720
acttgtatta	gtatctctct	caagtgttta	tttaaaatgc	agattttctgg	gacccacagc	57780
aaatctgaat	caaattttct	gaacgtgaac	ccagaaata	tgtattttta	aaggcagccc	57840
aggtaataat	ctgtttgtta	acctttgcca	tacttttaaa	atttctagtt	actcacataa	57900
ttcaattaag	aaagcagagg	cttttttatt	tacgttaact	tgattgtacg	attttattag	57960
tttcaatttg	cttaagagat	tacatgtctt	tgtlcatgta	attctgaacc	tctataaaaac	58020
ttttctctct	taaaaaaatc	ctactgcctt	cacaaccatt	taaataattt	atgatatttt	58080
attttgaagg	tgaagagaga	aactgagaaa	taatttgaatt	aaaaaatcct	ttgtgataac	58140
atgtttatata	tttcatgaac	aaagccaata	agtcataaaa	attaaaaatc	aacatactat	58200
tttttgaaag	gacctctgat	gotttgggaa	tttcaatcct	gtagttgatg	gctttcactt	58260
ttttttccct	tttattactt	ctttttgatt	gtagagttct	gcccnaatga	aaccatcatt	58320
ccagggctca	tgaattaaat	gaatgcactg	agagacactg	acaagcactg	agaattttct	58380
caaccacccct	ttttaaaaaa	caaagtctaa	ttggacataa	atatgagaac	aatagacatt	58440
ggggactact	agatggagga	gaaagggaat	gagcgagggc	tgaataacta	cctactgtgg	58500
gtactgtgct	cactacttga	gtgacagatt	cagtcgtact	cgaaacctca	gcatgggtga	58560
atataccctt	gtaattaacc	tgcacatgtg	ccctctctct	ctaaataaaa	gttgaaaaaa	58620
aatctacgag	gcacttatatt	tttaaaaata	ccactatgta	caaggcactg	tgcataatct	58680
ggaactacaa	atattagtta	aatagtccaa	gattcagtggt	gttcagagac	tctaagtatt	58740
tgccattccc	tttagatgga	aacgttcttt	ggtcacccaa	gocctatcgt	tctgctcttt	58800
ggaaattctc	cctcactttc	ttcataatgc	cgctccttgac	taactctcct	ctagcaatac	58860
tattgggttt	gtatgtgatt	taaaatcatt	cctgtaattt	cttctgttta	tatggcttcg	58920
tacaagagat	tcacattcaa	caaatagaaa	aaaaacgcta	ttgacatttg	gtagcttoga	58980
caattgtaaa	cacatgtggg	tttgcgtaat	acacattaaa	atagcatgaa	ttaggatag	59040
gtaaatctgt	tgcggtccca	agttgggtgg	tttttctagg	aagagtcaga	ccctttaaaa	59100
ggacctttta	tcaatctacca	aacaaatcct	tcatttatta	attcccaagg	ttttctccat	59160
cgglttgctt	actgtcatgg	aaattgatct	tgttttaala	gctacttact	tttttttatt	59220
ctaataaatg	atttcatttg	aaagaaaat	tttcaaacat	ggggaaagct	gcaatataag	59280
agaaaaacaa	tggagagaca	tcttcaactg	aaaaataacta	cggggccactc	tctataccat	59340
cctgcacccc	cagatggaga	aactgagggg	agtcgtggcc	tttcaacact	cttgggtctc	59400
catctggctt	ggaagggaac	gaaatggctg	tcaagagctc	cagaagcga	ctttcccggt	59460
ggttccctcc	ggttaaccctg	actcactttt	catctaccca	tccctcccaa	aaacaaggctt	59520
agccagttcc	aagctggaga	ggtgacccag	agttgccttc	tgtcatgtcc	tgtctttcgt	59580
ctcagagtcca	ctaaccctac	tcagactctg	tctgtctcca	ccccaccgc	ggccagtgaa	59640
atcccaatcg	tcttccacgt	ggaacccag	gtccgcagtt	atgataacgg	atcacatcgc	59700
tccctgcggaa	agtgcgcgcg	gtggagtgat	aattggacct	agcgtctaaa	ttcttgttgg	59760
aggacctcgt	tcacagctgc	agtttagcct	ctgggatccg	cagcgtctct	aggaattgag	59820
agagtyggga	agtttaggac	caggaggagg	atggtggggg	ctgaggagtg	gaggagcagc	59880
gtgcattcca	tctcttgtcg	ccgggagggg	gctctttcgg	gtccaggggc	cttgaccccc	59940
cagcgtgggt	ccggaggcgg	cgagacctgc	ctgaatttga	ttggaggggg	ctagagtgtg	60000
ottgtggggg	ggggtagtg	gggcggagag	aagagatccc	aagaaggggc	ccaagtgtct	60060
tgaccagagg	cctaaccaga	ggcaccttgg	aaacaggtat	agctacggat	ttatgggttt	60120
taaaatggaa	cgtcttgggtg	aatggacata	gcgtgcattt	cacagtctga	cgtcacagcc	60180

ctcgcaggtt	ttccagagac	ttaaagccac	gttctcgtgt	atgacactta	ascaactcag	60240
tttcttltgc	tttctccct	ccctaccat	ctaagggtag	agaagctctt	agttcatcca	60300
ctgtgttagga	ctgttaaccgt	gtgtcaaaag	ctttggnaat	gtatatttta	ctgatgatgg	60360
tcatagcact	ttggaaaact	caaaagtga	acgaagaaaa	taaataatcac	caaaacttttt	60420
ccccacccct	ctcatccctgc	ggaaaccatt	ataactaatt	tggtgagaga	gagagagaga	60480
gagagagaga	gagagagaga	gagaaactgt	ttactgtttg	gaatcttgct	ttaaaaaaac	60540
ctgaactttat	aatgcaatca	tttaacagtc	tatgaaatat	tcttcagata	cctgatgatc	60600
cagaatgtaa	ctgtaccata	atttaacact	ttattgctag	aattttatgc	agtttttgat	60660
ttcttgctac	tacttatcoa	tctgtattaa	tctttgtcag	aacctttctt	tccttaggat	60720
gatgcctgaa	tataaaatag	ctgaatgaaa	gtggatgggt	tcatttttaa	atacaaaatl	60780
gtttttcttg	atggtgaagt	gtttaagagg	tggattaatc	tcattgggca	acaaatagag	60840
aagatattag	tagttaggta	tatgagaalc	agaattcaga	taatttgtct	taaaaaatca	60900
tattcaatgt	aaaaatttta	tattlagaaa	atgaaactgt	accatttgtt	tatataactt	60960
aaactlgccaa	aataaagcac	cacaaaaact	ttttatcacg	ttgggtttttg	tatcaggctg	61020
ggctttgcag	cagatggagg	agctaggcca	agcttgtcca	acctgtgggc	cagagggtca	61080
catgcagccc	aggatgggtt	tgaatgctgc	ccaacacaaa	ttcatacact	ttcttaagat	61140
atcatgaglt	tttttttttt	tttaagctca	tcagctattg	ttagtgttag	tgtattttaat	61200
gtgtgtccca	agacaattct	tcttcttctt	atgtggccca	gggaaggtaa	agaattgaac	61260
acctctggcc	tacagtgttc	tactatgaag	tttcagtttt	agttcggcct	agaatgtttt	61320
agtacagaag	gcaagtgaag	ttttctctgt	ttctccsagg	acttttgasa	aagtgtaaaa	61380
gcactgggcc	cactgttgaa	ccttgctata	aaaaagrat	tttgatacca	tttgtatcac	61440
tttagtaata	ggagtttttc	atatgttggg	aaatgggttt	agcttaactc	tatcatggta	61500
gttgatagtg	atgaactaac	gtggaataat	ngatctgtaa	accatcatag	acggtaatat	61560
gctatgthgt	tgctacctta	ggatcataat	ggactttcta	aaattoaaga	gtactcaaag	61620
aagtaaaatg	aatataagtc	ttgattttctg	aaagggctat	ggttcacttg	gaacacaata	61680
caaactgtga	atcatgtaca	catggggaat	aatggtttat	actaaactga	cagtgtctac	61740
cttgagagga	ctctgtgcta	ttaaagaaaa	aaataacctg	agccttctga	agtagctata	61800
aaanaatgaa	tattttaactt	cataataaaa	atatgactat	tttgtaaatg	caccaaggta	61860
gaaglaacaa	atacaactatg	gcaatttttc	aggtttctgt	ggtaagaaa	ctggtaacct	61920
ggaaatttag	tatatgtatt	tccaatcata	taaaaaataaa	aagtcataat	aaacalattt	61980
gcagaaactt	aaaaaaagtt	aaaataacat	cttatrtgca	atgatattaa	ataattcata	62040
caagtaattt	ttagcacttg	tgctctcaa	ggaattgtat	gaatcctaac	ataattagaa	62100
tcctatatata	ttcccaaatc	aatatagcca	tgggcataaa	atatattaat	gtgaaatata	62160
taattacata	tcattataat	taacaccgct	agattttata	ttatgtatat	cattttacat	62220
atgaaattgg	aaaattgcct	atatttcaag	acattctatc	caagctgtgt	tctatcttga	62280
gaacttccct	gaagattggg	cttttcacat	acgtcttgaa	aattgattta	tacctaaata	62340
acaaaaaatg	atctattttoa	atgaacctat	catttaataa	tttttgcat	tcattgcata	62400
acattaaact	actataaaat	attttctcta	acttaaaatc	accacaatgt	tatgttttat	62460
aggcttaaac	taaaaaatac	ataattatgg	catttatata	cattgacatg	ttctactttg	62520
ttactacaga	ttttcagagg	caacttaate	atttaaacaa	aatgatttta	tatagaataa	62580
tattaaactag	agtaataaat	atttttatat	agacaataat	attaagaact	atattcalac	62640
agttaccgggt	cacagtgggt	aaacttttgc	tgatacggat	aaaccactgt	taaaaaaac	62700
aaacaaccagg	gtcttgtcaa	tgtttcaaaa	tgaattaaaa	tcaaatccag	caacaggccc	62760
tgaattccctt	tataagctcc	tttgactaaa	ttaaaaaaat	taacttgcct	aatatgaaa	62820
glaaaaaata	aatgtgcat	ttatcctata	gattataaat	ttttgcta	agaaattgag	62880
acactaaatt	aaacactgat	agttttaaca	ggttttatatt	tcctatgtcaa	agagacaatt	62940
aacattgcag	taaaaaaata	attacccctc	cgctggcctt	tgtcttttga	agctatatat	63000
tcctggcgaa	gcataccaca	aggacgggtca	taaaagtga	gcctcattaa	attactttta	63060
gacttaattac	acaagtttta	attagcattg	tacataattt	aactgtacat	atattctttc	63120
agttttccctg	gttataggaa	attacactgg	ctgtgtcaac	atttgtcaat	gtgaggacaa	63180
aactaccttg	gattctgttt	ttcaagaagt	aggcctcatt	tttaaaactgt	gctaactgtc	63240
gtctgagatg	actaaaatac	latcagttgg	gatttctcag	gaacagttct	acagttctgt	63300
cgtttgctaa	acatacagac	attgtcccga	gcagtttcaa	tcactcagge	cgccggacct	63360
ctacctctaa	ctcacaagaa	aagcccattt	ccctgttggc	tgcaaaactc	ccccaggaag	63420
caagtgtttg	ctcctcgag	cagtaactga	tcctaogato	cttggttagca	tttcagggaag	63480
tcgctgcttg	cgctgccccg	atctcacagg	tcctccactc	tcctgggaagg	tgggagaggg	63540
tgaccccgcc	gggaggctgg	ggagaaaaaa	ggccgcctcc	agaaaaactta	gatggttagc	63600
aataattctc	cccaggagaa	aagaaagtgt	gcttgaataa	cacctttcct	actgtgtgtg	63660
tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	ttagtcatte	ccaccagga	63720
tattcgggac	tcactgactt	ctgaggtggg	tttagaagct	ctgttgcct	cagtttccca	63780
cgattgaggg	gctgtgtgaa	gggaggtcca	ggttcaatgg	tactgcgaga	accacatgtc	63840

taagtctgtt	taacccgaat	ggggaagcct	ccacccggcg	ttatctcttc	ctctctctag	63900
cctgggctag	agacgaatta	tctgtttacg	aaatcacacc	aaacaaaaca	agtgccgaat	63960
gcgccccgga	cttttctagg	gcctttctta	cctgggtctt	taggaagcgg	ctgctgccct	64020
agacgctggc	tcctcagtag	catcagcacg	agggccacag	cgggcgggcg	ccctgygcct	64080
gcccactccc	ccgtgagccg	cgggatgtga	accacgaaaa	ccctcactcg	cggcggggcg	64140
cacgcgcgcc	gaatccggag	ggtcaccaa	aacctgcgca	ccatgttttc	gccgcctcca	64200
gggcccagct	cggcagccgc	tgcgcgcgcc	tttggcacca	gaggtgagca	gcgccactcc	64260
tgccccctta	actgcagact	gggaaccacg	caccgcccc	tgcccatctc	cgcgcccgag	64320
gcgcgcaccc	gccttccctg	agcgcgcgcc	ccccccacct	tcacccccac	ccccaccca	64380
ccccactccc	cacccggacc	tccaagatct	cggaacggct	ctgagccctg	ogcagcggg	64440
aaggcctgcc	ggaggcgccc	gtagggaggg	gcgcgcggcg	gcggctcagg	gcccgcgttc	64500
ctctccctcc	cgcctaccgc	cactttcccg	ccctgtgtgc	gccccacccc	ccaccacccat	64560
cttccacccc	tcagcgccgg	cgccccgcgg	tgacggccca	ggggccggac	gcctggaacg	64620
caactccagg	cagctcgccc	cctagctaca	tccgtcacct	gacacggccc	taccaggaac	64680
agccgcgctc	ccgcggatct	tgggtctgct	cgcgtccccc	ctccctattt	cccttatttt	64740
tattcctggc	tccccctcgt	gaaagtcttc	cattcttcaa	actagattat	ttaaaaatga	64800
aaaagggaaga	aaggaaagcg	aggctcatct	attgctctat	ccgccaatca	ggaggctgaa	64860
tgctcagtttt	gaactaaaag	ccgctccgct	cctcttctag	atttggaata	caagcgaat	64920
taaactaaac	cgctgcacgc	ctctgacggc	acatctggac	acggcgcgcc	gctggcgctg	64980
ccggagctgt	cgacccgccc	tggcgccggc	ctaggtaggt	ggagtcgcac	cggggggtcc	65040
cagctgggtc	cggggcgccc	tccccctccc	agctgcgcgc	gtcgcggagg	gcgcctggct	65100
gggacaagca	cggagtcctt	tgtgtctagc	ccatttttat	tttcgggttt	aaccttcacg	65160
acagcccgcg	agcatctgag	cgcttcttcc	tctttctctt	tcccccgccg	tccccctccc	65220
tgttgccggc	tccccctctg	tgcgcgcgtc	ctggcgtaga	atgggttgtct	tggcgaccgt	65280
tggcgcgtgc	cgcctccacg	ctctgccccg	cgcccagaca	cccgcactcc	ccttgatccc	65340
gcccgcctgac	tcctcggcgt	acgttctctc	tccggtctcc	ccctccatgt	ccctctctcc	65400
ccttttcttc	cacatcaccc	atcctttctg	gactctctcc	cttctctctt	tccagctggg	65460
agacaggaaa	agcggctcct	tttgggaaca	gtaaaagcag	ggcaaggaaa	ggaaggagcg	65520
gcagaaagga	ggggtgagtc	gaggaacacg	gggcagocgg	agaatgcgga	ggagccgggt	65580
cctgagcgcg	gtctaagcga	ggctcggctc	tgcctccagga	actcggagcg	gggtcgcgcg	65640
gtctctccgc	cgcgggaagt	cgaagccagg	acgcgcctct	caggccggcg	cgctgacccg	65700
gtccccgac	cgggagcctg	cggctcgcct	ggatccgtcc	taaaacctcg	gggctggacc	65760
cgcggcctga	gtgggtgggt	gtgtgccaga	ggattcggga	ctaggccccag	ctccgggaac	65820
ctggaaatgt	ggcccgcttc	tcagtggctt	cctgttcatg	cgcttgggcc	tagtggccta	65880
gttgaagaag	tggaaaccaca	gcgtgagccg	acagggcctt	acagatcaga	cgtcaagccc	65940
cccagacctt	acaggggagg	aaagtgaggc	ctgcactggc	cgagccaccc	acttaaggcg	66000
gtgcggtagc	ctagaggagc	ggcagacttc	tctttcccca	tcccccgccc	catcacttga	66060
cgttgcctgcc	ggacctcggc	acaaaaccca	gacaaaacgg	ggccctttgg	aaaaagtga	66120
attlagcgat	cactcttaag	tagccactct	aaatatctat	ctagatattt	acaaatgcac	66180
ctccccggta	ggtagatttc	actcagaatt	tacccaacac	cgtgctttgt	gctggggcca	66240
catgccacgt	ttctgtctag	tatggctgct	ctttctccct	cttcgcaaat	atagcttttt	66300
ttccttcagg	tctcttctga	agtaagtagc	ccttccctcag	aaatgcttcc	cttttcaggc	66360
acctccatac	caccgtgatt	ttttcttlla	tagcacttag	gacgaagaga	ttattttact	66420
tatgtacttg	tttacttggt	tgttgttag	aatgtcagct	ctatgggaac	cagatccttt	66480
tatgggtott	cctctgcacc	tatgccacgc	ccccagcatt	ccctctctac	caccaccttc	66540
agccggcctc	cgcctctgta	ggggggcatt	agggtttctg	tcccacagag	gaagggcgct	66600
ttagaagggg	ttagttctac	ctggaagaaa	aacgatgtcg	gatgocagca	tagtgtcatt	66660
taaagatact	ggagggaatg	agtgggagcg	gtgaggggtt	cttgggccta	gacaatgtaa	66720
ctagtgtgtg	caataaagca	tgggtgggaa	aggagaaaag	gcacgtattt	aacatctttt	66780
gaagtcgcta	ctatatcag	tcagttctcc	agggaacag	aacocattgt	gtgtgtgtgc	66840
gtgccagtac	cacacatatg	tatatgtata	tacacaccgt	catgggggtg	cttaacaaca	66900
gggatacatt	ctcagacatg	tatctttag	cgatttccatt	gttgtgcaaa	catcatatac	66960
aaacctaggt	ggtatagtct	attatacatc	taggctgtat	ggtatgggct	attgctccta	67020
ggctgcaaac	ctttacaaca	tgttactata	ctgaatactg	tagataattg	taacaaaatg	67080
tagttttata	tctaaacaca	tctaaacata	gaaaaggtag	tatgttgtgc	tacaacttta	67140
ggacagctat	gacatcacta	ggggatagga	atttttcaca	tccattataa	tcttatggga	67200
caocaccaat	atgtgactgt	ggttgactga	agcatcgtta	tccagcacat	gactctgtgt	67260
gtgtatacaa	ttttatatat	acgtacatta	tatgtctaca	cacacatatg	tgggggagag	67320
aaagagaggg	agggagagag	agagagagag	agagagaaag	agaaagagag	aaaatactta	67380
ttttaaggaa	ttgtctcaga	aaatgggtgg	ggttgacaaa	tlggagaccc	aggggaaggt	67440
tgttgttgca	agacttgaat	ccaaaggcaa	tctggaagca	gaatttcttc	ttccttgagg	67500

gacotcagtc	atttctctta	agctcttcaa	ctgcttggt	gaggaccacc	catattattg	67560
aggataatct	gctttttcaa	gtctactgac	ttaaatgtta	atcatatcta	aaaaatacct	67620
ccacagcaat	attlagactg	gtgtttgact	caaacaactg	gtaccacagc	ctagccaagt	67680
tgacatacca	aattaaactgt	cacattatcc	cgicactgct	gaggggttct	ctgacctca	67740
gttttctgag	gatcaaattt	aaattgaggg	atctatcttt	gtttattgga	gccatatagc	67800
tcaaagtata	atcattttct	ctccacagga	actagacctt	gggataaggg	taattgctta	67860
tttcagagga	atgccatctg	ataaaaagga	taattatata	gtaagctctc	tgttcaaaaa	67920
atgtaaata	taaagtttga	acatctaaat	tccatcttgg	tttccccac	tgccgctgcc	67980
caataacctgt	tctctttcag	ttgcagtatg	caggggaatt	ctaagtttaa	tattagcttc	68040
agcassaatac	aatgggtgaag	atgactcttt	ctagcataac	aatgggtatg	tggatttcca	68100
aatacttttg	gaatgcggag	tgactattgg	ctatgtgctc	ttcaaaaaat	taataatgaa	68160
gaactgagca	tgtatttca	cttatattac	ttattttatc	ctccagtggt	cctttcaaaa	68220
ttgggattat	tactcctgtt	ttacaggtgg	aaagaatgag	gcctagaaag	gctcaaatct	68280
tgaacacttc	atggccagca	agagccaggg	ctggaatcat	caggcaggcc	tttgggttac	68340
aagccttgtg	ccttttctgt	tgtccnaaag	gccagggtca	atagggagtg	agttatctgt	68400
gggtcactta	tgcagacaga	atcactgaat	attggaagtt	tttggggttc	tcttccactg	68460
gcctaaaaac	ctgagttaat	tgagtttttt	ttaacagggg	taaataattt	tctgttttag	68520
ctcagcaaat	tcattccata	ggcagggata	ggggagaaaa	atottactga	atatcccttg	68580
tctgtttctc	tctctcccca	aactlaatgt	cotatgacac	tagctttatc	ccttaggtaa	68640
ctcttgatta	tccaaatttc	atgagaaact	ttcctaacat	tgcacatgct	caaactcaaa	68700
accccaaggt	cataagaaaa	aagataacat	aagcaagaat	aaaaaacat	tatttgatca	68760
tatatgtcaa	aagattaatt	actagactat	ataaataaat	acataatcca	gtaasacaac	68820
aatccaataa	aaaaggcaaa	ggatataata	gtttatagta	gaatatgtgc	aaatagttaa	68880
aaataaaaaag	ataatcttac	tcattaataa	atgtaaacag	aaacaatggc	atataaccac	68940
aagtgtggca	aaaagaaaaa	agactacttt	gacaaagttg	tcaggaaaca	atcactctta	69000
ctattacaaac	ttgggtgtaat	tgttttgaaa	ggcagcatta	caatatctag	tcaaaaactgt	69060
atgagaatat	aggtaccctt	tgactcagct	attccactat	tttaagtatg	taaagacaca	69120
cacaaataat	gtatggaaat	atatatacac	atatatacta	tatagtatal	atagtttoata	69180
tgtatgttat	atgttttgtt	atatatacat	atacttatac	acaccctttg	actcagcaat	69240
tctatttcta	taactcatgt	atgtaacata	tataatcacat	atctttatat	acacatatgt	69300
acacacatat	ctgtaagtat	gggaagatgt	atacacatgt	acacatatat	atacatatat	69360
atgtatatat	gtattttatg	tatggatana	tatgtatata	tggatagatt	ttcacacctac	69420
agacacattt	agatatgtaa	cttcagctaa	agcaattcac	tctatatata	attgctacag	69480
ataacttgta	laagtatgca	gaaatgtttc	tttatagcag	tgtgtattag	caaacaaagt	69540
gcaagaaaga	gaaaaatgat	tgacatgctt	gtgaggagac	tttttttgtt	gttgttgttg	69600
ttagggtcca	ttcataaaat	aataaaaactg	tgcattccata	aacataaatg	aagcacatct	69660
atatgoactg	acaatgggaag	ttgtcaaaaga	tctatttgcta	attaaagaaa	gcaagtgaca	69720
gaatagtatg	atcccattca	tgttttccaa	atatgcattgc	tgggggagag	atgtttgcaa	69780
ttatatgtac	ttatatattct	ggaaggataa	ttaaatattt	gtaatagtgg	ttacotttgg	69840
gtagtaaga	tgaggttggg	aaaaatttca	gatttttgtc	tactactttt	tgctttctgg	69900
actgtttgaa	agtttaccat	gagcaagaat	tattaaataa	caaccacagg	aatatttggg	69960
ctcaaaccta	gagatttctaa	ttttgtagac	ctggagctga	tcaacaagtc	taaatgttaa	70020
aacatcctca	cgggtgatte	tgcattggag	ccaggattga	gaaacaattt	tctgaaatgg	70080
aaggggtttt	aaacttggtg	tccatcaaatg	actactgagg	caaacaccat	tcttatagac	70140
ataagacata	cttgggagca	aatgtataat	aaagtgggtat	gcttccctag	aaaggggacg	70200
accttaaatc	tttctgttta	tgggtggtatt	taaacatatt	aaaaactact	aattttggaa	70260
tagtcttact	gtgataagtc	taactatcaa	aggcagtccta	gagattagca	aataatagag	70320
gatgatcaaa	tgttttttcag	aaaatatttat	aggltggcact	ttggcaggag	attctgagaa	70380
tggtgagagg	gtgcctctgt	gccctaggaa	aggtgataga	gcttagaacc	tcagaactca	70440
gatggaatga	ggagccatgc	catatacatc	tttacaacag	tcaccctcta	cgagaaaaact	70500
ctgtgttgac	aataaatctgc	tgaactgtct	gtgggttttt	gaacagaata	aaotgtttct	70560
tcttttatgt	ttgtgtatta	ttgcttataa	atatattcta	aaatalataa	taacaaacaa	70620
taacagtact	tgcagcttaa	ttaaagaaaa	aatgcaagta	tcttattttat	actaagagaa	70680
gagagaaacc	cgaagaacaa	tggattatcc	ttacatattt	ggtttgggat	tacattgaga	70740
gctaocctaa	taccagacac	tcattcttgg	tcttgactcc	tactctgtta	tccatagctc	70800
agtacctagt	atctggcgca	gaaagaagtg	gaatggaatt	atcaggggaga	cccagttttt	70860
agccaagact	aaaaggtttt	agccaagggg	atggaagaat	ttgtgcatag	atagacggca	70920
gatgggaatt	cgttttaaaat	ggaatggaga	cccagaggtc	acataagaca	gggttcagag	70980
gaagttagccc	caacaacatc	ataatagaga	acattgataa	tgagaggata	gatagattat	71040
gcatttgggg	aggaggccaa	atatgagaaa	laagacatgg	ttacttact	gtaattgggtc	71100
tkaaagtrtt	gaagtgaact	ctgttgtaaa	atattttctg	tgccagagct	gactccatat	71160

atctactgga	agtctaattgc	caggggcttc	tgagtgtgaa	gtggattaat	aggtgttttg	71220
ggctcccttgt	aaacttctag	tgtaatgtga	alagctgtga	ggtagtcagt	gtgtcatctt	71280
aatacattgt	tcttagttct	ttttccagca	aactcttttg	ttttacattt	agttcacacc	71340
acaaattagt	aagtcaggct	tgggtgcttt	tgacccatag	atlaattttc	attactgtgc	71400
ltaatatata	atccatgcca	attacatatt	attaattagt	ggcactagta	ttagttcata	71460
ttttctttta	ttatgtaatt	aatagggcct	atatgtgaaa	gttactgtgt	ttctgtaaaa	71520
tgaagtattc	tttttccctt	cgcaagggaat	gacattaaaa	tcttctgagt	aggggaattt	71580
agaggcaaga	aaggagtaat	ttcattttgg	tagctgaaat	tgagaaacgt	tttatagaaa	71640
cttttcagggt	atgaaggata	gtagttagaga	tgttacatga	gttagcactc	atatattgaa	71700
ttagtttaagg	aaccaatgtg	ggaatcttag	tcttctatct	tcagtcagg	tccttggttc	71760
acttttcttc	attccctctt	tctttcctgt	cgttataggt	agaataggaa	aatattgaaa	71820
gtattgaggc	tcaactgttg	ttgccccttt	aagtaatttc	taaaatttaa	attgtcttat	71880
tttcatatat	gtgtgattgt	gtatctaggt	atctctttgt	agcttagtaa	ttgaacactg	71940
tgaactacac	caacctaaagc	attattctcc	aagtittcat	caaataacta	gacagtttct	72000
gttaaktactg	aaaatctagt	aaacgtgtca	gaatttgggt	atgattagtt	gctgacataa	72060
aacatgagggt	cagacctcac	tgtactttag	aagatactgg	ctttcacatt	tgccccagta	72120
ggtagttcac	atgagtgctt	cttcagataa	tgtctctaaq	ttttgcatat	cattagttct	72180
acttgctcca	cttttgatag	agtggcaatg	tattgaacat	tgtaaaaatt	atgctctatg	72240
atttaaaaaa	tccatctctg	gtaaagcata	aatgagttat	atgttttact	gttttaataa	72300
attgaggggt	aattatagaa	tcagcaaaaa	gaaaaaaaaa	ccctactgac	tattacatat	72360
caatgcacac	agtggtgtta	tattttcaaa	aaagggagggt	caatctcagt	gtaagtgtaa	72420
atgaatttag	ttttgtata	tatttgctga	agatcagtta	cctagcttca	tatgataaat	72480
tatttggtgc	tggtcacaaat	attgtgcttg	ccatcttagg	gaaataaaat	atcatgaaag	72540
tattccctag	talacatttt	cccagaggcg	tttggggttt	latcagttct	gagctctcct	72600
cttgaacttg	tttcatctct	tagttatgaa	attactaat	ttaaccattt	aaggcatagg	72660
aaattttaca	tagattttgc	tttaacagca	aaacacctt	taaaaaattc	atccacttaq	72720
gtgaaaaata	aagataaaa	atgaagccaa	atgaatgtta	ttaaatttat	aaatttattt	72780
aactttccag	atcttcttgg	aataaatgtc	aggtagtaga	atttgtacaa	accttggtaa	72840
tgtcttaggt	ttagatagca	acttaacagg	tatatttaat	tttctgtatt	ccacaalqga	72900
gctagaagca	ggactcatga	aaatagtaac	tatatgtttt	gcactgtatc	ttcaaatgga	72960
aatccctaac	aaattttaaca	gtatatatta	ggctgtctgt	gaaacagcta	aacctgtctg	73020
ccaggtgggt	tggaaaaatgg	aatttaatttt	tacatggcat	tgataagtta	ctattttcaat	73080
acaaccagggt	ggtaattgat	acccaataat	gtttgagggt	tgcttlaaat	aaaaaaaact	73140
aacaaaaaaa	acaaaaaaa	cagtgttaat	tagtactgtg	ggatccacaa	taacattttc	73200
tttagtttcc	cttaatatca	ggttgtcatt	aggaaagatt	ccacaagtta	tttaaacagg	73260
aaatgaagta	acatgtttca	tatctatttc	aaaggataat	ttttcatgac	ccagtataat	73320
gcaactagca	aatttaaaaa	tcttggaaat	taagatatag	aggtcaaat	aagggaattt	73380
ataaaocaaa	tgggagattt	taaaagtatca	actgacttct	tttatataga	atgttttcta	73440
ataattgtaa	aatactgtaa	ctttaaaaa	attattcttg	tagcctctaa	tgattgagtg	73500
cttaagtgtat	aactagaaat	ataattttctg	tccctgtgct	tcagtttgaa	aalggagggt	73560
ccattatctt	tgttccaaaa	atttggggtt	tctaatgtgt	gttggggggg	gttattctcc	73620
atatatttga	catctttaa	tagttttcaa	acaaacggtt	tatatattact	agaagttaga	73680
gaaagaaaag	ccaccttagg	agcttacaag	ggagatcatt	gtgtattttct	gotttttttt	73740
aaaaaaagtt	atcttcatgt	gtatcattca	tgattttgga	ggacaagctg	gtgcaatggg	73800
aagaaaagca	agacaaccat	aatcagctgt	ggaactagat	gcacttcttt	gtgcatccat	73860
ggaatgaata	tcttgaacc	tttggcaagt	tacttgatat	ttctttgco	cattgtccto	73920
atctgggaaa	caatacctat	ctctcagggt	taaatattaa	attaacaaal	atattttaat	73980
gcatacctgg	tacagattat	gtgtcaataa	acatatccct	tccccaataa	catatgctct	74040
gatttctaac	taactttccc	cagtaatatg	ttcatttttg	gaataggaat	tggttagagaa	74100
gtaangattt	gtgtattcaa	ctcaaatgta	ctccttctta	taagtctcca	ctctcaaatg	74160
acttgtttct	gttccctttt	tctcttttaa	atgtgtatct	ggtagaatga	gcattttaga	74220
gcataatata	tgtatacact	ttgtgtttaa	tttctatgg	cataagtaag	cagtttttat	74280
gaattgtctg	tattgtcttat	gagcaattat	tacaacatt	gagagaagggt	aacctctgtg	74340
aacttttaac	atttctcagg	agtttagtgt	aaacccatga	acatgtattt	ttaaacaaa	74400
ttacccacct	cttggaagtic	aatctctgtt	aattctttat	taaaagtatg	aagtatcagt	74460
tgttccaatg	atataatgat	caagcaaccc	tggaaattaa	atcccaaagc	agtgcacctt	74520
tagtttgggt	agtgatagta	ggacatccca	cgagccatca	tatattttca	agtttttata	74580
ctcaatctac	tttttcagca	atcttttggg	aactatccca	agataattta	ctgcataagt	74640
gcattctatct	tctaaaagac	atttggaata	tttcttagtc	tgacctctgc	acctgagac	74700
actctataaa	ggaaacaatc	agaaaaattt	ascasagaaa	taaatagggt	agagaagaa	74760
caatctaggc	gtttgcaactg	agtttgcaac	agtgcatttg	ctacatttaa	gagctgtagt	74820

tcttctctac	attttaactg	agagccacta	gttatgttac	ttaaaatctc	cccattaaat	74880
aagacagttg	ctgaaccact	aaaaagtaca	aaatalcaca	aatcaaaaa	gtagcaagtc	74940
ataaggggat	ttccgcctcc	tagcatgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgaaaga	75000
aaacgtttaca	gttaaccgtt	acaattgctc	tcactccact	ccaccacctc	atcctgtgta	75060
gtctgcctgc	ggaaccccg	ggaatctctc	ctcagtgtag	taagagcaaa	ggccagcatc	75120
ctgtgcacag	gtgctctgca	gcgtcgtgat	ccagggattt	tagcatctgt	cgtcgcttgc	75180
acatcctctc	ttacccctct	gctatctggt	ggagttgggc	gagggctctc	agggcttcca	75240
gagagtgtcg	tttaacgcatg	tgacttgcca	tgcgctcaaa	ctaaagcgcc	gccggggact	75300
tactgaagcc	cacctgggcc	ctcctccact	ttgtcctcag	tcttcagggt	ttcctttctg	75360
ccgctagggc	ctaagttgtg	ggttaccat	aactcctcag	cagacattgg	agtgaacgca	75420
tgcactgccg	tcacccaagt	gcataacaot	gccttctccc	actcagcgct	ggagtgggag	75480
attcatccat	cgggaagattc	gtagccacca	ggtccagtca	aggatttcat	atgcactttc	75540
cctcagaaaa	ccctgaaaaag	caaacgacoc	ctggaatgtc	acacactcct	aatatccct	75600
ggaaatccgc	ttctctgtgt	ttcgcttcat	ggtgagtgtc	gagggccaga	taagacaaag	75660
aaaaaaatgt	atggaagggt	attcccggtc	ggctcctcct	tctgtgagt	ctcagacagg	75720
cttgcaggct	tacaggcttt	ccgcgcctcc	ccgttggcag	ccttcatega	attaggtggg	75780
tgggggtggg	aaattgggta	agaaaaataa	gtcgttgtgg	gcggctgggg	aacctggcgt	75840
cagtcctccg	tggctgtgog	caggtacctt	gcaacgtcgc	ggtggccccc	ctcctcgcc	75900
aagtccacgg	caggtcgaac	ccaggcatcg	cgcacgtcca	gcgcgcctcc	ggcccggtgc	75960
agcaccacca	gcgtgtccag	gaagccctcc	cgggcagcat	catgcaccgg	tcgggtgaga	76020
gtggcagggt	ctgcgcagtt	gggtcccgcg	ccgtggagca	gcagcagctc	cgccacggcg	76080
gcgctgcccc	tcctcatgac	ctgccagaga	gagcagagtg	gtcagagcca	gggtgggggc	76140
aggtatggga	gatgcgggce	ggggcaaggc	aggtggagcc	atttaaagaa	acacctaat	76200
gcaaagtgtt	cacccagtgc	aggggtgttc	aggtctctga	tgtctggtgt	ttcttcat	76260
gctgatgcaa	tcactttcc	cacccacact	tcaggttata	ctcagtacaa	attaaatgcc	76320
attttattct	ctaaacgtgc	agagacaaga	aagttgatgg	taaagtgatg	atcatcatta	76380
tggaaaaaca	aatcttgatt	tccattggaa	catgggaatc	tattttgtta	aatgatttag	76440
gggcagagtt	aaatttatcc	ggcttttaaa	gttttaaat	atttgccttg	ctgacctc	76500
ctccataatc	aatatttatt	aatatttatt	agttagtcas	ctactgtttg	ctagaagttg	76560
ggagtaatgg	tttaggggag	aaaaataaca	actaagtttt	tttctttctt	tttttttaa	76620
tttatttagt	tctcatagca	aatcccggtc	ggaaggcttt	tggtttgtcat	gtgtctgagc	76680
tcataactgg	cttgtagtgt	gataatttga	gccaaagtgg	gagattagaa	gggaaaagta	76740
aattaaatca	tgcaaaatct	tataaaatta	taataaatga	tttttccctt	acagttcatc	76800
attttaaatt	tagactataa	tatttttaat	gtaatatata	actaactata	tttgtatact	76860
acaggatttt	ataatagcta	agatttaaaa	atgttaasca	gtaaatattt	tgctatatata	76920
aaagagcttg	ggccaggccc	agtggcttat	gcctgtaatc	ccagcacttt	gggaggccat	76980
agcaggcaga	tcacctgagg	tcaggagttc	gagaccagcc	tggccaacat	ggtgaaatcc	77040
cgtctctaac	acaaaaata	aaaaatttag	tgggcaggtt	ggggcggtgc	tgtagtccca	77100
gcaactcagg	aggctgaggg	aggagaatcg	cttgcatcct	ggaagagggt	gcagtgagct	77160
gagattgtgc	cactgcactc	cagcctgtcc	gacagagtga	ggcctcatct	caaaaaaat	77220
aaaataaata	ataaataaaa	tagagcttgg	atgttagcag	tcaatcagga	tgatgcataa	77280
cttagaaaaa	atgatgtttt	gcaggagtaa	tcctgtagca	gccatttgtg	tacatgaaca	77340
ttatgaaaac	atttgcgtgc	atattttaaag	tcaattataa	gacaattttt	ggtaactaaa	77400
tgtctaaaat	cgagttattt	gttatgggtt	tatgcacttt	aaaatatacc	atttaattga	77460
aaggcagtat	acttctcatg	tttggttggc	ttgtttcatt	aatattagaa	atgttcattt	77520
catctcttaa	aaaccgtgat	aagtttatatc	tactagtgat	gtaaggatat	tttacataga	77580
aaaaaagggg	aaaatagctg	ctglttagtat	ttcagaaaat	ggtgaattac	atatataact	77640
tgtttttata	attattaata	aaattttaag	tttttaagat	gcactttaca	atatttttgc	77700
tccttttaaa	atccctcat	tgltatacca	tatttctaag	aattcaaaaag	aatgaacac	77760
ttcttttaaaa	tctatactat	taacaagatc	ccttaatat	agcttagttt	tagaggggtga	77820
tagtgaggtg	agtactgaat	atgaccacta	gccaacggta	agttacaaaa	gagttgtccg	77880
agattgtaaa	agaataaaaa	aatatcagta	ctaattaaag	caggattcgt	acttaaacat	77940
tgaataagtg	tattttaacs	atgaagataa	agatgcatta	tttatgaaga	tcctttgcca	78000
ttcaaaaagg	acctaacagt	tgtctgcagga	atatttttgt	aatctgggca	ctgagtatga	78060
taattaaaga	atgagaacc	tatagaacta	tatatttttt	ctcttatgca	tcactcataa	78120
gacactgcta	acataaaaag	aactaagtac	tgtggttgag	gaatcccgtc	tcattctcaa	78180
ttaacctcta	tgagaaaaca	atacaacaga	tttcatalag	tagcttagaa	gtttacattg	78240
attttttcca	tgtactatga	ttttgtagaa	ttcottaat	ccaatctaga	atgcgtaact	78300
tatactttac	ttatctttat	cgttgaaagc	agacagacaa	gataatcttc	ttccctaact	78360
aagccttctc	tttctccttt	tctccccaat	tcagtcctat	ccttgcatct	ctgatcatga	78420
gatggcagaa	caaaaaccac	taaaaaaagc	ttaaaacagt	ggtttttcaa	tgtctctctt	78480

taggattttt	gctgggtaaa	agcctglttt	acgcgtggaa	tgcacacctc	cggecaacgy	78540
agactcctgt	acaaatctac	atcggcgatc	taggttccag	ccccgatccg	cogaggccgc	78600
gccccgggtt	cgcgcgcccc	ctgcggcgga	ggccctgggg	ccccagotac	ctggatcgcg	78660
cgcctccga	aaoggttgac	tccgttggga	tccgcgcggg	cttccaggag	ctgtcgaccc	78720
ttctccacta	gtccccgcgc	cgcggcgctg	gccagaccct	catcgctgcc	gccccactg	78780
ggcatgccct	tgtttctctc	gogcattccg	cagccccag	acgcgcagcg	gccccgataa	78840
tccaccgttg	gcgtaaaact	taacgacact	cttcccttct	ttccacgcct	gctccggcgc	78900
actctctctc	tcctaggaga	cctgggctca	gcttcattac	cctcccgctg	tccttctgcg	78960
gcttggggcc	ccgtgcagtg	gccgagcggc	cggctcgttag	ctccgggctt	ttcctggcgc	79020
tcaagaacca	gcgggcgcgc	ctggattgct	tctgggaaaa	agcgccctagc	gcggacgcag	79080
ccagagctcaa	agccgctctg	cgcgcagggg	gcggacgcgt	cgcggagctc	tcactgcccc	79140
gcctcgctct	ggcagagtg	ggagccagcc	ggcaaaagaat	tcggttttca	gctgggcca	79200
ggggccggcg	tctccccacc	ccctkaggct	ccgccccctg	tccgctgtga	tgcgggggag	79260
gccaggcccc	ggcggagcgc	tcacgagggc	ggggaagcct	gccccaaagat	gctaggacgc	79320
atgcgccaga	gactgggcca	gggagccgcc	aggaatgctg	gctgcactgc	tgcctggatg	79380
tccagtaaa	ccaaggctaa	tattttggga	atgttcaacca	ctgcctcag	ctcctaactc	79440
ccagtagggc	gagcagagga	tttctgttcc	ttcagccagc	cagttgggtt	cactgtggag	79500
acgttgggtg	ctcccttctg	accgagagaa	agtcattcaa	ataaactlccg	tgtttcttaa	79560
gatgtctgaa	agcgacagct	ctgcacctgt	catacaagtt	aaattcatcc	ccaggcagta	79620
cttgggcttc	acaagtttca	taacttgtat	caacttagc	aattttctct	tggatgtgtc	79680
tttctgtttg	aattagttcaa	ccataaaaaat	agagaaaaaat	cccgagaatc	atgttttgcg	79740
tgtgcttttl	aattctttcc	atttttgcat	tatggalaca	acccttaaaa	gagaaaaaaa	79800
ctagtctcag	attgagagtg	gcaacctggc	acacataaga	caaaaaaaa	ttatacttta	79860
agaatctgag	atcccagttt	catcataatt	gtacagtaaa	tctttgtttg	cactcttacc	79920
tatttaaaac	cactttgtca	ggtatcttat	ttttatttat	catgagtaat	aaaggaaatt	79980
tatgcagtaa	taatgaasca	tcataagaga	ggggtgtggg	gctgggcttg	tcattaaaca	80040
ggctgaacct	gtcattaaat	tctcttctga	agatttaaat	gccaagtgtc	ttttttcccc	80100
ttcctaactc	tcctagggtga	gtttgaatca	acattttatta	cttaaaatat	ttaaaacatt	80160
tcagcggatg	ctaacattgga	taggaagaga	accgcaagtt	ctggatttgt	tgcctaataa	80220
cttttggtag	gaactgcata	agtggacctc	tcttaaaaagt	gaacaatttt	tgtttacaga	80280
atcttctttg	ttcggagtgc	tgaaggagac	aaagtcttaa	caggaggcca	attgcttgtg	80340
tattgcaaaa	tgaagatctt	cacatgtttt	ttttaggata	ccttagctct	gactcctcat	80400
cccccaaatc	cctgtagaat	taaaaaagc	tttttctttt	aaaggcgtg	gaagtgcac	80460
caccatggaa	gtgctggtta	gggctgaaaa	tctactgaca	gagcctcaac	agagctgaaa	80520
tccacctgga	caggggaagg	aaaccgggtg	cattaataac	aatttctttt	tctttcccat	80580
ccaaccccc	tttccctagtc	ttcagtttct	taattttctt	accttttact	cttatgtctt	80640
tgttttgacc	tttgagtttc	tctgaaactt	atcagaaaa	ttaggacaag	alagtctgac	80700
ccaattcttg	agccattttc	ttaggtagta	aatatgtcag	aaaaatgaaa	gctgttttga	80760
gttgataagg	aaatggaaga	taatgttttt	ctttgagggg	gacataaaga	atggtgtag	80820
ggaaagaacc	aatgactaag	taaaatgact	gagaattctg	cgcgaggcag	atgtgtgagc	80880
ttcgcgaagc	taagttagctg	aatgaaaaac	aactttgggt	agggaaaacg	ttgccggggg	80940
cattcgcgct	tactagcacc	acggacagcg	ctttgcttat	actcaggcct	gggtgggtct	81000
aacagagctc	agacagaatt	ctaaagcttc	acacttgatc	ttccaaagcc	ccttttctcc	81060
cgtcaaatag	aaaggacatt	atggaagctc	aatgaatttc	tttgaaaaac	caacctgctc	81120
aacctgggtt	tcaaatatga	ttggatttta	tctaattatc	tctgtataaa	gaatattata	81180
tagtctatat	ttagaagacg	agaagagaaa	tcaaaacttat	tgtgtactct	gtacgaagtg	81240
ctttacagct	gttgtttcat	ttaatactca	taaaactcct	ctgtggcatg	tgtccatatt	81300
tcatttttac	agacaagcca	aaaggatcag	agaaattgag	tgaattgtat	actagotaat	81360
cattgttggg	ggtgggtata	acttttgoga	cttcagagtc	tttttacctt	ttatactaca	81420
tagtgttttt	tttagcagct	gtcatggtag	gcttaactgg	aaaaagtaaa	taaaactggct	81480
tataattatt	tttcagttca	cactgtgttt	tccagatggc	tcacctcaca	gcacaccttt	81540
accagacttc	aaagatgaca	tttcacatgt	aalacaatag	cacatttgtc	ttggacaata	81600
gagtgaatt	atgaaacatt	ttacctctcc	ttgsaaccga	gctgtctcta	gggtgaaaca	81660
caatctgttg	ttaatgcttt	aaacacattt	aaaagatgaa	gtggatggga	acatagtggg	81720
cagctgaaac	ttggaattgt	cagagccatg	tctttlaata	aggtggagaa	tttataattg	81780
agaagaaaga	aagagaaagt	taattggtaaa	ttggcataga	attttggagg	tcagtagaag	81840
ggaatgagtg	gcatccattc	caatgttgca	cataactcag	atcactagta	ataatatttt	81900
tatattctag	ttggtgaaat	tgtctgtata	tgaccttgat	atagaagtat	gaacagatct	81960
gccatcctct	ttttcttcag	cagggcagcc	gagctgcaga	cacagagatg	cagatctttg	82020
tgaagacctt	cacgggcaag	accatcacc	ttgaggtcga	gcccagtgac	accattgaga	82080
atgtcagtgc	gaaaattcaa	gacaaggagg	gtatccccc	tgacaagcag	cgtctgatat	82140

ttgccagcaa	acagctggag	gatggccgca	ctctctcaga	clacaacgtc	cagaacacgc	82200
ccaccccgca	cctgggtgctg	cacctgcgag	gtggcattat	tgagccttca	ctcttccagc	82260
tcacctagaa	atcacagctga	aacaagatga	tctgccataa	gcgctatgct	ctcctgcacc	82320
cctatgctgt	caaltgccgc	aagaagaagt	gtggccacac	caacaacctg	caccccaaga	82380
aggteaanata	aggctcttcc	ttcctcggag	ggcagcctcc	tgcccaggcc	ccatggccct	82440
ggagcctcaa	laaagtgctc	ctttcattga	ctggaaaaaa	aaaaagtatg	aatagaactg	82500
gttgactggc	caagagaaac	agcgacctaa	ccttgccctc	alittatgcac	acttttgcat	82560
atgattagga	ctaagatagt	gtttataagt	gagaagagaa	ggaaattcat	aatcaccttt	82620
ggggcttttt	caaatttttt	atgaacacac	cttcccacca	agaggtttga	ttttctccat	82680
tttatgagtt	gggtttatrg	ctccgtgac	cacagtatat	ccacttctat	atccccatgt	82740
atttttcaag	attaattaaa	tggtggactt	gttcattcatt	ttagtatcng	tattagtittg	82800
ctagggctgc	cataacagaa	taccacagac	tgagtagctt	aaacaacaaa	tatttatttt	82860
ctcagagtll	taactttctc	tgaggcttct	cttcttgact	tgacatggc	catcctactg	82920
ctgcctcttc	acatagtcac	ccctctgtgc	acacgtgccc	ctggatctct	tgtgtgtgtc	82980
caaatttctc	cctcttttga	ggacaccagt	cagattggat	tagggcccac	cccaatggcc	83040
ttatttlaac	ttagtcaact	ctttaagggc	tctattttcca	aatacggta	aattgtgagg	83100
tattgggctt	aggactttaa	tataaaaatt	tagaggtgac	agaattttaa	ccataacaa	83160
agcatcttaa	tttttacaca	ttttactttt	cafttctttt	taaaactgta	ttataaattt	83220
atcattttga	ataaggatta	aaataaggct	aggatattga	aattggttga	aattgtctaca	83280
gtctcttcta	tctctctctc	tctctttttt	ttcttataag	ggacaggttt	cattcacctt	83340
gtcgaccagg	ctggagtga	atactgtgag	caagggctac	tgctgectcg	aattcctggg	83400
cttaagggat	gctcctgccc	catcctccag	agtagatggg	actacagggtg	ttggccacca	83460
tgactggcta	atatttttac	ttttttgaag	agatgaagtc	ttgccatctg	gcccaggctg	83520
gtcccgaaact	cctgggctca	cacaattctt	tcacctoggo	ccccaaagt	gctggattgc	83580
aagtgtgaac	cactgcacct	ggcgtcttgt	ttcctcttaa	tctacagttt	cccccttttg	83640
ccttcttttt	ttttctttca	atttatctat	tgagaaaatt	ggctttatct	gtagttttct	83700
aaagcttggg	ttttgtgaa	tgtctcttta	taatgacact	taacattttt	ctttgtcatt	83760
tgtatttctc	ataacttatt	atttaggcct	agagctctga	tgtgattcag	gkttgatatt	83820
tgggcaaaag	tatttaataa	gtgggattac	gtactttcac	caagagacac	ataatatggg	83880
tgtctctttc	tgtgattcta	gcagccatgg	ataatttatt	catagattat	tattttcttg	83940
gggatggcaa	aatgggtgata	ttctaatttt	actatttctt	catttactag	ctggaatgtc	84000
tttttaaaat	atttatttat	ttatttatta	tttgagacag	agtcttgca	tgtcannccag	84060
gctggagtgc	agtgggtgtga	tcatagctca	ctgcaacctg	caactcccag	gctcaagtga	84120
tcctcccacc	tcagcttccc	caatagctag	gactacagge	acacatcacc	lggctaattt	84180
ttaaattttt	tgtagagatg	agggtcttgc	ttttttgccc	aggctggkct	ctaactactg	84240
ggctcagcct	cctaagctcc	tcctgcttca	gcctcccaca	gtgttgggat	tacagacata	84300
agccactgtg	cctggcctgg	aataatttcta	tatagaaaat	lctcttctat	atctacttca	84360
ttgctttcag	tctatagtta	gaaagacagg	ataaacact	agattttgaa	atgtatttat	84420
aaaatttcaa	aataatgagt	tgagtccatg	aacttttctt	ttattattat	tattattata	84480
ctttaagttt	tagggtagat	gtgcacaatg	tgagggttag	ttacataggt	atacatgtgc	84540
catgctgggtg	tgtgcacccc	attaacttgt	catttagcat	tagatatata	tcctaagtct	84600
atccctcccc	cctcccccca	ccccacaaca	gtccccagag	tgtgatgttc	cccttccgtg	84660
gtccatgtgt	tctcattggt	caattcccac	ctatgaagtga	gaacatggcg	gtgtltgggt	84720
ttttgtccct	gtgatagttt	actgagaata	atgatttcca	atttcatcca	tgtccctaca	84780
aaggacatga	actcatcatt	tttatgactg	catagtatct	catgggtgtat	atatgccaca	84840
ttttcttaat	ccagttctatc	attgttggac	atttggtttg	gttccnagtc	tttgctattg	84900
tgaatagtgc	cgcaataaac	atacgtgtgc	atgtgtcttt	atagcagcat	gatttataat	84960
cctttgggta	tatacccagt	aatgggtagg	ctgggtcaaa	tggattttct	agttctagat	85020
ccctgagaaa	tgcgccact	gacttccaca	atggttgaa	tagttttacag	ttccaccaac	85080
agtgtaaaaag	tgttccattt	tctccacatc	ctctccagca	cctgtttttt	cctgactttt	85140
ttttctatatt	tctagactct	ttattaagat	tcatttttct	atgaaaaagt	ccattcttta	85200
gtcagttcta	cactgtcttg	attaaggtag	cttttatagga	agttttttaa	tcaggtaaatg	85260
taacccctcc	aaattcatcc	tcctttttcg	aaattgtttg	gtcattctga	atcctttact	85320
ttttaatata	aatttataaa	ttatcttgcc	aaataatctt	gtttgaattt	taattgggat	85380
tgtgtgggaat	ttatagatca	atttggggaa	gactgtcatc	taaaaatatt	gaactttcaa	85440
ttcattaaaca	tgaatttatt	ccccatttca	tttttattta	ttkatttatt	tttctttatt	85500
attattatac	tttaagtrtt	agggtacatg	tgacacaatgt	gcaggtttagt	tacatatgta	85560
ttcatgtgccc	atgctgggtgc	gctgcaccga	ctaacctcatc	atctaaccatt	agtttccatga	85620
ctgttttaagt	attgccattg	taactgggtg	gagatgggtat	ctcatttggg	ttttgatttg	85680
catttctctg	atggccagtgc	atgatgagca	tttttctatg	tgtctttttg	ctgcataaat	85740
gtcttctttt	gagaagtgtc	tgttcatatc	cttgcgccat	tttttgatgg	ggttgttrgt	85800

tltttttctt	ttaaatttct	tgagttcatt	gtagattctg	gatattagcc	ctttgtcaga	85860
tgagtaggtc	gggaaaattt	tctcccattt	tgtaggttgc	ctgttccctc	tgatgatagt	85920
ttctttttgct	gtgcagaagc	tcttttagtt	aattagatcc	catltgtcaa	ttttggcttt	85980
tggttgcatt	gctttttggtg	lttttagacat	gaagtccctg	cccatgccta	tgctctgaat	86040
ggtaattgcc	aggttttctt	ctagggtttt	tatgggtttta	gggtctaatac	aaggggacgtg	86100
aaggacctct	tcaaggagaa	ctacaaaacca	ctgctcaatg	aaataaaaga	ggatacaaac	86160
aatggaaaga	acattccatg	cttatggata	ggaagaatca	atatcgtgaa	aatggccata	86220
ctgcccagg	taatttatag	attcaatgtc	atccccatca	agctgcgaat	gactttcttc	86280
acagaattgg	aaaaaactac	tttaaaagttc	atatgggaacc	aaaaaggagc	ccgcattgcc	86340
aagtcaatcc	taagccaaaa	gaacaaaagct	ggaggcatca	tgcaacctga	cttcaaaacta	86400
tactacaagg	ctacagtaac	caaaacagca	tggtactggt	acaaaaacag	agatatagat	86460
caatggaaca	gaacagagcc	ctcagaaata	acaccgcata	tctacaacta	tctgatcttt	86520
gacaaacctg	agaaaaacaa	gcaatgggga	aaggattccc	tattgaataa	atgggtgctgg	86580
gaaaactggc	tagccatatg	tagaaaagctg	aaactggatc	ccttcccttac	acctatataca	86640
aaaattaatt	caagatggat	tgaagagctg	tagcatcttt	caaagggtgac	taatgatttt	86700
aacattatta	ctataaacct	atagatttaa	acataattgc	tatgttttaa	cccattatag	86760
ttattattcc	tggtgatgat	caagctctat	ctttggccag	tgggagccctc	tgcaaatgga	86820
ttagtgaate	tctttgacat	ggaactatta	gtctttgaca	aatcttttga	tttctgggtat	86880
gacaatatat	tccagtttta	tctttatalac	ltccagtcct	atacataata	tttaactttt	86940
ttcaaagaat	tactgggttt	atttttagtg	ggaaatggca	tttaaaataa	ggaagtlggc	87000
gaggcgcagt	ggctcacgcc	tgtaatccca	gcaettlugg	aggccgaggg	gcgcagatca	87060
caaggltcagg	agttcgagac	cagcctggcc	aatatggtga	aaccccatct	ctactaaaaa	87120
caaacaaaat	tagccagacg	tggtggcaca	cacctgtagt	cccagctact	caggaggtctg	87180
aagcagaaaa	aaataaataa	aataagggaag	tctgccfata	tggtttatct	acctcttttt	87240
tagggctcaa	cctacccgtt	tcacacaaaac	ccaactgaat	toggactcta	tatgtgctag	87300
gcaagtttga	gctttttcag	gtgtacacac	agggtttact	gaacletggc	atataattat	87360
ttattttattc	atttttalcaa	gttttgtcct	atcatlgaaa	ctcattcttg	aataaaagtt	87420
tlatatattag	ttcagttaca	gcagacaccc	catlttgaaa	acattlatgtc	aacattggct	87480
tggtgacctt	gtcacatcag	taatgtacag	ttctcatlla	ccagaaattt	ttatatgaac	87540
aacatataga	agttattaa	ttaatgaatt	ctgccaaagt	attgggtatat	atttgttcat	87600
tataagcatt	taaaaacaaa	ggaacctttt	aaagltgaag	ataatttaat	gggccaltgc	87660
atgcaaagag	gtgttgcatt	agtaaccaac	cttaaaactac	tgctgaaaac	actttatgct	87720
tgagttagat	atgttgatgg	gagccaataa	ttgtgaaatt	tggtgatcca	gactctcttc	87780
tgctctgttc	ttaatggatc	tagtgtaaat	gttagaatct	agtgcatttc	acaactgttg	87840
ctattataga	tggaatatca	ggaggggtag	tgaggtattg	agatagatga	aaacattttc	87900
taaaagtggc	tcacgcctgt	aatcccagca	ctttgggagg	ctgaggtggg	tggtcacctt	87960
gaggtcagga	gltcaagacc	agcctgacca	acatggtgaa	accatgtctc	tactaaaaat	88020
acaaaattta	gctgggggtg	gtgtcaggca	cctgtaatcc	cagctaacag	ggaggctgag	88080
gcaggagaat	tgcttgaacc	caggaggcag	aggttgagtt	ttctccacag	ctttggatcc	88140
tgatgacttt	ttttttttta	attgttactt	tcaacttccct	tgctttgact	gaagccatac	88200
ttacatatata	ctgataacat	atgccatggg	ccgcgcattg	tggtcacgc	ctgtaatccc	88260
agcacttttg	gaggcogagg	cggttggtac	acctgaggtc	agcagttcag	accagcctgg	88320
ccaacatggc	ganacccctg	ctctactaaa	aatcacabaa	ttagctgggc	ttggtgggtg	88380
gctcotgtaa	tcccagctac	tcgggaggct	gagggaggag	aatcgcttga	acctgggagg	88440
cagaggttgc	ctgtgcactc	gggcccactgc	cgtccagcct	gggtgacagc	gcaagacttc	88500
atctaaaaaac	aaacaaagaa	aaacataatc	catgtatgtg	atgtaaaagag	cgccaacatg	88560
tttatatcct	cctattttcaa	tctactttta	cttcatctac	atttttagca	ataatgtgaa	88620
catgaaatct	tgaataattta	gctatctgta	atatacttac	tcatccaactc	aaaaatttga	88680
gcccccccaa	taaatatcat	acactatatt	ctagggtacag	gtgalaaaca	attcagagag	88740
tattaatttc	aaaacatggc	aagtgcatag	tgagagagct	galctgggtct	gggtgggtgag	88800
ggaatcaaga	gatatattgag	ttgaggtctg	caglatatata	gaaaattaac	taatcaaaag	88860
agaggcagtc	attccaagga	aggggatgtg	agtcagaaga	aactgcagct	ggcaagctct	88920
gaggtgggac	aaagcaagga	catattgaag	gaattgtgac	tggaagcatag	ggatggaggga	88980
aaacattgta	gctagctgag	aaataagcat	ggaaaaatgt	tgtagagctg	tataggccat	89040
gttaggactt	ttgtctttat	cttaaggata	agccattgat	gtgtttataa	agacacatga	89100
tgtgatcaga	ttttcagttta	aatttaaaaa	atacttggaa	tgcattttgg	agaatggttt	89160
aggggagagg	caagagtggg	ttctgtgggc	cagtagttca	gaggataggt	tatggtagct	89220
tggaactaaag	tgcttgagcc	aagatggaga	gaagtagatt	gctttaagac	atattttaag	89280
ataaacatca	gcacttagca	atgaactgga	gatggaaagat	gagggaaagg	aaggtgttag	89340
gcagggtttt	acaatgagag	aggttggtga	tcatggtcac	caaggtaggg	aatgctggat	89400
gaggatgcag	tttaaggtga	agattatgag	ttcaggttca	gcaaaaactga	acttgagaca	89460

tggtgaacta	tcaagggtgga	gatataccagt	gaaagttaga	gagaggggtc	tagagctcag	89520
ggaggagtg	gtatccctaa	tttagactaa	tttgcattaa	cagctgtagt	aatgcaattt	89580
tctctatact	gaaatgcaga	catttgagta	tagaaaatta	gcagacattt	gaatatagaa	89640
gaaagallta	ctttccctca	gaaaaagaat	agttagagta	aaagaataat	attlaalcct	89700
aggaattaat	accaaaccc	ttaaaaaaa	cttttaagtt	caggggtaca	tgtgcaggtt	89760
tgttacatag	gttaaaecttc	tgtcatgagg	gtttgttgta	cagattgttl	catcaccacag	89820
gtattaagtc	tagtacttgt	tagttagtta	ttttccctta	ttttctccct	ccacccatct	89880
tccaccttct	gataggcccc	gggtgtgtgt	gttccctct	gtgtgttcat	gtgttctcat	89940
catttatctt	ccacttatna	gtgagaacat	gtggatattg	gttttctgtt	cctgcattag	90000
tttgctaagc	ataatggctt	ccagctccat	ccatgtccct	gcaaaaggac	atgctattgt	90060
tcttttttta	tggctgcata	gtattccatg	gtgtatatgt	accacatttt	ctttatccag	90120
tctatcactg	atgggcattt	atgttgattc	aatttttttt	ggctatttgt	aatactattg	90180
caataaaca	acacatgcaa	gtgtcttcat	aatagaatga	tttatattcc	tttgggtgta	90240
taccocagta	tgggatttgt	gggttgaatg	gtatttctgt	ctttaggctt	ttgaggaatc	90300
atcgccacagt	ccccacaa	gggttgaacca	atttacactc	ccaccagcag	agtctaagt	90360
ttcccttttct	tccactacct	caacagcacc	tgttattttt	tttgactttt	taataatagc	90420
cattctgact	tgtgtgagat	agtatctcal	tgtgggtttg	atttgcattt	ttctaataat	90480
cagtgtgtgt	gagcttttct	tcatalgat	gttagccaca	tgtatgtctt	ottttgaaca	90540
gtgtctgttc	atgtcccttg	cccatttttt	aatagggttg	ttttattctt	gtaaatttgt	90600
tttaaggtctt	tatagatgct	ggatattaga	cctttgtcag	atgcatagtt	ttaaagaaatg	90660
ttctcccat	ctgtagggtg	tctgtttact	ctgttgalag	ttctttttac	cgtgcaggaag	90720
cttttttagtt	taattagatt	gcatttgtca	attttttctt	ttgatgcaat	tgtctctgtg	90780
cttccctcatg	aaatccttgc	ctgtacctat	gttctgaatg	gtactgccta	gactgtcttc	90840
cagggltttg	atagttttg	gttttacatt	taagtcctta	ctctatcttg	agtttaagttt	90900
tgtatatggt	gtaaggaaag	ggccagattt	taactctctg	catatggcta	gccagttatc	90960
ccagcaccat	ttattgaata	gggaatctgt	tctccattgc	tlgtttttgt	caggltttgt	91020
gaagatcaga	tagttggagg	tgtgtagtct	catttctggg	ttctctgttc	tgttccatta	91080
gtctgtgtct	gctttttttt	atgttcttaa	cttttattta	tttatttatt	catgtattca	91140
tttattttta	ccagtgccat	gttgttttg	ttgtcttagc	cctgtagtat	agtttgaagt	91200
caggttaattg	gatgcctcca	gctttgttct	ttctgcttag	gattgggttg	gaaaattagg	91260
gcactttttt	ggttccatat	gacttttaaa	atagtttttt	ctagtctcat	gaagagattc	91320
aatggttagtt	tcatagggat	agcactgaat	ctataaattg	ctttggccag	tatggccatt	91380
ttcacacaat	tgattcttcc	tatacatgag	catagaatgc	ttttccattt	gtttatgtta	91440
tctctgattt	ccttgagcag	tagtttgttg	ttctccttgt	agagattttt	ttttgtatcc	91500
tgagagattt	ctgaagtgt	ttatcagctt	aagaagcttt	tgggctgaga	caatggggtc	91560
ttctagatat	aagatcatgt	ccactgcasa	gaaagatagt	ttgacttctt	ctcttcttat	91620
ttggatgcct	ttatttcttt	ctcttccctg	attgcccttg	ccagaatatt	caatactatg	91680
ttgaatagaa	gtgttgaata	gaaactaatg	ctgcaagcat	tagtttcaaa	gaacttcttg	91740
atttctgcct	taatttgatt	gtttacccaa	aagtcattca	ggagcaggcg	tttccacttc	91800
cgtgtaattg	tatggttttg	agtgaatttc	ttagtattca	tctctaattt	aatgtgtctg	91860
tgggtctggg	gacagtttgt	tatgalttca	gttcttttgc	atttgcctag	gagtgtttta	91920
attccaattta	tgtgatcaat	tttagagtat	gtgcnatgtg	gtaatgagaa	gaatgtagat	91980
tctgttgttt	ttcactggag	agttttgtat	atatctatca	ggttcatttg	atccagtgtt	92040
gagttcaggt	cttgaalate	ttggttaatt	ttctgtctcg	gtgatctgtc	taataattctc	92100
actggggtgt	tanaagctcc	factattatt	gtgtgggagt	cagtctcttt	gaaggltctgt	92160
aagaacatga	ttatgaatct	gggtgttcc	gtgttgggtg	tatatataat	taggatagtt	92220
agattttctc	gttgaattga	accctttacc	attatgtaat	gogtltcttt	gtcttttttg	92280
ttcttgttg	ttcaaaagct	gttttgtcag	aaactaggat	tggaaacctg	cttttttctg	92340
atttgcattt	ccttgatata	tttttctcca	tccttttatt	ttgagccat	ctcattgcat	92400
gtaagatgga	ttcttgaag	acagcatacc	gatgggtctt	ggctctttac	ttggcttgc	92460
gctctgtctt	ctaattgggtg	catttagcct	atttacattt	aagggttatga	tcctgtcatc	92520
ataatgctag	ctggttgcct	tgcagacttg	tttttgtgg	tgttttatag	tgttactaat	92580
ttgtgtactt	cagtgtgttt	ttatagtga	tggtaatggt	ctttcctttc	cacaattagt	92640
gcttccctca	ggagctcttg	taaggcagg	ctggtggtaa	ctaattcctt	cagcatttgc	92700
ttgtctgcaa	aggatcttat	ttttccttct	cttatgaaac	ttagtttgac	cagatataaa	92760
actctgggtt	ggagtctctt	ttctttaaaa	acalltgaata	ttggcctcca	atcacttctg	92820
gtcttgagg	ttttagctga	gaggtctgtt	gttagtctga	tggggttccc	tttgaacctt	92880
gggttctctc	tctggctgcc	tttaaacatt	gttcttctcat	tttgacctta	gagaatataga	92940
tgattatgtg	tcttggggat	gaacttatta	tgggttatct	tactggggtt	ctctgcattt	93000
cctgaacttg	aatgttggcc	tctctggcta	ggatggggaa	gttctcatgg	atgatatttt	93060
aaaatagtct	ttccaagttg	gttccactat	cttccatttt	tttcaggtaa	accaatgaat	93120

tgtagatgtg	gtctctatat	aatcctatat	ttctaggagg	ttttgtttat	tcatttttat	93180
tcttttttct	ctattcttgt	ctgcttgtct	aattttggaa	aggtagtctt	caagcttggg	93240
aattctctcc	ttcacttagt	ctattctgtt	attaatactt	gtgattgcat	tatgaatttt	93300
tgggggttgg	gagtggtggc	tcacacctgt	aattccagca	ctttgggagg	ctgagggtgg	93360
tggatcattt	gaggtcagga	gtttgagacc	agcctggata	atgtggtgaa	accccaacctc	93420
tactaaaaat	acaaaaaaa	aaaatcatag	ctgggcatgg	gggaacatgc	ttataatctc	93480
agctactggg	gagactgagg	caggagaatt	gcttgaacct	gggagatgaa	ggttgcagtg	93540
agctgagatc	gtgccactgc	actccagcct	gggtgagttg	agagtccgta	tcaaaagcaa	93600
acctaacat	ttttgtggcc	tgttttttagc	tctatcaagt	cagltacatt	cttcttgtatt	93660
ctagcttttt	tatctgtaag	ctcctgcaat	gcttttattag	aatttttagt	tcctttgcat	93720
tttgttaca	catactctta	taactctgcy	aacttcatte	ctalccatat	tctgaattct	93780
gcttctatac	tttcagccat	ctcagcctca	gcctgggtact	gaacgcttgc	cagagaggtg	93840
atgtggctct	ttggaggaaa	gaaggtaact	ttgattattg	agttttcagt	gttcttgtgc	93900
tgattatttc	ttatctttgt	gggtccatct	accttcaate	tttgaggttg	ctgacatttg	93960
gattattttt	tcttttatcc	tatttgatga	ccttgagggt	ttgatttgtg	tataagggtca	94020
attcaaccaa	ctagctttgt	atctggaaga	ctttaggggg	ccatcgltca	cctcccaact	94080
cctggactgc	atgttctaac	cttggatgac	ttgtattggg	ccccaacttt	gttctctggt	94140
tcttcgagg	ttggagtcta	ctttgttggg	ggaccaagg	gtggcagctc	cagctgggtg	94200
ctagcggatt	caggggtgcc	tgcttccctg	caggcattca	coatgctagt	gaaggcaagg	94260
catrttttgt	gggaacagga	ggctcctgct	atagactgtc	tgtgcttttg	cactggtgat	94320
ggtgttgtt	tggtagaggg	cactgaccag	tgcagatctg	agtgccttct	tggtcacctg	94380
cagcaggag	ggattgctca	gggtgtggga	ggatcctctg	ttctccatgc	agcattacca	94440
caagagttag	gcactggcag	ctgcagggtc	tgctggctgt	gtgctgctaa	ggttctgtct	94500
gcaatggtgg	ttgacagagg	tcaaggggca	taactccctc	ctgtatgcta	gtggggcaac	94560
taaagcaaat	tccacctgtg	cagacatgtg	cctgcaaagt	gatgtgggga	gttgccatgg	94620
gctcaggsga	agttgcagta	tgggtagcga	acacccggct	ggtgtgcgca	gtaagggtcg	94680
tcttgcttga	gttctccact	ggtcaggcat	ggcccacttg	tgcagaagct	attctgtggg	94740
ccaccacagc	acccaagatg	gccttagaag	aggccagcag	accaaggagt	gctcagggtg	94800
caccagccct	gactgatgta	caagaccact	ctgcagatat	caagtctgaa	aattcccta	94860
gggccaaagt	ctatttatgg	agcaagtga	gcctagaggg	atcgocatcc	ctgtccatgc	94920
actgctgtag	acactcctgc	actaaaacct	ctgggctcca	catcagctgg	cttgcctgct	94980
taccaccttg	cttctctctt	gggggctcca	ccccagagag	atgtgggtca	gcaatcattc	95040
agttcaatca	gcccaggatg	gagagtctgt	gctatgggcc	caagccaggg	gctctctgtc	95100
tggtagcag	cagctggggg	gtgggggtgg	acctgtggga	gatggactgg	cctcctctcc	95160
ttgagtcaac	tgtgtcttat	tggaggtgtg	gatgagacac	ttagggtctt	tgtctcttta	95220
ttagtcaag	ggtagcaagg	acagttccat	tgcagaggta	gtggcagaga	ggctttcagt	95280
tgtccgtggc	ggctctgtcc	agggagtgtc	tgagtgtcta	ttggcttgat	atctctggtg	95340
gggtgtggct	agaggtccag	gcctggaggg	cctgctcggt	gaagagatgt	gggaatgggc	95400
acccacataa	cagtctgttc	acttttccat	agggctgctg	tagtatgctg	ggggccagct	95460
ccagtccctg	gtcactttag	attttccagt	acctggagg	gtcaccagtg	aaagctgcga	95520
aacagcaaa	atggtggcct	tcttttctct	ctgggagctc	catccctggg	aaalacaggc	95580
ctgttgcctg	cccgaacaca	ctggtaggac	atggttgaa	acgctagtgg	ggagacctca	95640
cccagccagg	aggaatagga	tcagggaact	gctttcaaaa	gtagtcttgc	ccattttca	95700
tagaggagtt	gtgccatact	gggggtatgc	tttagccctt	gattgcctca	gacactctga	95760
agcccaaagg	ctggaatggc	taagttgttc	taacagcaaa	tatggtgggc	tgtctctctc	95820
cctgggacaa	aggtoccatg	gaagtctgaa	acctctctca	gtcagagaa	accagttggg	95880
gtagccgggg	accccgatg	ggagactcta	cccagtgtat	aggaacggga	ttggggacct	95940
gctaaaaaaa	aaaaaaaagc	agtgtggcca	catttttgtc	gggcagctgt	tctgtgtgtg	96000
ggttccctct	ccacccctgc	ttaaagctcc	caaagcctga	aggctgggat	gggtlaagttg	96060
cccaaacagc	aaagatggca	gcctgccctt	ccctctggga	gctctgtccc	agggagtttt	96120
cagatctctg	tcagctggag	aacactggca	ggtgtggctg	gagggcccat	ttgggaggtc	96180
ccgctgttaa	ggatgaatgg	gatcggggac	caacttaag	cagcagctct	gccacatttt	96240
aatagagcaa	ctgtgctgtg	ctgggggata	ctgttggccc	ctggttagtt	tggactctcc	96300
aaegcccaaa	ggcacaatg	gctaagttgc	ccaaacagca	gagatggggg	cctgcccttc	96360
ctcctgggag	ctttgtacca	gggaggcaca	atgttgctac	tgggtggctag	ctggaattcc	96420
aaagcagtg	gtcttatcct	gtgaggcgct	gtggaagtgg	ggcctgtaga	ccttctctgc	96480
tgatctcgct	ggattcagcc	tcttttctgg	ggtatgtatg	ggagtctaac	ctcctggggg	96540
atgtttgggg	gtctaaacct	cagctttgcc	aaagtcgoag	ctacttttgc	ccagacaccc	96600
agaaagctgg	agttagctaaa	gctcttgggt	ctccatgcat	gcctgagtg	ctgctctgct	96660
gagactccac	gtgctgtgtg	gtgaagggcc	taatggagtg	agttcacaa	gggatctcct	96720
gatctgaggt	ttgcaaagat	ctgtgagagc	agltgtggatt	cccagagttg	cgcattcact	96780

taccacttcc	ctgggaaggg	gagtttccct	tgactccacg	totttcccaa	gtgggtgttc	96840
ttccctgcctt	gatttgcctc	ggtctccgtg	ggctcgagtg	tttcccttgat	taacttccaat	96900
gagagtacct	taagtgttca	gttgaagggtg	ctatatattlag	tcacccctttt	ctttccggccc	96960
tgtgagagtc	acacacatta	actgcttcta	gltggccatc	ttggccacttc	ctggccctaaa	97020
cctttctagc	aaaaaaaaaa	aaaaaatttaa	taacatgttg	atctaccgct	tctctctctt	97080
kaaatttatt	taataatlat	gaattttttt	acattttatt	acattgtttaa	gctgttttat	97140
tttaaaatlt	ctagggtccag	ctcttccctgg	attgctttta	tataaggaaac	ataatclcatg	97200
aaataaataa	aatttcacatt	caaatagcaga	agaatctatt	ggaaaaaaact	cagaggacog	97260
gataaaagca	ctcagaaaaa	atgccaggag	aaggcgltta	tcacataata	tccgtgataa	97320
gagtctctcg	aaaattttttc	tctctattca	ttctttacca	atatagaaag	tgaacaaaac	97380
aatatttagta	ttagaaaaaa	catccaaaaa	taatgacctt	tctgaatgaa	gactgctttt	97440
ttcatgggtta	ctcttttttg	ggtacagttc	tatgttgatt	tatccaatlt	atcaaatagc	97500
cattcagcaa	atattttattg	agtgctctgtt	atgtcacagg	cactcttttc	ggtccctcaa	97560
atacatccgt	gacaaagagt	aaaagattcc	tgttcatggc	tcttacattc	caggagggat	97620
agcaatttct	tttgtaaagt	taatacacaca	acagaaatgt	gaaataatat	tgatgctgtt	97680
aggaaaggaa	aaataaatga	aatataattga	aaaagaaatg	tgaaggata	attaaaagag	97740
gctatatttt	attgaataaa	aataaaagag	gctatgtttt	attgaatatg	ctccatgttt	97800
tatactatat	cataaaacat	acaagatctg	gcttttaaga	aatcaatato	ttcatcaata	97860
tcttcattca	gactcatcta	gattagatta	ctctgaatct	aatcacatag	agacttgtct	97920
gacaaatcca	gatttttttg	acgttctgca	ggactatttg	tcaggatatt	tcacaggatt	97980
ccaagaaata	atattgggtg	ccatgctata	atgatltctc	agctccctcc	atctgataaa	98040
atattgattt	cttatacata	taaaaocat	aaaatatttt	aaaataatttt	ttgttatatg	98100
agtgaatcaa	taataaaaacc	actatctcaa	taatcatcaa	ctgattgcaa	actgattgtt	98160
catctcagaa	aaaccttggc	agagttaaaa	taaaagtttc	aaaatacaga	acttagtacc	98220
aaaattaaag	cagtgttagg	tttctaattt	tgctattcac	atgttaaattg	aattttcaaa	98280
attcagtagc	taatactagc	tagggtttta	aacaagacat	agttaaaatg	aaactttaaa	98340
aaaagaatca	taaaactcag	tatcatcatg	attggcagtt	taggatttta	attgtgacac	98400
cctagtctca	aatlttgtact	taatgtgggt	atatagctag	gcagtgcctg	agtgaaggtt	98460
tcaaaacaaa	ttaaaatcaa	aagttaagaa	aaaaatatga	aggcaatttt	aagggtgttt	98520
atltggcact	gtagtttcaa	aatagttacct	gaaacttaac	agcaaagtat	cagattcatt	98580
tataaaacaa	tgtgactgat	ctttatgtat	ggtttgtgaa	acattttatgc	agtgtcactt	98640
cagaaactc	tgccattata	gatttgaatt	gettaaggat	atccactcct	ttccttggca	98700
tgatacaaat	aaattactaa	agtataattg	taaccaatgat	aaatataagt	gacaatacca	98760
ccatattact	atgaaacaca	gattgattat	ggtataalac	aatttagcat	ctccatattt	98820
ttgaaatga	acttggttct	ctaactgycl	taatttggga	caatttggac	atcaaaaaga	98880
atgatgatgc	aattttaaac	atacaaaaaa	taaaaaaaaa	aatccaaggg	acgggtggtga	98940
aagtcttctt	tctagaagaa	tagcagctaa	tatacacaga	acgaatctta	gaattagaaa	99000
atcactatat	tttgatccoc	ttcccaaaag	ggtgacaaaa	ccattggtag	acagtgggtg	99060
agaaacagaa	tagtctcagg	atalcaactoc	gtagatttat	tcatttaatta	aaaagagaaa	99120
atgtgctttg	agagagagaa	agctattacc	gtctttatca	aataggagag	cctgatcatg	99180
tgtggtctga	agtttatcta	atgggattcc	tgatggaatg	tttagtctga	atctaatac	99240
atagagactt	gtctgacaaa	tccagatttt	ttggatgttt	tgcaggacta	tttggccacga	99300
catttcaaaag	gattccaaga	gagaatattg	gtgtccatgc	tgtgatgatt	cctcagctcc	99360
tctcatctga	tctccgtcct	ggcccccctg	actttctttg	tggtagtlag	ggtgtggtat	99420
gtgccactga	ggccacacac	tattgctgta	agtgtgtttt	gggaaacct	catctttcag	99480
gtctgtgtga	taaaagaaga	gccttggggg	aatgttctct	tccaaattta	atcttttcat	99540
tattagaaaa	tattttgatg	acctgttttc	aaatattttc	ttataacttt	ccattttcat	99600
gtgtttattc	tgacagttta	ttttatcttg	tatttataat	cactaagatg	ttagtattgt	99660
aatattaata	ttacatgatt	taaattagga	aaaatgtgtt	ttctattaca	aatggatag	99720
tggataattt	aagtatagaa	agtaatat	tctatatggg	actatttcac	tctctgtaat	99780
atcctgaatt	ctaattccca	ctgtagttag	ctalaacttt	actaatcagt	tttcttaca	99840
tcgattttaa	gtctatlttg	ttagatctaa	agacataaag	ccaaaagtto	ttcttgagaa	99900
gaagcacatt	tcagttacgt	ttataacttg	aaatatctgg	ttttactcaa	aactcacatg	99960
tcatactgaa	aaacagaagg	gagatgttgt	cttttctttga	ggagagactt	ctctgcagtt	100020
aaacagctca	ccacatgttt	agagtacata	gacaatacac	ttcctctttt	gtaattgtaga	100080
tttcagcttt	ttgcttctag	aattatcatt	ggcgtggagg	ttatcacagg	gaagtgtga	100140
aaaatgtagc	caataccagg	aaccttagga	agtgtctgaa	cttcatcttt	tclgtgtctc	100200
ttttccctta	gggggtcagt	gtaagagttt	gggctaggaa	gagattgctt	cttttactct	100260
atttgatttg	tacttctcat	ctgggtattt	gacaataaat	gactcatctt	ctttgtttgc	100320
cctgggtgtg	aaaaattttc	ccatatgcca	gagaaaaaat	gttacagtga	cacaatgtaa	100380
aattgtaaga	gggtgaaaaa	gatgaggtat	ggacatagtg	aatggaagtt	cagcccttta	100440

aaactactgg	cagagtagat	tttactcagg	cttcaattaa	gtagacctga	atgtaaatc	100500
aggtctagct	ctgcaactka	ctaggtaagt	gacttttagtc	ctctttaaga	tttagtttcc	100560
tcattacagg	atataataat	actatttttcc	ttatgaggta	agtatttaatt	gaaatagtat	100620
atgtacattc	tagcatacag	tgatccctta	ataaatggaa	cttatcatta	atcacattgct	100680
aggaaaagaa	aaacacatca	gggaacaaaa	gatalaactg	tcttattgal	aacaggggat	100740
ggattcttgt	ggacaaaaaa	atttagaatt	gaattttcaa	ggggtcattt	ctttcaccag	100800
gtgtagtiag	gtttgtctct	atggtaacaa	tgaatatggt	tgtttagctt	cttaaacggg	100860
catcatggaa	cgttaattaa	taaacagaat	tcaatgtatt	tgtggggcat	tttatttttt	100920
atgcaatcat	ttgtatctgt	caccttcaca	atgcattgcca	cattctcaga	ccacctatta	100980
tgttattttc	ttaacatttt	tcttcaaat	cactcacctt	tttaaaaaat	ttactgaagt	101040
ctcacttaag	cacataattt	gtaaaaatcat	gggtttgttg	tgcaagtttt	gtttttctaa	101100
tacactctaa	aacaaatacc	ttaaaagagt	tacacctaca	gtccatatac	cacccataat	101160
catctcaagt	acctccagt	cttggtactg	cacttttgaa	aacactaaca	tacattattc	101220
tcattagttt	ttataatagt	tatatgaggt	gaatagagaa	ggcataacta	taccattttt	101280
aaagatgaga	aaagcagggt	catggatasa	atctcatagt	aaattgctag	aattggtcct	101340
gatactcatg	ctttcttttag	atcaacctcag	tgtcttact	gtaattgata	ccaaattctt	101400
taaggaaact	tagagctaaa	agtaaaattt	tttgtaittta	gacctgatta	ttttgtggta	101460
atttgaatat	aggtcaatat	gaaaaaaaat	aaaagatgaa	acaaagaaac	tgagagcaga	101520
tcaccaagtt	gcggtagggt	agcctaagat	agcttttggt	tttctcagcc	ttctactatt	101580
cacagctttg	tgtaatcccc	lccacttgag	tatcttgctc	ataccaatag	aatatggtag	101640
tagagtagag	gtcacctctc	tgataagttt	acagaagatt	gcgacctccg	tcttgccaga	101700
gtaotttecto	tcttgctggg	tttgatgaag	caggctgcca	cagaagagag	gtcacatagg	101760
cagggacctg	agggcagcct	ctggccaaca	gcaagcagta	aacagatgcc	ctcagttcaa	101820
tatccctcaa	agaaatgaat	cttaccaca	gccagttgtg	ttagctggga	agcaaatctt	101880
tcacctaaagg	agalttcaga	tgaggcccc	agccttggtt	gacaccttga	ttgcagtctt	101940
gtgagagatt	gtgaagcaga	gctattctca	gaattcatgg	gtgttttaag	ctatgagggt	102000
ttttttgggg	ggagaatggg	catttgtgat	tcagctatac	ataagctcac	aaaagtcatt	102060
ccagaagtga	ttcagtgga	gtagaatcat	gtggttggtg	gccocaggca	cttggagttc	102120
tgtatgaatt	gtgacttcta	acactggaca	cccttttctt	ttctcttatt	ctcccatttt	102180
tctcccttcc	ccttttctc	ccttcttcc	cttcatctct	tctacttttt	ccgtacttta	102240
aattaataga	gcagttggaa	acacaaaagc	aatgtctgta	tctacaaaat	gtcattattt	102300
atactttgta	tcacagtggt	gtgcctagg	gcttcatgcc	tgaggtgcat	ctgtagaagg	102360
tgtctaacaa	aggcttggcl	gttgggtatta	ttgaatcact	gtggagttaa	ttcattgttg	102420
tccatgccat	tttgagtttt	cattttttta	tttatgggag	tgtcttltatt	cttttaaaaga	102480
gcttctgttg	tacactcatt	ttctctctct	ctcttttctt	ccacaggcaa	tttatagcac	102540
tgtatctgtca	tcaataccac	ttgctgtctt	ggatgtgaag	atgatttttc	ctgcagggat	102600
tcctctctaca	aaattaaaaa	cactgggcct	gtggaaataa	tattcatgct	ttaaattgtc	102660
ttttctcttc	actacaccag	gggtccccc	cccttaggcc	acagactgtg	gccctagttg	102720
agtgaataga	aaagacaatt	taaggcgtga	atattatttc	ctcatgccca	gtgtttttta	102780
ttttgtactg	gtctgtggct	tgttagaaac	caggctgcac	agcagaaggt	gggcagcagg	102840
tgagcaagca	ttactgcttg	agttccggct	cctgtcagat	cagcagtggt	attagattct	102900
cataggagca	caaaccttat	tgtgaactgc	acacgcgaag	gatctagggt	gtgcgcctt	102960
tatgagaatc	taactaatgg	ctgatgactc	gacgtggaac	agtttcaacc	cagagcacc	103020
cccacccacc	tgagaagaa	ttgactttta	cgaaccaggt	ccctgggtgc	aaaaaggttg	103080
gggaccaccc	ctgcactaca	ctacctaaaa	gattttcact	ttcacagtgt	tgtctgtctc	103140
tgttttacat	gcacaagttag	ctaaaagctag	ccttctggta	aatggagggg	cagagcagat	103200
ggtggggggag	gagtacatac	ggacgaattt	gaatcacaa	ttctcacta	tatgccagca	103260
aaattttaata	atagcaccta	aacatacaca	tgcatatgta	aatgagtcac	actataaaaa	103320
ctttttaacaa	gtactggcaa	gtcagatggc	agacttaccc	tgaacctgc	cactccaa	103380
aaaacctcat	aaftaaaaac	aaaggctgtc	ataaagcata	acataataa	acaattat	103440
gcaactggta	caaggctaga	ttagaaggtt	gaaagttaac	tttctcaggt	aaaaatgctt	103500
ttccclataca	gtatgcagcc	agcagattat	catccatagt	ttgagtagtg	agatgccact	103560
tgtctccaaca	attaacacct	gctgatgttg	gtccaagaag	agactgaggt	gatgcagttt	103620
caactgtttt	gtagaataaa	cgctgggtgt	tgccalctat	tgacagagtg	cttactacgt	103680
gccagatgct	ttgttggcac	tgaatgtgct	atctcattcc	agtttcttta	tactcaatga	103740
aaaaccaact	acatttatat	tgcattgagg	cttaaaagtgg	tttactgact	tgtttaagat	103800
tatacaagta	gtaggtggct	acagcagggt	ttgaacccaa	gtatgcttga	ttccccaaac	103860
catgcttttt	aaaaaatcaa	aggtgtaact	tngataaaaag	acatgaagtt	aatgaatata	103920
tgaagatgg	tgaatagata	cagatacaat	gtggccttag	gccagatcat	gttgaacatg	103980
tggtgggata	gataagagaa	ggttcttctt	tgttgttacc	tggttctcaa	ttggttatta	104040
ctttatgtgc	tttccatatt	aaaattctat	tattctgggc	tataaattca	cccacccaga	104100

cttgccctaaa	ctaatttaaac	ccctgaagttt	ggcatgtctc	ttttttgggg	tgccctctatg	104160
atagggtggt	gaaatgaaa	tggaattaaa	agttttgtga	agctatagca	ctactttttc	104220
attgtgttcc	cccctgactt	tctgccctag	gtgtttactt	tggtgagata	tcctggggaga	104280
aattgaggtg	aaaagaagcc	cgagtttaga	ttaggggaaga	gatgaagtag	tcaataaaat	104340
tcaaatctct	gtattctgaa	acgcaactat	totttctcca	acttggtttt	ggacagaatg	104400
tcttagtgta	gctgttaaca	aagaaattga	tgacaattaa	ctcccatctc	tcagaatttc	104460
atcattcttt	gaaagtgttt	atcatactca	atcttctaaa	aatccttaag	gcatactaca	104520
gtgtagaggt	tggcaaacctt	ttctataga	ggctcctgata	gtagcttggt	tcgcttttga	104580
gggccaatga	gtttctgtca	caactactca	tctctgctgt	tgtaataaag	actcaccat	104640
agacaataca	tgaatgaagg	agtatctatg	ttccaataag	acttttataa	atasaattag	104700
gcagcaagac	tgatttgaca	taagggtcat	aatttgctaa	cctgtggtat	agtgaaggga	104760
gttcaactag	agtttgatga	tggtgtgccc	attctagtgt	ggtagtctta	ggaaagtatt	104820
ttaatttaga	tttgatgtag	ttttctcata	tgtaaaatgg	ggataataaa	acctgcttca	104880
caagactact	atgaggagta	agctatgtag	ctaaalatag	caaaatatct	ggcatctaat	104940
agatgcctaa	tcaatgggtga	ctataatgat	tcttatcatt	actgtattat	tttaaacatt	105000
tatctttttt	ttttaggttg	ttgtctaaat	aagggtattta	gagaaaataa	gtgctgetga	105060
gggcagclgg	aactgttttg	ctgggtccatc	actgaaattc	tagttcttgt	tggtgcttat	105120
ttcataattta	tgaactaat	tcttttgaaa	agaacttgaa	gtagagcaac	aagaactaag	105180
atagacaataa	taccattctc	tctcagttct	tattgtctta	cttcaagctc	ttttgaaag	105240
aattacatag	tactgggtgc	atgtgtttgt	ttattttcct	tgttgggtaa	tcgtgaatat	105300
gttgattggc	gtcaaacatg	ggctccacct	atacccatgg	cagtaagctt	ctattgaltt	105360
gaattcagac	tagccclgg	ggccctgtga	gtgggaaggt	ctagggtgtc	ctagcttggt	105420
ctgtggttcc	acgaggggtt	ggatgcattc	gttctacttg	tggaaatgtg	gcaccaatat	105480
attggctgct	tctccgagta	tttgcccttg	tcttctttgt	gaaaggctac	tggtcggttt	105540
gagctattgg	gctgttttatg	ccacatcctg	tgcatgccac	actggcttct	tttctgtggt	105600
gtttccagag	atnagtttgc	ctgatagaag	tcagactctg	tggtctttta	tcattataga	105660
tttttctaga	aggagaagag	gccatgatca	catctgagga	tcctgagtca	ttgtagacat	105720
gtactgaatt	aaagagaatt	ttttgactaa	aggagaattg	catcaatcac	ggtgaaggag	105780
atgccacagg	acagggcctg	aggtgtttgg	ttagccacag	atgtaagggc	tacagttaac	105840
agacaacttt	cagtttccac	tattggaagg	gatgatcagl	ccttccctcc	tctattttct	105900
tgagccccgt	ttttcccttt	tcttttctc	tctcctttct	tatcatgaag	aataaagaca	105960
aatgagaaca	gactacactt	aggtgatcac	agggcagggg	atccatttaa	taataaaacg	106020
tgggtcaaaa	ttcaactttc	tccttttgaa	ttgaaattat	attgtgcattg	ggctaattag	106080
attgaatgct	gtaaacatga	agataatgct	tgcaaaagtag	ctacagagaa	agagaaaaag	106140
cctaaaacaa	ccagttagtgc	ttaggacca	tagtataagt	ctttacacac	tacatttgaa	106200
taatactgta	agacacaatt	ctttgatagg	ttaaatagca	aatctaggcc	ccccaaaatt	106260
atttaaaaaa	ttgtcatttt	aattctagag	gtataacaac	agtgtgtaag	ttgcatcaaa	106320
taacaaagtt	agtctacagc	ctaaatttgt	tcgtccctgt	tttttcaact	ctatgcatac	106380
ttttataact	ccatgctaga	gctacctcat	tcttttataa	ttgtgagata	ttctataaatt	106440
tattttgtatt	ccctatttaa	tatattttta	gcttattagt	ttacttataa	agatttatgt	106500
ttgectttcta	atgtcaaaagt	taggagtcac	ctgtccattt	aacagggtgt	gttttcttgt	106560
gtaactcctc	tgcttcatg	caaacctttg	agaacaatct	cttgaacaaa	ggctaataatg	106620
cctttggaga	ggtatttatag	atgatcatat	ctactttgtg	cctcttcca	ttacttagct	106680
gcattagagg	cccagctgtg	taggtgtaac	tcaaaatcca	ccaaaactaa	tactgtggtt	106740
agattctggt	caaacaagtt	gccattaatc	cagatgtaga	atgggattga	aagggtggctc	106800
ttccacaccc	tgacatcaat	gtaccagttt	ggctctgtgc	attctttctc	cccttctccc	106860
tttaccaccc	tcataataatt	gtttgtgtac	atgtctggtt	tcgtcactac	gctgatggca	106920
aggatcatgc	atgccttatt	catattttgt	ttattcaagg	attctactct	gggttctatt	106980
atggggcctg	gcctaaagtg	gttgttcaag	aaatgtgtgt	tagagaaatc	atacataaac	107040
tgcaactct	catttggatt	cctgtatctg	aacaactaac	tttcagcttc	ttcagtgagg	107100
taaagaagaa	aaatgggggtt	taaagtacat	actattcagt	attaatgtag	aatttaacag	107160
ctgccatcca	agtgcagaat	cctctgtagt	ttcccaggtt	taacotcact	tctatctcta	107220
gccatgtctc	agtgtgggtt	gactctctcc	tgcatgttct	tggcaagact	ctacctgggt	107280
tgcgtaatct	acatcggtct	ctagtctcca	caagaattgt	ttatatgcac	ttaattttag	107340
ctcttgggct	ataacatgtc	attgttcttt	ttacttatct	cctcttactt	ctggaaacag	107400
ggcaggcacc	ttcaataactt	gctgttccctg	tttgggtgtgc	tcttagatta	attttaactt	107460
tcctcttcag	ccttcatgac	acttcaagac	atcttccagt	catatttccct	gtataagaaa	107520
atacagacta	tgtcaccaca	aagggtagtg	gagattgggg	ggcataaatt	aattcattca	107580
gggaactcat	atcttgggtg	gaatggaaat	taaagcaagg	tatttggatt	aatttacctc	107640
atcttggctc	atactccatt	tagaggataa	cacattaagc	ttttattcaa	ttttatctgt	107700
tatggtcaca	gtgaatctgg	aaaaaataat	atatggggct	tagttttcat	atttagggga	107760

aatgaatat	cctagagaat	aataataaaa	gttagggaaa	ataatgtttt	cctaagagta	107820
ggcaalgaaa	atctgaaggt	actcaaagca	gtcttgacaca	agtgttttga	aaagcctctt	107880
gcacaatttt	atttctttat	agtacttaca	caatcatatt	tcataatgac	ttgctataaa	107940
caatgttctt	gacaagaagc	ttaaagatac	aaaactgaag	gaagcacttt	tgggagaaaa	108000
tacttttata	tttgcttact	tctacactac	aacagacata	aaatttatgga	tttttttttc	108060
agtgcatttt	tcatatgtca	gttctaggag	acaggaaatg	tgaacacttg	tagggaggtat	108120
gagtttgcca	cctagaggag	agaggtgaaa	ttcaactttt	ctccaatttc	tttagtataa	108180
ttcattaat	tatttaatta	tttactcgtt	taattattca	aaaataatta	tctaccuagc	108240
tttaactatt	tgccagcgca	gatttgataa	atctgttcaa	gatttatgag	ctcaaagaaa	108300
ccacaagtg	catcttactt	taattgctca	gtgcctctct	ttaaaaatct	tttactttta	108360
agagagtata	gcacaaatat	ctgaacaaact	ctaaatatcc	atacttggga	tggatattac	108420
tttgagctct	tgcactataa	taaaacttta	ttcttttgta	ctaattcagt	ccttttactt	108480
tttctttttt	aatgtttaag	aaacaagtlg	gatatggaca	agatgtaatt	tcttctgtca	108540
aggaacccac	aggataatag	gttaatgata	gagaccaaca	atgctgatgc	attttttaag	108600
acggagataa	tgtctagaaa	aaaatccatt	atttggtaaa	gacaaagtat	gcataatgat	108660
tcctttgttt	caattatttt	taaagttaaa	aaacaactgc	ttatctcctt	ttgtactaca	108720
agcaatatct	ggtatagtgt	atgcatagta	agtattctag	aaatagtaat	ttcaattgtg	108780
acttgattat	attggagtgg	aacttactct	ggaagagatc	ctaactttca	tttatctgag	108840
aaaatttcca	gttaggacat	ggaaattttt	tccttgtcaa	takttattct	taatgtgttt	108900
agaattttta	aaaatggggt	tagggattta	gaaatttctt	tactaaataa	ctctagggaa	108960
cagtaacctta	aaaatattca	aaatgacaaa	aacttaaaat	gacatctaak	tttttaaggc	109020
caagaatcat	taaaaaggga	tccaaatctt	tagactttgt	tgctcgggtg	aactagaatc	109080
attaatatct	cagtcagggy	aagccatgtc	aacttactgg	tttaatttcc	tgtgagcttc	109140
ccatgttctc	tccttgcaag	gaccacctca	aatccctcag	tagtccgtgc	tttatgaaac	109200
cagtataatt	tttcttttcc	ctcttgtcct	tcacottcct	gtggcaacaa	gagtcaattc	109260
tcctatatata	aatactcggc	ccttgtttta	gtgtgtgtct	aattgcgcaa	catctgttta	109320
ctctgtgttt	taacatctgt	gtgatatgca	ttgttgtttg	aatattttga	ctgtaagctt	109380
ctaggaggta	gaggccagca	ttaktttctc	cattttttgga	atgagaaaat	acagattacc	109440
acaatcaaa	tagaatggca	gcttatagta	gttattttgga	taatttatat	agtcctctaa	109500
aaaaacagat	tatagtaaga	agtggctgag	caattagcta	tggcacactg	cacgggtttt	109560
tcgacctctc	agctcctaag	tbaactttgc	caaactctca	ggccctcaaa	attttttcat	109620
ttgatttgtt	atgggctgaa	ttgtgttcc	ccgaaatgac	tatgctgaag	tcctaactcc	109680
tagtgcttca	gaatgtgacc	ttatttggaa	acagggtcat	tgcaaatata	attagtttaag	109740
atgcgatctt	actgacatag	gagaagctcc	taalcattggt	gtccttataa	aaaggagaat	109800
tttggccata	gagacatgca	ctgggagaat	gtctcttgaa	gactggagtt	atgctgctaa	109860
aagtcacaaa	attaacagaa	gctacgggaag	agaccttgaa	tbaattcttc	cctgtagcct	109920
tgagggagag	gatggcccag	ccaactgcta	atctcagacg	tctagcttcc	agagctgtga	109980
gacaatttct	ctttttaggc	cactcagttt	gtggcacttt	gtacagcagt	cctagccgac	110040
taacacacca	ctctaactgt	tgatcaaggc	aagagcctgt	gatcatgtat	tatcttgctt	110100
atttcttctc	agcatctctat	ggtgtagata	ttagtgccat	ctatatataa	attaggaatt	110160
ggagcctcat	agaaattaaa	tgacaagtta	aaggtgtcat	ggctatttca	ttatagtccc	110220
agtgcttgaa	cacaaattca	tttgactcca	aaactactca	actctactca	atttctagttc	110280
aatccagatg	ttcacaaaca	accagactat	agtgagagatg	tgggtgggtgg	gttgagaagg	110340
agatcataac	caacatcaga	ctgtcagtga	agcagactgg	gagaagtttt	atgaagccaa	110400
gcagctgtgc	aaggtacagt	agagatggtc	agattgtttca	tgtgtatgga	ttccatcttc	110460
tggaggaatga	actccttgat	attcctgagt	tagtccagtt	taggcaggag	tbaacagaag	110520
gtaaacagaa	gattggagac	tgtgtgtgtg	cacgaatgcc	tcctttgtag	ctggatgtct	110580
aacatcatga	tagccacact	cacatgaata	cagagataca	caattttaca	attaatgtaa	110640
cataaaaactc	ccatgcagtc	tgatttcctc	ttactgacat	ttctgtcagt	cagtgttagc	110700
atcttaatta	tataaatgtg	gaaactgaaa	tactcaagag	gttccctgac	ttcccaggcc	110760
acacagtaag	ctttgggtgcc	agaatgtatc	tctaggcctt	ctcatctcaa	cccagcattc	110820
attatactat	tgtctcactgc	gtgtagaatc	agatttgatt	tctctgactt	ttcttagtca	110880
cttctgtggt	tttgtaccac	tcctctctct	actaaataac	tgcctgcaaa	agtaaaaaat	110940
tcctatgaaa	cagaaaaaca	atgtaccaga	aatgttgatg	gtgtaagaga	taaaactggg	111000
ataaagagaa	aatgtgttgg	aaagtgggtg	cctttaatgc	aacagaaaaag	latattggga	111060
gaaaangaaa	agagagaaaa	atagacaatc	tgaagtgatg	agaagagcaa	atgctacaga	111120
tgtacctgaa	cctcttcagt	aggtgtgatc	ctgaagagtt	gtgtataaca	acaatgaaca	111180
aaaataaaat	gtactgtgga	aattgtctag	ctgttgagat	cctcctgtgc	gatatttttc	111240
aaagtgaaaa	ctccaatcaa	ccctagctta	tttatggaga	agactttgcc	ccacagtacc	111300
cagaaagttt	cttgacaata	tcatatatgc	ataataaacc	tgagacaatt	tttgtttacc	111360
aggaaaacat	ataaaaggga	acattaaact	ttgtctagtt	ctactgcata	aactgtgtat	111420

aatgtgcatg	gtgaccttct	gttgtaaatg	gaaagagtta	agctctctga	atctactgct	111480
gaaaggtgaa	aacactttct	tagggtcttg	aacttcattt	gaaatcttac	tgaaaaaaca	111540
ctacagactc	tattttcttt	atatttgaa	ataclttaca	taaaaatcta	aagcattttg	111600
acttatgttt	tcatctactt	gagaaggaaa	ctcacagact	ccaaagcaac	tgttgtctgt	111660
tttgaaaaaa	atttcagaaa	tcaccagaag	caatagggag	tggccttgat	tccctgttctt	111720
gtatttatgg	gtagctaaag	ttcatatttc	tcaacatacc	ataatctctg	tgtaatggc	111780
caaatccat	ggtggalaat	tagatctagc	ttaccagggc	agatttggat	ggtgagagca	111840
gtcacactgt	tctgggaata	tgttagccaa	gtttactatg	tttlacatga	gttgacagac	111900
tcacctcaact	tgtgaaagga	ctagcccagc	agggttctacg	ggtgagatca	ctgctagctc	111960
attcacgtgt	gggcctggta	ggcacaagag	gccaaagaaat	aaataatgtg	aatttgggct	112020
tcagaagttc	tctttcctat	tttctttcct	aaaccctttc	ttctaccagc	tgtctagggg	112080
ctaaaacatt	tgttcatagc	tttalttaact	aattcaacaa	atatttacca	accatgtttc	112140
aggcaactgga	cactagaaat	ataatagtga	actagacatt	ttctgccttc	aagggtctat	112200
gaacaattat	aattattctga	aaaatattac	aattcacaga	gctcagtaat	ccaaatcctt	112260
attaltttctg	tctttaaaaa	gcagaaagtg	aaaaatgctc	ttaaaagagg	atggcataga	112320
aatgtatttta	tgcattgcaa	cagataaaat	taaggaaatgc	atgaagactg	gttcatctgt	112380
gtggttgtga	gtcaagaata	aatcccaccc	tccctggaagt	actcagactc	taccttgccc	112440
catggccacc	actgtggccc	aatggaagca	ccagtcacag	gggtctccat	tcatgctgtc	112500
tttggatgtc	ttcagaatgt	tgtttcacaa	gtactcagac	ccaacagtaa	gattttaaaa	112560
altgtccata	atattaacct	tggcettatt	atgttaaaga	aagcaaaaaca	gatatactgt	112620
agtttacttc	tcaaaaaaac	cttgcgctcc	tgcaaaagtt	tcttgaattc	tgactcttgt	112680
cacacaatca	cacaagaatg	gctatactta	aacctttcta	atcaattata	tccttaatat	112740
gtatgactga	gtgatgtgtt	ttcatgacta	tgaatgtat	acatgtttgg	aaaatctatt	112800
cacaatagag	ttttatgata	ttcctgttaa	caggctgtca	ttgtaacact	gtttatgcag	112860
gaattgtaat	tctatctgtt	tttattttta	gcgtcttttc	tctccatccc	ccaaatttta	112920
aggagctatc	aggctctgtat	tttatttgg	tttgaagttt	taggttattt	gtagttataa	112980
tagccatate	aattattcat	ttagcaaaaa	tgtattgagt	gctactatgt	gcttagattt	113040
ttccaatgtt	gtgaaggata	atlggctaaa	acttttccac	ttttattagt	aattttagag	113100
ttttttctc	catggatttt	agtcactggt	aaaggctgtt	tcatattcat	agattttttt	113160
ctacggtaag	aaacatatga	tgttgaataa	ggatatgaatt	aaaaattaag	gcttttccac	113220
ettcgctgcc	tttataagat	ttttttttct	tcatcaaaat	ctattcacac	acacacagac	113280
acacatgcgc	tgttttgatt	ttcttcaaat	atatccagtg	ttcagttctt	gggcacatat	113340
taataatactt	gcctagatga	agactatgtg	tcclcaggga	tttataatct	agcagggtgaa	113400
agatttgctt	ccttcaaaat	gtgactctac	ttccccactc	ccttaggttgt	gaaagcagtt	113460
gtttacgctt	tatttcattg	ttttccaaac	tttagttatt	tatgtgccat	cctcatgatt	113520
algtatttca	cataccacct	atactattat	gcttctgaaa	atatactatg	attttcaact	113580
taattaaatt	tgttttagtaa	taacagtatg	tgttacatca	ctagggttgat	gtgtcagttt	113640
aaaattttta	aatatacttt	aatataaata	tgttactact	aaattatttt	tttgtctgta	113700
tgcacccaaa	tcttctcctt	tagtagtact	acacatatca	tgctttggga	aaactctacc	113760
atgagattca	tattcaagca	tgaggaaatg	caaaagaaaa	tacagaaata	gtgatagtaa	113820
ccatagcaat	ggtaataaga	gctattattt	attgaggact	tttaogtatgt	catrttaattt	113880
tatttttatcc	tcacaacaaa	ttltagccat	gagtatoaga	taaatatgag	gcaaaaagggc	113940
eggaagaag	gaacagtgg	agtcaagctt	tttttgcctt	aggtcagcta	taactaacac	114000
gacaagatgt	tttagtattt	gtactttatt	tttagtcagc	tcagatttca	cacctgacta	114060
ttttacaaaa	atttggatgt	gatggtggca	gattaaacata	attactttta	gcaattatta	114120
tgggacaaat	tagttaaagg	ttgtaaaatg	cctagaaaca	gagtagaata	tccatgtagg	114180
atatccatga	atatccata	attaagttat	caaaacaatta	ctctgattat	ttttcacagt	114240
agttcaatca	aagtgtact	ttgggtotgt	tagtatacat	gagtgtgaat	actctggaga	114300
tttgatcttt	ggctttcctg	tgtaaagttca	tatatatttt	tgttatttato	ctgtasataa	114360
ctgaattata	gtacagtgat	tctgtaaaaa	acactttagt	tattaatatt	ccttgggtgtg	114420
aagttcacat	taaaaaattgt	tatattttcca	gaacctgggt	tttacctgtg	aaagtcaatg	114480
catccttctt	ttastcctct	gcattgggtt	tgcatagctt	gatgaaatat	gacttgcttc	114540
tccctccctcc	cctccttcc	tgtgcctgta	tcccatcat	tttttttct	attcctcttg	114600
gtatctggac	ttctttttct	gccaaatgag	tcagtaagag	aggaatgtt	laaccacat	114660
ttgtcatctt	ggctgggaaa	gaagtttgaa	ggcaaaagggt	gcctgaatat	gtttcactag	114720
gatgetgaca	caaccttttt	gactctctcc	taagaatact	actctatatt	caagttatna	114780
agtgetaaat	gatctatttc	cacctgtat	acatttcata	tgatcaatac	ttattttgta	114840
acttttttct	ttgaggagaa	gtatttttct	tttggaaaaa	tattatttat	ttgtgtgtgt	114900
gtgtgtgtgt	gtgtgtgtgt	gtgtatttat	tttcttttaa	latgtgtgtc	ccctatgcaa	114960
aggatttgat	tttataaaca	gaagcaatag	gattaaaggg	ataaaggaaa	aataggagaa	115020
ggggaaatat	gagtatcatg	ataaggtaaa	aatgaattgc	ttgtattcta	acatagaata	115080

gctactacct	ggtgagtggt	tatttatatat	tagacattta	agactaatca	aaatatctaa	115140
lotaatgaaa	taatcactgt	tttgaatttg	cttagattta	gtagatgtag	aaactgagac	115200
ttagagaggt	ttatttactc	aactccacac	tgctaattac	tggtgaaagt	agaaattttac	115260
tcctctgggt	ttctcatcca	gcacatcatc	actataaccc	ttatagtttg	cttttggcac	115320
aagtattcat	tattaatgga	aatgcatagt	attatctcag	caaatgtaca	aatagttttag	115380
cttcactaaa	ctagtcaatt	ttttttttct	aaacatcaat	gcttaggaag	caaaacaggc	115440
tggtgggaa	gtagtgttac	tggtggcagc	tggtggtgctg	atggagggaag	tggtgggaatg	115500
catagggtgc	tcatgctttt	tgccacaatg	aaggtcaaaa	agtagatcac	ttaaagtcta	115560
aagttaacct	tggtgggtcat	attcttcacc	aaaaactatg	tttatacata	tagacttagc	115620
agtatgctat	aaaagtgaag	atatagcact	ataaaattcc	accataaagt	aaatttgttca	115680
agattgtggt	ccaagctctt	caaaatgctc	alaaatcaga	aggtgtattt	attnaacaat	115740
attttatatg	tacctataat	aatacaatac	tatactacac	aaattggacc	taaaatgaat	115800
tctcttgcta	tattaaatat	taaacattaa	ataggcagaa	attttgtttg	caactggactt	115860
agaatataag	aagaaaattt	gggacaacct	gaatagttga	ggtctcttga	gnaacccttc	115920
agcttctttt	cctccaaata	aatttctctg	tagcaaatgg	aagccatcca	aatgattccc	115980
tagctacctc	aaagtactgt	aatltgtcta	cttcacaaag	tgaggagcta	tatctagcaa	116040
taattcaaga	aaaatgcagt	gactcccat	atatcttagg	cactatgcta	ggaagtltat	116100
gcalatcatt	ttgtttgatt	ttaatagcaa	cttcatgaaa	taaatcatca	taataaatca	116160
ctatttcaga	tattgagaaa	ccacagaaa	agagaagtta	aataattttc	ctgtcaaaaga	116220
ccacatcaat	gaatttgagg	gaatttgagg	tcattgtactt	aaccactgga	ctacctgcct	116280
gacctgtcga	ggaacagcta	aggttgtcat	agagtcttga	ctgtgtatag	atagttgttt	116340
gaagagagaa	aaaaggcagg	aggatctggg	gcataatgtt	aaatcaggca	ttggcatctg	116400
tactagaatt	gaaagggtgga	actattattg	tgttctattt	attgagtata	ggtataccat	116460
attcaatgta	tttctctgtc	tcatacacta	tccaagggtga	taaaagtgtt	tatgaagagg	116520
gattagggaa	tatctgctgt	gtttaggtca	tagtccaacc	aaaggattaa	ttaacatttg	116580
cctctttttt	ctcctacatc	cagtgtccct	tttgatgaga	agaataagoc	tcattctgat	116640
tcaacagcag	agatcaaaga	aaagacttct	gttttctggc	caccagatat	algttatctg	116700
tgcttaaaga	attgaaaaac	acacatcaaa	ggagaatttt	cttggaagaa	gaggtaatga	116760
gatacagtga	aagagaatgg	agattcttta	aatcacagag	acclaggatc	aaatcctgtg	116820
attagcactt	tttagtaaatg	tagcctactt	catttctttg	agccctcgtt	tatttttctg	116880
aaaatgaggg	tgatctaaat	tacgtctgga	gtagtataaa	agattaaatc	catgtgatcc	116940
aggtaaaact	atgacaataa	tagacatgaa	acaaatagtc	tttcactctc	ctcctttgct	117000
caagcattgc	tctgctcttc	tcacctcctt	tcccttccct	tttcttttct	cctctttatt	117060
ttgtctgtac	ccaatagctt	ttcccaagcc	ttaaaactat	gtataggtat	atttgttcag	117120
caaaatgcac	aaaggagaca	ctcattattt	gcattccattt	atatgctgat	ataaatattt	117180
catcctcaca	agtttcagag	ggaaagacca	catgctgggtg	atttgtgtgag	aaagaagcua	117240
ctattttctgt	gatttaattt	caacctgagc	attaaagagg	caccttttca	ctactagtgg	117300
taactccatg	cttccaagaa	ctantgagct	gaagaactta	gcacttgtga	tgaattagtc	117360
aagcaaaaat	tatgaagcga	gtaatctata	acattatagt	acattacaaa	tgctgaataa	117420
tattagttat	tattttattt	gattcttata	gctcatttat	actgtacaaa	attcttctgt	117480
catttttatga	agatgtttaca	catatacata	acaaaactta	gctaattaga	tacaaagact	117540
atagaaccaaa	ataactcttt	tetaaatatt	ttccctttta	ggaggltttg	caatccagct	117600
ttgctgtggt	tagacactgt	tgatgagaaa	actttttttt	tctttctttt	tttttttttag	117660
acagggaatc	attctgtttg	ccaggctgta	atgcagtggc	acaatcatgg	ttcattgagc	117720
cctcaacctc	ttgggtctata	gtcgtccttc	tgctcagtc	ttctgagtag	ctgggactat	117780
ttgatgtgca	ctcccatgtg	cggctaattt	ttgtattttt	ttttttttgt	agagatgggt	117840
tttcaacatg	ttgcclaggc	tggtctcgag	ctcctaggct	caaggatatcc	acctgcctca	117900
gectctcaaa	gtgctgggat	tacaggcgtg	agtcagtgcg	cctgacctgg	atgagaaaat	117960
attgagttgg	aaacccaaaa	tatgacataa	ataattggta	tatttttagag	ctggatttca	118020
acaacttttc	aacactgttca	tcoctgtaaat	guctttccgt	cctaatecca	ttgcccatgc	118080
actcagcaga	agtgtgtgcc	tctaagggtg	atgtctggtat	gaaatatctc	agctggggca	118140
ggtctctgaaa	gggagagatc	tygtttaaagt	gctcatacca	aacaaagctc	ctcatgatgc	118200
tggtcttaact	ctcccaatcc	tgcatttctc	aacaaaactt	tttgcctctc	tctttcacat	118260
aactcccggtg	gaataaattt	cattgaattg	catggaagag	gctgttcatg	gggttagtct	118320
ggcagataag	aggctctccac	tggttttttt	cattttgcaa	tcagtttcat	acatatacgt	118380
acataactttt	cttgaggtca	tagttcoattc	tcaggctctt	tagagttaaa	tatctttcat	118440
ttcttctttt	aaggtcttaa	tttcttgttt	ttcgagtttc	atgggagata	tcagtcaccc	118500
aatccaatcc	atatogggga	aaagtacaac	aatgagtgga	aatttgtaac	caaccttgga	118560
tgatggaata	agacattttg	gagaacacag	gagaagtggg	gaggttaagg	agggatagct	118620
ctgtgaaaat	tttgcatcac	tcttgccctga	ggtctactct	tccttgctcat	gttggtgggt	118680
gttttgacaa	tgagaaatat	ttaatggcaa	acttagtctt	ctaatttgaa	aatggaaatc	118740

ataacagttc	ttgcctctta	gggalagtg	gagacaagtg	aaataatcca	tgtaaagaggt	118800
atagtactat	gcttgccatt	ctttaagagc	tcaacaaata	ttcacttttt	acctattaqt	118860
atcaatctta	attctaaaa	tcattatttt	aatattttcc	aglggtgttt	ctaaataata	118920
tctaattgact	aggctaatac	actatgtggt	tcttctaggg	ttcaagcacc	actgttaggt	118980
tggtctggaat	cctttcccca	gtcagtactg	ctttctagaa	gaaaaccggg	gagatctatt	119040
tggaaatgtat	ctaaactcca	agaaaccatc	agaggtaaca	ggtaggagat	atgaaacgac	119100
cttttagata	tgaaccctaa	ttgaataaaa	gttgccaaac	aactgttccc	aaacatctaa	119160
agaagagttt	tagtctaagt	ggaatggctg	gagagtattg	gaagagttct	ttcctaactct	119220
gtccaaaaoac	aagccctctgt	gacatttata	aaagaaatgc	agccctttta	atctgggtat	119280
aagtcocgaaa	ggltgctttcc	ttgtgaagct	tcttttgtcc	tctgctttta	ggactctctg	119340
cacactgcat	cctctatgtc	accctccagc	acatctgctc	ttacacaagg	ggccccacag	119400
ggactggccc	acacaccagc	cagggcacat	gggccaaact	ttaacagcaa	aaggaaatgc	119460
taaatcctag	agtagggcag	atgagaaaaa	tggcattctt	cagagagctg	ggatgactca	119520
cattaagatc	aagggccctg	aagtaagaca	gacctgagtc	tgaatctcaa	ttccaaacat	119580
aaatttgttt	atacacttaa	ggcatcatgt	atagtattgt	taaatagata	ctttacaaga	119640
ttgtactaa	gaggaagcaa	aataatatct	gtaaagcgtt	tcatagattg	gccagcatat	119700
agtaaacatt	taakaattag	tagctattat	tatttttctt	taaatatttt	ttttctggtt	119760
tactagcaat	cataaaattt	agtcttgtat	agactccatg	gctaggactt	gcagaattaa	119820
aaatgggtctg	aacaatttag	acattgcctt	tttgtctcca	aaccaagggg	tgaattttta	119880
ttctaaaaata	tccagattgt	ccatafcaat	taaccagltg	attgtctaagt	ctgtatttct	119940
cttttatgca	attgggaaac	attaaaaagt	tgaatgtata	tactgtacac	atcacatgcac	120000
acacatagac	ttaagtacat	aatgtgtat	gtaccttcca	tagcacttag	ctcatctgtt	120060
clttccclaly	accttttcta	taatcctgtg	aagtaggttt	tattattatcc	tattttatga	120120
ttaaaggaga	agggaagaca	gaaaagcagc	ctggcttggc	cagaggcctt	gcaattgatt	120180
acgtatagag	caggggagtc	ctgacccttt	ttcagttttt	cttctctgtt	actgtctgtg	120240
tgactgtgga	agtgaagtac	ttctttggct	gccaaaggag	tcccagctga	aaggtaacca	120300
aaggaaagga	gtatttggga	gcagcatggc	tgaatccag	ttaacagtta	aaatcccgtt	120360
gggcaatttc	togttaattg	acaacaggaa	ttgctgtcac	tgtcctgtct	agccactttc	120420
aaacgggtggg	gatgttagca	agagctccca	gtgaatgctt	cctaggagag	cagtgtattg	120480
tttggtctagc	ttcttctgta	gcagttttct	ggcgttgaaa	agtctgtact	aagacaattg	120540
gaggttggtaa	tcattttcta	ataaccacct	caggcttttg	gcaccttaatt	cgctggcact	120600
glctagggaa	gtcctttatg	ctaactcatg	ottcttgcca	tgtcaatctg	cttatctaat	120660
tttgctggga	aatctgatat	cacccttcaa	atagttcacc	tcagtgggat	ccagtgtgtg	120720
acctgcaaa	tgtcaagga	agagtctgat	cagctctgac	aagcaaacag	cagaagaag	120780
ttttgaaaaa	acggctaccg	tttttgagc	tttttcaact	tggttccatg	gtgtttgaaa	120840
tcagaatgta	atattgagtt	aatgacacaa	ggaaacactt	ggatgttcat	attgtctact	120900
tggttttcat	gaacctcaca	tggactggct	tcactcctgt	tcagagtcca	ttcaactgta	120960
atttccactc	taottcctgt	gcaggccctc	ctctggtttg	tgggctgtac	atttcagcct	121020
gtctccttta	ggggccccc	gagctgaaaa	tgaagagac	attttgttgc	ttctgctacc	121080
tgcttatctgt	ccaatcccaa	tctcagattt	tctttttcta	ttttttaaac	ccgagtagca	121140
cttttccaac	tagtltgtag	tttttctttc	aattctctgc	tcttcacagt	aattaaacaa	121200
gagctagcct	ccttttccaa	atcttgtttt	tgtataacct	ttattcccaa	agagttatgc	121260
ttataagagt	aacataaatg	tgttaaactt	ggrattgatt	tgatgatttc	ataaaaccca	121320
gactccttga	aattctgcag	gttttttgtga	aaggacttgc	ttaaaatctt	tgctaatact	121380
cctgaatttt	cttccaaagg	cagtttatata	caatgtttct	taaaaclaat	tctccaaatt	121440
tgcattttgg	cagcatccta	ctgggactct	agaaagctga	taaatcatgg	agagttagta	121500
ttcatatagg	aactatgaaa	gctgtatgta	gtaaacacta	cttaagaagg	ccttacattt	121560
cataaaaaagt	tggagatttt	tgtggagact	cataaaatgc	atcctttata	tcagtgaagt	121620
ttttgcttct	aggtatatata	tactcacatc	gaaacactcc	agggattttg	ttttcagcct	121680
gcataatacca	cgtatattta	ttatctggat	agataaatta	gacgtataca	tttaaaggag	121740
tttgcatcag	ctgctgctag	gaagtttttc	ttgtgttagt	taagatcctg	tgaacaaccc	121800
cttgacattt	cactagctgc	acagtttgta	ataaaatcca	ttttagcctg	aggttaaatc	121860
atgactgtgg	tcctcacatc	atggtggggg	atcctggtgg	ccagattaaa	ggaaactcca	121920
cattctcatt	tctgacttcc	ctacaacctt	gtattaagac	cttaattgaa	aaacttattg	121980
cctctctcac	caaaatattt	caaattttta	tagtttcccc	caatgaaatt	acaagtacta	122040
tttctacttt	ttcagtgcoc	ttggaatttc	gaggctggat	ggggggcttc	aatgtctgac	122100
tcattaaagt	ttcatatatac	aaagccctac	atggtcccta	gagcatagca	ggcattcagt	122160
gaatgaaatg	aatgaatgaa	aagctagagt	cacatttttag	tgacctaaact	gtatattttc	122220
agagtaantgt	agtgccttaa	aaaggacaat	gataaacagt	ttctacaaag	agatgcatag	122280
cagataaacac	ttctcaagaa	gaaggaattt	agcttctgtc	atttgatcta	ggttttcaat	122340
vacagaagca	ttgagaattt	cctgtggctg	gataagggcg	aatctttaag	gcaagttgaa	122400

gacccaggct	gcccattgtg	acatcaatc	tcccacagag	cactcttcat	gaagaaaagt	122460
gtgggcttgc	tgtcttttca	tcaaaactcg	tagaatltgg	ctgactgcct	ggtttatccc	122520
aggacettag	tcagcccaca	aalcccgcac	ttgtttattc	agtccagagc	aagtgaatac	122580
tgccattttc	tcxltctcctt	tgttggcaac	actttgttaa	cctgaattgg	gttctcaaca	122640
taaaatgaag	tgactaatct	tttggggggg	tccccctccc	aggltcttgt	atgagcaact	122700
aaatctacac	accacaaagc	cccatgctgt	cattttttct	catcctgccc	ctttattttg	122760
atgattccac	attgtagttc	atganaccac	taccttctag	agtgtggctg	aactggcgcc	122820
agcattaaag	aaaggagttt	ccaaactttt	taglttttgt	agaaaatgtt	agaggaagag	122880
ggagggttag	ttgactatct	atacttatgt	aatcttctgt	guatttgca	tagttatcac	122940
cttgtactct	caaaagtttt	ctagctctga	gtatgtgaat	ctgaaagtgc	aggaagttag	123000
aatcttagca	caaaaacaac	agtttggatt	atcacacast	taatatggga	cggagctgga	123060
ggatggacct	gaacagaatg	tatatctctt	atcactagg	tatttactca	tctacagatg	123120
tctagaaaga	cctgggcttt	tttagcaaac	gtttgagaat	ctaggtttct	aagtttccat	123180
tgaccatgaa	agagtgatta	gttttagaag	acagttgggg	gcaacattgt	gcaagtcaga	123240
agaggggatg	aagaaaatca	taaagctaaa	catgtttgcc	ataggcccag	gctgtttttc	123300
agcatgtttc	acctagcagc	ttggcagata	attcccagtg	atcattagg	ctgtggaaat	123360
tctgtttggg	ttataaagtt	ttggccctga	ctatgtgtac	cactgataac	ttgtttttct	123420
ctctcttccc	ttttcctcca	actcgtagcc	agagctacct	tccagatgac	ttctttctac	123480
cactttcttt	cttcccagtg	taagagaatg	caagtatatg	ctgatgtttg	gagcaagaac	123540
attcaaaaat	tttcttatta	acataaactc	taattggaaat	acagtatact	actatggtgc	123600
atacaaagaa	gaaatagcaa	catatatttg	ttttagacct	gattgotgta	ttttattcct	123660
taggtcctcc	ttgatgtctt	gtagaccgtc	actagotaat	tgttacagcc	atcgaaggaa	123720
aaaataagga	tttttactta	ggacatacgt	aacagaaaaa	gagatgggtt	agcaaaaaag	123780
cacaggcttt	gcaataagca	gccttaaat	aaaaaanaaa	aagttaactc	ataactaact	123840
gtgtgacctg	ggataagtta	ctgacctct	ttagggtcta	gggtccta	ctgcaaaacg	123900
gaaattataa	taataacctt	agctagcatt	tcttgtgcac	atactataag	ctgggtgata	123960
acaattttta	cacactatct	catttaatcc	tcacaacaat	cctgtgagat	aggtactatt	124020
atcattttct	ttttacagat	gaagaatcca	gacataagaa	gtgaagttaa	gtactttct	124080
caaggctgca	cagctaccat	atgatggagc	tggaatgtga	atctctgcag	tttgacgcca	124140
aggtgcctgc	tollagtcac	tacatttgtc	tacaaatcta	aaacacgtaa	gacacatagg	124200
agggtgctcag	ttagtgggat	ctattattaa	atcagactat	aaataatcac	caggcaatac	124260
ttgaaaggcc	acaaacaatt	tcttaggatt	tgtgacaata	ctaataatta	taactgatta	124320
tgagcatacc	ttgtgtcagg	cacttctttt	cataghattt	cagtcattat	ttaagagatt	124380
tattottatt	tttatttttc	tagtgagaaa	actgaggctc	aaaaaagccg	acaaatttgt	124440
ttaggattac	aaaaatatca	aatgatagga	ttgaaaatca	aatccatata	ctttctatgt	124500
gaaaacctgt	gttctttcag	ctttttttat	ttttattttt	ttatttttta	tttatttttt	124560
taaattttta	tttattttat	ttttttattt	tataagcctt	tttattttta	tttattttac	124620
tttatttggt	gttgotgggt	ttttttctt	gagacagagt	ctcactctgt	ctcagctcac	124680
tgtaacttct	gcctcccggg	ttcaagcaat	tctcctgcct	ctgcctccca	aggagctggg	124740
actacaggca	cctgccacca	tgctggctc	acttttgtat	ttttagtaga	gatgggggtt	124800
caccatgttg	gcagggctgg	tctcgaactc	ctgacctcaa	gtgatctgcc	tgccctlgcc	124860
tcccaaagtg	ctgggattta	caggcatgag	ccaccacgcc	cagcctgcct	gctttttaaa	124920
attattaaat	tcataattgt	tattttatcag	atgcctctgc	cactttattt	tttaaaaatt	124980
tattttttatt	aaggtaagtt	taacaaataa	aaattctata	tattttattgt	gtacagtggg	125040
atgttttgat	atatgtatac	attgtgaat	ggttaaatca	aactaagata	tctgtcatct	125100
catatgcatg	ccataatttt	gtggtgagaa	cattttatgat	ctactctctt	agcaattttt	125160
aatattctgc	tgtttgactt	ttaaaccaag	gcttggatta	ggacagtcct	tgtagcttag	125220
ttttagggtc	agggataaca	aaagttgttt	tatccttttg	gotttttgcaa	cttgccattt	125280
tcttaatgaa	gatctgggag	aaaaatttag	ttaaagtgggt	tttaaaatag	ccattagctc	125340
aggacatact	cagccaaggc	aggataagta	gttttgccag	cattcttctg	taggtagggt	125400
ggttggtttt	tgtttttttg	ccacagtcct	tttaaaaaat	ataactttta	aaaaaccttg	125460
gttttctgtg	attgatcttt	ttcactattt	tttatagagg	gccaggaata	tgagtaataa	125520
attcttgggc	ttgggtgcag	atgatccacg	tgctggcaga	cagaaatcta	aagggacaaa	125580
agaggctgtc	ctttgaagat	acttttctct	gcttgggttt	tatatttttg	gatttgattt	125640
agtgaataat	tttatttgagg	acctactgca	taccagacac	toggctacat	tatgagaggt	125700
ttggggggcc	tatatgggca	tatagggagg	atgaataaag	aatacaaaac	attatagtac	125760
aaatcagaat	aaaattttgg	atgcaacggg	ctatcagata	gtatggagga	agaaagcata	125820
ttttattagt	ggagctagga	aatagcttac	aaagttgata	gcattcttga	tgggtcttga	125880
aggttacata	gatttttttt	tctttttttt	tttttgagac	ggagtcttgc	agtgctcgtc	125940
gggctggagt	gcagtgggtc	aatctcacct	cccggttcca	agtgactctc	ctgcctcage	126000
ctcctgagta	gctcggatta	gaggctctct	ccaccacatc	cagctaattt	atatatgtgt	126060

gtgtgtatet	atatatatat	atataatatt	tttttttttt	ccagtagaga	cggggtttca	126120
ccatgttggc	cagactgggc	ttgaactctc	gacctcgtga	ttcgcccgcc	tcggcctccc	126180
aaagtgtgg	gattacaggt	gtgagacacc	acacccggcg	gatagagaga	atthtgacag	126240
gtgaggaggt	attccaatgc	aaaagaataa	taggagcaas	agcacagtgg	tgagaaattg	126300
gaggggaact	gtgaaaattg	ccacatagat	tagaggcagg	aaaaataagg	acggctaagt	126360
ttatatagtg	aacagtgagc	cgcatggaca	caggtgactg	ttttctcctt	tttgaacccc	126420
tgcltaactcc	agagtcacca	cctctccttg	ctttctgcca	atcttcltgg	ccacagtttc	126480
tcgggtcttct	tttctggctt	ctcttccttg	gcctgaatgc	tacatgttaa	gtgatgtcag	126540
cttcagtttt	cttaacctct	cttctcttaa	gttgcctatca	tttaaatatc	tttaaatatc	126600
atctacatcc	aagtgaacctc	taaacagta	attttaccca	tgacccatct	cctcaactcc	126660
ggattgtata	taaaactgtc	tactcaacat	cttcaacttt	gatgtctaaa	tctctatgtc	126720
caatttagaa	ttcttgatct	tttgccttcc	ctccctcctg	gaaatcctgc	tcttaccagt	126780
cttcccccac	tttaattaatg	aacctgacat	tcacctagta	gcttagtcct	caaaactagg	126840
gattaateta	gatttagtca	ttttctctac	tcttgccata	taataacata	ttattctgag	126900
tttaacctta	cccgacccca	aataggtaac	tgtctgtttt	gttataagat	agtaatat	126960
gcctctgagt	gtatgtgaat	tattttgata	aaaataaata	ttatttttaa	aatatttaatt	127020
ttacagggat	tgtctcttga	tttctttcca	aaagtttaact	cataagttgt	tcagcagagc	127080
tatgtattct	tcagtatgtt	ataatttctg	tcacattctcc	aaaaggcctt	cacatttctct	127140
tggtcttacag	actcagatgc	tatggattag	atacacaaagt	acatgttccct	gtatatctat	127200
tatatagtga	acataaccaat	tatgattgtg	atottocaaa	gctcgtattt	ttaatcaaaa	127260
tttaattaaat	atttttaagcc	aaagaatana	ggtagatgca	gcactctagt	aaaaggatat	127320
ttctgctggc	cacactcagg	aagacataaa	gatatagttg	tagaaagtga	tatagtattg	127380
gccagggtgtg	gtgggtcaca	cctgtaatcc	cagcactttg	ggaggccaag	gtgggtgat	127440
tgcttgagct	caggagtctg	agggcagctt	gggcaacatg	gtgtaaaccc	cctctctaca	127500
aaatacaaaa	attagccag	tgtgggtgtg	ggcacctgga	gtctcagcta	ctcaggaggc	127560
agagggtggag	gattgcttga	gcctgcgagg	tgagggttgc	agttagctga	ggtagtcca	127620
ctgcaactcca	gcctggggca	tagagtgaga	cctgtctctg	agaaaaaaaa	aagcaaccca	127680
gtgataggct	gggcaagggtg	gctcatgcct	atatttctag	cagtttgaga	ggccaaggcg	127740
ggtggatcac	ctgaggtcag	gagtttgcaa	ccagccttgc	caacatgggtg	aaacccctgtc	127800
tctactaaaa	atataaaaaa	ttagccaggt	gtggtggtgg	gcacctgtaa	tcacagctac	127860
tggggaggct	gaggcaggag	atttgcctga	aaaaaaaltt	gccagggtgtg	gtggtgggca	127920
cctgtaatec	cagctactgg	ggaggtgag	gcaggagatt	tgcttgaaac	cgagaggcag	127980
aggctacagt	gagccgagat	tgccgcattg	cacttcagcc	tgggcagcaa	gagcgaaact	128040
ccatctcaaa	aatgaaccaa	acaaacccag	tgaaaaccag	tattgaaact	agattgcctc	128100
tcctttgctt	catggctctgt	tcttacgtaa	ttttcaagat	aagttcattt	tgggcggtac	128160
tgacaaaattt	ccatttattt	acttttttcc	cttacattca	tttcttctca	gtctctccaa	128220
tgaaacgctt	cactgatata	caaagcatga	aggacacacc	agggaanaac	atagacctaa	128280
tcaggagcaa	atggaattat	tagaaaactt	ttctagcaga	agaacactat	tcgtttgcca	128340
tttgaattctt	tggttttgac	tcaggtttgac	aatgagccta	tcataataagc	ccaatgttaa	128400
acagaaagag	gttgaatcag	tcacgataag	cccaattatg	ctgttggtaa	aaacaacctc	128460
aaaatctcat	tggcttaaaa	tatacagaat	tattcttact	catggcacat	atccatctat	128520
catctgcagg	ggatctgtct	actgaagtca	cttaggaact	tggactgatg	gaacggccac	128580
tttttggtca	ctatatgtat	taatctgttt	taatctctgt	gataaagacc	caaaattggg	128640
aaacaaaaga	agtttaacta	gacttacagt	tcgcgatggc	tgaggaggcc	tcagaatcat	128700
ggtgggaggc	gaaaggcact	tcttacatgg	tggcagcaag	agaaaatga	ggaagaagca	128760
aaagcggaaa	cctctgataa	acccatcaga	tcttatgaga	cttattccac	tatcaagaga	128820
atagcatggg	aaagactggc	tcacataatt	tacctccctc	tgggtccctc	cctcaacatg	128880
tgggaattct	gggagaaaca	attonagggtg	agatttggtg	gggatgcagc	caaaccacgt	128940
aatttcaccc	ctggcccttc	caaactctcat	gtcctcacat	ttccaaacca	accatgcctt	129000
cccaatagtc	acccaaagtc	ttaaactcat	tcagcattaa	tccaaagtc	cacagtccaa	129060
attctcatct	gagacaagggt	tagtcccttc	tgcctatgag	cctgtaaaaa	caaagcaagc	129120
tagttacttc	ctagatacaa	tgggtgtacc	agtattgagt	aaalacagct	gttccaaatg	129180
ggagaaattg	gccgaagcaa	aagggttaca	gggcccattg	aagtocaaaa	tcagcgagg	129240
cagtcaaaact	ttgaagctcc	aaaatgatct	cctgtgactc	caggtctcat	atccaggtta	129300
tgctgatgca	ggagggtggg	tgccatgggtc	ttgggcagct	ccgtccctgt	ggctttgcag	129360
ggtacagcct	ccctccaatc	tgctttcacc	ggctgggtgt	gagtgtctgt	ggcttttcca	129420
gatgaatagt	gtaagctatt	ggtagatcta	ccactctggg	gtclgaagga	cgatggccct	129480
cttctcacag	ctccactagg	cagtgcctag	ggactgtgtg	tgggggtctc	aacccacatg	129540
ttctctcttg	caatgcctga	gcagagggtc	tccattgagag	ccccgcccca	gcagcaaaact	129600
tttgcttggtg	cattcaggca	tttccataca	ttctctgaaa	tctaagtga	ggtttccaaa	129660
cctcaattct	tgacttctgg	gcacccacag	ggtcaacacc	aogtggagac	tgccaaggct	129720

tggggcttcc	acccctctgaa	gccacagccl	gagctatata	ttggcctctt	tcagccacag	129780
ctggagcagc	tggaacacag	ggcactaaat	ccctaggetg	cccatggcgc	agggacccctg	129840
ggctccagtc	atgaaaccac	tttttccctc	tgggcctctg	ggcctgtgac	gggaggggct	129900
gccatgaagg	tctctgacaa	ggcttgga	catftttccc	atggctctcg	ggattaacat	129960
taggccccat	gctacttatg	caaatttcta	cagctagctt	gaatftcttc	ccagaaaatg	130020
ggtttttctt	ttctattgca	tagtcaggct	gcaaatfttc	tgaactctgt	ttccctttta	130080
aaactgaatg	ccfttaacag	tacccaagtc	acatcttgaa	tgcfttgctg	cttagaaatt	130140
tertccgcca	aataccctaa	atcatctctc	tcaagttcaa	agtftccacaa	atctctaggg	130200
cagaggcaaa	atgccaccag	tctctttgct	aaaacctaac	aagagtcaca	tttgctccag	130260
ttcccaacaa	attcctcctc	tccatctgag	accacotcag	cctggatttt	attgtccata	130320
tccgtgttgg	cattttggac	aaagccattt	aaacaattct	taggaaattc	taagcattcc	130380
cacattttcc	tttctcttcc	tgagccttcc	aaactgttcc	agtccctgcc	tgftaccocag	130440
ttccaaagtc	acttccacat	ttttggglat	ctattcagca	aagcccccac	ctactggtag	130500
caattttactg	tattagtctg	tttctatgct	gctgataaag	acatacctga	aactaggaac	130560
aaaaagaggt	ttcattggac	ttacagttag	ttccacatgg	ctggagaggc	cttagaatca	130620
tggcaggagg	tgaaggcac	ttctcatgtg	gcagtgccaa	gagtaaaatg	aggagggaagc	130680
aaaagtggaa	acccctgata	aacccatcag	atctcgtgag	acttacttca	ctatcaggag	130740
aatagoacga	gaaagatcgg	ccctcgggat	tcagttacot	cacccctggat	acctccocaa	130800
aaatgtggga	attctgggag	atacaattca	agttgagatt	tggtaggggac	acagggcaaac	130860
catatcacta	taccacaaat	ttttttaaaa	aaacaaactt	ttgagaatct	cgttagata	130920
attaatattc	tgctctggaag	tgaagcacat	ttctttttct	tgcaactgat	tgccagaaac	130980
cagctagatg	gccccaccaa	gccaacattg	ggggagaact	gaaatatttg	gcaaacagca	131040
accatgaacca	tcacagctgg	aagttctcag	tctggaactc	cttcccccagg	cctcccatft	131100
ctggaactct	gagaacaaca	atccagggaat	ctgatgacat	cttttccctt	actagccaaa	131160
atctgatgan	atfttttctc	ttactagcoa	aaagggagaa	caalaagcaa	ataaattcaa	131220
ttttctccca	tttatacttt	taaatctgag	aacgaattgt	gtgtttataa	gaaagtgggg	131280
gttgagcctc	atgaagaaaa	atataaagat	ctttaaaaag	tatatatttg	gcctattagc	131340
tacaaacatg	gattcattat	aatatgtgtc	tgactgacat	ttaaaatgca	taatcaaaat	131400
caagccctgtt	agatacaaaa	ttcatccatt	aatagcaact	aaatttctat	aggtaaagtag	131460
tagtgctatg	tttaaaaagag	taatctattt	ggaaacaggga	attaaatactc	agaaatttat	131520
tattaatata	tttgaaaaat	acttgtgttt	atttgtccca	gcccttacaa	ggtgtgtggt	131580
aatgggttaag	gtattttctcc	tctatatgcc	tgaagtttct	tctttacaaa	agggggggagg	131640
gaataatagc	acctgatttt	acttttgttg	tgaagattaa	atttgtacat	atataaatct	131700
atataatctat	atatacactt	atataatgtat	gtaaaatattg	taggcttggtg	cctgacatta	131760
aatactaaaa	aatactagct	attatttttta	tctcatattt	atcagatatg	acacattcat	131820
aattttaaaca	gaagccctacg	aagaactcat	aaattaaaag	aagataatct	tttcacaagg	131880
taacaaatft	tggaaacaatt	ttttagagtc	tctagacatc	tgftactgac	gttgtgagtg	131940
aaatgggtct	gtgaaggga	gatacagggtg	gaactgggccc	agtgtttgca	gaggaccatg	132000
atattttctat	atctctgctg	gctccctatc	agttcttagag	ctagtccaag	tgaagccctc	132060
ataacctctg	gacaataaaa	atgcaccatg	ctattgttag	catgatgaat	gaattttatt	132120
ttgttttagct	tacagaaaat	tagtagtttt	caaaagggtc	ttlatgtata	caattgaaag	132180
tactacattc	ttgaaaaggga	aatctttaca	gcatacagggt	ccctggcact	aatacctcat	132240
ttctgggcac	agcttgatat	ggaggtatag	tttgtgtttt	atctgaggaa	aatttaggtt	132300
gggtgttatgt	tttgggctag	ctctgctgaa	acattattct	cttttctttt	agagccaggg	132360
ctgtgggctg	tgtcacttgt	gacttggcag	cccttaaltgg	ggctacatga	ggaagacatt	132420
tcottacatg	attccaagag	tctttctctg	gggttctgag	gtagtctctg	tgfttcttgg	132480
agatatcgtt	ggctctaaaa	tttcccttaa	gtgagggtgat	attctgtcat	ctcatgcag	132540
ggtttttggag	gctgagggggt	gtctgggttg	gctccaccac	ctaccagttg	ggtaatattg	132600
tgtagttttt	tttttaaac	tttctcagct	ttagtttctc	tatttgaaca	gggttaaaaa	132660
ttgggcttga	gagaaggatt	agagataata	ttagtagata	ttgttgatga	attgggcgaa	132720
gcagaggggg	ggggcaaggt	tgactacctt	tgfttctgtc	tcaacaagat	aggtgggtgat	132780
gcctttgagg	agataagaaa	agtgaactgt	gtgtgtgtgt	gaaagacaga	cacacacaca	132840
tatatatata	tagagagaga	gagagagaga	gagagactta	taaatttttg	atataatggtt	132900
tcaaggcaact	tttctggatg	cataagtgtg	aatgttcagt	tgaagtftta	atgggtgctta	132960
ggagagagat	gtgaacgata	atagagattc	caaaggcctt	tacatcaaga	ggataactga	133020
agctatagga	gcagatgagg	cacacctgta	aagatgagac	aagaagaaag	cctagggttag	133080
ctctgagaa	tttgctattt	agtgtcctca	tagaggggat	ggaggattct	tcacaaaaag	133140
ttcagttttg	tgaaccacca	ttccctgat	tttactctta	cctcttgaga	caccaatttt	133200
ttaatgaaga	agaaaattat	gttgccctgct	taaagtaagg	aaagcaggtg	ttgggtgggat	133260
tctttaatatg	aaatatagag	gtttaaata	cctacaagag	taggagatag	aattgatcaa	133320
gtaaaaaat	tgaagagatt	aattgaggac	ttaacatcag	agaccatag	tttgttgtga	133380

caataatcca	aattattgta	ataatgtgtt	taggagttat	tagccttgta	ggtaccaaga	133440
ttgcatlgat	cctgtgttag	gagtttgcca	ggglgtgtca	atagttagaa	agacatgaag	133500
ggattttgagg	ttgctgatga	gtgaccagtl	tagatgacaa	ctactgtttc	ttcaactcct	133560
tcttcaactt	caactgtctg	tttltgggaaa	ggclagtggc	ctgtgaggaa	acgaagaccc	133620
cggagctgga	ggactcaaa	agtttggaga	gcagacgtgt	gcaagtgaag	gtttttgtgag	133680
cactggagga	caggcagctg	gggaagagag	tglgttattt	gcagttatga	tattgggtgt	133740
ggagctatct	ttggtggcag	caaagctcag	gatgtatltt	tttattatc	ccataggtga	133800
tggaggcttt	ttattttgoc	acaaaaaccac	tggtgacgtt	gcctgtggcc	accttggaga	133860
agacactgga	ggtacncagg	atgtatccct	ggaagtggca	gggggtataa	gttttagtagg	133920
agatttgta	ctgagtattt	aagggtctagg	aacagattga	gggtgttggg	tggattgccc	133980
actaagacac	tgggttttct	agcatgatga	cagaaattgg	agtttggggg	gagaagagtt	134040
ctatttgtgt	ttgaagaatg	tgalcaggag	gtattttctaa	tqacacaaac	atagaagtat	134100
acacactggg	atagtccagat	ggcatgagta	ccaaggtlga	agtgtggtgg	tcctaaagtg	134160
gcattaagga	gccaataaat	tgtcattcct	accttagctc	tgtgtcagat	gaaatacaca	134220
gcataglgtg	gggagaaaat	gttgggctta	ttggggatgg	ggtctttcac	ataaagggaag	134280
aaaggtttcag	aaggcatagt	ggtatgaaaa	gaggagaaac	caaaggaggg	aagggtcaata	134340
aagggttaag	aacgagggga	ggcaaatgga	ctttctttca	gcataatgag	attataggaa	134400
tggaaacctt	aatttgaatt	aattgaccac	aaatatltcca	aagatggagt	gaatcagttc	134460
gagacagaga	tatctgaggg	tctgaggggtc	tgaagtagga	tttgtcccag	tcgtgtgtgg	134520
gtgggttcac	tgtgtggagc	ctggggtctt	gaggatctga	acatgggctg	cctcctgtgt	134580
gcacgggtgga	ggcatctggc	ctgttctccc	tgggggtggac	tcatgatgag	ctgagtggcc	134640
aaacacacaa	tggttttcat	ttaacatctc	atttctagcc	taacgacama	cctaaaaggt	134700
gggcataaca	ataatgttaa	taaaacatct	gcatttctcc	catccttggg	gttgtgagga	134760
tttaatgcaa	ttgtttgtgg	gaaagcaact	taacaaactc	aaattacgat	atatatgeta	134820
ggttttattg	ttaccacac	ctttgatgta	tttctctttg	tactcttcac	tgtatctgta	134880
acacattccc	taggataatt	agggctaccc	tttaacaaag	ccaagattct	atttatagtg	134940
glaagctggc	acctgggctg	attctctctc	gtgattatgt	agttttgatg	tggactggca	135000
ttcttccctg	gagtttgagt	acctcogtca	gcacttctcc	cgtcacagag	ttccatctct	135060
gtgtttttct	attacaaagc	ccagacaccc	atctaggcca	cccaaccaggt	tcctctttcc	135120
agtcttaagg	acatctttag	ctcctggctc	atttgtgaga	tggagtggac	tqacatgccc	135180
taagcnaaga	ttgccagcct	gggtctagttt	tcagggtctc	ccttgaactcg	acaataaagt	135240
aaccactaga	ctttgagaat	tgcagtttta	caittgtctag	agtcttctag	actttcatga	135300
agataggcaa	atatgatctt	aaccaagatg	tattaatacc	tcctacttcc	tttgaaatgt	135360
aactgagact	gtacttgaga	cgttacaatt	tcttgggaag	ggaaagggaag	cttctgctat	135420
tgaacgaact	ttttgttaag	gtagctccca	agcaggttca	gtagctttgt	tctattatca	135480
cttttctact	gacagtgaat	tttttccctt	gaaggcctgg	gacatggaga	ctgcttttct	135540
gcagaaacca	catcccttgg	agtaatgagc	tacacctacc	tcaattatc	agtgcagtac	135600
aacactccag	gtcagctatt	aagaggtgca	cacattatct	ttagaaaatg	ttgactgctc	135660
ttgggggaaa	caaatctatg	ctatatgttc	tttttactca	cttgatttac	aacatactgt	135720
gatgtattct	ttttctattc	agcatctttt	tgtaccogta	gctctttgtt	ctgagcataa	135780
atgtgacctt	ttggcttcag	gtagaaactc	tgtctcatga	gcactccctg	gacacgggaag	135840
ttctttgaaa	tagcattgat	tttgttlaag	ccttcatgtt	cccctgggaag	gctgattaac	135900
cttagtgcc	tctttctgta	atagctcata	ttgaattatc	tccctctgtc	tgatttatatc	135960
catttgaatc	acctgcaagt	ttcttttaca	tgtctagagt	gaggacaatg	tgggtgatga	136020
agagctgaaa	tcttctagggt	aaacattaga	tttttaaaaa	ttctattttt	ttttttttat	136080
ttttaagaca	gggtctcact	ctgtcaccca	ggctggagtg	tattggcatg	attacagctc	136140
actgcaacct	tgaactccca	ggctcaaac	tgaagcagctg	ggactacaga	tgcaccacca	136200
tgcattggtta	gttttttaat	ttttttttgt	agatagagggt	tctcactatg	ttgcccaggc	136260
tcatctcaaa	ttcatlggccl	ccagagatcc	acctgcctca	gccttccaaa	gtgctgggat	136320
tacagacatg	agccactgca	ctaagccaaa	aactcctgtt	caaattacal	tttctgcctt	136380
agtaatgotg	ctttcctagc	ttctgagaat	ttctaagacc	caatggtaec	tctatgctaa	136440
aattaaaaata	cgaatgtcc	tttcaaaact	gcacaatatc	tttgctattg	tcaataatgt	136500
ctcaataaac	ataaaatagc	aaagagattg	tgcagtttta	aaaagaacat	tcgtatttta	136560
attttagcat	agagttacca	tggggtctta	gaatttctca	gaagctggaa	aagcagcgtt	136620
actaaggcag	aaaatgtatt	cacaatagca	aagactlga	accaaccocaa	atgtccatca	136680
atgatagact	ggattaaaga	aatgtggcat	atalacacca	tggataacta	tgcagccata	136740
aaaagggatg	agttcttgtc	ctttgtaggg	acatggatga	agctggaaac	catcattctg	136800
agcaaatcat	cgaaggaca	gaaaaccocaa	cactgatgtt	ctcactcata	ggtgggagtt	136860
gaacaatgag	aacacttggg	cacaggggtg	ggaactcac	acaccagggc	ctgttggtgg	136920
gtggggagag	gagggaggga	tagcattagg	agaataacot	aatgtaaatg	acgagttaat	136980
gggtgcagca	caccaacata	gcacatgtat	acatatgtaa	taaacctgca	cattgtgcac	137040

atgtacccta	gaacttaaaag	tataataata	aacaaasasa	accactgcac	aatctctagt	137100
altcagatgg	agactaagca	tgatttttct	tataaaagag	cagatcagaa	tggtgtatct	137160
tttattcaga	agactggagt	taatcaactgt	tatctttagt	acttagtgct	gccaaaggctg	137220
tgtgttcaca	atgaggatag	gatgtcdaat	aatgaagct	tcatagaaca	agagcaggat	137280
tgagtcatgl	aggcaactgt	ttcaggttcc	tcacctaaact	tagcaccaaa	atgtgttatt	137340
gtcattacag	agtgtttatt	taaagaaaaa	taaaaagaac	acacacccac	acgcacgcac	137400
acacacacgc	acgcacacac	acacacatgt	agctacatgt	ctagggaagg	tgtagagagc	137460
tgaatatga	aggcaaaaata	aaacatcttt	ttcaaaaglat	acagcctaca	gtggttagca	137520
cagagctggc	cacatagcag	gggtttcata	aatgcttggt	gattaaactc	ttttttttga	137580
aaacaataat	gtagaagcaa	agagcctaaa	gtgttttcat	aaatcttaag	tggttagcttt	137640
atgttccagt	tcagcaaaac	acaaatttga	aggcaatctg	tacgttaggg	ttcaggtgaa	137700
gaaggcaaa	gaatcaatga	naattgtaaa	gctttccaaa	tttgcttttt	ctcttaagat	137760
tgctcttctc	tcattctctt	ctccctattt	caggaatgca	aatatcctgt	ttcatcaatc	137820
ttttgttttc	tgactcaaga	taacaacaat	aatttattga	gcaaaaacca	tgacttttgg	137880
gtctgtgtag	ccccgaagct	tcatagttca	atatctgaca	cataagaggg	gcttactcta	137940
cacttaaaatg	ttagttttgt	cctcactttt	ttctctttct	cagagatctc	ccttttcccc	138000
tacttgatata	agcatgaaga	aatctttctt	ttcattctct	ccaagtttaa	tcagacaact	138060
ccacatacat	acactcttct	tcacaactat	gaacaagaca	gaaaagttgc	tgagcctcaa	138120
ggactttaca	atcaatctgg	gaaggcaaac	attgaacata	taatgtccag	ctgataagt	138180
gttaggggaag	gaagctcag	aatgcaaggg	aatataatct	aatctaggag	atcgtgggaa	138240
atatcactgg	ggaatttgg	actgaaagaa	aaataagatt	tgattagggg	aaattgaagg	138300
atcagggagt	caggcggaga	agaatgtccc	ggcagatgag	acactatgta	ccaagcccca	138360
gtttgacaga	gagcgtgggt	tcagaaagga	atctaaaagg	tgtagtttct	gtagcagaag	138420
tglaaggggtg	ttactcgtag	gaggcctcta	ttgaactctt	ttccagtga	gtagtgtgtg	138480
gtctttaagt	ggctttgcaa	tgatagtaag	atcagcattg	catctactga	tgagctcctt	138540
tagtaaacgt	ggatatgtgc	tttctgaatc	talittgtttg	tttttcccaa	gtcataaaca	138600
gtgaatcaag	caaatgaaac	ataatcaagc	ttggatagta	tcttccacta	atttccctgg	138660
tcttaagtaa	gactgacagt	aaactgatgg	tcaacctggt	caatgggctt	taacaagttag	138720
tagccacatc	caagtcaaca	aacagtacag	gcaatcaggg	ccctggcct	acagtgaatc	138780
atgggaatta	ccccagggac	ctatgctttg	gggactcgtc	cttctggcca	gctatagatg	138840
ccatcagaaa	ctcatttgc	cactcttata	accaagataa	gggcaatgg	tagtcccctg	138900
tcattgcacg	ttagctttct	ttcccttttc	taggcttttt	cagatgcctc	ttttacatta	138960
ttacttttcc	tgtgtgaaaa	taatgcgtgg	gaaatgggta	ggtctacag	agcgataatt	139020
tcattctctg	gcccctgtct	tgacgctccc	taagtaaaag	tttgccgctg	gcactcctct	139080
ggcatagtaa	cctctgacaa	acccttgggt	aatagaggag	tagcaaaacc	catgggtaat	139140
ggaggagtag	caggaatatt	atgattagct	aacaaatlca	caaagtacat	agaaattttt	139200
ttctcgaata	accactatag	ctgaggaata	tagattagtg	acaaaaltgt	gcactcaacc	139260
aactctatta	aaagtatttc	attattccc	tgaaaaaact	cctaggaaaa	tgattcactg	139320
agagatatac	gattgtataa	gtattgagaa	acagcttttc	ttttttgctt	tttatttatt	139380
tatttaalat	acattatagt	tacacataat	tatgggatac	aatttgatgg	ttcgatacat	139440
ttttatgttg	tataataatc	caatcaagg	atatttagtg	tactcatcac	ttcatgcatt	139500
tattattcct	ttttgatgag	aacattcaaa	agcctctctt	ctagctcttt	cgtaatatca	139560
atacccttact	gttaatcata	gtcactclac	tgtgcaatag	aatgctagaa	tttattcctc	139620
ctattgaatt	gtaactttgt	acctgtcgac	cagcctctcc	ccatcttctt	cccccttctt	139680
cttgcttccc	cagtcctctg	taaccactgt	tctattcctt	tttttggttt	ttcttttttg	139740
agagttcgc	ctgccgccca	gactggagtg	cagtgcacaa	tcttggtcca	ctgotacctc	139800
cgctcccag	gttcaagtga	ttctttctat	tttttgggaa	tgtgcgttat	ctaatactta	139860
ggtgcctcag	atttaattgg	ggtaaatctc	actcatttta	tgaaaaccaa	atgaacacta	139920
tcctcacaat	ggttagaagg	caagatcagc	tcaactttat	gaaaatatga	ctataaaacc	139980
atttattatt	gccaagtgg	tggagtggag	ttgacagaaa	gatgcattat	tttaaatgtt	140040
gttttagatg	acagaacagg	agtcagtaat	gttccagttt	ggaggaaatta	gagttaatlg	140100
gttaattgat	tgattcgaatt	cagtcaaaat	tattgaatga	ctgctgtttc	agacactgta	140160
tttggtoctg	ggaaaacaca	gataaataat	atataattgt	attataaatt	astaaaatag	140220
ttttttccct	ccaaatgtca	gtagtccttg	gaaaggacat	gtaaacraatg	aatataaaagt	140280
gacacatagt	ccagtcaaga	taggtaggaa	ggtctaagta	caattgagtg	gtcaattttca	140340
cttcaggggaa	gggcaatgat	caggggaagat	ttcccaggga	aagtgatgct	tgggcaataa	140400
agtaagcaat	ttacaaaagag	aoaaggaaag	atagggcgtc	ctgggcagag	gaaggagtg	140460
gtacaaaggc	caagtgaacat	atgaocacat	tgtacatgaa	ggaaactacc	atcagggcaga	140520
gctgaaatgt	tggcccatgg	tgaagtgcata	gttacoggtc	ccagccatga	oagtagtgta	140580
acaaatgcct	gcctctgggtg	cacagcaaga	tattaagatt	cctcaaaaca	gttcatatat	140640
tttataaaat	aagatagaca	ttaacagaag	ctcatagaat	caattaatgc	aatgtaagt	140700

gacctaagag	gcatttttgt	cagcatagtt	attgattttg	cctgacccag	aggatttgaa	140760
tttaggaaga	tgtaaagcta	gagtagctgt	cagttatctt	gtgatacatg	ggccttggaa	140820
gcaagggtaca	gggacacagt	ggaccaastgg	gggaagatta	ggtcctgggtg	atgtgattca	140880
agccaacttga	ttaagccaca	tctgaaacgt	ctatttctgt	actcttcagt	tacaagagat	140940
gttagtttga	attattttgt	taagtcagtt	tttaaaaaat	tcaatttgcaa	cttagggagt	141000
acatctggcc	tcttcaattt	acaacttagg	agactaatat	ctagtatgac	aaagtgactt	141060
ggcaccgaat	ggctggttaa	aaactgatac	caggacccag	atctaatgac	tcagaggcca	141120
ggcttagaaa	tatctagctt	tttttttttt	tttttttttt	ttttttttta	gacacggagt	141180
cttgctctgt	tgaccaggct	ggagtgcagt	tgcgcgatct	tggctcacag	caaattttta	141240
aagcatctac	atgtgagggc	ctaegtatac	gagtaacctag	aaatctattt	tgcagcaact	141300
atatatttga	tagagtgtat	gagtttagtt	taaagatgac	atctctaagt	ggtagtgtctg	141360
tcaaaagagc	attgcattga	atcaagaatc	tggcattctg	tgttcatagt	tcacttttgc	141420
cactaattat	ttttgtgacc	ctgggtattt	ctttctggga	ctgtattcat	tggatatgag	141480
tatctctaaa	tcttcttcaa	cttctatgat	tctaaatgga	agtcactca	attttcaagt	141540
atccattgtg	gattttatat	actgctatgt	atcctgagaa	aatcttccct	ttgaattatt	141600
tttcgtatta	atgagttcaa	cttcacaaat	atttactgaa	caccaactat	gagctagggtg	141660
atgtaaaggt	gaatgtttac	ttctagtctg	tattactttac	ttacttttgt	attccacagt	141720
gcagtttgat	attgtttgtg	gttccaaagc	atcaaacaat	gccttttaat	ctaggacatg	141780
tggaaatctt	aaataagagc	agaattacaa	agagttttag	actgccactt	tgcattcattc	141840
tgagaggcaa	taccataagt	gttcagcagt	cagaagaagg	gacaggggaa	agtcctgagc	141900
agtgcagggtg	gattaaagaac	taaatatgcc	tacaaagcca	cattcatgcc	taaatgtcat	141960
tgcatttggg	tcacaggcct	tgagaagatc	tgtaccatca	ctgtgggtaa	cttgggacca	142020
tttagagtac	ttgcctctga	gggaaataaa	aatttgctag	caattttctc	taaatgacat	142080
tatcataggc	acttaattcc	ttgataggtt	cttttagata	atttttttat	aatgaagcaa	142140
ttaatttgat	tcacgaaagt	aagtttctag	tttatataaa	gaccagatct	ggcctatttc	142200
ttagcttgct	tacatttgag	tagttccatt	gctggaaaat	gacctggag	cttttcaatc	142260
tcatttgaag	agtcacaggg	acagacagag	acactagttt	tgcagtttac	tagagccagg	142320
ttocatttca	tctotaataa	ttttgcctg	tgtgcgcctg	cacatgtagc	ttaaagctatc	142380
taagcccttag	ttagttttgt	catcagtcac	aggggaatag	tgatatctcc	ctctaagggt	142440
tgtacaacat	ggtggttatt	tatagcacag	cttgaataaa	tgttattaga	tgatatagtc	142500
tcagtcagggt	tttctttgga	ccatgtttta	gtgacatatt	agactccaaa	gaagcabaat	142560
gctaggagca	caaggcagcc	taacttgtga	gttgatgtac	agtgtgaaga	tgaccacag	142620
atttagaatt	tcagttgact	agaagaataa	gtggtagaat	ttgtccctgg	ttgactactg	142680
tcttaacttt	gtgtcttttg	ggaaatattt	aagctctcca	gacttctatt	tcttcatggt	142740
taaatcgga	ataatattcc	tttctcattt	cgtagaaatt	gaaaggagat	aagtatgaaa	142800
gcgtttlatga	gagtagaaat	catgagtgtg	aaagttcatg	ctattatggc	acaattgatg	142860
ttgaaagctt	atattacaga	ccattccttt	tttgccacgt	gaaaatttgt	ttatatccat	142920
attggccctt	gtccacatatt	aaaataattat	gttctcttat	taatttctat	gagataaata	142980
ctgccttcat	acttttataa	agggaccctag	gaaaccaata	tttgtctaat	gtttcaggct	143040
aaagagttaa	aaggantagg	tatctctctg	aaaatagatg	gctatttgtca	atatttttcc	143100
taccaagaaa	ataatttctt	ctctataaa	aactgttact	gttttagagca	atattttcac	143160
gattcaaaaa	gattatctga	gcattgtgtc	aaccataact	gacctctgca	aaatatttct	143220
aaaagcactg	tgcctctagg	ctgggaagta	tgcataaatta	gcaaaaatcc	cctagcattt	143280
tcacaccaag	ccatgtgtat	ttaatataca	ccacctcaaa	gaggaaacatt	accacccctag	143340
cactatgagt	gaggtgagac	agagagattt	ctaagaatat	atgggtgtaa	ttttctgtta	143400
actgagagtg	attgacagtt	cgtggaaatc	tgccttccaa	aataaccctgt	tttgacgac	143460
ccttagtttt	atttgatatg	aagaaactgc	ctgctgtttt	gacctattta	gctactagga	143520
actctattta	ctaccctaac	tgcctaaatc	cctatggata	aatttaggcag	tatctgttta	143580
ttttagttta	gatttatttt	taaaaccagt	gttcccttga	ctgttctttac	tatttctatt	143640
tgagagtttg	ttgaaataag	atcatgtaaa	taaaataaca	atgtagtcta	gatctsaagt	143700
caclgtacat	acctagataa	tttttttttt	ttttgagaca	ggatcttgct	ctgtctccca	143760
ggctggagag	cagtgttatg	atcacagctt	actgcaacct	ctggctccca	gattcagggtg	143820
attctccac	ctcagcctcc	ctagtagttt	ggactacagg	tgtgtgccac	cacacctggc	143880
taatttttgt	atttttgttag	agatgggttt	ttgccatgtt	gcccaggctg	gtctogaact	143940
cctagggtca	agtgatctgc	tcatcttggc	ctcccaaatg	agaaggatta	caggtgtgaa	144000
ccactgtgct	tggcacctag	aggatttcaa	taaaatttga	ggtcctataa	ttttaagatc	144060
acatttccaa	aggaaggagt	tttgccttct	ttcaaatgca	tggacaatga	gcaactatat	144120
tgttttggtg	aaactagtag	tcccaaataa	gaaagaggtc	ctactagtcc	ctagtgtct	144180
agtcctctga	ctagaagaaa	aagtcaagcc	caattttatt	tatctgcagg	agtggtttta	144240
agggggattt	taaaactatc	accacataaa	gtctttgatg	aagaggacat	agggggagtgt	144300
agggagtagt	tcagagatgc	atctggtcac	tctcgaatac	ataacacatt	tacataaata	144360

tatatatacca	agtaaaccttc	agacttcaca	tattttgtttc	cttttgtttc	cttgttgaaa	144420
atcttttatec	aagctgacaa	tcacagtaca	ctgctcatgt	agattccact	gctgagagct	144480
ggaagctgag	agtagagtgg	gctggggagc	gactttcttg	ggactattat	gcttttcttg	144540
cactttacta	ggttcctgtt	cttccccacc	cactacctct	cctgggcact	gattccaggc	144600
aagtgagatg	catatctgtg	gactatgggt	aagtgaagc	ctttgttctg	gaaagctcta	144660
tctggtttct	cttaagccag	acagaccagc	ttgccatgaa	ggctttcata	ggctctggtc	144720
cacactttag	acttccaact	ggtctgtac	tgacattcta	ggctattgtt	lctccaagta	144780
atgaatgagt	ataccattgg	tggtggaaga	gagaatttta	gatggtagat	agacaaatgt	144840
ttttattgtg	attgttatgt	atttttaatt	catatgagaa	aatgttttc	cattcatggt	144900
agcaatatac	agtttcttct	ttaaatacat	ttacttaaaa	atgtgagttg	atttaagag	144960
aaatattaat	aagacttctg	gggaaactca	ggcatgacaa	aatacatgaa	ggtgacatgt	145020
gagtagttga	ggtttagaaa	gcactgcaat	gttatagact	ctaggctagc	tccttgccca	145080
tcocccaggcc	agttaactag	ttgaattctc	tcaagagtca	ggatgtcttt	gcctgttggc	145140
cttcacactta	agaaagtcag	gcaatgatga	ggaaatcacac	ctgaggagat	tgtaggagac	145200
ctttaactta	aagagtgggt	atgaatatga	aagaaagagt	catagtatat	gatcaaagca	145260
gagaggactt	tgagactcag	cgattgggat	gtaggaaggf	ttcctgtaaa	aataaagtct	145320
taactgggct	tcaaaggatg	aacaggaatt	atcctgtgga	gaaaagttag	agaagaatga	145380
catatgocaa	gtttgtttct	taaaaccaca	acccccaat	tgtgagctct	gggtcttaat	145440
ttggtgggga	tgggaagcgc	caatctatct	gtgactctcl	tcctgacatg	ggctttcaag	145500
tgcatgtaac	ttgacattta	tgatttctct	tgcaaaagaa	gaaaggaaca	gggtgatggt	145560
gcctctgtga	tcagttgcat	ttatgggtgc	aacagcaaa	gaggtgggac	acctaaagga	145620
caaccgttca	cgtgaaatga	agcagggatg	agaagaaalg	cocgtttgta	tttaatacat	145680
cccagaaatg	aaccccttta	tttctggga	ctgttagagc	agggaaacta	tatatctcta	145740
agaatggggg	ctctgctcaa	atcttctgtat	tacagtacaa	agaagggtga	ggacaggaag	145800
cagtgggtgat	cttgcctctt	ttggaagagt	ttgtgtctgt	ccttttaaa	tcaggtatga	145860
ttgataggaa	agtcaagtac	tggcatcctc	agattggaga	ggttttatct	tattttatct	145920
tttttaatgg	agctcttgctc	ttgtcatcca	ggctggagtg	caatgccacg	atttcagctc	145980
actccaacct	clgctctctg	ggttcaagca	attctcctgt	ctcaacctcc	caagtagtgt	146040
gattcacggc	acctgccacc	atgcctatct	taatttttgt	atttttagta	gagacagggt	146100
ttcaccatgt	tggcccggtc	ggtcttgaac	tcctgacctc	aggtgatcca	cccgccctgg	146160
cctcccaaa	tgtgggatta	caggtgtgag	ccaccacacc	tggcctgagt	tttaacataa	146220
caaagaaata	aaaataatat	aatctctcaa	aatagcaaa	aacagggttg	tctaatacaa	146280
atatataact	atttattttt	aatagccaca	tlacaaaggt	aaaaagaaac	aggtaaaatt	146340
aatttaattt	aattttaaaa	atatatttta	aggtatacaa	cacggtgcta	tgggtaaaa	146400
ggttattaca	atgaacaaca	ttaacatctc	catcatctca	catagttacc	tgcttccctt	146460
cccactccaa	acctctcatt	gcaagagcag	ctatagttta	ctcatcttagc	aaaaatcctg	146520
aacgcaatac	accatttttt	ttatttttta	aatttatctt	tttgagacaa	ggtctcactc	146580
tgtcacccag	gctggagtgc	agtggcgcaa	tcttggtctc	ctgoaacctc	cacctccagc	146640
gctcaaggca	tcctctcacc	tgagccttgc	gagtagctgg	gactacaggc	acgggccacc	146700
acatttgggt	aatttttgt	gagacagggt	tlcaccatgt	tgctcaggct	ggtctcgaac	146760
tccttgggt	taagtgatct	gccacacctc	gcctcccaaa	gtgctgggat	tcagggcattg	146820
agccatcatg	cctggcctac	aatgcactaa	tatttaactat	agttggcagg	ttgggcatta	146880
gatcttcaga	cttgttctac	ctacatatct	gctaotttgt	atccttttag	gtacatctac	146940
coatttctct	cacccacctc	acctctggta	atcactatct	tattctctat	ttctgtatat	147000
ttgactttta	aaaaaattct	acataatagt	aaaataatgc	aatagttttc	tttttgtatc	147060
tggcatattt	tacttaatat	aatttaata	atatacttca	tttaactcaa	tatatttaaa	147120
gtatttttaac	atacaatgaa	tgtaaaaata	ttgaaatgtt	ttgcactttt	ttcatgtaaa	147180
tattttaaaat	ttggggata	tgttatagta	catgccattt	aggacattaa	attgccaatg	147240
gaaataatat	tcagatttta	taacatttgc	agttgaaaaa	gtagatacac	gtatccaagt	147300
tgtctctcaac	atacttaaa	ttttccaata	actgaattaa	atatcagttt	atcagtttaa	147360
tataaacaat	tagggtaaat	gaaaaataaa	tttcagctct	ttggttccat	tagccatggt	147420
tcaggagcag	aatagtcacc	tgaggctagt	gacaacgctt	ttggatcaca	ggaaagaaga	147480
aaaaaaatca	aaataatttt	tcttggctcac	atttagctcc	ttttcttcca	ggatgattac	147540
ggagctagga	atttcttacc	aagctgggtg	ataaaaggac	attggacaaa	aacacagata	147600
gcttcatctc	ataccaggat	ccatcactga	ttagctgtat	tatatctgtc	tctactgtaa	147660
tttgaggaga	atgataacct	cttctctatc	ttgttgggtt	ttacagatga	tgtattgaaa	147720
gttcaataaaa	atctataaac	aatagatctc	tgtggcttga	atggtctctc	gatattcttga	147780
ccaatgattc	tcaaatgctt	accatagacc	ataatttttc	cccacatgac	actgcttcat	147840
attttttaagt	tttttttca	caaatatttt	gttttactat	ctccaagccc	tgaacttttt	147900
tttctccctc	aaacatgact	tcaactttac	tatccttggtc	cctttctatt	gaatgtgttt	147960
tgtttgtgtc	tatatctctt	akagtgtctt	gaactgattg	tacttacgat	atgacttgac	148020

tacgataaga	tagaataggg	cagtcacctt	ctttgatcta	gactagatgc	tatccttcta	148080
ttaatgcagt	tgctagtttt	gtatttgctt	gctttcaatt	tttttttttc	agatttttgg	148140
aaccactgtt	acttgactcg	tatcaaatct	atcagtagct	aaaaccccca	ttttccctct	148200
tctgtgctt	atttgactag	ttttgttgcg	ctttctgaaa	tgtttclcac	ttgttttga	148260
ccaaaaaaat	aaaaataaca	aatgccattg	attctgtgtc	tatactattt	gaggcagtta	148320
ggcctttact	tacttcttcc	aacattttta	gcagtgttgc	attcaatttg	aacaagaggs	148380
ataaaaaggc	ttgagaaatc	ttagggaaag	gtgtctcaag	ctttagcaaa	caaacaacag	148440
atctgcaggg	galottgtta	aaatgctaaa	ttctgattca	gcaggtctgg	agtagggctc	148500
asgattttac	atttctagta	agtttctatg	gattatgttt	tgagcaacaa	attcttagag	148560
tgtctgaaag	gtttttaaaa	taactgattt	cccttcaaaa	tcttcttcat	taggagtaaa	148620
atatacatct	tctcactctg	taaatcagct	ctgagatctt	ctataatctt	agctgaggtt	148680
lqgggatgca	gagttttgaa	actcttattt	gcttaagaga	ggagccatgt	atgatcttct	148740
tttgggtttc	cccatgttct	gglaaaaalga	ggagcattac	taaacggcac	tcacttttac	148800
tgagtttgtt	tggatcccac	agagaactga	aaagtcaccc	attatggaag	ccttatcaga	148860
gagatggggg	caagtgcgcc	caaagcagtt	gtcaatatct	ggaagatatt	tttctagtgt	148920
gccttatatt	tcatctctat	tttctcag	tctaattcag	tttatccaaa	taaaaaagaa	148980
accaatgaaa	aacataaata	tlggagatca	tttgatttca	ttggaggctg	gaaaggatag	149040
aaaggctgaa	aagtggcggg	gtgcagtggt	tcacgcctgt	aatcccagca	ctttgggaag	149100
ccgaggcggg	aggatcacct	gaggtcagga	gttcgagacc	agcctggcca	acatggtgaa	149160
aaacctctct	tactaaaaat	aaatacaaaa	attagttggg	cgtggtggca	cgtgcctgta	149220
gttcgggcta	ctcgggaggg	tgaggcagga	gacttgcttg	aatgcaggaa	gtggaggtta	149280
cagtaagccg	agactgtgcc	tctgtactcc	agcttgggtg	acagagcaag	acagagtgtg	149340
acagagcaaa	acacctctta	aaaaaaaaaa	aaaaagggaa	agaaaaaaaa	gaaaaagctga	149400
aggggtgtgt	gggtcctgtc	ctgggtgagg	gaacaacttg	tggaaaagtg	aattgaggct	149460
tatcggaatg	tttggggctc	ctcaataatg	ttggcactct	gagatacaga	ccaaaagtga	149520
ggtaaaaagc	gagtggtttc	tttttttoag	aataggactt	tactccagat	tttcttactc	149580
ttctcttgat	tccttcacca	tctttgatcg	acattcacct	cagatgccca	tgtcccttct	149640
ccaccggcat	agcttgtttt	cttcttaact	ttcttgtgtt	catctagcct	cacattgcat	149700
ttgtcaaccl	togtugaaaa	cctactgttt	gtcaaagtgt	ctttctagta	atccagatat	149760
ctcttccccc	atgccttttg	tgtggtttcg	gtagagtcat	acagagcagc	aatgccttat	149820
gaaaacgaat	tttacagaat	ctgcctgttc	atcaaaggag	gccagacagg	aggtgagaaa	149880
aaccagggtg	gtccacaccc	agtctcaatg	aagccttttg	gggtgtcttg	tgctcttgac	149940
taaatctcag	atggtactga	atgaataatc	accaaaggcg	tgagctgtta	aggaatccca	150000
gttttgctgg	ctctgtgcag	tcagatgtag	ccagccctgt	ttatgtgtga	aaggattggg	150060
ttttcccca	gctgttttgt	aatgttgcaa	gaacagactt	tccctccctt	ggctccctgg	150120
agtaaaatgg	ctgccaaagt	attttggaac	agaaacttag	aatgtaccg	accactagaa	150180
gagatgaaca	agggctcctt	gatattttcc	gtgttcacta	tgatcaagct	ggcatcgttt	150240
ccttctgagc	taaaagattct	gagctatcat	tggcttagtg	gagcttgtga	octagctact	150300
tctgttcaca	atacactgtg	gaggggcagc	gggggcagcc	ctatttgggt	tgagagtctt	150360
taaggagagc	tttacagatg	agttctagtg	aagcccatca	gggagaagaa	aatcaaacac	150420
aatgggaaat	gtttaaccaat	taaaaccagg	ctttgcctgt	gtggctcctg	gttttaccac	150480
alcactctat	ggaaatgggc	tgttgggaag	aagactgtat	ttctgacagt	ttgcagagcc	150540
aaaaacclgt	tgaaggcctt	tlgtaaagta	gtggagaaaa	tggcaaaacc	tttaaaactt	150600
aagggaat	acttgatagt	tctgatgacc	acaggccacc	agactgotgg	gtcatgggat	150660
tatagctaca	tgacaaagaa	aataggaggg	tgggctgagc	cagactcaga	aactattcca	150720
aaagtactat	gactttttag	gaagctagtc	cttttttatt	gaatatattt	gtgttttttt	150780
gcatgagaat	tagcctatgc	ttcttaaaaa	tatcataaaa	tgtcagctag	tagaaaaata	150840
aagagtttaa	tctccactcc	gactacctag	agtcacccct	tgtlcalact	gcagtacatt	150900
tttttctttt	agttctgttc	tatgctttta	ataaaaaaac	aattagggtc	atattggcaat	150960
ataattttga	ctccttttaa	aactgtagct	tatatcataa	gtctatttga	tgttgttttg	151020
aagttgtcat	gtacattttg	tcatacaagt	ttttaatgac	tgttttttatg	gggttgtgct	151080
ccaagttact	tattcatctc	catgttatca	gatattttgt	tcttttagctt	tttttttttt	151140
tttttttaca	ttataactaa	tgaggcaatg	tgtcttgagt	attttgaaat	aatctctctag	151200
aatcgattct	tggggagggt	atttactttg	aagltgatga	cagagtgtag	gagattttatg	151260
agtgaactct	tgtctgattt	ggaaatatag	agttgttttag	gctagggtatt	accaacocaa	151320
agttgacact	tgagtcacct	aagttcttct	ctactccaga	gacttggccc	tgccctggcct	151380
gatcccagga	aaagagattt	tagggattac	agaaatggga	acuaagttgtg	ggtctgagca	151440
cagcatgcaa	alttaattcaa	cacagccccc	gggacaggcc	catgatcagt	agctgaaac	151500
tcccccttca	agtgccttca	tgatttagact	ccagcctagg	aagcttgtct	gattgttgtg	151560
taatcttgaa	aaaatctctg	acacttttcc	ctctgactca	gtttccccc	ctggcaccca	151620
atctttttaca	gtgttatgaa	aaatagggaa	aatgtagaaa	ggaagacat	ggcaccacat	151680

ccttaatgga	cactcagtgga	aagctggcta	tcatcatcat	ttttgggggt	gttgtgttct	151740
acaaalgtat	tttcccagga	gtttttttta	ctctgtctcc	tctttccttc	atatacccc	151800
agcctgtggc	tggggctcttg	cttcaaccac	catgcacctt	tctgaaaccc	aagttttact	151860
ccttgataaa	ggtattgacc	tcttgttggg	ctcatcctcc	agacctacct	atacttaaga	151920
aatgacatc	tctttaaact	ggtccccagt	tcacttggtt	tccctaacat	tttaattcac	151980
aagattaate	acttccctta	caggccagtc	ttactgcaga	gttgattttt	ataatttttg	152040
gcctgttggf	ctggttltac	ttttctcttt	ctgtctgtct	gctagtata	gcgggtcttg	152100
aaagcagtgga	tatgttatga	cattgtcacc	acctcalka	ttgtcttta	tataacagta	152160
gcagcataac	tgtgttttga	tttcttgtac	aaggcataaa	gtgtgctagt	ggctcactat	152220
tcacatcaat	ctcatcagaa	aatgttatft	cctccttttg	ttgatcatga	tatagaggcc	152280
cagtgaacatt	aggtaacttg	ctcaagatca	cacatgtgga	aagctacaga	gccagacttg	152340
gaactgagtc	cattatatct	taatcccact	gcactccaaa	atttgttgaa	tgaaggata	152400
gataaacgta	tcatgatttt	gatgttctga	ctaattcgta	gccagtactt	tattgctatc	152460
ggagcttaag	ctlttaagtac	tggctaggaa	atagtcagaa	ctttattttt	aaggaggagc	152520
alataaktat	gtatatttta	tacctgtagt	aaattgggaa	ctatagaaaa	catgtagagg	152580
attgtgttta	ccaacttcat	gtagagtga	gataccgcac	tctagcttgc	tggtagttag	152640
gtaagtcaga	catgggcagg	ggataaacca	aattagacta	tttccatttg	actaagccat	152700
ataatcaggt	gtaagccacg	gaagaaatc	tggaaagaca	ggtgcaatat	tagaagatgg	152760
ctactgatag	tgtactattg	aggttcaggc	tgtgaaagc	caatttgaat	caagaaggcc	152820
taactctggg	gttctgtcac	agaaaagaa	gtgtgttagca	ggaagaggac	atgtaacatg	152880
aattacatga	ttagatttgt	gtcataataa	caaaaacaat	aatgataata	acactaatag	152940
cttgtttat	gccatgccct	gtactaagaa	ctatacgtat	gttatcccat	ctaaatcaca	153000
tttaatatag	tcccattttt	ctcatgagaa	aattgcacat	tacagagatg	aactaacttg	153060
ctcaaggcta	tagacctggt	aattagcaaa	gcagggattt	gaatttagat	gtatttttct	153120
ctgaaggctg	ggttttagata	aatggatctg	gaagcactgg	gaaggatgaa	ttaatgggat	153180
ggagtgcagg	ggatgcagag	tgcccactta	tggaaatgatt	tcattcaaga	gagacaggag	153240
ggtcagaggt	aagaatgcta	ccgctgggac	agagaggaa	gtacagatat	gagatatggt	153300
aagaaggat	actacaacag	tggctcccaa	atctcaatga	gtagccagtt	ctcatggagg	153360
ttttgttttt	atttttgaat	gaagattccc	atggcatacc	ttgaatatcc	gtactcagaa	153420
tctctggaat	acaaacttgg	attcttataa	agcacccctag	gtgatgttga	agctctgcc	153480
ggttcaagaa	ccacagctcg	atcagccat	atttagatgt	ttgggttgg	gaatgagaga	153540
aagaaaagat	tttaggggtg	catccagglt	tctgaatttt	gtgactcagt	gaagtttttg	153600
gagggtaggt	aagatgctga	gttcagtttt	ggatgtgttg	agatggactg	gtcctgttga	153660
tttagtttgg	tattagagtc	taacgcttag	aacagaggct	aaggctgtag	atttagatat	153720
ggaggacact	ggtgttttgg	tggtagtgcc	gctatatatt	acatggaatt	ttcaaaatac	153780
tcaaaacttc	agttttccct	caataattaa	tcactttaca	tctttgtgat	cttaaatctc	153840
ttttotgacca	ttgattgaaa	cttttgcctt	taaaatttac	attacctttc	ttaacagttc	153900
cttaagatttc	atgcatttgt	gtaagttagt	acttgaccca	tttcaattga	ttcacaccaa	153960
caattgtttaa	agtaaaattt	atttttccct	tgttttagat	gaagagattt	agcaggttta	154020
tgtaacacac	ccaaggtaat	atagtcaat	aatttagcca	gaatttgagc	ccaagctctc	154080
ttctgactct	aggcttagag	ctttagggtc	atttcacaaa	agggctgttc	ctaggctcagg	154140
catgacaact	tctatattac	cttcgtaaaa	gaagcaatat	aatctaccac	tattaaattt	154200
tgcaggttaa	ttttatatta	tgttttaata	cagaaaactt	tatttlaaac	tcagttgaat	154260
ttctcttgag	aaattggccc	tgtagttaat	tatattlaat	agaagagttt	gtgtacttcc	154320
caggggagcag	agtatttgcc	tgatcaaa	acctttcagc	ctttgtctaa	cagcatgttg	154380
gtaggctaca	ttttttttac	tctcagagaa	aggggggtgg	cagggggtgt	atatgggttt	154440
ttgtctcttg	gagttctgtt	gcattgattt	acctcccaaa	ttgttttgtg	gggcatatcc	154500
aactttgggt	tgaaaactaaa	atgggttctt	ggtaatccca	gattgaaat	atgtctcagc	154560
agtaacattg	tttatcttta	ggttttaggt	aatacacaga	tttgccatgt	cttcttggt	154620
gcactgtlaag	aatgagtagg	gctgtgaaa	atgcacaggg	cattcattat	gaagactggc	154680
tgggtlaaac	tgtatacacta	aagaaattgc	attcctttcc	acaagctgag	tcatcacgct	154740
gaaatttgtg	aatcatctga	gccagcagct	gtaatatgat	acttaatctc	cataagtgac	154800
agatattctaa	gataaacgga	acaccagac	gacaactcag	gcaaccccag	cacagtgttt	154860
tggtagaga	acaggagaaa	tgttagtaga	gtgaacattt	ttccacagag	aactcaata	154920
tggtaacatt	ctcatagott	tgataatccc	caataaactg	tggttactaa	aatgcagac	154980
aaaaagaact	tctatctata	aagaacttct	ttatacattt	ccaatacttg	ggttatgac	155040
aaggagaaaa	aagtttatca	gttaatttaag	agttaggtag	ctagtttgcc	cacagettta	155100
tttgtatgag	gttaaggaaa	tctcacctaa	ctgggaaaaa	gcaagcttac	cctcaaggta	155160
tgttatcccc	aaccccaccc	tgcacagtgc	attccttatt	cctcaggtgt	gcctgtttat	155220
cccaaggacc	tagccacacc	tacatcttgt	tctggcccca	caccaaggaa	catataaaag	155280
ttccctctct	ggccggggcc	ggtggctcac	gcctgtaatt	cccagcactt	tgggaggctg	155340

aggcggggcgg	atcaccgaggt	caggagatca	agaccaccct	ggctaaccag	gtgaaacccc	155400
gtctctaacta	aaaaatacaa	aaaattagcc	aggtgtgggtg	gcggggccct	gtagtcaccag	155460
gtactcggga	agctgaggca	ggagaatggc	gtgaaccctg	gaggaggagc	ttgcagtgag	155520
ccgagatcgt	gccactgcac	tcacggcagg	gcaacagagc	gagactccgt	ctcaaaaaaa	155580
aaaaaaaaaaa	aaagtccctc	tctttatata	tcagggtatc	ttggagtcac	tactgatcc	155640
tgaacctccct	cccttctctg	accatgtcta	gacaagtgte	cagggtctct	gtgccaaatg	155700
tctatttgggt	gcctggatta	ggttttgact	tgtttttcta	tttcttttga	tctcgtagcc	155760
catttctttg	attcaatttc	acaatctctt	gatttttgte	tttaagtattt	ggcaacacaa	155820
accctcgaga	ggcaggatag	ttcaacagaa	agaagatgaa	ccttgggggg	cagaagattc	155880
aaacttccag	aatttaaatc	ttcattctgc	tattactaga	tttataaact	ttatcaaatc	155940
actctcctac	tctatccctt	aattcaacat	atttaaaatl	ggaataaaaa	tctcaatgtg	156000
ylagagltat	tattgagatg	aaaatcagaa	lagatacaaa	gaacttgata	gccccaaagg	156060
gcttgatcag	tgtttgttta	atggcccttc	ctctcttctc	atatctcagt	tcagatccca	156120
ctcagccatt	tattttatto	tgtctctttt	ggagtagaga	ataaagccaa	gaattatgct	156180
taaaaagtag	cataattaaa	agtattttaa	acacaagtta	ccttgagaaag	gtgagttgga	156240
agtttatata	taacctcagt	tttttttggg	gagaaattta	cccgtcaggg	ccagattaaa	156300
acatttaca	gtcccaagca	cacgtgagat	gaagatgcc	ctcaottatc	tcacatgtaa	156360
gttgaaagtt	aaaaagtgaa	aatgltctact	agagttcaat	aatattcttt	tttccccatg	156420
acttctctga	agctttttaga	aaatatgaaa	ttcttaaaaa	caataacagt	aacccacatt	156480
tttattgccc	tggtttgccc	tatcttatct	ttctcttgc	cacagggtct	gaggcagctg	156540
ggatagggga	gaatgattac	cagccaatca	atattttttg	aaccccagag	attattttat	156600
tatctatcca	tttatltat	ttgagatctt	attttatctg	gaatcttaat	aaacgattag	156660
tttccaaact	gtatctactg	tgtgtatttt	atccatattg	cccagatttg	tattacttat	156720
ttgtgattct	gaataatatt	ttttccaaac	ttaattatca	gcctctctgt	gcccctccag	156780
aattgltaca	acctatgtta	atgcacacta	tggcaagcca	tgtgaattgc	ctacgcaggg	156840
aagttttctt	catacttctt	tggcaagaga	accccaaltat	tggtcagtta	ctagtcacat	156900
gatcttcttt	agccctctct	tagccctctg	agtgaatcag	gagtagccta	aggccatggt	156960
ggtaactccc	ctttttcttg	gaatgtttgt	atttagatat	ggagaagagg	tgcacactttg	157020
cttatgaaat	gggaggggcaa	atatgggaaa	ctttaaggta	agttttcttt	ccctctgaag	157080
gggacaaaaa	agttgtgggt	tatactttct	tgaactctgt	cactgttggg	tgaagagttg	157140
gtgctatgga	agccatcttc	agaccatgag	gggacaagtc	tgaggataca	attacatgct	157200
accggtggca	gaggacagta	tagcaagaaa	ctggatccct	gatgacattg	aaccatgac	157260
tgaatctacc	ctggaacctat	caggaaataa	tccttagttt	tttaagatg	cttttagttg	157320
tgttttttat	tacaaagtacc	tgaagcatac	ctaactaatc	aatgctaant	gcactctctca	157380
cagtttatgc	ttatttttca	gaaatgccta	gtggaaatlt	ctattgctga	ttataatatt	157440
tgtcclaaat	aaattgaata	gactgtcaat	cttttgaaaa	taaaagcatg	acttgattag	157500
caattgttta	gtctgatgtt	ttcctaattt	ctgtcatttg	cataccactt	ctttgatctt	157560
gtcatactct	tgtactatct	gcactaalag	aaattttttt	ccttaagttg	ttctctcttt	157620
aaaaaattat	atccatttat	ttgaagaga	aacttttttca	ctaactataa	attgaaaacc	157680
gatatacttt	gccttaataa	gaagattgtc	ataaaaagaa	atgccatgag	tgaataatg	157740
ttattaaata	tttgccagat	atagtttctt	atgaagactc	tgagcttgtg	gcttgotgtc	157800
tctgttgaaa	ggagagacta	gggagtgtta	tagaagtggt	aaaataatcc	ttccactgac	157860
tgagactatt	tccttgccac	aatcagaaga	actaaaagaa	aggaggatat	ctgttaatat	157920
atgaatttat	ctaatgttca	tgcagtgaat	tctaaaatca	tctgggtgtc	tctgtttccc	157980
cttgagggtg	acttaggcct	ggcatcccaa	acaatacata	ctggagtga	gctccaggaa	158040
accctgagga	gaagagaagg	gcttaaaag	caatcagcct	tcgattgctg	ggattatgaa	158100
aggtcgttaag	aagcgaatgt	tgcattgttt	tattatactt	gatattgaag	caaggacaa	158160
taataattta	ttattctctc	catgtcagtg	gtatttacct	ttttggaatc	atgtgcccc	158220
ttgagaattt	ctggaaaacc	atggttcttc	tactcaggag	aatgcacaa	tgcacacata	158280
cacaaatgtg	caagcacaca	cacacacaca	cacaacacac	gaattgccac	agaagggtcag	158340
taggttloaca	ggcccttagg	taagaaccag	cattctgtat	atttttacatg	tgttctctta	158400
caagttaccg	tgtgattcag	ttcactccaa	actgcgggtt	agtgcaaaac	atggttttga	158460
atatttctat	caattagtaa	gagtggatag	tttaatttaa	tacaccaaag	tggagaatta	158520
ctgtctctct	aatagctact	ttaaatagac	ataagttaca	gtgatattgc	cttccaggag	158580
gcttcaagaa	atgagatcag	gctctataaa	agaaaaatcac	ccnaccctat	aaagtcatct	158640
ttatgaactt	tgaacaccaa	ctgtatgtac	ctagtataaa	ttattccttg	gtaagcagac	158700
tcccaggcct	gggtggagtt	cacatgagtc	ccttttgctaa	aataaacaga	agtgactggg	158760
aactttggat	tgcctttgtc	tgaacttgag	tgtctggatg	gatcagcatc	agcagcatat	158820
cacacactcg	ctgtctcagc	caaagagaaa	cccaaagact	tggcatttgt	tttttacctt	158880
gtcaactgtg	cataaataatc	acgattctaa	tttatgaggg	tccatgagtt	ttaaaaacac	158940
cccctgacat	ttttctagcc	aaataatttt	tcttttaaaa	ggcacaggat	gagcaacaag	159000

attaggtaga	tcacttcaat	ctcctaatttc	aaaagataat	agttaaaaat	tcaactgtag	159060
gactaacaca	ttaactatgt	aataagaccc	agaatagtct	ttggagaaaa	tttcagtgga	159120
tacttgatca	aaataatggt	gaagacaaaa	tcttgatttg	atgalattta	tctgatacaa	159180
ttatttacat	aacaaatggt	aaaagaatta	gaaaaatttc	ataggttaaga	tggtcattat	159240
cttcaagtga	agttacttgc	tttatattaa	gaaccacaaa	aacttactaa	actttttttt	159300
tiaaaagggg	ctcactctgt	caccacaggct	ggacccggagt	ggctcaatca	cagctcactg	159360
cagccttgat	ctaccacgat	tcaagtgatc	ttcccacctc	tgcctcccaa	gtaactggga	159420
ctataggcac	atgcoaccat	gocctggctaa	tatctctctt	ttcttttttt	ttccccctat	159480
tttgtaggga	caagttttct	ccatgttgc	gaggctgggt	ttgaactcct	gggtccaagt	159540
gacccctcta	cctcagcctc	ccaaagtgtc	ggagttatag	gcctgagcta	ctttgcccc	159600
tagcagacgt	cttacttttt	tttttaattt	ggtattagat	tgagccaatg	actaatttca	159660
aacatttata	aattactaaa	ttcttttttt	taattatact	ttacgtttta	gggtacatgt	159720
gcacaacgtg	cagggtttgtt	acctatgtat	acatgtgcca	tgttgggtgt	ctgcacccag	159780
taactcgtca	tttaatatata	ggtatatctc	ctaattgctat	ccctccccc	ttccccccacc	159840
ccacaacagg	ccccgggtgt	tgatgttccc	cttccctgtgt	ccattttgtt	tcattgttca	159900
attcccacct	atgagtggaga	acatgcagtg	tttgggtttt	tgtcccttgt	ataatttgc	159960
gagaatgatg	gtttccagct	tcatccatgt	ccccacaaag	gacatgaact	catecttttt	160020
tatggctgca	tagtattcca	tggtgtatat	gtgccacatt	ttcttaatcc	actctatcat	160080
tggtggacat	ttgggtttgt	tccaagtctt	tgtatttgtc	aatagtgcca	caataaacat	160140
acgtgtgcat	gtgtctttat	agcagcatga	tttataatcc	tttgggtata	gaccagtbta	160200
tgggtaggct	gggtcaaatg	gtatttctag	ttctagatcc	ctgagggaat	gacacactga	160260
cttccacaa	gggtgaacta	gtttacagtg	ccaccagcag	tgtaaaaagt	ttcctatttc	160320
tccacatcct	ctccagcacc	tgttgtttct	tgaactttta	atgatcgcca	ttctgactgg	160380
tgctcagatg	tatctcattg	tggttttgat	ttgcattttc	ctgatgccc	gtgatgatga	160440
gcaatttttc	atgtgtcttt	tggtgtcata	aalgtcttct	tttgagaagt	gtctgttcat	160500
atccctcacc	cactttttga	tggtgtgtgt	tttttttctt	gtaaaattgt	ttgagttcat	160560
tgtagattct	ggatatttag	cctttgttgg	atgagtagat	tgcacaaatt	ttctcccatt	160620
ctgtagggtg	gctgttcact	ctgatggtag	tttcttttgc	tgtgcagaag	ttcttttagt	160680
taattagatc	ccatttgtca	atrttggctt	ttgttgccat	tgcttttggg	gttttagaca	160740
tgaagtccct	gcccattgct	atgtcctgaa	tggtattgoc	tagggtttct	tctagggttt	160800
ttatggtttt	aggtctaaca	tttaagtctt	taatccatct	tgaactaatt	tttgtataag	160860
gtataaggaa	aggatccagt	ttcagctttc	tacatatggc	tagccagttt	ttccagcacc	160920
alotattaaa	tagggaatcc	tttcccatt	gcttgttttt	atcagggttt	tcaaagatca	160980
gattgttgta	gatattgtgc	attatttctg	agcgtcttgt	tctgttccat	tggtctatat	161040
ctctgttttg	gtaccagtac	catgctgttt	tggttactgt	agtctttagt	tatagtttga	161100
agtcaggtag	cgtgatgcct	ccagctttgt	tcttttggct	taggattgac	ttggcaatgc	161160
aggctctttt	ttgggttccat	atgaacttta	aagtagtttt	ttccagttct	gtgagaaaag	161220
tcattggtag	cttgatgggg	attgcattga	atctataaat	tactttgggc	agtatggcca	161280
ttttcatggt	attgattctt	cctacccatg	agcatggaat	gttcttccat	ttgtttgtat	161340
cctcttttat	ttcatttgag	agtgttttgt	agttctcctt	gaagaggctc	ttcacatccc	161400
ttgcaagtgt	gattcctagg	tattttatct	tctttgaagg	aattgtgaat	gggagttcac	161460
tcatgatttg	cctctctgtc	tgttatttgt	gtataagaat	gcttgtgatt	ttcgacacatt	161520
gtatttttat	gctgagactt	tgtgaagtt	gcttatcagc	ttgaggagat	tttggctgag	161580
acgatggggg	tttctagata	tacaatcatg	tcatctgcaa	acagggacaa	tttgacttcc	161640
tcttttccta	attgaatact	atrttatttc	ttctcctgcc	tgtttgccgt	ggccaggaact	161700
tccaacacta	tgttgaatag	gagtgtgtgag	agagggacac	cctgtcttgt	ggcagttttc	161760
aaagggaatg	cctccagggt	ttgcccattc	agtatgatat	tggctgttgt	tttgttatag	161820
atagctctta	ttatttttag	atacatccca	tcaataccta	atttatttag	agtttttagc	161880
atgaagggtg	ttgaattttg	tcaaaggcct	ttctctgcac	cgttgagatt	atcatatggc	161940
ttttgtcggt	gggtctgttt	atatgctgga	ttatgtttat	tgatttgcgt	atgttgaaca	162000
agccttgcct	cccagggatg	aagcccaact	gatcatgggt	gataagcctt	ttgggtgtgt	162060
actggattca	gtttgccagt	atrttattga	agatttttgc	atcgatgttc	gtcagggata	162120
ttggtctaaa	atrtctcttt	ttttgttgtg	tctctgccag	gottttgggt	caggatgatt	162180
ctggcctcat	aaaatgagtt	ggggagaatt	ccctcttttt	ctattgaatg	gaatagtttc	162240
agaagggaatg	gtaccagctc	ctctttgtac	ctctgtgtga	attcggctgt	gaatccatct	162300
ggtcctggac	tttttttggg	tggttaagcta	tttaattattg	cctcaatttt	agagcctgtt	162360
attgctttat	tcagagattc	aaacttctca	tggttttagtc	ttgagaggat	gtatgtgtcg	162420
aggaatttat	ccatttcttc	tagattttct	agtttattttg	catagagggtg	tttatagtat	162480
tctctgatgg	tagtttgtat	ttctgtggga	ttggtgtgtga	tatocccctt	taattttttta	162540
ttgtgtctat	ttgaktcttc	tctcttttct	tctttattaa	tcttgcctagt	ggtotatcaa	162600
ttttgttgat	cttttcaaaa	aaccagctcc	tggattcatt	gattttttttg	gaggggttttt	162660

tgtgtctcta	tttccctcag	ttctgctctg	atcttagttg	tttcttgcc	tctgctagct	162720
tttgaatctg	tttgcctctg	cttctatagt	tcttttaatt	gtgatgttag	gggtgcaatt	162780
tttagatcttt	gctcctttct	cttgtgggca	tttagtgcta	taaatttccc	tctacacact	162840
gctttgaatg	tgtcccagag	attctgggat	gttgtgtctt	tgttgtcttt	ggtttcaaag	162900
aacatcttta	tttctgcctt	catttttgta	tgtaccaggt	agtcattcag	gagtgaggtag	162960
ttcagtttcc	atgtaggltga	gcggttttga	gtgagtttct	taatcttgag	ttctagtttg	163020
cactgtggte	tgagagacag	tttggtataa	ttctgttctt	tttacatttg	ctgaggagtg	163080
ctttacttcc	aactatgtgg	tcaattttgg	aataangtga	gtgtggttct	gagaagaatg	163140
tatattctgt	tgatttgggg	tggagagttc	tgtagatgtc	tattaggtcc	gcttgggtga	163200
gagctgactt	caattcctgg	atctccttgt	taactttctg	tctcgttgat	ctgtctaattg	163260
ttgacagtgg	gggtgttaag	tgtcctatta	ttattgtgtg	ggagtctaag	tctccttgta	163320
ggtttctaa	gacttgcttt	atgaatcttg	gtgctcctgt	attgggtgca	tacagattta	163380
ggatagttag	ctcttcttgt	tgaattgatc	ccttaccatt	atgtaatggc	cttctttgtc	163440
tcttttgatt	ttgttggttt	aaagtctgtt	ttatcagaga	ctaggattgc	aacccctgcc	163500
tttttttgtt	ttccatttgc	ttggtagatc	ttcctccatc	cctttatttt	gagcctatgt	163560
gtgtttctgc	acatgagatg	ggattcctga	atcacgcaca	ctgatgggtc	ttgactcttt	163620
atccaatttg	cgagtctgtg	tcttttaatt	ggagcattta	gcccatttac	atttaaggtt	163680
aatatgttat	gttgtgaattt	gatcctgtca	ttatgatgtt	agctggttat	tttgcctatt	163740
agttgatgaa	gtttcttctt	agccttgatg	gtctttacaa	tttggcatgt	ttttgcagtg	163800
gctggtagtg	gttgttcttt	tccatgttta	gtgctttctt	caggaactct	tttagggcag	163860
gcolgggtgg	gacaaaatct	cttagcattt	gcttttctgt	aaagtatttt	atttctcctt	163920
cacttatgaa	gcttagtttg	gctggatatg	aaattctggg	ttgaaaattc	ttttcttttaa	163980
gaatgttgaa	tattggcccc	cactctcttc	tggcttgtag	agtttctacc	gagagatcag	164040
ctgttagtct	gatgggcttc	cctttgtggg	taaccogacc	tttctctctg	gctgocctta	164100
acatttttct	cttcatttca	actttggcaa	atccgacaat	tatgtgtctt	ggagtgtgct	164160
ttcttgagga	gtatctttgt	ggcattctct	glatttctctg	aatttgaatg	ttggcctgcc	164220
ttgtctagatt	ggggaagttc	tcttggtatc	tatectgcag	agtgttttcc	aacttgggtt	164280
cattctgccc	gtcactttca	ggtaactcaa	tcagaagttag	atttgggtctt	ttcacatagt	164340
cccatatttc	ttggaggctt	tgtttgtttc	tttttattct	tttctctcta	aacttcttgc	164400
ttcttttcat	tcatttgatc	ttccatcact	gatacccttt	cttccagttg	atcgaatcgg	164460
ctactgagge	ttgtgcattc	gtcatgtagt	tctcgtgccc	tgggttttcag	ctccgtcagg	164520
tcttttaaag	acttctctgc	gttgggtatt	ctagttagcc	atttgtctaa	tttttttttca	164580
aggtttttaa	cttcttttgc	atgggttcga	acttctctct	ttagcttgga	gtagtttgat	164640
catctgaaga	cttcttctct	caactcgtca	aagtcattct	ccatccagct	ttgttccatt	164700
gctggtaggg	agctgcattc	ctttggagga	ggagaggcac	totgattttt	agagtttcca	164760
gtttttctgc	tctgtttttt	cccatctttg	tgggtttatc	tacctttggg	gtttgatgat	164820
ggtagcgtac	agatgggggt	ttgggttgga	tgtcctttct	gtttgttagt	tttcttctta	164880
acagtcagga	ccctcagctg	cagggtctgt	ggagtttgct	ggaggtccac	ttccagcctg	164940
gtttgccttg	gtatcagcag	cggaggctgc	agaaacggga	atgttgctga	acagcaaatg	165000
ttcctgcctg	attgttctct	tggaaagctc	gtctcagagg	ggtaccacgc	cgtgtgaggt	165060
gtcagtcctg	ccctactggg	gggtgcctca	cagttaggct	actcgggggt	cagggaacca	165120
cctgaggagg	cagtctgtcc	attctcagat	ctcaaactgg	tttcaaagaa	catctttatt	165180
tctgccttca	ttttgttatg	taccagtag	tcatlcagga	gtgggttagt	cagtttccat	165240
gtaggtgagc	ggttttgagt	gagtttctta	atcttgagtt	ctagtttgca	ctgttggtctg	165300
agagacagtt	tgttataatt	tctgttcttt	tacatttgct	gaggagtgtc	ttacttccaa	165360
ctatgttggtc	aatttttgaa	taagtgcagt	gttggttctga	gaagaatgta	tattctgttg	165420
ttttggggtg	gagagttctg	tagatgtcta	ttaggtccgc	ttgggtgcaga	gctgacttca	165480
attcctggat	atccttggtta	actttctgtc	tcgttgatct	gtctaattgt	gacagtgggg	165540
tgttaaagtg	tccatttatt	attgtgtggg	agctlaagtc	tccttgtagg	tttctaaggc	165600
cttgctttat	gaatcttggt	gtcctgttat	tgggtgcata	cagatttagg	atagttagct	165660
cttcttggtg	aattgatccc	ttaccattat	gtaatggcct	tctttgtctc	ttttgatttt	165720
gttgggttaa	agtctgtttt	atcagagact	aggattgcaa	ccctgcctt	ttttgttttt	165780
ccatttgctt	ggtagatctt	cctccatccc	tttattttga	gcctatgtgt	gtttctgcac	165840
atgggtgatg	gaggtactgg	tattacaaaa	agcttctccc	ccgtgggtca	aatctaagct	165900
gagtgttgag	acataattga	aattcactag	atagatagga	gataggggta	gggaattcta	165960
atcagagggg	atagcacctg	taaggcaaac	aatcacgtgc	atctgggaaa	gctatacaat	166020
tttattgtta	taggacaaat	gttgggggaa	gttgagagat	ggaaactggg	agtgaggcag	166080
aagttagcat	ttatttcaatt	attcagcaga	cctttatcta	ttacctacat	tgcactaagt	166140
actgtgtgag	catttagagag	aaaaagatga	atgagattgg	acaccattcg	ttcattctctg	166200
actatgaact	tggcattggt	ctaggtacca	gagatataat	aatgagaaac	agacatgctc	166260
cctcccctca	ttgaggttac	agcttagtgt	ggagacacac	agatgcctaa	cgcactatgg	166320

tatggaaggt	gctatggaca	cagtgetcaa	atccatgate	tacataggt	tgagagtga	166380
tttctacaa	cttaaatctg	atctgttat	tccctgctta	aaalcctgca	gtagctccca	166440
gtagtgcctt	ctgggttaaaa	tacaagatat	ataglatgac	ctctcaagga	cctttgttat	166500
ttgtctctgg	ccacctctcc	aatttttcac	catgacctg	gccctgtccc	actggcattc	166560
catctccaat	cacacggaac	tatgtggagt	tattaaaatg	ccctatgtta	tttoaagact	166620
cagagattta	gtgectcagc	ctgttttgtt	ccctctcccc	tccctccacct	ggccttctcc	166680
agctcactca	tcaatctatt	agactcaggc	atcatctgct	tgccttcgta	accctcccca	166740
ccccgtcac	cttgctggat	tctgtgcctt	tgcttgctgg	ttcccagaga	tccttgccct	166800
tatttttctt	tgcctgctgg	atttgcagtg	ttgtgtccta	tatggtgtag	aaaaccagct	166860
caggctccca	cttctctggg	cttatgtggt	cagatgcaga	cctgtcttcc	atccctacca	166920
aaggccatca	gggagtttct	tttgtcctct	tcaccagccc	attcttaatc	tttctgataa	166980
attttctgca	ctgtgtgcgc	gtgacaaatt	gggtcaaggt	gatggtaatt	tacagcatga	167040
gatggtgaac	ttgtgtgcctg	tgctgatgag	cccattggat	ttcccctaac	tagtctgttt	167100
ccctaccag	gtggagaact	tcagtagagg	aagtggcagg	aatttgggaa	tgaggagcac	167160
agtgaatta	ctggggccat	tcatatgaga	gtttaagaac	tcagaccagt	gacttaggtg	167220
agtaaaaaata	tcagaaaaag	ggaaagagga	taagagcaac	ttggggccata	attaacttg	167280
tcaatgaaat	gaaggctctgt	tattctaattg	cctacatttt	gccaaacctt	tgtgcttata	167340
acttcatcat	ttgctgtgat	taacaaagtt	gaaagaataa	taactactta	caaggcccac	167400
atccctccct	tataccacta	gcttttgcct	tcctgtacaga	catagcttta	aaaagtgcac	167460
atccctattct	gtacctgagc	cacaacccta	aaagggaact	tgtttacaat	tctaagaata	167520
atattgtcct	ttaaaggtga	aggctcgctg	gaaaacatgc	cattcatgtg	ataaaaagca	167580
ggtagcaggt	agtgtctaaag	acttactaga	ctgcatgttt	gtgctttctg	ctgcattcct	167640
ctaattctcaa	ggcagtataa	ggagataaca	tcttcacagc	cctttcagcc	ctggttgcatt	167700
ttctttgacc	ctggcctgat	ataaaaggca	aaacttggttt	ttcactgttc	tagtcatgca	167760
gtttctttgt	ggttcccttt	agaaagactt	gaggctatga	gtcaaagctt	ttacgtcttg	167820
ctgatagtgc	agagttgtga	tgtgaagcaa	taaataaaat	ccctccttcc	acatacttgt	167880
ctccttgatt	agaatcattc	tgggcaaat	tagaggctca	taaagtccat	ttagatattt	167940
agtgaaaaaa	caccagcact	cagaacagaa	tgttgataat	gtagatggaa	tatctttctc	168000
tctctgtctc	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tttatatatg	tgtgtattta	168060
tattatatat	gtgtatattt	atatatgtgt	gtgtatcat	tttatatgtg	atatgtattt	168120
atagtaaaata	tatcacatgt	atktatatat	agtaaaaaag	aggggactat	aatatatctt	168180
tatatgttag	catttatattt	aaaaagaaaa	cacaggaata	tctaaaagaa	actattactt	168240
ataggggtta	tgggaaatgc	catgggcaag	aatttttttt	ttttttatca	ccatgctttc	168300
tgsaaacaca	cgatatgtat	cacctttata	aaaataaaat	aaaataaaaa	atgaaaaaca	168360
aagtccactt	gtaaccacat	gtcagttagc	tgtttgcttt	cagggatcat	caaatgcatt	168420
ctatagcaca	ggatgttcca	gtcactctaa	caaaagatgt	cctgttttga	acaccactc	168480
tgtatcagtt	acttcagaca	ctttctctca	ttgagtccct	tcagcaagcc	cttttaggtt	168540
tatgttctta	gatgaggaaa	ccaagtctta	gaacatttaa	ctggccaac	taagatcaga	168600
gagltagaaa	tgtcagagcc	cagaactggc	atctctctgac	ttcagatccc	atgtactttc	168660
ccctcacctg	tgtcagccac	acctccatta	ctacagatgt	gttgattaca	tctaggggcc	168720
aaagtacaca	ttcatccaat	aaatgcttac	tgaatgctta	ccgtgttcag	ggcactgtgg	168780
caatcttttg	taatgcaaga	aaataagag	tagtgaagac	agtcaaggaa	acaaagaagc	168840
ctaatactag	gcaagaagtg	cttttgatgg	aattaaagcac	aatgaggggtg	ttagtacaga	168900
aaggacattt	aattgaactg	ggaaagttca	tggcagtttt	cccagagatg	agtcttgaag	168960
gacaaatggt	atttagccag	gaggaaaggg	ggtcaagtgt	attccaggga	gagggaacaa	169020
catgtacaaa	agcacagttt	tgaaagacaa	ctccattttt	gaggaatagc	caatagctgg	169080
gcacgltctag	agcatagggt	agtagagaga	aaggaggccg	gaaatgggaa	gagacttgaa	169140
tgccacattc	agttatgtgg	acttcactct	gtagcaatgg	gagcotacaa	aatttttaagt	169200
agaggaaata	aaagattcca	tctaaaactt	agaaaaatta	ctttggcagg	ataagagaca	169260
atgaattgac	ggggagctgg	gtttgatagc	aagaaactgt	ttgggagact	gttctaatta	169320
catattttct	tgtttttaga	tgcacatata	cgttaclttt	tagctgggtca	tttctttctg	169380
aaatttgaat	gaatcttaca	atcaatggca	tgttataatt	tcatttggag	cattatttctg	169440
ctcttaagggt	cccccaata	atagtgtgtc	acataactga	tagcatctca	aatttagatga	169500
aatacagtag	tocaggcaag	aaatactgag	atggtgggggt	ggtaagaggg	gaaaagattt	169560
gagccacatt	tagctcctga	tgtgggtatt	attattaaagt	aaaaaaaagg	aatgtgcagt	169620
acatattcag	tatgccacaa	gttgtggaaa	aaagggtgtgc	atggatagat	gcacatgtat	169680
gtattcataa	agttaatgtg	gatgcataaa	gcgtctctag	aatgatacac	aagaaacaaa	169740
taacacccgt	ggcttttagt	ggggggcatt	gggtggctga	gggagaacag	cggtaggaaa	169800
atttttcatt	gtgttclatt	ttgtacattt	gatagtttga	actagtctga	ttatgcactt	169860
caaatatgta	aaaagataaa	aagttagaga	tatttagaaa	ggagcattga	cacatttgtt	169920
gacagattgg	ttatgggata	aaggcgatag	tattttattg	actatatttt	attcttttaa	169980

ttattcctct	aatttcclaa	aacaacttta	ttgaggtata	acttccacgy	tataatttca	170040
ccatttttaa	gtgcataaat	tcagtatttt	ttagtagagt	cattgagtag	tgtaaccatt	170100
cctacaatgg	ttatagcaca	tttttatcat	octaatgaga	tccttcacgc	tcattttattt	170160
aatctccatt	cccatctcca	tccccaggca	accataatct	tcocatgttt	taaaatagct	170220
ttgcctatatt	ttggatgttt	catacaaatg	gaatcataca	aaaggtgggtg	ttctgtgtct	170280
agcttctttc	ccttaggata	atgttttctg	gtttataaat	gttgcaaatg	tcagtatgat	170340
acttcalicc	tttttatttg	tgtctacaaa	atactctatt	ttatgtatat	accacctttt	170400
gtttttctgt	tcacagattg	aagaacattg	cagccgtttt	tgctttttga	cttttatgaa	170460
taatgclgtt	ataaacgtht	atgttttaagt	ctttgtgtgg	aagtattttt	tcatttcctt	170520
gggtagacac	ctagaagtag	gatgttgtat	ggaaaattaa	tgthtgcctt	tttaagaaac	170580
tgthttccaa	agtggctgta	acagtttaoa	cttctactaa	caatgtatgg	aggttccac	170640
ttctccacat	ctttgcttac	acttattatt	gctgtctttt	ttggcagact	taagcctagt	170700
gggtgtgaag	tggtacttca	ttgtgggttt	gaacttccatt	cccctaataga	ccaatgatth	170760
cggacatctt	tcaagtgtct	attaaccaat	caggtgtctt	ctgtgatgaa	atgtctattt	170820
gaatattttg	cccaatttaa	aactgggttg	tttacctccc	tattcttgac	ttgttaggat	170880
tctttgtatt	tttaacttta	atttgactga	ggataatgat	ccaccagtaa	agagatgcat	170940
ttattttctgt	atttatgaaa	atcttttaaaa	ttcctctacc	tttcagagac	acccttcaac	171000
agactgcgct	tcttattttt	agagtatgta	tttccatgat	aacacaagta	tcaattataa	171060
ctattaatta	caactttccc	tctctactgc	agactcaaco	aagagttata	aactctgtga	171120
ttactttcaa	tgctcataac	aatctttctta	accaccataa	gcagactgaa	aaactcaatc	171180
tagttgaatt	gttttacttt	ataatgcttt	tataagatac	tcagtctgaa	actgaaagat	171240
aggtagctct	agaaatgtga	taaatggcca	cagaagtaac	aaactttaat	aaattaaatt	171300
atggatgtta	tgtcaatttt	aagtaatgtc	tcagttttat	atcttgthac	ctgacctaaa	171360
talcatlccc	tttagtaaaa	tatctattaa	agctttgtgg	caaaaataaga	acagaaaaat	171420
ggthtttgat	tttcagcttt	ctctgggtgaa	taatttltgtt	tcttttattt	ttccttctaa	171480
aataatcaca	cgtttcattg	caaccttaac	cctcttcaac	acacacacac	acacacacac	171540
acacacacac	acacatggct	tctagattct	acatgtacaa	gagtgcacat	caaactacca	171600
tagaaaaact	aagaagagag	gcctagaagc	aagaggctga	tacactatct	caggcttcaa	171660
caaaaatattt	atctctgact	ataccaagga	tgggcagagc	ttgcattgta	gtggcttggg	171720
ctagcagact	gggttttgaa	ggaggacaac	atggccatgt	tcttggttcg	gtcatgaact	171780
gtctatggca	cataccttaa	atactglttg	aaggatccgt	tagctccaga	gactgcaacc	171840
aaactgcctat	ggtcataact	cagctctcag	acacattttg	ttgtgcccac	agagtgcctgt	171900
ttgcctgttt	ggthttttaa	ccaacactta	aaatgcaggg	aatttaagat	aaaaatttga	171960
taaaaatggg	aagatttggc	cgtattgggc	tcattggtaac	tgagatgcat	ctgaatgaca	172020
ggcaltccct	tgaattgcac	atttgcctct	gtttttacta	taggcccactc	tcactttctg	172080
tttttttccc	cggctttgaa	acgatcagtt	ttagtactga	aaaattatct	aggatactaa	172140
aaccagaatt	tctctgctag	atggcttget	cattacatta	cctacatgat	tctgtgttaag	172200
ggatttgtga	agthttctat	ggthtgcata	actatcacaa	acttgatggc	tttataacaa	172260
cagaaatgta	tttacagttt	ggaggcagaa	ggtctaaat	caagacttct	gattttagtc	172320
tgthcaagag	cctctgctgg	tagggccatg	ctctgggcag	aggtctcttg	ggagaactctg	172380
ttccttgcoct	cttccacctt	ctgtgtggctt	cagggttttt	gtggcttgtg	gctgtatcac	172440
tccaatttct	gctctgtttt	tcgtatggcc	ttctactctg	ctcctttagt	ctctccttta	172500
ggctgtttct	tataagacac	tcacctaata	cccaaaaaca	atctaaagaa	ttttgcaaat	172560
atgaacattc	taattacctt	agagttaaga	ttttcttttt	tgctaagtga	gggcatgggtg	172620
cagagagcag	gaaagatgtg	aaactagata	gcatacaaaa	ataggtgttc	atagatctgg	172680
gcctaacaag	ggtgttggcca	gcaactctgc	cctgctttat	cagcattaga	aagocagtoc	172740
tctcagaaaq	tgcccagttta	gctaaattca	tgagattata	gactattaag	gtggaaatgga	172800
cctcagagat	ggtccttgct	ctcatctgag	gcttcagttg	ggccagtcag	aatgttggga	172860
aaattgagggc	aggtcaaata	accaggagta	caaacacaca	caatctatcc	agaaaactag	172920
aaatcttact	agtgaacttt	cacaggttac	tttctgcatt	ctggggthtt	cattctagaa	172980
cagatgtgtg	tgtgtgtgtg	tgthtgtgtg	tgthtgtgtg	tgthtgtgtg	tgthtgtgtg	173040
agagagggga	gggggtgcca	gaaaaccata	ccacttttcc	cacatatccc	aactatgact	173100
gggcaattat	gtcattatca	ccactgatat	atagctggaa	gagthttagt	ttgcccgtct	173160
aagatctgga	ttttcttttt	tgagcttgg	ctattggggc	attgagaagt	ccagccagga	173220
ggthtggctag	aggctaacc	aaaaagcttt	gcttaactct	gggctacagc	tggggggttgc	173280
cagagagaaq	tgccctggcat	tctgcatgc	tgacatcaag	cttcgaagtt	gctgcccctct	173340
ggtgagtcag	cagcaaaaggc	ccacatcgth	cgagaatgct	gcccacacag	aagatgtgat	173400
gccacacctc	agaaatcttt	ctaaacctca	gcattctgta	gacttcaaac	aactcctcct	173460
gagaaagaat	gtagaaataa	ctaaatttat	aagattaaag	ttataaaaag	catagagcct	173520
ataataataa	cagcaataag	ataaactcca	catttgcttt	taaaacaatt	tatttgagta	173580
gacagccaac	ccctgtattt	gtactccttt	aaaaaatatt	ttaggctttt	taaaatgctga	173640

ggcaaggggga	cataccaaaac	actaacagggc	acattgggggt	tttctgggcta	ttgaaataaaa	173700
aatgtcctta	cataacactg	atgtactlgya	atagcactgc	gttccagtgga	cggttatgtgc	173760
aactcagcca	gcatactctgt	agcttgtgag	cttttcttat	cagaatttta	tctataaata	173820
tacatatacg	taaattctat	tgtgaaataa	aaataaaatg	togaatcttc	tcatctttct	173880
tattagtcaa	tattgtgcta	ctctttaata	atttctctca	attttttcat	taagcagata	173940
ttactagggga	aatatacatg	aggcagaagg	caaattatft	gcttagtgca	atgcaaactt	174000
gcttaacagg	taagagcaga	gtcccttcca	tagcattgcc	accatatggc	attgccatat	174060
cgtggaggcc	ataaagagga	atgacattgt	aaagattaac	tggattttac	ttggcaaggt	174120
caggcaccta	gatggcatgc	tataaaatgg	ttagaagtgc	aaaggaaacc	tgtagctaga	174180
ggccatgtga	gattatggaa	gtgacttttc	ttacaatcct	gccatctggg	ttggattgtc	174240
aggatcaaaa	catttcaact	goccaaagtga	ggatgctctc	tacatggtrt	tggggatgag	174300
ggagactcag	aaataatgtt	tgtggtactg	tagcaccact	aggaaaagag	aaaaattgga	174360
cctgacatga	agaaaaagcal	gcagccagcc	actaagacta	cttcccacag	gactggaaal	174420
ctctaccacc	gtacctctcc	tacatgctgg	gtataagaag	ttaaaggga	gccagattat	174480
atttacctac	tctttcattc	attcatlcac	tcattoattt	attcatccat	ttaccatttg	174540
tttgtttttt	gttcattttac	ttatttaata	aaaatttgtt	tttgcatatt	ctaggtgcca	174600
ggcatttgaag	aaccactgtt	attgttctca	aatgactgac	agtttagagg	agaaaatgga	174660
agaataaata	gacacttgtg	atgcaatata	atagtgtctc	aataagagca	acatatattg	174720
aataccactg	aattatgaat	accagggact	ttgctaggag	ctataaatta	atctccacag	174780
tacatctaag	atagaagttt	tataattact	ctcttttagga	ggaaaatagg	gtctatagag	174840
gttaagtctc	acagcctgga	aggagtcaac	aaaaaaatac	tcagccttag	gtattctgac	174900
tageagcttg	ggtccttaac	cacctactca	ccaatttgaa	gaaagatgat	tgaactgca	174960
acagctacac	tgactcttga	aagcaagta	actcgttaaa	tgagggtatg	tgtatactgg	175020
ctgggatatt	gtgggctcat	gatgacttgt	aggccgaggg	agctgcacat	atgaagacta	175080
tggagggtat	atcalcagcg	gaaatgaaa	tgattagtgt	tggaggtttc	agtgcataat	175140
ctggttttct	attactgcat	aacaaatcac	cctaaaattt	agtgacttan	ataaacatga	175200
tcatttattt	agctcatgaa	tttgcaagtt	gtgcagcact	tgggtgggat	agctcacctt	175260
tcttccatgc	agtgtctgct	gggactgcat	gatttgcata	agcggggctg	ggcagctaga	175320
gctcttcatg	aatctctatt	tttgcatgat	attttcacaa	ggtctctcaa	gcctggggagc	175380
ttcaggtagc	agaacttctg	acagggcagc	ttagtccctt	gaaaagtgtat	gtctgaaaag	175440
agagactcag	gcagatgcta	tattgccttt	tgtgaccaag	ccttggaaat	cactagtctc	175500
tcttgtgttg	agggtggtat	aagagcctgt	ccagggttcag	tagggagcat	aaatttcacc	175560
tctgaatgga	gaagtgccaa	tgtcctgaaa	aagcatgtgg	gcccagaaat	actgtttgtg	175620
caattttttg	aaaalcaagt	gtgataaaga	cagcatagtg	tagtcabaaa	aaacagatta	175680
ggagcatgat	gtgctttgat	ttcaactatg	ggctttatta	cttactaact	gggttacttt	175740
ggttaagttg	tttgactctt	gttttttgag	atggagtcag	tctgggagac	tccagctctg	175800
tcgcccaggg	cggagtgcga	tggcacgcat	ttggctcact	gcaacctctg	cctcccggt	175860
acaagcgatt	ctcatgcctt	agcctccoga	gtagctggga	ttacaggcac	ctgccaccac	175920
atctggataa	tttttgtact	ttttttcttt	ttcgagaccg	tgtctcactc	tgtcaccoga	175980
gctggagtgc	agtggcatga	acteggtctc	ctgcaacttc	cacctcctgg	gttccagcca	176040
ttctcctgcc	tcagcctcct	gagtagctgg	gagtcacagg	acacgccacc	atgcacaggt	176100
aatttttgta	ttcttagtaa	agataggggt	tcagcatgtt	ggccaggttg	gtctcgaact	176160
cttgacctca	tgatccgcc	gcctcagcct	ctcaaaagtgc	tgggattaca	ggcatgagcc	176220
actgtgcccc	gcctaatttt	tgtattttta	gtagagacag	gattacacca	tgttgaccag	176280
gctggtctgg	aactcctgac	ctcaggtgat	ctgcccacct	tggcttccca	aagtgtctgg	176340
attataggca	tgcgctacgg	tgcccagccc	aagttgtctg	actcttaatt	ctcagctttc	176400
ttattttgtaa	aatgaaggta	ctagfactaa	tttggagagt	tgttaaagat	taataaatat	176460
atgtaaatgc	cttggcataa	gggactggca	caaagtaggc	acttcatata	taaaagclgt	176520
gattattlgat	gaaccagtag	tgaggtaacal	aaclggggaa	ggagaagggg	ccagtttgtg	176580
ggaatgcttt	tttagttatt	aatagtaagg	tggtaaaata	ataantagtaa	taataaccaa	176640
aagttactga	aaactaataa	cagtgctaaa	ctcttttaaaa	ggagtatcta	attggatctt	176700
aacaacaaa	ctatgaaagca	ggactaatgt	tatctcattt	tataaatgag	gaaatgtaag	176760
atcaaacagg	ttaagaaact	ttcccaaagtt	gatcagtagc	aaagacagga	ttcgaaccaa	176820
ggtaattgtc	ctatcagaaa	ctgtactagg	atagtctgca	tttcatggta	aagactatca	176880
gatgccacta	aaacttttta	aaaagggaag	tcttgtgggtc	aaatttgctc	tttagaaggc	176940
agtatggagt	gcagatcaga	tgtctggcagc	aggagatca	gttagaagat	ggttgtctcta	177000
attcagttga	gaaatactga	gacatctgaa	atattgaaga	catcagtagt	gtgggtgatg	177060
tgaagtggt	tctaagaaac	tagcggcaat	catccttoat	tactgattgg	gcgtggagag	177120
aaagagaggt	agcattggta	gccgttagtc	aactctgagt	gcaggcactg	gcattgtcat	177180
tattacccag	ggclctaagt	ggagaaagaa	aacaacccca	gggtgtcttc	aaacctaaag	177240
catatttctt	aagcctttgc	actctcagtc	tagactaaaa	acaaacaaag	cagcctcttc	177300

tgaaatgctg	gaaactttcc	ccacttgaaa	ctctcagatc	tcttaccttg	caattctagc	177360
tttcaaatcc	caagctgagc	ttcctttccc	acaccccgag	tccttgtagt	ggggattaca	177420
atgalcaatt	gtatgtacta	ggtgattglt	ccttccacat	caggggcttc	ggagcggatg	177480
acctaaagct	gctttctcct	gtcctgactt	tctccaccca	gcactgcaac	catacataca	177540
atuttcctggt	cttglagaga	atgactgact	ggtcattata	gtcttccaaa	aggataagag	177600
attagtgtca	tgatgtggcc	ttcaggcgagc	caggggggaat	ctccatataga	ggtacttglt	177660
gactgtatta	cttagtttta	ggtgaacttc	ctgtggaggg	acaatatgtg	cttagaagga	177720
cagagaagga	atgtattagg	taaggcattc	tacatctcag	ataaagaact	tcaatgaatt	177780
gttgggtcaa	ggtctaagaa	acaaaccagc	cgtcaatggg	aaagttaact	aaaatgaaga	177840
acccaacata	caaccccaaa	tcctagtttt	tctgactatg	ttttcttaaa	ctgaaataat	177900
ttctgagatt	aaaaagaagt	tgctgtgact	ttgtctgata	gatgtatttt	tttgttatat	177960
attagtttgg	gccttctatc	tctcctactt	tgttttcttt	atoatagaat	taatctctga	178020
aaagtaactt	tactgtattc	tgatgtccca	ttttgaataa	gtcagttctt	ctccgaatgg	178080
gctctggaga	ttggcatttg	attgaacagc	ttttgtgtat	tgalltgttt	aggtagactg	178140
ggtactccat	ttacttagt	atttctgaca	ataaatcagt	cgagaaggga	gtattactct	178200
aacgggttga	acacttgctt	atgcacattg	cttgggtcatt	caataagtag	ttattggtga	178260
gatcgggcac	gttcagggtg	gtatggccat	agacaataaa	tggttagcac	ttgtccctca	178320
gctgtaccag	tatttaagtt	ataaggtagt	taagttacac	cagtgcacaa	tcatacagtt	178380
tggtcacagt	cctacttgag	gatctcaaac	ctagctcccc	ttacacaaaca	tggaaggctta	178440
atcttggtct	tgcacactga	attattcctt	tagaaaaata	cttgggtgtac	aaactcatcct	178500
tttcaattac	aaagaaacaa	atttgagcag	tttcacaatt	taaaaagtct	cccaaatgga	178560
tttatattta	ttgtccattt	ccaatgaaac	tcactaaatt	ggtaaatagc	agttagtgaa	178620
taactgatga	ggtcalactt	tettgttttg	gactactaca	aacaccacgg	agcaacaaca	178680
gatlagaata	taaagggttaa	gcaaggggtt	agtttttgtt	caaaagccgt	tttgcttglt	178740
acaaaggcta	ccaaaccttt	gaacatcaga	ccaaaccaaa	aacaaaccaa	aacaaaataa	178800
aaaaaacccc	aaaactgaaa	gatgaaaaca	tagtttgata	atctaagctg	ctcttccttt	178860
atttaacctt	gaatttatga	gattattttt	ttccccagaa	gaaaaattct	cttaggggca	178920
ctttcagcaa	tttaacattt	tctaagcatt	acaggcaata	agaggcgatc	atcattcttc	178980
agtcataaag	ataagccaag	gaatgaaagt	gttttgacag	tcatgtcacc	tgacagaaac	179040
tttggaactg	tcctttcctg	gttcaagagt	tcagccataa	tacctacttt	ccctatcagc	179100
tggtctcaag	tgataagggtc	ctgaagcaag	caaagcttct	ttatgagctt	ttatttaatt	179160
gtccttgcca	cataagggtt	gaggggattc	gtctgtacag	agttacttct	tggttggtct	179220
ttttttcttt	ggaataaate	gctgtctccc	ctgactggat	agagtaaata	gagtttggtt	179280
aaacactttt	catcaaattc	ctagtgccta	gtacagagct	tttaacccta	atacgtttcc	179340
tgcggtgact	tattgaagga	ataatgacaa	actctgcctt	agattggtga	ctggctaggg	179400
agaacatgg	ttcaagagct	gaataagtaa	gagcaagtat	tttattgtat	goccatcaaa	179460
tgtattcgat	gctggtgatg	gaggtaaag	tgtgatagag	gctgagttct	ctgaaattac	179520
atatgagatg	tcacttgcca	tttagtatta	gctgtgtctg	tcttttttcc	aggaatttgg	179580
ccttaaaaaga	gatctatcaa	aagtattacc	caatgtctga	tttatcaggc	tttattgttg	179640
ggaacctaaa	gtggattgca	actgctatgg	tccctttgaa	gggagctggg	gcaagatttt	179700
ccatgcctaa	tcacactcat	tttcccttgc	tctcccaatg	acctcccata	tttccctcta	179760
tttggtctga	taaacaacca	caataggatc	ctttctgcag	cttccatcct	aaactgtatt	179820
ctagccttaa	cactgcacaa	aactcactgt	lacctagaag	tcaattgact	tccctgaatg	179880
ttagcttctt	tagctgtaaa	taagtaaltg	latgaggtga	tggttaaggt	gatttactaa	179940
ttttacaatt	ctattatttt	atgaatagac	cctagtttag	atagtttgaa	atagataact	180000
aatccactat	tattctctct	tctaagatat	agttactagt	tgatcatact	tttccctaaa	180060
ggctgaactg	aattctctga	tatcagcaac	taaacatctc	atatttgtca	gtatgaacat	180120
ccactgggtg	cctgttattt	aaccaggtag	aattcttagc	tgtgattgaa	aattctaggt	180180
tccttctctg	tactatcact	tggatgagta	aagtttgaaa	accattaaat	tgacatttct	180240
aataggactg	tggattttaa	atagattccc	agaagtcttg	gaatacaaca	gtgtacacag	180300
atgaagatac	agtaactttt	ggtattttct	ttttgcaagt	gttacaataa	tctgcactgc	180360
ataacatcat	cactatggat	cccatctttt	aatgagagct	tagtatatgc	tacacactgt	180420
cactaaacat	gtaggatctt	gttttagttt	ctcaaaatgt	tgtagttact	atgattattt	180480
tttgtgtctt	gcaatcattg	tgtataagtg	cgtaaaccat	gtatctagag	tttatagaag	180540
aattaaaatt	caaaaaccc	atactcatct	ctcattttta	aaaaatacca	ttttacctgt	180600
cttttagatg	cctgtatttc	ctccccaatc	tcatcccgtt	cctaactctg	aaagtgatca	180660
ctatccaaat	tttgtgccaa	acattaaact	gttttcttta	gctttgocat	ctatgtatgt	180720
atccctaggt	aatacatggc	ttagttacac	ttgtttttta	atgtgatgta	aatgtaatcc	180780
tatagtatga	attttctaag	acttgattaa	tctatgaaca	ttttattttg	agattcatca	180840
atattgatgt	gtgtagctat	agtttattca	ttgtgtttgc	tgaaaaatat	tctattggat	180900
gactttgcta	caatttattc	taaccattgtt	ggataatttga	gttgttccca	ttttattlat	180960

ttatttttatt	tttttgcctgt	tatgaacaat	gtggctttga	acattctttat	actacctggc	181020
gtgtatatgt	atgtatctgt	ctgtctgttc	atcttaagat	gcactacaaa	actgaggcct	181080
agagtcacca	agcaacttgt	ttaatgtcag	agttaggttg	tggtagggcc	aaagtctgaa	181140
ttcagcagtc	tgttaccata	gttttcctcc	ttaaccacaa	tactctatga	atccttattt	181200
taaaaaggaa	ggtctcggaga	attttaaata	acttcctaaa	gagcagggat	tcaacnaagc	181260
tcagtetgac	taatgccttc	cattttttaa	aaatcaccca	aagcacatat	tatgattcta	181320
tttgtgaagt	atttagctaatt	tacaagagaa	tgagttcata	cttggcacta	ctatctcttt	181380
cttacaagtg	atcagatgtc	aaaatgtgaa	aactatacat	ttcacattat	ccatatatat	181440
gtgacatttt	tccttttagga	atatgagtag	aaatagaaag	acagggtttt	acagtgaatt	181500
agattttttt	tctctctctt	tagcctacca	aatctcttct	gcaatacctt	acacttataa	181560
atgcatttaa	tttcagtgcc	aattaaagaa	attcgaaagt	agataataag	tgagacaagc	181620
accagtaaaa	tgtttatgat	gtgacactga	caaattatgg	gctgctataa	tcaagatagc	181680
attaaaaatt	ttaaagtgtt	tgtatgaaca	aaccattttg	gaaggagtgt	ttggtgtggc	181740
agttagcnaa	acaaccaggt	aactatggca	gttagtggtt	aagctctgat	tttgacatga	181800
aaggatataa	aattggaagtc	cagctaaatc	acaagtgtcc	tggagaaact	tggtatgagt	181860
tcttggtcag	agggtttttc	caccacagta	agtattttca	aaggaaaaaca	aagttaaaatt	181920
tttctcttgt	atgagtcaca	tctctgttgg	ttgtaagtgg	ctgaaactca	tcttgaacta	181980
ccaaggtaag	agaagaaaca	tactgtttaa	tggaaattcca	gaaaggactg	acaactcaaa	182040
ccattttgaa	ggacagcala	gagctggact	ctagaacago	caaaaacaagg	ggftaaacca	182100
ctgcgaggga	tctctctcca	actcttgcct	aggcttttct	ccctggcttg	actttcttct	182160
ctttcactgt	agatttggctt	ctctcacatg	gcaagaaaca	ttgctgctag	cacttcccga	182220
gttctacgtt	ctacaacatc	caccacttgt	gagagattaa	cttatgggtt	ttctgttgaa	182280
aagtcaaaaa	ttacctggga	aaagtctgat	tgtctcagat	tggagatggt	gcccattctct	182340
ggaccaatac	actattatgt	gtggctgact	atataaaaac	atggatattt	tcttgggaatc	182400
acttggtttg	actgggagaa	gaccattctc	aaaacaaagg	aagtgcattt	tatagaaggt	182460
agtagaatag	gcagataaaa	caataattct	tcactatatt	gctcaataaa	tcccatgac	182520
atttttatag	tattataaag	agagttctaa	agtgtttcca	aactattata	gcbaaattta	182580
atcttataat	aattttctct	tgaactatgt	ataatttacc	tgaatatatt	tccaaaaagc	182640
aatcaaatgtg	agaaaatgag	agccctgltc	totttaaaaa	atgagtaaaa	gtccacaagt	182700
tcagaacaaa	agaaaatgag	gtaaggccta	aaataaattg	tgctaagaaa	gctaaaattc	182760
tagacaaaag	cacatcggca	aaactagaag	gttggtagctg	tgcttcagtt	tactgcttgc	182820
tgtttgggtt	agaggggggg	tgatgtgata	aaaatagtga	cgaagtgaga	aaactgacgt	182880
attagttttc	tattgcatta	taacaagtca	ccacaaactt	agagggttga	aataacgccc	182940
atgtattatc	tcgcagttcc	tgtgtgtcag	acotccaggc	actgctgggc	tcgggtgggt	183000
tctctgctta	gaatctcaca	ggtcaaaaatc	aaagtatcaa	tgggagctgc	agttctccca	183060
agctggagcc	tgtgtccctt	ttaaactctc	aggctgctgg	cataatttat	ttccttatca	183120
agccatccat	atgatccctt	ccatcttccg	gccagcaatg	gectgtlcaa	tccttctcat	183180
tctttgaaaa	tctctgactt	ccctttctgt	cacagctctg	taacttcttt	tctcttctgc	183240
caccagcaga	agaggttttt	aagagtttat	gggattagat	tacatccgtc	ttgttaattc	183300
tttacttaaa	ggtcaactat	gctalalaac	atagccaatc	acattcgcac	attgcagaga	183360
ctagggtata	aaatcttcgg	ggtcattcct	agaaattctg	cctgctgcag	cctgggttct	183420
tgcttggaact	ctagkatata	tttgctaaat	ctcccaagcc	tcagtctcac	tatttgcaaa	183480
agtgaagttt	aatgctcttt	gccctgcttg	cctcacagga	tcttaacata	gacgtaagat	183540
caaatgcaat	agcatgtcaa	acaatgtgta	actccagtta	tacaaacatt	actgtatctc	183600
attggggata	cgaagctcta	cacacttgaa	gctgggtgaag	gaatataaaa	atgtaagtat	183660
tgctttttat	ataaatgtgt	tcctattggc	tgaasatttc	aatatctgat	acaaatagtc	183720
aactttctat	tttacttttt	ctaattatgc	aagaccttgt	aatcacaaat	gtasaaattg	183780
caagccacat	gcccttaagg	ccaaataaaa	atttgtaaaa	ttctctttaa	aagactctat	183840
agagtcacaa	tgaanaatcc	tcgagtcctt	ttaaaaggat	ccaaccacat	atatcaactg	183900
atatacatgg	taccaaaaaac	aatggaatct	tttcagattc	tctaattggc	ctttggaact	183960
tatgtagcat	cagglatgca	aatgaacaac	ttcagacctt	gattactcca	acctcctctc	184020
ccactgtcac	agccacttct	gtcatgacct	agttgttctc	agaaagttcc	ctcttatacc	184080
tggtcaaaact	tctcttacaa	tcacctgtga	ctttccctct	tggctcttga	tcaaatcctc	184140
ctaaatacat	taaaagtctt	gattcttctt	gtccctttaa	tatatctcta	cttgaatcac	184200
tgtgttagtt	caggctcctc	gagagaaaga	tgttaagatg	aaatttagatg	tgaagagat	184260
tcgccgaggt	aaaccttgtg	ggagaaaatg	gagaggtaaa	tagaggagcc	tgggcagact	184320
gtgtggctac	tatgtaagac	tcattcccat	gaaggagaaa	ggagagggaag	gcaaggaaga	184380
aaaaccttaa	gatttcaatt	ctaagaacgt	tttgacaaaag	ctgatttagga	gtattttaagg	184440
caaagctgcc	caccagaaga	gtactgcate	tttcaggaac	ggacttgctt	tagtacatct	184500
gctgtgctta	gtaattggct	gggagcagcc	atagaaagca	tggactcagt	acaaacttgg	184560
tgatgaattt	cagaggcagc	ggctaagacc	atcagtctat	tattttcctt	gcaatagctg	184620

tcataattac	tatcagagca	aacaattttt	tgtgtgtgaa	ttcatgagat	aatggtcttt	184680
tctttcctgc	tttcaagagc	catgtcattg	aaagagctaa	tcatttcaa	ttatgctgca	184740
tlactgacta	aatactttca	tttatcatac	tttatlttaa	aatactttaa	ctcatggccc	184800
gatgattttc	agttaaccac	attcttccct	actatccctg	ttgccccttc	tgtcttttcc	184860
ttagaaatgt	tattgtagta	tttgcaagat	ggcctgaatc	ctgaaccccc	catcttcaat	184920
gagcaccaaa	tggttaattat	agattcccaq	ctgtagagct	atgtcagaca	aaggaaactt	184980
cattagtatg	taccaatggt	tggactccaa	atgcttttgt	gtctgagtca	caaggactcc	185040
tcttccctgg	tggcttaaaag	ttaggctlgaa	gaagatttacc	attatgttgt	gcattgacctc	185100
tttagtttgg	ttctacttat	actttcaagg	aggggaagact	ggggaaggltg	tcccttagtg	185160
agcatatttt	gtacaaatga	aaacagggtta	ctaacaactta	tgccaggacg	catgcataaa	185220
ctaggatggg	tctgagaaaa	ctgcgatata	tgateactcc	aggggtctccc	ctctcagaag	185280
cgaggggagac	ttaaaccttt	tacatcacca	agtacatgga	aagaangaca	gcagggaagt	185340
gattccgaag	agaaacctga	aaaaagcaat	gtggaaagat	agacacttta	gccttttctt	185400
tcttctcaas	acttcacatt	ccttttcaact	ctgcttcaact	taagctgccc	tagttccaga	185460
gtgtttcctc	tcttgggtga	agatgggaac	aaqtacatgg	ggtagcaagg	ggtgggtggg	185520
acctgtgctc	ccattaaggt	tcttccagaa	tcattttctat	gtgattatca	gcttggatca	185580
catggacttg	gggattattg	gtggttttct	agggtaacaa	gggcataattg	tgtctgagga	185640
catattttat	atgtaacaa	ttggggaaat	ttctttttal	attaaataaa	actgagatat	185700
gtaatgaatt	aggatgaaaa	attcataatc	atctgaattt	tataagtga	tcattgagaac	185760
tcaaagatac	ttagcccttg	ggaccatttt	ttactcctgt	tccgatccct	tcagctaagc	185820
atgatttttt	actattttca	gctattagtt	atgtcttgtt	gaaaaagtat	gaaaagagct	185880
gcccataaaa	ttagagtgt	tgtcaacal	tctcttagct	tctttatctc	tttccaaaat	185940
tggatcaaat	gacaltggac	atgatcaact	tcttactgtt	ttgacaaaca	tctgaggata	186000
ctttttataat	tgataatttg	gactagatta	tgcaatgtgt	gatgagacac	aaggtagtct	186060
gtactcccca	tgatatgtat	atctgtttga	tataactcaa	cgggtgtatat	caaacggata	186120
taagttttag	taggtatgga	gatgagccag	ggttttatttc	ttcaactagt	atttactgaa	186180
tgttcttatg	tgccacaact	gttctggasa	ctgtgatata	tttaataaca	gataaagcct	186240
ttccctcac	atgcataaca	gacccaacag	agtatgaatg	tacatacaaa	taqtaaaata	186300
agaaaaaaaa	taaaagtatt	cagatagtgc	tataactact	gggatgaaaa	tccagcagga	186360
aggaataat	agcctgcttg	atgtggaaga	cagggatagc	ctctctgagg	aggtgacatt	186420
tgacccaaga	cctaaatgag	gagaaggaga	cagttagatg	aaaatgaggg	aaacagcaat	186480
ggcaaataca	gagaacttga	gacaacttgg	cccatlggag	ggacagagac	aaagccaatg	186540
tgggaccaca	ggggatgaaa	gggaggctga	ttggagaaat	aggcagtgtc	gaggccataa	186600
aaggctcotat	aggctcatgga	aagacatttg	gttaccattc	taatgacagt	gagatgttac	186660
tggggagttt	tanaactggag	aatgtcataa	ctgtccagat	gtaaccaaat	agtaaaacca	186720
ttcttctctga	ataacttggc	taaaaggaat	attatgacta	cagatgtaca	tgaagattaa	186780
gcagaacatg	gaagaaggc	ctcaagtaaa	cttgacctca	cataaatatg	ggaggaagat	186840
caaatggaag	ctgggagtg	tgaagaatg	taagggaat	gacttcta	aatgaacaaa	186900
aagctgttat	tttattatga	agaaaaatgt	taagcatctt	atgcatgcag	aaqaaaltoc	186960
cattcaaaaag	acttggaaaa	tgtcttgggt	gtttactata	ataaaccttt	taagatatag	187020
aaaattcaca	tatttagagc	tttaatttct	aagagctcag	acttctcagt	ttatttatatg	187080
ctatgaaatt	ttgtttattt	tttaatttaac	ctacttgtgt	gcaaaatcaa	taagggaagct	187140
taagggaatat	aaacaaactat	ttacatggc	cattttaata	gattcaaatg	aaagaatatc	187200
agcatagtgt	ttctttgata	tgacaacccc	tcttcccagg	gcacttaaat	gaagggttgg	187260
gggggaatct	taacctgaaa	ttgaaaaccc	tgaaatcatg	tttccaagga	aggagaagga	187320
aaataggaaa	aacaaaacaa	aaaagcagca	actcatttgg	aagctcgtgg	gagaggagag	187380
gaggattcat	acatctcgga	ctgggttggc	ttagcaagtg	aatcatttaa	ataggaaaaa	187440
acagggggct	gactcagctt	gagcaaacct	ttgtcttccc	ctgctgaggt	cgcacttgc	187500
tgtggccctc	ggcgctctcc	tgggaccttg	ctgcccctcc	cctttgtcac	tgtggagaaa	187560
caggaaggaa	tgtttattag	caagactgac	tggggtcaca	cccaaggcaa	tatcagggtt	187620
ttacctctcc	caggcctggg	aagaggttca	aggatcaagg	acaagctccc	ggttagagtg	187680
agaggcaagt	tcaaaccttt	gaaaaataaa	ctcacaacca	gcatttggca	caggcctctg	187740
gagtttacag	aatgtatctg	cctgtgtgtg	atttcattag	ttcctcctgc	caatctaattg	187800
agattttacg	tcctgtaaca	gtgaggcaat	tggagltctc	gcagggaag	gaacttgcct	187860
aaactgcag	gatgggtagc	gcttggatcc	tgaacttctg	actcctagga	ctgtgtctgc	187920
ttcagatgat	cacatgcctt	cttggcagat	gtttcttaaca	aaggagagag	ttgccagggg	187980
tggggctctg	ctagctccct	tgtcatgagc	cattctctcc	acattgcctt	ttagttgcac	188040
cacatagtca	ccttcaatta	gctgtgcgaa	taggctcact	cttatgctaa	catgtactaa	188100
aagtgaatat	ggggagagag	agagagagag	agaaagagag	acacacagag	agagagactc	188160
ataltatggt	atgttctctg	ccccacccca	ctcactccc	tctcaacagg	gagaaagtac	188220
ctgaagaaaa	tcattgctat	gaagggcata	gccagctaaa	tgggtgtcac	ttagtctgaa	188280

aaatctcaaa	gatgtcaata	agccactcga	gacaacaagg	aacctgtttt	cctgtcatca	188340
ttcccttctca	gtcccttggct	ttgggaagg	taactttatg	gagagagaag	aaacctctgtg	188400
gagttaaaag	gtttatgaac	ttttttccct	gcaacaatc	agtacacagt	gttccacagg	188460
ctgatgggtt	tccctttacc	tttcgttttt	taacagctat	gtctcacagt	ccagacttgg	188520
agtacaagta	ataagaagaa	taaaacttaa	tcccttaagt	agattcacca	taagtttagct	188580
cagagcaatt	ccagtgcaag	tatggtctgt	gatccagtag	gtgagtgact	ctgctgctga	188640
aattcacatg	tatgtgaatt	tcacagtggc	ctttgctttg	tagcatgctg	taatcctttt	188700
gtccaltttc	alcacacgaa	ctgctgaata	taggattggt	aaatggatgg	ggagatatca	188760
tgaanaatgat	taaagaagaa	agttcttatt	taggggtgca	tacctgccta	tcggaccatt	188820
gtacttaggc	aalcgggatc	ttgctttaag	aaaaggtagg	cattggagtc	aggctgctgg	188880
agtatgaatt	actatgctat	catttttcat	ttgtttttgc	tctgttacat	taggaaagtt	188940
atgtgaattt	ttgtgcctca	gtttcctcat	tcaatatggg	tgtataaact	gtgctgtct	189000
tgtaggatta	ttgtgaggcc	caagtgaat	aatalatagt	acactgtgtc	tggcatctag	189060
taagcattca	ttaagatgac	atgaagataa	cacagatata	tcttaacatg	taattatgat	189120
tttgcttatt	caaggccaag	cattccaatt	taatggagtt	aggcaaacac	agtaaattca	189180
ttgctctttc	ctttttatgc	tacttccttt	gaagaggcag	tcaagttcca	tttgactgat	189240
tgggaacttl	ttagcaatgt	atattatgct	gacttcactc	ttatgcgctc	ttggggctat	189300
aaltcatcaa	gttagggcag	caaagaagtg	tgttggtgaa	agagaaatga	ggaagaacaa	189360
ggagaaaaaa	aagggtcatg	agcttattca	ctgccaatat	ttatttatatg	gaacaatgac	189420
catccttcag	aagtgtttgt	tcctctattat	actgtagggtg	tggagaagatt	ctcattgctc	189480
aatagctgtc	tcagtcacta	ccgatagac	ttgggaggtc	tggctatttc	agggcgcat	189540
tgacatcacg	tgacattttt	ggattaaagc	tttcatgatg	agtgccagtc	tgggtccaaa	189600
aggggtgaaa	gctgtcgcca	tctataggct	agttgtttgt	agtaaaatad	tttccctcac	189660
tgcattaggt	tcttggtacc	atttatctag	cagagttctt	cagtgggctt	gaggcttagc	189720
agtcgaagta	aaacaataac	caacatccca	aaaccagtg	ctgtcaaatt	tcagtgaagt	189780
ggcatagAAC	tttagcatga	acttgagctt	gggttcagct	agactttcat	ataaatcctt	189840
gtttgaagtt	agtagctgtg	tgatcttggg	cactgstatt	aaacctttat	gagaaagtta	189900
tgtctgaaat	atgggaaata	aaacctccac	ttaggttgtt	gtgaagattc	aatgagttgt	189960
aacgatltga	tacactataa	tgatctatat	tacagttgtt	tcataaatat	gattgccttc	190020
attttattct	ttccttgtct	cgttcttccc	agtatcttac	agacagcaag	ttgaacattg	190080
tgggatgcat	gagctatttg	ggcctttgca	gctttctgct	acatggaggc	tagggccaga	190140
gtcaagattt	atgctttgca	gcaocactgt	cagctgtttt	tgcAAatcag	attaaatgat	190200
ttttaaatga	ggctgagagc	atgggagata	ctaagtgtgt	tttccctgtg	agctactgca	190260
taagtaagt	ctttgtaaaa	tgtcaggggc	tccaggatta	tatgggtatta	ctgtcactat	190320
tgaagcact	tctacctttt	ttttctcctt	ttacaggtta	ggaaattgaa	atacagaaag	190380
atgaaaagtg	atttgcccc	gcatatagat	caaagctgtg	gcagaaccag	gactggaacc	190440
tatatctctc	tactaatgg	ttttttaaaa	aaataaccct	gtttcaaaaa	tatttaaaaag	190500
tcacaagaaa	gglaaacatg	tggataaaca	aatgaagaa	aataaaaaatt	atccagtaat	190560
aacatattgg	catatgtctt	tctgggtatat	tttccgtgtg	tgtcatcatt	atcatctcca	190620
tcacatatt	atccatcatt	atcatcatca	tcacatcat	catcatcatt	alcatoacca	190680
tagtgaacat	gtaatgctta	cctagtgcac	gatgtgtct	aggcatttta	catgtgttac	190740
tggtaactca	tgtaatcttc	ataacaacct	tataagggtg	ttgctattat	ccccatgta	190800
catatgaaga	gacagaagca	taaagaagtc	gcaccgctgg	taattggctg	ggattttgaa	190860
ttaaagcagtc	taacottaga	gtaatgattt	taacaactat	gctatataca	tacaaattta	190920
caaaataaaa	ctgggctcag	acaataaaaa	cagctctctt	ttoatgttat	aatacttttt	190980
caccccataa	cacataatca	ctaagtgttt	aaagatcaaa	acaatgcaca	taaaatgtac	191040
tgggttttaa	aaaaagagga	aatagccact	tacctcaacc	aaactaactt	ggagatagat	191100
tagattgata	atggcaagg	tgatgggtag	atgggttagg	gttgcctcaa	aagaaacaca	191160
aaatataatc	tcttttaagg	atcctgatgc	tttgcctcaa	gtaattttta	ttotttttaa	191220
actaaaaaaa	aactgtacaa	aattccatag	gtacatagt	gcgctttgat	atatataatg	191280
latagtgatc	agatcaggg	aattcgcata	cccagtcac	ctatagtggg	tatagaacac	191340
cagaacttat	tctttctatg	tagctataat	ttgtatcct	ttacaacttc	tctccctatc	191400
cctcccttcc	ccctactttt	cctagcttct	agtatcctct	gttctacttt	ttactttctat	191460
gaaatcaaat	ttttcagctt	ctgtatgtga	gtgagaacat	gcgggtgttt	gtaggaaatt	191520
tctgttctct	gcttattttc	cttaacacag	tgtcctccaa	gagcatccat	ccaggatttt	191580
attgcttttt	atggcttaat	agtatttcat	tgtgtatata	taccatattt	tctttgtcca	191640
ttcctttgtt	tttggatgcc	tggattgatt	ctataaactg	gctattgtga	atagtaactgc	191700
aaataaacatg	gtctgtagat	gtctctttga	tataatgatt	ttctttcctt	tggataaatt	191760
gctagttaatg	ggattgctca	atcataccat	agtaactatc	gtagtttttt	gaggaacctc	191820
cattotgtcc	tccatagtgg	ttgtactagt	ttacgttccc	accaacagt	tataagaatt	191880
cccttttctc	caaatccctg	ccagcatttg	ttattttttt	ttttttgtct	ctttgacaat	191940

agtcaccta	actggggtga	gatgatacct	cattgcagct	tcaattcaca	tcctcccgat	192000
gattagggat	gttgagcatt	ttttcatata	tttattggcc	atttgtatgt	gttcttttga	192060
gaaacgtctg	ttcagalcatt	tttccctactc	tttaattaga	ttgtttttac	tggtgagatg	192120
tttgagtcoc	ttatatatttc	tagatattaa	tctcttgcga	gatgagtagt	ttgcaaatat	192180
tttcttccat	tctgtagttt	gtatattcac	tctgttgatt	acttcccttg	ctgtacanaa	192240
gctatttggg	ttgatataat	cccatttctg	talitttgttt	gtgttaccta	tgtttttaag	192300
gtattattca	gaaaattttt	gccagacca	aggtccctgaa	gcatttcttc	tatgttttct	192360
tctagtaatt	ctattttttca	tgtcttaacat	ttagggtttt	galccatttt	gcaatgatat	192420
ttatataggg	tgagagacgg	gaatctagtt	taattcttct	gcataatgat	atccagtttt	192480
cccagcacca	ttcgttgagg	agactgtctc	ttacccactg	agtgttcttg	atatctttgt	192540
taaaaatcag	gtgggttgtag	atatgtggat	taatttctgg	gttctctatt	ctgttctatt	192600
gatctatgtg	tctgttttta	taccagtaac	atgctatttt	gtttactata	gctttgtlagt	192660
atactttgat	gtctggtagt	gtgataactc	cagctttgtt	ctttttgctt	aggattgctt	192720
tggctgtttg	gggtcttttg	tggtccata	taaatttttag	aatttttttt	tctatttctg	192780
tgaagaacgt	cattagtatt	ttgataggga	ttgcattgaa	tctataggtt	gctttgggca	192840
gcagatatct	ttccattttgt	ttatgtctct	ttccatttct	ttcatcagua	ttttgtagtt	192900
ttagtgtcag	aggtcttttca	cttcttgggt	tacatttatt	ctttggtatt	ttattgtttt	192960
cglagctatt	gtaaaatggga	ttgcttctct	gatttgcctt	tcagctagtt	cattgttcat	193020
gtatagaaat	actactgatt	tttgtatatt	gatctcgtat	tctgcaactt	tacagaattt	193080
gttatlagct	ctgagttttt	tggtagagtc	attagatttt	tctgtatata	aatcatgttc	193140
atctgcaaac	aggaacaatt	tgacttcttc	ctttcccaatt	tggatgtctc	ttatttcttt	193200
gtcttgccct	gttgccttggg	ctaggacttc	cattactgtg	ttgaataaga	atgttaagag	193260
tgggcacctc	tgtcttgttt	cagtctcttag	aggaaatgct	agtgtagctg	aggagagaaa	193320
tgaaaacaga	ataaaaactt	cagtagaagt	tggggagaaa	tgtgtttgca	ccaaaagagg	193380
tgggggatgg	aactgaggga	ggtctcgagg	ggtaagagag	gccaaagagc	tggcaggtgc	193440
tgcctattagg	atggcccaatg	atccagaagt	aatgatgaat	gagaagatgg	attaaaaaaa	193500
ccttgacatt	gttttaactag	aagaagaaga	cagtcagaga	gaagtgaggg	cttacttttc	193560
atgtttaaag	tctgtttatgt	ggtaaaaggga	ttagattttat	ctgtgtttgtt	ccagggggaca	193620
gaaataggac	aaatggatgc	aaatagagtg	aggaagattt	aaaacaaatg	gagaagacat	193680
tctaaaatca	actacaatga	gcgtaaaosa	tgacaacgga	aaggactatt	tttgcaatta	193740
tgtagctctt	gttctctata	gatagatgtg	taagcagacg	ctgaataaoc	atttactgaa	193800
aatataaata	aaaacaaagc	aaattgcagg	caataaatat	tgtattagtt	ctcattttgt	193860
aaaacttata	caggtatcat	atgcatagac	aaatacacca	aaotgatgaa	tatttgcctt	193920
gtataatctt	tttgtagttt	ttttatgaac	atatattact	caaacaattt	agaacatttg	193980
gcaatatata	tatatttcat	ttataaaagg	ttaggagat	taattacact	ttctgaggtc	194040
gcaactaaaa	gccaaagttt	taatccattt	ctattttagt	taaagtctgg	tcttttttca	194100
gcaaacacca	atcccacatt	ttaagggcct	taagaaaggg	atgggtagac	aaaatgtaga	194160
ggtagtaggt	acagaatata	aagtttcaag	aaattaaaag	cttctaact	aaacaaacag	194220
caatttgtgg	agtgtcactg	gaaagtgaac	aaggaggacag	ttaagttagt	tggaaactgaa	194280
ctgaggccag	acagggtctgt	gggacaagtc	aggggtgtgt	cattccggta	agcagcgatg	194340
cagaatcaag	acagagtagt	ttctcttctc	ctctctctct	tttaattgtaa	cgctttttat	194400
aacaaacaaa	tattatgctt	atttctgtct	ttaaattttt	tgtagtaatt	tctcatcaot	194460
taacctctat	tttttaaaaa	actaaacttt	ctcttgtttt	tctagttag	ctatcattca	194520
tatttaltat	gtggaactag	aggtagtctc	ggctacttgg	gaacagcgtg	gagtctagcc	194580
atgtcagggc	cagaagtctg	ctcagctaag	ttagaatgtg	ataccattgt	ttacacaagt	194640
gtggcctgcc	ttcaagatag	ggtgaggtgt	tttatgacca	caggctttat	gagttatagc	194700
tataaaacaa	tcaatctttt	aaagcaaaac	ceccacaatg	tctacacgca	aatgagaatt	194760
gtccttcagg	gctgtgacct	tgggaacctc	ttcacacata	ctagcataaa	acataattaa	194820
actcttcact	gaaaatatta	ttcagacctc	gtttctctct	cagtctctct	ctatgtttct	194880
ctctcacatg	taagtgcagt	cacgcacacg	tgtgcacaca	cacatatgct	cacatcattt	194940
taagatacat	ctcattttta	accaaaaacca	ttttatcttg	cttgataacc	aattttattt	195000
gttagatgac	ttggctataa	atgccttttg	ctatcaggaa	aatcaaatca	aaattaaaag	195060
acactgttac	tactgaagaa	gtaaaaaaag	aatgggctgc	tgactctgaa	gatcataccc	195120
gaagttagagc	tgcasagata	tttgggaatct	tggtaatatc	caataaagaa	tgaccttcat	195180
gctattttga	ggagatgttt	aaatgtcgaa	ttattgaaat	atttataaaa	tacaaaataa	195240
ctaactctgc	ttcatattcc	aaactgtgta	tgacacttct	taggctatca	tttcattcca	195300
aatttatggg	cactacccca	ctgtcattcc	tcataactaac	catatgatca	acagttgaaa	195360
agcagccact	cgcagaggtc	agcaagatac	atggtaataa	ctgtgttgac	aaaagtatgc	195420
agaagcagct	acatttatac	agtagtgaaag	gaattgttaa	ttggacaaac	tttttgggaag	195480
ataagttgag	aatgtcaaaa	atcasaacac	actttctgtt	ttattcagca	attatgagcc	195540
ctttgtttta	cagctatgct	cacaaaatata	tacaaacatg	tatgcacaat	tatgttcaot	195600

gtggtattgc	gctagaaaaa	tactaaaaac	aaaccaaagt	ttcatcaata	gggaaattgt	195660
tcaacaaatt	acagtatatc	taaaaaaaga	ataatatata	acaactgaaa	aaatnaaata	195720
gttgatataa	gcagatatto	caagatctgc	cagacatatt	gttaaacgaa	aaatclagat	195780
acaaaattgt	ttatagttct	ctttcalact	atagccaaag	aaatttcaga	aaaaactact	195840
tacagttgat	ccttgaataa	tgcagcaggt	aggggcacca	gcttcctgcg	cagtcraagaa	195900
ttgcataata	cttttgactc	ccccaaaact	ttgclaatag	cctactgttg	actggaagcc	195960
ttatcaacaa	catcaacagt	tgattaacac	tggaaaaagga	ggggttggtc	ttactgtctc	196020
aaggggtggc	aaggcggaag	aaaagccacc	tataagtga	cccttgaagt	tccaacctat	196080
gtttttccag	ggcaatcata	catccatgtc	cataktcatg	atgaatatgt	gaaagggtag	196140
ataagaaaat	gtgatagtgc	tttccctctg	agaataaaat	gagaggtcta	tcataaggtga	196200
gaaaataaatt	ttttattata	tattcttttg	taggtttatt	tttttctcat	gtgtatgtat	196260
tcttttcaaa	ataataaaaa	caataacaac	gattaaaata	tacaagggga	aatgcatttg	196320
ccaaggttta	gttgagagca	aagtllgctt	atctttcgaa	agaggtgaac	taagcttttc	196380
ctttttctct	llgggtatct	ttgaatgggg	atggagtga	tggattcttt	tttttttttt	196440
tttttttllga	gacggagtct	cgctcgccca	ggccgactgc	agtggcgcta	tctcggtcca	196500
ctgcacaaact	cgccctccgga	gttcaacgcca	ttctcctgcc	tcagccctccc	gagtagctgg	196560
gactacaggc	gcccgcact	gcacccgggt	aattttttgt	attttttagta	gagacggggt	196620
ttcaccalgt	tagccaggat	ggcctggatc	tectgacctc	gtgatcagcc	cgccctcggtc	196680
tcccaaagtg	ctgggattac	aggcgtgaga	agtgaagtga	ttctaaggag	tatcgagaac	196740
agtgaattaa	acagaagggt	gggaggtgct	ataagcttat	ttgtagggtga	agtatttaaga	196800
ctagaagaat	gcatttatgc	atcaaatctt	ttacatttgt	tgatctcttt	tacctaaaaa	196860
caaaaacaaga	tacttttttg	ttgtttgaca	tatgaccaat	tagcagccag	ttggagctaa	196920
atgttttctt	ttttottttt	cttttctttt	tttagatgta	gtgtcaactct	gtcgcccagg	196980
ctggagtga	gtggcgtgat	ctcggtctac	tgaacctct	gctacccagg	ttcaagcgat	197040
tctcctgct	cagccctcca	aggagctggg	attgcaggca	cctgccacca	cgccagcta	197100
atttttlgtag	ttttggtaga	gatggtgttt	caccattttg	gccaggctgg	tcttaaaact	197160
ctgaccttgt	gatccacctg	ccttcgcctc	ccaaagtgtc	ggtattacag	gcattgagcca	197220
ctgtgccag	cctaaatgtt	ttcttttaaa	gcaaggttaag	tatgcctaga	tgcactgcct	197280
cttagtaatt	tttgaggatg	gattattcat	taaatltgctt	ccctttctca	cagctggtga	197340
attagaacga	tagtgagctt	acaagagctt	taacgaggaa	aagatggltca	ttgttttaaca	197400
gagaaggatg	gtttgggtga	gcatttttgt	gtttttggag	gggaactttg	agggcaatga	197460
gtgttgacac	tgtgtccact	gaggatctct	ggggggggta	aaaggsaggc	agggatgaga	197520
gtgaggaagg	gagacaggag	ggtcccaaat	acgaactttg	acttaacgag	gatgattact	197580
agaagggaag	gattgtggat	tcaattgatga	gatgttgaa	catgaaaact	ctaatttgtag	197640
aactcacttc	agactgaatt	gactttggctt	tcagttagcag	aagccctttg	tctacttctc	197700
tagtattgaa	gtgaatgcaa	atttctcaat	gtaagaaaag	tagagtgggtg	aaataagagt	197760
gtgggttcca	gggtcagaca	actgggtgca	taaaaagggt	aaggatgcta	caactggtaa	197820
gccclgtgag	aattatttaa	tcttccatg	tctcattccg	ctcatctgga	aaatgatgat	197880
catactaaat	tatgagatgt	gtgtacagac	tagatataat	attaaaacat	ttctgalacc	197940
tatgcattat	attggatcaa	tatatatttg	caataaatga	tcaacttttt	attaatgaag	198000
ttagtactta	tttcataaac	agattgttita	cttctaatatt	actagtattg	toattattac	198060
tgttgcgtgt	atacgcctac	tgtctgttgc	actaaactct	tatgaaglac	ctaatatgct	198120
ctaagccttg	ctctaggtgt	tgtatatgaa	gtattttctaa	acctgaaaac	tatctaagat	198180
ggctcagtot	agoccatttt	atagacgaag	actgaagcca	agagagttga	aataatgagt	198240
aaagtgtgaga	tttgactttg	tcttccaaac	aactagaagc	ataaagcaat	ggaccaggtt	198300
ccaaagtggac	agggaggggc	attagtttg	cccataggtc	gcagagootg	tgaccacaga	198360
gccctatata	ttccagtgtt	gaattatgtt	tgggaatgtg	gcagaccata	tggctatggc	198420
atcgttagac	atgaggtgga	gagaggcaga	tgtgtggtta	ctcgattgag	ttgagngatg	198480
ccatggaaaag	gaggaagaag	agcctgagag	agcaacttca	ctcatgggga	gagaagctta	198540
tgtggagata	agcttcactt	cactaatggg	gagataagct	tcacttatgg	ggagacaagt	198600
aaggaagcag	ggatctccag	aggatgtgga	gtatgocctg	tacttttcat	gtttottttc	198660
cttattctctc	tttattctct	tcattatttt	acctaggtta	gatgttaaac	acttctgtt	198720
gtttagtcag	gcttcccttt	ctaattatna	gactaaacac	taagatttca	tttgtagata	198780
taattattag	agaattttga	taaaatttcc	aagcagttgt	ccctctgttt	atcatcgtgt	198840
tccctgctgt	tattagttca	cagtttggct	tggaaattact	ccagttaatc	ttgggggttc	198900
aggagagaaa	ttgtgctcag	ggtacatgag	aagagaaagt	ttagaaagcg	aagggcttcc	198960
ctgtctagtt	tctagctcag	aaaagcaaag	atatttctact	ttcatatgta	tgataattgg	199020
agctgagctg	actttaaaaa	cagataaatt	ttotttttta	tccctaataa	ataatgggtgc	199080
ttacagcaat	gagtgttgct	ggtaacagat	tccaccaatg	ggtgtggtgt	gaagtttagc	199140
atttgtggat	tttgagctt	ctgctattgt	ctacagcatt	tcctctcttg	tctcgagggt	199200
tcataacttc	tcaggcaagg	acacttttaa	ctccagataa	atgtctgggt	tttctcactc	199260

caaggataag	aagggtggggg	tgatggagtg	gtgggtggtag	ttgtggagtt	gtcttccttg	199320
cagggatttc	atttgtggggg	aaagtctgtc	tttagaaaag	aaatgtaaac	tgggcaagta	199380
gtctcatcag	ttaaatgatt	tccttgttga	cataagggtga	ggaaaagaag	aacaactttt	199440
gggaaaagta	actgtgagaa	tacaagggaa	gaagaaaaat	aaggggttga	acattgagga	199500
agacttatga	gacagataaa	gtataaaggc	aggtaatattg	ttctttcaat	ttggcatggg	199560
gacagtaaaa	attttttctt	actaaacaaa	taaagcccat	gtatttcttc	tgctctggga	199620
gcaccaatta	tattgagcct	claaataaag	aaagtcaaca	tccacaagtg	ttctaaattc	199680
catctcgtag	tgagagtcct	gaaaattgca	atagctagag	lcaataacttg	gagtatatgc	199740
ataagacgtg	gtgtctcaaa	laggatlaag	gcctactctt	ggcatcttct	gttaltgggtg	199800
ttgtttctct	gtattgattg	gtataacgtt	agacaaaact	gcagggtcatc	tttgagaaaa	199860
actcagtata	aacaatgaaa	aaaatgtgtg	gctgcacatg	taattttgcat	gtaacaaaaac	199920
caaaggatgc	tttagatagt	aacagcagcc	tgtactttac	tccaacccat	tagttttatg	199980
ataaatgtgg	tctgggggaag	tgctcgatct	aggttggttca	cttctgtgtt	ttgtttcttt	200040
ctalcattcg	ggtgttgagt	caactgtttg	tctgttgtcag	tgtcagagca	ctgggtcaca	200100
tcttcgaltg	tccaggtttt	attgggtccct	ttcttaaat	aaagctgatt	ttccacttaa	200160
agagaattct	gtctccttct	gcaattgttc	aaagtctagc	alcctcaagt	cagactctaa	200220
actgtatgta	tatgtattgt	gcaggctatc	tatcttctta	gctttgaatt	ctctagaagt	200280
attccagagg	tgtgatttcc	ctgttattca	agagtgtatt	ccaaattgcc	tcagccaatg	200340
tgccctgcaca	agttgtttgt	aaactcagggt	gtaatgggaa	atgctttaga	gccacatttg	200400
tggtttttga	tgggaaaaaa	aaaaaatcag	tgtcctccta	agacttatac	agtccttgaa	200460
gccttttagg	ctatttctgc	atctcatgtt	gcattccatac	ggactattta	gccatattca	200520
acaccatcct	cttgcatttt	tgttaagatt	tgaactgtgt	tgttgttgtt	tttaaatata	200580
aatgtgtgat	cacatgcaca	tacacagaca	atgatgtgtg	actcataaac	atgaaaagta	200640
aaaatttgaa	ttttaactga	agaaaaatca	gcattattca	taaaaagctg	gtaagatatt	200700
ctaaaagtg	aaattcatgc	agaaaattga	ttcttaagca	cttactaaat	gccagggaata	200760
ttttaaccage	atatttatcat	ttaattttta	aaacaagttt	agagatagag	atgtcttatt	200820
ttatagaaga	ggcaactggg	gttctgaant	gtgaaataac	ttgcaaaggo	tatggttaag	200880
ggcagggcca	gncacgtgtc	tagtgtctct	gacacctgag	alcacacact	gtatgctggg	200940
cttcaalttaa	tttgcagcta	cttgttgcat	taaattcaca	atccttgctt	tcattcataat	201000
aaaaacaata	ataatcatc	aacacaacta	ttttcagtg	gctctggcta	aggccatttg	201060
attcagagtc	aaaaccttct	atttgtatag	tatttttat	tgtcaaaatc	taataaggat	201120
agttttcata	tctgacgtaa	accagtctga	tctgtctcca	tttgatata	tgacatatca	201180
aattgttack	ttcatatctc	ttagtcaacc	tctatgttta	tcattctcta	tgtttttagaa	201240
agtaagaagt	ttaaatttac	ttcagaaaga	tttcttcttc	ataaacataa	aatgattaga	201300
tgctcccttt	aaaggcaaca	gcttcttctt	tttctttttt	cttttctttt	tttttttttt	201360
tttttttgag	aaggagtctg	gctctgcgcg	ccaggctgga	gtgcagtggc	gccatctcga	201420
ctcactgcaa	gctccacctc	ccgggtttta	gccattctcc	tgctcagcc	tcccagagta	201480
ctgggactgc	aggcgctgc	caatcgcct	ggctaatttt	tcgtaltttt	agtagagacg	201540
gcgtttcacc	gtgttgctg	ggatggtctg	gatctcctga	cctcgtgatc	gcgccgcctt	201600
ggcctoccaa	agtgctggga	taacaggcgt	gagccaccgc	gcccggccaa	ggcaacagtt	201660
tcttaattgag	agagtagna	tgagaattca	catttcataac	aaagagttta	ttgtctttcc	201720
tagtatactg	tactatctag	tagctaattct	gtctaaagac	atgtttctta	tctalttaata	201780
gtcctattna	taatgtaaa	tagctttaga	tatgccaaagc	tgttactggc	tggggeacta	201840
aaaaagcttc	cagagttata	tctagaaagt	ctttgggggt	tcttaattgt	atgtgattag	201900
caactaaaac	tgtgacagga	aggaaagtcca	catgaattga	gcattctacta	gtttcaagat	201960
ttatcattat	gcscattact	tataataact	ttgtgaagct	gatattaack	ttacaatgga	202020
taaaaagata	gatgaattag	taattttacct	ccagtggtgc	agacagcagg	atttgaattt	202080
agtctgtcca	acaccaaaag	ctccgtactt	ttcatttccc	tgcatccatc	tagtttbaaa	202140
aataaattga	ctaggcatag	tggtttgcac	ctgcaatccc	agctgcttgg	gaggttgagg	202200
ccagaggatc	acttgagccc	agaaagtcaa	ggctgcagtg	agtlatgagc	acacaactgc	202260
actccagcct	gggtgataga	cagaccccat	ctcaaaaaaa	aaaaaaataa	aaaaaaaaga	202320
gagagagaaa	ataaaagaaa	aatcgaatgt	attgcatttc	atgtctggac	cacctgtatg	202380
agaaaattgg	gcactttctc	tctgaagtaa	ctcatactaa	aaacaaacac	cttcttccctc	202440
ccaggagcct	cccaagggtg	aagagayyaa	ccctgaagct	ctaatatgcc	taagatgctc	202500
tctggtgtta	tcttaaaatca	aaatatatca	cctagagcac	ttattttatt	atttatttat	202560
ttttgagatg	gagtctagct	ctatcaccca	ggctggagtg	caatggcatg	atctcggtc	202620
actgcaacct	ccgctctcca	ggttcaagcc	attctcctgc	ctcagcctct	gggattatag	202680
gtgcacgcca	ccatggccgg	ctaatttttt	tatttttagt	agagatgggg	tttccaccatg	202740
tgggtcaggc	tggtctcgaa	ctcctgacct	cgtgactccgc	ccaccttggc	ctcctgaagt	202800
gctgggaatta	agggcgtgag	ccaccacgcc	cggcagagac	actttttttt	cttaattttt	202860
tatgatggaa	aatttcaagc	atacattaa	tagagaaaat	agtataatga	acaactgaat	202920

acttaaatct	ggcttcaata	atttctaart	ttatgttctg	tctaagtgtg	acataaagta	202980
tagtttgrat	gtatttggtg	gtgagtagat	aatggggcac	atgattltta	cclttttaggc	203040
tgtagtctta	catcagtalat	agatgggtgt	ttttttcttct	caatataaaa	tctaaagcgt	203100
tgtcggcagt	gacattttta	aaaacacat	atgagacgca	acaataaatc	agttattaaa	203160
ataagataaa	gtaggtatlat	aaatattttca	ccttgggaat	aaagcaaagt	cagtggaaaga	203220
gtgtgaagac	tgtgaagatt	aggagcatga	aaataaacga	ctattgggag	ccattctatt	203280
cccatgagtg	aatgtgtatt	ggttccattc	aatgtaggga	agagcagtaa	aagggaataa	203340
ccataaggat	aagaccactg	gattatctga	gagccacagt	tgtcctlttg	cacatggagc	203400
atctgcccta	ggtattacag	ctctgtgaga	aacagagggt	caaggaaaga	aatttgttat	203460
ttttcaatta	tctgcataaaa	ttctttggaa	cagggggcatg	gattataaaa	gatgtaagat	203520
aataaaaaagc	atttgtatttt	gactttggaa	tgtattgtac	ttacatttgt	ctagaggtgt	203580
gtctattctg	gctattctct	ttaaaggagc	catctatctg	tgaacagatc	ctgttggagc	203640
tgttttcttg	ttctaccaac	cttcagccac	ctctctgtct	ttcatattac	ttattggcag	203700
ggtttcaaaa	ggtttttagtc	cttacttaat	ataaacaaaa	atgtacaata	ttgacaaagt	203760
ttcagtttaag	cagatgaast	tctaagagtt	aagctgggat	tttccaaaat	aatcctgtta	203820
acagacttga	aagcacttat	cagttctgtc	taatgaagac	attagaacac	cataaccttt	203880
ccggcccaatt	ttctttgtca	ataagcgttc	ttgccctgtc	agcagctcac	ctccagcttt	203940
agttttctca	tgacagtaag	tctattaccc	tcttgatctg	tcttctggct	cctcctaccc	204000
aggatgggga	aggtttttga	ctttactgat	attctcagaa	caaatttttg	gaagtaata	204060
taaggttttc	oagtcgggtg	cagtggctca	cgccatgat	cccagcgtt	tgggaacca	204120
agggtgggtg	atcacctgag	gtcaggagtt	tggagaccagc	ttggccaata	aggtgaaacc	204180
ccatctctac	aaaaattagt	tgggcgtggt	ggggccacct	gtaaatccag	ctactcagga	204240
ggctgaggca	agaggattgc	ttgaatctgg	gagccggagg	ttgaagtga	ctgagattgg	204300
gccactgcat	tctagcctgg	gcgacaagag	tgaagctcca	tctcaaaaaa	aaaaaaaag	204360
atgaggtttt	ccttaagagc	actaacctag	tatactgcac	aggtgcctgt	attcatgcat	204420
cccacacaga	aagagaaaaat	acttgtctga	acttgtccat	aaatlccagaa	tcctgcccc	204480
taacttqtat	gccagggtttc	tggcatactc	tlatctgaaa	actcactcta	ttagaaaagc	204540
aaagcacagt	gattttccca	tcctgattac	ctggcactgt	tttttatttc	agltgcttctg	204600
tttctttgccc	atgtaaatgc	ctgtgatttg	ccaggctcatt	tgctctgatt	ttagttgaaa	204660
cagtgcagtc	atcatacttg	cagaatgata	caaaaataa	taaaatatat	tgcctttgta	204720
ctaaacagaa	gtgcctctct	gttggtgaaa	taatacatat	aaacaaaaat	aateattagt	204780
gatacttatt	gtgtgttcac	tatctactag	cactgtattg	agtgttttac	ctgcattgct	204840
tcattttctc	ctcacaaat	ccctattagg	taoattcagt	tataattccc	attttacaga	204900
tgggggcatt	gaggcttgat	gaggttagtt	aacctgcttc	atggtagtta	aagcagagct	204960
tggatttgag	cacagcatga	atgactccag	aacttacaca	cacacaccca	ctcacacaca	205020
tgc aaagaga	gagagagaga	gagagagaca	actgctgaac	atagacccaa	ggcaaaatat	205080
ccttgagtag	aggaacagtg	tgagagtga	gctgtagtgc	tggttggggt	taatcaggat	205140
gggtcactg	ggcaagacca	ggttgtgggg	ggcaaaggag	atggaaaatt	gtgtgaagag	205200
aagaagggtg	gactaggtag	ataaaggtag	tggactaggt	aaataaagggt	ggtaatccag	205260
acatecaatt	taggcttcaa	atcactttag	gagaagtgtg	ggctatttgc	tttgcccttt	205320
agtagcaaca	gtcttattat	acaatttaat	aagattotat	ccaatacact	gttttaagggt	205380
ctccatctct	cgggattaga	gctgagttct	aacttccctt	tccaatgata	atgatctgag	205440
aaatttccct	catgtttgac	tttttttttc	tgaagacttg	acatttgatgg	aaagaagtga	205500
aaaccaccta	tgcttttgat	tttggtagct	aatattaatt	gtcatgtatt	actaatagtg	205560
aatctgcatt	tttaaaagct	tgttggaaag	cacattaggt	gtgtatatata	aggtattaac	205620
cttgaaagta	tgaacgtgtt	ttctataaatt	agtcctatga	taatttataa	tttaacavgt	205680
gcttgacaca	tttgataaag	gctttgtcta	ctatgggttt	atttatgggt	gttaatttaag	205740
taggagcagc	agcatactac	ttgaaagtat	gaagggtgtcc	tctatagtta	gtcctatgat	205800
aatttataat	ttaacaggta	cttgacacat	ttgataaagg	ctttgtctac	latggtttta	205860
ttggaataga	caacttatct	tttcttaang	tatattttac	cttgggtacca	ggaacttga	205920
gaccnaaggta	aatgtataat	ctttataaaa	tgcctaataa	ggaactgtca	tatatagtta	205980
tatttaggggt	tgaattalat	tttgaattat	attctagaat	ataaaaacta	ctatatttta	206040
caattacttt	accaagctct	ctaatsatac	ctgtttacct	ttaaaatctt	ggtctttccc	206100
acagaggaca	agttattata	tttttaattg	ttaagccttc	tgaatcatatg	aattcttttc	206160
atatttcatt	gaaattatat	aaaacatttt	acttcaaagg	aaaaatgltta	tgaattttata	206220
atgcttttag	aattttaaaaa	tctgtttctc	attttgttga	ttaaagacaga	gaagcatttg	206280
ttgtgaataa	atagcatgct	atgttgaaaa	gaaaatttaag	gatcctgatg	tttctctgcc	206340
agataggaca	aaaactaagg	acgccacagg	aatttttcaa	cattttttaac	ctcttgacaa	206400
tatgtgggtc	gtataaagga	caaatgaetg	tttggatgga	ctgagaatgc	caatttttaac	206460
agattgtcca	atcactgtag	ataaatattt	gtgttctctg	ggatttatctg	attattatca	206520
agcaaatgga	attggaacaa	tagcatgtat	taagtcatta	ctacttatltg	tctagttctt	206580

tttctcatag	aagtgtctat	gtactagaag	agcactaagt	catcagttag	acatgatctt	206640
tatcatatcc	agacaaaaat	aaaaaccttl	taagaagcla	ctttacaaga	caactgcata	206700
gctttcttca	caggaaacttg	ttaaataaat	aatgattatt	aaagcaattg	ggtcagtcctc	206760
ttacactaat	ttaacaagag	cagttccaag	atgtctagcc	catcccat	tccgtgtgac	206820
taaccatggt	atccagagct	tggaaaatat	ccaggcaacc	cacagtagct	ttctttaaat	206880
gcattatggn	cactggaatg	taaggaaaagt	gatagaacta	ggtagacaag	aagagagtcct	206940
ttaaggcata	ccatttgtca	gtgtcgtaa	tggcctcaat	tgtatgttga	acattgttca	207000
aaagtaccca	tggctgaaac	agtgtagatt	tagctccat	ctgtattgaa	gttgataaat	207060
gcataaatct	taatcattga	catggaggtt	tattgtattc	aatgagacag	atatacttgg	207120
agttttccac	aaaccaccaa	taagagtcta	ttgtgaattg	gaatgattag	cttttaaaaga	207180
tglatacatg	ttaaccaccc	ttttatatta	agttggtgca	caagraattg	tgctttcaac	207240
ggcaaaaacc	acaattactt	gtgcaccaac	ctaataotta	cagttatgcc	aagatagggg	207300
tagaagcaga	aggaaaattt	agagtgagaa	gatagagaca	agagataggg	aggacaggaa	207360
ttgagtcaaa	caaagattct	ggaaagtctg	tgattaattc	tgtgggtgtt	aattaagtag	207420
gagcagcaga	tattataaaa	ctcaatatac	aagtggcaca	gttcagggaag	agccaaggag	207480
gagaccagtt	gatattctag	gtccatgttt	cttgtaagca	aagtttgga	accagaactt	207540
tggatctgtt	tcaagagccc	aaggtaagag	gctttagaat	aaagtctaac	ccaggccaag	207600
aatctgggta	acagaaccag	ggatctocta	gggcactagc	actaactggt	ggccaaggca	207660
agtacttcta	catctctgc	tttgagtcga	aactlgtgaa	aatttttaga	aggcctgagc	207720
ccacagattt	atcttttcat	caattcatat	ttattaggca	cctatatgtg	ccaggccactg	207780
tatttaggagc	atggactatt	ggtgatctca	atggacatac	tatccgtttt	tataaaggag	207840
atgtatcgtg	gaccagtaaa	taaagaagtg	aacaaatagc	actagaagga	aataaaaagg	207900
gcaataaatc	agataatcta	ggggagggtg	ttttagatag	aatgatcagg	gaaagcctat	207960
ccaaaggaag	gatgttttgag	aatgagaatt	aagtttgaga	atgagcagat	acatgaggag	208020
ctggaaggag	gacactccaa	agtctaggcc	aagltggaaa	gcttggaggg	gagaaaggcc	208080
ttggcatgtt	caaggcttgg	aaggaaagtgg	atcttagacgc	tagcaagcag	aaaagagagg	208140
gtgtgacttg	gggcataagag	aaattggtaa	gagccagatc	bagcagltgg	aggggaaaaag	208200
ccacttagct	agagtaaggg	atggaccaag	tactctgtag	aacagatatg	aaattaltea	208260
gtgtttttat	agotgtaaac	tggaaaaatag	attcacggga	cttaaaaattc	tccctaagta	208320
ctccatgcat	tgtgaagggt	ttactaatga	aatcttctta	gagatggaaa	gagtaggcag	208380
accattagtg	ctagatcatg	gtggtcatat	tagttctggg	gagtcagggg	ttaaaaaaag	208440
tagcttcagg	gcaaagcatt	gcagttcaag	agagtggtgg	taatagccag	agagttttgc	208500
ctttggatga	tgaaaactgg	tggcaaatga	cagtgaggca	gggtagttag	gcaoccaggg	208560
tgggctgggt	tgaaacagag	cataatgtga	gtgaacctgg	gatgcacatg	aataataaga	208620
tgggaagaac	ataaaagcatc	atccttctta	ggatttccct	tcttccacag	agtcagctaa	208680
gttatagggt	ccctgaggag	gtcttccaaa	tggttaaacag	tatattatgc	tcttcttttg	208740
aatttttagt	ttgaaaattt	gttaaatagcc	aaacaatagt	aatgatatcc	ttaccactct	208800
ttggattgaa	tgatgtcccc	caccaaacca	aaacatcagt	taagtcctaa	tccccagtag	208860
ctcagaatgt	ggtcttattt	ggaaacagag	tattctcaga	tgacattagt	taaatgaga	208920
tgaggctcata	ctgggacatg	atgggacatt	tatccaacac	gactggtgtc	tttacaagaa	208980
gaggaaattt	gaacacagtg	ggaaagatgg	tgtataaaga	tacaaagatg	gctgcagtg	209040
gtcatggtca	tgtacttgca	ctccagactg	gagcagagag	tgagaatttg	tctcaaaagg	209100
aaagaaaaag	aaasaaagc	taggcatagt	ggttcctgcn	tgtaaacctc	gcaactttgg	209160
aggttaaagt	tggaggatca	cttgagctta	ggagtttgag	acaagcatgg	gcaacatagc	209220
aagaccctgt	cttcgcaaaa	aataaaaacta	gccaggtgtl	gtggtgcatg	cctgtagtcc	209280
cagctactga	ggtggctgag	gtgggaggat	tgcctaagcc	cagcaggtca	aggttgagct	209340
gaccagtgat	ctcaccactg	caatccagcc	tgggcaaaaag	agcaagacc	tgtcaaaaaa	209400
agaagaaag	tagaaaagaa	gaaagagaaa	aagaaaacaa	aaagaaaaaa	gacagataca	209460
gagctgcaga	aggagaatat	tatgtgaaga	aggagacaaa	gattgaagtg	atatatctat	209520
tatcaaggaa	atgcttagggc	atgatgcctg	tcatacaag	ctgggagatg	gcattggaaca	209580
gattcttctc	tagggccttc	osaaggaaacc	accactgcc	caccttgacc	tcagaatttt	209640
agcctccaga	actgtgatat	aataaatttc	tgtttaaagc	cacctcagtg	gtggtactca	209700
ttagggcagc	cgtagaaaag	gaaaaactacc	ccttcccat	cctcttgtcg	tattcttttc	209760
caccgttttg	tctcacacac	tacaatcgat	gaaaaccaaa	ttgctttttc	taccacttgt	209820
actctttcaa	cccagaatatg	cctcctcttt	tttttttttt	tttttttttg	tctccaggga	209880
cctattttta	aataagaaaa	aagtttttta	gcatagtacc	tgatagtttt	ttaatcttca	209940
ccacacccca	cccttcccc	ataacttttt	tgattgatta	tgaatatatt	caagcaaaaa	210000
cagaaaataa	tatgacagta	ttcttctaaa	atctacattc	atcagattac	aattttttgc	210060
catatttgct	tcaaatcact	ccttttcacc	ctaaaaagaa	aattattactg	agagagagaa	210120
agtctcctct	cttcataact	tcttccactt	cactgttegc	atccttaatt	tttattttat	210180
tatttttcat	ttttttttta	gagacagggt	ctctttttgt	tgtccaggct	agagtgagct	210240

ggcacaatca	tagctcactg	cagcctcaaa	ctccttgget	caagcaatcc	tcattgtctca	210300
gcctcctgag	tagctgggac	tacaggtaca	tgccaccatg	ccccactcca	attcttattt	210360
atlttttaag	tggcatcact	ttgttagtaa	agccttccca	ttatcactca	gatttactta	210420
actctatcac	ctattcccac	aataktttat	acacaaatta	tattacagga	atgatcatat	210480
tgtatlttta	ttgtagtcac	tttttctcta	taagaaaaaa	atgacttggt	catttttast	210540
catctagtgc	ctatgcaata	tctaactctg	gglttaaaactg	aatttttaata	taatagtgtt	210600
facatcgaa	cgtttgacct	tcaaaagagc	cctaagagtc	aggactagaa	ttgtcattct	210660
ttattccaga	aatggcaact	ttatgaattt	tacgtgttta	atgttggtcga	ttattgtttg	210720
tcactggttg	tgaagtttac	ttccttgccc	tctctgatgtt	gggcttgggc	gtgtggtttg	210780
cttaggccag	tggaaaggcag	gtggaaagtga	caacatgtca	gttccaaact	gaggctgtaa	210840
gaagtctaca	tatttctgct	ttcttctttg	tgcttctgac	attcaocgtg	aaacatttcc	210900
ctgagtagct	gttggtccca	gaatgaagag	acagatggag	ccaacctgaa	cccaacttga	210960
aggctgaatg	ccaacaaaca	tagcaggatc	acagcaaacc	tgaagtgaat	gctcgtgat	211020
gtcagttacc	aagatttggt	gtggtggtta	cccagcatta	gcatagttga	aacctcactc	211080
atacacctag	atggttgata	ataaaggcag	aactagaata	oacgttatct	gatttagcaat	211140
atagtgtctt	tttactaaat	tattctgtta	ttcatctgca	cattcaacaa	gtatttcaatc	211200
atatattttac	tgtagaaaa	agcacatcat	taaacagaca	gactgtggtc	tctgccccca	211260
aggagaatat	gtttctagt	agggaagag	atacaaattc	ataaatctaa	actatagaaa	211320
atggcaaaact	ctatagcaca	aatgtctttt	gagagagaat	aatgggtgag	gggaaggaa	211380
ggagatgaat	acctttaagg	tggcagggtg	agagctcttt	gagagactgc	aaagcagaga	211440
agatgtctca	agaaaaagaa	gtcacacattt	ctctccctgg	aatgggtctca	gtggtctcag	211500
ataatgggtt	cagttttcca	tattccttta	tttatgtagt	gtcaggccaa	cagtgtactt	211560
tagctccagg	ctaaccagtt	gtccttggtt	tgcatccctg	gtattcagaa	agctattgga	211620
ttgttttgtta	agttcttaaa	gaaggactga	aaaaggcttc	attttccctt	tttccaaagg	211680
gagcaattac	atactgtcac	tggaaataata	aacttaagtc	ctaggolgcg	aatgaaattt	211740
gatttctctc	aggtagagag	tatttttgtat	atggaaagct	aaggaaagaa	atgcaatggt	211800
tttttttttt	tttttttttt	ttagcaatcc	agtagggaa	tgtggccagc	attgagctga	211860
taaagacctt	tgttttccat	gttttgattg	gccaglgag	aagocctcag	cagtttgcac	211920
acccatctgt	gtccatactg	gtggggcaga	aaagtgtctga	cacaggattg	cagattagcc	211980
cctgcagctt	gocagggtaa	acttgtgtaa	tgcactgtac	accacttcta	acaacagctg	212040
tctttttgtc	acttaaacag	aggttatttaa	gaatatgagt	cattaaaaag	agcttttagaa	212100
aagcaggcaa	cattttccaa	tacagtggct	ttaggggatc	tttgaaagt	atcagaagtt	212160
cgggaagaag	taaagcatct	cattataaac	taacaataga	cacagaatca	aaatctgaat	212220
tgtgaaaaa	aagtaatat	taaatgttaa	tttttgaaatg	ttgaaaagag	ccattttttg	212280
tagagaattg	gatgaggatt	aacttagata	ttttcttgaa	tglgtataaa	tattacatat	212340
aagaatactt	tcaagtcctta	aattggcccg	gggatctcca	gcttgctgat	aaaaacaaat	212400
caaagaaaact	accttttagga	cttctttttc	ttattttttga	aacattaaaa	agttgcaagt	212460
gocggaataa	tggggaaaaa	gtctttatlc	tattlatccag	acaaaaagct	ggtcaacatt	212520
ttaatgctgt	ttctgctggc	atttttctct	acaaatactt	tctatgtagt	taagatcata	212580
tggatatatg	aatcttggtt	cattcatatt	ctttcacttt	tgttatttct	tattcagtg	212640
ttggaaaaact	atggtttata	ggcaaaatct	ggactactgc	tacacgttga	acacagccac	212700
atgcatctat	tgtatgactg	tgtatgactg	ctgtctctgt	accataatag	aattgagggc	212760
ggctacagag	cttaagtgc	tcacaaagcc	tgaatatatt	gctctctgga	ccrttataga	212820
aacagttttc	cagtttgtga	gatagattat	tagagtcata	tgaacacaat	agaattttac	212880
aaaaatatac	caaaagttta	tacagccatt	gatactttaa	ctagcattgt	ctgatgaaac	212940
tgtttttattg	cctataacaa	tatatatggt	aaatatatat	ggttatgcat	atataaccat	213000
atatatgtaa	tagccagcta	tatatatata	tgtataatlt	tatatgtata	cagtttttga	213060
ttttaataga	catagaatgt	tagtgtatct	ctttttttgt	ttaatattta	tttcttttgg	213120
tagcagtttag	acaaaatgat	tttccatttt	tttagttctt	taattttctt	tatcttcaac	213180
tgccttctta	tgacgtttgc	ccctttttta	atagaggggt	tttttaaaaa	taaattttga	213240
agggctctat	atagatggg	aataccaact	cttattgttt	ttactttgac	tatttttct	213300
cagtttttta	atcctttta	ttgagagatt	tttttgaaac	ttgaaagttg	tttaatcagt	213360
gtaaaaatttc	ctctgtgatt	cttttccaag	ctccaatata	tcattgctgag	gaagtatctt	213420
atcattttta	atltttttaa	aatttataag	gattgatatt	ttatgaaagg	cctotttgagt	213480
gtctattttt	aaaaacatac	tttgttctta	gaatagtttt	ggacttacag	aaaaattgag	213540
aagatagtac	aaagggttct	cataaaactcc	acagtgtatt	ttccctgtca	ttaacatcat	213600
tcattagcat	tttgtcatta	gtatctttca	ttagtattgt	atgttcgtta	caatcaatta	213660
actaagattg	atgcattgtc	attacctaaa	gtccatattt	tattagaatt	gtttaagttt	213720
ttacctaatc	tactttttgt	tctggtatct	tgtcctagat	accaccattc	aaccattcat	213780
ttagttgtta	tgtctcctta	tgtttttctt	ggcttggtat	atttttctcat	agtttttttg	213840
tttttgatga	ccttgacaat	tttaaggagt	attgactagg	cattttgtaa	aactccttcc	213900

tattagaatt	ggcactgtg	agcagtcac	atttttagga	taggaagttt	tatttcccca	213960
tcttgagggt	gaagltgtt	cataaacttt	tggggattct	tctgcattgg	agattttttc	214020
tacttctcct	tttattttatt	tattcagtc	tttagtatga	gctcatagat	attaattttta	214080
tactttgggt	tataatctaa	tactttttta	ttatttttgt	gcttacatac	ttctagattt	214140
ggccactggg	agctctttca	gttgacttcc	gtattttctt	gacataacct	ggcaaatgta	214200
ggattttgtg	gtgtgtgtgt	ttattagcac	attttttcatt	tctggcacta	caagalcttc	214260
caggctcacc	ttgtttatttt	cctgtgcag	tccaggatt	agtcatttct	acaatgtgcc	214320
ctgattcctt	tagtcagttt	ccttttatta	ggaaaccaata	tctggacact	ggttatgctt	214380
atttgtacaa	gcattgtagt	acttctgggc	cctctcagct	tacagagcaa	ggaaccatac	214440
tatgtctatg	gtgtgtatgc	taagctgtgt	atacacacac	agaaaaaaat	atatatatat	214500
atatgoacac	acatatatttt	ctakacatag	ccatctgtat	caatttttgag	ctaaacatga	214560
gtgttcatac	tgggtgtctcc	aagtcctaat	cagtatcaca	tgtatcattt	tagccttatt	214620
cccttgltta	tctgtacact	cccatcccaa	cagtgataat	cctggctcct	gccatctgtc	214680
aattccagta	tacagggtatt	ggaatatcag	aattttttaac	ttgtactcta	gttatttttaa	214740
ccaagaaata	acttttgttaa	ctagagtaca	atgottatgt	actgtcaaac	gagattccac	214800
togtttccaa	agttattttag	gttctctctc	tgatttttaa	ctcttatttc	actgcatttt	214860
aatccggatt	tattttattgt	tcctgggtgt	cagtcctgaa	actaaagtgg	taataaagga	214920
aacaggttgg	atacgttgaa	ggctttcmaa	ttccttgagg	tcataaaata	tatatgtatg	214980
tgcattatatt	taaaataaag	ccttgaacag	gcagaaaaac	tgatattgca	ttgtagataa	215040
caaattggcat	aaaacactta	tgtagaatta	gtcccatcaa	aatatgtana	gaagtaagggt	215100
tcgataaag	ttgtgggcat	tataataaaa	tattttctct	cctttatatt	cctcccttac	215160
ctgttctcag	taaaataagt	tcaactctgt	acaattaatt	ttctgcatg	tctactgctt	215220
gtacttggga	acaaatgcta	tattataata	taaagatatg	tgtggaactt	ggtttcaaaa	215280
gtcaggtaat	gcaaatatca	aaaaacaggt	gatctctcaa	acaccttatg	ataagtcatg	215340
cagataaagt	gctctgcaga	actccagcca	acaaacagggt	tgattatcag	tgaagtatct	215400
catatttttca	ggtagtcttc	acactaagaa	agctaatgaa	aaagagtttg	agctcacata	215460
atcatgagaa	agtagacttt	aaaccacctt	cccaaatctt	ctgctgaggt	ttcttctctt	215520
tttactcatt	atttttcttt	ttacctcagt	ttactttctg	gttttcttgg	ctgagtgcct	215580
ttttaactgc	tttgaagtas	gatgctatct	tctttatcag	gtttgcaaac	tattttattga	215640
atttagcaat	taaaattgtc	gctgtggttg	aactggaaaa	tgctcttttg	gtacttgaat	215700
ttactgaata	taatgactga	aaaagcattt	caaacacaca	aatcaacaaa	caaaaaatct	215760
caattagttt	gttgcataga	cacatagta	actcacagca	ctggcatatt	atttttgatt	215820
cacaaaacac	atatagagcc	tggcatctat	tagacatgga	agccacttat	caagtattta	215880
tttaatcaat	gaatgcctca	aaggattagt	aatatcaact	tcaacacaa	cctglagtat	215940
atgtaatat	cttctctctc	cctaccttta	acaatgagga	atttgagctc	agaaggatta	216000
agtgaattac	ttgaagttat	attattaatt	aaactactga	agccagaaac	cgaatctaga	216060
acttaattac	cagaaggcca	actactacct	ccacctacgt	tactcatgat	agatttaaca	216120
tggtagcaca	gtggtacata	gtagtgtctc	attgaataat	atttagtaaa	agaaatgaaa	216180
agagtggtgc	tagatacttg	gaagaataag	aatctcaga	aggagaataa	aggtgtatat	216240
acatattcat	ttgataagta	ttcaaaata	agttaaagag	atgcatagga	tactgcagag	216300
ctctttcaga	attgagaagc	tgaaattaaa	agatgtatta	gacttggttc	catcttaaat	216360
catcatcata	tcaagtata	gacattggta	cctgcagtat	ttcagtggca	tttgattttt	216420
ttcctgcaga	gttctatttaa	tacaglattt	taaaatttta	ttgtatgtca	tttaaaaaat	216480
acttttaaaa	agcuagaaca	ccacattttt	ctgggcataa	gagacaagggt	tgctttttgc	216540
atgcattgat	gcaattctaa	cctttaaatt	tcctatgtct	ttattttttc	ccctgacttt	216600
agagcctaatt	attgaactaac	agctcatttt	gaaagataaa	aatccacaaa	ataataattt	216660
agaaagtga	aatgaaaat	tacattaatt	tctctctctc	cattgttttt	cgttcaaaa	216720
cacagttaac	atgagttgat	ttattttttt	taaatgaatc	tactgtgacc	ggccttatga	216780
tccacccatt	cgcctaagtt	tgaaccaca	ttgattcagt	caacaaaact	tataccacct	216840
actaattgat	aggtaatgac	tagttttgtt	aatacttgggt	tacagcgata	gctttgagca	216900
aattttcaaa	gtgaagcttt	tctcaacttt	ttcttggtga	ttcgggtatct	gaaatagctt	216960
attaattcat	tcttctcttg	ttccactga	cactgccaat	cagttgtagg	tgaaaactct	217020
aaactggtct	cctgtacttt	actatcccat	ttctgtcctt	aattcatctt	ctccagtgtc	217080
tcaagtgtaa	tcttgctaaa	atacaaacct	aattatgtta	ctctctgttt	tacagtcttt	217140
aaatgtttta	ccaaattaaa	tccaaactcc	ttgagaagtt	catacaagggt	tgtatcagag	217200
cctctgaaac	gctaaccac	atcttcacag	cttcatctct	tgattccagc	ctggatgcaa	217260
tgggcatctt	ggatttgact	catattacaa	caacaaaata	atctcaagtg	aataccatgc	217320
actgttttact	ttttttccac	tgggcttctt	cagtgccaca	cctgggaatg	gggttttact	217380
tgttaaagctt	acctatggag	ctccaaaatg	caaggaagtt	taacttttga	gagcaatgtc	217440
caaccaatga	gggatggaaa	catagaaaaa	catgctttcc	caagttattc	ttctaacaaa	217500
cagctctaag	gtacgttctg	tatgcttatt	ccccctagat	gtcagggttg	agttccagtg	217560

tcccaagct	atataataaa	aatgcacctt	ggtatagact	ttccgcctt	cccttactct	217620
cttttagctc	cttttgbact	ccataggatt	atctcattga	ctgggctttg	ctttctagta	217680
gaacctaaagc	tatgacatat	agtactagac	tctctacca	ggagtgattt	aggacgagga	217740
ggcgttgaaa	actgaagctt	tggacatctc	agatagttaa	agcactcgca	atctctggca	217800
tttatgtgct	cataatgtag	tggtagaagg	caatlgcggc	aaccttgccc	tgacaagagc	217860
aaggltcatca	agagcttaga	ttgtttggag	ctgaaggctc	gagtcacccc	attaggctaa	217920
aaacctagaa	aagtagaagt	gctgatggag	ggtgaggaaa	atctaataatg	gattgtggag	217980
gaaggagacg	atacatataa	aacatgactg	caggacctgc	agttgtagca	gtgagggctg	218040
taaccttatic	cattaaatatt	tgtgtgttaa	gtcacatgta	gagattgttg	ctaactacca	218100
ccttgaagac	ttagagggtg	ctggaaactta	ttctagggcg	tagggtgtatc	tgtgtggtac	218160
aaaggtataga	ctgtatgggt	tgtttttggc	ttcttgactc	atatcctctt	ggcttcatct	218220
ctgattacag	tgtagatgca	gtgggtagt	tggtttagct	caggctgaca	tctttcctca	218280
agcactggat	gttttgcact	tttgcctttg	ggtttttcca	atgccacaat	tgccattggg	218340
aagccctctg	ttcaagcagg	catgctcagt	cgagaagcca	acaggggttt	acatcccca	218400
agcaaacctt	aactaatgga	ggatacaagt	tgatggataa	aaatagtcaa	accttaagta	218460
cataattcca	aaaggtattc	taaacactcc	ttagaagatt	ccaggcaggg	ctgagcacia	218520
gttgccctaca	atggtgat	taataatgca	tctatatata	tgccttttca	oattccctcc	218580
ctcttctgtc	tctcactcct	gctccctgtt	cataaatttt	tgcagcaggc	tctgctttt	218640
ggaaaaactca	agctaaaaaca	aaagtcctta	aattccagta	tgcctctgtc	ctccactttc	218700
taoccaatttt	tgtgtttgtt	cttttgggtt	tttccctgat	atatgccaa	aaaataaatg	218760
gagaaataga	aggggtggac	tatcaacaaa	tactttaata	gaatttccag	aaggacttaa	218820
gctgtcagat	tgaagagac	cactaagtag	cccagaaaat	agtttaaaag	ttggttgttt	218880
tgaagttttt	ttctccctgg	ttgtttttaa	tctctacate	tgggtgtacag	ctgtcctcat	218940
gagatgcctt	gttactattra	ttctcttgtg	ccaaaacttc	tatttcttat	ccctglaatg	219000
ttttctttct	tggagcacct	cctaaatagt	cttagaaagg	atgcatggga	ggtaactttt	219060
ttgaggccctc	aaacatctaa	tgaagtctct	attttatctc	ctttgacctg	attgaatgat	219120
tatggattta	taggttagaa	actatttctt	tcaaatacat	gaaggagtg	tcttattttc	219180
tgtgtttgcta	ttaaaaagtc	ctaattgcaac	tctttttatc	attctgtgta	cagtgtatgt	219240
gatttttttt	cttctctgga	agcatgtgga	gtcttcttta	gtccctctgt	ttctgaatt	219300
tcaacagaaa	taccttatt	aaggctctgt	gcttgggttc	tattctccat	gttaaaactt	219360
tcacacacatg	tttggtaate	cttgggaagt	tttaaaattt	cagttatctt	ttaagttaagt	219420
taagagaaga	aaaaacttta	aaaaggcagt	ttttatgttt	actcatgtat	ttcccatttc	219480
tgtttgctctt	cattcttttc	tgtaaattctt	agttcccat	taatgtcat	ttcttcacct	219540
gaataacttc	ttttactgca	tattttctgc	ttataaattc	tctcagtttc	catttatccc	219600
ataaagtcta	ttttaccttt	attttcaaag	gatcttttca	ctggatatag	atttatgggt	219660
gacagtattt	tgttgttgtt	gttgttgtta	atttacttca	gtacttacat	atattctagt	219720
ttcttctgtc	tccactgttt	ctgatgagaa	gloattattg	gtatcagtg	tcttttgtat	219780
ataatatgtt	cttttccctc	cagctacttt	caagagtttc	cccttgtctt	tgttttttca	219840
gtttgattgt	gatgtacttc	gttttcttta	tgttttatctt	gcttcagggt	ccctgaatt	219900
cttggatatg	taggttgatg	ttttaataaa	atttttaaac	attagaccat	tatttcttca	219960
aatattttct	tcttctcttc	atctaagaat	tcaattgat	acatggagac	ctcttgatat	220020
tgttccattg	tcacaaagcc	tttattaatt	cttttcaata	gttttttctt	tttgcagctt	220080
gaacttaaaa	ttcactgcac	tctgcacctc	cttttccccc	cgtgaagtct	ccaatccatt	220140
gttaagctca	ttcaggattt	ctccacttca	gatatttatc	gctgtagtcc	taaaattttc	220200
atltttctgc	tgttatccca	tatgcattca	ctgattatga	ccataatttc	tatacatttt	220260
tgagcatatt	tataataagt	gctttaaagt	ccttttctac	taattataca	tctggggcat	220320
ttcagagtcc	agtttctcct	gactactttg	tctcttgagt	atgctttttc	ttccagtgtc	220380
taataalttt	taattctac	acaaagcatt	aaagataatt	tgttggccag	gagcgggtgt	220440
tcacgcctgt	aateccagca	ctttgggagg	ccaaggogga	cagatcatga	agtcaggaga	220500
ttgagatcat	cctggctatc	actgtgaaac	cctgtctcta	ctaaaaatc	aaaaaaaaga	220560
aaaaatttagc	tgggcatggg	ggcgggcggc	tgtagtccca	gctacttggg	aggctgaggc	220620
aggagaattgg	cgtgaacctg	ggaggogggc	ctgtagtga	gccgagatcg	gccactaca	220680
ctccagcctg	ggtgacagag	cgagactgtc	tcaaaaaaaa	taaaataact	gtagagattt	220740
tggagtctgt	tacctttctc	tgaagaatgt	tgtttttgtt	tgtagcagca	gggcatcagt	220800
gaatctctg	ctcgggtttac	aagtcttttt	ttcttttctt	ttcttttttt	ttgagatgga	220860
gtttcgctct	tgltgtctttg	ttgtccaggc	tggagtgcac	tggcgtgatc	ttggctcacc	220920
gcgacctcca	cctcccggtt	tcaagagagt	ctcttgccctc	agcctcctga	gtagtggga	220980
ttacaggcag	gcgccaccac	acctggctaa	ttttgtattt	ttagtagaga	cgtgggttct	221040
ccatgttggg	caggctgggtc	togaactcct	gaccttaggt	gatccctcca	tctcagcctc	221100
ccaaactgct	gggattacag	gcgtgagcca	cggcgcgcgg	cctagtcttt	taactattgc	221160
tatctgctgg	gcttttttga	gtctctacca	tgcattgcata	gtccagttagt	tagtcaagga	221220

tttgaagggg	gltgatacac	agatttltgtg	gcttcctcct	ctgtgcggtct	ctccttltcag	221280
caatttttct	gttttaaatlc	agtcacccctg	gaatccclga	gctcactctc	tgactccaca	221340
actcagaaag	acaatgactt	tctttatgaa	ttttagclac	cctgcatcac	ttgggctgca	221400
agatgctctc	cagagasaat	ctacattaaa	acatgtcact	caatgcagtt	accttctttc	221460
aaagggttgaa	tcacotttctt	tttgaatccc	tggtgggtgt	tattttgtac	cttaataaat	221520
tatttttaat	actgggtccag	agtttataat	tgttatctat	gaggagtgtt	agtctaacac	221580
aagatatttt	gtcattttcta	gaacaagact	actccactct	tatgtagctg	tgacattgtc	221640
atgcatttct	ttaaaacatt	ttagtggltc	tttattgttt	atcaaataga	aaaltattcc	221700
taaaactgcat	gtactctatt	ttttcattgt	ttcccataac	aaagaaatat	tatttcattg	221760
aaataktgaa	atattgagca	tgccctcaaa	tattatgttt	cacctgttct	ttttgtctcat	221820
accgttttcc	atccagaata	catttttccc	cctacatttg	aatgccc aaa	tcctgcctat	221880
tcttttaagat	ctagctaaaa	tgtcacccct	tcacagaaag	ctattcttct	ccctccagtt	221940
tcagttttga	ctaaattatc	tgttttctatt	tcattgcttt	acttatgttt	tataaggaca	222000
ataagagatt	agtgccttta	taaaaagagac	cccacaaagc	ttccttgccc	cttctactat	222060
gtgaggacac	agcaagaaga	cagccaacta	tgagcctgga	agcagggcct	catcaaaact	222120
tgagcatgct	ggtacactga	tcttggactt	tcaggtctcc	aaaactgtaa	gaaataaatt	222180
tctgttgttg	atgcttgggc	gtgggtggctc	acgcctgtat	ttccagcact	tgggaggccg	222240
agggtggggc	atcaogaggt	caggagatcg	agaccatcct	ggctaaccatg	gtgaaaccct	222300
gtctctacta	aaaatacaaa	aaattagctg	gggtgtgggtg	cagggtgcctg	cagtcaccagc	222360
tactcgggag	gctgaggcag	gagaatggcg	tgaacctgaa	agggtggagct	tgcagtgagc	222420
caagatctca	ccagtgcaact	ccagcctggg	tgacagagcg	agactccgtc	tcaaaaaaaa	222480
gaaagaaatt	tctgtttttt	ataagccacc	cagctctatgg	tactttgtta	tagctgcctg	222540
aatggactaa	gacacaaatgt	gaaagttacat	tatcttcttt	ttgattctca	agttaccacc	222600
ttttctcaaa	cgaccaccas	ctctctctgg	acttctgaaa	tattcttgta	actgggtctct	222660
ctgcttccat	tcttgtacct	ttaaacctta	gtattccaca	gtagcctaag	aggctcttagg	222720
gtatataaac	aaaatgacgt	taatttccctg	catctaatca	ttcaatagct	tcccatgtga	222780
ctaaagtggg	accctttctt	tagagtccct	gccatgatac	ataaggctctc	ctctcctaca	222840
aggatggggc	actgcctact	actctgacct	catttattac	actcttccct	gcctctaacat	222900
atgcaaaaag	tattcgacct	ttcccccaat	tctcaaacac	tgcaaaaaaac	ctcccaaggg	222960
cctactactt	tacagttgct	ctatcttctt	cctcgaatgc	cctccttato	tttatagatg	223020
gctccttctt	ttaaagttctt	agtaaaaaata	tcatctcctt	agagggacct	tcacccctctc	223080
agtcacaaacc	ttgttttaaa	ttcctcagac	cctcatgatl	altctgaaatt	atcttattat	223140
atttcttctt	ttgttgttta	atgtttctct	ctgtcacaaa	gcaatacatt	tttttttaaa	223200
gcaggaaatgg	gctatataatt	cttcatttttg	ttgaectcta	ggagctgcat	cagttgggggt	223260
cccttgcttc	tgccctccag	ttgagttcag	ttaaagtaag	accagaggat	aagaaaggaag	223320
gctactgtgt	gtttctactg	agggttatag	ctccttltcag	gcagtccctc	tctacagctt	223380
ttgggttcca	taactatttc	ttctccttga	tgatctccgg	taattcaact	tggtccttgg	223440
ttttctcttt	ctgtcctcct	cactgttgct	agccttaggg	tgcttcagtt	tcctctaacg	223500
cagttcacat	cttttaaaaa	cagactcttc	attaaattct	ctttaatgat	ttgtttcaag	223560
tatgacaaat	ctgtctttct	gggacottga	altttattct	toaaaatatt	accagccctt	223620
agcacagaaac	ctgttacatg	gtgaggttca	acacatattt	gttgaatgaa	tggtatgaatt	223680
aataggctct	tttgctcttc	attcagaatc	tattaagcta	tacactccct	cagtatttta	223740
aacccaaaat	tcagttttta	aaaactaaac	ttcttgagag	catagtctat	clatatctct	223800
ttaaaattta	ggcctaagac	aggacactgc	cccacattga	gtcccacaca	acaacctgtg	223860
agtctggctc	cccaggaggg	ccccagaca	gctcccaggc	acttcatagg	caaagccctgt	223920
ccccccact	caggattccc	aagggtctggg	gtcccgcctc	ccccgctttc	ctctcatgcc	223980
cagcctgacc	ccagggttca	gctgggagag	gccacttccc	ttagccaagg	aaaacgagaa	224040
ccccaggggt	acaggaggaa	gctgggacag	gtcccctggg	gtgtcactcc	ctcaccctct	224100
gcccagggccc	actcccactg	gtgctggagt	agccactggg	gggggggacc	tgctcagccc	224160
agcctggagg	gccccagtg	caccacaacc	aggggcacgg	caacatcatt	gatgggttct	224220
gcagcccagg	gcccccgatg	cggggtcaga	gtgtgtgggg	cacaggggccc	ccgatgcggg	224280
gtcagtggtg	gggggtgoag	ggcccccgat	gtggggctcag	tggggggtggg	gcgcagggtc	224340
cccgatgcgg	ggtcagagtg	tgtggggcac	agggcccccg	atgoggggtc	agtgtgtggg	224400
ggtgcagggc	ccccgatgcg	gggtcagtg	gggtggggcg	cagggtcccc	gatgcgggggt	224460
cagagtggtg	ggggcgagag	gcccccgatg	cggggtcagt	gggggtgggg	cgaggggtcc	224520
ccgatgcggg	gtcagagtg	gtggggcgca	ggggcccccg	tgccgggtga	gattgtgtgg	224580
agcgcagggc	ccctcctgtg	ccagggcact	ttggtacact	gtcccacaa	gcacctgtct	224640
cagaggaggg	gtcctggcag	gcagtggtgc	aactcccttc	cagagcccag	ctccatgtca	224700
acctcccac	agcaaccaca	cagagccaca	tccctgtctg	cacctggcct	gcaggagtg	224760
cccaggacag	gcccaggtca	gcccagcatg	cagctgcctc	cctaccctga	agaaggaggt	224820
gggctttcca	ggggacataa	ggatgccagg	cctggacctc	ctgggcagga	aaggggagcag	224880

gtcctgaggg	cctgtgcccc	acagccccag	caccaggtgg	actgcagcgc	agtgggtggg	224940
ccagtgagag	ctggggagaa	gccccccgtc	agcaggtctg	gggtctgcca	ccagggccctc	225000
cccacgctct	cctttgaggg	tgccctgccat	gccttggggg	atccttggtat	ctttactgga	225060
ctggaagcag	gagacagaac	agtgtctgtc	cgggggtgac	ttcatcagga	gaccgcccac	225120
atagagctgg	accccgagc	tgaagcggaa	atgtgagaca	ggctggcaoc	tccggaaaaa	225180
ctgcctttca	gccttggtgt	tccgtgcaag	gtgaaaaaaa	ataggtccctc	caagtttaca	225240
gcttgaaatc	aggctactgt	gtggccctgg	agaccacgag	gggagaattt	aaagtggccc	225300
cggctggcag	ggtctagggt	gctggcagag	gcacatgcag	accctacctg	gagcccggcc	225360
tagggacgct	gggcaggtca	gtctccgtgc	aggatgtgag	cagcgtccct	gggctctatc	225420
cgcgaggtgc	cagtagcgtg	tgcaaggtaca	tacacatgag	tgacactgt	tatgacaccc	225480
agaaatgtct	caggacgtcg	aaatgtgtcc	ttgggagcag	aagtgtcccc	ggttgagaat	225540
ctgtcccaga	ggaacacgac	caogacaggc	ctcaggattt	tgtgttgatc	aagtcccaa	225600
gaaaaggzac	atctcggcca	ggcgtgggtg	ctcacgcctg	gaatcccagc	acttgaggcc	225660
aggagttcga	gaccagcctg	ggcaacgcag	tgagagaacc	ccatctctac	aaaaaaaaa	225720
aagaaaaaaa	aaagaaagaa	agaaagaaaa	gaaatgaga	tctccagglt	taaaaattca	225780
taaacaccac	aaggaaacaa	tacactatga	gatccagcag	aagcaacaga	ttgactctgt	225840
agaccagat	actggaatta	tcagagagaa	tataaagtaa	cagtgtttta	tatatctaaa	225900
gaaataaaag	agalltctgg	aaaaaaaaat	ttaggcctaa	gaattagtga	aaatcccaac	225960
attaaggaa	ggatttatatg	ttcagttttt	gaaaggataa	tgtgtcattt	ttaatttttg	226020
ctatttccctg	gaatcttagt	tctaggatac	accataaatg	tctgctttta	taggtgaaga	226080
aaactgaggt	gagaactgaa	gagggtattt	tctgaagacg	ttatggtagt	ggaadcaatt	226140
tttactttta	tgttgttgct	ctcttgatga	tattagatgg	tttcatcaat	tactaagtaa	226200
attcccaaga	tttacctcga	agtacattta	ccctatttaac	ttattctcca	gttgaaccaa	226260
tttgccattt	cattctggtg	acaaagctct	cttactacaa	ttcagaaaaa	atttgggag	226320
cagctgccac	tgagcccag	ctttgacaaa	atatccctcc	acagaggccc	agttaaacta	226380
tggattgcac	tgagcattct	gtccttaggt	gctotggcct	cccagtagat	agcggatgct	226440
gtggtaat	atcacaaacc	tctacccctc	cgtttacctg	ccagggtgact	cttcaactct	226500
ggcttctgca	gcctctgctc	tccccaagat	ccagctctct	cagcccccca	tctaagggtg	226560
cacagtttag	gtacatgctg	aaatcaccaa	tacagaatcg	ttttaaaaat	cgaatttaatt	226620
ggctgagtg	tttgttaaga	cctgattgtg	ggcaagaact	atttgttaaa	tactctaaat	226680
tcttagaacc	cagcccagta	cttgctagtc	atcatttaaa	tacattgaat	gatagagaaa	226740
attcttctga	tcacaaacct	tataccagcg	ttgtcaaaaat	tataatgata	aagttagctca	226800
ttttaagcgc	gtcctgggtt	gggaacctta	acaattttta	aacttggaat	aaattcaata	226860
aaatgacata	gtatggttac	aatgtctgtc	tacagagtca	gggcaagaac	aaagaaattt	226920
gaaagaagat	tgttttagtg	tagtaaaaat	actggataat	tttcatttcc	tttgcctctt	226980
aaagaattat	ttgtaaaagg	tatttgaaat	gaaaacaaga	ttggagaaaa	acaacttggg	227040
agaaaaatcat	aggcaataaa	caataatgat	tgaagagttg	tgaataagga	gagttaggaa	227100
tcaagtgggt	ccaggtctgc	agaatctgaa	aggagcctag	agtgaggagg	ttgatctgtg	227160
aaggatgatg	atgatctcca	ttaaggacca	gacagggagg	aataaggctta	agctgcagta	227220
tgagggtatt	agataagaga	aaaggaaaaa	ttttcagaca	glgaggttca	tagattactgg	227280
aatgtgtaac	tgagggaact	tgtggaattt	ccttctctag	aagtctttta	aaaatagggc	227340
agtgtctcat	ctgcctgaag	gatggactct	atttgacctc	tcaaattgtc	tactgnaactc	227400
agaaggtgaa	ccacacctta	gataagaaag	agagcctgaa	tgatcctggg	tagcttgagt	227460
aataaagta	gggtgaaaca	gtcatattta	ttttgattta	tatatgtcat	atatglaaat	227520
tatgtctgct	ataattcctt	tttttctttc	aattgaatgt	tttcattttt	aaggccctaga	227580
gatttagagt	caagttaaga	tatttatagga	aagcaaggaa	gaactctttt	atcttactgt	227640
agaacaaatt	tttagaggaa	taaaaggaga	aaaggatata	ttggacatat	ttgattttga	227700
tttcaactcc	tattctaaat	aaaaaaaaat	acactgccct	ttctgttagc	tttagtattt	227760
taagggttaa	tttcaaaaag	ttaatttagt	gtaagtgttt	ctcacgggtg	ttttggcaga	227820
accggtatcc	caaactggaa	gaggttctct	gtattttaatt	tcctctcagg	aagtttaccg	227880
tcagaagtc	aaatgtgagg	tcaagttttg	ggttgcccga	aatggtaatg	tcccttactg	227940
tctgaacacc	cagacaacac	ttaatgaaac	attctacttt	gtggacattg	aaagaaatta	228000
aaatgctttg	tttccctcct	ttlatgattg	gtgatttctg	tattcagtct	tctaaaactc	228060
agaaacaaga	ctatgtgtaa	gtaagagcat	ctgcattctc	aggatoaagt	tataactgca	228120
gattttcagt	tacaggtgat	atccatcttt	tttttccctc	ctaaaaataa	aaatgtactt	228180
acttcaggcc	aaaggagagg	caagcttttag	aactcatttag	ccttcaagaa	aaacaatttc	228240
agagcattct	aaacctgatt	tclttctaac	tctgtttgag	ttgacctgag	gacttttaca	228300
ggttaaagca	gtgagtcatt	atatotcaca	ttcatacagc	tctacatatt	tgtcaaagtg	228360
cttacttcate	taatatctaa	tatgatctta	ataagaacct	tgtgaatgkc	attatcttat	228420
agatgaaaaa	atgatatctt	cataagatcac	agtttgctca	agatcacaaa	actagaaaaa	228480
gtagtttgaa	cacttctgat	ttcaaaggcca	gagttctctc	cactgccccca	tgctgtactg	228540

tttttgagaa	tttgtgattt	cctgggtgttg	tattatTTTT	accattgatg	agatTTTTtg	228600
ctgtgattta	tcctgaatca	aaatagatac	tgtgatatga	tactaaagta	attgttacca	228660
aacaaaaagt	tgtgctagca	ttcttatgaa	gtacagcact	aaagattttc	aaaacatttt	228720
gttattttta	cataatttgt	catgtaaatt	tctggttaga	cactccttat	gagattacaa	228780
cccattctaa	tttatgctag	ctattttattg	ttaagcagta	tgttgTTTT	attacaaaac	228840
ctcctttaat	cattgcatca	gtctctggca	gaatattaaa	aacaactccc	ataatccctg	228900
gcactctgtc	ctgggtgtct	ttgggggtac	agtggcttta	tttcttccc	taatagtctg	228960
gaagtttgtt	taatactgac	tcagaggaag	cattctagct	gagtcctcac	atggctcttg	229020
tlacagctcc	ggagtgtaca	taatagataa	gctactgact	tcacaagac	ccccacgctt	229080
cctgggtgtg	tgggtgtgtg	tgttgtgtct	tgtgaattaa	ggttgtgcaa	tctccctgct	229140
agctgcatca	ggttgcaaa	tcattttactt	ctctaaaaata	ttcctctagc	cagcctgact	229200
tgataaacca	aaatcattgt	attccatggg	ggacatgctg	gtaactcatg	ataaacacta	229260
aaaatccctac	gggtttataa	caagataaaa	cctgatattg	gggcagggtg	tagagaaatt	229320
tgcceaagga	aatatttgtga	aataaagttg	caaatggcta	tagatgaatg	cttttctatc	229380
tataggattt	ctttcttga	ttgtaattat	aaattctttt	actggttgta	aatataattta	229440
tgattcttat	gttaccagb	ctgtaccaag	aactttgtta	ggccaacaac	atcttacttg	229500
attglagtag	taaccttaaa	agataaatat	aggtataatg	ctttttcaga	agaaaaactg	229560
gagaattcaa	acatgttctg	cattgcacag	atggtaaattg	agtgalgaat	agggctcttt	229620
gactccaaag	atcaactagg	ttctttccac	atatctctct	ttggttccct	tttttgatat	229680
gactgtatga	aatataattg	tatttacata	aagtgcagta	gagttcatta	gaaaaactat	229740
ttctgaatct	tagggttcag	actaaagggtg	tttggaggct	gatgatagtg	ggctgcaaa	229800
agcttcatgg	tgggctgcga	atagcttcat	caaacc			229836

CLAIMS

1. A method for determining a susceptibility to cardiovascular disease in a human individual, comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual or in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the polymorphic markers set forth in Table 10, and markers in linkage disequilibrium therewith, and wherein the presence of the at least one allele is indicative of a susceptibility to cardiovascular disease.
2. The method according to Claim 1, wherein the at least one polymorphic marker is located within the genomic segment with the sequence as set forth in SEQ ID NO:94.
3. The method according to Claim 1 or Claim 2, wherein the at least one polymorphic marker is in linkage disequilibrium with the CDKN2A and/or CDKN2B genes.
4. The method according to any of the preceding Claims, wherein the at least one polymorphic marker is selected from the markers set forth in Table 3 and Table 21.
5. The method according to any of the preceding Claims, wherein the at least one polymorphic marker is selected from rs10811650, rs10116277, rs1333040, rs10738607, rs4977574, rs6475608, D9S1870, rs2383207, rs1333045, rs1333046, rs10757278 and rs1333048.
6. The method according to any of the preceding Claims, wherein the at least one polymorphic marker is selected from rs1333040, rs10116277, rs2383207 and rs10757278.
7. The method according to any of the preceding Claims, wherein the at least one polymorphic marker is rs10757278.
8. The method according to any of the preceding Claims, further comprising assessing the frequency of at least one haplotype in the individual.
9. The method of any of the preceding claims, wherein the susceptibility conferred by the presence of the at least one allele or haplotype is increased susceptibility.
10. The method according to Claim 9, wherein the presence of allele T in rs1333040, allele T in rs10116277, allele G in rs2383207, allele G in rs10757278, allele X in D9S1870 or allele D in D9S1814 is indicative of increased susceptibility to cardiovascular disease.

11. The method according to Claim 9 or 10, wherein the presence of the at least one allele or haplotype is indicative of increased susceptibility with a relative risk (RR) or odds ratio (OR) of at least 1.2.
- 5 12. The method according to Claim 9 or 10, wherein the presence of the at least one allele or haplotype is indicative of increased susceptibility with a relative risk (RR) or odds ratio (OR) of at least 1.3.
13. The method according to any of the claims 1-8, wherein the susceptibility conferred by the presence of the at least one allele or haplotype is decreased susceptibility.
- 10 14. The method according to any of the preceding Claims wherein the presence of the marker or haplotype is indicative of a different response rate of the subject to a particular treatment modality for a Cardiovascular disease.
- 15 15. The method according to Claim 14, wherein the treatment modality is a coronary stenosis method selected from balloon angioplasty, stenting, cutting balloon angioplasty, percutaneous transluminal coronary angioplasty (PTCA), directional coronary atherectomy, rotational coronary atherectomy, brachytherapy, drug-eluting stent (DES) insertion, metal stent insertion, and coronary artery surgery.
- 20 16. The method of claim 14, wherein the treatment modality is administration of a therapeutic agent for preventing and/or ameliorating symptoms associated with the Cardiovascular disease..
17. A method of identification of a marker for use in assessing susceptibility to cardiovascular disease, the method comprising
 - a. Identifying at least one polymorphic marker in linkage disequilibrium with at least one of the markers within LD Block C09 (SEQ ID NO:94);
 - 25 b. determining the genotype status of a sample of individuals diagnosed with, or having a susceptibility to, cardiovascular disease; and
 - c. determining the genotype status of a sample of control individuals;

wherein a significant difference in frequency of at least one allele in at least one polymorphism in individuals diagnosed with, or having a susceptibility to,

- 30 cardiovascular disease, as compared with the frequency of the at least one allele in the control sample is indicative of the at least one polymorphism being useful for assessing susceptibility to cardiovascular disease.
- 18. The method according to Claim 17, wherein an increase in frequency of the at least one allele in the at least one polymorphism in individuals diagnosed with, or

having a susceptibility to, cardiovascular disease, as compared with the frequency of the at least one allele in the control sample is indicative of the at least one polymorphism being useful for assessing increased susceptibility to cardiovascular disease.

- 5 19. The method according to Claim 17 or Claim 18, wherein a decrease in frequency of the at least one allele in the at least one polymorphism in individuals diagnosed with, or having a susceptibility to, cardiovascular disease, as compared with the frequency of the at least one allele in the control sample is indicative of the at least one polymorphism being useful for assessing decreased susceptibility to, or
10 protection against, cardiovascular disease.
20. The method according to any of the Claims 17-19, wherein the at least one marker within LD Block C09 is selected from the markers set forth in Table 10.
21. The method according to any of the Claims 17-20, wherein the at least one marker within LD Block C09 is selected from the markers set forth in Table 3 and
15 Table 21.
22. The method according to any of the Claims 17-21, wherein the at least one marker within LD Block C09 is selected from rs1333040, rs10116277, rs2383207 and rs10757278.
23. A method of genotyping a nucleic acid sample obtained from a human individual at risk for, or diagnosed with, cardiovascular disease, comprising determining the presence or absence of at least one allele of at least one polymorphic marker in
20 the sample, wherein the at least one marker is selected from the group consisting of the markers set forth in Table 3 and Table 21, and markers in linkage disequilibrium therewith, and wherein the presence or absence of the at least one
25 allele of the at least one polymorphic marker is indicative of a susceptibility of cardiovascular disease.
24. The method of Claim 23, wherein the at least one marker is selected from rs10811650, rs10116277, rs1333040, rs10738607, rs4977574, rs6475608, D9S1870, rs2383207, rs1333045, rs1333046, rs10757278 and rs1333048.
- 30 25. The method according to Claim 23 or 24, wherein genotyping comprises amplifying a segment of a nucleic acid that comprises the at least one polymorphic marker by Polymerase Chain Reaction (PCR), using a nucleotide primer pair flanking the at least one polymorphic marker.
- 35 26. The method according to any of the Claims 23 - 25, wherein genotyping is performed using a process selected from allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, nucleic acid sequencing, 5'-

exonuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation analysis.

27. The method according to Claim 25, wherein the process comprises allele-specific probe hybridization.

5 28. The method according to Claim 27, wherein the process comprises DNA sequencing.

29. The method according to any of the Claims 23 ~ 27, comprising:

10 4) contacting copies of the nucleic acid with a detection oligonucleotide probe and an enhancer oligonucleotide probe under conditions for specific hybridization of the oligonucleotide probe with the nucleic acid;

wherein

a) the detection oligonucleotide probe is from 5-100 nucleotides in length and specifically hybridizes to a first segment of the nucleic acid whose nucleotide sequence is given by SEQ ID NO:94;

15 b) the detection oligonucleotide probe comprises a detectable label at its 3' terminus and a quenching moiety at its 5' terminus;

20 c) the enhancer oligonucleotide is from 5-100 nucleotides in length and is complementary to a second segment of the nucleotide sequence that is 5' relative to the oligonucleotide probe, such that the enhancer oligonucleotide is located 3' relative to the detection oligonucleotide probe when both oligonucleotides are hybridized to the nucleic acid; and

25 d) a single base gap exists between the first segment and the second segment, such that when the oligonucleotide probe and the enhancer oligonucleotide probe are both hybridized to the nucleic acid, a single base gap exists between the oligonucleotides;

5) treating the nucleic acid with an endonuclease that will cleave the detectable label from the 3' terminus of the detection probe to release free detectable label when the detection probe is hybridized to the nucleic acid; and

30 6) measuring free detectable label, wherein the presence of the free detectable label indicates that the detection probe specifically hybridizes to the first segment of the nucleic acid, and indicates the sequence of the polymorphic site as the complement of the detection probe.

30. A method of assessing an individual for probability of response to a therapeutic agent for preventing and/or ameliorating symptoms associated with cardiovascular disease, comprising: determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, wherein the at least one polymorphic marker is selected from the group consisting of the polymorphic markers set forth in Table 3 and Table 21, and markers in linkage disequilibrium therewith, wherein the presence of the at least one allele of the at least one marker is indicative of a probability of a positive response to the therapeutic agent.
31. A method of predicting prognosis of an individual diagnosed with cardiovascular disease, the method comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, wherein the at least one polymorphic marker is selected from the group consisting of the polymorphic markers set forth in Tables 3 and 21, and markers in linkage disequilibrium therewith, wherein the presence of the at least one allele is indicative of a worse prognosis of the cardiovascular disease in the individual.
32. A method of monitoring progress of treatment of an individual undergoing treatment for cardiovascular disease, the method comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, wherein the at least one polymorphic marker is selected from the markers set forth in Tables 3 and 21, and markers in linkage disequilibrium therewith, wherein the presence of the at least one allele is indicative of the treatment outcome of the individual.
33. The method according to any of the Claims 30-32, wherein the at least one polymorphic marker is selected from rs10811650, rs10116277, rs1333040, rs10738607, rs4977574, rs6475608, D9S1870, rs2383207, rs1333045, rs1333046, rs10757278 and rs1333048, and markers in linkage disequilibrium therewith.
34. The method of any of the preceding Claims, further comprising assessing at least one biomarker in a sample from the individual.
35. The method of Claim 34, wherein the biomarker is a cardiac marker or an inflammatory marker.
36. The method of Claim 34 or Claim 35, wherein the at least one biomarker is selected from creatin kinase, troponin, glycogen phosphorylase, C-reactive protein (CRP), serum amyloid A, fibrinogen, interleukin-6, tissue necrosis factor-alpha, soluble vascular cell adhesion molecules (sVCAM), soluble intervascular adhesion

molecules (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, matrix metalloprotease type-9, serum sCD40L, leukotrienes, leukotriene metabolites, Interleukin-6, tissue necrosis factor- α , myeloperoxidase (MPO), and N-tyrosine.

- 5 37. The method of Claim 36, wherein the leukotriene is selected from LTB₄, LTC₄, LTD₄ and LTE₄.
38. The method of any of the preceding claims, further comprising analyzing a sample comprising genomic DNA from a human individual or a genotype dataset derived from a human individual for the presence or absence of at least one at-risk allele of at least one at-risk variant for cardiovascular disease not in linkage disequilibrium with any one of the markers set forth in Table 10.
- 10 39. The method of any of the claims 1-6, comprising determining the presence or absence of at least one allele in at least two polymorphic markers, wherein the presence of the at least one allele in the at least two polymorphic markers is indicative of an increased susceptibility to cardiovascular disease.
- 15 40. The method of any of the preceding Claims, further comprising analyzing non-genetic information to make risk assessment, diagnosis, or prognosis of the individual.
41. The method of Claim 40, wherein the non-genetic information is selected from age, gender, ethnicity, socioeconomic status, previous disease diagnosis, medical history of subject, family history of cardiovascular disease, biochemical measurements, and clinical measurements.
- 20 42. The method of any of the Claims 34 - 41, further comprising calculating combined risk.
43. The method according to any of the preceding Claims, wherein linkage disequilibrium is characterized by a particular numeric cutoff value for the linkage disequilibrium measures r^2 and/or $|D'|$.
- 25 44. The method according to Claim 43, wherein wherein linkage disequilibrium is characterized by a cutoff value for r^2 of greater than 0.2.
- 30 45. The method according to Claim 43 or Claim 44, wherein linkage disequilibrium is characterized by a cutoff value for r^2 of greater than 0.5.
46. The method according to Claim 42, wherein linkage disequilibrium is characterized by a cutoff value for r^2 of greater than 0.2 and/or $|D'|$ of greater than 0.8.

47. The method according to any of the preceding Claims, wherein the Cardiovascular disease is at least one of Myocardial Infarction, Coronary Artery Disease, Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary Artery Bypass Surgery (CABG), Restenosis, Peripheral Arterial Disease, Stroke, Abdominal Aorta Aneurysm and Intracranial Aneurysm.
5
48. The method according to Claim 47, wherein the Cardiovascular disease is at least one of Myocardial Infarction, Coronary Artery Disease, Restenosis, Intracranial Aneurysm and Abdominal Aorta Aneurysm.
49. The method according to Claim 47, wherein the Stroke is Large Artery
10 Atherosclerotic Stroke or Cardiological Stroke.
50. The method according to Claim 47 or 48, wherein Myocardial Infarction is an early onset Myocardial Infarction.
51. The method according to Claim 50, wherein the Cardiovascular Disease is
15 Myocardial Infarction and/or Coronary Artery Disease with an early onset before age 50 for males and 60 for females.
52. A kit for assessing susceptibility to cardiovascular disease in a human individual, the kit comprising reagents for selectively detecting at least one allele of at least one polymorphic marker in the genome of the individual, wherein the polymorphic marker is selected from the markers set forth in Tables 10, and markers in linkage disequilibrium therewith, and wherein the presence of the at least one allele is
20 indicative of a susceptibility to cardiovascular disease.
53. The kit of Claim 52, wherein the at least one polymorphic marker is selected from rs10811650, rs10116277, rs1333040, rs10738607, rs4977574, rs6475608, D9S1870, rs2383207, rs1333045, rs1333046, rs10757278 and rs1333048.
- 25 54. The method kit according to Claim 52 or Claim 53, wherein the at least one polymorphic marker is selected from rs1333040, rs10116277, rs2383207 and rs10757278.
55. The kit according to Claim 55, wherein the at least one polymorphic marker is selected from rs10757278 and markers in linkage disequilibrium therewith.
- 30 56. The kit according to any of the Claims 52-55, wherein linkage disequilibrium is characterized by a particular numeric cutoff value for the linkage disequilibrium measures r^2 and/or $|D'|$.
57. The kit according to Claim 56, wherein wherein linkage disequilibrium is characterized by a cutoff value for r^2 of greater than 0.2.

58. The kit according to Claim 56 or Claim 57, wherein linkage disequilibrium is characterized by a cutoff value for r^2 of greater than 0.5.
59. The method according to Claim 56, wherein linkage disequilibrium is characterized by a cutoff value for r^2 of greater than 0.2 and/or $|D'|$ of greater than 0.8.
- 5 60. The kit according to any of the Claims 52 - 59, wherein the reagents comprise at least one contiguous oligonucleotide that hybridizes to a fragment of the genome of the individual comprising the at least one polymorphic marker, a buffer and a detectable label.
- 10 61. The kit according to any of the Claims 52 - 60, wherein the reagents comprise at least one pair of oligonucleotides that hybridize to opposite strands of a genomic nucleic acid segment obtained from the subject, wherein each oligonucleotide primer pair is designed to selectively amplify a fragment of the genome of the individual that includes one polymorphic marker, and wherein the fragment is at least 30 base pairs in size.
- 15 62. The kit according to Claim 60 or 61, wherein the at least one oligonucleotide is completely complementary to the genome of the individual.
63. The kit according to any of the Claims 60 - 62, wherein the oligonucleotide is about 18 to about 50 nucleotides in length.
- 20 64. The kit according any of the Claims 60 - 63, wherein the oligonucleotide is 20-30 nucleotides in length.
65. The kit according to any of the Claims 52 - 64, wherein the kit comprises:
- a. a detection oligonucleotide probe that is from 5-100 nucleotides in length;
 - b. an enhancer oligonucleotide probe that is from 5-100 nucleotides in length; and
 - 25 c. an endonuclease enzyme;
- wherein the detection oligonucleotide probe specifically hybridizes to a first segment of the nucleic acid whose nucleotide sequence is set forth in SEQ ID NO:94; and
- wherein the detection oligonucleotide probe comprises a detectable label at its 3' terminus and a quenching moiety at its 5' terminus;
- 30 wherein the enhancer oligonucleotide is from 5-100 nucleotides in length and is complementary to a second segment of the nucleotide sequence that is 5' relative

to the oligonucleotide probe, such that the enhancer oligonucleotide is located 3' relative to the detection oligonucleotide probe when both oligonucleotides are hybridized to the nucleic acid;

wherein a single base gap exists between the first segment and the second segment, such that when the oligonucleotide probe and the enhancer oligonucleotide probe are both hybridized to the nucleic acid, a single base gap exists between the oligonucleotides; and

wherein treating the nucleic acid with the endonuclease will cleave the detectable label from the 3' terminus of the detection probe to release free detectable label when the detection probe is hybridized to the nucleic acid.

66. Use of an oligonucleotide probe in the manufacture of a reagent for diagnosing and/or assessing susceptibility to cardiovascular disease in a human individual, wherein the probe hybridizes to a segment of a nucleic acid whose nucleotide sequence is set forth in SEQ ID NO:94, wherein the probe is 15-500 nucleotides in length.

67. A computer-readable medium on which is stored:

- a. an identifier for at least one polymorphic marker;
- b. an indicator of the frequency of at least one allele of said at least one polymorphic marker in a plurality of individuals diagnosed with cardiovascular disease; and
- c. an indicator of the frequency of the least one allele of said at least one polymorphic markers in a plurality of reference individuals;

wherein the at least one polymorphic marker is selected from the polymorphic markers set forth in Table 10, and polymorphic markers in linkage disequilibrium therewith.

68. The medium according to Claim 67, wherein the polymorphic marker is selected from rs10811650, rs10116277, rs1333040, rs10738607, rs4977574, rs6475608, D9S1870, rs2383207, rs1333045, rs1333046, rs10757278 and rs1333048, and markers in linkage disequilibrium therewith.

69. The medium according to claim 67 or 68, further comprising information about the ancestry of the plurality of individuals.

70. An apparatus for determining a genetic indicator for cardiovascular disease in a human individual, comprising:

a computer readable memory; and

a routine stored on the computer readable memory;

wherein the routine is adapted to be executed on a processor to analyze marker and/or haplotype information for at least one human individual with respect to at least one polymorphic marker selected from the markers set forth in Table 10, and markers in linkage disequilibrium therewith, and generate an output based on the marker or haplotype information, wherein the output comprises a risk measure of the at least one marker or haplotype as a genetic indicator of cardiovascular disease for the human individual.

71. The apparatus of Claim 70, wherein the routine further comprises an indicator of the frequency of at least one allele of at least one polymorphic marker or at least one haplotype in a plurality of individuals diagnosed with cardiovascular disease, and an indicator of the frequency of at the least one allele of at least one polymorphic marker or at least one haplotype in a plurality of reference individuals, and wherein a risk measure is based on a comparison of the at least one marker and/or haplotype status for the human individual to the indicator of the frequency of the at least one marker and/or haplotype information for the plurality of individuals diagnosed with cardiovascular disease.
72. The apparatus according to Claim 70 or 71, wherein the at least one polymorphic marker is selected from rs10811650, rs10116277, rs1333040, rs10738607, rs4977574, rs6475608, D9S1870, rs2383207, rs1333045, rs1333046, rs10757278 and rs1333048, and markers in linkage disequilibrium therewith.
73. The apparatus or medium according to any of the claims 67 - 72, wherein linkage disequilibrium is characterized by numerical values of r^2 of at least 0.2 and/or values of $|D'|$ of at least 0.8.
74. The apparatus of any of the Claims 70 - 73, wherein the risk measure is characterized by an Odds Ratio (OR) or a Relative Risk (RR).